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Preface
Restricting the irradiated volume to the site and
shape of the tumor has been the goal of radiother-
apists since the beginning of radiation therapy
nearly 100 years ago. Even before appropriate
particle accelerators were available it was realized
that ion beams could be a means to get very close
to this ideal . In 1946, the young Harvard physicist
Robert Wilson published his pioneering article in
which he outlined the physical rationale for the
clinical usefulness of protons and other ions . But
unlike X-rays, gamma radiation and neutrons
which were used therapeutically very soon after
their discovery, protons and heavier ions did not
meet the immediate interest of therapists, despite
their obvious physical advantages .
Several reasons have been responsible for the
slow pick-up of this discipline . The new, expen-
sive accelerators were restricted to a few research
laboratories where they were fully occupied by
high-energy physicists . None of these facilities
had hospital access and there was no trained med-
ical staff to perform the treatments . Not the least,
the modest performance standards of the diag-
nostic techniques hampered a therapy which
required precision localization .
Only in the last few years, things have begun
to change . The last decade has brought great
improvements in imaging techniques, such as
MRI and CT, permitting tumor localization with
an accuracy of a couple of millimeters. More
radiotherapists became interested in ion beam
therapy when the first treatment results became
available which indicated clinical superiority of
ions over conventional radiotherapy for certain
tumor indications. In retrospect, these results
must be valued especially high, because many of
them were obtained with less than optimal irradi-
ation conditions or outdated technical equipment
which was not designed for medical applications
in the first place.
Today, the first two hospital-based ion beam
centers are operating : Aproton therapy center in
Loma Linda, California and aheavy ion facility in
Chiba, Japan. These two, which profit from
equipment specifically designed and built for
therapeutic purposes, and a number of other
institutions are developing innovative irradiation
components to exploit clinically the unquestion-
able physical advantages of ion beams.
But it has to be understood that the real ben-
efit of ion beam therapy can only be assessed
when the most suitable tumor types are chosen
and the highest standard of ion beam therapy is
compared to the most advanced control treat-
ment be it photons or any other modality. This
evaluation, however, needs a much stronger
foundation of information and knowledge, which
has to come from intensive future research and
clinical experience .
As the scientific knowledge of ion beam ther-
apy is scattered throughout the literature or con-
cealed in not easily accessible proceedings vol-
umes, it has been the intention of this book to
present a comprehensive overview on the present
status of ion beam therapy and an outlook on
where it is likely to go .
The title of the book implies that if focuses on
therapeutic applications of accelerated protons
and heavier ions . The term ion beam therapy has
been preferred over the common "charged particle
therapy" or the more recent "hadron therapy" to
distinguish the medical application of accelerated
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nuclei from that of electrons, pions, or neutrons,
which share some physical and biological proper-
ties with ions, but are not specifically addressed in
the book to keep the volume concise. Charged
particles is only used as synonym for ions when
the context is clear. Other terms that are occa-
sionally a source of confusion are "light" and
"heavy" ions . High-energy physicists or members
of the ion beam community might not conceive
the same when using these terms . Ions lighter
than argon mightbe considered light by physicists
in contrast to lead or uranium which they would
classify as heavy. Within the ion beam community
"light" ions are usually only the low-LET nuclei
of hydrogen (protons) and helium . Carbon, nitro-
gen, and all other high-LET ions are called
"heavy". By specifying the ions mostly by their
name we have tried to avoid confusion on this
issue .
Ion beam therapy is a highly interdisciplinary
field which unifies diverse disciplines from accel-
erator physics to medical and biophysics, radio-
biology and radiooncology. Colleagues from
these various fields contributed to this book and
hence permitted to examine the topic with all its
clinical, biological, physical and technical facets .
It has been a great pleasure to work within this
international community and I am very much
indebted to all those who contributed chapters to
this book . I am also grateful to the Forschungs-
zentrum Jülich for its support and permission to
prepare this book. My special thanks go to Mrs.
Eva-Maria Gottschlich and Ulrike Schmitt for
their very careful and meticulous assistance in
editing the manuscripts . Finally, I would like to
apologize to all those whom I was pushing too
much to meet one or the other tight deadline dur-
ing the making of this publication.
Jülich, June 1995
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The History of Ion Beam Therapy
M. R. RAIU
Introduction
Life Sciences Division, Los Alamos National Laboratory, Los Alamos, NM, USA
The term "ion beam therapy" is used to include
radiotherapy using protons and heavy ions, and
to distinguish them from fast neutrons and nega-
tive pions (pions) that are also of interest to radio-
therapy. The clinical experience of fast neutrons
and pions is relevant to ion beam therapy. Hence,
Table 1 . World-Wide Ion Beam Experience*
* from : Particles, Newsletter (Ed J. Sisterson) No . 14, July
Cambridge Massachusetts
although this article is primarily on the historical
development of ion beams, it also brings in the
results of fast neutrons and pions within the con-
text of ion beams . For further details, the reader
is referred to two books on this subject [1, 2] . The
ionbeam therapy centers are listed in Table 1 . The
historical developments in the use of protons in
radiotherapy and -surgery in different countries
2,487 Light Ion Beams
13,974 Proton Beams
1994 . Harvard Cyclotron Laboratory, Harvard University,
Institution Countr Ion Date Date Reccnt
First Last Patient
Rx Rx Total
Berkeley 184 CA, USA P 1954 - 1957 30
Berkeley CA, USA He 1957 - 1992 2054
Uppsala Sweden P 1957 - 1976 73
Harvard MA, USA P 1961 6138
Dubna Russia P 1967 - 1974 84
Moscow Russia P 1969 2550
St . Petersberg Russia P 1975 891
Berkeley CA, USA Ne 1975 - 1992 433
Chiba Japan P 1979 86
PMRC, Tsukuba Japan P 1983 393
PSI (SIN) Switzerland P 1984 1574
Dubna Russia P 1987 31
Uppsala Sweden P 1989 34
Clatterbridge England P 1989 513
Loma Linda CA, USA P 1990 805
Louvain-la-Neuve Belgium P 1991 21
Nice France P 1991 338
Orsay France P 1991 402
N.A.C . South Africa P 1993 6
Indiana Cyclotron IN, USA P 1993 1
UC Davis CA, USA P 1994 4
4	
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will be presented first, followed by that for heavy
ions .
Medical Use of Protons
Berkeley
The use of ion beams in general, and protons in
particular, for radiotherapy was first proposed by
Wilson in 1946 [3] . Berkeley wasthe birth place of
particle therapy, including ion beam therapy,
because of the discovery of the cyclotron princi-
ple by Ernest O. Lawrence, the development of
cyclotrons with increasing energy in Berkeley
under his leadership, and his interest in biomed-
ical applications in physics.
Two years after the publication of the paper by
Wilson, the 184-inch cyclotron was available for
experiments . Tobias, Anger, Lawrence [4] con-
ducted extensive studies of the physical properties
of protons, deuterons and alpha particles and con-
firmed the predictions of Wilson . They also
demonstrated, after careful radiobiological investi-
gations, the potential applications of these beams
to medicine . There were some interesting reasons
for the concentrated effort on pituitary treatments,
rather than radiotherapy at Berkeley. Because of
the difficulty in delineating tumor and normal tis-
sue boundaries and the negative experiences with
fast neutrons earlier, both Ernest O. Lawrence and
his brother Dr. John Lawrence who was amedical
doctor, discouraged cancer treatment and were
interested in other medical applications . They
were searching for a scientifically and medically
worthwhile project . There were some interesting
research and clinical developments taking place at
that time on the nature of growth hormone and its
control by the pituitary gland. The Swedish sur-
geon Dr. Oliveerona [5] observed some startling
remissions of advanced breast cancers after sur-
gical removal of the pituitary gland. The rationale
for doing a hypophysectomy for such cases dates
back much earlier. The radioresistance of the
pituitary was demonstrated by Lacassagne in
France as early as in 1934 [6]. Dr. John Lawrence,
inspired by Dr. Cushing, was interested in
influencing the function of the pituitary but found
it difficult to accomplish with X-rays [7] .
The pituitary is a well localized gland closely
surrounded by sensitive structures and hence is an
ideal and appropriate target for sharp dose local-
ization of ion beams. Tobias and his associates [8]
attempted to irradiate selectively the pituitary
gland of the rat with deuterons. The rats became
hypophysectomized in a similar manner to the
one obtained by surgery. The first use of ion
beams in humans was for pituitary hormone sup-
pression in the treatment of patients with meta-
static breast carcinoma [9] . Subsequently, pituitary
suppression/ablation was applied to the treatment
of proliferative diabetic retinopathy and pituitary
adenomas . The improvements of the 184-inch
cyclotron, driven by the high-energy physics
research, led to the acceleration of protons and
deuterons to much higher energies with longer
ranges, thereby losing most of the favorable,
Bragg-peak characteristics . However, the bio-
medical work was continued at Berkeley using a
helium ion beam. The clinical experience of
pituitary treatments in more than 800 patients
was reviewed by Levy et al . [10] .
Uppsala
The famous protein chemist and Nobel Laureate,
Svedberg and his associates turned to Berkeley, in
the late 40's and early 50's when they designed
and built the 230-cm proton synchrocyclotron in
Uppsala, Sweden. Like Lawrence, they wanted to
use the accelerated particles, not only for nuclear
chemistry but for physical and medical studies as
well . Inspired by the work ofTobias et al . [4] and
their pioneering studies of radiation hypophysec-
tomy, Svedberg engaged a young biophysicist,
B6rje Larsson in 1954 and gave him the task of
implementing the Berkeley pituitary irradiation
method in Uppsala. This task was performed
under the guidance of Tobias and the endocri-
nologist Rolf Luft who worked with Olivecrona .
The project was successfully completed in
1956, but the Swedish group could not pursue the
pituitary work further for lack of funds . So Lars-
son turned to basic radiobiological and physiolog-
ical experiments, with the available biomedical
proton beam line . On the basis of this research, a
collaboration was initiated with a community of
Swedish , clinicians . The famous neurosurgeon,
Lars Leksell in Lund, inventor of stereotactic
instruments nowused world-wide, participated in
the development of functional radiosurgery using
protons and the radiation oncologist, Sten Graff
man, for proton irradiation of tumors in the 60's .
This modified research program ended with two
new clinical applications : stereotactic functional
radiosurgery of the brain [11] and fractionated
proton therapy for large tumors with the spread-
out Bragg peak [12] . Larsson, Graffmän, and
their associates also developed innovative tech-
niques for large field radiotherapy and treated
about 60 patients [12] . They demonstrated that
almost any volume in the body can be selectively
and uniformly irradiated using proton beams.
Cambridge and Boston
Dr. William Sweet, chief of the neurosurgical ser-
vice at Massachusetts General Hospital, became
quite interested in the studies being carried out at
Berkeley andUppsala. He decided to investigate
the possibility of doing such work himself or with
his colleagues . Dr. Sweet helped to arrange to
send Dr. RayKjellberg, then a junior-member of
the neurosurgery staff to Berkeley and Sweden,
to observe the proton beammork . Dr. Sweet per-
suaded the Harvard cyclotron group, headed by
Dr. Preston at that time, to work with them .
Koehler and his associates of the Harvard cyclo-
tron group developed precise techniques to do
hypophysectomy using the Bragg peak . The
Berkeley group at that time was doing hypophy-
sectomy mostly by using the cross-fire technique
rather than the Bragg peak. The uniqueness of
the Harvard cyclotron program is that since the
early 60's the cyclotron operation, including the
staff salaries, was completely supported by the
modest income generated from patient treat-
ments and it is still functioning that way today.
The Harvard cyclotron, under the leadership of
Mr. Andrew Koehler, developed numerous tech-
niques appropriate for various medical applica-
tions. Kjellberg, in collaboration with the Har-
vard cyclotron group, also developed techniques
to treat arteriovenous malformations with pro-
tons [13] . His work used the technique developed
Russia
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by Leksell and his associates, who in turn used
the gamma knife developed for Leksell by Lars-
son and his associates .
A turning point in proton radiotherapy took
place during the early 1970's . Dr. Ian Constable,
an ophthalmologic surgeon from Australia,
joined the MassachusettsEye and Ear Infirmary,
next door to Massachusetts General Hospital,
and he started working with Koehler and his
associates in 1972 . They conducted animal experi-
ments using monkeys to determine normal tissue
tolerance levels . They also worked out proce-
dures to make the technique suitable for more
localized intraocular lesions such as malignant
melanoma, which Constable saw as more impor-
tant clinically [14] . The wisdom of this choice has
been supported by its wide acceptance and im-
pressive clinical results [15] . Thesuccessful results
in treating uveal melanoma led to the use of
proton beams from the cyclotrons as.generators
for neutron and pion radiotherapy.
Suit, Goitein andtheir associates, in collabora-
tion with Koehler, initiated fractionated radio-
therapy using large fields of protons. Goitein and
his associates developed three-dimensional treat-
ment planning techniques [16, 17] . The spectacu-
lar clinical results for boney and cartilaginous
tumors of the skull base and cervical spine also
aroused international interest in proton radio-
therapy [18, 19] .
The use of proton beams in radiotherapy and
radiosurgery in the former USSR has an interest-
ing beginning and a long history. It started from
an illness due .to cancer of the esophagus of Aca-
demician Pomeranchuk. When he was irradiated
with X-rays in the Oncological Centre in Moscow,
without a mention of his own disease, he asked
why protons are not used for radiotherapy. W11-
son's paper was not known to either Pomeran-
chuk or to the others there. Pomeranchuk died,
but his illness wasinstrumental in developing pro-
ton radiotherapy in Russia .
During the mid-to-late 60's, in collaboration
with high-energy physicists, Prof. Ruderman
initiated an ambitious proton therapy program at
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Dubna and Moscow. The Uppsala group, headed
by Larsson, helped the development of proton
therapy in the former Soviet Union starting in
1969 . A Proton radiosurgery program was initi-
ated at the Gatchina proton accelerator facility by
Konnov and his associates in 1975 . The Russian
group has treated about 3600 patients, approx .
25 % of the total number of patients treated with
protons in the world (see Chapter 12 for details) .
The Soviet physicists, oncologists, and neurosur-
geons should be congratulated because, in spite
of the difficult political situation in the USSR,
they held the first international seminar on Dec.
6-11, 1977, on the uses of proton beams in radia-
tion therapy. Another international working
meeting on proton therapy was organized by the
Central Research Roentgen-Radiological Insti-
tute andwas held in Leningrad on October 14-18,
1986 .
The particle therapy groups of the world can
take pride for their success in international col-
laboration during the cold war years. During the
last five years, the interaction of Russian col-
leagues with European and American scientists
has become a common occurrence .
Japan
The development of particle therapy also has a
long history in Japan, and there has been US-
Japan cooperation in these efforts . Neutron ther-
apy has been carried out in Tokyo and Chiba,
Japan since the early 70's . Proton therapy in
Japan was initiated in 1979 at the National Insti-
tute of Radiological Sciences (NIRS) in Chiba,
using a 70 MeV proton beam, and also begun in
1983 at the Particle Radiation Medical Science
Center (now Proton Medical Research Center,
PMRC) of the University of Tsukuba using a ver-
tical beam of 250 MeVprotons . The Chiba group
pioneered the development of a three-
dimensional, spot-beam scanning technique to
reduce the dose outside the treatment volume
considerably [20] .
The Tsukuba group concentrated on treating
common tumors such as lung-mediastinum, eso-
phagus, digestive tract, gynecological, genito-
urinary organs . They have also developed an
innovative technique to compensate for inhomo-
geneity problems in the treatment of lung tumors
by using a respiration-gated irradiation system
(cf. [21] and Chapter 32).
Current Status of Protons in
Radiosurgery and Radiotherapy
Pituitary Treatments
Although the initial efforts in Berkeley and Har-
vard were primarily focussed on pituitary sup-
pression/ablation for treating patients with mam-
mary carcinoma, these treatments are not com-
mon anymore in the Western countries . With the
increasing availability of gammaknives and linear
accelerators modified for stereotactic procedures,
and the development of new methods to select
hormone-dependent mammary tumors protons
are less commonly used today. With the recent
developments in imaging technology such as MRI
and CT, it is now possible to localize accurately
most microadenomas . With this ability and the
concurrent development of modern transphenoi-
dal surgical techniques, surgical procedures are
increasingly used for pituitary suppression/abla-
tion because of their immediate beneficial effect
without the delay in suppression of pituitary
hypersecretion that is normally experienced after
radiation treatment .
The data obtained with protons and helium
ions, however, are still of value for the use of
gamma knives and linear accelerators . Currently,
pituitary treatments are being routinely carried
out using protons in Russia .
Arteriovenous Malformations
The treatment of arteriovenous malformations
using protons is being continued at the Harvard
cyclotron, and in Russia . With the shutdown of
the ion beam facilities in Berkeley, the associates
of late Fabrikant are continuing to treat arterio-
venous malformations at Loma Linda. Gamma
knives and linear accelerators modified for use of
stereotactic radiosurgery are currently being
increasingly used for AVM treatments . While
small size AVMs, with diameters less than around
3 cm can be treated as effectively by these devices
as with protons, protons continue to have an
important role in treating larger AVMs .
Uveal Melanoma
The proton therapy for treating uveal melanomas
was the treatment of choice and is pursued at
many of the centers around the world that have
proton beams . Char and his associates compared
helium ions with brachytherapy using I-125 . The
helium ion results have been found to be superior
[22] .
Large Field Radiotherapy
The Harvard group has made a concentrated
effort to treat sarcomas of the skull base/cervical
spine by taking full advantage of the dose local-
ization characteristics of protons. Immediately
adjacent, radiosensitive, critical normal struc-
tures, such as brain, brain stem, cranial nerves,
etc., normally restrict the dose that can be deliv-
ered to the tumor using conventional radiations .
The resulting control rate was estimated to be
about 35 % . The five year actuarial control rate
after proton treatment was found to be 94% for
chondrosarcoma patients and 63 % for chordoma
patients [23] . This substantial gain in the results
strongly suggests that post-operative proton ther-
apy is the treatment of choice for these tumors .
Nearly 100% local control rates were observed
after treatment with protons in several small
groups of patients with inoperable meningioma,
craniopharyngioma, rectal carcinoma, and soft
tissue sarcoma [19] . The results from the group in
Tsukuba, Japan are also found to be favorable in
treating some of the common tumors [21] .
The impressive clinical results obtained with
protons in some of the well investigated tumor
sites, led to the development of medically dedi-
cated proton therapy facilities . One such facility,
which is equipped with three gantries to allow
convenient treatment with a high patient turn-
over, was built and is now in operation at Loma
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Linda, California . Another such facility is in the
initial stages of design at Massachusetts General
Hospital, Boston, and there are plans for many
more (cf . succeeding chapters) .
Heavy Ions
Dr. Tobias was primarily instrumental in initiating
the heavy ion therapy program at Berkeley. His
interest in heavy ions dates back to his graduate
student days at Berkeley. His thesis in 1942 was
entitled "High Energy Carbon Particles" . Zirkle
had already demonstrated in 1935, the big effects
of alpha particles from polonium [24] and, subse-
quently, those with fast neutrons . The radiobio-
logical studies of low-energy heavy ions provided
the rationale for the use of heavy ions in radio-
therapy. Since the protons did not produce bio-
logical effects much different from X-rays, it was
then thought that heavy ions had all the advan-
tages of protons and, in addition, they also had a
high-LET effect . This prejudice, combined with
the fact that the physicists decided to raise the
proton energy to 730 MeV with no possibility of
getting a lower-energy proton beam, explains why
Tobias and his associates at Berkeley deviated
from protons . Heavy ions with ranges adequate
for radiotherapy were not available until 1974,
when the two existing accelerators at Lawrence
Berkeley Laboratory, the heavy ion linear accel-
erator (HILAC) and the Bevatron were modified
and connected together in order to accelerate
heavy ions to energies suitable for heavy ion ra-
diotherapy. This combined facility was known as
Bevalacand it was the only biomedical, heavy-ion
facility in the world until its eventual shutdown at
the end of 1992 .
After extensive radiobiological studies using
helium ions at the 184-inch cyclotron and heavier
ions at the Bevalac, a collaborative clinical study
under the leadership of Dr. Joseph R. Castro, was
undertaken by the University of California, San
Francisco Medical Center (UCSF) and Lawrence
Berkeley Laboratory (LBL) . Helium ions and
neon ions were selected as ions to be tested .
Helium ions were used mostly for dose localiza-
tion characteristics similar to protons and neon
ions for both the physical and possible biological
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advantages of high-LET. After shutdown of the
184-inch cyclotron in 1987, the work with helium
ions was shifted to the Bevalac.
The clinical results with helium ions in treating
sarcomas at the skull base and uveal melanomas
were impressive and consistent with proton
results. Thephase I-II clinical trial with neon ions
suggested improved results for several types of
tumors : advanced and recurrent microscopic
salivary gland carcinomas, paranasal sinus
tumors, advanced soft tissue sarcomas, micro-
scopic sarcomas of bone, locally advanced pros-
tatic and bilary tract carcinomas [25] . These
results are consistent with the notion developed
earlier from fast neutron radiotherapy experience
that slowly growing tumors may be effectively
treated with high-LET particles .
The Bevalac was prematurely shut down. It is
ironic that there is no particle therapy facility left
in Berkeley, the very birth place of particle ther-
apy. The confirmation of these favorable heavy
ion clinical results has to come from heavy ion
facilities that are built in Darmstadt, Germany
and Chiba, Japan (see Chapters 34 and 36) .
Recent developments in sophisticated imaging
techniques have helped to make use of the excel-
lent dose distributions of heavy charged particles.
Because of the biological complexities of tumors
and their variations, the optimum utilization of
high-LET beams requires considerable research
effort in developing methods to identify tumors
that have a better prognosis for high LET The
clinical experience with fast neutrons is relevant
to heavy ions with regard to the potential applica-
tions of high-LET radiations . In principle, for the
tumors that are found to be better treated with
fast neutrons as compared to conventional radi-
ations, heavy ions should be even better than fast
neutrons because of their good localization char-
acteristics . An international and cooperative
effort is required to find the appropriate role for
heavy ions in radiotherapy.
Acknowledgement
I would like to thank Dr. GeorgeA. Baker, Jr. for
his suggestions to improve the manuscript .
References
1 Raju, M.R . Heavy Particle Radiotherapy. Academic
Press, NewYork, 1980.
2 Fowler, J.E Nuclear particles in cancer treatment.
Med. Phys . Handbooks 8, Adam Hilger Ltd, Bristol,
1981 .
3 Wilson, R.R . Radiological use of fast protons. Radi-
ology 47, 487-491, 1946 .
4 Tobias, C.A., Anger, H.O., and Lawrence, J.H . Ra-
diological use of high energy deuterons and alpha par-
ticles . Am . J. Roentgenol . Radiat . Ther. Nucl . Med.
67, 1-27, 1952 .
5 Luft, R. and Olivecrona, H. Experiences with hypo-
physectomy in man. J. Neurosurg. 10, 301-316, 1953 .
6 Lacassagne, A. and Nyka,W Sur les processus histolo-
giques de la d¬struction de 1'hypophyse par le radon.
Comptes Rendus Soc. Biol . 117, 956-958, 1934 .
7 Lawrence, J.H ., Nelson, WO., and Wilson, H. Roent-
gen irradiation of hypophysis . Radiology 29, 446-454,
1937 .
8 Tobias, C.A., Van Dyke, D.C ., Simpson, M.E.,
Anger, H.O ., Huff, R.L., and Koneff, A.A . Irradi-
ation ofthe pituitary of the rat with high energy deute-
rons . Am. J. Roentgenol . Radiat . Ther. Nucl . Med.
72, 1-21, 1954.
9 Lawrence, J.H . Proton irradiation of the pituitary.
Cancer 10, 795-798, 1957 .
10 Levy, R.O., Fabrikant, J.I ., Frankel, K.A., Phillips,
M.H ., and Lyman, J.T. Charged particle radiosurgery
of the brain. Neurosurg. Clin . N. Am. 1, 955-990,
1990 .
11 Larsson, B., Leksell, L., and Rexed, B. The use of
high energy protons for cerebral surgery in man. Acta .
Chir. Scand. 125, 1-7, 1963 .
12 Graffman, S., Brahme, A., and Larsson, B . Proton
radiotherapy with Uppsala cyclotron. Experience and
plans. Strahlentherapie 161, 764-770, 1985 .
13 Kjellberg, R.N . Proton beam therapy for arteriove-
nous malformations of the brain, in Operative Neuro-
surgical Techniques, Vol. 1. Schmidek,H . and Sweet,
W (eds .), Grune and Stratton, New York, 1988, pp .
911-915.
14 Constable, I.J ., Goitein, M., Koehler, A M., and
Schmidt, R.A . Small field irradiation of monkey eyes
with protons and photons . Radiat . Res. 65, 304-314,
1976.
15 Gragoudas, E.S ., Goitein, M., Koehler, A.M.,
Verhey, L., Tepper, J., Suit, H., Brockhurst, R., and
Constable, I.J . Proton irradiation of small choroidal
malignant melanomas. Am. J. Ophthahhol . 83,
665-673,1977 .
16 Goitein, M. and Abrams, M. Multi-dimensional treat-
ment planning : 1 . Delineation of anatomy. Int. J.
Radiat . Oncol. Biol . Phys . 9, 777-787, 1983 .
17 Goitein, M., Abrams, M., Rowell,D., Pollari, H., and
Wiles, J. Multi-dimensional treatment planning: II .
Beam's eye-view, back projection through CT sections .
Int . J. Radiat . Oncol. Biol . Phys . 9, 789-797, 1983 .
1 The History of Ion Beam Therapy 9
18 Suit, H. Potential for proton beams in clinical radia- 22 Char, D.H., Quivey, J.M., Castro, J.R ., Kroll, S ., and
tion oncology, in Proc. of 9th ICRR Meeting, Toronto Phillips, T Helium ions versus I-125 brachytherapy in
2, 3-13, 1992 . the management of uveal melanoma : A prospective,
19 Suit, H. and Urie, M. Proton beams in radiation ther- randomized, dynamically balanced trial ., J . Ophthal-
apy. J . Natl . Cancer. Inst . 84, 155-164, 1992 . mol. 100, 1547-1554, 1993 .
20 Kanai, T, Kawachi, K., Matsuzawa, H., and Inada, S. 23 Goitein, M. Personal communication, 1994 .
Three dimensional beam scanning for proton therapy. 24 Zirkle, R.E . Biological effectiveness of alpha particles
Nucl . Instr. Meth . 214, 491-496, 1983 . as a function of ion concentration produced in their
21 Mujii, H., Muji, H., Inada, T, Maruhashi, A., Haya- paths. Am. J. Cancer 23, 558-567, 1935.
kawa, Y, Takada, Y, Tada, J., Fukomoto, S., Tat- 25 Castro, J.R . Heavy ion therapy : The Bevalac Epoch, in
suzaki, H., Ohara, K., and Kitagawa, T Clinical Hadrontherapy in Oncology, Amaldi,U. and Larsson, B .
results of fractionated proton therapy. Int. J. Radiat . (eds .), Proc. Int. Symp . Hadrontherapy, Como, Oct
Oncol. Biol . Phys . 25, 49-60, 1992. 18-21, 1993, Elsevier, Amsterdam, 1994, pp . 208-216.
The Role of Ion Beam Therapy
in Cancer Management
Introduction
J . DEBUs and M . WANNENMACHER
Department of Radiotherapy, Rupprecht-Karls-Universität Heidelberg, Germany
Over the last decades advances in the field of
radiation oncology have improved the cure rates
for patients with various malignancies . Clinical
results of surgery alone or combined with photon
radiation therapy are improving for cancers of
many sites . Nevertheless, there are still about
30 % of all cancer patients with localized disease
where failure in the treatment of the primary
tumor factually means death for the patient.
Improving the local control rate of these cases by
50% would improve the overall survival rates of
cancer patients by 10-15% [1]. Ion beam radio-
therapy may be one tool to help achieve this goal .
Since 1957 more than 16000 patients have
been treated with ion beam radiotherapy [2]. Pro-
tons and helium ions, in particular, were investi-
gated because of their improved dose distribu-
tion . This has translated into superior clinical
results for several tumor sites in comparison to
conventional radiotherapy with photons or elec-
trons. Heavier ions gained additional interest,
because of their experimentally and clinically
demonstrated increased biological effectiveness.
Conformal Radiotherapy and the Risk
of Treatment-Related Complications
The radiation tolerance of most organs depends
on the volume of normal tissue treated [3] . Con-
formal irradiation techniques which restrict the
treatment volume to the actual target volume
reduce the probability for normal tissue complica-
tions. Depending on the total dose and the frac-
tionation pattern prescribed, these techniques
might also prompt better tumor control.
There are two categories of treatment-related
morbidities due to radiation therapy: the acute
and subacute radiation reactions on one hand,
and so-called late delayed radiation reactions, on
the other hand . While acute radiation reactions
(e.g ., hair loss) occur within days or weeks after
radiotherapy, late radiation effects (e.g ., brain
necrosis) may appear years later. The natural his-
tory of acute and subacute reactions is often self-
limiting, whereas late radiation reactions tend to
be progressive and possibly manifest as unin-
tended severe treatment complications . The aim
of treatment planning is to minimize such side
effects.
As irradiation-related morbidity often devel-
ops in non-target tissues, it can be assumed that a
dose distribution which spares normal tissue leads
to less frequent and less severe treatment-related
morbidities and complications .
It is obvious that the overall treated volume must
not be smaller than the size of the medically
required target volume . Defining the proper plan-
ning target volume is, therefore, a crucial step in
the treatment preparation and determines the
potential clinical benefit of conformal therapy.
Figure 1 illustrates schematically the differ-
ence between conventional and conformal radia-
tion therapy. Clearly, conformal techniques can
reduce the volume exposed to significant dose
levels and spare organs at risk . But it has to be
kept in mind that organs at risk which are part of
the planning target volume may not be spared
because of the risk of local relapse . Thetreatment
conventional technique
irradiated volume
Fig . 1 . Comparison between conventional and conformal
technique with different radiotherapeutical volumes accord-
ing to ICRU 50 . While the organ at risk 2 can be completely
of carcinoma of the prostate stands for such a
problem . As the anterior rectal wall is part of the
target volume, radiation induced morbidity of the
anterior rectal wall is generally put up with .
Enhanced Radiobiological
Effectiveness
The radiobiological effectiveness of proton beams
is nearly equal to conventional high voltage pho-
ton radiotherapy. Hence, both are comparable
from the radiobiological point of view. Fast neu-
trons and heavy ions (e.g ., carbon and neon)
which are examples for high-LET radiation, ex-
hibit an increased relative biological effectiveness
(RBE) or a higher cell killing efficiency which is
less dependent on oxygen saturation or the
mitotic age of the cells (see subsequent chapter
for details) .
From early fast neutron radiotherapy it is
known that high-LET radiation may improve
local control [4] in selected indications (Tab . 1) .
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clinical target volume
planning target volume
brgan at risk 2 -
irradiated volume treated volume
spared by conformal techniques the organ at risk 1 is part of
the planning target volume and may therefore only partially
be spared
Table 1 . Advantage of high-LET neutron therapy over con-
ventional photon/electron radiotherapy 141
Patients to Profit
from Precise Dose Localization
Technically, tumor conform treatment requires an
accurate definition of the whole target volume,
i .e ., the outline of the target volume based on
three-dimensional image information and the
clinical knowledge of the microscopic tumor
growth . Modern three-dimensional treatment
planning is, therefore, a prerequisite of successful
conformal treatment [5] . Defining the proper tar-
get volume is an essential step in the whole radio-
therapeutical treatment . If it is too large, the risk
of radiation morbidity increases and/or the total
deliverable dose might not be sufficient for tumor
control . Smaller target volumes bear the risk of
Site/Histology Number of Significance
patients
Salivary gland 150 ++++
Prostate cancer 285 +++
Bone sarcomas 105 ++
Soft tisse sarcomas 540 ++
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higher failure rates, because parts of the tumor
margin might be excluded from the target vol-
ume. Despite a successive reduction of treatment
volumes since the introduction of simulators, CT
and MRI-based treatment planning, local control
rates have increased. But this is possibly due to
the fact that up to now treatment volume con-
tours have largely been defined by structures
which are unambiguously non-target .
In general, patients will very likely profit from
target volume conform irradiation and sparing of
non-target tissues, if
- acute morbidity due to irradiation of non-
target tissues is high, as, e.g ., in prostate carci-
noma, where radiation-induced rectal mucosi-
tis can be dose limiting,
- the cure rate is high but associated with signifi-
cant radiation-induced morbidity as in the
treatment of childhood cancer,
- the dose prescribed is limited by the late radia-
tion morbidity of unnecessarily treated non-
target tissue, as in the case of benign skull base
tumors, where the tolerance of the adjacent
brain structures is dose limiting,
- organs at risk have lowered tolerance due to
previous radiotherapy, as, e.g ., in the treat-
ment of a local relapse or a secondary neopla-
sia years after the initial treatment.
It can be assumed that target conform treat-
ment by ion beam therapy will increase the num-
ber of patients with complication-free local cure .
For certain lesions, surgery might even be
replaced or at least the scope of surgery reduced .
It has been shown that stereotactic single high
dose irradiation (radiosurgery) of brain metasta-
ses can achieve similar tumor control rates as neu-
rosurgical intervention with fewer cases of
treatment-related morbidity [6] .
A comparison of radiosurgery and conven-
tional whole brain irradiation of solitary brain
metastases revealed that radiosurgery could con-
trol 90 % of the metastases locally. With conven-
tional whole brain irradiation the corresponding
value was only 45 % . This example illustrates how
tumor control can be improved by dose escalation
in selected clinical situations after conforming the
treatment volume to the target volume .
Presently and in the near future, conformal
radiotherapy with ions will only be available to a
very limited extent . Patients suitable for ion
beam therapy, need, therefore, carefully be strati-
fied according to the expected benefit. A system
has recently been proposed by Drumm [7] . It sug-
gests to favor patients who are likely to experi-
ence significant radiation morbidity after conven-
tional treatment, due to unintended irradiation of
non-target tissue outside the target volume . A
second criterion is a high likelihood to improve
the tumor control by dose escalation, and finally
it should be evaluated, if modern photon treat-
ment techniques combined with sophisticated
treatment planning could achieve the required
dose distribution at lower cost than ion beam
therapy. Patients who meet the two former crite-
ria and for whom the latter question can be an-
swered with "no" are considered first priority.
There are a number of indications where the
treatment of the disease is associated with the
unintended but currently unavoidable irradiation
of non-target tissue, e.g ., mantle field irradiation
in patients with Hodgkin's disease . They are
always exposed to a currently unavoidable irradi-
ation of the lung which is a non-target tissue in
early stage Hodgkin's disease, and the patients
may suffer from radiation-induced pneumonitis.
Currently, there are no techniques routinely
available to solve this problem . Ion beams have
the potential to spare such sensitive structures, at
least in part .
The greatest benefit from ion beam therapy
can probably be expected for the treatment of
tumors located directly adjacent to an organ at
risk . Chordomas of the clivus would be an
extreme example, with the brain stem, the optic
chiasm and the pituitary gland surrouding the tar-
get.
In randomized trials, it could be demonstrated
that ion beam therapy of Chordomas and chon-
drosarcomas of the spine and skull is superior to
conventional radiotherapy (see Section III for
details) . Patients with constitutionally reduced
radiotolerance, including young children with
brain tumors may also profit considerably from
ion beam treatment [8] .
Patients to Profit from
Increased Biological Effectiveness
For salivary gland tumors, prostate cancer, and
certain sarcomas (see Tab. 1) survival and tumor
control could be considerably improved with
high-LET radiotherapy [4] . The late radiation
effects observed with neutrons, however, are
mostly attributed to the poor dose distribution of
this kind of high-LET radiation from former neu-
tron generators . They should be avoidable with
heavy ions, which combine the radiobiological
advantage of high-LET radiation with the ideal
physical characteristics of fast protons . Patients
with tumors that respond to high-LET radiation
next to organs at risk should, therefore, benefit
most from heavy ion beam therapy (head and
neck tumors, rectum, retroperitoneal tumors).
A recent detailed study on the clinical rel-
evance of heavy ion therapy concluded that
approximately one third of all patients with local-
ized tumors could, in principle, benefit from
heavy ion radiation [7]. The selection was based
on the following clinical criteria :
Fig . 2 . The pyramid with the distribution of patients to dif-
ferent kinds of beam quality is based on socioeconomical
data from [7] . It is assumed that there is only limited avail-
ability of ion beam therapy. The patients were stratified
according to the expected benefit from improved dose dis-
tribution of ion beam therapy (I, II) or improved biological
effectiveness due to high-LET effect (I, III) or the combination
of both by heavy ion beam therapy (I)
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- strictly locoregional tumor growth,
- tumors with no or low tendency to metastasize,
- cure rates either low or side effects with con-
ventional therapy inacceptably high,
- patients young to middle-aged.
The study also considered the fact that heavy
ion beam therapy is still not very widely available.
Therefore, the author attempted a ranking of
indications to select those patients for whom
there is really no satisfactory alternative . It was
concluded that the absolute minimum of patients
with localized tumors who would require heavy
ion therapy is 4% (see Fig. 2) . Even this very nar-
row indication spectrum translates into approx .
11000 patients per year within the European
Community and would require at least 4-5 heavy
ion facilities .
Summary
The treatment of more than 16000 patients has
demonstrated that ion beam application is feasi-
ble in clinical routine . Recent cost estimates,
assuming very conservative numbers come to the
conclusion that the capital cost of a proton facility
is at least comparable to that of photon facilities
of similar clinical capacity [7, 9] . If one further
considers that higher cure rates produce less
follow-up costs and bring more patients back into
the work process, ion beam therapy becomes
even more competitive .
The clinical data of proton and heavy ion treat-
ment have confirmed the theoretical considera-
tions regarding higher tumor control probability,
less side effects and higher survival rates in a
number of benign and malignant lesions, even
though most have been obtained under subopti-
mal conditions as far as accelerator technology,
beam delivery and treatment planning are con-
cerned .
In the future, much more attention needs to be
payed to a careful patient selection . The treat-
ment plan should indicate that the equivalent ion
dose in the target can be at least 10 °lo higher than
in the reference treatment and the dose to the
organs at risk be lowered as compared to the cur-
rently available best possible photon technique .
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The reference treatment should yield tumor con-
trol probabilities below 60% and be associated
with a significant level of radiation-related mor-
bidity due to non-target tissue exposure . If
patient selection will follow these rules, one has a
good chance to verify, where ions offer an actual
advantage in local control or treatment-related
morbidity.
Clinical studies with ion beams have been sug-
gested for a number of malignancies, including
carcinomas of the head and neck, prostate, uter-
us, rectum, soft tisse sarcomas, gliomas, meningi-
omas, retroperitoneal and pediatric tumors .
International participation in clinical studies is
now necessary to investigate the effectiveness of
protons and heavier ions in Phase III studies .
Many more years are necessary until a compre-
hensive final judgement on the value of ion
beams seems reasonable, not only because of the
still limited number of clinical facilities and the
long time periods needed for follow-up and
detailed evaluation of a curative treatment, but
also, because further diagnostic progress, ad-
vances in 3D-treatment planning, and new ways
to compensate patient and target motion are
being awaited. Improvements in these fields will
also be responsible, at least in part, for the suc-
cess of ion beam therapy.
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3Introduction
Physical and Biological Rationale
for Using Ions in Therapy
U. LINZ
Forschungszentrum Jülich (KFA) GmbH, Jülich, Germany
Since the beginning of clinical radiotherapy
approximately 100 years ago, it has been the goal
of radiation oncologists to restrict the irradiated
volume to the site and shape of the target vol-
ume. With ion beams it is nowpossible to get very
close to this goal (Fig . 1) .
X rays (B)`
tumor
liver
kidney
bone
marrow
Fig . 1 . Ideal vs . real radiotherapy : A) radiotherapeutically
ideal situation : the full dose (100%) is given to the tumor plus
a small safety margin, while non-target structures receive no
The fact, that ions of appropriate energy are
suitable to irradiate a tumor at any depth of the
body with a minimum dose to the surrounding
healthy tissues is the strongest argument to con-
sider protons and other accelerated ions for radio-
therapy. This is achievable, because the penetra-
tion depth of ions can be taylored precisely by
their initial energy and can be made to coincide
with the location of the tumor to be treated. In
protons (C)
dose, B) depth-dose profile of megavoltage X-rays, C) depth-
dose profile of a spread-out proton beam, D) depth-dose pro-
files of A, B, and C along the central beam axis
150
d2 125
; 100
tumor ö 75
liver 50
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marrow
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addition, the so-called Bragg peak effect prompts
damage mainly at the end of the ions' range inside
the tumor and keeps the radiation burden on the
healthy tissue of the entrance channel low. Due to
the finite path of ions, it is possible to limit the
range of the radiation field to the distal part of the
tumor and to spare the structures beyond from
any radiation exposure .
In addition to a more favorable axis depth-
dose distribution, another important feature
distinguishes ions favorably from the conven-
tional therapeutic radiations (photons and elec-
trons) : it is the lateral scattering of ions, which is
negligible and leaves an incident beam greatly
unchanged in size and shape when it penetrates
the body.
The physical rationale to use protons and
heavier ions in radiotherapy was conceived
already nearly 50 years ago. In 1946, the Harvard
physicist Robert R. Wilson published his pioneer-
ing paper on the radiological use of fast protons
to "acquaint medical and biological workers"
with some of the physical properties and possibil-
ities of ions [1] . Since then, many others have
reviewed the properties of ions that give reason
for their clinical application (e.g ., [2-4]) .
Interaction of Photons and
Charged Particles with Matter
When photons such as X- or gamma rays strike
condensed matter, they release electrons from the
atoms they interact with . The processes by which
their energy is transferred to the medium are sto-
chastic events, such as inelastic (Compton) scat-
tering, photoelectric processes and - at higher
energies - pair production . Due to the statistical
nature of the absorption process and the fact that
photons are strongly deflected (scattered) during
their interactions with atoms, a photon beam
entering condensed matter spreads rapidly and
has no defined range. The respective axis depth-
dose curve of a photon beam reveals an initial
build-up domain, followed by a region of expo-
nentially decreasing dose (Fig . 2) .
In contrast to the indirectly ionizing electro-
magnetic radiation, all charged particles are
0.5
0.0
n (p(66)/Be) \e (E = 425 MeV/u'
. . . . . . . . e (E = 22 MeV) --- rr (E = 86 MeV)
-- y (E = 24 MeV) -p (E = 200 MeV)
0 5 10 15 20 25 30
range in water (cm)
Fig . 2 . Depth-dose distributions of various kinds of radia-
tion in water
directly ionizing and all exhibit a finite, energy-
dependent range.
Due to their low mass, accelerated electrons
reach rapidly high velocities close to the speed of
light (at energies > 1 MeV) . Passing through mat-
ter, they, therefore, deposit a relatively constant
energy dose per unit length for a good part of
their range. Their penetration depth, however, is
rather short (range R [g/cmZ]= 0 .57 E, nax [MeV]-
0 .16, for E,n,,x > 1 MeV), as their low mass makes
them also subject to strong lateral scattering . The
low-intensity tail at the end of the depth-dose
curves of high-energy electron beams (Fig . 2) is
due to bremsstrahlung photons which are pro-
duced as a by-product of the stopping process of
the electrons .
The depth-dose curve of protons and all heav-
ier ions show a slow initial increase and a steep
rise and fall towards the end of the range (Fig . 2) .
As a consequence of their much higher mass they
experience significantly less lateral scattering
than electrons.
The interaction of accelerated atomic nuclei
with matter is predominantly an interaction with
the target electrons (Coulomb interaction) .
Quantitatively, the energy loss of heavy charged
particles is described by the Bethe-Bloch equa-
tion
dx -	ß
[In
\~1ßzßI/ _ßa~
where K is a constant, no the electron density
of the target material, Zeff the effective charge of
the projectile ions, ß the velocity of the projectile
in units of the speed of light ((3 =%), I the mean
ionization energy of the target atoms and me the
mass of the electron .
With decreasing velocity the energy deposition
increases . At the same time, the projectile scav-
enges electrons, thus reducing its effective
charge, Zeff . Together, both effects produce the
sharp rise and fall -the Bragg peak -at the end of
the particle track.
Most particles travel the same distance in a
monoenergetic proton beam. Loss of particles
due to nuclear interactions is low. But not all par-
ticles experience the same number of collisions .
Their range is, therefore, somewhat different .
This phenomenon is called straggling . In tissue
the difference is of the order of 1% of the mean
range [5] . For heavier ions, range straggling
varies approximately inversely to the square-root
of the particle mass. This means, helium ions
show only 50 % and carbon only 30 % of the
straggle of protons.
As the mass of an ion is at least 2000 times (for
protons) higher than the mass of an electron, the
projectile ions are barely deflected from their
initial path during collisions with electrons . Still,
multiple deflections cause lateral spreading and
lead to divergence of the beam. For large parallel
beams this affects only the outer edges which
E
c
0
Ü
äm
4 8 12 16 20 24 28 32 36
range In water (0m)
Fig. 3. Lateral beam deflection as function of penetration
depth. Data from M. Phillips, LBL
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tend to get a little diffuse. The central axis
remains unaffected, because the number of par-
ticles scattering out are compensated for by
others scattering in . When applying narrow
beams, however, the central dose decreases with
depth, as particles scattering out are no longer
compensated for.
The transverse spread of an infinitely narrow
starting beam amounts to approximately 5% of
its initial range [1]. Just as for range straggling,
the deflection from the incident beam direction
by multiple scattering (angular deflection) de-
creases with increasing charge and mass. Figure 3
illustrates this correlation graphically for several
ions . For helium ions the effect is approximately a
factor of two, for carbon a factor of four lower
than for protons [5].
Tumor Conform Treatment
The narrow Braggpeak of amonoenergetic beam
which is only a few millimeters wide, is exploited
in specific radiosurgery procedures ([6-7], cf. as
well Chapter 16) . For most practical irradiations,
however, it is necessary to spread out the radia-
tion field laterally and in depth to cover a larger
target area (Fig . 1) . Up to now, this has been
done by passive beam shaping devices, such as
scattering foils and energy modulating absorber
media which broaden the beam profile trans-
versely and extend the Bragg-peak dose from the
distal to the proximal end of the target volume,
respectively (for review cf . [8]) .
The charge of the ions provides another means
to tailor the irradiated volume very precisely to
the shape of the tumor. By deflecting a pencil-
thin ion beam magnetically in horizontal and
vertical directions, a tumor slice of the approxi-
mate width of the Bragg peak (- 5 mm) can be
irradiated point by point (Fig . 4) . By reducing the
energy stepwise and repeating the irradiation for
each slice, a tumor of any arbitrary shape can be
successively irradiated from its most distal to the
most proximal part . This unique irradiation tech-
nique, which is only possible with protons and
heavier ions, permits the ultimate in tumor con-
form radiotherapy, minimizing the radiation bur-
den on healthy tissues. In addition, it facilitates
1 8
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slice B
Linear Energy Transfer (LET)
slice A
Fig . 4. Schematic view of scanning technique . Individual
slices of approx . 5 mm (= Bragg peak width) are irradiated
starting from the most distal part of the tumor and gradually
moving forward . Within a slice the magnetically controlled
ion beam is moved line-wise or from spot to spot to cover
the desired target shape . The fact that proximal layers
receive some dose (indicated by the dark central spot of slice
B) when more distal layers (A) are treated has to be taken
into consideration by appropriately designing the irradiation
protocol (e .g ., give higher dose to the lighter margin of slice
B than to the preirradiated central spot)
the application of individualized treatments with
local boosts or other desired non-homogeneous
dose distributions. It can be applied to increase
the dose in the tumor (as compared to photon
irradiation) without increasing the dose in the
entrance channel or to reduce unwanted radiation
in the beam entrance without changing the tumor
dose . Even though this irradiation mode has not
yet been achieved clinically, several groups are
working on its realization (cf . Chapters 35 and 36
for more details) .
The energy loss per unit length or LEThas long
been viewed as amajor parameter to describe the
qualitative differences of the biological effects of
various kinds of radiation [9]. Numerically, the
LETis identical with the stopping power of a par-
ticle for which all secondary electron energies are
considered .
LET- usually expressed in keV/[,m - is not a
constant value. As charge and energy of a projec-
tile ion change along the particle's path, the LET
value changes, as well . The depth dependence of
the LET displays the characteristic Bragg maxi-
mum. The maximum LETvalue of electrons
amounts to approximately 30 keV/[tm. For pro-
tons, the corresponding value is roughly 100 keV/
Rm and for heavier ions it might be well over 1000
keV/[,m.
It is the increase in stopping power of acceler-
ated ions towards the end of their tracks which
leads to more biological damage or an increase in
RBE at the site of the Bragg peak. In general, the
RBE rises with increasing LETup to approx . 100
keV/R.m and decreases at higher LETvalues [24,
25].
Even though more recent systematic experi-
ments have shown that the LET is not a good
parameter to describe the full spectrum of biolog-
ical radiation effects [9, 22, 23], it is still a widely
used parameter to categorize ion-induced damage .
The limitations of LET become particularly
prominent, when ions of different atomic number
are compared [22, 26] . In this case, different
biological responses can be observed for particles
of the same LET(Fig . 5) . This is explained by the
3
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103
Fig . 5 . Relative biological effectiveness (RBE) of ion beams as
a function of linear energy transfer (LET) . The compilation of
data for a number of cell types shows that there is a trend but
no simple relationship between the two . Adapted from [8j
fact that the energy of accelerated ions is de-
posited in individual "packets" of varying density
along individual particle tracks rather than evenly
throughout the overall irradiated volume.
Ions of the same velocity or specific energy
produce tracks of secondary electrons with the
same kinetic energy. However, the dose density
within the track, i.e ., the number of secondary
electrons produced, need not be identical.
According to the Bethe-Bloch equation, the
deposited dose increases with decreasing velocity
and the square of the effective charge (cf. eq . 1)
of the beam ions . Therefore, the heavier ions
which can have higher charge states have, in gen-
eral, higher ionization densities than singly
charged protons, for example.
Biological Properties
Relative Biological Effectiveness (RBE)
Prior to the clinical use of accelerated ions, their
biological effects were studied with a number of
experimental systems . In the late 50's, the Uppsala
cyclotron was intensively used for such studies.
Larsson and his colleagues provided a wealth of
radiobiological data of protons [2, 10-13] . Similar
investigations were also performed in Russia [14,
15] and the United States [16-18] .
Cultured cells, plant seedlings, healthy and
tumor-bearing animals were irradiated and cell
survival, chromosomal aberrations, histological
changes, LDso etc. examined (for review cf. [4,
19]) . The central question of these experiments
was the biological effectiveness of the accelerated
ions in comparison to certain reference radi-
ations, mostly 250 kVX-rays or 61Co gammarays .
For protons, these studies revealed a relative
biological effectiveness (RBE) close to one. This
means, that the proton dose required to produce
a given effect is comparable to the reference pho-
ton dose . More recent, refined studies indicate,
however, that low (< 1 MeV) and very high (>
1GeV)-energy protons may have RBE-values of 2
and more, depending on the biological endpoint
studied [20-231 .
An elevated biological efficiency in the Bragg
peak region has clearly been demonstrated for
3 Physical and Biological Rationale for Using Ions in Therapy
ions heavier than helium . This specific ionization
density pattern is seen as the key element of the
biological quality and effectiveness of particle
beams [27-30] . For the same reason, RBE pre-
dictions of heavier ions cannot simply be made on
the basis of LET information . Detailed knowl-
edge of the beam composition, such as fluence,
charge and velocity are required, in addition .
Oxygen Enhancement Ratio (OER)
Oxygen acts as sensitizer, rendering the cells
more susceptible to radiation damage [31] . When
irradiating cells with photons or low-LET ions,
they demonstrate different survival behavior,
depending on the presence or absence of oxygen
(Fig . 6) .
dose (Gy)
1 9
Fig . 6. Cell survival curves of T1 cells after irradiation with
ions or X-rays in air or nitrogen atmosphere, respectively.
Adapted from [26]
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The oxygen enhancement ratio (OER) of radi-
ation is the dose (D) required to produce a cer-
tain biological effect in the absence of oxygen
(hypoxic conditions) to the dose (Do) required to
produce the same effect in the presence of oxygen
(oxic conditions)
OER = D(Effect E)
Do(Effect E)
For X-rays, the OER ranges from 2.5 to 3
which means that the killing of oxygen-deprived
cells requires 2.5-3 times higher X-ray doses than
killing the same cells under aerobic conditions .
Many independent studies have shown that the
OER-value decreases with increasing LET and
approaches unity at LETvalues of approx .
150-300 keV/[,m [26, 32] .
Radiosensitivity becomes maximal at oxygen
pressures of approx . 20 mm Hg (2700 Pa) . Well-
vascularized normal tissues exceed this value at
least by a factor of two. They are, therefore, gen-
erally fully radiosensitive as far as the oxygen
effect is concerned [33] .
In all experimentally-induced animal tumors
studied, hypoxic cells have been found [34, 35] .
For human tumors, the existence of hypoxic cells
is recognized but its clinical significance is de-
bated, in particular because of the reoxygenation
phenomenon after fractionated radiotherapy [36] .
Reduced oxygen partial pressures have been mea-
sured, e .g ., in carcinomas of the rectum or bone
metastases, but considerable intra- and inter-
individual variations in oxygenation even among
tumors of the same clinical stage and grade make
general statements difficult [37, 38]. Still, a reduc-
tion in OER has become one of the rationales to
use high-LET radiation in cancer therapy.
Variation in Radiosensitivity
with the Cell Cycle
The cell cycle of eukaryotic cells is divided into
several phases of growth and maturation (Fig . 7) .
The postmitotic rest or gap phase Gl is followed
by the S or DNA synthesis phase and a second
gap, the so-called premitotic or GZ phase which
precedes the actual mitosis (M) . The duration of
S, GZ and M is relatively constant for cells from
S
Sublethal Cell Damage
GO
cells
Fig. 7 . The phases of the cell cycle . M = mitosis, G, = post-
mitotic gap, S = DNA synthesis phase, G z = postmitotic gap .
Cells can leave the cycle temporarily to rest in G o
the same species in contrast to Gl which can vary
widely.
Single-cell survival data with cells in different
stages of the cell cycle showed that most cells are
sensitive during mitosis and more resistant in the
late S phase. The effect can be significant with
survival rates differing up to a factor of ten at
large doses per fraction [39] .
Areduced but not completely eliminated cell-
phase dependent radiation sensitivity was also
observed for heavy ions . However, the extent of
the effect is well reduced [4, 24] . More recent
studies with synchronized cells revealed that the
cell-cycle dependence recedes with increasing
LET, vanishing at approximate LET-values of 200
keV/[tm [40] .
Survival curves of exponentially growing cells
irradiated by X-rays are characterized by a shoul-
der due to the capacity to accumulate sublethal
damage (see Fig. 6) . If the irradiation scheme is
divided into multiple fractions, the survival is
higher or a shoulder appears with each new frac-
tion, indicating that repair occurs after each treat-
ment .
With increasing LET of the radiation, the
shoulder recedes. Heavy ions with a LET of
100-200 keV/Rm prompt an exponential survival
curve . After fractionated irradiation with heavy
ions, the survival curves remain exponential, i.e .,
no significant repair occurs (for review cf. [25]).
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Cancer has an increasing impact on the death
rates in the western world, as well as in the devel-
oping countries [1, 2] . Although there is a promi-
nent progress in the field of medical oncology,
high cure rates are mainly related to solid pedi-
atric tumors, leukaemias and lymphomas, and
testicular tumors . But these tumors represent
only about 5% of all cancers seen in the general
population [3, 4] .
At the moment of first admittance approxi-
mately 65 % of the patients have localized
tumors . About two thirds of these are cured
either by surgery, radiotherapy, or a combination
of both . In this group, some patients with prob-
able but unproved subclinical metastatic disease
may profit from chemotherapy or immunother-
apy used as an adjuvant treatment [3, 4] . Among
the other 35 % of patients presenting with inoper-
able or metastatic disease at the moment of first
admittance, only about 5% will be cured by com-
bined treatment including chemotherapy and
immunotherapy as well as radiotherapy and/or
surgery.
Local control of the tumor seems, therefore,
the key to more successful treatment results [5,
6] . Following Devita [5], it is even "axiomatic" to
control the local disease if one aims ultimately at
curing any cancer patient.
The techniques of surgery have already
reached a very high level . Further improvement
will be seen in a reduction of mutilating proce-
dures (limb sparing operation, breast conserving
surgery, reduction of colostomies and urinary
diversions). On the other hand, wider excisions
are still forseeable in relation with safer anaesthe-
siology, intensive care support and improvement
in reconstructive surgery. The combination of
surgery with irradiation, on a wider scale, will
help to increase the local control rate .
Radiotherapy is still open to new develop-
ments. Further improvements can be expected
from the use of better fractionation schedules, for
example, or a combination with new radiosensi-
tizers . But it is through the development of new
irradiation techniques that the most promising
progress may be expected . An increase in total
dose to the tumor, without exceeding the toler-
ance dose of the normal surrounding tissues, has
always been the key to a better clinical result .
New techniques like stereotactic radiotherapy,
intraoperative radiotherapy, high dose rate bra-
chytherapy and conformation therapy offer
already very encouraging results . These tech-
niques can be applied in several large, well-
equipped and well-staffed radiotherapy depart-
ments .
However, one of the most promising technolo-
gies seems to be the use of ion beam therapy.
Application of ion beams, in safe conditions,
implies large and expensive investment, as well as
adequately trained staff. Therefore, only a few
ion beam therapy centers are likely to open (as a
rough estimate according to the CEC: one per ten
million inhabitants) . This in turn implies the orga-
nization and agreement upon a system of refer-
ring those patients who could benefit from this
advanced technology.
Indications for Proton Beam Therapy
The rationale for proton beam therapy is an
improved physical selectivity (cf. previous
chapter) .
Generally speaking, an improvement in phys-
ical selectivity is always an advantage . Therefore,
principally all the photon patients could be poten-
tial indications for protons . However, only clin-
ical experience will reveal to what extent the
improvement in physical selectivity can be con-
verted into a better treatment outcome.
Looking at the possible tumor sites, one can
identify two main types of indications for proton
beam therapy.
The first type of indications are small, rather
resistant tumors, located close to critical normal
structures [7].
The best example today is uveal melanoma
treated in several proton therapy centers and con-
sidered to be the typical indication for proton
beam therapy. Other good indications are tumors
of the base of the skull [8], brain tumors in child-
ren [9] and tumors close to the spinal cord . For
these localizations, the adequate depth-dose
curves and the narrow penumbra of the proton
beam are definitive advantages and can be fully
exploited. Proton beams can also be indicated for
larger and/or deep-seated target volumes, such as
brain and pelvis, reducing the irradiation of sensi-
tive structures outside the target volume .
In that respect, it is interesting to compare the
types of patients treated at the Harvard Cyclotron
Laboratory (HCL) on the onehand, and in Loma
Linda on the other hand (Tab . 1) . At HCL, the
patients are included in well defined protocols,
the machine availability is limited and the beam
characteristics have also some limitations . Under
these conditions, patient selection is always crit-
ical. In contrast, in Loma-Linda, a larger number
of patients with different types of tumors can be
treated, several treatment rooms are available
full-time and there are nearly no limitations as far
as the proton beam characteristics are concerned
(e.g ., energy, field size, orientation) .
For small fields, as used for uveal melanoma,
for instance, it is probable that the geometry of
the irradiation is the major factor of success. The
total dose, overall time and dose per fraction are
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Table 1 . Distribution of the patients treated with protons at
the Harvard Cyclotron Laboratory (HCL) and the Loma Linda
University Medical Center (LLUMC)
', :veal melanomas and 33
other eye tumors' :"
-BrainICNS .
' Cordomas/Chondro-
sarcomas
Soft tissue sarcoma
Tiead,and Deck''.
,tumors
Radiosurbery (AVM, 50
L pituitary tumors)
Prostätic ädenocärci
'nomas
Miscellaneous
(a) 5949 patients by Sept . 1993
(b) first 300 patients treated by Oct. 1992
Potential Value of Heavy Ions
in Cancer Therapy
probably ofless importance. In contrast, for large
fields, the current rules of radiobiology, in partic-
ular, those for fractionation should be followed as
for photon beam therapy.
Heavy ions combine the advantage of a high
physical selectivity with the potential advantage
of high-LET radiations (see previous chapter for
details) .
Radiobiological data indicate that high-LET
radiations could be of interest for the treatment
of some tumor types. A review of the clinical
results of fast neutron therapy, another high-LET
radiation, indicates that neutrons can indeed
bring a benefit for several tumor types or sites,
such as salivary glands, (locally extended) pros-
tatic adenocarcinomas, or slowly growing soft tis-
sue sarcomas [10-12]. The Berkeley experience
with heavy ions is an additional argument for the
use of these particles, although the clinical results
were obtained from limited, selected groups of
patients .
The best results obtained at Berkeley with
neon ions [13] were obtained for those tumors for
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which fast neutrons were also shown to be of
interest (Tab . 2) .
The potential value of heavy ions in cancer
therapy has to be analyzed in relation with the
causes of local failure after conventional radiother-
apy, for which at least 4 factors can be identified :
- intrinsic cell radioresistance,
- the oxygen effect,
- cell. repair,
- repopulation during the treatment .
These factors are discussed in more detail in the
previous chapter. Here, they are only mentionied
as to their clinical consequences . Regarding the
intrinsic radioresistance of a cell population, high-
LET radiation could bring an advantage for
tumors particularly resistant to photons such as
adenocarcinomas or sarcomas . On the other hand,
it is obvious that heavy ions should not be given
for tumors that exhibit an exquisite radiosensitiv-
ity to photons, (e.g ., seminomas or lymphomas) .
Table 2 . Local control rates for various tumor types
obtained with neon ions at Berkeley in comparison to con-
ventional treatment results from various sources (RTOG =
Radiotherapy Oncology Group, NCOG = Northern California
Oncology Group)
Glioblastoma/Brain
-
Median surviVal Median suvival
' 17 montlis 9-12 möriths '
;(13 patients), (UCSF, .,
RTOG,
NCOG) .
Modified from J.R, Castro [13]
As far as the oxygen effect is concerned, the
OER (oxygen enhancement ratio) is lower for
high-LET radiations than for photons and this
could bring a benefit for those tumors for which
hypoxic cells constitute the main cause of radio-
resistance .
Repair of sublethal damage is also reduced
with high-LET radiations, and a smaller number
of fractions and/or shorter overall time can be
chosen with high-LET radiations, compared to
photons . High-LET therapy could thus bring a
benefit for those tumors which repopulate
quickly compared to the critical normal tissue .
General Principles of Patient
Selection for Heavy Ion Therapy
As summarized in Table 3, there are two main
groups of indications for heavy ions : those, for
which the biological effect of high-LET radiation
is thought to be the most important factor (A)
and indications for which the high physical selec-
tivity of the beams is thought to prevail (B). In
addition, some specific indications with poor
prognosis (C) can be proposed [14] .
Concerning the first group of indications, it is
possible to make a tentative prediction of the clin-
ical benefit which could be expected from heavy
ion beams by considering both the conclusions of
the neutron studies andthe heavy ion results from
Berkeley.
At present, over 14 000 patients have been
treated with fast neutrons alone, or in combina-
tion with photon irradiation . From the data
described in the literature one can schematically
distinguish [10-12] :
superior results, e .g ., salivary gland tumors or
prostatic adenocarcinomas ;
conflicting results, e.g ., head and neck tumors
[15] or cervix '[16] ;
disappointing results, e.g ., brain tumors [17] .
Two types of comments need to be made here .
Firstly, not all patient series were randomized .
Oneshould, therefore, be careful before deriving
definite conclusions from them . Secondly, neu-
tron data probably reflect the lower limit of what
could be expected with heavy ions, since - as
i Tumor Site Local teüirol : räte
Neön'löns = . - Conventional
Treatment
Salivary Gland 80% ', 28%
(10 patients)- 188
Patients -
(Literature
review)
Nasopharynx/ 63% 21%
Paranasal sinus (21 patients)' (97 patients
`45% ,
(UCSF)
Sarcoma , 28% -
(24 patients) (Literature
review)
Prostate 100% - 60-70%
(9 patients) (Literature
review)
,39,% 22-40 % -
(UCSF) , .
Table 3. General principles of patient selection for heavy
ion therapy
Trimors inJechnically difficult situations, where
high-LET radiation may be superior (e .g ., slowly
growing tumors) .
~' adjaccnt .to QNS: meningionra, phäryngionia, .
chordoma, optic nerve, gliorna,'AVM, paraspi-
nal cord tumor, pamäortic lymph node, etc .
-
	
root of neck disease:, upper esophagus, post cri-
. coid .careinöma, etc:
thoracic disease :=tumor o¬ the lung with mediastinal
disease after resection of primarytumor, mesotheli-
oina ; etc.
high-LET radiation already dembristrated tobe
useful lot, , .
salivary gland tumors
päranasäl sinuses
fi~ ed lymph nodes
=, prostatic adenocarcinomas
sarcomas, etc-
b) . .ädditiönal informatiöri is_needed for-
-:pelvic.turnors- bladder, :rectum,-cervix, e
other tumors : stornäch, biliary duct, etc'
Thephysical seleetMty'' ~(dose .dis nblr, rön üf,
eams;:is thoui lit to b~:xhe TUosfi~nprirtänt ~8ctot
ollo~ued bq the.',rad~o~i(ilogxc~l ädz~atr~ä~es of7rigii,
Modified after G.R.H . Sealy [14)
often stressed - neutrons were, in many centers,
not applied under optimal technical conditions . A
similar remark applies, however for other
reasons, also to the neon results of Berkeley (cf.
Chapter 15) for which, in addition, patient selec-
tion was insufficient.
Concerning the group of indications wherethe
physical selectivity is considered to be the most
important factor, we can expect the same results
as with protons, but with the additional advan-
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tage of high-LET radiation for slowly growing
tumors . In this respect, heavy ions could extend
the field of indications by allowing the oncologists
to envisage irradiation of groups of tumors "tradi-
tionally" considered to be radioresistant (e.g .,
adenocarcinomas) .
Since an improved physical selectivity is, in
any case, an advantage and since a high physical
selectivity is more important for high-LET than
for lowLET radiation, the superiority observed
for some localizations with fast neutrons can be
expected to be even more pronounced and clini-
cally more relevant when the physical selectivity of
heavy ions becomes available . The physical selec-
tivity is especially important in tumors located
near normaltissue, e.g ., tumors adjacent to CNS.
In addition, there might be some miscellane-
ous indications (C), including tumors where more
precise irradiation can reduce normal tissue
effects, and tumors with a very poor prognosis
such as unresectable hepatomas, pancreatic
tumors, retroperitoneal sarcomas, or recurrences
after previous irradiation .
Due to possible higher tumorigenicity of heavy
ions, tumors in children are not considered as
indications for heavy ions (high-LETirradiation) .
They should preferably be treated with proton
beams (low-LET irradiation) . With protons, as
with heavy ions, the possibility of achieving a pre-
cise irradiation minimizes the effects on the nor-
mal tissues, and especially growth retardation [9,
18].
Boost irradiation could be another interesting
field for heavy ions . In fact, one might assume
that all tumors that are now treated with a boost
after large-field locoregional irradiation are good
candidates for heavy ions, since boost irradiation
is applied to a residual malignant and usually
resistant cell population against which high-LET
radiation is likely to be more effective. This could
include a large group of tumors such as carcino-
mas of the bladder, the esophagus, colorectal,
and selected gynecological tumors, locally
advanced pharyngeal and oral cavity tumors,
especially with fixed cervical lymph nodes, or
bronchus carcinoma with relatively resistant
histology.
Finally, the treatment of solitary and -slowly
growing metastases could benefit from heavy ion
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therapy. Among the possible indications are sar-
comas, kidney tumors, and adenoid cystic carci-
nomas. These tumors tend to distribute solitary
and/or slowly growing metastases to distant
organs which force an immediate and efficient
local therapy. Metastases in brain and vertebrae
are examples of such malignancies, and they
could be the only clinical sign of disease progres-
sion . In these patients, the local problems remain
more important clinically than the problems of
the systemic disease. A comprehensive list of
tumor types or sites which could be indications
for heavy ions has recently been published [19] .
Estimation of the Cost
of Ion Beam Treatments
Due to the wide variations in the reimbursement
rates and systems, even between the countries of
the European Union (EU), the only relevant way
to express the cost of the ion beam treatments is
by comparison with other radiotherapy tech-
niques and other cancer treatment modalities .
Dedicated Proton Beam Therapy Facility
Arather accurate evaluation of the cost of a dedi-
cated proton therapy facility was requested for
the new program at the Massachusetts General
Hospital (MGH) and simultaneously by the Bel-
gian "Fonds National de la Recherche Scientifi-
que" (FNRS) in 1993 [20] .
In both cases, the evaluation was based on
data from Ion Beam Applications S.A. (IBA), a
Belgian company manufacturing cyclotrons for
medicine and industry. In early 1994, IBA was
selected as supplier for the equipment of the
Northeast Proton Therapy Center (NPTC),
planned by MGH in Boston (cf. Chapter 39).
They established the initial investment cost for
a dedicated proton beam therapy facility as fol-
lows :
20 MECU for a 230 MeV compact cyclotron
and 4 treatment rooms (3 with isocentric beam
line (gantry) and 1 with horizontal beam);
4 MECU for the building ;
1 MECU for the medical equipment (simula-
tor, CT, treatment planning, etc.)
The annual running cost would be about
1 MECU, including maintenance, electricity, and
salaries for 3 engineers and office personnel.
The salaries of the medical staff (radiothera-
pists, hospital physicists, radiographers) need not
be included in the cost evaluation, as they are the
same as in the case of X-ray treatments, at least
for complex treatments, e.g ., conformation ther-
apy. The medical staff is simply "transferred"
from the existing conventional therapy facilities
to the proton therapy facility.
Assuming an amortization of the equipment
over 25 years (which seems reasonable for this
well established conventional cyclotron technol-
ogy), the same for the building, and 1 MECU for
the annual running cost specific to the proton
facility, the study of the FNRS [20] came to the
conclusion that the cost per patient, related only
and specifically to the proton therapy facility,
would be about 1250 ECU per patient, if 1600
patients were treated each year (600 full treat-
ments and 1000 boosts). This amount of 1250
ECU has to be added to the other costs such as
the salaries of the medical staff, the amortization
of the current medical equipment, etc. (which are
assumed to be the same for proton and conforma-
tion photon therapy) . The amount of 1250 ECU
is somewhat lower than the present reimburse-
ment rate by the Social Security in Belgiumfor a
conventional photon treatment . Hence, it can be
concluded that the total cost of a proton treat-
ment is less than twice the price the Social Secu-
rity is presently paying for a photon treatment.
In a recent evaluation of the cost of proton
therapy, based on the situation in Nice (France),
Chauvel [21] compared a cyclotron (and 3 treat-
ment rooms) with 3 photon linacs (for conforma-
tion photon therapy) . Assuming an amortization
over 20 years for the cyclotron and over 10 years
for the linacs, he concluded that the cost per year
(machines + buildings) is 1.4 to 1.8 times higher
for the proton as compared to the photon therapy
facililty. For 1100 patients per year, he estimated
the cost per patient (machines + buildings) as
860-1140 ECU for protons vs . 640 ECU for pho-
tons . The cost of staff salaries, patient accom-
modation, patient transport, maintenance and
furnitures are comparable for proton and con-
formation photon treatment (i.e ., 8000-9000
ECU per patient, for 1100 patients treated),
according to the author.
These two evaluations based on the situation
in Belgium and in Nice, respectively [20, 21],
agree that a proton treatment is somewhat more
expensive than a complex photon treatment. The
argument that protons cost exceedingly more can
thus no longer be retained . Along the same line,
Chu [22] came to the conclusion that proton ther-
apy could even be cheaper than photon therapy.
He based his evaluation on the assumption that
one proton facility (4 treatment rooms) can treat
the same number of patients as 10 photon linacs,
which have to be replaced after 10-12 years which
means about twice as often as a cyclotron. Chu
also assumed that the number of beams per treat-
ment could be lower for protons, that the number
of fractions could also be lower, and that treat-
ment planning is easier for protons than for pho-
tons .
In contrast, a significantly higher cost estimate
was made by Suit and Urie [7] who reported that
a proton beam treatment would be 2-3 times
more expensive than conformation therapy with
photons. A more expensive evaluation was also
reported from Loma Linda in California, but it is
obvious that more sophisticated and expensive
choices were made in Loma Linda when design-
ing and constructing the facility in comparison to
the compact cyclotron indicated above.
In any case, when making comparisons, one
should check whether the different components
of the budget are taken into account in the same
way (e.g ., equipment amortization, salaries ofthe
medical staff, etc.) .
In addition, when comparing protons andpho-
tons, one should compare the cost of a proton
treatment with a complex photon treatment per-
formed with great accuracy with the help of all
available modern technology (e.g., conformation
therapy, etc.) . Comparison of ion beam therapy
with a single photon beam or 2 parallel opposed
photon beams is, of course, not relevant .
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Proton Therapy with "Physics Machines"
Several proton therapy centers are using or will
use existing "physics machines" adapted for ther-
apy applications, such as Harvard, the Russian
facilities, Uppsala, Louvain-la-Neuve, Orsay, etc.
Cost evaluation must be done in each case
individually, and completely different situations
have to be taken into account:
- the investment needed to adapt the machines
for therapy applications ;
- the cost of the machine time (ECU per beam
hour) ;
- the salaries of the machine engineers;
- the running cost and the maintenance cost .
In particular, maintenance and running costs
are usually higher for these machines not initially
designed for therapy and may vary widely from
machine to machine. For these and other reasons,
no general estimation can be made concerning
the costs of proton beam treatments, using phys-
ics machines adapted for therapy applications .
Heavy Ion Therapy
Whatever the approach and the hypotheses used
for cost estimation, and the way of funding the
program, the cost of therapy with heavy ions is
significantly higher than that of proton beam
therapy. As a result, it is reasonable to expect that
no more than a few heavy ion therapy centers will
be installed in the world in the foreseeable future .
In any case, the cost per treatment will to a large
extent depend on the number of patients treated
per year. In that respect, similarly to the case of
proton beam therapy, one has to clearly separate
the cost evaluation for a dedicated heavy ion
therapy facility from that of a therapy program
using an existing, high-energy physics machine.
It is difficult to derive general conclusions
about the cost of heavy ion therapy from the Ber-
keley experience or to make general predictions
from the HIMAC (Heavy Ion Medical Acceler-
ator) project in Chiba, Japan, or from the GSI
(Gesellschaft für Schwerionenforschung) project
in Darmstadt, Germany. The local factors are not
comparable . In particular, the HIMAC facility
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offers large possibilities but is generally consid-
ered to be very expensive.
In 1990, the Commission of the European
Communities (CEC) decided to support a feasi-
bility study called EULIMA (for EUropean Light
IonMedical Accelerator) for a heavy ion therapy
facility, designed and devoted exclusively to ther-
apy applications . This hospital-based facility was
planned to treat a large number of patients (up to
3000 patients a year) . For the evaluation of the
costs of EULIMA, the following assumptions
were made [23] :
1. One heavy ion accelerator (cyclotron or syn-
chrotron) is serving four treatment rooms:
room 1 and 2 equipped with both a vertical and
horizontal beam;
room 3 equipped with a horizontal beam only ;
room 4 equipped with a 45* oblique beam and
possibly, in a second phase, an isocentric
gantry.
2. The beams can be switched rapidly and safely
between the different treatment rooms.
3. On the average, 2.5 patients can be treated per
hour (room set-up time 15 minutes, beam time
5 minutes, 4 minutes "contingency" reserve for
possible medical or technical difficulties) .
4. Afull treatment consists of 12 fractions (it was
assumed that hypofractionation is possible with
high-LET treatment), aboost of 5 fractions .
5. Hospitalization is necessary for only 10 % of
patients ; full treatment patients for an average
of 3 weeks, boost patients for 2 weeks.
A total number of 27000 fractions per year
could be derived from those figures, assuming, in
addition, 10 working hours per day, 6 working
days per week and 45 weeks per year (due to the
high investment and running costs, one must aim
for the maximum possible working hours) .
With the further assumption that two thirds of
the patients would receive a full treatment and
one third only a heavy ion boost, 1860 patients
could be treated per year for a full treatment and
930 for a boost.
Roughly 300 patients would need hospitaliza-
tion, for whom 20 permanent hospital beds and
approx . 200 out-patient beds ("low care" hospital
beds or hotel rooms) were projected.
As cost for the equipment the following was
assessed [21] :
15-20 MECU for a dedicated accelerator (cy-
clotron or synchrotron),
10-15 MECU for the beam delivery systems
serving4 rooms,
20 MECU for the building .
To this investment, annual running costs of
approx . 17 MECU have to be added, which
consist of the following :
7 MECU for machine and treatment rooms,
6 MECU for medical staff,
4 MECU for beds/patient transport.
With the figures for the investment and run-
ning costs and the above made assumptions on
the patient spectrum, the cost per patients would
be around 7000 ECU. For a 50% cure rate with
heavy ions, the cost would then be around 15 000
ECU per patient cured, which is very reasonable
when compared to other radiotherapy modalities
or other cancer treatment techniques (Tab . 4 and
5) .
Table 4. Cost estimation of the current cancer treatment
techniques . The relatively wide range depends on country
and/or extent of disease
j Treatment Average Cost Range
Surgery
Conventional
radiotherapy
Bone märröw
transplantation:
~ Technique . . .
Modified from [23]
Table 5 . Cost of some current cancer chemotherapy and
hormone therapy schemes in Belgium . Prices taken as refer-
ence are prices valid on November 5, 1994 for in-patients,
according to the Belgian Social Security. Cost given are for
the cytostatic agents only, and normalized for a patient with
a body surface area of 1 .6 m2 . Drugs such as antiemetics or
Conclusion
Ion beam therapy appears to be a promising
approach in cancer therapy, able to improve local
control but also survival . Due to the clear
improvement in physical selectivity, proton beam
therapy, used either as full treatment or as boost,
can bring a benefit for a large number of patients .
On the other hand, heavy ions, which combine
a high physical selectivity with the potential
advantage of high-LETradiations for some tumor
types, are indicated for a smaller percentage of
patients for whom they could bring a significant
benefit as can be derived from Berkeley and the
past fast neutron experience.
Ion beam therapy - protons or heavy ions -
still requires expensive investments and will be
somewhat more expensive than conventional
radiation therapy, at least for the near future . In
order to make this additional cost tolerable for
the Social Security System, it is important to
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anxiolytics, perfusion fluids, perfusion material, room
charges, medical fees, etc. are not included. Prices are calcu-
lated for each cytostatic agent administered during one
course and for the total number of courses usually given for
the whole treatment. After J. Longueville, UCL, Clinique Uni-
versitaires St .-Luc, Brussels, Belgium
optimize the machine characteristics (reliability,
compactness, user friendliness, low running
costs, etc.) and to rationalize the patient recruit-
ment and referral . Only if the number ofpatients
treated per ion beam facility is high enough, the
cost per treatment will be acceptable, and not
higher than the cost of accepted cancer treat-
ments such as surgery or chemotherapy.
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il . Models and Preclinical Studies
Practical Implications of Microdosimetry
Introduction
.1 . F DICELLO
Clarkson University, Department of Physics, Potsdam, NY, USA
This chapter reviews the basic physical concepts
underlying the field of microdosimetry and how
they apply to therapeutic proton beams. It discus-
ses the extension of these physical concepts to
problems in radiobiology and radiation oncology,
and finally, it examines the microdosimetric simi-
larities and differences of protons with other
heavy charged particles and with conventional
photon beams. Mathematical analyses have been
kept to a minimum as have descriptions of both
the experimental and theoretical methods, in rec-
ognition of the diversity of backgrounds and pri-
mary interests of the readers. Likewise, special-
ized aspects of the field have not been empha-
sized.
The Meaning of Microdosimetry
Microdosimetry is the study of the physical pro-
cesses associated with the transfer of energy to
matter and their relation to the subsequent chem-
ical and biological processes. Historically, the
initiation of the field is generally attributed to a
group of scientists at Columbia University under
the direction of H. H. Rossi [1] and other re-
searchers who recognized the limitations of the
average physical parameters for characterizing
radiation fields used in biology and therapy. The
absorbed dose, that is, the mean energy imparted
to matter per unit mass, is the quantity most com-
monly specified to establish the amount of radia-
tion delivered to a biological site or to a patient,
but it is necessarily a macroscopic quantity, not in
the optical sense but rather in the thermodynamic
or statistical-physics sense, in other words: it is an
average property of a large number of atoms or
molecules. Like other macroscopic quantities
describing the state of a system, such as tempera-
ture and pressure, it is a concept applicable only
to macrostates near equilibrium. In contrast,
most initial physical processes responsible for
transferring energy to biological systems are tak-
ing place at the atomic or molecular level and are
not accurately approximated by static or quasi-
static situations . Such situations are classified
thermodynamically as microstates or microscopic
states . Hence the designation "Microdosimetry"
for the name of the field. Unfortunately, the
name is to some extent oxymoronic in that the
term dose as an average quantity of the state
should not be applied to particles traversing
single atoms, a few molecules, or even a cell
nucleus . Despite early attempts to arrive at a
more appropriate name [1], it is nevertheless well
established and the field continues to be so la-
belled even today.
The Need for Microdosimetry
The success of radiation therapy depends upon
our ability to define a specific treatment which
will control the disease while sparing normal tis-
sues and preserving the welfare of the patient.
Protocols evolved largely from clinical observa-
tions. The philosophy of conventional therapy is
assumed to be to deliver the maximum uniform
dose to the treatment volume with minimal effect
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to adjacent normal tissues . The manner in which
treatment planning is done, however, somewhat
contradicts this philosophy. For high-energy, high
atomic-number ions (HZE), we must modify the
physical dose distributions to account for the
nonuniform response as the beam penetrates the
tissue . Protons, argumentatively, owe at least part
of their success in comparison with HZE particles
to the relative ease (cost) with which they can be
used to localize the physical dose while achieving
a relatively uniform response throughout the
treatment volume . Yet protons and even photons
produce differences in biological response
throughout that treatment volume ; those differ-
ences are simply smaller than in the case of the
heavier charged particles. Even in the case of
photon therapy, we compensate for sensitive tis-
sues within the volume, implicitly invoking a uni-
form effective dose, that is, a nonuniform phys-
ical dose selected to produce a uniform biological
response . The clinical experience with protons
has demonstrated the advantage of precise deliv-
ery of uniform (effective) doses. The success of
protons has been amajor catalyst for the develop-
ment of comparable treatments with X-rays using
conformal therapy and radiosurgery with compa-
rable improvements in response . Significant gains
have been achieved with better localization and
improved uniformity of response irrespective of
the type of radiation. At the same time, the
potentials of radioimmunotherapy and brachy-
therapy have not been fully realized in part
because of microscopic nonuniformities in energy
deposition . Continued improvements in radiation
therapy require more detailed information con-
cerning the variation in biological effects at the
microscopic level, and this requires more detailed
information concerning the interactions of the
radiations andthe subsequent physical processes .
Each type of particle being used for external
beam therapy and each type of source in brachy-
therapy produce different types of response and
different levels of response for the same absorbed
doses. The reason for these differences in
response is simple and indisputable ; the distribu-
tions of the physical interactions and the energy
transferred at the relevant biological sites are dif-
ferent . These differences are illustrated in Figure
1 for photons and alpha particles, where the num-
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Fig . 1 . A schematic representation of the relative number
of secondary electrons, on the left, produced byan exposure
of cells to a megavoltage photon beam in comparison with
the same dose of alpha particles on the right. For the total
energy per unit volume, the dose, is to be the same in both
cases with much fewer tracks of shorter length from the
alpha particles, because alpha particles can deposit much
more energy along their tracks
ber of particles and the lengths of their tracks are
shown schematically for cells irradiated with
equal doses . Even though the average macro-
scopic dose is the same, in the case of the alpha
particles, the cells see fewer events per cell, per
cell nucleus, or per DNAstrand, with each event
depositing a greater amount of energy on the
average . Each type of radiation produces a differ-
ent distribution of dose (energy) at the cellular
and subcellular level even for the same macro-
scopic dose distribution . Differences in response
must be caused by the differences in the distribu-
tions of energy transfer. That is not to say that
there are no other factors affecting response . The
same radiation delivering the same dose, for
example, may produce a different response in dif-
ferent organs . These differences result from the
differences in the structure of the targets and the
subsequent biological or chemical processes, as
well as differences in the initial physical interac-
tions . There is a physical component to each pro-
cess and a biological component.
All of the physical information is contained in
the frequency and energy distributions for the
various types of particles, and it behooves us to
study these distributions as a means of under-
standing the basic physical mechanisms . Micro-
dosimetry establishes what the probability dis-
tributions are for depositing energy in a given tar-
get volume for various particle types under thera-
peutic conditions . It is the only internationally
recognized method for describing probabilistic or
stochastic processes initiated by radiation [2-5].
General Features of Microdosimetry
In the present context, there exist two basic phys-
ical quantities responsible for biological pro-
cesses :
1. energy, resulting in work and the transfer of
information and
2. sources and/or sinks of energy in the form of
masses and charges .
In principle, we totally define the radiation
field by specifying the number or frequency for
the various types of particles per unit volume or
per unit area (fluence) as a function of their ener-
gies and direction . In practice, the frequency dis-
tributions needed for therapeutic situations are
usually difficult to obtain either experimentally or
theoretically and difficult to utilize. Simpler
quantities and methods are frequently invoked.
Theuse of dose rather than the complete distribu-
tions in energies, masses, and charge is such an
example. Moreover, we wish to characterize the
radiation field only as an intermediary step to
determine the biological consequence.
Once a particle transfers energy to a particular
site, such as an atom, a molecule, or even a per-
son, there is a certain probability that we will
observe a particular physical or biological result,
and there is a certain probability that we will
observe nothing. The physical occurrences are
called events and null events, respectively. The
probability is simply the fraction of occurrences
of the event of interest .
In Microdosimetry we are specifically inter-
ested in the frequency or probability of physical
events which transfer energy from the radiation
to relevant biological sites such as the cell nucleus
or DNA as a function of the energy deposited . If
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the energy deposited is betweenE andE+dE, dE
being the differential energy, we say that the dif-
ferential probability in the energy interval dE is
f(E)dE . If we integrate over all energies, the total
probability or fraction, F, would be one corre-
sponding to 100% . The distribution f(E) as a
function of E is called either the probability dis-
tribution, the frequency distribution (frequency
of events as a function of energy), or the differen-
tial (probability or frequency) distribution .
The number and type of events we observe in
some specified volume is obviously related to the
number of incident particles and the size and
shape of the target . We, therefore, express the
probability of an occurrence or event in terms of
the number of particles incident on the volume of
interest . The number of particles, N, incident on
some specified volume divided by the cross-
sectional area, a, of that volume is called the flu-
ence, 4). In the limit, this becomes
(D=dN/da (1)
where the volume for the purpose of calculating
the fluence at a site is usually chosen to be a
sphere [4] . The choice of specifying the volume,
as in absorbed dose, or the cross-sectional area of
that same volume, as in the fluence, is somewhat
arbitrary because the two are directly related.
We define the differential probability in the
interval between E and E+dE divided by the flu-
ence as the differential cross section because it
has units of area :
do(E)dE = f(E)dE/~D (2)
It should be interpreted only as the probability
for a given fluence, not as the actual area of the
target . There is, then, a direct and unique correla-
tion between probabilities or frequency distribu-
tions and cross sections .
Recognizing that the amount of energy trans-
ferred by an event can be as important biologi-
cally as the event itself, we frequently discuss fre-
quency distributions of energy transferred as dis-
tinguished from the previously discussed fre-
quency distributions of the events which depo-
sited the energy. Thesefrequency distributions of
energy transferred are often identified in the liter-
ature simply as energy distributions or, unifortu-
nately, dose distributions. For such distributions,
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the cross section for energy transferred would be
the amount of energy transferred divided by the
total amount of incident energy per unit area .
This latter quantity is utilized in the literature less
frequently than distributions of energy transfer.
The energy transferred or absorbed per unit
mass is the dose, andthe energy lost per unit path
length is the linear energy transfer (LET) . Note
that the energy absorbed in the mass must be dis-
tinguished from the energy lost by the incident
particle . The absorbed energy will usually be less
than the total energy lost, significantly so in many
cases, because energy can be transported outside
of the mass, even in the case of a patient.
The dose, as we have noted earlier, is an aver-
age, macroscopic quantity. Nevertheless, there is
energy deposited by each event in the target site
even for microscopic sites, and there is a microdo-
simetric analogue of the dose . To avoid confusion
with the macroscopic dose, this microscopic
quantity is called the specific energy, z, although
it has the same units as dose . Just as we were able
to define a probability for an event occurring
between E and E+dE, we can define a probabil-
ity for an event occurring between z andz+dz as
f(z)dz with the corresponding cross section for
that event being
a(z)dz=f(z)dz/4) (3)
In the macroscopic case, we frequently consid-
er the energy lost per unit pathlength, the unre-
stricted linear energy transfer or LET [4] . For the
microscopic case, we consider the energy
absorbed in the site per unit average pathlength,
rave, through the site, andwe define this quantity
as the lineal energy, y, usually expressing it in
terms of units of keV/pm. For a volume, V, of
area, A, andknown shape, composition, and den-
sity, p, we can calculate the mass of the volume
andthe average pathlength across that volume, so
there is a direct and unique relationship between
the specific energy and the lineal energy.
Although there is no obvious advantage of the
use of one or the other, historically, lineal energy
is more frequently used as the independent vari-
able .
Microdosimetric Attributes
of Beams of Photons and Ions
A measured spectrum of the number of events
with lineal energies within a fixed interval as a
function of lineal energy is shown in Figure 2 for
an energetic beam of protons. The details con-
cerning the experimental methods and proce-
dures are discussed in a previous publication [6] .
In order to show some of the physical charac-
teristics of this spectrum, it has been presented on
a log-log plot . Note that this spectrum extends
over a factor of 10000 in lineal energy with the
relative number of events within that interval
changing by a factor of 10000000 . Typical spectra
will extend from a few eV/jim to over a thousand
keV/[tm. Although events of higher lineal energy
are relatively infrequent in the case of protons,
each of such events can deposit thousands of
times more energy than typical events from pho-
tons . Despite their infrequency, such large events
can 'have significant biological consequences .
They are responsible for the higher effectiveness,
for example, of neutrons and pions. Even in the
case of photons, the greater abundance of higher
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Fig . 2 . The number of measured events per unit interval of
lineal energy is plotted as a function of lineal energy for-an
energetic beam of protons incident upon a detector simulat-
ing a sphere 2 wm in diameter
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Fig. 3. The frequency distribution of events presented in
Fig . 2
events from orthovoltage X-rays, in comparison
with 60Co gamma rays explains the higher RBE
frequently observed for the lower-energy X-rays .
It is difficult to extract quantitative informa-
tion directly from the presentation used in Figure
2, but those data can be used to calculate a nor-
malized frequency (probability) distribution . In
Figure 3, we have plotted the differential proba-
bility or frequency distribution for the same pro-
ton distribution shown in Figure 2. In this repre-
sentation, the integral
is the total probability equal to one (100%), and
the integral between any two values of y
is the probability that lineal energy will be depo-
sited in the range between yl and Y2-
Because these integrals are simply the areas
under the curves between two values of y, the
area under each curve in a given region is propor-
tional to the probability that events will occur in
that interval . Such curves could provide a power-
ful means of examining the differences in energy
deposition by the various types of radiation,
except they are usually too close to the two axes
to be distinguished from the axes . If we plot the
data on a log-log plot, it would look similar to the
distribution of data in Figure 2, but the area
under the curve would no longer be proportional
to the probability. To obtain a representation
which will allow us to see both the structure of the
curves, including those rare but important events,
with the area proportional to the probability, con-
sider
f f(y)dy = f f(y)yd(ln y) = yf(y)d(ln y)
kyf(y)d(log y)
	
(6)
where k is the factor to convert natural logarithms
to log base ten, d(ln y) and d(log y) are the dif-
ferentials ofthe natural log of y andthe log to the
base ten of y, respectively. From elementary cal-
culus, d(ln y)/dy = 1/y, and it follows that dy =
yd(ln y) .
This shows that, if we plot yf(y) versus log y, as
we have done in Figure 4, instead of f(y) versus y,
the area under the curve is still proportional to
the probability of an event with lineal energy
between y and y+dy. The advantage is merely
0 .4
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Fig. 4. The same data as presented in Figure 2 have been
used to calculate the product yf(y), which is plotted versus
the log of the lineal energy. In this representation, the area
between two values ofy is proportional to the probability of
an event occurring in that region
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that we can discern the structure of the distribu-
tion, and we can see better portions of the dis-
tributions that were close to the axes in the earlier
representation . This proved to be a significant
advantage and most data are presented in this
fashion .
The mean lineal energy is simply
I (Nyi)/Y- Ni
where f;(y)= (N/EN ), i.e ., it is the average
energy deposited pergm by each event. In the lit-
erature, this is usually designated as yf . It varies
from a fraction of a keVi1.m for photons to as
high as several hundred keV/Rm for some heavy
ions . Even for a particular type of particle, the
mean lineal energy will depend upon the energy
distribution of the particles and the physical char-
acteristics of the object being irradiated . For ther-
apeutic proton beams the mean lineal energy can
vary within a treatment volume from typically
1 keV/[,m to well over 10 keV/p,m.
Biological endpoints are frequently correlated
not only with the number of events but the
amount of energy deposited by those events as
well . We can use the event distributions to calcu-
late the corresponding distributions for energy
deposited in the same site . The differential energy
distribution is the probability of depositing a
given amount of specific energy (rather than the
probability of an event) between z and z+dz
expressed here as 0(z)dz . The total specific
energy deposited in a given interval is simply the
specific energy, z, associated with each event
times the number of such events . The number of
events between z and z+dz is f(z)dz, so the frac-
tional contribution to the total energy deposited
per unit mass is zf(z)dz. Again, we can use the
conversion from dz to zd(ln z) as discussed above,
and we have
z2f(z)d(ln z) = kz2f(z)d(log z) . (8)
This tells us that, if we plot z2f(z) versus log z,
the area under the curve is the fractional contri-
bution to the total energy deposited from events
within that interval of specific energies . As noted
earlier, this is frequently designated as the (differ-
ential) energy (deposited) distribution . Histori-
cally, researchers developed a preference for plot-
ting lineal energy in research articles rather than
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Fig. 5. The probability distribution for energy deposition as
a function of lineal energy
specific energy. Because one is proportional to
the other, we may just as easily plot y2f(y) versus
log y; the area under the curve would still be pro-
portional to the fractional contribution . The
curve corresponding to the event data in Figures
3 and 4 is shown in Figure 5.
The average lineal energy for this distribution
E Ni(yifj(y))/1N (9)
is called the dose mean lineal energy and is
designated as Yd- The dose mean lineal energy is
admittedly a more esoteric parameter than the
frequency mean lineal energy, yf, and its physical
meaning may be less easily understood. It is best
appreciated as the microscopic analogue of the
dose . Because the dose arose historically as the
parameter best related to biological response, we
might expect that the microscopic mean to be
even better correlated . It is frequently considered
in biological modelling.
We have discussed two basic distributions, the
frequency distribution and the energy distribu-
tion, each as a function of lineal energy and spe-
cific energy. The frequency distribution is in fact
proportional to the distribution of differential
cross sections; it presents the probability that an
event with a particular lineal energy will occur
while the cross section is the probability per unit
fluence. The energy distribution presents the
probability that energy will be delivered by events
within a particular lineal energy interval . The lat-
ter distributions are generally the more relevant
ones biologically, and the ones usually presented
in research articles . We could calculate a cross
section corresponding to the energy distribution,
but that is seldom done .
Microdosimetric Differences
in Therapeutic Beams
We now can examine therapeutic differences in
the response to different types of radiations in
relation to the microdosimetric distributions for
the various particle types . Figure 6 presents a
comparison of typical measured dose distribu-
tions for 6°Co, protons, and energetic heavy ion
beams [7] of helium, carbon, nitrogen, neon,
argon, and iron . In this figure, the total dose, pro-
portional to the total area under each curve, is
the same for each type of particle . We see imme-
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Fig. 6. Typical energy distributions for beams of 6°Co-
photons, energetic protons, and heavy ions [7]
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diately that the dose from the heavier ions is de-
livered by many more events of high lineal ener-
gies . For equivalent doses, we have fewer events
with larger energy depositions per event when we
irradiate with heavy ions .
Proton distributions are relatively unique in
comparison with other particles . A large fraction
of the energy is being deposited at lower values of
lineal energies, but not as low as most of the
events from high energy photons. Events from
protons tend to be more comparable to those
from low energy orthovoltage photons. This is a
partial explanation for the fact that responses to
protons tend to be slightly higher than the
response to cobalt-60 and more comparable to
those from 250-kV X-rays . Furthermore, recall
that most proton distributions exhibit a small con-
tribution, around a percent or so, of high lineal
energy events around 100 keV/[tm, a region which
tends to produce maximum biological damage for
some biological endpoints. These higher events
represent secondary protons nearing the end of
their range and events from recoil ions and
nuclear secondaries, including a significant con-
tribution from secondary neutrons [8] .
In a true sense, a proton irradiation might be
considered to be an irradiation with a beam of
intermediate quality with the simultaneous irradi-
ation with a small dose of low energy, high-LET
heavy particles, (the atomic and nuclear second-
aries) .
Finally, there is a great deal of variability in the
energy deposited by most light ions, including
protons as evidenced by the larger spread in the
distribution for these lighter particles. If, for
example, a large amount of energy from a single
event is necessary to inactivate a cell, we immedi-
ately realize that there is some probability that
such an event might be produced by relatively
light particles with relatively low LETs.
Particle energy, the size and shape of the treat-
ment volume, and the depth within that volume
greatly alter the distributions of most particle
types [9] . A proton beam nearing the end of its
range, for example, can have a microdosimetric
distribution with a mean lineal energy compara-
ble to that of an energetic nitrogen or neon beam
and almost ten times that of an energetic photon
beam. A comparison of the distributions
42
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Fig. 7. Acomparison of the microdosimetric distributions in
the proximal, central, and distal portions of a volume irradi-
ated with a proton beam at the Loma Linda University Med-
ical Center
observed in the proximal, central, and distal re-
gions of a proton beam used to treat ocular dis-
eases at the Loma Linda University Medical Cen-
ter is shown in Figure 7 for spherical targets of
unit density. The shapes of these distributions dif-
fer as a function of the size and shape of the tar-
gets . Consequently the relative effectiveness of
different particle types, such as iron beams versus
protons, for double-strand DNA breaks can be
significantly different than that for single-strand
breaks simply because of differences in the dis-
tributions of energy as well as for differences in
biological processes .
Calculation of Biological Response
The ultimate goal of Microdosimetry in radiation
therapy is to understand responses and to be able
to predict responses for individual treatments .
Although there have been strides in achieving this
goal, there remains much to be gained . Microdo-
simetry has been most successful to date in
explaining cellular responses in vitro (e.g .,
[10-13]) . It is only recently that significant in-
roads have been made at the molecular levels or,
at the other extreme, in tissues and organs . In the
developmental days of Microdosimetry, the need
for simplifying assumptions was a major consider-
ation; the physical cross sections for the plethora
of different processes were generally unknown
and were too many to be either measured or cal-
culated in treatment planning . If we realize that
even three-dimensional planning of the macro-
scopic dose is just beginning to be available in the
clinic because of the complexity and uncertainty
of the input data and the need for large amounts
of computer power, we can appreciate the
amount of effort needed not only to calculate the
dose but also the distribution of interactions and
reactions with a target molecule, to say nothing of
modelling the molecule itself. Nevertheless strides
are being made rapidly in applying microdosimetry
to molecular biology [14, 15] and the capability of
incorporating microdosimetric concepts into treat-
ment planning appears now to exist .
Many earlier models were based upon the ear-
lier linear quadratic approach. The basic premise
in these models has been that the initiating
biological event is proportional to the energy
deposited or the energy squared. Kellerer's and
Rossi's "Theory of Dual Radiation Action" [16]
extended this concept to the microdosimetric
level and, in one model based on this theory, it is
assumed that the initial microscopic changes
induced by the radiation are proportional to the
dose mean specific energy, ZD . Such assumptions
were extended [17] to account not only for the
differences in radiation quality of different beams
but also changes within the treatment volume tak-
ing into account the dose rate, fractionation
schedules, and repair. Nevertheless, it was still
difficult to take into account repopulation and
organ response, particularly in complex tissues
wherethe organ response is influenced, for exam-
ple, by the unirradiated microvasculature [18] .
More recently, we have begun to address the
problems of organ responses from the microdosi-
metric viewpoint . Perhaps most importantly, this
type of an approach could be implemented in
newer treatment planning codes with only a
modest effort .
One of the major limitations of models which
correlate biological responses mainly through the
mean values of the distributions, is that they fail
1. F . Dicello
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to take into consideration variations in the dis-
tributions themselves . It is possible that two sig-
nificantly dissimilar radiations can have approxi-
mately the same dose mean specific energy but
significantly different distributions and, conse-
quently, different biological impacts. To account
more precisely for the differences in the distribu-
tions themselves rather than the mean values,
Bond and Varma [19, 20] proposed that there is a
specific biological response associated with each
event determined by the value of lineal energy
(or specific energy) associated with that event. If
we know the response as a function of lineal
energy and if we have the probability of an event
with a specified lineal energy, we can determine
the net response simply by adding the expected
responses weighted by the probability that each
will occur. They chose to call this method "hit size
effectiveness", in that each hit of a particular size
has associated with it a particular effectiveness
for a particular endpoint . This model introduces a
level of sophistication in the calculation previ-
ously lacking and is being applied rapidly to a
variety of problems . At the present time its appli-
cation is limited to low doses where the occur-
rence of multiple events at the target can be
ignored . This appears, however, not to be a limi-
tation of the model so much as a limitation of the
present mathematical techniques for it . The con-
cept has the potential to be applied at therapeutic
doses to the clinic .
There are now sophisticated models capable of
simulating complex molecules such as the DNA
and capable of tracking individual atomic and
molecular transitions, at least for specific cases
[14, 15]. Such models may not be incorporated
into routine treatment codes for external beam
therapy in the immediate future . Nevertheless,
such analyses are becoming an integral aspect of
radioimmunotherapy and brachytherapy. There is
no doubt that their area of application is expand-
ing into HZE therapy (cf. the succeeding chap-
ter) and that it will ultimately be applied to rou-
tine clinical treatments .
Future Applications of
Microdosimetry in Therapy
The future of radiation therapy lies not in achiev-
ing uniform dose, but rather in achieving uniform
response in the treatment volume and uniform
response from patient to patient [21] . Recent
gains in conventional external beam therapy were
motivated in part by the results of clinical studies
with charged particles and neutrons showing the
need for uniformity and localization, a need
which cannot be eliminated at this time by the use
of exotic particles if the underlying physical
mechanisms are insufficiently understood [11] .
Studies in radioimmunotherapy and in
brachytherapy seem to reinforce the need for
microdosimetric input [22] . The maximum gains
are most certainly to be achieved with
microdosimetry-based treatment planning striv-
ing for a uniform response [11] . Likewise, preclin-
ical biological research is requiring an increas-
ingly sophisticated knowledge of the physical dis-
tributions . From the physics viewpoint, many of
the simplifying assumptions which were invoked
in the early stages of Microdosimetry are rapidly
becoming inadequate, and our abilities in physics
and physics research must expand accordingly.
As long as there is a need to consider physical
processes at the cellular and subcellular level,
there will be a need for Microdosimetric studies;
the two areas are equivalent .
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Modelling Heavy Ion Radiation Effects
Introduction
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Gesellschaft für Schwerionenforschung (GSI), Darmstadt, Germany
Therapy planning for charged particle beams
requires the knowledge of the biological effect of
a complex charged particle field. There are two
factors contributing to this complexity :
- In order to achieve a flat dose distribution
throughout the tumor volume, beams with dif-
ferent penetration depth and thus different
energies have to be superimposed .
- For particles heavier than protons, nuclear
reactions lead to abreakup of primary particles
and thus to an increasing contribution of lighter
fragments with increasing penetration depth.
Consequently, the composition of the radia-
tion field varies significantly throughout the
whole irradiated volume and will consist of a
spectrum of particles with different atomic num-
bers and energies at any given point. The situa-
tion is even more complex, because the radiation
field is not solely characterized by the physical
dose deposition . RBE effects have to be taken
into account and RBE is not a constant value .
Experimental results show, that a single variable
like LETis not sufficient to describe the RBE of
a particle beam [1, 2] . Instead, two variables like,
e.g ., LET and atomic number or energy have to
be used to characterize the RBE, which in turn
depends on the biological endpoint, the level of
the biological effect and may also differ for vari-
ous cell types.
As a consequence, it is impossible to deter-
mine the radiobiological characteristics at each
point of these radiation fields for all conditions
occuring in the therapeutical practice . Therefore,
biophysical models have to be used in order to
interpolate or extrapolate from experiments per-
formed under well defined conditions, e .g ., track
segment experiments with defined atomic num-
ber and energy.
Basic Considerations
The most obvious difference which can explain
the enhanced RBE of charged particles as com-
pared to photon fields is the different spatial
energy deposition pattern. Photons deposit their
energy nearly homogeneously throughout the
irradiated volume, at least when considering
dimensions of the order of the cell nucleus and
dose levels relevant for therapy.
In contrast, charged particles deposit their
energy by emission of secondary electrons in a
narrow region close to their trajectory (Fig . 1) .
The local dose distribution around the particle
path roughly follows a 1/r2-law, which is con-
firmed by experimental results as well as by
numerical calculations and Monte Carlo models
[3,4,5]. The radial extension of the dose distribu-
tion, i.e ., the track radius, is defined by the
highest energetic secondary electrons .
Thus, the track radius increases with increas-
ing specific energy of the primary particle . Dueto
the sharp decrease of the dose, the major fraction
of energy is deposited in a cylinder with a diam-
eter of the order of 1 gm around the path of the
primary particle even for highly energetic parti-
cles . The local concentration of energy deposition
suggests an explanation of the higher RBE of
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The radial dose profile of charged particles follows a 1/rz
dependence, resulting in sharp spikes with extremely high
local doses. The comparison with the size of a mammalian
cell nucleus (shaded area) shows, that the dose distribution
inside the nucleus is very inhomogeneous
charged particles as a consequence of a more
complex and thus less repairable damage.
Mainly two different approaches to model the
biological action of charged particles have been
developed, which focus on the specific spatial
energy deposition pattern:
1. the microdosimetric approach, which empha-
sizes the stochastical nature of the energy
depositions by the electrons ;
2. the 'amorphous' track structure approach,
which is basedon the radial dose distribution as
a continous distribution, representing an aver-
age over many tracks .
Because the microdosimetric approach is dis-
cussed in more detail in the preceding chapter, we
will focus here on the second type of models .
The Track Structure Model of Katz
and Coworkers
General Considerations
The radiobiological models developed by Katz
and coworkers [4,6-8] are based on observations
obtained with charged particle tracks in photo-
emulsions, where the spatial energy deposition
pattern can be directly made visible . The work
includes two major parts. As a first step, algo-
rithms for the calculation of the radial dose distri-
bution across the particle track are developed,
utilizing a simplified kinematics of the secondary
electrons. In a second step, these radial dose dis-
tributions are used to derive the biological
response to charged particle radiation .
As mentioned above, the basic idea behind the
radiobiological application of track structure
models is that the differences in the radiobiolog-
ical effects for different radiation qualities can be
attributed completely to their different spatial
energy deposition patterns . For X-rays as well as
for charged particles, the biological damage is
mainly produced by electrons . It is assumed that
the action of a certain local dose deposited by
electrons is independent of the physical process
leading to their production . If this assumption is
valid, charged particle radiobiological effects
should be predictable by an appropriate convolu-
tion of the X-ray-effect curve with the radial dose
distribution . This convolution is particularly easy
to apply in the case of point-like targets such as,
e .g ., small viruses or enzymes. These objects can
be interpreted as small detectors testing the local
dose in the particle track. The biological effect of
a local dose can directly be taken from the X-ray
effect curve, which is usually exponential and
determined by a single parameter like, e.g ., D37 .
Correspondingly, modelling of the inactivation of
viruses and enzymes was the first successful appli-
cation of the track structure principle to a radiobi-
ological phenomenon [4] .
Application to Mammalian Cell Survival
The application becomes more difficult in the
case of spatially extended targets such as mam-
malian cells, because the cell nucleus, which is
the assumed critical target, is considerably larger
(diameter typically 10 [tm) than the extension of
the radial dose profile . Therefore, the dose distri-
bution inside the cell nucleus is completely inho-
mogeneous (cf . Fig. 1) . In addition, the dose-
response curve after X-irradiation in general ex-
hibits a shouldered shape, in contrast to the purely
exponential dependence observed for viruses and
enzymes. Therefore, several modifications and ad
hoc assumptions have been suggested by Katz et
al . for the prediction of mammalian cell survival
after charged particle irradiation [6, 8] .
In order to handle the transition from shoul-
dered to exponential survival curves with increas-
ing LET, two different modes of inactivation are
introduced : y-kill mode and ion-kill mode. y-kill
dominates at low LET and represents the non-
linear dose-response curve showing a shoulder.
Ion-kill mode describes the case of efficient
energy deposition, dominating at high LET, so
that a single particle traversal is capable to pro-
duce sufficient damage for cell inactivation .
Accordingly, survival in the ion-kill mode is deter-
mined by a one-hit statistics and leads to purely
exponential survival curves .
The energy deposited by the particles is split
between the two inactivation modes. A certain
fraction acts in the ion-kill mode with survival
probability Pi,, and the remaining fraction in the
y-kill mode with survival probability P,, . The rela-
tive dose contributions for both inactivation
modes are given by a free parameter, which is
adjusted by fitting experimental survival curves
for charged particle irradiation . Because both
modes are assumed to act independently, the total
survival probability is given simply by the product
P = Pi,, x Py
	
(1)
In the case of extended targets the target size
plays an important role in order to reproduce cor-
rectly the stochastic properties of particle radia-
tion, e.g ., the number of particle traversals
through the cell nucleus. Experimental results
indicate, that the cell nucleus including the
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nuclear membrane is the sensitive target for
radiation-induced inactivation . In contrast, in the
Katz model a substructure with a size of approxi-
mately 1 [,m is assumed to be the sensitive target
for the ion-kill mode. In order to determine the
biological response to the passage of a charged
particle, the energy deposited in the critical target
is integrated according to the impact parameter of
the particle . Then, the inactivation probability is
taken from the X-ray survival curve at the corre-
sponding dose level, and inactivation cross sec-
tions are determined from the slope of the surviv-
al curves . As the target size in the model is
smaller than the geometrical nuclear size, all cal-
culated inactivation cross sections have to be
scaled by a factor of nine in order to achieve a
smooth transition between the low-LET and the
high-LET region [8].
It has been pointed out by Katz and coworkers
[6], that this model should be understood as a
phenomenological model, and that literal inter-
pretation of the parameters is not possible . Apart
from this disadvantage, the model calculations
reproduce the experimental results quite well,
and for a long time this model was the only one
able to reproduce the measured inactivation cross
sections over the whole LET range up to 15 000
keV/gm quantitatively correct. It was, in particu-
lar, the first model, which could explain the sepa-
ration of the inactivation cross sections as a func-
tion of LETinto different, Z-dependent branches
for very heavy particles. The complex 'hook'
structure of inactivation cross sections was attri-
buted to the correlation between particle energy
and track diameter and thus to track structure .
Similarly, the model has demonstrated its quali-
fication to describe other biological endpoints
including chromosome aberrations and mutation
frequencies as well .
Nevertheless, some problems arise from the
approach discussed above:
1. The algorithm for the calculation of inactiva-
tion cross sections in the ion-kill mode implies
an integration and thus averages the energy
deposited in the critical target . Because the tar-
get has a diameter of typically 1 Rm, the fine
structure of the radial dose distribution is
washed out by this method, and differences
48
	
M. Scholz
between particles with the same LET, but dif-
ferent energy and thus different track structure
will disappear.
2. The separation between y-kill mode and ion-
kill mode is artificial, and there is no direct
experimental evidence supporting two com-
pletely independent modes of inactivation .
3 . Due to the small target size assumed, calcu-
lated inactivation cross sections have to be
scaled by a factor of nine . If the complete
nucleus is assumed to be the critical target,
scaling should become unnecessary.
A Unified Track Structure Approach
Calculation of Local Biological Effects
Recently, a unified track structure model has
been developed, which combines to some extent
principles of microdosimetry and usual track
structure models [9-11] . Rather than the Katz
approach which uses the integral of the energy
deposited in the critical target, it is based on the
integration of the local biological effect . This dif-
ference is crucial especially in the case of shoul-
dered X-ray survival curves . The shoulder indi-
cates, that at high doses the same dose increment
is more efficient than at low doses. This consider-
ation is assumed to apply likewise in the case of
local dose depositions. A given energy deposited
as high local dose in a small subvolume of the
nucleus should be more efficient than the same
energy deposited as low local dose in a larger sub-
volume . Consequently, calculations based on the
total energy or average dose deposited in the
nucleus will always underestimate the biological
effect .
In order to determine the local biological
effect, an additional, but very general assumption
has to be made, which is concerned with the geo-
metrical structure of the sensitive target . In a first
approximation it is assumed, that the sensitivity is
homogenously distributed within the cell nucleus,
and that inactivation is the result of point-like
damages, so-called 'lethal events' .
After X-irradiation, the expectation value N,
i.e ., the average number of lethal events,
depends on the dose D . The fraction of surviving
cells can then be attributed to the cells, which
actually carry no lethal event. Assuming that the
distribution of lethal events obeys the Poisson
statistics, this can be written as
S(D) = eN(n) (2)
Vice versa, the number of lethal events can be
derived from the X-ray survival curve as
N(D) = 1nS(D) (3)
and rewritten, relating to the linear-quadratic
model as
N(D) = aD + ßD2	(4
Although lethal events are assumed to be dis-
crete, point-like events, the probability for their
induction at a given position can be described by
a continuous function, which depends on the dis-
tribution of sensitive sites . A homogeneous distri-
bution corresponds to a constant probability
within the nuclear volume and is defined by the
event density
v(D) = NyD) = 1nSVD) (5)
Equation (5) allows an easy calculation of sur-
vival in the case , of partially irradiated nuclei or
inhomogenous dose distributions. The expecta-
tion value for the number of lethal events is
obtained by an integration of the event density
v(D). For example, if only a part AV of the
nucleus is irradiated with a constant dose D, the
average number of lethal events will be
Nlethal = N(D)V (6)
and in the case of an inhomogeneous dose distri-
bution D(x,y,z), dependent on the position in the
nucleus, Nlethal is obtained by an integration over
the nuclear volume :
Nlethal = f,,fyfZ v(D(x,yz))dxdydz =
f f f 1nS(D x,y,z)) dxdydz (7)XvZ V
As in Equation (2), the fraction of surviving
cells is given by the cells carrying no lethal event,
and thus survival is calculated to be
S = e-rr 1 -1'a'
As can be seen from Equation (7), three sets
of experimental data will be required for the pre-
diction of survival after charged particle irradi-
ation:
1. the local dose distribution D(x,y z), which is
defined by the radial dose distribution D(r)
inside the particle track andthe position of par-
ticle trajectories ;
2. the geometrical description of the cell nucleus,
defining the sensitive volumeV;
3. the X-ray survival curve S(D), which is used to
derive the average number of lethal events
N(D) and the event density v(D) .
Comparison with Experimental Results
Figure 2 compares model calculations with exper-
imental results obtained at the UNILAC at GSI
(Darmstadt) . The comparison is based on inac-
tivation cross sections, corresponding to the slope
of the survival curve as a function of the particle
fluence . There is a slight underestimation of the
efficiency in the LET range from 100-300 keV/
[tm, but the general structure of the LETdepend-
ence is reproduced very well, even though these
calculations were based on several simplifica-
tions, e .g ., the same size and radiosensitivity for
all cells of a population and a cylindrical shape of
the cell nucleus .
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Fig . 2. Comparison of model calculations for inactivation
cross sections oinact (full lines) with experimental results
obtained with V79 Chinese hamster cells (symbols, redrawn
from (12])
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Fig . 3 . Inactivation cross sections for V79 Chinese hamster
cells as a function of the specific energy for carbon, argon
and uranium ions
The key to the understanding of the complex
hook structure at very high LETvalues is depicted
in Figure 3, where inactivation cross sections are
plotted as a function of the specific energy for
three representative ion species . At low energies,
all ions exhibit the same efficiency. The inactiva-
tion cross section is calculated to be 50 lime, which
is equal to the effective geometrical size of the
nucleus. Thus, a single traversal of any of the ions
is sufficient to kill the cell with a high probability.
With increasing energy, changes in LETas well as
increasing track diameters are reflected in a
change of the inactivation cross section a. For the
energy range shown in Figure 3, uranium ions
exhibit only a slight decrease in LET, but a signifi-
cant increase of the track radius . Because of the
very high LET, high local doses are deposited even
at large distances from the trajectory. Therefore,
not only direct traversals of the nucleus, but also
traversals in a certain distance can inactivate the
cell . The probability of these 'indirect' inactivation
events increases with the track diameter, resulting
in a rise of the inactivation cross section.
The LET of argon ions declines from 3000 to
800 keV/[tm for specific energies of 1 to 20 MeV/
u, and despite the fact that the increase of the
track radius is exactly the same as for uranium
ions, the inactivation cross sections remain nearly
constant over the whole energy range. This is a
consequence of the much lower local doses at
large distances from the track center, so that inac-
tivation by a particle traversal outside the nucleus
is very unlikely. In contrast, only the high local
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doses in the center of the track have a high prob-
ability to kill the cell, and thus direct traversals
are required at all specific energies for the inac-
tivation of a cell . For carbon ions, the decreasing
LET dominates the ß-E-dependence . Here, only
low energetic particles deposit high local doses
sufficient to kill the cell by a single traversal. As a
consequence of the decreasing LET with increas-
ing specific energy, the energy deposition per par-
ticle traversal and thus the probability of inactiva-
tion, decreases as well .
For light particles like protons, helium and car-
bon ions, which are more relevant for therapeutic
applications, details of track structure play also
an important role . This is demonstrated in Figure
4, where calculated RBE values are compared at
different survival levels . At a given LET, the
lighter particles are more efficient as compared to
the heavier species. This higher efficiency is a
consequence of the higher local doses in the track
of the lighter particles, resulting from a lower
energy and smaller track radius of these particles
as compared to heavier ones of the same LET. In
addition, the position of the RBE maxima
depends on the atomic number. Whereas protons
reach a maximum RBE at approx . 30 keV/p,m,
this maximum is shifted to approx . 90 keV/[tm for
a-particles and to 300 keV/Rm for carbon ions .
These model predictions are in good agreement
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Fig . 4 . Model predictions for RBE as a function of LET for
protons, a-particles and carbon ions in the energy range of
1-20 MeV/u .
with experimental results reported by several
authors [2,13,14] .
For LETvalues above 100-300 keV/gm, a rapid
drop of RBE is predicted. This decreasing RBE
cannot be attributed to the still increasing local dose
depositions, but is related to the stochastic proper-
ties of particle radiation. For LETvalues above 300
keV/p,m in the saturation region of the inactivation
cross sections, particle fluences at the 1%-survival
level lead to an average of a few particle traversals
per cell nucleus. According to the Poisson statistics,
this corresponds to large cell-to-cell fluctuations of
the number of particle traversals, ranging from cells
with no traversal up to cells with many traversals .
The decrease of RBE can then be demonstrated
most clearly in the case of 'overkill', where a single
particle traversal deposits more energy than neces-
sary to kill a cell . Consequently, only cells with no
traversal will survive. If a cell, however, is hit by
more than one particle, the additional traversals are
ineffective and their energy is wasted, leading to a
reduction of the RBE at high LET. However, even
at lower LET values cell-to-cell fluctuations of
energy depositions lead to a significant reduction of
the RBE [15] .
With respect to these stochastic properties it is
obvious, that mean doses are not adequate to
describe the biological effects of particle radia-
tion . Instead, the concept of particle fluences and
related quantities including inactivation cross sec-
tions should be used .
Biological Effects of
Complex Charged Particle Fields
As mentioned at the beginning, charged particle
fields applied in radiotherapy are more complex
than those used for the track segment experiments
discussed in the previous section. In order to calcu-
late the biological effect of such complex fields,
time consuming numerical integrations have to be
performed for every point of the radiation field .
Therefore, approximations which preserve the
basic ideas of the model calculations but reduce
the required computer time are necessary.
The basic idea of the approximations is to sep-
arate the two effects which determine the RBE of
charged particle radiation:
- The energy density in the center of the track
and the corresponding high local dose which
lead to an enhanced relative biological effi-
ciency of a single track.
- Cell-to-cell fluctuations of energy depositions
due to the stochastic distribution of particle tra-
versals through the nucleus which reduce the
overall biological efficiency.
The separation is achieved by introducing a so-
called potential or 'intrinsic' RBE, denoted as
IRBE. This IRBE is a hypothetical value, de-
scribing the situation where all cell nuclei are tra-
versed by exactly one particle . Of course, this
IRBE cannot be measured directly, but it can be
easily calculated . The measurable RBE is then
predicted by folding the IRBE values with the
stochastic distribution of the particle traversals .
The advantage of this approach is, that time con-
suming numerical integrations have to be per-
formed only once for the calculation of IRBE,
which are than tabulated and used for the calcula-
tion of survival in complex charged particle fields
by means of avery fast iterative algorithm [11] .
Figures 5 and 6 show a comparison of calcula-
tions based on the approximations discussed
above and corresponding experimental results.
The first step from track segment experiments to
N
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171 Exp.,130mm
-Model,0mm
.. . . . Model,60mm
-- - Model,120mm
--- Model,130mm
0 5 10 15 20 25 30 35 40
Entrance particle fluence (10'/cm2)
Fig . 5. Survival curves at different penetration depths of a
270 McV/u carbon beam in water (Lines : model calcula-
tions ; symbols : experimental data) . Survival is plotted as a
function of the entrance particle fluence at 0 mm penetra-
tion depth . Model calculations include the effects of frag-
mentation of the primary beam
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Penetration depth (mm H20)
Fig . 6. Comparison of physical dose distribution (top) and
biological effect (bottom) of a 270 MeV/u carbon beam pen-
etrating through tissue, (simulated using a water column of
variable thickness) . Entrance particle fluences of 2 x 10'/cmZ
and 5 x 10'/cmZ correspond to doses of 0.44 and 1 .1 Gy at
0 mm penetration depth, respectively
the more realistic situation is to include effects of
fragmentation of the primary beam andthe corre-
sponding build-up of lighter fragments due to the
penetration of the beam through matter. The
experiments were performed using water as
tissue-equivalent absorber material . The survival
curves were measured at different penetration
depths of a 270 MeV/u carbon beam in water. For
the survival predictions, fragment spectra were
taken from a model which was adjusted to repro-
duce the experimental data [16] . In Figure 5, sur-
vival as a function of the particle fluence is shown
for four different penetration depths . Figure 6
comprises survival values for two different parti-
cle fluences plotted versus the penetration depth,
which yields the specific depth-dose distribution
of charged particles, the Bragg peak. There is a
good qualitative and quantitative agreement
between calculation and experiments, justifying
the discussed approximations.
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Concluding Remarks
Investigations of track structure models reveal
that many of the high-LET specific aspects,
including the RBE-LET dependence, inactiva-
tion cross sections as a function of LET and
energy, the Z-dependent shift of RBE maxima
etc., can be attributed to the different micro-
scopic pattern of energy depositions of charged
particles as compared to photons . The approach
discussed here explicitly disregards the stochastic
nature of the energy depositions by individual
electrons in particle tracks, but it uses the local
radial dose as a mean or expectation value of the
individual events . The predictions based on the
average radial dose profile are in good quantita-
tive agreement with experimental results . It
seems that in standard survival experiments,
where a large number of biological objects is
irradiated with a large number of particles, the
average radial dose profile is representative for
the biological effect . As it has also been shown
that the model reproduces the survival curves for
decelerated beams including the effects of the
lighter fragments, it is expected that similar cal-
culations will agree with experiments applying
superimposed Bragg peaks, as in the treatment of
extended tumor volumes .
Differences in sensitivity and repair capacity
which translate into different slopes and shoul-
ders of the X-ray effect curves, are directly inte-
grated into the calculations by using the X-ray
curves as input for the predictions of the response
to charged-particle exposure . It will be necessary
to simulate the response of different cell types
from tissues relevant for the therapeutic situation
and to compare the response of the healthy tissue
in the entrance channel with the response of the
tumor cells . These calculations can help to
develop guidelines for the optimization of differ-
ent treatment modalities .
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Early and Late Responses to Ion Irradiation
Introduction
R . SCHULTE
Loma Linda University Medical Center, Loma Linda, CA, USA
A general trend in the development of radiation
therapy has been to improve the three-
dimensional dose distribution resulting in better
normal tissue sparing and allowing higher doses
to be delivered to tumors . The current surge of
interest in ion beam therapy throughout the
world reflects this trend. But even with sophisti-
cated ion beam irradiation tumor and normal tis-
sues adjacent to the tumor can never be
completely separated, because almost all malig-
nant and even some benign tumors infiltrate into
the surrounding normal tissues. As the exact
extent of this microscopic infiltration is usually
unknown, the radiation oncologist must include a
variable shell of normal tissue in the treatment
plan, which is assumed to be infiltrated by tumor
cells and needs to be treated with therapeutic
doses of radiation. Particularly, when large and
irregular targets are treated, the amount of nor-
mal tissues included in the high dose region may
be comparable or even larger than the tumor vol-
ume itself.
Understanding the pathophysiology of normal
and tumor tissue responses to ionizing radiation
plays, therefore, a key role in clinical applications
ofion radiation . Particularly, for the development
of innovative clinical therapy protocols utilizing
ion beams it is important to know and to under-
stand the responses of normal and tumor tissues
to ion irradiation in order to achieve a maximum
benefit from this treatment modality.
Basic Concepts
Definition of Early and Late Tissue
Responses
Tissue responses to ionizing radiation are com-
monly divided into early and late (alternatively,
acute and delayed) effects reflecting the time
after irradiation at which the biological or clinical
endpoint is typically observed . The same concept
is also applied to normal tissues which are classi-
fied as early or late responding tissues depending
on the time after irradiation at which the clini-
cally relevant effects occur. The latter definition,
however, is not always compatible as early and
late reactions can occur in the same tissue . Atypi-
cal example is skin which can develop an acute
erythema within a few hours followed by des-
quamation days or weeks after the irradiation due
to depletion of the basal stem cell layer. Even-
tually, a delayed wave of damage is seen many
months to years later evidenced by slow develop-
ment of telangiectasis, fibrosis, atrophy and - in
its severest form -necrosis .
Cell Depletion as the Origin of Radiation
Effects in Tissues
Sufficient evidence has accumulated that both
acute and late radiation effects are caused by a
combination of parenchymal, endothelial and
stromal cell depletion due to mitotic death. It is
likely that most, if not all, normal tissues and pos-
sibly many tumor tissues show a similar pattern of
response which can be divided into two distinct
54
	
R. Schulte
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Normal Tissue days -weeks-r
Late Responding weeks-monthsNormal Tissue ----,
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Effect
Initial
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Tissue Architecture and Volume Effects
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Parenchymal Cell ' Non-parenchymal
Depletion t Regeneration Cell Depletion
waves of damage (Fig . 1) : the parenchymal
response (e .g ., mucositis, pneumonitis) which is
due to depletion of normal tissue parenchymal
cells or tumor clonogens, and the non-
parenchymal response (e.g ., fibrosis in submu-
cosa or lung) which usually, but not necessarily,
occurs after the parenchymal response . The latter
is of stromal etiology andmanifests as chronic tis-
sue damage. Secondary injury may be seen at the
time of non-parenchymal response in parenchy-
mal cells of normal tissues which is related to
damage of the microvasculature and loss of sup-
ply with oxygen and other nutrients . Finally, pro-
gressive atrophy and eventually necrosis may
occur due to continuous loss of capillaries, endar-
teritis and obliteration of arteriols or even nar-
rowing and occlusion of major arteries . There has
been a long-time debate between those who
believe in a mere vascular origin of late injury in
normal tissues and those who claim that delayed
radiation effects are primarily the result of paren-
chymal and/or stromal cell depletion with vascu-
lar effects secondary. It is likely, however, and
there is ample evidence that in many tissues late
radiation damage is caused by a combination of
depletion in more than one cell compartment.
Most radiation therapists are intuitively aware of
the importance of the volume factor in radiation
therapy. It has long been known that the proba-
bility of normal tissue complication increases with
Laie Effects
Fig. 1. Schematic illustration of the path-
ways leading to radiation effects in
acutely and late responding tissues . Note
that the two tissue types differ with
respectto the timing of the initial (paren-
chymal) response
increasing area or volume irradiated and that the
probability of tumor control decreases with
increasing tumor volume . Furthermore, radiation
damage to larger areas or volumes of normal tis-
sue appear to be less tolerated by patients than
smaller amounts of tissue even when the average
grade of tissue damage is equal.
Over the last decades, many investigators have
tried to define a scientific basis for volume effects
in radiation therapy [1-8]. Ageneral concept that
has emerged from these studies is that of inde-
pendent tissue subunits, which means that each
subunit responds to radiation as if it were isolated
from all surrounding units . Withers et al . [9] sug-
gested that some tissues are organized into func-
tional subunits (FSUs) which are either structur-
ally defined or undefined tissue entities . Typical
structurally defined FSUs are nephrons of the
kidney, or alveoli of the lung . The FSU model
implies that FSUs can be repopulated when at
least one single cell of an individual FSU sur-
vives. Cells from neighboring FSUs cannot sub-
stitute it .
Another important concept in the context of
volume effects is that of serial and parallel tissue
architecture, which is schematically illustrated in
Fig . 2. The tissue or organ may be considered as
an arrangement of equal-sized subvolumes which
respond to radiation independent of each other.
In a serial organ (Fig . 2A) loss of function in any
one of these subvolumes results in a clinically rel-
evant complication . This type of response has
been called critical element response . A typical
serial organ or tissue is white matter of the
Fig . 2 . Schematic representation of three different tissue
radiation-response types which are related to volume
effects . (A) Serial organ response ; (B) parallel organ
response ; (C) graded response (for further explanation see
text)
spinal cord . Interruption of any of the long spinal
cord tracks due to necrosis within a small volume
of white matter leads to a serious function loss . In
a parallel organ (Fig . 2B) a clinically relevant
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complication can be expected when a certain frac-
tion of subvolumes has been destroyed or has lost
useful function . This type of response has also
been called integral response . Examples for
parallel organs include the kidney, lung, or liver.
Over the last few years several authors have
stressed the importance of organization of tissues
into serial or parallel arrangements of subunits
for radiation tolerance and volume effects [3, 7,
9] .
Serial type tissues or organs may exhibit two
different types of volume effects . Firstly, when
the irradiated volume is reduced below a certain
size, a steep increase in tolerance is observed, for
example, in rabbit brain or rat spinal cord
[10-13]. This has also been observed in patients
treated with functional radiosurgery, when very
large single doses are needed to destroy very
small amounts of brain tissue . This phenomenon
may be explained by "penumbra effects" : when
the irradiated volume is surrounded by unaf-
fected tissue, migration of target cells from the
surrounding tissues or diffusion of oxygen, other
nutritients, or response-modifying cytokines may
increase the tolerance of the irradiated volume .
This means that the assumption of independence
of individual subvolumes may not generally hold,
particularly, when neighboring tissue volumes
receive largely different dose levels . Secondly, for
larger volumes a less dramatic volume depen-
dence has been observed for serial type tissues,
which is predictable purely based on statistical
principles including the assumption of indepen-
dent subvolumes [3] .
The volume effect in tissues or organs with
parallel architecture is in many respects different
from that of tissues or organs with serial architec-
ture [8] . When only relatively small amounts of
parallel organs, such as lung, kidney, or liver are
irradiated, the functional outcome will show no
volume dependence . Once, however, a critical
fraction of tissue subunits in such organs has been
destroyed, a steep increase in the probability of
complication (i .e ., loss of organ or tissue func-
tion) is observed . It should be noted that not all
tissue subunits may be equally important for
proper organ function and that loss of certain
areas in a parallel organ may be functionally less
important than others .
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Both serial and parallel organs may show
graded responses after irradiation (Fig . 2C) . A
graded response means that there is a gradual
increase in the severity of acute or late reaction as
a function of dose . Most acute radiation effects,
e.g ., skin reactions, are graded responses, but
also many late effects can be categorized accord-
ing to their grade (e .g ., fibrosis, intellectual func-
tion loss etc.) . When graded responses are
defined per unit area or volume of tissue, they
seem to be relatively independent of the area or
volume irradiated at a given level of dose . For
example, if a certain average grade of skin ery-
thema is observed after irradiation to a certain
dose it tends to be independent of the total area
irradiated . On the other hand, larger areas or vol-
umes of tissue affected by radiation are less likely
to be tolerated by patients than comparably small
areas .
Tissue Effects
In this section the results of experimental studies
of ion irradiation effects on normal andtumor tis-
sues will be reviewed . These studies have been an
important part of the research programs leading
to the clinical use of protons, helium and heavier
ions at the Harvard Cyclotron Laboratory (HCL)
in Massachusetts and the Lawrence Berkeley
Laboratory (LBL) in California . One important
aspect of these studies has been to define the
RBE of ion beams with respect to tolerance doses
for organ and tissue systems that were judged to
impose critical dose limitations .
Clinical RBE values, which are usually based
on the results of experimental studies, play an
important role in present and future ion beam pro-
tocols and in treatment planning of ion beam ther-
apy because they determine the maximumphysical
dose considered not to exceed an acceptable risk
of complication probability in critical normal tis-
sues and the minimum physical dose required for a
sufficiently high probability of tumor control . One
must remember, however, that experimentally
determined RBE values depend on the particular
experimental set-up and that clinical RBE values
derived from these studies must be used prudently
(cf. succeeding chapters) .
The following review focuses on the major
dose-limiting critical organs and tissues, i.e ., skin
and the gastrointestinal tract as indicators for
early radiation effects, and lung and spinal cord
as important late responding organs . For the sake
of brevity, other valuable indicators for early
(e.g ., testes) and late (kidney, lens) reactions can-
not be discussed .
Early Normal Tissue Responses
Skin
Skin, although not a critical organ in the stricter
sense of the term, is an important dose-limiting
tissue as its radiation side effects contribute sig-
nificantly to both early and late patient morbidity.
In addition, skin has been traditionally used to
study RBE effects of new radiation modalities
[14] .
Different animal skin systems have been used
such as the mouse foot [15], mouse thigh [16], or
mouse flank [17] . RBE values derived from these
studies are characterized by relatively large con-
fidence intervals, typically in the order of
20-25% of the mean value.
Raju and Carpenter [15] performed an ex-
tensive comparative study of mouse skin effects
with various ions ranging in mass from protons
to argon ions and using 6°Co-y-rays as refer-
ence radiation. They found that the time course
of development of skin reaction and sub-
sequent healing was similar for all radiation
modalities indicating that epithelial cell depletion
and repopulation are not principally different
when high- and low-LET radiations are com-
pared.
Single dose RBEvalues for an early skin reac-
tion of grade 1 in mouse skin obtained by these
investigators are summarized in Table 1. For the
lighter ions (protons and helium ions), the RBE
in both the peak andthe plateau region was found
to be only slightly above 1.0 . With increasing ion
charge the RBE increases both in the peak and
the plateau region and for neon and argon the
RBE of peak and plateau region are approxi-
mately equivalent, The highest peak-to-plateau
ratio was found for carbon ions . The RBE values
Table 1 . Single dose RBE values (RBEsd) for early skin reac-
tions in mouse skin after irradiation with various ions in the
peak (pk) and plateau (pl) region of a 10 cm SOBP ionization
curve . From Raju and Carpenter (151
reported by Raju and Carpenter are in good
agreement with those reported by Leith et al .
[17-19] who performed similar experiments in
mice .
While the mouse skin RBE studies were per-
formed with single doses, Leith et al . [20] inves-
tigated the response of hamster skin to various
fractionation schemes with either X-rays or car-
bon ions using single, split or multiple exposures .
RBE for acute skin reaction was obtained in the
proximal portion of a400 MeV/u carbon ion 4 cm
SOBP From the data obtained by these investiga-
tors a maximum RBE of 2.3, and an RBE at 2Gy
per fraction of 2.1 was derived . When comparing
these values to the single dose RBE in 'fable 1,
there appears to be a trend towards increased
RBE values for fractionated exposures, as
expected from basic principles . For protons, the
fractionation effect seems to be less pronounced :
a multi-fractionated dose study in mice using 20
fractions delivered with the center of a 160 MeV
modulated proton beam performed by Tepper et
al . [21] resulted in an RBE value of 1.1 for acute
skin reactions, which corresponds to the single
dose RBEvalue obtained by Raju and Carpenter
[15] .
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Gastrointestinal Tract
The mouse gut microcolony method, which was
originally developed by Withers and Elkind [22],
has found wide application as a clonogenic assay
for acutely responding tissues and has also been
used for comparison of radiations of various LET
values, both neutrons and heavy ions (see also
Chapter 9) . Briefly, in this assay the mice are sac-
rificed three to four days after irradiation and
hematoxylin-eosin histologic sections of the jeju-
num are prepared . The number of regenerating
crypts per circumference is then determined
according to criteria established by Withers and
Elkind . Assuming a Poisson distribution of the
number of surviving cells per crypt, the number
of surviving cells per circumference is calculated .
Table 2 summarizes the results of two such
studies by Tepper et al . [21] and Goldstein et al.
[23] . An increasing effectiveness of ions is seen
with increasing ion charge (and mass) . As the ion
charge increases, the increase of RBE is first
observed in the peak region of the Bragg peak
ionization curve and then extends to the plateau
region . For ions up to the mass of carbon, the
quality of the plateau region radiation is almost
independent of the ion species and is character-
ized by RBE values slightly above 1.0 . The Bragg
peak radiation of protons and helium ions is also
only slightly more effective than 6°Co-'Y-radiation,
while the Bragg peak radiation of carbon and the
heavier ions has high-LET character. When the
different ions are compared, carbon ions are
characterized -as in the case of skin (Tab . 1) - by
the highest peak-to-plateau RBE ratio .
Late Normal Tissue Responses
Compared to the number of ion beam studies
using early endpoints, there is a relative paucity
of studies evaluating the chronic response of vi-
tally important organs to ion beams. Late
response studies are difficult to perform because
they are time-consuming and expensive and often
confounded by the limited life span of rats and
mice . In order to be concise, only lung and spinal
cord, the two late responding normal tissues in
Ion Energy
(MeV/U)
Location RBE.® Peakto-
plateau
ratio of
RBE,d
Proton 160 pk 1.1 0.9
pl 1.2
Helium 910 pk 1.1 1
pl 1.2
Carbon 400 pk 1.5 1.25
pl 1.2
Neon 400 pk 1.7 0.85
pl 2.0
Argon 400 pk 1.9 0.9
PI 2.1
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Table2. RBE values for single (RBEsd) and fractionated doses
(RBEZ and RBE...) for jejunal crypt cell survival after irradi-
ation with various ions in different positions of the SOBP ion-
' reference radiation
Lung
which most information on ion beam responses
have been collected, will be discussed below.
Lung is an organ where complex cell kinetic
changes determine the course of radiation injury
[24] . No clinically important physiological
changes are observed during the first three
months after irradiation, although microscopi-
cally there seems to occur a marked increase of
inflammatory cells in the alveolar septa and
spaces as has been observed in hamster lung dur-
ing the first month after irradiation [25] . The first
wave of clinically significant damage, which is
called radiation pneumonitis, shows up 3 to 6
months after irradiation. It is histologically char-
acterized by capillary loss and type II pneumo-
cyte depletion . After single doses exceeding 10
Gy in mice, the onset of capillary injury and
pneumocyte depletion is accompanied by
platelet-induced thrombosis and occlusion of
many alveolar capillaries . If this acute phase of
ization curve (pk = peak, pl = plateau, dp = distal peak, mp =
central peak, pp = proximal peak). Data for protons from Tep-
per et al . [21], all other data from Goldstein et al . [23]
lung damage is survived, an attempt of repair is
seen over the next six months with ingrowth of
new capillaries which, after higher doses, is
accompanied by excessive growth of collagen
within septal spaces . The end result at 12 months
after irradiation with single doses higher than 10
Gy is lung fibrosis, which is characterized by a
reduced number of capillaries and alveolar air
spaces and thickening of alveolar walls in most of
the remaining alveoli.
Woodruff et al . [26, 27] investigated the late
responses of hamster lung after single doses of
230 kVp X-irradiation and 375 MeV/u neon ion
irradiation in the plateau region . Dose levels
ranged from 2.25-15 Gy for X-irradiation and
from 1.5-10 Gy for neon irradiation . Hamsters
were chosen for these studies as they are free
from chronic lung disease. Using morphometric
techniques, these investigators found that 12
months after irradiation with either X-rays or
neon ions the volume density of pulmonary sep-
tums, septal cells, collagen, and type II pneumo-
cytes was increased, while the volume density of
alveoli, empty alveolar space, and capillary
Radiation Source Energy
(MeV/u)
Modulation
(em)
Location RBE. RBE2 RBEsd Peak-to-
plateau ratio
of RBEZ
'Cobalt' - - - 1 1 1 -
Proton 160 10 pk 1.2 1.3 1.2 1 .1
pl 1.2 1.2 1.1
"Cesium' - - - 1 1 1 -
Helium 225 8 pk 1.5 1.5 1 .2 1 .2PI 1.3 1.3 1 .1
Carbon 400 10 dp 2.4 2.2 1 .5 1 .7
mp 1.8 1.8 1 .4 1 .4
pp 1 .5 1.6 1 .4 1 .2
PI 1 .2 1.3 1 .3
Neon 557 10 dp 3.4 3.0 1 .6 1 .4
mp 3.0 2.6 1 .5 1 .2
pp 3.0 2.7 1 .5 1 .3
pl 2.3 2.1 1 .4
Argon 570 10 dp 4.3 3.6 1 .8 0 .8
mp 4.5 3.8 2.0 0.9
pp 4.3 3.6 1 .9 0 .8
pl 5.2 4.3 2.1
lumen was decreased. Most of these changes were
dose dependent and the RBE for these histologi-
cal endpoints varied between 1.6 and 1.8 .
While these RBE values are not significantly
different from RBE values for early endpoints
(see Tables 1-2), they may not reflect clinically
relevant RBE values as they were obtained after
irradiation with large single doses. Travis and
associates [28] investigated the influence of frac-
tionated irradiation with 1, 4, or 7 fractions of X-
rays or neons ions in the center of a 4 cm SOBP
on mouse lung function . They found that the
RBE increases markedly from a single dose value
of 1.5 to a value of 3 .3 at 2 Gy per fraction and a
maximum of 4 .3 in the low dose limit.
Spinal Cord
Similar to lung, the central nervous system is an
important dose-limiting tissue, that often compels
the radiotherapist to underdose nearby tumor tis-
sue. In particular, spinal cord is considered an
important dose-limiting structure in the treatment
of many head and neck and intrathoracic tumors
as overdosing the cord may lead to serious and
irreversible injury. Ion beams appear to be an
attractive radiation modality for the treatment of
such tumors, as isodoses can literally be
"wrapped" around the cord .
Spinal cord studies in rats with heavy ions at
LBL have been performed by Leith et al . [18, 29,
30] . Table 3 summarizes a few results which illus-
trate the major trends .
Table 3. RBE values for single (RBE sd ) and fractionated doses
(RBE2 and RBE,,,,) for rat spinal cord at the isoeffective dose
level (EDso) for paralysis after irradiation with various ions
Radiation
	
Energy Modulation Location
Source (Mev/u) (CM)
230 kVp
X rays
Helium
Carbon
Neon
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Even more pronounced than for late effects in
lung, there is a fairly dramatic increase of RBE
for 50% radiation myelopathy with decreasing
fraction size . For carbon and neon ions the RBE
increases from single dose values, which are close
to those reported in early responding tissues, to
values between 4 and 6 at 2 Gy per fraction and
between 6 and 10 at the low dose limit. Despite
the evidence that an increase of isoeffective dose
with decreasing fraction size occurs after ion
irradiation as well as after X-irradiation, it must
be appreciated that at small doses per fraction the
RBE of ions for late effects in spinal cord is con-
siderably higher than at higher doses per fraction .
Therefore, caution is necessary whenever spinal
cord or other CNS tissues are exposed to multiple
small fractions of high-LET ion irradiation .
Carcinogenesis
The mutagenic and carcinogenic effect of ionizing
radiation have long been recognized under exper-
imental, clinical, and expositional conditions and
have extensively been documented (for review,
cf. e.g ., [31]) . Induction of secondary cancers
many years after treatment with ionizing radia-
tion, although fortunately relatively rare, is of
major concern, particularly in young patients and
those irradiated for benign conditions . With
regard to treatment with ion irradiation an impor-
tant question is whether the high-LET compo-
nent will lead to a higher incidence of cancer
induction than observed after low-LET X- or 1' -
ray irradiation .
based on data from Leith et al . [30] . Irradiations were per-
formed in the plateau (pl) and the peak (pk) position of the
SOBP ionization curve
so(GY) RBE RBE2 RBE,d
le Dose Fract. Dose
- - - 25 .6 49 1 1 1
225 6 pk/pl 23 .8 - - 1.1
400 4 pk 17 .5 25 .1 6.8 4.1 1.4
pl 17 .9 37.6 9.2 5.5 1.5
425 4 pk 13 .8 22.5 7.7 5 .3 1.9
PI 17 .5 27.2 7.2 4.5 1.5
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Studies of mutation induction in vitro after
exposure to accelerated ions have shown that ion
beams in the LET range below 200 keV/[tm are
many times more effective with respect to induc-
tion of mutations and neoplastic transformation
than lowLET radiations . The relationship
between RBE and LET for neoplastic trans-
formation andmutation induction shows-similar
to that of cell inactivation - a peak between 90
and 200 keV/[tm. In the peak region, however,
the RBEs for mutation induction and neoplastic
transformation appear to be higher than those for
cell inactivation [32, 33] .
The mutagenic and carcinogenic potential of
ion beams has also been measured in animal sys-
tems [34-37] and it was found that the effective-
ness of ions in producing secondary tumors per
particle was approximately constant for ions with
LETvalues larger than 100 keV/[.m .
Fractionated exposure to ion beams was found
to be about 1.5 times more effective than the
same dose delivered in a single fraction (p <
0 .01), which is explained by the existence of a
sensitive phase for cell transformation in the cell
cycle which is more likely to be hit when the num-
ber of fractions increases . Other interpretations
include the effect of reduced cell killing for pro-
tracted as compared to acute exposure increasing
the number of cells at risk for transformation,
and the possibility that radiation acts as a pro-
moter of cells which were initiated during prior
exposures.
Tumor Responses
The response of tumor tissues to radiation is in
many respects similar to that of normal tissues.
There is, however, a radiobiologically important
difference between normal and tumor tissues: a
variable fraction of hypoxic cells is present in
many tumors, particularly, in larger and rapidly
proliferating tumors, which is usually not found in
normal tissues (see the preceding section for
details) . Studies of tumor responses to ion beam
irradiation have, therefore, focused on both the
increased RBE and the reduced oxygen enhance-
ment ratio (OER) of high-LET ion beams, which
may result in a therapeutic benefit.
RBE values measured for different tumors
confirm the general trends already described for
normal tissue responses to ion beam irradiation .
For helium, carbon, or neon the peak region had
a higher RBE than the plateau region ; for argon
the RBEmeasured in the peak was slightly above
or below that in the plateau, indicating a satura-
tion effect in the peak region . RBE values are,
generally, similar to those observed for early
responding normal tissues or lower than those for
late responders .
In all experiments evaluating the effect of oxy-
genation on the response to ion irradiation, the
RBE for killing hypoxic cells was larger than that
for killing oxygenated cells . The differences
between hypoxic and oxic RBE values increased
with increasing LET of the ion irradiation . The
higher RBE for hypoxic cell kill may be interpret-
ed in terms,of the additional damage produced in
the presence of oxygen due to low-energy deposi-
tion events which prevail after low-LET irradi-
ation, while the damage due to high-energy
deposition is widely unaffected by the presence or
absence of oxygen . The larger RBE for hypoxic
cells is also reflected in a reduction of the OER,
particularly for high-LET ion beams.
Summary and Conclusions
Irradiation of deep-seated tumors with ion
beams, replacing conventional X-ray or y-ray
sources, offers the possibility of increased tumor
doses without increasing the dose to surrounding
normal tissues . Despite the superior three-
dimensional dose distribution achievable with ion
beams, normal tissues can, however, never be
completely excluded from the dose delivered to
designated target tissues . Typically, in the treat-
ment of malignant tumors infiltrated normal tis-
sues have to be intentionally irradiated . There-
fore, knowledge and understanding of early and
late effects of ion beams is important for their
clinical application.
Most early and late effects have a common
pathophysiological pathway, namely, the deple-
tion of parenchymal and stromal target cells.
Early and late responses differ in the time inter-
val after irradiation at which they occur due to
differences in cell kinetic parameters of pertinent
target cells. Furthermore, tissues differ in their
response to radiation according to the regenera-
tive capacity of target cell populations, which is
usually large in early responding epithelial tissues
and low or absent in late responding parenchymal
or stromal cell populations .
Tissue effects to radiation are also modulated
by the volume of tissue irradiated . Volume effects
are particularly important for conformal ion
beam radiation therapy, as smaller amounts of
normal tissue are included in the target volume
compared to conventional radiation therapy,
although these limited amounts of tissue may
receive a greater dose . Volume effect models and
experimental studies are needed which would
allow the prediction of the complication probabil-
ities under these circumstances.
Ion beam irradiation up to average LETvalues
of 200 keV/[,m is usually more effective at the
same level of absorbed dose than low-LETX-rays
or Y-rays . This increased effectiveness is observed
at all levels of biological effects including cellular
inactivation, mutagenesis, malignant transforma-
tion and functional tissue responses, and is usu-
ally expressed in terms of RBE values tied to a
particular form of radiation. When applying the
RBE concept in clinical practice one needs to be
aware of the many factors besides LET that may
modify the RBE. Among these factors are the
depth of irradiation, dose per fraction, and tissue
type . Similar to the experience with high-LET
neutron beams, the RBE of ion beams tends to
be larger at small dose levels and also for late
effects . Another concern is the increased RBE at
the distal edge of the Braggpeak for all ions light-
er than neon. This may lead to an increased risk
of complications when the beam is stopped on a
critical structure .
Experiments with tumor tissues have sug-
gested that Bragg peak ions with a maximum
LET of about 100 keV/ltm may significantly
enhance the biologically effective tumor dose
without substantially increasing the risk to sur-
rounding normal tissues . Some caveats to this
hope may apply : RBE values for immediately sur-
rounding late response tissues may still be higher
than those for rapidly proliferating tumor tissues,
thus, diminishing the beneficial therapeutic ratio.
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Furthermore, reduced OERs and increased
RBEs found for tumor cells under hypoxic condi-
tions may not be of clinical significance when
reoxygenation occurs during a course of fraction-
ated radiation therapy.
It could well be that the superior three-
dimensional dose distribution which is associated
with significant normal tissue sparing will eventu-
ally prove to be the clinically most relevant fea-
ture of ion beams . More basic research and
improved radiobiological modeling are needed in
the near future to further investigate their volume
effect .
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Biological Beam Characterization
E . A. BLAKELY
Introduction
Lawrence Berkeley Laboratory, University of California, Berkeley, CA, USA
Physical characterization of ion beam fields is
conventionally accomplished in the practice of
radiotherapy to ensure uniform clinical effects . A
demonstration of auniform physical dose across a
radiation field does not always guarantee, how-
ever, a uniform clinical outcome . It is acknowl-
edged that there are tissue-specific differences in
both acute and late tissue effects to low-LET radi-
ations, as well as considerable variability in indi-
vidual radiosensitivities presumably due to inher-
ent genetic susceptibilities [1] .
The additional consideration of variations in
radiosensitivity due to radiation quality can be at
first somewhat staggering due to the large num-
ber of variables and the range of potential differ-
ences. The higher ionization densities of alterna-
tive radiation modalities, such as neutrons or
heavy ion beams are known to be associated with
greater biological effectiveness than what is mea-
sured for conventional photon therapy [2-4] . The
picture becomes further complicated as published
experimental data at very high LET (greater than
2000 keV/Rm) indicate a reduction in the radiobi-
ological differences between radioresistant and
radiosensitive systems [5] . Most alternative radi-
ation modalities for cancer therapy (such as pro-
tons, alpha particles, pions, or carbon ions)
involve intermediate LET values (between 20 to
200 keV/[,m) where the greatest variation in RBE
is observed . This presents a practical problem to
the clinician in choosing a specific appropriate
dose regime at intermediate LET.
Neutron radiotherapy was initiated in 1938 and
proton radiotherapy in 1956, yet even today there
is controversy regarding the assignment of a qual-
ity factor or RBE value for neutrons andprotons,
especially as a function of dose or energy [6-9]
For charged particles the range of changes in
biological effectiveness can be even greater. After
Stone's [10-12] early experience with neutron
cancer radiotherapy resulted in severe adverse
reactions in normal tissue, considerable attention
has been given to reducing the total dose to nor-
mal tissues unavoidably in the treatment volume
of alternative radiation modalities having a high-
LET radiation dose component. The limiting
radiosensitive normal tissue is identified in the
treatment field, and a reduced dose fraction of
the high-LET radiation is selected based on what
is thought to be equivalent or comparable to what
is tolerated in conventional photon radiotherapy.
Although physical detectors of altered radiation
quality are available, their use for this purpose
has been limited and biological characterization
has historically served as the basis for the mea-
sure of the reduction in dose fraction needed .
This chapter reviews aspects of this practical
approach, and discusses the need that remains in
the field to standardize the protocols for biolog-
ical measurements . Although not intended to be
all-inclusive, several examples of techniques cur-
rently in use to measure radiobiological parame-
ters are reviewed . Preclinical radiobiology for
charged particle radiotherapy is provided as
illustrative of the methodologies that have been
used to complete biological beam characteriza-
tion .
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Representative Biological Systems
Biological characterizations for clinical radiother-
apy have primarily been accomplished with cell
systems in vitro andwith animals in vivo [13, 14] .
For reasons of practical necessity, representa-
tive biological systems have been selected for the
measurement of biological effectiveness . Due to
the ease of techniques and availability, emphasis
has been given to the measurement of cell killing
and repair using cells that grow easily in tissue
culture, and using tissues having highly prolifera-
tive cell renewal systems amenable to quantita-
tive assays . However general concern exists in the
field that appropriate biological assays are not
available for all of the critical tissues and
endpoints that perhaps should be screened for a
thorough understanding of clinical responsiveness
to a particular radiation . The shortcomings of the
present approach still need to be evaluated.
Essential to any of these studies is the need for
deliberate coordinated physics measurements
(including dose calibration, assessment of radia-
tion field composition and uniformity, or micro-
dosimetry) under the exact conditions of the
biological exposure, and for parallel studies of the
biological response to a standard low-LET refer-
ence radiation (see [15-17] and additional discus-
sion below) .
In vitro Systems
Cell systems in vitro can generally be divided into
two categories : primary and established cultures .
Primary cultures are those that are newly derived
from normal or tumor tissues and have not under-
gone many passages in culture, during which
changes in the cells or selection of specific cell
types could have occurred . The primary normal
cells, and even some tumor cells are usually diffi-
cult to grow on tissue culture plastic, as evidenced
by low plating efficiencies for colony forming
assays . Low plating efficiencies mean that large
numbers of cells are required to measure statisti-
cally the colony forming assay endpoint . Estab-
lished cultures are cell lines that have been in cul-
ture for a significant number of passages to allow
convincingly a characterization of the system .
Plating efficiencies are usually higher than for pri-
mary cells, probably because there is a selection
for cell subpopulations that grow well under the
artificial conditions in tissue culture. The question
that remains is, whether the selected cells that
survive are representative of the original popula-
tion of cells from which the culture was derived.
The answer is highly dependent on the criterion
selected for the comparison .
Radiobiological characterization of accel-
erator-based alternative radiation modalities fre-
quently requires comparative experiments com-
pleted over the course of several years. Since the
living cell can be a very sensitive LETdetector of
alternative ionization densities, it can be used to
determine changes in radiation quality. For tech-
nical ease, established cultures of mammalian
cells, including those of human and rodent origin
have been used to examine cell killing, repair,
chromosomal rearrangements, mutagenesis and
transformation, and the reduction of the radiobi-
ological oxgen effect, long thought to be a signifi-
cant factor in overcoming tumor resistance [18] .
The merits of this approach are that a very large
matrix of data has been generated with a large
assortment of established cell systems . The
remaining problem is that - except where individ-
ual investigators have conducted exhaustive com-
parisons of various radiation modalities with the
same system [14, 19] - there are in most cases,
very few opportunities to make identical RBE
comparisons. In many cases the low-LET refer-
ence for the RBE determination has been either
cobalt-60, 100-250 kVp X-rays, or cesium-137,
which confounds any strict RBE comparison
since physical differences among these sparsely
ionizing radiations can themselves produce up to
20 % differences in the biological responses.
In vivo Systems
An early observation made in vitro was that
single, acute dose responses of cell systems were
not revealing all of the necessary information
required for adequate treatment planning in the
clinic . Dose fractionation and delayed plating
studies revealed that repair of radiation damage
moderated the end effects considerably [20, 21] .
Repair studies conducted in vitro are limited in
scope due to technical considerations . Experi-
ments with animals are more amenable to the
dose fractionation regimes used in the clinic .
Rodent tumors are a good indicator of superficial
human tumors in terms of actual physical size and
geometry. Extrapolations must be made to pre-
dict the effects of larger, deeper tumors found in
man.
RBE Mapping Techniques
Once the decision is made about which cell is
appropriate for representative biological charac-
terization, one must next decide what geometry
to use to complete the radiation exposures. Cells
grown in tissue culture that attach well and make
individual colonies are highly amenable to the
biological characterization of accelerator-based
radiations . This is primarily due to the fact that
accelerators designed for physics usually have
fixed horizontal beam lines that necessitate a
vertical exposure geometry. If the question being
asked is "what is the average biological effect
over a range of beam depth?", then exposures
can be made with cell suspensions. However, if
one is interested in mapping the RBE as a func-
tion of depth over a few millimeters range, for
example, to cover in detail the drop-off of dose in
the distal portion of the Bragg peak, then cells
must be held in a rigid conformation during the
exposure . This can be accomplished for example
by using cells attached to vessels in monolayer or
held in a gelatin matrix . Illustrations of each of
these approaches are described below.
Cell Suspensions
Chapman et al . [22] designed a cylindrical glass
chamber which allowed cells to be in a stirred sus-
pension of less than about 2 cm width. This cham-
ber might be placed at various depths within an
extended Bragg curve (Fig . 1, upper panel) . A
glass sampling port allowed the removal of con-
trol, unirradiated cells prior to the start of an
experiment, and subsequent sampling after a
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Fig . 1 . Vessels for the irradiation of cells in vitro on a hori-
zontal accelerator beam line . Upper panel : glass cylindrical
chamber for cells in suspension . Lower panel : an array of tis-
sue culture flasks with cells grown in monolayer
sequence of graded doses . The irradiated cell
samples were immediately diluted into a test tube
containing warmed medium for rapid serial dilu-
tion to the appropriate cell number required for
the level of cell killing anticipated . A magnetic
stir bar driven by a motor under the chamber
assured a uniform cell concentration throughout
the experiment . The sampling time was short
enough (less than 2 minutes) that the dose frac-
tionation was inconsequential to the survival mea-
surement . This approach has several advantages :
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1) the technique is easy and rapid,
2) the uniformity of cell treatment, handling and
origin in the suspension technique is well-
controlled, allowing for good reproducibility
in the survival measurement,
3) there is a significant saving of beam time since
the survival measurements are from accumu-
lated doses.
Limitations include:
1) the depth of the radiation field to be studied is
defined by the width of the vessel over which
the survival effect is averaged,
2) the requirement for the cells to be easily held
in single cell suspension without clumping or
adverse plating effects,
3) restrictions on the use of the technique for the
study of fractionation effects .
Helium 230 MeV/u
Cell Monolayers
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The traditional radiation exposure protocol for
many cultured cells has been to grow the cells in
monolayer attached to tissue culture plastic petri
dishes or flasks . For colony forming assays, cells
are trypsinized, counted and serially diluted to
the appropriate concentration for the anticipated
survival . There are several variations on the
monolayer protocol that have been devised to
accommodate small beam diameters for eye
tumor treatments for example, or to map varia-
tions in cell killing radially. Figure 1 (lower panel)
illustrates a linear array of tissue culture flasks
filled with either medium or water. Flasks with
medium have cells grown on one of the inner sur-
faces. Flasks can be exposed in such arrays where
each plane of cells is approximately separated by
the width of one flask. Alternatively, in a variation
first proposed by John Lyman, pairs or arrays of
flasks can be exposed with only nominal thick-
nesses of additional absorber upstream to shift the
Fig . 2. Illustration of human T-1 fibroblast cell survival data obtained with the techniques described in the text over
extended 230 MeV/u helium ion Bragg peaks of 1 .5, 2 .0 or 2 .6 cm width used in the radiotherapy of uveal melanoma
full depth of range covered . This approach allows
a measure of biological effects at closer spacings
in the millimeter range . Figure 2 illustrates the
kind of cell survival effects that were measured
with this technique for high energy helium ion
beam configured for eye tumor treatments .
If the diameter of the beam is limited to an area
within the width of the flasks either due to acceler-
ator constraints, or due to the configurations
imposed for a specific treatment geometry under
study, cells can be plated only within a small circular
region on the flask . Depending on the cell line used,
the cells firmly attach to the flask within one or two
hours . after which the flask can be filled with addi-
tional medium . If the radiation field covers the corn-
Fig . 3 . Twelve 25 cm' tissue culture flasks that contained a
uniform density of single human T-1 cells in monolayer when
irradiated with the collimated 225 McV/u helium ion beam .
The flasks were irradiated in pairs with variable amounts of
absorber to cover the depth of the beam range . After irradi-
Cells in Gel
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plete surface area of the flask, the flasks can be
exposed to a horizontal beam and then processed
for colony formation in the traditional fashion, or
allowed to grow in situ to permit an assessment of
the radial uniformity of cell killing (Figs . 3 and 4) .
For a fixed dose, cells surviving within the irradiated
field can be scored in radial sectors and plotted as a
function of beam diameter to assess flatness of the
biologically effective dose .
Skarsgard et al . [23] devised a creative gel tech-
nique for biological characterization involving
single cells suspended in a stiff gel matrix . After
ation, the medium was replaced and the cultures were
allowed to grow to clonal density . A highly collimated con-
trol region of cell killing can be seen on the right . Flasks on
the left were beyond the range of the beam and show no
killing
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Control 1 .5 Gy
Fig . 4. Three sets of four 750 cm' tissue culture flasks that
contained a uniform density of single human T-1 cells in
monolayer when irradiated with 580 McV/u neon ions de-
irradiation, the gel is extruded and sliced (Fig . 5) .
Each 2 mm slice contains about 105 cells which are
resuspended by melting the gel in a tube contain-
ing warm medium for the biological assay desired .
Spatial reconstruction of the biological effect can
then be mapped, allowing a detailed and accurate
description of the radiobiological properties of the
radiations studied which were pion beams . Raju et
al . [24] have adopted this approach for the study of
a number of different radiation types .
The gel technique has been further refined by
Skarsgard et al . [25] with the use of a cell sorter to
deliver a known number of cells into the test
tubes for the survival assay. Cells are identified on
the basis of light scattering in the cell sorter, with-
out the use of a cell stain . This additional step
increases the accuracy and precision of this
method, which offers the following merits :
1) excellent reproducibility and RBE mapping
precision,
2) high resolution for dose range covered, espe-
cially at low doses,
3) ease of exposure technique,
4) reduced beam time requirements.
The only limitations involve the moderate
degree of preparation and handling required for
sample processing .
In vivo Assays
3.6 Gy
livered in a rastered mode . Left panel : unirradiated control
set ; Middle panel : 1 .5 Gy ; Right panel : 3 .6 Gy.
Since single, acute cellular responses in vitro do not
provide complete information on tissue responses
and their repair, most new radiation modalities have
been screened with a few specific in vivo endpoints .
The primary goals are to investigate dose fraction-
ation effects after a significant number of fractions
as is used in the clinic, and to assess late sequelae .
Late responses to irradiation are discussed in detail
in the preceding chapter. Therefore, only a few gen-
eral remarks are made here regarding the selection
criteria of in vivo systems .
One of the major limitations of the in vivo
techniques is their degree of resolution of mea-
surement of RBE which changes across the depth
of the pristine Bragg ionization curve . This fact
prevents the study of the sharp, unmoderated
Bragg curve, but allows one to map RBE values
over defined widths of Bragg curves that have
been extended to cover the width of a tumor. The
physical dimensions of the animal used in particle
studies defines the width of the Bragg ionization
curve that can be studied since RBE averaging is
implicit over that tissue thickness .
The Withers intestinal crypt assay was an
important contributor to our understanding of
Fig . 5 . The gel slicing procedure . The gel is extruded and
sliced at intervals of 2 mm or more . Each 2 mm slice contains
10 5 cells, which are resuspended by melting the slice in a 5
ml tube of warm medium . Photo courtesy of Lloyd Skars-
gard
neutron effects [26, 27] . It is highly amenable to
the exploration of dose fractionation effects . This
led to its selection in the preclinical feasibility
testing of heavy charged particles. The crypt assay
can also be recommended as a standard protocol
for interlaboratory comparisons, since it has few
uncontrolled variables and good replication of the
technique can be achieved . There is recent inter-
est in using this assay to standardize some aspects
of the proton therapy programs that are increas-
ing in number world-wide (cf. also the subse-
quent chapter) .
Traditionally skin erythema reactions have
been the most immediate and visible part of a
course of radiotherapy . Skin reactions have been
used to investigate the time-dose relationships of
radiation effects, as the biological reaction is
directly proportional to the total dose delivered,
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and the time of appearance of the erythema reac-
tion is inversely proportional to the time course
of the irradiation . With the acquisition of suffi-
cient information necessary for radiotherapy
treatments using conventional radiations and
neutrons, and with the advent of animal rights
advocates whoquestioned the necessity of further
studies, this work has received much less empha-
sis in the laboratory. None the less, when the
novel high-LET ion beams became available, skin
reaction studies were scored in rodent models
because it was one of the baseline biological mea-
surements understood and trusted by radiothera-
pists . Recently, there have been retrospective
attempts to score acute skin reactions from
patients after charged particle therapy [28] .
Although skin reaction studies have large confi-
dence limits, these data clearly indicate an RBE
relationship that scales with LET value . Smaller
doses per fraction per field of increasingly higher
atomic number ion beams yield the same maxi-
mum acute skin reaction .
Due to the serious medical complications that
can result from nervous tissue toxicities to radia-
tion, spinal cord effects have long been a normal
tissue of interest to screen for complications such
as paralysis. The charged particle radiotherapy
community supported the investigation of this
late effect that takes more than one year to
develop in rodents at clinically relevant doses to
avoid duplicating the serious complications that
resulted in early applications of neutron therapy.
Unlike other normal tissue endpoints such as skin
and intestinal crypts, the spinal cord radiosensi-
tivity has a significantly different X-ray response,
and the particle studies suggested a caution in
situations in which spinal cord might be exposed
to even moderate fractions of high-LET particles .
Summary of Pertinent Issues
Frustration with the variables introduced in the
photon Gray-equivalent concept have led several
clinical programs investigating new high-LET
radiation modalities to report only physical dose .
However, Gray-equivalent dose must still be con-
sidered in treatment planning to avoid normal tis-
sue toxicities . This issue will become even more
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important as alternative ion beam delivery sys-
tems are implemented to optimize tumor treat-
ments.
In the opinion of the author, the choice of
model systems should not be based on trying to
be all inclusive in determining RBE. Instead, the
selection should be based on having a representa-
tive radiosensitive and a radioresistant respond-
ing system . This provides the clinician with an
appreciation of the range of responsiveness that
may be anticipated. Depending on the treatment
site, particular normal tissue toxicities should be
investigated for individual organs . It would be
exceedingly helpful to the international effort to
compare clinical protocols and results if radiobi-
ologists could agree with the clinicians about
which representative measurements should be
made. Many primary cell lines are very radiosen-
sitive with very small shoulders on the survival
curve, even after exposure to low-LET radiations .
This means that there will be very little variation
in RBE in primary cells, in comparison to cell lines
with large shoulders on the survival (as is the case
for many tumor and established cell lines) where
the high-LET response collapses the shoulder.
None of the radiobiology of ion beams is worth
doing unless adequate controls and sample num-
bers allow a statistical assessment of the signifi-
cance of the results. The error analysis of a rela-
tive measurement between two independent
modalities (one low-LETstudy and onehigh-LET
study) is at best a challenge. The typical photon
daily dose fraction is 2 Gy, and equivalent high-
LETdose fractions are usually smaller. Biological
endpoints must, therefore, be able to examine the
biological response selected with sufficient accu-
racy to distinguish what may be similar responses
as biological endpoints come together at low
doses . Some may argue that measurement of high
dose responses are adequate, since theoretical
modeling would allow extrapolation to the low
dose region . However, this statement assumes
certainty in selection of an appropriate theoret-
ical model to use for the extrapolation . The
"stretch" to lowdose response is well known to be
variable with supralinear, linear and quadratic fits
all represented amongthe various low-LET radia-
tion responses measured . Very few low dose
responses are available for high-LET radiations .
The strictest definition of RBE requires one to
compare the high-LET biological response to
s0CO. Since cobalt sources are no longer available
as commonly as was true when the RBE defini-
tion was made, the high voltage X-ray machine
has gained acceptance in the field as a substitu-
tion low-LET reference. When comparing results
obtained by different investigators, it is critical to
correct for differences due to the choice of the
low-LET reference radiation . Obviously in the
need to establish a common standard, a low-LET
reference that is available to the largest number
of groups is desirable . The author would argue
that it may even be important to propose a low-
LETparticle as a reference .
Once there is a solid basis for defining equiva-
lent doses, a decision must be made regarding
how the measurement should be included into the
treatment planning effort . Three-dimensional
analysis of isodose contours accomplished by
examining all pertinent two-dimensional axial
tomographs for each treatment port begin with
the physical dose, but must include a considera-
tion of criticial tissues that each may have unique
values in each field. The 1987 NCI report on
evaluation of treatment planning for particle
beam radiotherapy [29] concluded that there was
no satisfactory way of handling the potential vari-
ation of biological effectiveness in a particle
beam, andthey were not able to come to anycon-
clusion about the additional need to compensate
for internal inhomogeneities or for the shape of
the target or the external patient surface, not the
least due to the lack of sufficient particle data on
individual normal tissue toxicities . These data are
still required for the fullest optimization of ion
beam radiotherapy, no matter what mode of
beam delivery is chosen .
The main conclusion of this paper is that there
is a strong need in the field of ion beam therapy to
standardize the biological beam characterization
and to complete parallel, coordinated physics
calibration and dosimetry under the exact ge-
ometry of the biological measurements . Several
candidate approaches are reviewed and re-
commendations are made to steer the selection of
the standards . Such effort will advance the inter-
national attempt to optimize ion beam radio-
therapy.
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9Introduction
Preclinical Radiobiological Experiments
) . GUEULETTE and A. WAMBERSIE
Universite Catholique de Louvain, Cliniques Universitaires St-Luc, Brussels, Belgium
Before applying a new type of radiation in cancer
therapy, two types of radiobiological experiments
are required : first, the so-called "pretherapeutic"
studies which are usually performed before a new
facility is planned and which aim at identifying
the rationale of the new radiation. Secondly,
when the new facility is completed and the beam
ready for application, the actual "preclinical"
experiments need to be performed . They aim at
the application of the new radiation under safe
and optimal conditions .
For proton beams, the therapeutic benefit is
first of all based on an improved physical selectiv-
ity. Pretherapeutic studies have shown that no sig-
nificant benefit is to be expected from an
improved biological effectiveness [1] . Only pre-
clinical studies are thus needed today. They pro-
vide an overall check of the dosimetry and irradi-
ation procedure, and, in addition, help to select
the "clinical" RBE for which the accuracy should
be better than 5% [2].
For heavy ion beams, the therapeutic benefit is
based on both an improved physical selectivity
and an improved differential effect . Prethera-
peutic studies are, therefore, needed in order to
identify the biological rationale and to evaluate
the potential benefit of the improved differential
effect . Thereafter, preclinical experiments have to
be undertaken . They are more important than for
protons, since RBE values are high and do vary
largely with dose and the biological endpoint cho-
sen [2-10] . Moreover, for a given type of particle
and energy the radiation "quality" and, hence,
the RBE changes with depth. As a consequence,
the selection of the clinical RBE of heavy ion
beams becomes the main goal of the preclinical
studies. They raise complex problems related to
the choice of the biological system to be used for
RBE specification and the method to be followed
for the dose and volume specification.
Since RBE determinations are the common
denominator of most radiobiological studies, a
first section will be devoted to the concept of
RBE. It appears necessary to define its different
acceptations and to clarify some ambiguities
about its use. The next sections will be devoted to
the description of the different biological systems
and their relative merit for preclinical studies .
The RBE Concept
Historical Review
In radiation therapy with low-LET radiations, the
biological effect can be predicted from the dose
level and the dose distribution . The specification
of the type of radiation (gamma-rays, X-rays or
electrons) and of the energy is of little importance
since there is little RBE variation between
gamma-rays, X-rays and electron beams from a
few MeV to a few tens of MeV, at least for the
effects relevant in radiation therapy. Therefore,
dosimetry alone and dosimetric intercomparison
are needed .
In the 50's and 60's, however, when 200 kV X-
rays (orthovoltage) were progressively replaced
by 6°Co y-rays (and electrons), a dose weighting
factor of 0.85 wasintroduced to take into account
the fact that, at equal doses, the 200 kV X-rays
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are somewhat more effective than high-energy
radiations . As a result, the RBE concept was rec-
ommended by the ICRP and the ICRU [3, 4] .
Later on, it became more and more obvious
that the RBE value could be different for differ-
ent systems. The RBE of 200 kV X-rays relative
to 6°Co y-rays was not always 0 .85 but could reach
values of 2 and more for some biological
endpoints or very low doses, relevant in radiation
protection [5] . However, it could be assumed that
the conversion factor of 0 .85 was sufficient to
take into account the radiation quality differences
between 200 kV X-rays and high-energy X- or f-
rays for the dose ranges and the effects relevant in
radiation therapy [6] .
The RBE problem became much more impor-
tant in fast neutron therapy. RBE values of neu-
trons relative to y-rays ranging from about 1.5 to
5 were observed, depending on the neutron
energy, dose and biological effect . Theproblem is
less relevant for protons (KBEs 1.0-1.2), but
again significant for heavy ions for which the
RBEvalues can go up to 10 .
Definition of RBE
The relative biological effectiveness (RBE) of a
test radiation, relative to a reference radiation is
given by
RBEtesdref = Dref / D,est
where D,est and Dref are the absorbed doses of
the test and reference radiation, respectively, nec-
essary to cause the same biological effect .
When comparing tworadiation qualities, there
is not a single RBE but a large number of RBE
values, i .e ., one RBE value for every set of
biological system, effect and experimental condi-
tions. Therefore, the commonly used jargon that
a certain radiation has a certain RBE is funda-
mentally incorrect and misleading . RBE values
cited in this way are ususally not the result of indi-
vidual experiments but are judgements based on
experimental RBEs or sometimes clinical experi-
ence . Although this practice is wide-spread and
reflects some convenience of procedure for a
complex issue, it cannot be stressed enough that
such comparative values for different types of
radiations should not be confused with true
"experimental" RBE values .
Reference RBE
Due to the wide variation of the RBE with the
biological system, the dose andexperimental con-
ditions, it is useful when exchanging information
or prescribing the dose in non-conventional radia-
tion beams to select reference conditons for RBE
specification. These reference conditions should
be as relevant as possible to the clinical situation
and in that respect the following conditions
appear to be most suitable :
- a dose level of 2 Gy (X- or 'Y-ray-equivalent)
per fraction,
- a biological system and endpoint which can be
considered relevant to represent the "average"
or "overall" late tolerance of normal tissues.
The RBE for these reference conditions is the
"reference" RBE . Reference RBE values are
derived from experiments performed for late
tolerance of, e .g ., CNS (brain and spinal cord)
[7], lung [8] or skin [9] . The reference RBE is still
a radiobiological concept, although it implies that
a single RBE value can represent the average or
overall tolerance of a patient's normal tissue .
Clinical RBE
In contrast to the reference RBE, which is a
radiobiological concept, the clinical RBE is a
clinical and operational concept. The term "clin-
ical RBE" has been particularly used in the US
for neutron treatments, and is understood as the
ratio of the absorbed dose which would be pre-
scribed for a photon treatment and the dose
which is actually prescribed for neutrons and for a
given tumor localization [10] . The clinical RBE
can also be used for all non-conventional radia-
tion therapy modalities .
Although the clinical RBE is a dose ratio for
two radiation qualities, it is not in a strict sense a
RBE. It takes into account the reference RBE
plus the several weighting factors (e.g ., geomet-
rical factors related to the beam penetration)
which the radiation oncologist has to consider
when prescribing a dose . As in the case of select-
ing the target volume and the fractionation
scheme, it implies the judgement and responsibil-
ity of the radiation oncologist .
Preclinical Radiobiological Studies
The radiobiological experiments discussed here
concern primarily RBE determinations which
should be performed prior to the clinical irradi-
ations . This section does not deal with experi-
ments designed to justify the rationale of using a
newbeam and to evaluate its potential advantage .
Cell Survival in vitro
Mammalian cells grown in monolayer have
widely been used for RBE measurements, since
1956 [11] . The improvement of cell biology tech-
niques makes it possible today to cultivate many
mammalian cell lines in vitro . Particularly useful
are cell lines with a high plating efficiency
(60 %-80 %) such as V79, EMT6, or CHO, which
are also relatively easy to maintain under stan-
dardized conditions . These cell lines also have a
radiosensitivity and repair capacity corresponding
to the average normal or tumor cells.
RBEvalues are generally determined after the
survival data have been fitted to curves of the
linear-quadratic or two-component model [12] .
This allows to derive RBE values over the whole
dose range . However, the derived values depend
on the model, especially in the region of small
doses where the different models exhibit the larg-
est discrepancy andwhere the accuracy of the sur-
vival data is particularly poor. Therefore, the reli-
ability of RBE values for small doses may be
questionable as is the reliability of RBE values
derived from a-ratios, which are supposed to cor-
respond to the maximum RBE. This is especially
true when comparing survival curves of high-LET
and low-LET radiations which have radically dif-
ferent shapes (Fig . 1) .
The shape of the cell survival curves reflects
the repair capacity which in turn determines the
influence of fractionation . The analysis of survival
9 Preclinical Radiobiological Experiments
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Dose
Fig . 1 . Typical survival curves for high- and low-LET radi-
ations . When the experimental points are centered on high
doses it is difficult to discriminate between the different
biological models . As a consequence, the RBE for small
doses can vary according to the model
curves should thus help to choose the proper dose
per fraction when determining the reference
RBE.
Growth Inhibition of Plant Roots
Growth inhibition in Vicia faba bean roots is a
well documented system [13] which has been used
successfully for RBE and OER determinations .
The end point (Gio) is the relative growth of
the central root over a period of 10 days following
irradiation, the mean growth of unirradiated
roots being taken as reference. The sensitive part
of the bean to be irradiated is the root tip . Dose
delivered to other parts of the plant is of little
importance for the growth of the root .
"Sutton Exhibition Long Pod" is the classical
strain of Vicia faba used in radiobiology. How-
ever, it has been reported that this strain could
raise technical difficulties for OER experiments
involving oxygen deprivation during long peri-
ods. "Belgische Boerenbond Extra Lange
Hangers" has been introduced as alternative and
has proven to be more resistant to hypoxia [14] .
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Running tap water (19° C)
for 4 days
Gas outlet
-18cm
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19 Ä
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Gas inlet Thermostat
Fig . 2. Schematic illustration of cultivation and irradiation
conditions of Vicia faba beans : 1) only roots of which the tip
points out will be planted in vermiculite, 2) vermiculite boxes
are stored in a dark place at 20 °C, 3) the roots of
The cultivation and irradiation technique is
schematically illustrated in Figure 2. RBE or
OERvalues are determined from the doses corre-
sponding to 50% growth inhibition and are
obtained with confidence levels of 3-5 % (p =
0 .05) as is shown in Figure 3 .
Chromosome Aberrations in Vegetals
Determination of radio-induced chromosome
aberrations in vegetal roots is another system
which can be used for RBE determination .
While Vicia faba is most popular [15], in our
laboratory we have used Allium cepa onion roots
(variety "jaune paille des vertus") for many years
following Markus and Kolliopoulou [16] . Allium
cepa has relatively few (2N = 16), large chromo-
somes (=7 pm) and exhibits frequent and regular
mitoses. Past experience with this system has
- 60 cmE--------___--------------->.-
Selection / randomization
4-8cm
100 cm
--__--------______---__------------___------------____-----
which the tip is twisted are discarded, 4) for irradiation in
hypoxic condition, air is replaced by high-purity nitrogen (at
least 30 min before irradiation), 5) after irradiation the beans
are allowed to grow for 10 days in a stainless steel tank
revealed that the best criteria forRBE studies are
the number of aberrations per cell in anaphase or
telophase and the number of intact cells without
aberrations (Fig . 4) .
In an unsynchronized cell population the rela-
tion between primary chromosome damage and
the frequency of observable aberrations is com-
plex . It is, therefore, important to make sure that
the number of aberrations per cell, as well as the
number of intact cells, does not depend on the
incubation time between irradiation and fixation
(3-9 hours) . With such precautions, the system
provides RBE values with an accuracy of 3-5 % .
Intestinal Crypt Cell Regeneration
The regeneration of intestinal crypt cells of mice,
wasintroduced by Withers and Elkind [17] . It was
developed to quantitate the cell survival curve of
1.0'~
0,9
0 .6
~, 0.7
b 0,6
O
0.5
ä 0.4
0.3
0.1
0 1
	
1 1
Absorbed dose / Gray
0.1 0 .2 0 .5 1 2 5 10
Fig. 3. Relative growth of Vicia faba root tips in 10 days as a
function of dose (logarithmic scale) after irradiation under
aerobic and hypoxic conditions with d(50)+Be neutrons and
eoCo y-rays (the shaded areas correspond to the 95 % confi-
dence interval). The slopes obtained under aerobic and
hypoxic conditions do not show significant difference for
either radiation quality (OER does not depend significantly
on dose) . On the other hand, the slopes of the dose-effect
relations for neutrons and gamma are different, which
implies an increasing RBE with decreasing dose
intestinal stem cells. In the meantime, it has been
widely used to study the influence of fraction-
ation, dose rate, effect of radiosensitizers and also
to determine RBE under different conditions .
The intestinal mucosa may be described as a
two-compartment tissue . The first compartment
located in the lower part of the crypts contains the
stem cells, which are able to proliferate . The sec-
ondcompartment contains differentiated cells and
functional cells which are no longer able to divide
and are lining the "villi" (Fig . 5) . Only the stem
cells (crypt cells) are radiosensitive and a single
surviving stem cell can regenerate a crypt. There-
fore, the number of regenerated crypts and the
number of surviving stem cells can be assumed to
be equal when less than 20 regenerated crypts are
counted per circumference; this corresponds to a
dose range of 12-20 Gy (X or 1'). The conditions
described hereafter are those which have been
applied in our laboratory since many years .
1
0.2 0.3 0 .4 a5 0.6 0.7
Absorbed dose / Gy
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A
Fig. 4. Average number of chromosome aberrations per cell
as a function of dose (top), and percentage of intact cells as
a function of dose (bottom) . The figures are derived from
the same experiment and were performed in a He" beam of
which the kinetic energy was modulated by a copper ridge
filter between 650 and 530 MeV The Allium cepa onion
roots were positioned in the initial plateau (A) or in the
beginning (B), middle (C) and end (D) of the SOBP, respec-
tively. The indicated confidence intervals correspond to one
standard deviation; the lines drawn through the experimen-
tal points serve as eye-guides, only. The data are corrected
for the background (0 .02 aberrations per cell or 98 % intact
cells in unirradiated controls)
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Female NMRI, Balb/c or black C57 mice, typ-
ically 11-13 weeks old, are used, because of their
comparable radiosensitivity. Eighty-four hours
after irradiation the animals are sacrificed and a
3 cm jejunal section is taken 1 cm from the pylore .
The samples are immediately fixed . They are then
embedded in paraffin, sliced and stained
according to the classical trichrome technique
[181 .
Fig . 5 . Schematic view of a histological
section of the intestinal mucosa, which
would go both through the axis of a
crypt and the axis of a villosity (top) . Part
of the 32 crypt cells "piled up" along the
longitudinal axis are shown . The upper
limit of divisions (position 16) practically
demarcates the compartments of stem
cells and differentiated cells . The direc-
tion and the time of the migration of dif-
ferentiated cells is indicated .
Transversal section of the intestinal
mucosa, 3 days after irradiation with 12 .6
Gy (bottom) . The length of the villosities
is reduced and the crypts have practically
disappeared . Only few piles of apparently
viable and nucleated cells are visible
(regenerated crypts) . They result from the
multiplication of one cell which kept its
proliferating capacity
The basic experiment compares the dose-
effect relationships obtained after single-fraction
irradiation . As can be seen from Figure 6, the
number of regenerated crypts (scoring only crypts
exhibiting =:~ 10 surviving cells) decreases expo-
nentially with the dose .
With 6-8 mice per dose level and 8-10 dose
levels, the RBE can be determined with an accu-
racy of ±3-5%.
Mouse Lung Radiotolerante
U
U
4121
r+
U
H
U
Fig. 6 . Dose-effect relationships for crypt
cell regeneration in mice after irradiation
	
+-~
with "Co r-rays and 200 MeV protons at cd
different depths (indicated in the figure) .
In order to facilitate the comparison, the
dose-effect relationship fore°Co is
redrawn on each panel . The shaded areas
correspond to the confidence interval of
the slope of the (exponential) curves . q-aThese experiments were performed at o
the National Accelerator Center (NAC) of ~.,
Faure (South Africa) as part of an inter-
comparison program with the 75 MeV
proton beam of Louvain-la-Neuve (Bel-
gium) . They were designed to "calibrate"
the beam (over-all check on the dosi-
metry and irradiation procedures), and
were associated with a dosimetry inter-
comparison
100 -5
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Lung radiotolerante in mice, assessed by LDsoil8o
(dose corresponding to 50% animal survival 180
days after irradiation), has been taken as a model
for the evaluation of the late tolerance of normal
tissues [8] .
The technical issues concerning the irradiation
procedure are analogous to those of intestine.
The only difference is that the mice are submitted
to a selective irradiation of the thorax, which
implies that the beam is collimated and that the
dose homogeneity inside the field is carefully con-
trolled .
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Since the animals survive the irradiation and
are followed-up for 4-6 months, randomization of
the animals to equalize "cage effects" and
hygiene of their housing are important concerns .
Probit analysis is generally used to fit the dose-
survival curves from which LD50 and RBE values
are derived (Fig . 7) . Five to seven doses (12-16
animals per step) each increasing by about 10
compared to the previous step are usually suffi-
cient to obtain well balanced data . The useful
(total) doses range from 6 to 16 Gy (X or y) for
irradiation in a single fraction and from 12 to 20
Gy (X or 1') for irradiations in 10 fractions sepa-
rated by a time interval of 12 hours .
inside the target volume, i .e ., in the spread-out
Bragg peak region varies according to the size of
the volume . The reference RBE for a specific ion
at a given energy is thus not a single value typical
of a certain type of normal tissue but varies with
the size of the tumor.
Radiobiological Intercomparisons
Radiobiological intercomparisons are the obliged
counterpart to physical dosimetry intercompari-
sons to determine the biological equivalence of
different radiation beams. They are a prerequisite
when comparing clinical results from different
facilities and pooling experience . Radiobiological
intercomparisons became compulsory in neutron
therapy since the RBE values of the different clin-
ical beams vary widely, depending on the nuclear
production reaction and the energy of the incident
particle . Moreover, type and composition of the
collimator, the thickness of the target, the filtra-
tion of the beam, etc. can influence the RBE as
well ; sometimes, more than 5%, which is beyond
the dose variability tolerable in radiotherapy.
What is true for neutrons is in principle true
for heavy ions and, to a lesser extent, also for pro-
tons, since the energy of ions changes with depth,
and the production and the delivery of the beams
are related to numerous parameters including
type of machine (synchrotron, linac), repetition
rate, beam shaping (scattering, scanning, wob-
bling, spot scanning), etc. Even if eventual
changes in the radiation quality can be traced by
different types of physical measurements, includ-
ing microdosimetry [24], track structure analysis
[25], and TLD measurements [26] and if calcula-
tions would permit to predict the corresponding
KBEs, the actual RBE values would still have to
be measured .
When the beam quality differs only by a small
amount, RBE differences related to the biolog-
ical system are negligible . Therefore, the choice
of a biological system for intercomparisons can
mainly be determined by its convenience, porta-
bility and reproducibility [27] .
Crypt cell regeneration in mice appears to
meet these requirements and has widely been
used by different authors for intercomparison of
neutron [28] and proton beams. This system is
more advantageous than other "simple" in vivo
systems, e.g ., mouse testis, mouse skin [29, 30] or
in vivo cellular systems, in so far as it is particu-
larly independent of environmental conditions,
easy to handle and capable of a good precision
due to its steep dose-effect relationship .
Radiobiological intercomparisons should be
associated with dosimetric intercomparisons and
performed according to a strict experimental pro-
tocol in conjunction with the radiobiologists and
dosimetrists from the respective facilities .
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In particle radiotherapy a primary interest has
been to use animal models for the determination
of biological response to different ions, different
energies and specific irradiation conditions . Infor-
mation can be drawn from experiments with
single cells and tissue cultures but animal models
have also contributed substantially to the current
knowledge . The need for animal models is obvi-
ous, since many clinically relevant hypotheses
cannot be tested on human beings for ethical
reasons . Animal tumor models should serve as a
pattern for analogous situations in human tumors
[1] . This chapter gives examples of studies per-
formed with conventional research animals and
introduces companion animals as an alternative
animal model which may be of use in ion beam
therapy.
Conventional Research Animals
Normal Tissue Studies
Various animal models have been used to study
the effect of accelerated particles on normal tis-
sue. Most of these models have been established
for the determination of RBE for neutrons [2].
The parameters investigated for charged par-
ticles were RBE for various depths along the par-
ticles' path, in the entrance region as well as in
various parts of extended Bragg peaks. An excel-
lent overview on normal tissue response to accel-
erated ions has been given by Leith et al . [3] . For
pion therapy target volumes and shapes had to be
studied in even more detail since the RBE is
dependent not only on the extension of the Bragg
peak but also on the shape and size of the treat-
ment volume [4] .
The mouse foot system is very useful for study-
ing the development of the skin reaction after
graded doses [5]. Over aprolonged period of time
recordings on the skin reaction are made and
scored according to an arbitrary scale . One leg is
irradiated, the opposite serves as a control. Dose
response curves can be drawn and RBE values
can be derived. The mouse skin system yields
results on early and late reactions. The late reac-
tions may not be independent of the severity of
early reactions. Values can be obtained for single
or multiple fractionation protocols. Raju and Car-
penter [6] studied skin reactions to various ioniz-
ing radiations and concluded, that there was simi-
lar temporal development of skin damage for
both low- and high-LET radiation . When various
ions were compared for a single dose response in
the peak and plateau region a higher RBE was
found in the peak region . Other systems included
ventral thoracic skin of hamsters and studied the
repair capacity for various physical conditions
and different fractionations . For protons, Tepper
et al . [7] evaluated the response of mouse leg skin
to 20 fractions of irradiation given in three-hour
intervals . The assay of both acute and late skin
reaction indicated RBE values of 1.09-1.14 in the
spread-out Bragg peak (SOBP) .
In hamsters or mice, a large portion of their
skin in relation to the animals' size is irradiated,
the physical volume, however, is small compared
to volumes treated in human radio-oncology. The
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radiation may therefore differ substantially from
large volume irradiations .
A wide spectrum of fractionation schemes,
covering the entire range of interest in human
radio-oncology can be studied with this radiobi-
ological system and radiobiological models, e.g .,
the linear quadratic model, can be tested . The use
of inbred and small-size animals is practical but
has its limitation in transferability to humans.
The use of pig skin which resembles human
skin in many features has been pioneered by Fow-
ler [8] . Disadvantageous is the larger size of this
species and the higher experimental costs com-
pared to mice . But on the other hand, multiple
fields ofrelatively small dimensions, typically of a
few centimeters in diameter, can be irradiated on
a single animal . The possibility to apply both the
unknown radiation quality and the reference
irradiation on the same animal reduces the statis-
tical variation of the results.
In the treatment of deep-seated tumors in
humans, skin is usually not a dose-limiting tissue
for ions . But the skin irradiations may also give
valuable information on the reaction of underly-
ing connective tissue and vasculature. The sharp
dose fall-off with depth makes it difficult to pre-
cisely correlate dose and effect .
The mouse gut system is a technique first
described by Withers and Elkind [9] . Whole body
irradiation is performed on mice applying a single
or up to 20 fractions with a minimum of a 3-hour
interval . The test is based on determining the sur-
vival of jejunal crypt cells after graded doses. The
animals are sacrificed 3 .5 days post-irradiation
and sections of jejunum prepared . The regenerat-
ing crypt cells per circumference of the intestine
are counted and plotted as a function of dose . At
levels of 10 to 50 cells per circumference, the dose
response for various radiations can be compared .
RBE values for plateau SOBP are determined
with this system . The whole body irradiation
allows to use irradiation volumes more similar to
those applied in humans. The system is, there-
fore, also well suited for intercomparison studies,
e.g ., determining the radiobiological efficiency of
different treatment facilities, radiation sources
and qualities.
Another system extensively studied is the spi-
nal cord, particularly of rats [10] . Damage to the
spinal cord is characteristic for late damage. It
develops after a latent period of several months
as muscle atrophy and myelopathy causing neuro-
logical deficits . The dose needed to produce para-
lysis in 50 % of the animals within a group is the
endpoint of this system . It was used to study the
influence of the spinal cord's position within the
plateau or SOBP for various ions .
Induced Tumors
Various solid tumors can be grown after subcu-
taneous injection of tumor cells or implantation
into specific anatomical sites . Rats, mice and rab-
bits are most commonly used . The tumors are
allowed to grow to a predetermined size and are
then irradiated in vivo to graded doses. To score
the tumor response, the growth delay for a spe-
cific irradiation condition is measured and com-
pared to untreated animals. For tumors with sig-
nificant shrinkage after irradiation the time until
the tumor reaches the size before treatment is
taken, whereas for tumors with minimal or no
shrinkage the time it takes to reach a preset vol-
ume is measured . Tumor control probabilities and
RBE values can be determined with this system .
Amodification of the described in vivo system
is the following: the tumors are irradiated in vivo
and then removed from the animal andprocessed
to a single cell suspension, and colony forming
ability determined in vitro. This system is more
convenient, cheaper and faster, than growth mea-
surements or the dilution technique, where tumor
cells are removed from the animal after treatment
and then injected into a recipient animal . This last
technique has been used for the study of pion radi-
obiology with Ehrlich tumor cells [11] .
All the above-mentioned systems have in com-
mon, that they permit large numbers of exposures
with relatively modest efforts, resulting in sound
data with small statistical errors . The use of inbred
strains of animals and pure tumor cell lines further
contributes to the good reproducibility of the
results .
However, the shortcomings of induced animal
tumors is the fact that physiologically, the tumor
environment in these transplanted tumors may be
quite different from spontaneous tumors in
humans.
Companion Animal Research
Tumors of Interest
Spontaneous tumors in dogs and cats provide an
opportunity to study new therapeutic agents and
cancer biology. The pet population is a vastly
underutilized resource of animals available for
study. In clinically related anti-cancer protocols
pets can be used as alternative models, reducing
the need for traditional research animals. Pri-
vately owned animals can be entered into experi-
mental studies with informed consent from the
owner. Animal owners are willing to cooperate in
humane experimental approaches to therapy
when hope for cure can be offered.
Many canine and feline animal tumors behave
biologically very similarly to their human coun-
terpart. Common aspects of human and animal
tumors include similarity of histological types,
cell kinetics, tumor volume and anatomical site of
occurence . Tumor volumes are of similar propor-
tion relative to the body size for dogs and man.
The weight and surface area of dogs are suffi-
ciently large so that small extrapolations can be
made to adjust for the increased size of humans.
In contrast to chemically or virally induced
tumors, naturally occuring malignancies display
the same relationship between tumor and
tumorbed, vascularization and surrounding
healthy tissue, as is encountered in human cancer.
Compared to human patients, canine patients
which have not undergone previous or concurrent
therapy to complicate the analysis of response,
can be selected .
The expenses of clinical trials in dogs are
greater than in mice, but are much smaller than in
man. Pet dogs are supported and cared for by
their owners, limiting the costs for follow-up care .
Animal owners are not expected to pay for the
actual treatment, but they are expected to bring
their dogs for follow-up exams and permit a nec-
ropsy at time of euthanasia . Most animals are
euthanized once the quality of life is judged to
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have deteriorated . This allows a final, thorough
examination before euthanasia . For dogs on
experimental protocols a 98 % follow-up rate for
at least a year and a85 % necropsy rate have been
reported from the Colorado State University-
Animal Cancer Center [12] .
Spontaneous animal tumors can serve in pre-
clinical trials, designed very similarly to those for
man. Animals can be assigned to different doses,
and estimates of the therapeutic ratio can be
made. Accordingly, judgements of optimal dose
can be made prior to entering more expensive
human clinical trials . Dose-effect curves and
RBEs for multifractionated treatments can be
obtained for various tissues. With respect to con-
formal therapy, animals may be used to study par-
tial volume effects . It is also possible to random-
ize animals to a single treatment modality, such as
surgery, radiation therapy or a combination of the
two, which is ethically more difficult to justify in
humans.
Tumors which have served as models for
human cancer biology and treatment, i.e ., tumors
with potential relevance include canine osteosar-
coma, soft tissue sarcoma, oral melanoma, oral
squamous cell carcinoma, nasal tumors, mam-
mary carcinoma, brain tumors and malignant
non-Hodgkin's lymphoma [13] .
Spontaneous animal tumors have been exten-
sively used to determine dose response for irradi-
ation, hyperthermia and the combination of the
two [12-17] . For example dose response curves
for tumor control and normal tissue reaction for
canine oral carcinomas were determined for radi-
ation alone and for the combination of radiation
and heat (Fig . 1) .
For studies on ion beam therapy nasal and oral
tumors and soft tissue sarcomas appear to be suit-
able . Squamous cell carcinoma of the oral cavity
is the second most common malignant oral tumor
in dogs and carries a better prognosis than malig-
nant melanoma (most common oral tumor) or
fibrosarcoma for local control and long-term sur-
vival [16-20]. Squamous cell carcinomas usually
originate from gingival epithelium and are char-
acterized by rapid growth, early invasion of bone
and late distant metastases . Dogs with rostrally
located tumors have longer survival times than
dogs with caudally located tumors . Canine oral
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squamous cell carcinomas are considered radio-
sensitive [21-25] .
Tumors of the nasal cavity and paranasal si-
nuses are locally invasive but metastasize rarely.
Carcinomas account for two thirds, sarcomas for
one third of the nasal tumors . The disease usually
presents in a relatively advanced stage in a critical
location near the brain and eyes . Bone invasion
occurs early and curative surgery is virtually
impossible . The only improvement in survival has
been gained with radiation therapy alone or in
combination with surgical debulking [26-28] .
These tumors are particularly challenging for con-
formal radiotherapy.
Theincidence of soft tissue sarcomas in dogs is
much greater than the rate in humans with 350
cancers per 100,000 dogs at risk [29] . The term
"soft tissue sarcomas" refers to a group of tumors
with similarities in pathological appearance, clin-
ical presentation, and behavior. Soft tissue sarco-
mas tend to have poorly defined margins and
infiltrate through and along fascial planes [30] .
Local recurrence after conservative surgery is
common . Soft tissue sarcomas are generally
thought to be resistant to conventional doses of
irradiation [31, 32] . Although higher doses have
higher control rates, the chances of normal tissue
complications also increase .
Experience at PSI
Fig . 1 . Dose response curves for
tumor control and probability for
necrosis after irradiation (XRT only) of
hyperthermia plus radiation (XRT+
heat). From (24) with permission
At PSI soft tissue sarcomas, oral tumors and
nasaUparanasal tumors are selected to study con-
formal proton radiotherapy with a dynamic appli-
cation technique .
In preparation for this study, spontaneous
tumors in dogs and cats are irradiated with the 72
MeVproton beam used for the treatment of ocu-
lar melanomas . These treatments allow us to
study acute and late reactions of fast protons in
various tissues of dogs and cats and to estimate
tumor control compared to results of photon
beams in veterinary medicine . To our knowledge,
ion beam therapy has not been studied in canine
and feline tumors .
Ten animals have been treated so far and we
feel the procedure is now well established . Six of
the treated animals had squamous cell carcino-
mas, three had melanomas and one had a recur-
rent basal cell tumor. Theproton beam's diameter
of 3cm and its depth range of 3cm were consid-
ered limiting factors andenabled the treatment of
small tumors only. The current protocol for
human ocular tumors at PSI is 60 Gy given in 4
fractions over 4 days . We chose to treat twice a
day to a total dose of 40.5 CGE over 4 days . This
relates to a biological effective dose for late
effects of 66.6 Gy and for early effects and tumor
response of 53 .0 Gy in treatments with 35 frac-
tions. A RBE of 1.1 is used to convert physical
dose to biologically effective dose . Especially in
cats, the volume irradiated is greater in relation to
body size as compared to the volume irradiated in
human ocular tumors . Even so performed in the
beam for ocular melanoma treatment, the project
aims at data concerning proton therapy for larger
tumors outside the eye . The finer fractionation
protocol was chosen as preparation for humans
and dogs which will be treated with a more con-
ventional fractionation protocol on a gantry.
All animals had skin in their treatment fields .
They developed various degrees of edema, ery-
thema and moist desquamation 10 to 14 days after
completion of radiation therapy . The skin reac-
tions healed within the next 2 weeks . Hair loss
was apparent in the second to fourth week . Dur-
ing the same time period dark colored skin would
lose pigmentation . Four weeks after completion
of therapy acute reactions had subsided and a
hairless, pigment free, but dry and non-
edematous skin was present at the irradiation
field . Mucosa appeared to respond earlier than
skin . On the last day of treatment mild erythema
and hyperemia could be observed - progressing
to mucositis, which peaked 7 to 10 days after
irradiation . In none of the animals ulceration or
necrosis was observed, neither for the skin nor
the mucosa . The acute reactions were graded
between 2 and 3 according to the acute radiation
morbidity scoring criteria of the Radiation Ther-
apy Oncology Group [33] . Some animals required
local treatment, but the acute effects were well
tolerated by animals and judged transient and
manageable also by the owners . Hair grew back
within 4-6 months, often in a different color.
Some animals were treated only a few months
ago, so we are continuing to collect information
on late effects . One animal with a squamous cell
carcinoma on the toe and thus with bone tissue in
the treatment field developed a coarse bone pat-
tern with decreased bone density 6 months after
treatment . There was no lameness or pain on
palpation . One year after treatment this dog
remains free of tumor and lameness . No other
late reactions have been observed until now.
It is premature to report in detail on tumor
response . The squamous cell tumors appeared to
be very radioresponsive . Within the first month
after treatment the tumor mass shrank substan-
tially and reepithelization occurred .
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Fig . 2 . CT of infiltrative Iipoma at the level of the distal tibia
For the high energy proton beam our first goal
is to test the feasibility and safety of all aspects of
the dynamic application technique . The long-
term goal is the determination of early and late
normal tissue reactions in dependence of dose .
Only dogs are entered in the study, because
tumor volume and animal size are more compara-
ble to human patients than in the case of cats . The
animals undergo a thorough clinical work-up to
Fig . 3 . Scout view of the dog in treatment position
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exclude those, which might not tolerate the
course of therapy due to other serious diseases or
evidence of limited organ function . To character-
ize the primary tumor, radiography and computed
tomography are performed. Ultrasonography is
Fig . 4a,b . 3D-treatment planning of the dog's
tumor. Dose distribution is overlayed (color-wash)
over the reconstructed CT-image . a) saggital,
b) cross-section
used where indicated for further definition of
tumor extent and lymph node involvement . Tho-
racic radiographs are made routinely to exclude
animals with pulmonary metastases .
The WHO has provided staging criteria for a
variety of animal tumors [34] . These criteria are
used to stage the disease .
The treatment volume is chosen on the basis of
physical examination, CT information and tumor
histology. The same safety margins found to be
appropriate for cure with photons are applied .
Special consideration is given to the individual
anatomical location to make full use of the
advantages of conformal proton radiotherapy.
In veterinary medicine a commonly used pro-
tocol is 49 .5 Gy given in 15 fractions over a period
of 19 days . This accelerated and hypofractionated
scheme has evolved empirically, mostly guided by
the idea to limit the number of anaesthesias . For
the dynamic proton study a dose escalation study
is planned beginning with 12 fractions of 3.5 CGE
to a total dose of 42 CGE within 26 days. A draw-
back might be the necessity to adapt the treat-
ment protocol to the PSI accelerator schedule
which will direct Mondays, Tuesdays and Fridays
as days of treatment . Additional fractions will be
given on Thursdays increasing the total dose to
45 .5 CGE, 49 CGE, 52 .5 CGE, and 56 CGE.
Follow-up is of prime importance for clinical
evaluation, statistical conclusions and compari-
son, and for future veterinary and human clinical
studies . The treated dogs are examined the first,
second, third and forth week, the third, sixth,
Fig . 5 . Radiographic films
taken during irradiation of
the dog according to the
treatment plan, shown in
Figure 5 . a) before the leg,
b) behind the leg
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ninth, twelfth month and every sixth month
thereafter. The animals undergo physical exams
at every reexamination . Thoracic radiographs and
CTs are planned at half-year intervals . Special
procedures, ultrasonography or more frequent
CTs are done as indicated .
The acute effects are scored according to the
radiation morbidity scoring criteria established by
RTOG [33] . The potential late effects will also be
evaluated and scored . The course fractionation
scheme of the protocol should be particularly sen-
sitive to detecting late effects . The endpoint for
tumor response is the lack of tumor progression
at 1 year as evidenced by physical examination
and CT scans . Once the status of the animal
deteriorates, owners are asked to have their ani-
mal be euthanized . This provides the final phys-
ical exam . A gross histological exam can be per-
formed at the time of necropsy and histological
samples are taken from various locations in the
irradiated field to correlate tissue response with
dose .
A dog with an infiltrative lipoma of the hind
leg was the first patient to be treated on the
gantry at PSI, just before the 1994 fall shutdown
of the accelerator. The purpose of this treatment
was - besides offering an alternative to amputa-
tion - to verify that voxel scanning does not yield
b
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a significantly different RBE than the 1.1
described in the literature .
A simple treatment geometry, namely a single
vertical port, was chosen . The dog was fixed in
treatment position in a mould on the table, pro-
duced from polyurethane foam . In this position
serial CT slices were taken as a basis for treat-
ment planning (Figs . 2 and 3) . The target volume
was defined to encompass the entire leg from the
metatarsi to the distal femur region (Fig . 4) . For
partial sparing of the lymph drainage, the target
contour excluded a small strip of skin at the cra-
nial side of the leg . The prescribed dose was 36
CGE, assuming a RBE of 1.1, in 10 fractions over
16 days . The dose was measured by an ionization
chamber in a homogeneous Plexiglass block, and
the dose distribution checked by exposing films in
various depths of the block (Fig . 5) .
The dog tolerated treatment and acute reac-
tions, including moist desquamation, well .
Conclusions
Small, experimental animal models have proven
very useful to study fundamental radiobiological
questions concerning normal tissues and tumors for
various treatment modalities . This knowledge can
be supplemented with valuable information gained
from treatments of spontaneous, well-selected ani-
mal tumors in carefully designed protocols .
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III . Clinical Results and Indications
Introduction
Proton Therapy with the Harvard Cyclotron
) . E . MUNZENRIDER
Massachusetts General Hospital, Boston, USA
TheHarvard Cyclotron began its life as a research
instrument in Cambridge, Massachusetts, USAin
1948 . Initial animal experimentation designed to
study the biological effects of the 160 MeV syn-
chrocyclotron proton beam commenced in 1959,
and in 1961 human proton therapy was initiated
with that beam at the Harvard Cyclotron Labora-
tory (HCL) . In collaboration with the Neuro-
surgery Department of the Massachusetts Gen-
eral Hospital, Boston, promising clinical results
in patients with intracranial targets were
achieved . A Biomedical Annex was constructed
in 1963 specifically for patient treatment; single
fraction stereotactic proton radiosurgery con-
tinues there to the present day.
A second clinical collaboration for fraction-
ated proton beam radiotherapy, with the Radia-
tion Medicine Department of the Massachusetts
General Hospital and the Retina Service of the
Massachusetts Eye and Ear Infirmary was initi-
ated in 1974 . A second treatment room was
developed at HCL in 1978, specifically to allow
large field treatments to be carried out.
The HCL is currently dedicated primarily to
clinical use; 15-22 patients are treated there each
day, with the beam available for clinical use four
and a half days each week, fifty-two weeks per
year. The patient population treated through Sep-
tember 30, 1993 is listed in Table 1.
Initial research support for the Stereotactic
Radiosurgery Program was obtained from the
U.S . Office of Naval Research and later from the
National Aeronautics and Space Administration,
andthe National Science Foundation . Single frac-
Table 1. Patients Treated at Harvard Cyclotron Laboratory
1961 to September 1993
* numbers in parenthesis are% of fractionated patients
tion treatments have been self-supporting from
patient treatment fees for many years. Since the
inception of the fractionated proton treatment
program, the National Cancer Institute has sup-
ported research in the clinical application of the
proton beam in fractionated proton beam radio-
therapy. Superiority of protons for patients with
uveal melanomas and skull base chordomas and
chondrosarcomas was relatively quickly recog-
nized, and such patients are currently charged for
the treatment . Patients with other tumor types
continue to be treated under research protocols
with support from the NCI.
The 160 MeV proton beam has a maximum
range in tissue of 16 cm. Addition of preabsorbing
material, such as water or plastic, can reduce the
residual range of thebeam to that appropriate for
a given clinical situation .
Patient
number
Percentage
(%)
Radiosurgery 2982 50
Fractionated treatment 2967 50
Uveal melanoma 1957 (66)*
Chordoma, chondro- 354 (11.4)
sarcoma
Prostate cancer 166 (5 .6)
CNS 103 (3 .5)
Soft tissue sarcoma 94 (3 .2)
Head and neck 67 (2 .3)
Bone sarcoma 68 (2 .3)
Other sites 158 (5 .3)
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Table 2. Current Treatment Categories
Ocular Tinnors
Uveal melanomas
Angiomas and hemangiomas
Choroidal metastasis
Retinoblastomas
Skull Base, VertebrallParavertebral Tumors
Chordoma, chondrosarcomas
Other histologies
Head and Neck Tumors
Paranasal sinus
Nasopharynx
CNS Tumors
Benign meningiomas
Malignant meningiomas
Glioblastomas
Acoustic neuromas
Large arteriovenous malformations (AVMs)
Pelvic Tumors
Prostate cancer (T3T4)
Anal & rectal carcinomas
Sacral chordomas & sarcomas
Planning and treatment techniques currently
employed for fractionated proton beam therapy
at the HCL, a broad overview of results in pa-
tients with uveal melanomas, skull base and cer-
vical spine chordomas and chondrosarcomas,
Stage T,,4 prostatic cancer, and some CNS tumors
will be presented in this chapter. Treatment cate-
gories currently in effect at the HCL are listed in
Table 2. In Chapter 39 of this volume, plans for
proton beam therapy at the Northeast Proton
Therapy Center in Boston are discussed .
Ocular Tumors
Charged particle beams are ideal for treatment of
intraocular neoplasms : relatively large radiation
doses can be concentrated in the tumor, and unin-
volved intraocular and orbital structures can
largely be spared . Extensive experience has been
developed at the Harvard Cyclotron Laboratory
in ocular proton beam therapy, primarily of uveal
melanomas, involving a collaborative effort
between that laboratory, the Radiation Oncology
Department of Massachusetts General Hospital
(NIGH), and the Retina Service of the Massachu-
setts Eye and Ear Infirmary (MEEI) [1] .
Preclinical Studies
Studies on normal and simulated tumors in mon-
key eyes used single proton doses of 50-100 Gy
through 7 or 10 mm diameter beams. Opaque
areas of edematous retina and choroid developed
within 20 hours in each eye, while the non-
irradiated retina and choroid appeared entirely
normal [2] . A marked fractionation effect was
seen : 125 Gy/5 fx produced the same effect at 24
hours and at 1 year as did a single dose of 30 Gy
[3]. Chorioretinal changes persisted within the
irradiated area, but normal retinal architecture
was preserved immediately outside the discrete
retinal proton scar at 42-51 months [4] .
Planning and Treatment Techniques
A computerized treatment planning program has
been used for all patients, whether or not they
had undergone surgical tumor localization [5-7].
Treatment decisions are routinely based on clin-
ical evaluation only, since diagnostic accuracy of
current non-invasive ophthalmologic techniques
is quite high [8] . Input data for the treatment
planning program include :
- ultrasound-measured axial eye length and
tumor height, and
- tumor configuration drawn manually on the
computer from presurgical tumor sketches and/
or fundus photographs .
If surgical tumor localization is done, the clip
position is determined visually from measure-
ments taken at the time of surgery for clip place-
ment, and from simulator radiographs usually
performed on the second or third day following
surgery. A transparency with appropriate magni-
fication shows the desired clip position, and the
projection of the proton beam onto the front of
the eye. This transparency can be used for treat-
ment set-up . Individualized brass apertures are
specified from the treatment planning program
directly to a computer-controlled milling machine
for fabrication. Compensators are not employed .
Planning and treatment techniques have been
generally similar at all centers using protons for
ocular radiotherapy. Anterior lesions involving
the ciliary body and the peripheral choroid have
been treated with a light field only, verifying
tumor location for treatment by transillumination
after initial computerized planning from fundus
photographs, tumor sketches and ultrasound . A
light field set-up has also been used for metastatic
choroidal lesions involving the posterior pole .
Patients are seated for treatment, the head
immobilized with an individually molded bite
block and face mask. Retractors are employed to
limit the volume of eyelid irradiated . Voluntary
fixation on an external light source positions the
eye for radiographic or light field set-up and dur-
ing treatment, with video monitoring of eye posi-
tion during the 1-2 minute treatment.
Clinical Results
Between July 1975 through October 1993, uveal
melanomas in 1957 patients were treated at the
Harvard Cyclotron Laboratory. Approximately
half the patients were female . Using the Collabo-
rative Ocular Melanoma Study (COMS) size
categories [8], 7% of patients had small tumors,
62 % medium tumors, and 31 % large tumors .
Over 80 % of treated eyes had initial visual acuity
of 20/200 (6/60) or better. Standard dose has been
70 Cobalt Gy Equivalents (CGE = proton Gy
times RBE 1.1) in five fractions in 7-9 days . Local
control of tumor within the treated eye was 96 .3
± 1.5 % and 95 .4 ± 3.3 % at 60 and 84 months,
respectively. Wo failures occurred after 48
months, and none after 6 months ; 236 and 82
patients were available for follow-up at those
times after treatment. Zivo failures occurred in
the full dose (70 CGE) region, with 10 recurring
at the margin of the irradiated volume [9] . Five
year survival approximates 80% for all patients
[1,10,11] . Survival in proton treated patients is at
least as good as in patients undergoing primary
enucleation [12, 13] .
Visual acuity is improved or preserved in over
50 % of treated eyes ; a lesser degree ofvisual pre-
servation is observed in eyes with larger and with
more posteriorly placed tumors . Visual prognosis
in conservatively treated eyes has been found to
be significantly associated with tumor height, dis-
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tance of the posterior tumor margin from the
optic disc and/or fovea, pretreatment macular
retinal detachment, initial visual acuity, and radi-
ation dose to both disc and fovea and to the lens
[14, 15] .
Acute reaction occurs only if the eyelid cannot
be completely retracted from the irradiation field;
in such cases, moist eyelid desquamation usually
involves a discrete (2-5 mm by 8-15 mm) lid seg-
ment, which heals in two to four weeks. Some
scarring and permanent lash loss usually occurs in
such areas . Late complications include rubeosis
iridis with neovascular glaucoma, occurring from
2 months to 5.2 years (median 1.4 years) after
treatment, which can be treated successfully in
the majority of patients . Macular vasculopathy,
macular edema, optic atrophy and radiation
papillopathy can be seen in small percentages of
patients [1] . Cataracts develop in some patients,
predominantly those with large choroidal or cili-
ary body tumors in whom a large portion of the
lens has been irradiated . Successful cataract
extraction with restoration of vision after intraoc-
ular lens implantation has been reported [16] .
Uveal melanoma patients were also treated
from 1978 through 1992 at Lawrence Berkeley
Laboratory with helium ions in a collaboration
between the Radiation Oncology and Ocular
Oncology Departments of the University of
California-San Francisco . Results with doses of
50, 60, 70 or 80 CGE (CGE, equal to helium ion
dose in Gy times RBE factor 1.3) have been
encouragingly similar to those described above
for proton beam therapy (cf. Chapter 15 for
details) . That group began treating patients with a
cyclotron at the University of California-Davis, in
May, 1994 . Similar results are also being achieved
at PSI [17] .
Angiomas, hemangiomas and metastatic intra-
ocular tumors are other examples of malignancies
which have been treated at HCL. Doses have
been 25-35 CGE in 4-5 fractions for the blood
vessel tumors, and 28 CGE in 2 fractions for
metastatic lesions. Palliation of ocular symptoms
in patients with metastatic disease can be
achieved very efficiently. A light field treatment
plan can be prepared from fundus photographs,
tumor sketches, and ultrasound obtained at the
first clinic visit . After fabrication of the treatment
98
	
J. E . Munzenrider
aperture, the first of two treatments can be given
at the initial particle facility visit .
Charged particle dose localizing qualities are
particularly attractive for the treatment of reti-
noblastomas [18] . Significant reduction in normal
tissue volume treated can be achieved, which
might reduce the incidence of second malignant
tumors in patients with the hereditary form of the
disease . Previously untreated retinoblastomas in
14 eyes showed good acute tolerance and tumor
regression . Patients are planned with the 3D-
planning system described below, and have
received 40-46 CGE in 20-23 fractions over 5-5
1/2 weeks. Targets have included individual
tumors, retina posterior to the equator in cases
with posterior multifocal disease, or the entire
retina and vitreous in more advanced cases. No
dose is given beyond the midline with a single
lateral proton portal, resulting in a much smaller
volume of bone and other nontarget tissues being
irradiated than would be treated with photon
techniques . The dose distribution for treatment of
retinoblastoma with a single lateral proton beam
is shown in Figure 1, and illustrates how the dose
can be conformed to the target in the orbit, with
lesser doses to the skin, subcutaneous tissue, and
bone .
Significance of Particle Therapy
of Ocular Tumors
Uveal melanomas can be treated conservatively
with a high degree of success, using particle beam
techniques, with good expectation for visual pre-
servation, eye retention [19], and low complica-
tion rates. Even for very large tumors, treatment
can be justified if vision is poor or absent in the
fellow eye ; in such cases expectations for visual
preservation must be low, and the probability that
enucleation will be necessary in the future
approximates 20% .
Further follow-up of particle-treated uveal
melanoma patients will be needed to determine
the ultimate impact of such therapy on survival
and long-term visual outcome . Available evi-
dence, however, strongly suggests that survival is
not compromised, local control is achieved in
almost all treated eyes, and useful vision is pre-
served in the majority of patients .
Additional clinical experience and possibly
clinical trials are required to clarify the role of
particle beam therapy relative to other conserva-
tive techniques in the treatment of other ocular
tumors, such as retinoblastomas, angiomatous
tumors, and metastatic lesions.
Fig. 1. Dose distribution
with a single lateral proton
portal to a retinoblastoma
patient . Note target defined
in globe, absence of dose
across midline, and localiza-
tion of the 90% isodose
line within the globe
Planning and Treatment Techniques
with Other Tumors
Both planning and treatment techniques for pa-
tients with other tumortypes are markedly differ-
ent from those used for eye tumors . Proton beam
dose distributions are perturbed by inhomogene-
ities, such as bone or air cavities, to a much
greater extent than is the case for conventional X-
ray beams . Tissue density in the volume to be
irradiated must be accurately known for proton
therapy, to allow compensation for tissue inho-
mogeneities, both in planning and treatment
[20-22].
Metallic markers, either small gold screws or
coated lead spheres surgically implanted into the
skull prior to treatment planning in patients with
head and neck, intracranial or skull base lesions,
serve as fiducials for patient positioning [23] . A
treatment planning CT scan is performed on the
immobilized patient in the treatment position
[24], with tumor and normal tissues of concern
throughout the treatment volume then being
defined on each CT section .
The "beam's eye-view" feature of the interac-
tive treatment planning program is employed to
define appropriate apertures to treat the defined
tumor volume, while minimizing dose to dose-
limiting normal tissues [25] . Fields are defined
with brass or Cerrobend apertures, while dose at
depth is determined by portal-specific Lucite com-
pensators. Apertures and compensators are indi-
vidually fabricated for each field . Up to 12
aperture-compensator sets have been required for
some patients . Most patients receive a portion of
their treatment through two or more X-ray portals,
to achieve some skin sparing, and to allow treat-
ment five days per week (HCL beam has been
available only four days per week for the fraction-
ated proton therapy program) . Prior to plan imple-
mentation, 3D-dose distributions throughout the
treated volume are reviewed, allowing necessary
corrections prior to actual treatment.
Patients are treated in their immobilization
device, their position having been radiographi-
cally verified prior to each treatment. Set-up
accuracy and reproducibility is ± 2 mm with skel-
etal fiducial [24], and ±1 mm when small surgi-
cally placed skull fiducials are employed [26] .
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Full 3D-dose distributions can be displayed on
the monitor or printed out as hard copy, with
either conventional isodose lines or color shades
with the appropriate scale . Up to four different
plans can be compared simultaneously. Dose-
volume histograms can be produced for any struc-
ture which has been defined on the planning scan .
A full data set for each patient is archived at the
completion of treatment, and can be recalled for
clinical or research purposes at any time after
treatment has been completed [27, 28] .
Clinical Results with Other Tumors
Chordomas and Chondrosarcomas
A large number of patients with cervical spine
and skull base chordomas and chondrosarcomas
have been treated at the Harvard Cyclotron,
using 3D-planned combined proton and X-ray
treatment [29, 30] . The HCL 160 MeV proton
beam is particularly suitable for treating such
tumors, although lack of a gantry has required
some patients to be treated in the upright posi-
tion . Between February 1974 and December 1991,
45 patients with cervical spine and 209 patients
with skull base chordomas and chondrosarcomas
were treated. Tumor volumes ranged from 3.3 to
318 ml; median volume was 70 ml for cervical
spine and 40 ml for skull base tumors . Tumor
dose ranged from 56.8 to 80 CGE, with median
dose being 69 .9 CGE for patients with cervical
spine tumors and 68.4 CGE for skull base pa-
tients . Local recurrence-free survival (LRFS) for
the skull base tumor patients was 77 ± 5 % at five
years, significantly better than for cervical spine
tumor patients (58 ± 14%, p = 0.0076) . Skull
base chondrosarcoma patients had significantly
better LRFS than did chordoma patients (95
±4% vs . 62 ± 9%, p = 0.0001) . In skull base
chordoma patients, males fared significantly bet-
ter than did females. No significant difference in
LRFS was observed between cervical spine chor-
doma and chondrosarcoma patients (p > 0.05) .
Improved cause-specific survival for skull base
tumor patients relative to patients with cervical
spine tumors, and for skull base chondrosarcoma
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patients relative to skull base chordoma patients
was also observed (p < 0.05 for both compari-
sons) .
Relatively few complications have occurred,
considering the high doses delivered . In skull
base patients, significant brain injury was seen in
approximately 6 % and severe visual complica-
tions in approximately 2% . Post-treatment pitu-
itary insufficiency can occur in 10-15 % of pa-
tients, being partial in most, although a few have
developed panhypopituitarism . Unilateral hear-
ing loss also has developed in 10-15% of skull
base patients . Neurovisual and neuroendocrine
sequelae of treatment have been described [31,
32] .
Treatment with conventional radiotherapy fol-
lowing surgery results in locally progressive dis-
ease and ultimately death in most patients [33] .
Local recurrence-free survival achieved with the
313-planned combined proton and photon tech-
niques in these patients are superior to results
described in the literature . Similar encouraging
results have been reported from LBL [34] .
A randomized prospective clinical trial was
initiated in 1985 through the NCI and the RTOG
(Radiation Therapy Oncology Group), as a colla-
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Fig. 2. Local control (local recurrence-free survival) for
lower risk patients (male skull base chordomas and all skull
base chondrosarcomas) and for higher risk patients (female
skull base chordomas and all cervical spine patients) with
chordomas and chondrosarcomas of the skull base and cer-
vical spine
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Fig. 3. Overall survival for lower risk patients (male skull
base chordomas and all skull base chondrosarcomas) and for
higher risk patients (female skull base chordomas and all
cervical spine patients) with chordomas and chondrosarco-
mas of the skull base and cervical spine
boration between MGH-HCL and UCSF-LBL .
Tumor control and treatment sequelae were to be
prospectively assessed after doses of either 66.6
or 72 CGE, given predominantly with protons or
helium ions .
As the study progressed, it became apparent
that this population contained two separate
groups, in terms of the risk of both local failure
and survival . Treatment failure was significantly
more likely to occur in female skull base chor-
doma patients, as well as in patients with cervical
spine tumors, regardless of sex or histology.
Lower risk patients (male skull base chordomas
and all skull base chondrosarcomas) had a 91 ±
4% probability of local control at five years, com-
pared to 48 ± 10% for higher risk patients
(female skull base chordomas and all cervical
spine patients), p = 0.0001. Cause-specific survi-
val was 94 ± 3% for the lower risk group, and78
± 8% for the higher risk patients . Local control
(LRFS) and overall survival for both groups are
shown in Figures 2 and 3, respectively.
Accordingly, the protocol was modified ; lower
risk patients would continue to be randomized
between the original dose levels (66.6 vs . 72
CGE), using the standard normal tissue dose con-
straints, while higher risk patients (female skull
base chordomas and cervical spine tumors of
either sex or histology) would be randomized
between 72 and 79 CGE. Dose constraints for the
72 CGE arm would remain unchanged, but be
increased by 5% for patients randomized to the
79 .2 CGE arm. One hundred forty-seven patients
were randomized through September, 1993, 118 at
MGH-HCL, and 25 at UCSF-LBL. Patient treat-
ment has been terminated at LBL, but Loma
Linda will be participating in this trial .
Complication rates have been acceptable,
especially in view of the major morbidity followed
by an invariably fatal outcome in patients with
uncontrolled tumor growth . Neurological, visual,
endocrine and auditory problems can appear at
various times after treatment, dictating that
initial and continued multidisciplinary surveil-
lance with specialists in those areas be per-
formed, to allow identification and appropriate
treatment of tumor recurrence, extension or
metastasis as well as of treatable complications.
In summary, 3D-planned high dose radiation
therapy delivered with combined proton and
megavoltage X-ray techniques following appro-
priate surgery appears to represent the best man-
agement policy currently available for patients
with chordomas and low-grade chondrosarcomas
of the skull base and cervical spine. This potenti-
ally hazardous treatment is expensive, time-
consuming and demanding for both the patient
and those involved in their care . Nonetheless, it
offers major improvements in outcome, relative
to that anticipated with conventional megavolt-
age X-ray techniques, or with surgery alone.
Prostate Cancer
Initial results in 66 prostate cancer patients
treated with a perineal proton boost following
high energy X-ray whole pelvic irradiation were
encouraging. Doses ranged up to 75 CGE,
10-20% greater than those then being given with
conventional megavoltage X-ray techniques, and
were associated with no greater rectal or bladder
morbidity than would have been expected after
treatment to conventional doses with X-rays [35] .
APhase III clinical trial based on that experience
was initiated in 1981, and closed in June, 1992
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after 203 patients had been enrolled . Patients
with T3_4 NX-0Mo disease received 50 .4 Gy to the
pelvis, followed by a randomly assigned boost to
either 67.4 Gy with X-rays or 75.6 CGEwith pro-
tons .
Local control at five years for the entire group
was 90 %, with overall survival 81 % (median
follow-up 41 months, range 14-74 months) in an
interim analysis [36] . Trial design had estimated
local control at 5 years with the lower dose to be
approximately 70% . Another interim report on
this trial has been presented in October 1994 .
Mild (grades 1 & 2) rectal bleeding occurred in
16 % of patients treated to the lower dose (X-rays
only), and in 34 % of patients boosted to the
higher dose with the perineal proton portal (p =
0 .013). Dose volume histogram analysis in 41
patients showed that the total volume of anterior
rectum receiving ?75 CGE correlated signifi-
cantly with the probability of remaining free of
rectal bleeding . No rectal bleeding was experi-
enced by 80% of 27 patients in whom >40% of
the anterior rectum received >75 CGE, while
only 40% of 14 patients in whom >40% of the
anterior rectum received ?75 CGE remained free
of rectal bleeding [37] .
Intracranial Tumors
Techniques for treatment of skull base tumors are
also appropriate for the fractionated treatment of
patients with discrete CNS tumors, such as
meningiomas, craniopharyngiomas, acoustic neu-
romas, and some gliomas .
Thirty-two meningioma patients with recur-
rent or incompletely excised meningiomas have
received doses ranging from 55.8 to 71.6 CGE
with combined photon and proton treatment . No
tumor progression has been documented in 26
patients with benign histology, although two of
six atypical or malignant meningioma patients did
show progression. Some of these patients are
included in a report on results in 36 patients with
benign meningiomas treated at MGH between
1968 and 1986 [38] . There was a trend toward
improved local control in patients treated with
combined photon and proton techniques and 3D-
planning. A Phase III clinical trial has been initi-
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ated, to evaluate prospectively local control and
morbidity after proton and photon treatment of
incompletely excised or recurrent benign menin-
giomas to doses of 55.8 CGE or 63 .0 CGE. Pa-
tients will also be entered into this protocol from
LLUMC.
Twelve craniopharyngioma patients have
received doses ranging from 52.7 to 63.4 CGE .
No tumorprogression or complications have been
seen in 10 patients (median follow-up in excess of
5 years) . One did require cyst evacuation after
treatment . Two died, one with blindness and
dementia, and the other without obvious tumor
progression from complications of diabetes melli-
tus. Superior dose distributions for craniopharyn-
giomas can be achieved with proton techniques,
relative to those possible with X-rays . However,
conventional megavoltage X-ray treatment to
moderate doses, of the order of 50.4 Gy in 28
fractions, produces acceptable results, and fur-
ther treatment of patients with these tumors at
the HCL is not currently planned.
Early experience in treating high grade glio-
mas engendered little enthusiasm for use of once-
daily fractionated proton beam techniques in that
group of patients . Three of four such patients
died of progressive tumor growth at 11, 30, and62
months after treatment ; another died at two
months with leukopenia and sepsis following che-
motherapy at another hospital . We recently
demonstrated that a dose of 90 CGE in 50 frac-
tions over 5-51/2 weeks to the CTenhancing vol-
ume of patients with glioblastoma multiforme
was well tolerated: all nine patients entering the
protocol completed the treatment . Although
none survived beyond 26 months, recurrent
tumor was seen only in the lower dose volume
immediately outside the volume treated to 90
CGE, suggesting that the target volume designed
from the CTenhanced scan had underestimated
true tumor extent . A new protocol has been
developed, combining findings from CT, MRI,
and PETin the initial definition of the target vol-
ume. The dose fractionation schedule described
above will be employed in that protocol .
Arteriovenous Malformations
The most common indication for single fraction
proton or helium ion beam treatment in recent
years has been for arteriovenous malformations
[39-40] . Although benign, these vascular abnor-
malities can result in major CNS morbidity or
even death from uncontrolled hemorrhage . If sur-
gical treatment is not possible, single fraction
radiosurgery is a viable option for smaller (<5
cm) lesions: fractionated radiotherapy may be
beneficial for larger malformations . Such treat-
ment may be given with protons, although other
centers have employed the 60Co Gamma Knife or
specially modified linear accelerators to deliver
stereotactic irradiation to small intracranial tar-
gets .
It may be difficult to demonstrate any advan-
tage for particle beams in treating small CNS
lesions, since few if any symptoms may be mani-
fest after injury to a small volume of the CNS.
However, it is likely that particle beams will be
particularly advantageous for fractionated treat-
ment of larger AVMs, as suggested by a compar-
ative treatment planning study recently presented
by Miralbell and Urie [41] .
Assessing the Value of Proton
Therapy: Clinical Trials through PROG
Suit et al . [42] have discussed criteria for as-
sessing the value of proton therapy: "In planning
the clinical trials for proton radiation therapy,
special attention has to be directed toward defini-
tion of the control arm and to select tumors for
which there are excellent prospects of administer-
ing doses which are higher by >10 % than is feasi-
ble with high technology photon therapy."
The initiation of proton therapy at several new
proton therapy centers may accelerate the accrual
of patients into cooperative clinical trials . An
administrative mechanism to facilitate and
coordinate such trials has been set up by the
American College of Radiology and the U.S .
National Cancer Institute. They established the
Proton Radiotherapy Oncology Group (PROG)
to
1. stimulate cooperative clinical trials by the vari-
ous proton therapy centers in the US and
abroad,
2. organize and manage the clinical trials,
3 . provide data management for the trials,
4 . encourage the prompt reporting of trial results.
The initial PROG trial will extend a two-dose
level trial for patients with skull base and cervical
spine chordomas and chondrosarcomas, as dis-
cussed above. Other active PROG protocols
include treatment of recurrent and incompletely
excised benign meningiomas, advanced paranasal
sinus carcinomas, and T3/4 carcinomas of the ton-
sil. New protocols will be developed for atypical
and malignant meningiomas, for high-grade glio-
mas, and uveal melanomas, as well as tumors at
other, sites. Initial PROG members include
MGH, UCSF-LBL, and LLUMC. Participation
by other centers in North America and abroad
will be encouraged . Despite initiation of cooper-
ative clinical trials by PROG, it is not likely that
the true efficacy of proton radiation therapy will
be assessed before the end of this century. Testing
proton therapy against various tumor sites is
really just now beginning, and radiation therapy
clinical trials require long observation periods to
properly assess the end-points of local control,
patient survival, and acute and chronic morbidity.
Summary and Conclusions
Protons are not "magic bullets" . Proton beam
therapy is not a revolutionary development in the
treatment of malignant disease. It is better con-
sidered as an evolutionary advance in radio-
therapy practice, similar to improvements in dose
distributions which were made possible when
kilovoltage X-rays were supplanted by megavolt-
age photons, and, in some cases, by the availabil-
ity of electron beam techniques .
The impressive clinical successes achieved by
the Massachusetts General Hospital and the Mas-
sachusetts Eye and Ear Infirmary in the proton
therapy program at the Harvard Cyclotron, par-
ticularly in patients with uveal melanomas and
with bony and cartilaginous tumors of the skull
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base and cervical spine, continue to fuel the bur-
geoning interest in the United States and
throughout the world in ion beam radiotherapy
for the treatment of human malignancies .
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Introduction
Clinical Results of Proton Therapy in Russia
E . I . MINAKOVA
Institute for Theoretical and Experimental Physics, Moscow, Russia
The clinical application of proton beams has been
a subject of medical research in Russia for over 25
years . There are three proton therapy facilities in
Russia in
- Dubna (the Joint Institute for Nuclear
Research, JINR),
- Gatchina (the Institute for Nuclear Physics,
INP) and
- Moscow (the Institute for Theoretical and
Experimental Physics, ITEP) .
Each of the three facilities has a different phys-
ical environment (Tab . 1) which has to some
extent determined their clinical programs.
More than 3600 patients hadbeen irradiated at
these three facilities by June 1994 .
The treatment categories can be grouped into
four programs :
a radiation oncology program which started in
Dubna in 1967 and in Moscow in 1969 .
a radioneurosurgical and neurooncological pro-
gram which started in Moscow in 1972 and in
St . Petersburg in 1975 .
an endocrinological program (an important
branch of the radioneurosurgical program)
which started in St . Petersburg in 1975 and in
Moscow in 1976 .
an oncoophthalmological program which
started in Moscow in 1976 .
Radiation Oncology Program
The radiation oncology program has been di-
rected by the Cancer Research Center in Moscow.
Clinicians from other medical centers, e.g ., the
Moscow Research Institute of Roentgenology
and Radiology, the Research Institute of Urology
took part in this program at various phases .
During the first phase of this research the
physical, medical and technical equipment and
the dose delivery system were tested under real-
istic conditions irradiating skin cancer, solitary
soft-tissue metastases or metastases in lymph
nodes (with the primary tumor cured), vulva
tumors, etc. Visual control and histological post-
irradiation investigations showed that morpho-
logical changes in the tumors and radiation reac-
tions in tissues surrounding the target were
adequate for the treatment plans.
The Early Phase
Among the earlier treatments were, e .g ., 37 adult
patients (75% of them older than 60) with carci-
noma of the vulva (clinical stage I-IV,
TINOMO-T4(,)N3Mp) who were given combined
radiotherapy : proton irradiation of the primary
tumor at the ITEP and conventional irradiation
of the locoregional lymph nodes. All patients had
somatic counterindications to surgical treatment .
In about 90 % of the patients clinical local control
was achieved . The 5-year survival rate was 51
without complications or treatment related mor-
bidity. Thecombined proton therapy proved to be
the only successful treatment for such cases [1] .
Table 1 . Three Russian Proton Therapy Facilities
Institution
	
Accelerator Date of First Reconstruc-
', Place Treatment tion Interval
Institute for Synchrotron 1969 1972-1975
Theoretical reopening
and Experi- 1975
mental Phys-
ics (ITEP),
Moscow
Joint Synchrotron ; 1967 1974-1987
Institute for Phasotron reopening
Nuclear after recon- 1987
Research struction
(JINR),
Dubna
St . Peters- Synchro- 1975
burg's Insti- cyclotron
tute for
Nuclear
Physics
(INP),
Gatchina
It is known that proton beam irradiation en-
sures a much more favorable ratio of tumor to
normal tissue dose for deep-seated tumors, in
particular. The results obtained from the early
investigations (approx. 100 patients) made it pos-
sible to begin assessing the treatment efficiency of
broad proton beam therapy of malignant sinovi-
oma, osteogenic sarcoma, of deeper seated
tumors of the larynx, the cervix uteri, lung, eso-
phagus and prostate .
First attempts to irradiate larynx cancer with
protons failed . Large fractions (5.0-6.0 Gy per
fraction, total dose of 75 Gy during 10 weeks) had
to be applied due to the beam time schedule of
the JINR accelerator. Complete primary tumor
resorption was achieved, but late radiation com-
plications with necrosis of the larynx cartilage
occurred which made subsequent surgery neces-
sary. Of a total of 14 patients, 6 lived three years
and 3 lived 5 years after the irradiation without
External Beam Data Number of PatientTotal
Teatment by June 1994
Rooms
Energy Max. Intens .
pp s
70-200 2 x 10'0	3 2700
MeV
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6608) 2 x 10'3 >110
1000 not 5 x 10' 1 >850
variable
a) The proton energy can be degraded down to 100-200 MeV.
b) There are also other beam channels : negative pions up to 80MeV, neutrons of ca . 350 MeVand a reserve gamma-
unit with a 'Co-source .
recurrence and metastases . Retrospectively, it is
assumed that the complications were due to the
fractionation regime . Thehigh dose fractions very
likely exceeded the tolerance of the delicate,
regenerating larynx cartilage [2].
Single-Fraction Preoperational Irradiations
The results of single-fraction preoperational
irradiations of limb osteogenic sarcomas (doses >_
100 Gy) at the ITEP proton synchrotron proved
to be dramatic . The high intensity of the ITEP
synchrotron beam made it possible to accumulate
high doses rather fast even in large volumes. The
goal was to ablate the radioresistant tumor before
the amputation of the limb [3]. Approximately
3-10 months later all 14 patients had metastases
in the lung . A subsequent analysis showed that
the tumor boundaries in the limbs were not well
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enough defined and that there were cold spots in
the dose profile . In addition, some patients pos-
sibly had remote metastases prior to irradiation .
It remained unclear, if proton irradiation is capa-
ble to ensure tumoricidal radiation doses.
The single-fraction presurgical irradiation of
16 patients with skin melanomas was more suc-
cessful. More than half of them had disease-free
survival periods of 5 years [2] .
Cancer of the Cervix Uteri
Radiation therapy is the basic method for 90 % of
the patients with cervix uteri cancer and it is the
only treatment for 75 % of the patients in Russia .
Until June 1994 more than 180 patients with
cervix uteri cancer in clinical stages I-III had
been treated at the ITEP and the JINR. The first
phase of the clinical trials comprised 110 ran-
domly chosen patients for a combined preopera-
tive transvaginal proton irradiation of the primary
tumor in 3 large fractions and a conventional
irradiation of the small pelvis (with protection of
the uterus) . A control group of patients was only
administered to the standard conventional radia-
tion therapy without proton boost. Total dose
delivered to the tumor core (point "A") was 35-45
Gy for both groups .
No significant differences in the cumulative
survival rates in trial (81 %) and control (78 %)
groupwere observed during 15 years of follow-up
period . Acute and late morbidity levels were
acceptable .
Aphase II unrandomized clinical investigation
started in 1980, comparing a radical gamma-
therapy or a combined proton-gamma therapy in
more than 50 patients with cervix uteri cancer of
stages I-II1 . The total dose at point "N' was 60-70
Gy. The survival rate was 88 % after 3 years
(some patients died due to remote metastases
without local recurrence) . A comparison of the
results of the proton boost therapy with a com-
bination treatment of intracavitary implants and
external locoregional conventional irradiation
showed no significant difference in the survival
rate . The proton boost irradiation yielded, how-
ever, considerable improvements for the patients'
quality of life : while proton therapy led to no
complications at all, the combination of intraca-
vitary implants with external irradiation resulted
in rectitis and cystitis in 14-20% of the cases, and
recto- and vesicovaginal fistulas in 1-5% of the
cases, respectively. Moreover, proton transvagi-
nal irradiation required no cervical canal expan-
sion or premedication and decreased the irradi-
ation times to 1-2 min [4] .
At Dubna, this method was attempted in 26
patients .
Prostate Cancer
The first phase of the clinical trials to assess the
efficacy of combined proton boost and conven-
tional radiation therapy of pelvis-limited prostate
cancer was performed between 1981 and 1985 . For
17 patients with various clinical stages, a split-
course scheme with X-rays and protons was set up .
The conventional external therapy was per-
formed as standard "box" technique . Proton
spread-out Bragg peak (SOBP) irradiations were
performed using one transperineal portal .
The second phase of unrandomized clinical
investigations with new clinical protocols for
stages TI-2 and stages T3_4was started in 1987 . The
proton boost therapy group comprised 88 pa-
tients . Control groups included patients adminis-
tered to megavoltage photon irradiation (105
patients), and patients administered to a standard
conventional external 60Co gamma therapy only
(68 patients) . A comparative study of the 261
cases performed in 1990 revealed no statistically
significant differences in complete and partial
tumor regression rate between these methods for
TI-2 stages . On the other hand, there was a pro-
nounced advantage of combined proton-boost
irradiation for advanced T3_4 cancer. The 5-year
local recurrence-free survival rates were 87.5
for the proton group, 76.4% for the megavolt
photon group and 69.8 % for the 6°Co patient
group, andremote metastases were established in
14.4%, 25.8% and 47% of the cases, respec-
tively. Treatment-related morbidity included
urological complications. They were 1.5 %, 8.3
and 17.5 %, respectively, for the different groups
[5, 6] . Some patients were found to have bone
metastases after 12-27 months .
In the case of cured primary foci and the pres-
ence of metastases of the skeleton, proton "hypo-
physectomy" was applied with the intention to
relieve pain . Stereotactic proton irradiation of the
pituitary (100-130 Gy in a single fraction) for
advanced prostate cancer patients has been
applied since 1972 .
More than 100 patients with estrogen-resistant
prostate cancer stages III and IV have since been
irradiated at the ITEP Proton "hypophysectomy"
does not only lead to a recovery of the hormonal
status with a response to estrogenic agents . It fur-
ther ensures a mean survival of 20.6 months for
incurable patients [7] .
Cancer of the Thorax
In 1970, Dubnabegan to develop equipment and
a proton therapy procedure for broad beam
irradiation of thoracic tumors .
Until 1974 a total of 56 patients received treat-
ment . There were 23 lung cancer patients and 33
cases of oesophageal cancer.
A group of 14 patients with peripheral lung
cancer (stages II) or with solitary metastases in
the lung (primary tumor cured) was involved in a
phase I clinical trial using 130 MeVproton beams.
Patients in a sitting position were irradiated twice
a week (due to limited availability of the acceler-
ator) with anteposterior fields and Bragg peaks
superimposed in the tumor center. Tumor dose
per fraction was 4 Gy, total doses were up to 52
Gy (tumor sizes [t 55 mm). 6 patients were irradi-
ated preoperationally (lobectomy) with tumor
doses of 27-33 Gy. Future studies will stipulate a
more precise proton therapy of these tumors with
rotational beam portals where the Bragg peak
position will be controlled and adjusted in accor-
dance with the proton range calculations based on
calibrated computer tomography data .
Static multi-field and rotational proton irradi-
ation was used to irradiate the esophagus tumors
(clinical stages III-IV) in a phase I clinical trial .
The tumors, situated in the middle third of the
esophagus, ranged in size from 70-160 mm . The
target doses were 4 Gy per fraction, two fractions
per week, up to a total tumor dose of 48-60 Gy.
Local radiation reactions did not differ from
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traditionally treated patients . Six and 3 patients
were alive 1 and 3 years, respectively, after the
irradiation . Local control and survival rate were
comparable to conventional therapy. Proton
beam therapy, however, did not cause serious side
effects, as were observed after conventional radi-
ation therapy of lung and esophagus tumors [8] .
Five more patients with esophageal cancer had
been irradiated until June 1994, after extensive
reconstruction of the accelerator.
For these cases a new method was used . The
esophagus was irradiated with the proton beam
moving in several steps along the target length .
The Bragg peak position was matched to the
tumor using the signal from a miniature remov-
able silicon diode, inserted into the esophagus.
The radiological depth from the patient's surface
to the tumor was first measured for every single
angular position . The data were then used to set
the Bragg peak position with the beam energy
degrader in the sessions to follow. The reproduc-
ibility of the patient's position was checked with
X-ray computer tomography [9]. The clinical
results have not yet been reported, but the
method described seems to be challenging for the
treatment of such tumors .
Breast Cancer
According to statistical data, lung, stomach, skin
and breast cancer are the most frequent localiza-
tions of malignant tumors in Russia . The high fre-
quency of breast cancer was also a reason to look
into proton therapy in order to improve the
results of radiation treatment . Single-session
pituitary stereotactic proton irradiations of pa-
tients with generalized breast cancer began in
Moscow in 1972 [10] . 100 incurable patients with
generalized breast cancer were treated until 1979 .
Fast pain relief in the skeleton - in 70 % of the
patients - objective stabilization or resorption of
bone metastases, and improved quality of life
were reported [11] . This method was later widely
used in Moscow as part of a combined radiation
treatment of breast cancer ("hypophysectomy"
with proton beams at the ITEP plus conventional
6OCo or proton irradiation of the lymph nodes,
soft tissues, bones and solitary liver metastases) .
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The mean survival reached 36.4 months in a
group of more than 190 patients [12] .
Direct irradiation of primary nodal breast can-
cer with SOBP was started in 1982 . Proton ther-
apy was the only treatment for 18 patients
(T1_2NOMO) . All patients had 5-year local
recurrence-free survival without remote metasta-
ses. All women had a good cosmetic effect and
organ preservation .
Another 87 patients (T1_4N1_3Mo_1) were
treated using both combined proton boost ther-
apy and photon irradiation of the whole breast
and eventually any locoregional metastases . The
full course of radiation was given within 11-14
days . Patients having bone metastases, were
administered to the proton Stereotactic "hypo-
physectomy", as well . 78 % of the patients in this
group were alive for more than 4 years. A com-
parison of the clinical results of the proton boost
therapy (in combination with pituitary suppres-
sion) with conventional procedures proved the
advantage of protons in the therapy of nodal
breast cancer in T1_ZNo_3Mo_1 stages [13] .
Since 1975, the Central Research Institute of
Roentgenology and Radiology (CRIRR) in St .
Petersburg has treated 102 patients with general-
ized and 48 patients with primary, locally dissemi
nated breast cancer (T3N2Mo-T4BN1_ZM1) and dif-
ferent metastases, by means of proton "hypophy-
sectomy" plus external conventional irradiation
of the primary tumor and the metastases . A 5-
year survival rate of more than 30 % was reached
in the second group [14] .
Radioneurosurgical and
Neurooncological Program
For more than two decades proton beams have
been used in Russia for the treatment of benign
and malignant brain diseases . The program is
jointly coordinated by the Burdenko Neurosur-
gical Institute in Moscow and the Polenov Neuro-
surgical Institute in collaboration with the
CRIRR in St . Petersburg . The experience of
these centers exceeds 1500 cases.
Narrow (5-30 mm diameter) proton beams,
have been used for the following indications :
1. Stereotactic radiosurgery of vascular diseases
of the brain.
2. Stereotactic large-fraction proton therapy of
intracerebral, deep-seated, midline malignant
and benign tumors .
3 . Stereotactic proton radiosurgery of pituitary
adenomas .
4. Functional Stereotactic radiosurgery.
Stereotactic proton radiosurgery of the pituitary
gland ("normal" and adenomatous) proved to be
a highly efficient treatment for a variety of endo-
crine and hormone-dependent metabolic states
(including hormone-responsive metastatic can-
cer), so that these directions formed a separate
endocrinological proton therapy program (in col-
laboration with the Endocrinological Research
Center in Moscow and the Institute for Advanced
Medical Training in St . Petersburg) .
Two techniques of proton irradiation were
applied:
- through-and-through technique, with unmod-
ulated high energy (200 and 1000 MeV) proton
beams using the plateau of the depth dose
curve,
- Bragg peak irradiation using the unmodulated
or spread-out Bragg peak (180 MeV, Moscow) .
Arteriovenous Malformations
Arteriovenous malformations (AVMs) are the
traditional target for stereotactic proton radio-
surgery world-wide (cf. as well Chapter 16) .
Approximately 330 angiographically visible
AVMs have been irradiated in St . Petersburg
since 1978 and Moscow since 1983 .
Deep-seated, inoperable AVMs or AVMs
located in functionally important areas of the
brain have usually been treated by stereotactic
proton therapy alone. In some cases intravascular
embolization of the AVM feeder vessels or a par-
tial resection of the AVM was carried out prior to
proton therapy.
A single through-and-through irradiation has
been used at Gatchina . The preradiosurgical vol-
umes of the malformations ranged from 1 to 10
cm' in the main group . The size of a single irradi-
ated area was 5-10 mm (included in 50 % iso-
dose), and the maximum dose varied between 40
and 80 Gy. In some cases 2-3 fields of irradiation
were used .
In almost 50 % of the cases, the AVMs were lo-
cated in the medio-basal region of the brain. The
highest number of patients with complete
response was observed among those who had
malformation volumes of less than 2.0 cm3
(68 %), while complete obliteration was angio-
graphically documented in only 38 %, when the
malformation volume was 10 cm3. Neither
treatment-related complications, nor decline of
neurological symptoms was recorded . The first
experience with the treatment of cerebral arterial
aneurysm (6 patients) was unsatisfactory, presum-
ably due to the fact that the dose level was kept
very low in order not to risk vessel breakage
[15,16] .
Bragg peak proton radiosurgery has been used
for AVM treatment in Moscow. Preradiosurgical
volumes of the malformations varied from 1-48
cm3. Bilateral opposed portals (6-8) and narrow
beams (15-30 mm diameter) were used . The tar-
get was included in the 50-80 % isodose of the
resulting dose field. The dose level (usually 30-50
Gy in 1 or 2 fractions) was chosen according to
size and location of the target (brain stem, thala-
mus, corpus callosum, basal ganglia, some critical
areas of the cerebrum cortex) .
Total obliteration rate was approximately 60
for all volumes of AVMs, partial obliteration was
observed in 25 % . For larger and partially irradi-
ated AVMs different degrees of thrombosis of the
pathological vessels were observed . Four cases of
serious radiation reactions of the brain occured
(AVMs located in the wall of the ventricle of the
brain and in the basal ganglia) which could be
treated by drugs only [17,18] .
Spontaneous Arteriosinusal Fistulas
Another type of vessel pathology cured with pro-
ton beams in Moscow are spontaneous arteriosi-
nusal fistulas of the cavernous sinus (sASF) caus-
ing severe changes in eye and orbit (40 patients
since 1983) . Single-session plateau irradiations
were performed with 50-60 Gy (beam diameter
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up to 12 mm) . Within short time ophthalmo-
logical and neurological improvement or com-
plete recovery was observed in almost all cases.
No complications were recorded . Angiography
revealed total and partial obliterations in 95 % of
the cases [18,19] .
Meningiomas
For large fraction proton therapy meningiomas of
the cavernous sinus were chosen as primary
indication because complete surgical resection is
very often impossible and they are too radiore-
sistant for conventional radiation therapy alone.
Depending on the size and shape of the tumors,
spread-out Bragg peak or through-and-through
methods were used for the treatment of approx .
80 patients in Moscow since 1982 . Tumors, mostly
20-30 mm in diameter, were treated with 60-70
Gy in 2-4 fractions during 1 or 2 weeks. The tar-
get margin was usually confined within the 50
isodose . In some cases the treatment was posto-
perational .
Total clinical effectiveness (stabilization and
improvement of symptoms) was achieved in 87
of the observations . Objective local control (CT
assisted follow-up) was recorded in 84% of the
cases. There was no case of damage to the sensi-
tive anatomical structures of the cavernous sinus.
Some relapsing meningiomas were only partially
irradiated . In one case (female patient with a
tumor of more than 35 mm in diameter) the
irradiation resulted in brain necrosis . Atotal dose
of 68 .7 Gy was delivered in 3 fractions from 5 por-
tals in ipsilateral temporofrontoparietal region
during 10 days . Treatment related morbidity
symptoms and objective images (CT and MRI)
indicating brain damage were obtained 2 months
later. The patient received three courses of medi-
cinal therapy and 8 months later the clinical
symptoms had completely disappeared as did the
abnormal changes of the CT [20,21] .
Narrow proton beams do not only help to over-
come the radioresistance of meningiomas. They
permit to irradiate selectively tumors with orbital
spreading.
The following beam conditions were used in
these cases: frontal through orbit (1 portal),
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through lobe area (2 portals) plus through parie-
tooccipital regions of the skull (4 portals) . There-
by, it was possible to create a dose field which
optimally covered both the intracavernous part of
the tumor and its intraorbital part .
The patients were irradiated in blind-eye side
lying position . The total dose of 50-65 Gy was
delivered in 3 fractions (dose on eye: 6 Gy) . Pain
remission, regression of exophthalmus and
restitution of proper eye movement was observed
after the irradiation [17, 22] .
Besides meningiomas, some other histological
types of tumors of the cavernous sinus were
treated such as pituitary adenoma invading para-
sellar structures and pseudotumoral Tolosa-Hunt
Syndrome. Patients with steroid-resistant recur-
rent Tolosa-Hunt Syndrome recovered complete-
ly after the irradiation of their cavernous sinus
and they remained without local recurrence for
periods up to ten years [23] .
Other Intracerebral Tumors
Large-fraction proton therapy is a very promising
treatment for small intracranial tumors, particu-
larly for those which are inaccessible to open rad-
ical surgery. The following types of tumors fall
into this category : primary intracerebral low-
grade glioma, germinoma, pineocytoma, hamar-
toma, various craniopharyngiomas (17 patients in
total), secondary metastatic tumors of the brain
(4 patients) in Moscow. The specific location of
these targets (pineal region, internal capsule,
brain stem, third ventricle, basal ganglia) and the
vicinity to critical normal tissues are the limiting
factors for conventional therapy. Spread-out
Bragg peak stereotactic large fraction proton
therapy with beam diameters of 20-30 mm doses
of 30-60 Gy was used . The treatment was deliv-
ered in 2-4 fractions within 1-2 weeks. The target
was usually included in the 50%-80% isodose.
The proton irradiation was complemented with
conventional radiation in some cases.
The best results were obtained with the very
radiosensitive germinomas . The tumors disap-
peared completely within two weeks. Pineocyto-
mas and hamartomas disappeared within 1-1.5
years. Patients with metastases of lung carcinoma
responded well to the combined radiation treat-
ment. The size of astrocytomas grade I (remnant
after surgery) started to decrease 6 months after
the proton irradiation . Acute and late morbidity
was acceptable, treatment-related mortality was
not recorded [21] .
Pituitary Adenomas
The first intracranial tumors to be treated with
proton beams in St . Petersburg andMoscow were
pituitary adenomas . Twenty years of clinical expe-
rience have revealed that proton irradiation is
best suited for microadenomas, macroadenomas
with endosellar localization and no or only local
invasion of the dura mater and for adenomas with
a little suprasellar extension or sharply asymmet-
rical parasellar growth . For the latter two indica-
tions it is necessary to use Bragg peak irradiation .
Precise irradiation must be used for radical treat-
ments of hormone-secreting and non-secreting
adenomas with curative intent and for the irradi-
ation of unresected parts of the tumor (after non-
radical surgery) .
If contraindications to surgery exist, partial
irradiation of large adenomas might be recom-
mended to minimize the mass syndrome (pallia-
tive radiation therapy) . There are no age-related
or somatic contraindications to stereotactic pro-
ton therapy of pituitary adenomas [24] .
The total number of observations amounts to
approx . 300 in St . Petersburg and 650 in Moscow.
Stereotactic through-and-through radiosurgery is
used in Gatchina, while both through-and-through
and Bragg peak irradiations are used in Moscow.
The largest group - more than 500 patients -
were diagnosed with Cushing disease. These pa-
tients were generally treated with 70-100 Gy in a
single fraction .
More than 90 % of the patients examined had
complete clinical and biochemical remission with
lasted for many years of follow-up . No hormonal
replacement therapy was necessary and no
radiation-induced tumors were observed [25] .
Today, proton pituitary irradiation complements
the complex treatment of Cushing disease includ-
ing medicinal and hormonal treatment and, if
necessary, one-sided adrenalectomy.
The second largest group (a total of about 320
in both centers) were patients with acromegaly.
For targets less than 15 mm in diameter a similar
through-and-through technique was used as in the
case of the pituitary adenomas . Patients with
adenomas larger than 15 mm were treated with
the Braggpeak technique. The maximum dose of
50-120 Gy was delivered in 1-3 fractions within
1-2 weeks.
Clinical and metabolic improvements were
observed for 50 % of the patients within the first
year and for 80 % after 3-5 years with normaliza-
tion of the serum growth hormone level. The
results depended, e.g ., on tumor size, the pres-
ence of suprasellar or parasellar tumor spread,
and the invasion of the dura mater.
Nelson's syndrome, prolactinomas, thyreotro-
pinomas, non-functioning adenomas did not dif-
fer significantly from the well-known radiation
experience of proton therapy of pituitary ade-
nomas (cf . as well Chapter 16) . Transient com-
plications (extraocular palsies) were exceptional.
When local failure was indicated by a definite
increase of the tumor volume in CT or MRI
scans, the irradiation was repeated and in some
cases transnasal surgery was performed [21,26] .
The improved anatomic resolution which is now
possible with CT and MRI scanning provides bet-
ter localization of pituitary adenomas and a more
accurate assessment of extrasellar tumor exten-
sions. This should result in an improved local con-
trol rate and less treatment failures due to unsa-
tisfactory treatment planning .
More than 50 patients with diabetic prolifera-
tive retinopathy and progressive endocrine oph-
thalmopathy treated with through-and-through
technique (100-120 Gy) in St . Petersburg and
Moscow showed stabilization and regression of
their retinopathy and visual acuity was preserved
or improved. Patients with progressive ophthal-
mopathy responded less favorably [26] .
Functional Brain Disorders
Stereotactic proton radiosurgery of functional
disorders of the brain is not extensively
developed in Russia . The number of patients in
these categories is very limited (5 patients with
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epilepsy in St . Petersburg and 1 patient with epi-
lepsy and 2 observations of trigeminal "ganglio-
tomy" in Moscow) . The proton therapy experi-
ence in this field has not yielded clear answers as
to the value of the technique . However, it can be
assumed that modern methods of diagnostics and
localization of epileptic foci and small functional
structures will provide a possibility for more pre-
cise stereotactic proton radiosurgery [26] .
Oncoophthalmological Program
The program started in 1977 after a series of pre-
clinical studies with animals. Narrow proton
beams from the ITEP synchrotron were used for
precision radiation therapy of malignant eye
tumors . This clinical program is headed by the
Moscow Helmholtz Institute of Eye Diseases .
More than 570 patients were administered to
Bragg peak proton therapy during 17 years. Eye
tumor patient follow-up varied from 1 to 12 years.
Melanoma or cancer of the eye lid and con-
junctivae (T3NOMo-T3_,N1Mo) with the extension
to the upper or lower vaults located on the edge
of the cornea, the epicanthus and lacrimal carun-
culae. The tumors' diameter and height were
18-20 and 6-8 mm, respectively. Large-fraction
irradiation consisted of 3-5 fractions per week,
15-20 Gy per fraction up to a total dose of 60-100
Gy.
Local control, i.e ., complete or partial resorp-
tion and stabilization, was 97 % for eye lid cancer
and 98% for conjunctival cancer. The eye was
preserved in 95 % of the patients . Exenteration
had to be performed in 2.3 % of the patients who
showed no treatment effect . Proton therapy was
therefore an alternative tool for exenteration
operation of the orbit and enucleation of such
tumors [27] .
Intraocular melanoma (T2-3NoMo) of the ciliary
body andchoroid (more than 100 patients) is rou-
tinely treated as a one-field irradiation . 15 Gy are
administrated per fraction, 4-5 fractions are given
during a 2-week period (total dose : 60-80 Gy) .
Local control was recorded for 78 % of the
cases during a 7-year period (22.4% complete,
55 .6% partial resorption and stabilization) . In
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22 % of the observations - corresponding to
tumors of more than 15 mm in diameter - no
response was recorded and enucleation had to be
performed. Visual functions were preserved in
50% of the patients with the preserved eye. Some
patients had postirradiational glaucoma . Mortal-
ity following distant metastases amounted to
approx . 10 % . Proton therapy of such tumors is
clearly seen as a meaningful alternative to enu-
cleation of the diseased eye [28] .
Fifty percent local control was achieved in
patients treated for secondary malignant orbital
tumors after enucleation following melanoma of
the choroid after 5-7 years. The patients were
irradiated in a sitting upright position using one
portal and Bragg preak irradiation mode. The
procedure consisted of 4-5 fractions given within
8-10 days . The tumor (maximum diameter 12-30
mm) was included in the 80 % isodose. The total
tumor doses amounted to 80-100 Gy. This
method was developed as an alternative to the
crippling interference-subperiosteal exenteration
of the orbit [29] .
Conclusion
Both, organizational and technical conditions of
the clinical work at the Russian proton facilities
have not been optimal for the treatment of pa-
tients . First, the present proton therapy facilities
are away (5-150 km) from the specialized clinical
centers which host the patients during pre- and
post-irradiation periods. The non-medical accel-
erators have had peculiar time schedules and
unstable running conditions which often inter-
fered with traditional fractionation schemes and
finally, the fixed horizontal beam lines greatly
reduced the number of accessible portals . A num-
ber of other technical problems have also limited
the types of clinical indications for proton therapy.
At the ITEP the technical circumstances are
slightly more suitable for clinical practice . As a
result 75% of all Russian patients have been
irradiated here and ITEP has turned out to be the
only center in Russia to run all four clinical pro-
grams .
Technical, economical and organizational
solutions to overcome the difficulties characteris-
tic for the first stage of proton therapy have been
found. Particularly designed medical accelerators
with rotational gantries and techniques for 3D-
conformal therapy provide an optimistic outlook
on proton therapy. The technical capabilities of
proton therapy do not differ from those of mod-
ern electron accelerators . However, all the
advantages of proton beam irradiation prevail
[30, 31] .
The practical basis of a new phase of proton
therapy in Russia will be the construction of a
special proton therapy facility at the Moscow
Cancer Research Center, designed at ITEP.
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Treatment of Eye Tumors
P CHAUVEL
Biomedical Cyclotron and Radiotherapy Department, Centre Antoine-Lacassagne, Nice, France
Introduction
Aclose collaboration between the Massachusetts
Eye and Ear Infirmary, the Massachusetts Gen-
eral Hospital Department of Radiation Medicine
and the Harvard Cyclotron Laboratory gave rise
to the treatment of eye tumors (mainly uveal
melanoma) using a proton beam in July 1974 in
Boston (Massachusetts). In 1978 the Lawrence
Berkeley Laboratory (Berkeley, California)
started treatments using helium ions the charac-
teristics of which are close to those of protons. In
1984, Continental Europe joined this effort with
the opening of the OPTIS facility at the Paul
Scherrer Institut (formerly SIN) in Villigen, Swit-
zerland . Since then, a constant increase in the
number of facilities treating eyes has been noted:
Clatterbridge (United Kingdom) and Uppsala
(Sweden) in 1989, Loma Linda (California, USA)
in 1990, Nice and Orsay (France) in 1991. Up to
now the total number of patients treated in these
institutions is around 5500 .
Uveal Melanoma
Epidemiology and Natural History
Uveal melanomas are infrequent tumors usually
occuring in the second part of life (mean age in
our series of 450 treated patients : 56 years)
mainly in whites . In 1947, incidence in the USA
was reported to be 5.2 per million and year [1] .
For the period 1942-53, Jensen reported an inci-
dence in Denmark of about 7.5 per million and
year [2] . A study by Wilkes et al. [3] found a sig-
nificant difference for the incidence in people
under the age of 50 (3/1M/year) and over 50 (21/
1M/year) . Uveal melanomas are much less fre-
quent than choroidal nevi reported to range from
1 to 2% in various clinical studies to 6.5 % in eyes
studied post-mortem [4, 5] .
Diagnosis and Staging
The diagnosis of uveal melanoma is generally per-
formed by specially trained ophthalmologists
working in ocular units. The diagnosis is essen-
tially based on non-invasive modalities, because
these intraocular tumors are not readily acces-
sible to biopsy. Clinical examination, including
indirect ophthalmoscopy is associated to slit-lamp
biomicroscopy, fundus photos, fluorescein angi-
ography, ultrasonography (A and B scans), to
assess the nature of the tumor. CT scan and mag-
netic resonance imaging are often performed not
only to help the diagnosis but to have a better
representation of the tumor shape, size and rela-
tionship to adjacent structures .
Physical examination, liver function tests and/
or liver ultrasonography or CT scan are also per-
formed before the treatment, to evaluate the
metastatic situation. These examinations allow
diagnosis and staging. In theTNM classification,
the stage is mainly based on tumor dimensions as
listed in Table 1. Nodal and metastatic extensions
are quoted as present or not.
Cytological data obtained from fine needle
aspiration refine the prognosis : spindle cell mela-
nomas are less aggressive (mortality within 5
Table 1. Tumor classification on the basis of the tumor
dimensions
Diameter r [mm]
	
Thickness d [nun]
TI a 57 <_2
TI b 7<r<_10 2<d<_3
T2 10<r<_15 3<d<5
T3 > 15 >5
T4 extrascleral extension
years 15%) than epithelioid tumors (mortality
within 5years 40 to 60 %) and mixedtumors have
an intermediate degree of malignancy. The site of
the tumor may also affect the prognosis: ciliary
body tumors are generally larger, more likely to
metastasize and to yield complications [6].
Therapeutic Approaches Other Than Ion
Beam Therapy
During the last 20 years the treatment possibil-
ities have changed alot. Proton therapy, new iso-
topes available for brachytherapy and elaborate
local excision procedures have come up during
this time . Due to the rapid advancement of these
techniques, their relative place in the whole
spectrum of treatment modalities is more and
more difficult to assess .
The treatment policy of uveal melanoma
remains rather controversial, depending on the
characteristics of the tumor, the accessibility of
the different techniques and on the specialist to
whom the patient is referred . This seems to be
mainly due to the fact that the long term survival
results are only partly influenced by a successful
local treatment and that there is no . clearcut
definition when to use which procedure. This
means that, for instance, the chances of local con-
trol of a retro-equatorial uveal melanoma 5 mm
thick and 10 mm in diameter, will be the same
using local resection, brachytherapy or proton
therapy. But these chances are certainly different
if one of the techiques is performed by a not suf-
ficiently trained team . In that case, the best
choice of treatment is the best expert!
Surgery
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For a long period surgery was the only treatment
for uveal melanomas, and it meant almost exclu-
sively enucleation and exenteration . Progress in
knowledge, instrumentation and new techniques
have improved the situation. Whereas early stage
melanocytic tumors, presumably malignant and
apparently dormant seem to justify a simple peri-
odic observation, all other tumors have to be
treated as early as possible in order to decrease
the metastatic rate, and their stage determines
the respective procedure.
Photocoagulation
Xenon or argon lasers [7-9] may be used for the
treatment of small flat tumors (excluding the cili-
ary body) if they are at least 2 mm away from the
optic disc or the fovea. 65 % complete regression
and acceptable visual outcome were reported for
these kinds of tumors [10] . But photocoagulation
should be mainly considered as salvage treatment
for limited, flat, marginal relapses occurring after
either brachytherapy or proton therapy. The risk
of metastasis is comparable to that after enuclea-
tion [9] .
Local Resection
Since 1972, surgical procedures have been
developed for some limited tumors which allow
to resect the malignancy while sparing the vision
[11-13] . The techniques vary from full thickness
eye wall resection to more conservative proce-
dures [14] sparing retina and external sclera . It is
difficult to give formal results for these proce-
dures, as the patient numbers are still small and
the follow-up periods short. Nevertheless, the
majority of the patients seem to retain a dimin-
ished but useful vision without major complica-
tions and the local control seems to be as good as
for proton therapy. The classical indications for
local resection are small anterior tumors, but
some ophthalmologists have started to perform
larger tumor resections, as well.
Enucleation
For along time, enucleation wasthe only possible
treatment of uveal melanoma . The survival rate
was 40% over the untreated patient series [15],
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justifying the mutilation . But the place of enu-
cleation remains controversial [16-18], not the
least due to the work of Zimmerman and associ-
ates [19-22] . They showed a peak mortality of 8
2 years after enucleation as compared to a death
rate of 1% per year in non-enucleated patients .
This increase was attributed to metastases, and it
was thought that the surgical procedure could
play a role in cell spreading . Therefore, no-touch
techniques were described [23-25] and are widely
used nowadays in order to prevent this possibility.
Despite these careful procedures metastasic death
occurs in 30 to 45 % of the patients and it is pre-
sently impossible to know if surgery gives more
metastasis than conservative treatments . Some
randomized clinical trials are in progress and will
perhaps clear up the problem. Combined with
prothesis, enucleation is cosmetically acceptable
for the treatment of large tumors .
Exenteration
This substantial procedure remains the only possi-
ble approach in case of large extraocular exten-
sions invading the orbital content and/or eyelids
[26] as primary or salvage treatment.
Brachytherapy
In 1929, Moore [27] treated the first patient
(a monophthalm) by implantation of radon seeds
into the sclera in front of the tumor. This treat-
ment led to tumor regression . In 1932, Stallard
used the same isotope in a wax shell. Sixteen
years later, he began to use cobalt plaques
sutured to the sclera next to the tumor [28-30].
From a series of 100 patients 69 were successfully
treated, and 16 were enucleated . Lommatzsch
[31] developed a new plaque using 106-ruthenium
(106Ru/106Rh), a ß-emitter which reduced the
dose to non-target tissues. The survival rate of
patients with tumors distant from disc and/or
macula (> 1 to 2 diameters), less than 5 mm thick
and 15 mm wide was comparable to that of an
enucleation series . 18% of the eyes were enucle-
ated following brachytherapy (70% spindle cell
tumors) . 26% of the patients retained a vision of
>5/10. These results [32] were considered encour-
aging and the plaque technique grew up. Packer
[33] introduced 125-iodine-impregnated gold scle-
ral plaques which were initially described by R.
Sealy [34] . They have become the standard for
the Collaborative Ocular Melanoma Study
(COMS) in the United States [35] . Their choice is
based on sound scientific principles : 125-I can to-
tally be shielded, minimizing the radiation hazard
to the clinical personnel; it allows a marked
reduction of the radiation dose laterally and pos-
terior to the plaque, and it has demonstrated its
effectiveness to promote tumor shrinkage .
It was hoped that 125-I-plaques would lower
the incidence of radiation retinopathy and optic
neuropathy observed with other radiation
sources . However, it turned out that the long-
term evaluation was not so favorable . A progres-
sive increase in complications was observed for
good short-term results with a fast tumor shrink-
age [36] . In a series of 64 patients with a mean
follow-up of 65 months, 95 % had a tumor <_ 8
mm. The local recurrence rate was 12.5 % (8/64) ;
17% of the patients died of metastasis, neovascu-
lar glaucoma developed in 11 %, radiation retino-
pathy in 23 % and cataract in 45 %. 17 % of the
patients required enucleation for either tumor
growth or neovascular glaucoma . Some recur-
rences might be explained by technical inadequa-
cies, including insufficient plaque size, as initially,
the plaques were only 1 mm larger than the tumor
base diameter.
Considering that the tumors treated by brachy-
therapy are generally smaller than those referred
to charged particles, the complication rates are
significant and certainly not superior to those of
protons .
Ion Beam Therapy
General Considerations
The incentive to use ions in radiotherapy is to
treat the tumor volume with a homogeneous dose
distribution while decreasing the dose delivered
to healthy surrounding tissues. The particular
depth dose curve of protons and heavier ions
gives two important advantages : a low entrance
dose and a sharp distal fall-off at the end of the
particles' range. In addition to these characteris-
tics, the possibility to spread the Bragg peak very
homogeneously to yield a flat depth dose distri-
bution all along the tumorthickness is a very use-
ful feature. The length of this plateau can be
adapted to the length of the target volume, from
the whole path to a small portion (Fig . 1) .
The treatment of eye tumors has been among
the first applications of ion beams. The small vol-
ume of this sense organ and the close vicinity
between tumor and critical structures such as
optical disc and nerve, macula, and lens have
been a challenge for the potential advantages of
this technique.
Fiducial Placement
Uveal melanomas are usually invisible and always
radiotransparent . Therefore, markers have to be
inserted into the eye to permit tumor measure-
ment and irradiation modelling . After opening
the conjunctiva under general anaesthesia, the
ophthalmologist looks for an extrascleral exten-
sion and then, after locating the tumor base by
Depth (mm)
Fig . 1 . Adaptation of the proton beam for eye treatment, Depth-dose curves for pro-
tons in eye tissue A-Bragg peak for 65MeV protons . B-Spread-out Bragg peak
adapted to the characteristics of the tumor to be treated ; range reduced to 24 .1 mm
(calculated on distal 90%), modulation from 11 .5 to 24 .1 mm . Entrance dose com-
pared to plateau dose is 37 % less giving a protection for healthy tissues ahead of the
tumor . C-Conformation of the beam : 2 dimensions are defined by the collimator (X,
Y), 3rd dimension is given by the modulating propeller (Z) which superimposes Bragg
peaks at different energies
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transillumination, sutures four to five 2.5 mm
diameter tantalum rings (clips) around the tumor
periphery. The set-up of the clips may be verified
by indirect ophthalmoscopic examination, using
an indentator to push the clips which become vis-
ible as protrusion under the retina .
Once the clips are sutured, the distances
between the clips and the tumor base and the
clips and the limbus can be measured . These mea-
surements will be compared to those calculated
by the treatment planning system . The clips are
the only evidence of the tumor in the eye . A clear
drawing of tumor and clip position is made and if
possible the clip position is marked on a fundus
photo . After the surgical procedure an ultrasound
measurement of the distances between clips and
optic disc is recommended, if the tumor is close to
the posterior pole or reaches it .
Treatment Simulation
The treatment of eye tumors with proton beams
requires a very accurate determination of the
tumor volume, shape, site, relationship to critical
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structures and a reliable reconstruction of all
these elements for treatment planning and dosi-
metry.
Special treatment chairs permit accurate
repositioning of the order of 0.1 mm in x, y, z di-
rections, chair rotation and head tilting . Fixation
of the patient is ensured by a bite block and a
facial thermoplastic mask mounted on the same
support and attached to the treatment chair. A
counterweight pushes the head from behind into
the mask for immobilization . The chair is
mounted in front of the "optical bench" (Fig . 2)
which is an assembly of the elements necessary to
adjust the proton beam to the need of the patient
and to monitor the dose delivered to the tumor.
The size of the chair is adjustable to any adult size .
After centering the eye on the beam axis
represented by the crosshairs of the X-ray tubes
and laser alignment systems, couples of orthogo-
nal X-ray films are taken from different lines of
sight. The direction whichpermits the best possi-
ble positioning of tumor and critical structures
relative to the beam and minimizes the dose to
healthy tissues is then selected as treatment posi-
tion .
The clip positions for each visual angle are
entered in the treatment planning program . The
macular position is a reference position to which
other positions are compared . For patients with
poor vision it might be necessary to use the con-
tralateral eye for fixation . In this case, the diode
position is adjusted by adding the interpupillary
distance to the diode position on a paper with
polar coordinates. But this might only give an
vacuum pipe
estimate, as the vision is not always parallel under
close sight conditions .
During simulation as well as during treatment,
a TV camera views the eye with high magnifica-
tion . In order to recognize possible movements
during eye fixation, the contour of the limbus is
drawn directly on the screen of the treatment
room monitor and transmitted to the control desk
monitor.
After this first simulation a phase of treatment
planning including eye modelling, tumor recon-
struction, choice of treatment position, calcula-
tion of dose distribution and treatment parame-
ters follows.
A document issued from the computer show-
ing the clip position towards the crosshairs and
the collimator is compared to the X-ray films
obtained after repositioning the patient, in order
to verify that the treatment position and twist
angle (rotation of the eye around its axis) have
not changed or have accurately been planned.
This step is very crucial because it modifies the
tumor position in the collimator and could cause
an underdosage of part of the volume, if not per-
formed properly. Once a good position and twist
are obtained, position and thickness of the eye-
lid(s) in the beam are checked . This is another
important step which affects the range calcula-
tion .
To avoid problems when performing the final
simulation, the concept of "second simulation"
was introduced at the Centre Antoine Lacas-
sagne. This simulation is performed with a shad-
ow paper collimator allowing to use one or two
Fig . 2 . Schematic drawing of
the optical bench in Nice .
XRa
Wbe
blepharostats to tract the lid(s) out or the beam or
to treat intentionally through the lid taking into
account its thickness . This way, the risk to build a
wrong brass collimator, modulator or range shif-
ter is minimized .
A final simulation is performed with the col-
limator mounted (Fig . 3) . If a wedge is used in
addition, its position in the collimator and beam
is checked by taping a thin tungsten wire to the
ridge and taking a low voltage X-ray film of the
assembly.
Treatment Planning
The treatment planning systems used by the vari-
ous teams involved in ophthalmic applications of
proton beams are derived from a program
developed by Goitein et al . [37, 38] . This program
yields the following information :
- 3D-representation of normal structures,
- 3D-reconstruction of the tumor,
- 3D-representation of these structures in a
beam's eye-view,
- visualization from arbitrary angles,
- contouring of target volume and aperture of
the beam in this view,
- 3D-calculation of dose distribution,
- calculation of dose-volume histograms,
- calculation of range and modulation,
Fig . 3 . Schematic representa-
tion of the eye treatment tech-
nique
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- files for numerically controlled milling ma-
chines to produce beam shaping elements (col-
limator, modulating wheel, range shifter) .
The eye is pictured as a line-drawn 3D-model
according to individual measurements of the axial
length, thickness of sclera and lens, diameter of
the limbus and distance of the cornea from the
posterior lens . These measurements are made by
sonography.
Thetumorviewed from the beam ("beam's eye
view") is contoured and a safety margin defines
the apertures of the collimator. The depth of pen-
etration of the beam, the width of the spread-out
Bragg peak are also specified . These parameters
can be adjusted in order to optimize the dose dis-
tribution which may be represented in any plane
orientation (aligned or off the beam axis) .
In order to obtain a better protection of some
critical structures, it is possible to introduce one
or more wedge filters into the beam. They modify
the depth dose distribution andmayallow to treat
a parapapillar tumor without damaging the optic
nerve . Their use has to be carefully checked,
especially when a combination of two partially
overlapping filters is anticipated, in order to
avoid possible underdosage of part of the tumor
volume .
Modelling the eye is easy, as long as the eye-
ball is regular and the measurements are correct .
If, for instance, adjustments of the axial length
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are necessary, a CT scan in macular vision posi-
tion might help to remeasure eye length, diam-
eter, sphericity etc. But correlations are compli-
cated, because the eye model does not accept
asymmetric or ovoid shapes . Some compromises
have to be made at present . But new versions of
the program offering new modelling options are
upcoming .
Dose-volume histograms (DVH) [39, 40] are
calculated for the main structures of the eye .
They contribute to a better understanding of the
dose distribution in a whole organ or parts of it .
The DVHs are the first step towards a more accu-
rate analysis of the tumor control rates and an
evaluation of the normal tissue complication
probability (NTCP) [41, 42].
Treatment
The European centers give the treatment rou-
tinely in four fractions over four days . The total
dose are 60 CGE (Cobalt Gray Equivalent =
physical dose x RBE) . This is a slight difference
from the American protocol (see Chapter 11)
which prescribes 70 CGE in five fractions. Each
fraction is applied following the same procedure
including the final simulation of the accurate
position of patient and clips relative to the beam.
During the treatment the eye remains under con-
trol of aTVsystem . If any significant movement is
observed, the treatment is interrupted, the set-up
renewed and the treatment continued. In Nice,
the average time to deliver one fraction is 20
seconds.
Results
The treatment of uveal melanoma with protons
can be considered as one of the most successful
cancer treatments [43-46] . The 5-year local con-
trol rate is impressive : 96 .3 ± 1.5 % in 1989 and
97 ± 1 % in 1992 for Boston from a series of more
than 1000 patients, 96.8% for Berkeley from a
series of 307 patients . These numbers were
recently confirmed during the PTCOG (Proton
Therapy Co-Operative Group) meeting held in
Chester in May 1994 [47] .
The probability of eye retention at 5 years was
89.1 % in Boston and 83 % in Berkeley. As main
reason for the somewhat lower values, the devel-
opment of neovascular glaucoma and rubeosis iri-
dis were indicated . Tumor regrowth was responsi-
ble for only a small number of enucleations .
The factors influencing recurrence were
described as ciliary body invasion (9/270 versus
11/788 for other tumors), large tumor dimensions
(7/710 for a tumor diameter <_ 15 mm versus 13/
343 if > 15 mm, 5/539 for a tumor height <_ 5 mm
versus 15/514 if > 5 mm) and male sex (16/525
males versus 4/532 women) .
36% deaths from metastases and a 5-year sur-
vival of only 59 % were reported for patients with
ciliary body involvements despite an actuarial
local control rate of 98 % [6]. Neovascular glau-
coma and enucleations (26%) were also more fre-
quent among patients with ciliary body tumors .
A total number of 166/1078 patients (15.4%)
died of metastatic disease in the Boston series
[48] compared to 42/261 (16 .1 %) in the Berkeley
series [46] . The 5-year probability of metastatic
growth was 23.8 % in Boston, but only 11% in
Berkeley.
The visual outcome of patients is quite difficult
to assess . It depends on previous visual status,
size and site, and distance to disc and fovea to
name only a few parameters . Of a series of 218
patients [44], 194 developed some degree of radi-
ation maculopathy. At the end of the third year
after treatment 87% presented with macular
edema, 76% with microvascular changes (mi-
croaneurysms and/or telangiectasia), 70% with
intraretinal hemorrhage, 64 % with capillary non-
perfusion . A visual acuity of at least 20/200 was
observed in 90 % of the treated eyes after 1 year
and 67 % after 3 years, respectively. From a series
of 286 patients treated in Berkeley, 49 % had a
vision <_ 20/200, the length of follow-up ranging
from 6 to 90 months [49] .
NewApproaches
Local control of uveal melanomas with protons
must be considered as excellent . But some pro-
gress could be expected for the visual outcome.
Discussions among the ophthalmologists partici-
pating in the South Europe Radiotherapy Group
(SERAG) which uses the cyclotron in Nice, initi-
ated a study to ameliorate these functional results
by modifying or adapting some technical param-
eters, even at the risk of a higher rate of marginal
relapses, knowing that this has not affected the
prognosis of metastases in the past .
Since 1992, Lucite wedge filters with reduced
distal safety margins have been used [50] to lower
the dose to critical posterior structures (Fig . 4) .
In order to avoid any mistake in eyelid thickness
evaluation, almost all patients are treated
through a bolus made from wax and/or sono-
graphic gel covered by a plastic foil which defines
a plane to measure entrance to the beam more
easily.
A number of experiments [51, 52] have also
been performed on human melanoma and other
cell lines in order to advance the understanding of
the biological depth-dose distribution of proton
beams used for eye treatments . It is suspected
that the increase of the relative biological effec-
tiveness observed at the end of the Bragg peak
and its variations along the spread-out peak may
enhance the dose delivered to critical structures
located at the end of the beam path, partly
Fig . 4 . Example of the treat-
ment planning for a posterior
pole tumor (reduced distal
margin and use of 2 wedge
filters)
Safety margin/range O.Smm, Lateral safety margin 2.Smm
45 degrees wedge filter/disc
30 degrees wedge filter/macula
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explaining the relatively poor functional results
obtained with proton beams . It is also possible
that the eye density of 1.05 g/cm3 used for the
range calculations is incorrect . It is known that
sclera, for instance, has a higher density than vit-
reum and, consequently, different densities
should be considered for the different tissues
crossed by the particles .
Several studies on these subjects are now in
progress trying to give protons the best chance to
compete with other techniques and to achieve
both local control and sparing of vision .
Tentative Indications for Ion Beam Therapy
Considering the different techniques used in
uveal melanoma treatment, it seems that the best
indications for proton therapy are the following :
- posterior pole tumors close to the disc and/or
macula regardless of size (as long as their vol-
ume is < 40 % of the eye volume),
- large tumors which are not suited for plaques
independent of location in the eye,
- extrascleral extensions with a very poor general
prognosis.
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Treatment of Other Ocular Lesions
Conjunctival Melanoma
Conjunctival melanoma mainly benefits from
surgery and low energy X-ray therapy. Multire-
lapsing tumors often lead to a salvage enucleation
of exenteration, although the eye itself is not
affected by the melanoma . Radiotherapy (includ-
ing low-energy X-rays, electrons, protons) has
been used to treat some of these melanomas but
give a more or less significant dose to the inner
eye. A modified proton treatment which allows a
homogeneous irradiation of the whole conjunc-
tiva with a total protection of the eye has been
proposed by our team [53] .
The fractionation schedules generally used
give 30 CGE in the non-invaded conjunctiva and
thereafter a boost of 15 to 30 CGEon the positive
margin or visible tumor. The most used schedule
gave 4 fractions of 7 .50 CGE/week.
The target volume to be considered is very
large. It includes bulbar and lid conjunctiva and
at least half of the total surface of the conjunc-
tiva, to avoid further relapses at the margin of the
treated volume . Thebeam has to pass through the
lid but must respect the internal structures of the
eye, in order to preserve the visual outcome. The
possible complications or sequellae are mainly
eyelid retraction due to fibrosis and/or sclerosis,
eye dryness when the upper lid is in the field and
lachrymal duct stenosis if the internal chantus is
irradiated .
The technical principles of the treatment are:
clip insertion on the eye for localization of the
target volume and repositioning purposes,
bolus set-up on the lid aiming to give a homo-
geneous flat entrance for the proton beam col-
limated to the size of the tumor,
use of a spherical compensator (1 mm steps)
milled in plexiglass in order to adapt the range
of the proton beam to the shape of the bulbus,
compensator set up on a collimator shaped to
the tumorvolume characteristics (at least half a
conjunctiva in surface) .
The first results obtained are encouraging with
a good local control in the treated area . Distant
relapses (in the non-irradiated conjunctiva) may
lead us to propose a prophylactic treatment of the
whole conjunctiva for these multirelapsing
tumors .
Vascular Malformations
Protons may also be used in the treatment of vas-
cular malformations as encountered in von
Hippel-Lindau syndrom or choroidal angiomas .
These benign lesions often affect the posterior
pole of the eye and give retinal detachment lead-
ing to blindness . They have to be treated as care-
fully as possible in order to limit the dose de-
livered to normal critical structures, knowing that
retreatment might be required . The technique
used in Nice is similar to the treatment of uveal
melanoma with clip insertion and simulations .
The aim of the treatment is to induce a fibrosis in
the malformation . Hence, it is sufficient to
include a good part of the lesion, but not neces-
sarily the whole structure. As a consequence, the
lateral and distal safety margins are reduced and
the dose delivered is either 17.70 Gray in four
fractions on four days or 42.50 Gray in 14 fractions
over 3 .5 weeks. The results obtained are satisfying
and seem to avoid adverse developments .
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By taking advantage of the excellent dose local-
ization properties of proton beams, various types
of tumors have been treated with proton therapy
and a paramount advantage has been demon-
strated in selected tumors, e .g ., uveal melanoma,
intracranial small lesions, chordoma and
chondrosarcoma of the skull base and cervical
spine, and prostate cancers [1]. Only limited
experiences, however, have been accumulated in
the treatment of deep-seated tumors . The Proton
Medical Research Center (PMRC) of the Univer-
sity of Tsukuba, has unlike other proton facilities
worldwide placed major efforts on the treatment
of thoraco-abdominal tumors [2], which are usu-
ally hard to cure with conventional photon ther-
apy. The following will give an update on the
experience with these tumors, emphasizing, in
particular, irradiation techniques, local control
and survival rates.
Treatment Conditions
and Patient Selection
For proton therapy at the PMRC, a booster syn-
chrotron of the High Energy Physics Research
Laboratory (KEK) is available which is shared
with various physics groups . Its primary energy of
500 MeVis degraded to 250 MeV (corresponding
to a range of 38 cm in water) by passing the beam
through a graphite absorber. For generating a
spread-out Bragg peak (SOBP), several types of
ridge filters are used, and the beam range is deter-
mined using a pair of wedge-shaped degraders .
The treatment facility has two separate treatment
rooms for horizontal and vertical beam lines .
Treatment planning is based on serial com-
puted tomography (CT) scans which are obtained
at the University Hospital . Precise positioning
and immobilization of the patients with thoraco-
abdominal tumors is achieved using a universal
cradle made of polyurethane material which fits
the upper half of the body. The target volume is
manually outlined on each CT slice displayed on a
computer monitor. Dose calculations are carried
out, field outlines are constructed, and a beam-
shaping compensator (bolus) is designed . The
compensating bolus which determines the distal
depth of the SOBP is fabricated by a numerical-
ly controlled milling machine using a water-
equivalent solid material . The collimator which
shapes the lateral edges of the field is made using
an array of brass.
At the PMRC a fractionation pattern of 11
fractions (Thu, Fri, Mon-Fri, Mon-Thu) per 3
weeks has been used . This unusual schedule is
determined by the operation schedule of the
accelerator. Thoraco-abdominal tumors are either
treated by proton therapy alone or in combina-
tion with photons . In photon therapy five frac-
tions are given per week using 10 MV X-rays or"'Co gamma-rays . Based on radiobiological stud-
ies with cell cultures and animals [3], an RBE
(relative biological effectiveness) value of 1.0 rel-
ative to Cobalt-60 is employed . When defining a
target volume the smallest margins possible
(mostly <5 mm) are added around the tumor.
The dose level at the target boundary is set to
90%, and the prescribed dose to 100% . Each
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treatment day the field placement is aligned
radiographically using our special positioning sys-
temwhich consists of a fluoroscopy and real-time
digital image processing unit [4].
For the treatment of lung and liver tumors
which move longitudinally with respiration, we
have developed a respiration-gated irradiation
system (ReGIS) using a strain gauge semiconduc-
tor sensor to monitor the respiration movement
of the chest or abdominal wall and to synchronize
the irradiation control system with the respiration
cycle [5]. An output timing signal is transferred
from the system to the accelerator permitting syn-
chronized irradiation . The timing signal for irradi-
ation is set during the expiratory phase for a dura-
tion of 1.5 to 2.0 seconds. This novel method (cf .
Chapter 32) allows to minimize irradiation to sur-
rounding normal tissues.
As of March 1994, a total of 272 patients with
malignant tumors had been treated with proton
beams (alone or in combination with photons)
with curative intent . This series included 128 pa-
tients with thoraco-abdominal tumors who were
followed-up until death or for at least 6 months .
The patients were selected for proton therapy,
either because they refused surgery, because of
advanced age, or because the tumors were unre-
sectable for medical or technical reasons. Patients
with distant metastases or previous external
irradiation were excluded from the study.
The treatment results were expressed in local
control whichwas defined as no evidence of local
disease progression or persistence determined by
serial clinical and radiographic observations .
Clinical staging was done according to the UICC
TNM classifications . For survival analysis, the
Kaplan-Meier method was used . Treatment com-
plications were scored from 0 (none) to 5 (fatal),
and the score 3 or higher was considered as a
major complication that should definitely be
avoided.
Results
Lung Cancer
Of 21 lung cancer patients treated with curative
intent, 4 patients had clinical stage I, 11 stage II,
and 6 patients had stage III disease. There were
18 males and 3 females. Eleven were squamous
cell carcinomas, 9were adenocarcinomas and one
was an adenoid cystic carcinoma. Eight patients
were initially treated with photons (36-45 Gy/
20-25 fx) followed by proton beams (40-50 Gy/
10-20 fx), whereas 13 patients were treated with
protons alone, applying total doses of 70-93 Gy
in 20-27 fx . Despite these high doses, radiation-
related side effects were relatively low and only
one patient developed severe symptoms of radia-
tion pneumonitis which resulted in a significant
fibrotic change which could be observed on X-ray
films. In some patients who were irradiated with
a single portal from anterior or posterior direc-
tion, a fibrotic change was clearly demonstrable
along the proton path until the end of the SOBP
The local control estimated from serial diagnostic
images was 73.9 % [15, 21] . The overall actuarial
survival rate at 3 and 5 years was 47 .6 % and
27.2 %, respectively (Fig .1). There were no signif-
icant survival differences between squamous cell
carcinoma and adenocarcinoma .
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Fig. 1. Survival curve for 21 patients with lung cancer
Mediastinal Tumor
The first patient to be treated for a locally
advanced malignant thymoma was a 66 year old
woman who had a big anterior mediastinal tumor
with multiple hilar lymph node metastases . She
was inoperable because of a long history of severe
asthma . She was treated with protons (50 Gy/16
fx/21 days) from the anterior direction . After
completion of the treatment, she developed a
moist skin reaction which eventually healed com-
pletely with conservative treatment . Four years
after irradiation, she is still without any evidence
of recurrence or side effects.
The second patient treated so far, was a 31 year
old woman who also had a big anterior mediasti-
nal tumor which extended posteriorly to form a
paravertebral mass involving the descending
aorta and pleura with pleural and pericardial
fluid. Because of the advanced disease, she was
initially irradiated with X-rays (40 Gy/22 fx) fol-
lowed by proton beam irradiation (30 Gy/12 fx).
The tumor regressed gradually and the collected
fluid disappeared. She temporarily complained of
dry cough which was consistent with a radio-
graphic finding of paramediastinal pneumonitis.
One and a half years after the treatment the patient
is doing well with no evidence of recurrence .
Esophageal Cancer
Twenty-eight patients were treated for esophageal
carcinoma. There were 3 patients with stage I, 13
patients with stage II, and 12 patients with stage
III disease. Except for one patient with adenocar-
cinoma, all patients had squamous cell carcino-
mas . Seven patients were treated with proton
beams alone with 75-87 Gy in 21-28 fractions.
The other 21 patients were first treated with X-
rays (31-50 Gy in 17-28 fractions) followed by
9-20 fractions of proton irradiation to yield total
doses of 70-87 Gy. Three to six months after pro-
ton therapy almost all patients developed radia-
tion ulcers of various severity, but except for one
they all healed with conservative treatments . The
treatment regime currently employed are 40-50
Gy of X-rays at a fraction size of 2.0 Gy followed
by 25-35 Gy at 2.5 Gy per fraction of protons up
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Fig. 2. Survival curve for 28 patients with esophageal can-
cer
to a combined dose of 75 Gy. Local control con-
firmed by repeated fiber-endoscopic examina-
tions was obtained in 82.1 % (23/28). The actuar-
ial 5-year survival was 53.7% for all patients,
100% for stage I, 49.2 % for stage II, and 46.7 %
for stage III.
Five patients were treated for gastric cancer. The
proton irradiation was only given to the primary
lesions neglecting the lymphatic areas. In 3 of the
5 patients local control was obtained . One of the
three was treated with X-rays and protons, the
other two patients were treated with protons
alone (83 Gy/30 fx and 86 Gy/28 fx, respectively).
The overall survival at 3 and 5 years was 61.0%
and 30.0%, respectively. Although most patients
developed some degree of gastric ulcers, they all
healed with conservative treatment.
72 patients with hepatocellular carcinoma (HCC)
were followed for 10 months or more after being
treated with a substantial, high dose of proton
beams alone. The diameter of the main tumor as
determined by CT scans was 3 cm in 18 patients, 3
to 5 cm in 37 patients, and 5 cm in 17 patients .

The clinical stage of the accompanying liver cir-
rhosis was assessed by Child classification accord-
ing to the hepatic function : 27 patients were Child
A (good function), 30 patients were Child B
(moderate function), and 15 patients were Child
C (poor function) . Initially, the majority of the
selected patients had poor hepatic function, but
with growing experience, patients with moderate
to good hepatic function were increasingly re-
ferred to proton therapy. 65 % of the patients had
solitary tumors (43 nodular type and 4 invasive
type). The rest developed multiple tumors which
are characteristic of HCC.
The total doses ranged from 60-88 Gy given in
16-30 fractions with 3.0-4.5 Gy per fraction . Dur-
ing the early period of the trial, more than 20
fractions were employed, which were gradually
decreased to 16 . The most recent fractionation
regimen prescribes 68 .8 Gy in 16 fractions over 4
weeks with a fraction size of 4.3 Gy.
Of 72 patients, 35 patients underwent intraar-
terial injection therapy with 5-10 ml of iodized oil
contrast medium (Lipiodol) mixed with 5-15 mg
of Mitomycin C, followed by definitive proton
therapy. The intraturnoral retention of the iodized
oil helped to localize the tumor and position the
fields . Alternatively, irridium seeds were
implanted at the edge of the tumor boundary and
visualized under fluoroscopy.
Since 1990 the respiration-gated irradiation
system (ReGIS) has been used to minimize irradi-
ation of the surrounding liver tissue . With this
technique, the high radiation dose has exellently
been restricted to the actual target volume
(Fig . 3) .
The overall 3-year survival rate was 43.0% .
For patients with Child Ait was 62 .1 %, for Child
B and C it was 38.0 % and 0%, respectively. For
65 patients with Child Aor B, and a clinical stage
comparable to operable cases, the 3-year survival
rate was 52.0 % . The majority of deaths of Child
C patients occurred as a result of hepatic failures,
whereas no patient of Child Adied of hepatic fail-
ure. In-field tumor control was obtained in
84.7 % of the cases, with higher radiation doses
yielding higher local control (Tab . 1) .
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Table 1 . Response of in-field hepatocellular carcinomas
according to radiation dose (TDF)
Summary
As described earlier, well selected tumors have a
distinct benefit from the improved dose distribu-
tion achievable with proton beams. However,
there is only limited experience with thoraco-
abdominal tumors . So far, only the PMRC has
treated these tumor sites to a larger extent by pro-
ton therapy. Based on preliminary local control
data and survival rates, it seems very likely that
primary malignancies of the esophagus, lung and
liver benefit from the improved dose distribution
of proton beams . For gastric and mediastinal
tumors, it is difficult to judge the results because
patient numbers are still too small. For 2 patients
with mediastinal tumors, however, only proton
beams delivered a high enough dose, sparing the
surrounding healthy lung tissues and spinal cord
at the same time . Hence, proton therapy could
have a distinct advantage for intramediastinal
tumors which require high doses in the immediate
vicinity of sensitive tissues .
Conventional radiotherapy of HCC has shown
only limited success. Surgical resection rate is
only in the range of 10-30% [2, 6] due to an often
accompanying liver cirrhosis and poor liver func-
tion . Furthermore, postoperative recurrence in
the residual liver occurs very frequently. Despite
such discouraging backgrounds, however, there is
evidence that hepatic resection prolongs survivals
[6], and this is the rationale for applying proton
radiotherapy. At PMRC, primary HCC has been
extensively treated with proton therapy with
some remarkable results.
Of 72 patients only 4 developed in-field tumor
regrowth, 2 of whom received a TDFvalue which
was lower than what is currently applied (160).
TDF No Control Recur-
rence
Unknown
<160 15 9 4 2
160-180 38 33 4 1
>180 19 19 0 0
Total 72 61 8 3
(100%) (84.7%) (11.1%) (4.2%)
Fig . 4. Survival curves of patients with HCC according to
Child's clinical staging
The current trial has demonstrated that proton
beams can achieve an ablative radiation dose
which warrants high control rates with acceptable
toxicities .
At PMRC an increasing number of tumor
types including thoraco-abdominal tumors are
treated. But a systematic replacement of photons
by protons may raise some problems . The clinical
benefit has to justify the increased cost and neces-
sary efforts. A new radiotherapy network is
required to coordinate the work of huge proton
facilities and, finally, the benefit of the physical
selectivity of proton beams will only be fully
exploited if the accuracy in patient positioning
and dosimetry reaches the same level as with pho-
tons . Proton accelerators should also be as simple
to use and as reliable as modern linear accelera-
tors for electrons . The recent progress in acceler-
ator technology seems to meet these require-
ments, and there is agood chance that in the near
future more difficult and highly demanding types
of cancer including thoraco-abdominal tumors
will be treated with proton beams.
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Indications for Heavy Ions - Lessons from Berkeley
Introduction
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Radiation therapy with ions was initially pro-
posed by R. Wilson in 1946 [1], and the first
charged particle treatment was carried out at the
University of California, Berkeley Radiation
Laboratory in the 1950's [2]. Beginning in 1975
ions ranging from protons through silicon became
available for clinical use at the Lawrence Berke-
ley Laboratory as part of a collaborative study
with the University of California, San Francisco
Medical Center (UCSF-LBL) . Interest in the use
of ions for the treatment of tumors arose because
of the unique physical properties of these ions
and their biological effects (Tab . 1) . Charged par-
ticles such as protons, helium, carbon and neon
have advantageous sharp lateral and distal beam
edges that are maintained throughout their depth
of penetration in tissue . Heavier particles such as
neon and silicon ions have higher linear energy
transfer (LET) than low-LET photons and are
more effective in cell killing [3] . As is described in
more detail in Chapter 3, these ions show an
increased effectiveness on slow growing tumors
since there is less repair of potentially lethal and
sublethal cellular damage and less variation in
cell killing through different phases of the mitotic
cell cycle [4-6] . These particles also have greater
ability to kill hypoxic cells [7], which was
expected to be of great clinical significance . Pre-
clinical work had shown an increased relative bio-
logical effectiveness (RBE) at depth and a low
oxygen enhancement ratio (OER) with silicon
* present address: Brooke Army Medical Center, San
Antonio, TX, USA
Table 1 . Ions of clinical interest
TheRBEvalue for protons is the one used at MGHin Bos-
ton. The values of the heavier ions are used clinically at
UCSF-LBL and represent approximate values for an 8 cm
spread-out Bragg peak and a fraction size of 2.0-3 .0 GyE.
RBE values differ for different tissues, fraction sizes and
position in the entrance region, Bragg peak or tail of the
beam
ions . However, as evaluated in the intestinal crypt
system, silicon showed very little difference in
effectiveness between the plateau, mid and distal
peak of the beam suggesting it would offer mini-
mal advantage for deep-seated tumors [3] . Argon
has an even lower OER than silicon but it also
has depth dose characteristics that are less desir-
able [4] .
Carbon ions showed a significant gain in cell
kills in the peak region of the beam compared to
the plateau, which is ideal for normal tissue toler-
ance . However, the carbon RBE for tumor
response was lower than for neon ions which also
show some normal tissue sparing with fraction-
ation [3] . The physical dose distribution for neon
ions, and the low OER in the distal peak of the
beam were factors in the selection of neon ions
for high-LET clinical trials . Helium, representing
low-LET radiation, was chosen primarily for its
Ion species Max. positive
charge
Relative
mass
RBE
Proton 1 1 1.1
Helium 2 4 1.2-1.4
Carbon 6 12 2.0-3 .0
Neon 10 20 2.5-3 .5
Silicon 14 28 3.0-4 .0
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dose distribution advantage and because it was
easier to produce in the LBL accelerator than
protons. Helium ions are uniquely suited for a
precise localization of the radiation dose with lim-
ited irradiation of adjacent critical structures such
as the brain, cranial nerves and the spinal cord .
For many tumors it has been possible to deliver
10-35% higher doses than is possible with stan-
dard radiation therapy [8] resulting in an increase
in local and regional control rates.
The use of these ions in clinical practice
required not only extensive biological studies, but
also technical developments in patient immobi-
lization, beam delivery, patient dosimetry and the
use of CT and later MRI for tumor targeting .
Development of a 3-D computerized treatment
planning system was critical to successful charged-
particle treatment planning and delivery [9-12] .
Ion beams used at LBL included helium, carbon,
neon, silicon and argon ions with energies rang-
ing from 230-670 MeV/u . However, carbon, sili-
con and argon ions were used in a limited fashion
only, as part of phase I toxicity studies. Time and
beam availability did not permit any significant
clinical testing of these beams . The majority of
the clinical studies at UCSF-LBL was accom-
plished with helium and neon ions . The choice of
beam in clinical trials depended on availability,
and whether it was desirable to exploit the high-
LETof neon ions, or the dose localization proper-
ties of helium ions .
The Clinical Procedure at Berkeley
Indications for the use of heavy ions can perhaps
best be illustrated by a brief review of LBL's clin-
ical experience . It reveals the importance of clin-
ical factors including histology, tumor site and
volume, extent of resection or whether a treat-
ment is for primary or recurrent disease. But it
also points at the questions that remain to be
answered .
After a thorough history and physical exami-
nation, treatment planning began with an individ-
ually constructed immobilization device . Gener-
ally, a thermoplastic splinting material was used .
A planning CT (and in later years, an MRI), in
the treatment position whenever possible, was
accomplished and the physician outlined the tar-
get volume on each image slice . A VAX IU780
computer was then used to produce multiplanar
Fig . 1 . An example of a biologically
corrected (GyE) neon ion 3-field plan
for treatment of carcinoma of the
pancreas . Normally isodose plans
would be prepared for several CT
slices of interest in the target volume .
Only one is shown here for brevity. A
physical isodose plan in Gy was also
prepared for each patient .
physical and biologically corrected dose distribu-
tions (Fig . 1) . Tissue compensators and beam col-
limators were designed based on CT data using
the LBL treatment planning system . In later
years, dose-volume histographic analysis of crit-
ical structures was also available to assist with
treatment planning . Digitally reconstructed
radiographs and other portal alignment aids were
also prepared from the treatment planning pro-
gram. To assist in accurate beam delivery, laser
lights, close-up TV monitoring and daily portal
films were used . The actual treatment times were
as short as possible to minimize the possibility of
patient motion during treatment . Typically, the
times ranged from 1-3 minutes, whereas prepara-
tory set-up times were in the range of 10-30 min-
utes, depending on complexity of the set-up .
Improvements in tumor targeting and treatment
planning, increased knowledge of late effects and
improved beam delivery techniques resulted in
better clinical results in the later years [8] .
The biologically corrected isodose distibution
at UCSF-LBL were defined in terms of Gray-
equivalents (GyE), with 1 GyE of charged parti-
cle irradiation being biologically equivalent to 1
Gray of low-LET megavoltage irradiation .
Selected Clinical Results
Skull Base Tumors
From 1977 through 1992, 223 patients were irradi-
ated with helium and neon ions at UCSF-LBL for
tumors either arising in or extending to the skull
base [8, 13, 14]. Histologies including primary or
recurrent squamous cell carcinoma of the naso-
pharynx or paranasal sinuses extending to the
skull base, major or minor salivary gland tumors,
chordomas, chondrosarcomas, osteo- and neuro-
fibrosarcomas and paraclival meningiomas.
One hundred twenty-six patients with tumors
arising in the skull base were irradiated with
heavy ions . One hundred nine of these patients
were treated with helium ions . Seventeen, who
received part of their therapy with neon ions, are
also included in the analysis .
The daily dose was 2.0 GyE, given in 4 frac-
tions per week to total doses of 60-80 GyE
15 Indications for Heavy Ions- Lessons from Berkeley
	
135
(mean: 68 GyE) . The RBE value used for helium
ions was 1.3 for most tissues except for CNS,
where 1.6 was used . For neon, the corresponding
values were 2 .5 and 4.5, respectively. Applying
these factors, the limiting doses to brain stem
were calculated to be 60 GyE, 55 GyE to the
optic chiasm, and 45 GyE for cervical spinal cord .
Due to limitations of beam availability, helium
ion treatments were often combined with photon
treatments for 30-70% of the total dose .
The Kaplan-Meier [15] local control rate (KM-
LCR) for the entire group of 126 patients with
primary skull base tumors was 71 % at 5 years and
51 % at 10 years. KM survival at 5 years was77 %
and 62% at 10 years . Follow-up ranged from
4-191 months with a median of 51 and a mean of
58 months (Table 2) . Clinicians will recognize
that local control and survival appeared improved
compared to historical data in all tumor histolo-
gies . Specific numerical comparison of overall
survival is problematic since patients referred to
LBL were often considered poor candidates for
conventional photons where outcome was
expected to be unsatisfactory.
In the group of 55 patients treated between
1977 and 1986, before the availability of MRI for
tumor delineation, local control was 60% . This
increased to 78 % in the 71 patients treated during
the years from 1987 through 1992 representing the
influence of improved treatment planning, immo-
bilization and treatment delivery.
The incidence of serious complications was
acceptable given the levels of dose required for
these tumors in critical locations. Just as outcome
had improved with experience, so too, complica-
tion rates decreased in later years [8]. During the
years from 1977 through 1986, when treatment
Table 2 . Results of skull base therapy with ions at Berkeley
Follow-up : 4-191 months, median 51 months
5-year
KM-LCR
5-year
KM survival
Meningioma 85 82
Chondrosarcoma 78 83
Chordoma 63 75
Other Sarcoma 58 71
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planning relied on CT and treatment techniques
were less well developed, 41% (12/29) had
RTOG/EORTC grades 3, 4 or 5 complications.
From 1987 through 1992, when MRI was used to
delineate the tumor volume and image correla-
tion techniques were developed to transfer data
between MRI and CT, the complication rate de-
clined to 20% (11/55) . This decline also reflected
better knowledge of late effects, and reduction in
the maximum total tumor dose to 72 GyE. Com-
plications observed were mainly injury to the
central nervous system including cranial nerves,
brain stem or temporal lobes . Temporal lobe inju-
ries were manifested by MRI changes (in some
cases asymptomatic), memory deficits or the
development of seizures . With recognition of
these changes, additional efforts were made to
spare as much of the temporal lobe as possible by
using multiple ports and non coplanar beams.
There were 3/85 patients with grade 5 complica-
tions, all of whom had had previous treatment.
Continued optimization of ion beam therapy for
skull base tumors should lead to serious com-
plication rates of not more than 5% in patients
that have not been previously irradiated .
Total resection remains the optimal approach
to treatment of meningioma of the skull or spine
but is often not possible when disease is located in
the orbits, near the clivus, sella or cavernous
sinus, or in the spine. Multiple reported series
have shown the benefit of postoperative treat-
ment in subtotally reflected lesions [16-20] .
Twenty-six patients with meningioma in the skull
base or spine were treated between 1981 and 1992
at Berkeley [21] . The total doses ranged from
53-80 GyE (mean 63 GyE) and were delivered
with helium . The 10-year LCR and survival rates
were 84 % and 80 %, respectively. There were 2
intercurrent deaths from other malignancies at 46
and 82 months and both of these patients had
local control of their meningioma. Four patients
with massive and/or recurrent tumors had evi-
dence of tumor progression and subsequently
died . These results are quite excellent in view of
the fact that only patients with either malignant
meningiomas or massive recurrences ultimately
failed . Based on this series of patients we believe
that at least 60 GyE are needed for control of
small to moderate meningiomas and possibly
higher doses for larger ones . The generally
accepted fractionation for photons is 50-55 Gy at
1.8-2 Gy per day [21] .
In the group of patients with tumors invading
the skull base from the nasopharynx, paranasal
sinuses or salivary glands, the general trend was
also to favorable local control and survival rates.
Feehan et al . [22] reported on 11 patients with
locally recurrent nasopharyngeal cancer showing
excellent results . All patients had previously
received full course irradiation to a median dose
of 70 .2 Gy and were treated at UCSF-LBL for
recurrence . The median ion dose was 50.3 GyE
(range 31.8-62.3 GyE) . Some patients had also
received varying regimens of chemotherapy. The
group as a whole demonstrated a KM-LCR rate
of 45 % at 2 years and a median survival of 27
months . For 12 patients treated with locally
advanced (T4) primary cancer of the nasophar-
ynx with skull base invasion, treatment to the
primary and regional nodes started with photons
to 50 Gy and was then completed with an ion
boost to a cumulative mean tumor dose of 72
GyE (range 68-80 GyE) . They had a 2-year KM-
LCR of 83 % . Follow-up ranged from 10-81
months .
In the entire group, patients with recurrent dis-
ease fared worse, having a 2-year KM-LCR of
50 % and 5-year survival of 20 % versus 80 % and
50%, respectively, for patients treated for pri-
mary tumors .
For patients with tumors either partly or com-
pletely surrounding the brain stem or spinal cord,
a specialized technique was developed at Berkeley
[14] . Dividing the target volume into 2 or more
portions and using a combination of beams
allowed a reasonably homogeneous dose distribu-
tion to encompass the target, yet also spared crit-
ical CNS structures . This technique requires care-
ful treatment planning based on metrizamide
contrast CT and/or MRI, accurate compensation
for tissue inhomogeneities and verifiable patient
immobilization to within ± 2 mm. In the initial
report of 47 patients with varying histologies
treated with this technique, local control was
62 % and complications 13 %. Radiation injury to
the spinal cord or brain stem was low occurring in
only 3 patients . Median follow-up was 20 months
(range 6-90 months).
Potentially High-LET Responsive Tumors
Beginning in 1979, a phase I-II clinical trial was
undertaken at UCSF-LBL using neon ions . Lin-
stadt et al . [23] reported on the initial 239 patients
who had received neon ions to a dose of at least
10 Gy (physical dose), or at least 40 % of their
total dose . The purpose of the initial trial was to
develop techniques for therapy planning and
delivery, evaluate the acute and late toxicity of
neon ion irradiation, and study the response of a
variety of malignancies . Generally, patients were
selected for treatment when their tumors were
not expected to respond favorably to conven-
tional irradiation . By May of 1992, a total of 299
patients had completed therapy receiving at least
10 Gy of neon ions . Compared with historical
results, the 5-year actuarial survival, disease-
specific survival (DSS) and local control rates
suggested that neon is of benefit in several tumor
types, namely advanced or recurrent macroscopic
salivary gland tumors, paranasal sinus tumors,
advanced soft tissue sarcomas, macroscopic sar-
coma of bone, locally advanced prostate carci-
noma and biliary tract carcinoma (Tab . 3) . Again
clinicians will recognize that these results are
quite excellent and merit further study. Compari-
sons with historical data are made cautiously with
all the usual caveats of the danger in doing so, not
the least of which is to ascertain that patients in
various series are indeed comparable .
Unresectable or Locally Recurrent Salivary
Gland Tumors
At UCSF-LBL 18 patients were treated with a 5-
year KM-LCR of 61 % andcorresponding DSS of
59 % [23] . Similar excellent results were reported
with neutrons from single institutions [24-26] and
in a phase III randomized RTOG/MRC trial in
1993 [27] . The significant differences between
photon and neutron results, coupled with the
neon ion results, are sufficient to establish high-
LET radiation as the treatment of choice for this
type of malignancy.
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Table 3. Treatment outcome comparing neon beam, neu-
tron, and conventional X-ray therapy for selected types of
tumors . Data from [23, 30, 32]
'humor and
endpoint studied
Paranasal Sinus Tumors
Twelve patients have been treated with neon ions
for paranasal sinus tumors, achieving an actuarial
5-year DSS and local control of 69 % . All patients
with microscopic disease remained disease-free
and 3 patients with gross disease failed 11, 37 and
76 months after treatment [23] .
Advanced Soft Tissue Sarcoma
Between 1978 and 1989, 32 patients with unfavor-
able soft tissue sarcoma underwent ion beam
irradiation with curative intent [23, 28, 29].
Twenty-two patients had tumors located in the
trunk and 10 patients had tumors in the head and
neck area . Macroscopic tumor was present in 22 .
livo patients had tumors felt to have been caused
by prior therapeutic irradiation . Follow-up times
for surviving patients ranged from 4-121 months
(median 27), and the 3-year KM-LCR was 62%
with corresponding KM survival rate of 50 %. All
patients with microscopic disease were locally
Macroscopic salivary 61 60-70 25-36
gland carcinoma
(Long-term local control)
Macroscopic paranasal
sinus carcinoma
(Long-term survival) 69 30+ 32-40
(Long-term local control) 69 50-86 N/A
Macroscopic soft
tissue sarcoma
(Long-term local control) 56 50-54 30-50
Macroscopic sarcoma of bone
(Long-term local control) 48 49-55 21-33
Locally advanced prostate 91 N/A N/A
carcinoma
Biliary tract 44 N/A 18
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controlled, whereas local control was only 48
when macroscopic disease was present. Patients
with retroperitoneal tumors fared particularly
well with 5-year KM-LCR of 64% and survival
rates of 62% . Complications were acceptable .
Overall, these results are promising and deserve
further investigation .
Bone Sarcoma
Uhl et al . [30] reported on 17 patients with unfa-
vorable bone sarcoma including osteosarcoma,
Ewings sarcoma and recurrent osteoblastoma.
Four patients had radiation induced tumors . Most
patients had tumors located near critical struc-
tures and gross disease was present in all but 2.
Six patients were treated for recurrent disease.
The 5-year KM-LCR was 48 % and survival 41 %.
The results of this preliminary work support fur-
ther investigation.
Sacral Chordoma
Schoenthaler et al . [31] reported on 14 patients
treated for sacral chordoma in whom the median
follow-up was 5 years . These patients were
treated to a mean dose of 75 GyE. Most patients
were treated after attempted resection but only a
few had gross total resection, with macroscopic
disease present in 10 . The KM survival at 5 years
was 85% and the KM-LCR 55 % . Atrend toward
increased local control was seen in patients
treated predominantly with neon (62%) versus
helium (34%), supporting the high-LET advan-
tage of the former.
Prostate Cancer
Twenty-three patients most with either poor or
moderately differentiated stage B2 (8 pts.) and C
(15 pts.) prostate tumors have been treated at
Berkeley using neon ions for the cone-down
"boost" portion of the therapy after pelvic irradi-
ation with photons .
KM-LCR in this group of patients is projected
at the 84% level at 7 .5 years post treatment . KM
survival is 85 % at 5 years post therapy and 64
at 7 .5 years . High-LET ion irradiation appears to
diminish the local failure rate in locally advanced
tumors to the level of 10-15% . However, at the
neon doses given (approx. 10 Gy), 3 of the 23
patients have had rectal injuries possibly attribut-
able to the neon ion treatment . Onepatient had a
very large tumor with the result that a larger than
usual volume of rectum was treated. Anal sphinc-
ter stricture developed leading to colostomy.
Another patient developed an anterior rectal wall
ulcer leading to a rectovesical fistula requiring a
colostomy and ileal conduit . Athird patient had a
colostomy following development of a rectal ulcer
inferior to the neon target volume . These results
indicate that caution should be used in treating
locally advanced prostate cancer with heavy ions .
After pelvic radiation therapy to 45--50 Gy, the
prostate should receive in the range of 5-7 Gy
(physical dose) or approximately 15-20 GyE of
neon ion irradiation .
Bile Duct Carcinoma
Initial phase I-II studies revealed encouraging
results in treating adenocarcinoma of the bile
ducts. Linstadt et al . [23], and Schoenthaler et al .
[32] subsequently published retrospective results
on patients who had received radiation therapy
for bile duct carcinoma at UCSF-LBL between
1977 and 1987 . Thirty received photons only to a
mean dose of 54 Gy and 18 received helium and/
or neon to a mean dose of 60 GyE. Thirty-six
patients had gross residual disease and none had
negative margins. With minimum follow-up for
survivors of 2.5 years, ion treated patients fared
better with an overall actuarial 2-year survival of
44% vs . 18% for photon treated patients
(p = 0.05) . Median actuarial survival for the pa-
tients treated with ions was 23 months versus 12
months for those treated with photons. Local
control was also improved for all heavy ion pa-
tients as manifested by a median disease-free sur-
vival of 20 months versus 4.5 months (p = 0.05) .
There was a trend to increased survival, disease-
free survival and local control in the neon-ion
treated patients . But as the numbers in the vari-
ous subgroups were small, further investigation is
needed, before final conclusions can be drawn.
OtherTumors
Improved outcome, theoretically postulated with
high-LET beams, was not realized in several
tumor groups treated at Berkeley. Though dose
localization for esophageal tumors with helium
ions was clearly shown to be superior to photons
[33], clinical results in an early trial of 32 patients
with squamous cell esophageal cancer and 18
patients with adenocarcinoma of . the stomach
were disappointing [34] . These patients received
60-70 GyE at 2.0-2.3 GyE per fraction . All pa-
tients had unresectable locally advanced disease
without evidence of distant metastasis . Median
survival for the patients with esophageal cancer
was 9 months and 7 months for the patients with
gastric cancer. Most patients developed local fail-
ure after therapy.
It should be noted that the esophageal cancer
patients were treated in the early LBL years and
did not receive systemic chemotherapy. With the
demonstrated safety of the delivery of high doses
of heavy ions a new trial of combined chemother-
apy and heavy charged-particle irradiation in eso-
phageal and gastric neoplasms should be consid-
ered .
The initial results obtained in the treatment of
pancreatic carcinoma were encouraging [35] and
based on this, a prospective randomized trial
comparing definitive helium radiation with split
course conventional photon radiation was carried
out . Patients received 60 Gy of photons or 60-70
GyE helium, both given concurrently with bolus
5-fluorouracil . There was no significant difference
in the overall survival of each treatment arm
though helium treated patients did show slightly
higher rates of local control [36] . Four of 5 helium
treated patients who survived longer than 18
months subsequently died of local failure without
distant metastasis suggesting perhaps that more
aggressive local treatment might result in
improved survival .
Asubsequent trial of neon ion irradiation com-
bined with 5-fluorouracil, adriamycin and mito-
mycin C chemotherapy did not yield superior
results, and treatment of pancreatic cancer with
heavy ions was abandoned at UCSF-LBL in the
mid 1980's . Retesting of this difficult to treat
tumor with heavy ions awaits better chemother-
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apy, both for enhanced local effect and control of
distant metastases . The use of dynamic ion beams
conformal therapy [37, 38] might help to reduce
the late gastrointestinal toxic effects .
In 1985, results of the Northern California
Oncology Group (NCOG) phase I-II trial of the
use of heavy charged particles for glioma were
reported [39] . The aim of the study was to deter-
mine local tumor response, quality and length of
survival, as well as normal brain tissue tolerance
to heavy particles. A total of 39 patients with a
variety of gliomas (33 de novo and 6 with biopsy
confirmed recurrence) were treated. Initially, a
group of 11 patients was treated with helium ions .
The next group of 12 patients received a portion
of their treatment with either carbon or neon ions
as a boost after helium or low-LET standard radi-
ation. Another group of 10 patients was treated
with neon ions alone to doses of 16-18 Gy. Over-
all, the results with glioblastoma appeared similar
to those obtained historically with standard radia-
tion, with a median survival of about 11 months .
A subsequent trial utilizing neon ions alone for
glioblastoma of the brain, randomized to doses of
20 or 25 Gy, was carried out without significantly
prolonging survival (median 13 .5 months) or local
control.
Future Directions
The use of protons and helium ions in the treat-
ment of unresectable or partially resectable neo-
plasms in critical locations such as the orbit, eye,
skull base, juxtaspinal area, retroperitoneum or
pelvis has clearly been demonstrated to be of
value. Delivering higher tumor doses while
preserving adjacent critical normal tissues has
resulted in higher rates of local control and sur-
vival compared to previous results with megavolt-
age X-ray or electron beam therapy. In the future,
these results should be compared with those of
dynamic conformal photon therapy, to determine
the best application of these modalities for vari-
ous tumor sites.
The Berkeley experience with heavy ions has
shown that there may be a role for this modality
in the treatment of slow growing malignancies
such as adenocarcinoma, or sarcoma. Unfortu-
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nately, lack of beam time at LBL limited the
amount of information that could have been
obtained regarding clinical use of these ions .
High-LET ions such as carbon, neon or silicon
ions have not had sufficient study to prove or dis-
prove their merits in clinical therapy. Neon ions,
while giving promising initial results, have had
significant late effects on normal tissues.
While much has been learned regarding the
clinical potential of particles in radiotherapy, it is
likely that a further generation of use will be
needed to fully assess their role in clinical prac-
tice . High-LET charged-particle radiotherapy
would certainly be aided by better modeling of
LET effects, but more radiobiological and dosi-
metric studies are required to achieve this goal .
Studies dealing with dose specification in particle
fields, biological models for estimating tissue-
specific RBE values andthe means to incorporate
them into treatment planning are needed . Com-
bined effects of chemotherapeutic agents and par-
ticle radiation, as suggested by Linstadt's prelimi-
nary work with neon and iododeoxyuridine,
should be pursued [40] . The late normal tissue
effects of high-LET radiations should be mini-
mized and may be obviated by selecting an ion
such as carbon and using dynamic conformal ther-
apy. Both of these should provide less damage to
normal tissues in the beam entrance region and
give a better therapeutic ratio . Coupled with pre-
dictive assays to select patients with tumors likely
to be helped by high-LET radiation, such data
would help to put ion beam therapy on a more
rational basis for the next 25 years .
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The clinical application of ion beam irradiation
has been the subject of biomedical research and
clinical development since 1946, when Wilson [1]
first proposed the therapeutic use of fast protons
based on their unique physical characteristics .
After completion of the 184-inch synchrocyclo-
tron at the University of California at Berkeley-
Lawrence Berkeley Laboratory (LBL) in 1947
[2], Tobias and Lawrence and their colleagues
[3-5] began the study of the biological effects of
fine focal beams of protons, deuterons and
helium ions, with particular emphasis on reaction
to radiation injury in the brain [6, 7] . Since 1954,
more than 6000 patients world-wide have been
treated with stereotactic charged particle radio-
surgery. The great majority of these patients have
been treated at LBL [7-10], the Harvard Cyclo-
tron Laboratory - Massachusetts General Hospi-
tal (HCL) [11, 12], the Institute of Theoretical
and Experimental Physics (ITEP) in Moscow
[13], and the Institute of Nuclear Physics (INP) in
St . Petersburg [14] . Proton radiosurgery pro-
grams have recently been initiated at Loma Linda
University Medical Center (LLUMC) and at the
University of Uppsala.
Clinical applications were constrained initially
by the limitations of neuroradiological techniques
for treatment planning, stereotactic localization
and dose distribution [6]. Early clinical trials,
therefore, were restricted to pituitary ablation
treatment, wherein small, well-defined intracra-
nial target volumes could be localized accurately
by existing neuroradiological procedures . In
1954, the first stereotactic irradiation procedures
utilizing ion beams in clinical patients were per-
formed at LBLfor pituitary hormone suppression
in the treatment of metastatic breast carcinoma
[4, 15, 16] . Shortly thereafter, charged particle
radiosurgery was applied to the pituitary ablation
treatment of patients with proliferative diabetic
retinopathy [17] and to the treatment of pituitary
adenomas [16, 18, 19] . With the development of
improved techniques of stereotaxis and cerebral
angiography, the radiosurgery approach, using
Bragg peak protons, was applied to the treatment
of arteriovenous malformations (AVMs) at HCL
by Kjellberg et al . [11] in 1965 . More recently, the
advent of high-resolution computed X-ray tomog-
raphy (CT) and magnetic resonance imaging
(MRI) has made it possible for reliable stereo-
tactic localization and irradiation techniques to
be applied to the treatment of a diverse collection
of disorders [20] . The expanded application of ion
beams in radiosurgery of intracranial lesions pro-
mises new and innovative approaches in radiation
oncology and neurosurgery.
In this chapter, the methods and clinical expe-
rience with helium ion and proton radiosurgery in
North America are reviewed . The emphasis on
helium ions reflects the authors' long-term clin-
ical experience . The Russian experience with pro-
ton radiosurgery is described in Chapter 12 of this
volume .
Methods
The methods of charged particle radiosurgery
have been progressively refined during the past
four decades to reflect concurrent theoretical and
technical advances in physics, neuroradiology and
computer science . To utilize fully the unique
physical characteristics of charged particle beams
for effective treatment, the target volume must
be defined and located precisely within a repro-
ducible three-dimensional frame of reference, the
physical properties of the materials to be tra-
versed by the beam must be determined accu-
rately, and the patient must be positioned accu-
rately with respect to the beam [6] . Treatment
planning consists of a series of stages involving
sequential stereotactic neuroradiological imaging
studies, computer-assisted correlations among the
different types of radiological imaging informa-
tion and calculations of the dose distributions .
Bragg Peak Radiosurgery
In this section, we consider Bragg-peak radio-
surgery for AVMs, a condition for which cerebral
angiography plays a major role in target defini-
tion and localization [6, S, 21]. The methods of
target delineation and treatment planning cur-
rently being used in the LLUMC-LBL-Stanford
University Medical Center (SUMC) collaborative
proton radiosurgery program are described [22] .
As of October 1994, 32 patients with AVMs had
been treated at LLUMC using these techniques .
Many aspects of the methods described in this
section, however, are also applicable to the treat-
ment of other intracranial disorders for which
angiographic data are of little consequence.
Neuroradiological Procedures
Patients are immobilized for stereotactic neuro-
imaging, treatment planning and (subsequent)
proton treatment procedures by a non-invasive
relocatable head immobilization system, consist-
ing of a vacuum-assisted dental fixation device, a
vacuum-secured stereotactic head frame and
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interchangeable CT and angiographic localization
devices. Biplanar orthogonal cerebral angiogra-
phy is performed for each arterial vessel complex
supplying the AVM. CT scanning without and
with contrast is performed in precisely matched
2-mm-increment axial slices . The CT imaging
data set is then input to the LLUMC treatment
planning system . MRI studies are performed
using standard T1 and T2 pulse sequences in
axial, coronal and sagittal planes .
Image Correlation and
Iterative Target Delineation
Initial AVM target contours are defined on
selected orthogonal angiographic films for each
arterial vessel complex studied. AVM contours,
external fiducials from the angiographic and CT
localizer boxes and implanted titanium skull
screw fiducials are digitized and their coordinates
entered into an image correlation software pro-
gram. The program then interpolates angiograph-
ically defined contours into CT space on a 2-mm
slice-by-slice basis . This procedure results in a
cramocaudal stack of quadrilaterals in non-
contrast CT space in the treatment planning sys-
tem. The corners of each quadrilateral are deter-
mined by the AVM nidus' angiographic extrema
in anteroposterior and left-right dimensions in
the corresponding axial plane. Target contours
are also defined on MRI and contrast-CT, and
then transferred to the non-contrast CT image set
in the planning system . After targeting inconsis-
tencies among the different imaging modalities
are resolved, further consideration is given to any
radiobiological or anatomical factors (e.g.,
proximity to radiosensitive structures, such as
optic chiasm or hypothalamus) that might influ-
ence the final delineation of the target volume .
The goal is to define a final set of contours for the
target volume and for adjacent sensitive normal
brain structures on each CT slice in the region of
interest .
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Treatment Planning
The general technique of treatment planning for
charged particle radiosurgery of AVMs has been
described previously [6, 8, 21, 23, 24] . By using
individually shaped collimators, tissue-equivalent
boluses and range modifying absorbers, each pro-
ton beam can be tailored to place a uniquely
shaped high-dose volume stereotactically within
the brain (Fig . 1) . Typically, a set of six separate
potential beam ports, reflecting multiple entry
angles and converging on the target volume, are
planned individually. Usually, three or four of
these beam ports are selected, with the assistance
of dose-volume histogram analysis, to comprise
the optimal composite treatment plan . Thegoal is
to match the 90 % isodose surface to the edge of
the target volume to the extent possible, while
Z
Stereotactic Coordinates
(Planes)
Fig. 1 . Schematic diagram of charged particle beam deliv-
ery system at LBL for stereotactic radiosurgery. The patient
positioning system allows translation along three orthogo-
nal axes and rotation about the y and z axes . The width of
the Bragg ionization peak is spread to the prescribed size by
interposing a modulating filter of comparable maximum
thickness (x cm) in the beam path, shown here as a variable
thickness propeller. The range in tissue of the Bragg peak
region is determined by a range modifying absorber.
minimizing the dose to sensitive adjacent brain
structures . The comparative physical advantage
of charged particles vis-ä-vis photons for shaping
the dose to conform to the target volume be-
comes progressively greater with increasing target
diameter and irregularity of the lesion [25], as is
illustrated in Figure 2.
Plateau Beam Radiosurgery
When an ion beam of sufficiently high energy,
and hence greater depth of penetration, is avail-
able, radiosurgery can be performed with the pla-
teau ionization portion of the beam. In this treat-
ment configuration, the beam passes com-
pletely through the head, depositing plateau
region radiation in the brain. The Bragg peak
Bragg Peak Width
Modulator (Propeller) Ion Chamber
An individually designed aperture, specifically tailored to the
size and configuration of the lesion, shapes the beam in
cross-section . Tissue-equivalent compensators adjust for
irregular target contours, skull curvature and tissue inhomo-
geneities, Multiple entry angles and beam ports are chosen
so that the high-dose regions of the individual beams inter-
sect within the defined target, with the lowest possible dose
to sensitive adjacent normal brain tissues . From R.P. Levy et
al . [24j
Target volume (cm3 )
Fig. 2 . The volume of brain tissue outside the target volume
that receives 80 % or more of the dose delivered to the tar-
get volume plotted as a function of target volume . These
data are derived from dose-volume histograms for defined
target volumes using photon irradiation ("Co gamma rays
or X-rays) and carbon ion (400 MeV/u) irradiation for stereo-
tactic radiosurgery of target volumes ranging from 0.5 to
65 cm3. For all volumes examined, focused photon irradi-
ation resulted in irradiation of 2 to 3 times more normal
brain tissue surrounding the target volume than did carbon
ion beams . From M.H . Phillips et. al . [25]
dose is absorbed in the wall of the treatment
room opposite the beam line . This method was
developed by Lawrence and his colleagues [4, 5,
17, 26] at LBL in 1954 for irradiation of the pitu-
itary gland with plateau beams of protons and
helium ions .
With the plateau beam (or through-and-
through) irradiation technique, consideration of
the tissue inhomogeneity normally encountered
in the head is not important, but accurate stereo-
tactic localization of the intracranial target vol-
ume and precise isocentric technique are essen-
tial . The plateau beam radiosurgical system
developed at LBL used a stereotactic positioning
table and head holder in combination with indi-
vidually fabricated plastic head masks. for immo-
bilization . Following delineation of the target vol-
ume, the ion beam was centered on the sella tur-
cica by means of orthogonal localization radio-
graphs and port films, and the beam contour was
shaped by a brass aperture . During irradiation,
the head was turned in pendulum motion around
a horizontal axis while the patient was positioned
sequentially at 12 discrete angles around a ver-
tical axis . The irradiation arcs were directed such
that the dose fall-off was very rapid in the antero-
posterior direction and toward the optic chiasm ;
the dose fall-off decreased more slowly laterally
toward the temporal lobes (Fig . 3) . With this
method, the optic chiasm, hypothalamus and
outer portions of the sphenoid sinus received less
than 10 % of the central axis pituitary dose [26] .
For small lesions, the dose distributions from pla-
teau beam irradiation are comparable to those
produced with stereotactic radiosurgical systems
using X-rays or gamma rays .
Clinical Applications
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Extensive clinical experience has been obtained
with pituitary hormone suppression, pituitary
adenomas andAVMs over the four decades since
the first patient was treated with charged particle
radiosurgery [6, 8, 20] . The emphasis here on
helium ion irradiation reflects the authors' experi-
ence at LBL and SUMC.
Pituitary Hormone Suppression
Charged particle radiosurgery of the pituitary
gland has been shown to be very effective for
inducing suppression of normal pituitary function
with minimal associated risk of injury in adjacent
neural structures [6, 7] . The primary goals of
hypophysectomy with ion beams have been con-
trol of the metastatic spread of selected hormone-
responsive carcinomas (e.g ., breast and prostate
cancer) [4, 15, 1] and regression of proliferative
diabetic retinopathy [17, 27]. In North America,
pituitary ablation treatment is no longer in com-
mon use. In the case of metastatic breast carci-
noma, for example, modern anti-estrogenic drugs
are now available for selective use guided, in
part, by reliable estrogen-receptor classification
of tumors . In the case of diabetic retinopathy,
pituitary ablation treatment has also fallen out of
favor. Nonetheless, the extensive clinical experi-
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SUPEI110R
ence accrued has served to provide considerable
information about radiation tolerance of the
pituitary gland, parasellar tissues, cranial nerves
and temporal lobes [7] .
HormoneDependent Metastatic Carcinoma
Between 1954 and 1972 at LBL, stereotactically
directed plateau beams of protons (initial 26
cases) or helium ions (157 cases) were used for
pituitary ablation treatment in 183 patients with
metastatic breast carcinoma [16] . Patients
received 180 to 220 Gy in six to eight fractions
over 2 to 3 weeks in the early years of the clinical
program and in three or four fractions over 5 days
in later years . Many patients experienced long-
term remissions . Eight cases of focal radiation
necrosis limited to the adjacent portion of the
temporal lobe occurred ; all were from an earlier
Diabetic Retinopathy
Fig. 3 . Three-dimensional iso-
dose contours for one octant of
the plateau helium ion (230 MeV/
u) radiation field used to treat
pituitary adenomas at the LBL
184-inch synchrocyclotron . From
C.A . Tobias et. al . [261
group of patients who had received higher doses
to suppress pituitary function as rapidly as possi-
ble [7] . Clinical temporal lobe injury and tran-
sient cranial nerve involvement occurred in four
patients . Comparable results have been reported
with Bragg peak proton radiosurgery in 31 pa-
tients at the Harvard cyclotron [28] .
Between 1958 and 1969 at LBL, 169 patients with
proliferative diabetic retinopathy received stereo-
tactic plateau beam helium ion pituitary irradi-
ation. The first 30 patients were treated with 160
to 320 Gy delivered in six to eight fractions over
11 days to effect total pituitary ablation ; the sub-
sequent 139 patients underwent subtotal pituitary
ablation with 80 to 150 Gy. Most patients had a 15
to 50 % decrease in insulin requirements ; this
result occurred sooner in patients receiving
higher doses, but ultimately both patient groups
had comparable insulin requirements . Moderate
to good vision was preserved in at least one eye in
59 of 114 patients at 5 years after pituitary irradi-
ation [29] . Of 169 patients treated, 69 (41%) ulti-
mately required thyroid replacement and 46
(27 %) required adrenal hormone replacement.
There were four deaths from complications of
hypopituitarism. Focal temporal lobe injury was
limited to an early group of patients that had
received at least 230 Gy to effect rapid pituitary
ablation in advanced disease. Four patients in this
high-dose group developed extraocular palsies.
Neurological injury was rare in patients receiving
doses less than 230 Gy [29] . Kjellberg et al . [27]
reported comparable results following stereo-
tactic Bragg peak proton radiosurgery in 183 pa-
tients .
Pituitary Adenomas
Since 1958, more than 2000 patients with pitu-
itary adenomas have been treated with charged
particle radiosurgery [9, 12, 18, 19, 30, 31] . This
treatment has been applied to acromegaly,
Cushing's disease, Nelson's syndrome and pro-
lactin-secreting tumors, as well as to nonfunc-
tioning and selected other adenomas . The thera-
peutic goals are control of tumor growth and hor-
monal hypersecretion, with acceptably low hor-
monal and neurological complications . These
goals have been met with remarkable success
over the past 35 years, especially considering the
limitations of the available neuroradiological
imaging methods during the early years of these
investigations . The great majority of patients
were treated before the advent of CT and MRI,
and adenoma assessment and target volume
determination, therefore, relied on relatively
crude neuroradiologic procedures such as polyto-
mography and pneumoencephalography. The
clinical and metabolic follow-up data describing
the response of pituitary adenomas to ion beam
radiosurgery have been reported extensively; the
reader is referred to references [6] and [7] for
more detailed reviews . In this section, the
emphasis is limited to selected clinical studies
and complications of treatment.
Acromegaly
At LBL, stereotactic helium ion plateau beam
radiosurgery was very effective for the treatment
of acromegaly in 318 patients [9, 30, 31] . The
maximum dose to the pituitary tumor ranged
from 30 to 50 Gy, most often delivered in four
fractions over 5 days . The choice of dose varied
according to the extent of disease and the corre-
sponding size of the target volume . Maximum
pituitary doses were selected so that the temporal
lobe cortex received no more than 15 Gy. The
mean serum growth hormone (GH) level in a
cohort of 234 of these patients decreased nearly
70% within 1 year and continued to decrease
thereafter (Fig . 4) . Normal levels were sustained
during more than 10 years of follow-up.
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Fig. 4. Median plasma human growth hormone (HGH)
levels in 234 patients with acromegaly treated with stereo-
tactic plateau beam helium ion radiosurgery. The numbers
of patients used to calculate the median plasma levels
before radiosurgery and for each time interval thereafter
are shown at the top of the graph . Fourteen patients did
not have pretreatment HGH measurements, but their HGH
levels measured 4 to 18 years after radiosurgery were com-
parable with those of the other 220 patients . The 20 pa-
tients in the series who subsequently underwent pituitary
surgery or additional pituitary irradiation were included
until the time of the second procedure . From J .H . Lawrence
et . al . [30)
148
	
R. P. Levy et al .
Comparable long-term results were observed in a
cohort of 65 patients who were irradiated with
helium ions because of residual or recurrent met-
abolic abnormalities persisting after surgical
hypophysectomy. Patients with microadenomas
(<10 mm diameter) had lower initial GH levels,
responded more rapidly to treatment, and had a
good prognosis for cure ; a lower incidence of
post-treatment hypopituitarism was also observed
in these patients . The more invasive tumors were
slower to respond, but by 4 years after irradiation
they were associated with GH levels not statisti-
cally different from levels found in patients with
microadenomas.
Treatment failures generally resulted from fail-
ure to assess accurately the degree of extrasellar
tumor extension [9, 31] . With recent advances in
MRI and CT scanning, the radiosurgical target
can now be better delineated, which in turn
should lead to improved rates of tumor cure and
control. These same imaging improvements also
make possible more reliable determination of tis-
sue inhomogeneities in the brain and adjacent tis-
sues and correspondingly more precise position-
ing of the Bragg ionization peak within the target
volume .
Kjellberg et al . [12, 18] treated about 600 pa-
tients with acromegaly using Bragg peak proton
irradiation at the Harvard cyclotron . Using a
nomogram based on lesion size and complication
rate in a large number of treated patients, maxi-
mal central doses selected were inversely related
to beam diameter ; intrasellar tumors typically
received single doses of 60 to 120 Gy. Therapy
resulted in objective clinical improvement in
about 90 % of a cohort of 145 patients 24 months
after irradiation . By this time, 60 % of the pa-
tients were in remission (GH level < 10 ng/ml) ;
after 48 months, 80 % were in remission . About
10 % of patients failed to enter remission or to
improve and required additional treatment, usu-
ally transsphenoidal hypophysectomy.
Cushing's Disease
Cushing's disease was treated in 83 patients at
LBL using stereotactic helium ion plateau beam
irradiation [9, 19, 31]. Mean basal cortisol levels
and urinary fluorogenic corticosteroids returned
to normal values within 1 year after treatment,
and these indices remained normal during more
than 10 years of follow-up . All five teenage pa-
tients were cured by doses of 60 to 120 Gy without
hypopituitarism or neurological sequelae ; how-
ever, nine of 59 older patients subsequently
underwent bilateral adrenalectomy or surgical
hypophysectomy due to relapse or failure to
respond to treatment . Of the nine treatment fail-
ures, seven occurred in the earlier group of 22
patients treated with 60 to 150 Gy in six alternate-
day fractions; when the same total doses were
given in three or four daily fractions, 40 of 42
patients were cured [9] .
Kjellberg et al . [12] treated more than 175
Cushing's disease patients with single-dose Bragg
peak proton irradiation . Doses were inversely
related to the beam diameter selected (typically,
60 to 120 Gy) . Complete remission with restora-
tion of normal clinical and laboratory findings
occurred in about 65% of patients followed up
for 24 months ; another 20% were improved to
the extent that no further treatment was consid-
ered necessary.
Complications
Variable degrees of hypopituitarism developed in
about one third of patients following stereotactic
helium ion radiosurgery, although endocrine defi-
ciencies were rapidly corrected in most cases with
appropriate hormonal replacement therapy [7, 9] .
In retrospect, larger portions of the pituitary
gland were designated for radiosurgical treatment
to assure sufficient dose to the adenoma than
would now be indicated based on current MRI
and CT techniques . Other sequelae were limited
most frequently to patients who had received
prior photon irradiation . These sequelae included
mild or transient extraocular nerve palsies, partial
visual field deficits and seizures due to focal tem-
poral lobe injury [7, 9] . After appropriate adjust-
ments of dose schedules, temporal lobe and cra-
nial nerve injury were rare sequelae, in the range
of 1% or less, and no other permanent sequelae
occurred . A very low incidence of significant
adverse sequelae has also been reported in pa-
tients treated with Bragg peak proton irradiation
by Kjellberg and his colleagues [12] .
Arteriovenous Malformations
Since 1965, more than 1500 patients have been
treated in the United States with charged particle
radiosurgery for AVMs of the brain, primarily at
LBL [8, 10, 23, 24], HCL [11, 32] and, since 1993,
LLUMC [22] . The therapeutic goals are to
achieve :
1. reduction or elimination of intracranial
hemorrhage
2. stabilization or reversal of progressive neuro-
logical dysfunction
3 . lower frequency of seizures
4. improvement in frequency and intensity of
headaches.
Between 1980 and 1992, we treated 455 pa-
tients with intracranial vascular malformations
using Bragg peak helium ion beams at the LBL
184-inch synchrocyclotron and Bevatron . In this
section, we describe the patient population, clin-
ical and neuroradiological outcome and complica-
tions in this cohort, with emphasis on patients
with angiographically demonstrable AVMs
treated through the collaborative LBL-SUMC
radiosurgery program [8, 10] .
LBL-SUMC Series
Patient Selection
Fifty-two percent of AVM patients were female
and 48 % were male . Seventeen percent were
aged 6-20, 61 % were 21-40, 18 % were 41-60,
and 4% were over 60 years . About 40% of the
patients had no interventional therapy prior to
radiosurgery, but the majority had undergone
microsurgery, embolization, or both. Twenty-five
percent of AVMs measured greater than 25 cm3.
Many patients presented with more than one
symptom; 70 % had hemorrhaged, 13 % had neu-
rological deficits unassociated with hemorrhage,
41 % had seizures, and 47 % had headaches .
Seventy percent were graded clinically as excel-
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lent before radiosurgery, 28% as good, and 2
as poor. Nearly half (44%) had AVMs located in
the brain stem, corpus callosum, thalamus or
basal ganglia, and most of the remainder had
large malformations in critical areas of the cere-
brum - sensory, motor, language, or visual areas
of the cortex .
Clinical Follow-Up and Outcome
Clinical evaluation, performed 24 to 72 months
(mean, 38 months) after radiosurgery, found that
63 % of patients presenting with seizures and
68% of patients presenting with headaches had
improvement of these symptoms [10] . These
improvements appeared to result from improved
regional cerebral blood flow, stabilization of
hemodynamic imbalance and reversal of vascular
steal, associated with progressive thrombosis of
the malformation [8, 10] . Clinical outcome was
excellent in 58 % of patients, good in 36 % and
poor in 9%. Worsening clinical grade generally
resulted from intracranial hemorrhage or
treatment-associated sequelae ; a few patients
have worsened from intercurrent medical disor-
ders . Seven percent of patients died from disease
progression (including AVM hemorrhage) or
unrelated illness .
Neuroradiological Response
Cerebral angiography was performed at yearly
intervals to evaluate response . The first hemody-
namic changes observed include a decrease in
blood flow through the AVM, due to progressive
obliteration of the small shunting vessels, with a
decrease in size of the feeding arteries and drain-
ing veins. This stage is followed by a progressive
decrease in AVM volume until stabilization or
complete obliteration of the AVM occurs .
Angiographic follow-up evaluation was per-
formed in 86 consecutive patients treated from
1983 to 1986 in the LBL-SUMC series, as part of
a dose-searching protocol [10] . In retrospect,
many of these patients were treated with some-
what higher doses than would nowbe considered
optimal . Two years after radiosurgery, complete
obliteration of theAVM occurred in 70 %, partial
obliteration (10 to 99 % obliteration) in 23 %, and
no change in 7 %. By 3 years after treatment,
90 % of the patients had complete AVM oblitera-
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tion, 6% had partial obliteration, and4% had no
change . The rate and extent of obliteration
appeared to be threshold phenomena directly
related to AVM volume and radiation dose .
Smaller AVMs had significantly higher rates of
obliteration than larger ones (p < 0.005 after 1
and 2 years) . AVMs smaller than 4 cm 3 throm-
bosed more rapidly and more completely than
larger lesions (p < 0.05 for the comparison with
AVMs 4 to 25 cm 3 and p < 0 .001 for the compari-
son with those greater than 25 cm') . Intermediate-
sized AVMs were obliterated more rapidly and
more completely than large AVMs (p < 0 .05) .
Complete obliteration occurred more frequently in
malformations treated with higher doses (30 to 45
GyE in one or two fractions) (p < 0.05 after 1 and
2 years) . AVMs treated with intermediate doses (24
to 28 GyE) also responded well at 2 and 3 years.
Preliminary results with doses <_ 20 GyE, however,
indicate significantly lower response rates .
Fig . 5. Cerebral angiograms from a 23-year-old man with a
large (40 cm 3) left frontotemporal AVM . Upper, lateral and
anteroposterior views of the internal carotid artery angio-
gram demonstrate the AVM supplied by branches of the
anterior and middle cerebral artery circulations . The
Complications and Sequelae
Serious early sequelae have been negligible fol-
lowing radiosurgery [7, 8, 10, 24] . A few patients
with previous seizures had transiently increased
seizure activity, which was readily controlled by
adjustment of anticonvulsant medications . No
patients experienced nausea, vomiting or hyper-
pyrexia. No deaths occurred from the irradiation
procedure .
Late treatment-associated sequelae can be
classified as white matter changes or vasculopathy
and include vasogenic edema, occlusion of func-
tional vasculature and radiation necrosis [7, 8, 10,
24] . The manifestations and incidence of clinical
sequelae depend, in part, on the region of the
brain involved, the volume of normal brain tissue
affected, the radiation dose, the presence of prior
tissue injury and the timing and nature of thera-
peutic measures . Clinical complications following
radiosurgery were most common in patients with
vascular steal is prominent . Lower, comparable views taken
18 months after helium ion radiosurgery (dose, 28 GyE)
demonstrate complete obliteration of the AVM . Normal
cerebral blood flow has been restored, with marked reversal
of the vascular steal . From R.P Levy et . al . [61
AVMs in the brain stem, thalamus or basal gan-
glia . Hemiparesis was the most common major
complication and visual field deficit was the most
common minor complication . Adverse sequelae
were limited almost exclusively to patients who
received doses above 25 GyE and whose AVM
volumes were more than 14 cm. . Complications
have been rare (2%) in the approximately 250
patients treated with lower doses since 1986 .
Many uncertainties remain, however, regarding
optimal radiosurgical treatment parameters for
malformations of various sizes and locations in
the brain [8, 10, 24] .
MGH-HCL Series
Kjellberg and associates [11, 30] of MGH used
single-fraction Bragg peak proton therapy at
HCLto treat more than 1300 patients with vascu-
lar malformations of the brain [28] . Irradiation
generally was delivered with parallel-opposed
treatment fields . Doses (typically, 10 to 50 Gy)
were selected according to diameter of the AVM,
using a nomogram based on lesion size and com-
plication rate in a large number of treated pa-
tients [11] . Findings of follow-up evaluation in
1000 patients with AVMs, 2 to 24 years after
treatment with proton beam therapy, were
reported [30] . In 104 patients, the clinical out-
come was unrelated to either hemorrhage or ra-
diosurgery. Of the remaining 896 patients, 818
(91.3 %) were unchanged or improved; 27 (3 %)
had moderate deficits from hemorrhage or proton
beam therapy, but functioned independently at
pretreatment levels ; seven (0 .8%) had severe
deficits and were dependent to varying degrees ;
two (0 .2%) were vegetative ; 39 (4.4%) were
dead (37 from hemorrhage and two from treat-
ment complications) ; three (0.3%) were lost to
follow-up after surviving hemorrhage . Analysis
by actuarial life table methods showed 98.4 % 24-
year survival for patients with AVMs <3 cm in
diameter and 93% 24-year survival for all pa-
tients ; these data were then compared to a 24-year
survival of 77 % reported for an untreated histor-
ical control group. Of the 37 patients who died
from hemorrhage, 22 died within the first 2 years
after treatment ; 33 lethal hemorrhages occurred
in patients with AVMs >3 cm in diameter. An
additional 101 patients survived hemorrhage .
Complications of treatment occurred in 17 pa-
tients (6 months to 6.5 years after treatment), but
only seven in the last 925 patients following
downward adjustments in treatment doses. In
general, treatment doses used in this patient
series were significantly lower than those used in
the LBL-SUMC series described above.
LLUMC-SUMC Series
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The LLUMC-SUMC collaborative program
represents the most recent development in
charged particle radiosurgery for AVMs. Using
the modern methods of iterative target delinea-
tion and treatment planning described above, 28
patients with 32 discrete (non-adjacent) AVM tar-
get volumes were evaluated and treated from
December 1993 through August 1994 . Ten small
AVMs (mean, 5.2 em'; range, 0 .9 to 9.9 cm)
were treated with 24.3 ± 2.4 GyE in one or two
fractions . Twenty-two larger AVMs (mean, 40.9
cm3; range, 11.6 to 114.0 cm3) were treated with
20.9 ± 2.3 GyE in two fractions . Transient focal
seizures occurred acutely in two patients, but no
other acute or delayed sequelae have been
observed to date . Long-term clinical follow-up is
in progress .
Future Directions
Arteriovenous Malformations
An increasing number of AVM patients are now
being evaluated for multistage procedures,
including embolization and/or partial microsur-
gical resection, to reduce AVM size and blood
flow prior to charged particle radiosurgery, since
smaller and slower flow AVMs respond more rap-
idly and completely to radiosurgery and are
associated with a lower risk of radiation-related
complications [8, 10, 20]. This multimodality
approach is proving useful for treatment of
selected large and complex hemispheric AVMs,
which now comprise the majority of cases referred
for ion beam radiosurgery in North America.
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Additionally, the role of microsurgery and embo-
lization in patients who previously underwent
charged particle radiosurgery is evolving rapidly.
Thus far, in the LBL-SUMC program, these pro-
cedures have been performed in 30 patients,
whose follow-up angiograms had shown little
apparent change 2 to 3 years after helium ion
radiosurgery. In nearly all cases, the AVMs were
found at surgery to be markedly less vascular and
more easily resected than had been anticipated
had they not undergone prior radiosurgery. Simi-
larly, the obliterative response to embolization
was much greater than anticipated. Complete
obliteration of the AVM has been ultimately
achieved in a majority of these initial apparent
non-responders . Selected patients with residual
AVMs are treated with a second course of ion
beam radiosurgery. Preliminary results in this
group are encouraging. Several AVMs have
already been obliterated completely following a
second radiosurgical treatment . Long-term fol-
low-up is in progress.
The rapid development of improved anatomic
resolution with modern MRI and CT scanning
now makes it possible to localize more accurately
abnormal vascular structures and to identify sen-
sitive adjacent neural structures [22] . It appears,
in retrospect, that many of the complications of
radiosurgery seen in the past could be attributed
to suboptimal target delineation and unnecces-
sary inclusion of normal tissues in the target vol-
ume [8, 21, 25]. As three-dimensional target
delineation improves, it is anticipated that higher
doses to the target volume, associated with higher
cure rates, can be given without significantly
increasing the risk of sequelae . These same imag-
ing improvements also make possible more reli-
able determination of tissue inhomogeneities in
the brain and adjacent tissues and correspond-
ingly more precise positioning of the Bragg ion-
ization peak within the target volume .
Neoplastic Disorders
Historically, stereotactic irradiation regimens
have not been designed to exploit the differential
response between normal cells and tumor cells
that is the biological basis for the use of fraction-
ated external beam irradiation [20] . Recently,
however, the use of fractionated stereotactic
irradiation for the treatment of neoplastic intra-
cranial disorders has been reported [33] . With the
development of stereotactic immobilization sys-
tems capable of reliable serial repositioning, this
new approach offers the potential for improved
treatment outcome by combining the excellent
dose localization and dose distribution character-
istics of charged particle radiosurgery with the
favorable radiobiological properties of fraction-
ated irradiation [20] . This approach is currently
under investigation for the charged particle
irradiation treatment of larger or invasive benign
tumors, and for primary and secondary malignant
brain tumors. It is anticipated that the application
of more extended fractionation schedules will
result in a lower incidence of cranial nerve neuro-
pathy (for example, in acoustic neuroma treat-
ment) and parenchymal brain injury, without
compromising the treatment's effectiveness
against neoplastic cells.
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Introduction
Early and Delayed Complications
of Ion Beam Therapy
J .-L . HABRAND, P SCHLIENGER, A. MAZAL, L . SCHWARTZ, L . DESJARDINS, F d'HERMIES,
E . FRAu, and H . RANDRIANARIVELO
Centre de Protontherapie d'Orsay, Orsay, France
Among approximately 15 000 patients treated so
far with ion beams, the rate of reported severe
complications has been extremely low. Neverthe-
less, the balance between tumor control and mor-
bidity remains crucial and approaches to further
improve the treatment outcome will remain of
utmost importance in the development of this
radiotherapeutic technique.
This section gives a review on clinical com-
plications and sequelae published in the literature
for proton andheavy ion treatment along with the
authors' preliminary personal experience with
protons at Orsay.
Complications and Sequelae After
Ion Beam Therapy of Ocular Tumors
Early complications from suturing the tantalum
rings seem to be very limited. A few incidents of
transcient diplopia have been reported in which
Table 1. Delayed complications following proton beam and helium irradiation of uveal melanomas reported in 3 studies [1-3]
the surgeon had to disinsert the inferior oblique
for ring placement . Keratopathy in patients
receiving high doses to the cornea have been
described as early complications and also lid epi-
thelitis, epilation and epiphora (by punctum
occlusion) have been observed during the irradi-
ation and in the following weeks in patients where
a complete lid retraction during the treatment
was not possible .
Delayed complications observed after proton
or helium ion irradiation of uveal melanomas
[1-3] are summarized in Table 1.
The most serious complication is the neovascu-
lar glaucoma . It manifests as increased intraocu-
lar pressure accompanied by a neovascular prolif-
eration involving the anterior chamber angle and
compromising the drainage of the Schlemm
canal. The cause of this proliferation is still
unclear and probably not correlated with a direct
action of the ionizing radiation . It might be
induced by the production of an angiogenic factor
from hypoxic retinal tissue overlying the tumor.
When established, neovascular glaucoma is fre-
Parameter
No . of patients
Mean follow-up (months)
Particle
Saunders [1]
75
3
He
Gragoudas [2)
786
18
H
Desjardins [31
146
12
H
No. (%) of patients with
Maculopathy 11 (15) 159(20) 51(35)
Optic neuropathy - 74(9) 7(5)
Neovascular glaucoma 10(13) 73(9) 10(7)
Cataract 6(8) 191(24) 33(23)
Vitreous hemorrhage 2(3) 53(7) 3(2)
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quently refractory to medical measures and re-
quires enucleation of the affected eye. Fortu-
nately, this complication is described in less than
15 % of patients treated with helium and less than
10 % after proton treatment .
Radiation retinopathy is a delayed vaso-
occlusive microangiopathy that can take various
pathological and clinical manifestations [4] . Many
findings are similar to those observed in diabetes
mellitus associated retinopathy although papillo-
pathy is more common after irradiation .
Radiation maculopathy is a major concern in
posterior tumors as was assessed by the group of
the Massachusetts General Hospital in Boston
[5] . They evaluated the risk in 218 eyes treated at
the Harvard Cyclotron Laboratory (HCL) before
January 1988 with the following result : 89 % of
the patients developed a wide variety of fundo-
scopic changes affecting the macula . Early modi-
fications (i .e ., within 1 year) were macula edemas
which affected 9 out of 10 patients at 3 years if the
tumor was located less than 2 disc-diameters from
the macula and microvascular changes (telangiec-
tasias or microaneurysms) which occured in 3 out
of 4 patients after 3 years. Delayed manifesta-
tions included intraretinal hemorrhages (70% at
3 years), lack of capillary perfusion by fluorescein
(64 %), intraretinal lipid deposition (55 %), nerve
fiber layer infarcts (48 %) and vascular sheathing
(36%) . Two thirds of the infarcts, 40 % of the
hemorrhages, and lipid deposits but only 25 % of
the vascular sheathing, and less than 10 % of the
edema and microvascular changes regressed
spontaneously.
To overcome the enhanced complication rate
of posterior tumors, a randomized study was initi-
ated by the Boston Group in 1989 . It comprised
small melanomas located less than 6mm from the
macula and/or fovea, and compared two dose
levels (50 and 70 CGE) . The results of this study
are still pending. Recently, however, a retrospec-
tive review conducted in children has found a
very low a/(3 value for retina (< 1.7 Gy) which
would suggest a possible protective effect of
smaller dose per fractions [6] .
Cataract can develop after conventional radio-
therapy with doses as low as 5 to 10 Gy. According
to data collected by the Seattle group, a single
dose of 10 Gy represents a 50% risk to develop
cataract within 5 years ; if 10 Gy were fractionated
the risk was approx . 5%, and 20 % after 12 to 16
Gy of fractionated dose . The low incidence
reported following charged particle irradiation
was explained by the limited follow-up of patients
and by the fact that in most patients only part of
the lens was irradiated . A recent evaluation by
Meecham estimated the risk for cataract at
7 years follow-up to exceed 90 % when more than
half of the lens was in the beam [7].
From two large series, the risk of enucleation
unrelated to tumor recurrence, was estimated to
be approx . 10 % after helium [8], and 6% [6]
after proton therapy. According to Munzenrider
et al . [10], this compares favorably with other
conservative radiotherapeutical approaches
including radioactive plaques.
Table 2 lists anumber of prognostic factors for
visual loss as evidenced by multivariate analysis
in 2 studies [11, 12] . In both studies, tumor height
played a significant role for the visual outcome.
This is very likely due to the fact that thick tumors
usually occupy a large part of the eye and induce
necrosis, inflammation and exudation. Distance
to the posterior structures also appeared of
importance . It reflects the deleterious influence
of radiation maculopathy and optic neuropathy
on vision .
Following ion beam radiotherapy, vision can
be theoretically affected by 4 major mecha-
nisms [13] :
Table 2 . Prognostic factors for visual loss after treatment of
uveal melanoma with protons . Results from 2 series [11, 121 .
RR = relative risk, D = optic disc, DD = disc diameter, F =
fovea, CGE = Cobalt Gray-equivalent
f Parameter Egger [11] Seddon [12]
No . of patients 466 440
Follow-up (months) >3 mean 19
Fractionation (CGE) 4x 15 5 x 14
Tumor height p>0.001 <5mm, RR 5.26
Distance to posterior p <_ 0.001 <2 DD, RR 1.86
structures (disc) (disc)
p <_ 0.005 RR 2.18 (fovea)
(fovea) RR 2.59 (D + F)
Vision before p <_ 0.01 <20/40, RR 1.73
treatment
Macular detachment - RR 1.67
1. Direct action of ionizing radiation on the reti-
nal cells (photo receptors, pigment epithelium,
and neurons)
2. Radiation vasculopathy that favors hypoxia
and degenerative processes of visual cells and
is also implicated in the capillary proliferation
in the anterior chamber angle
3 . Retinal detachment by subretinal fluid expan-
sion
4. Cataract
The potential role of the retinal arterial blood
supply in the development of post-radiation sco-
tomas was pointed out by Meecham et al . [13] .
They found that the deficit usually needed several
months to develop and that it extended both into
regions of the periphery and such that had
received doses of more than 50 Gy. This distribu-
tion was consistent with injuries of blood vessels
passing through the target volume .
Ion Beam-Associated Damage
to the Central Nervous System
Cranial Nerves and/or Nuclei
Irradiation of sarcoma of the base of the skull is
one of the major indications for proton andheavy
ion therapy [14, 15] . Cranial nerves and their nu-
clei in the brain stem are among the most critical
structures at risk with this type of radiation . Urie
et al . [16] conducted an analysis on 27 patients
with such tumors, treated with high doses
(67.8-74.7 CGE) of proton radiation at the HCL
between 1981 and 1984 . Only non-diabetic pa-
tients were analyzed . Follow-up ranged from 54.6
to 110 ,months . Dose-volume histograms were
constructed for individual cranial nerves and
"near maximum" doses, i.e ., the highest doses
received by at least 5% of the volume were com-
pared. The analysis showed that 17 nerves were
impaired in 5/27 (18%) patients . The minimum
dose for injury was 59.3 CGE and the average
was 74 .2 CGE. At 60 CGE the complication rate
was estimated to be as low as 1%; at 70 CGE it
was 5% . The latency period was not influenced
by the dose received . Half of the lesions mani-
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fested within the first 24 months and none after
60months . This study failed to show any differ-
ence in radiosensitivity between the various cra-
nial nerves ; nerve number VIII was affected 4
times, numberV3 times, numbers II, VI, andVII
twice, and numbers II, IV, VI, IX, XI once,
respectively; no lesions of nerves X and XI were
observed.
A previous analysis by Habrand et al . [17] on
tolerance of the optic nerve and chiasm in 20 con-
secutive patients, had shown that the risk could
be markedly enhanced by predisposing factors
such as damage to the microvasculature induced
by diabetes mellitus . Castro et al . [15] have also
published damages to the optic nerves andchiasm
following high dose helium and neon therapy for
tumors arising in the base of skull . Among 85
patients with no evidence of disease who were
followed-up for 1 to 15 years, 8/85 (9 %) patients
presented a cranial nerve injury, including 3
unilateral and 1 bilateral visual loss . One reason
for this apparently low rate might have been the
fact that "unavoidable" damages to optic nerves
or chiasms that were abutting the tumorwere not
included in this listing.
Brain and Spinal Cord
Tolerance values of brain and spinal cord as
estimated by the collaborative task force of the
NCI [18] are reported in Table 3. According to
Yoshii et al . [19] there is a correlation between the
latency period for brain injuries and the dose
administered . Injuries manifested within 10 to
20 months following a dose :t 100TDF (equiva-
lent to 60 Gy delivered in 5 daily sessions of
2Gy), and within 40 to 60 months after TDF70.
This wasbased on the observation of 19 injuries in
106 brain tumor patients treated with photons
plus or minus a proton boost. In the proton
group, brain necrosis was observed only after
much higher doses than in the photon group
(TDF 114 versus 70) .
Castro et al. [20] reported 2 cases of spinal
cord injury and one of brain stem necrosis among
47patients treated with helium ions for lesions
encircling the brain stem and/or the spinal cord .
The major cause of complications was attributed
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to an underestimate of the RBE value of He.
Increasing the RBE value of helium for CNS
from 1.3 to 1.8 resulted in no further complica-
tions.
Accuracy in treatment planning and treatment
set-up are also of paramount importance when
brain stem and spinal cord are encompassed in
the planning volume . The risk of radionecrosis
seems to be very low when a steep dose gradient
can be achieved throughout the structure (e.g .,
64 CGE to the surface of these structures and
50-53CGE to the center) . In this context, the
field abutment technique needs to be mentioned
as a possible cause for overdosing (cf . Chapter
29). In this technique, used for example, for
tumors encircling the brain stem or spinal cord
the distal range of one proton beam abuts the
lateral penumbra of an another beam. An over-
shooting of the beam past the junction conse-
quently results in a local overdosage . Moving the
Table 3 . Tolerance doses in Gy for normal tissues at risk in fraction . These constraints, used at the Centre de Protonthe-
the irradiation of intracranial malignancies . The risk corre- rapie d'Orsay, are mainly taken from [18]
sponds to 5 % complications in patients treated at 1 .8 Gy per
Organ Extent of Irradiation Type of Complication
Area
Skin 10 cm2 30 cm' 100 cm2
70 60 55 Necrosis, ulceration
50 Telangiectasias
Locus
Spinal cord Surface Center Opposite Myelitis, necrosis
<5 cm length 64 53 48
>5 cm length 60 50 45
Brain stem 64 53 48 Necrosis
Volume
1/3 2/3 3/3
Brain 60 50 45 Necrosis
Optic nerve 55 50 50 Blindness
Chiasm 55 50 50 Blindness
Lens 10 10 10 Cataract
Retina 45 45 45 Amblyopia
Middle Ear 55 55 55 Serous otitis
Parotid - 32 32 Xerostomia
Temporomandibular joint 65 60 60 Trismus
Cranial base 70 70 70 Necrosis
junction during the course of treatment could
help limit this risk .
Patients previously irradiated are another risk
goup susceptible to life-threatening necroses .
Three of five fatal complications (grade 5)
reported by Castro had been irradiated in the past
[15] .
Endocrine dysfunction following high dose
proton therapy of skull base sarcomas was one of
the most frequent complications of 14patients
treated at the HCL for a tumor of the upper cli-
vus with the hypothalamic-pituitary axis included
in the treatment fields, 4 developed hormon
abnormalities 14 to 45 months after irradiation
[21] . The 5-year projected rate of this type of
complication was 37% . The DVHs of patients
with and without complications showed no obvi-
ous difference, presumably because only simple
DVHs could be obtained due to the poor spatial
resolution of the pituitary in CT scans.
Fractionated Ion Beam Therapy
of Pelvic Malignancies
Proton boosts have been recommended in the
radiotherapeutic management of prostate carci-
noma to minimize dose to rectum and bladder.
The Boston Group postulated that a perineal pro-
ton beam used with a water-filled balloon placed
in the rectum could spare the posterior part of the
rectum . The sharp distal fall-off of the dose
beyond the prostate volume could also save the
bladder [22] . This technique has been tested since
1976 in conjunction with precise target localiza-
tion using gold seed implantation into the pros-
tate gland.
A preliminary study was conducted with
180 patients treated between 1972 and 1979 with
one of two approaches [23] :
1. X-rays only : 50 Gy of high energy photons in
5 1/2weeks in a 4-field box technique to the
pelvis, followed by 18 Gy to the prostate vol-
ume only (fraction size : 1.8 Gy).
2. X-rays + protons : 50 Gy of X-rays in a 4-field
box technique, followed by 24 CGE of protons
through a perineal port .
17 Early and Delayed Complications of Ion Beam Therapy
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Despite the higher dose, the second group
revealed no additional complications : dysuria and
hematuria were recorded in 10%, urethral stric-
ture in 5% and proctologic symptoms in 20 % of
the patients .
The encouraging results reported with protons
led to a randomized study inT3-T4 prostatic carci-
nomas, in which patients were allocated to
receive either 67 .2 Gy only with 10-25MV pho-
tons, or a total of 75.6 CGE with photons
(50.4 Gy) followed by protons (25 .2 CGE) .
Although definitive long-term results on tumor
control and functional outcomes are still pending,
a preliminary analysis of rectal tolerance in
191 patients has been published by Benk et al .
[24] . Dose-volume histograms of the anus, the
anterior rectum, the posterior rectum and total
rectum were calculated for each patient. Rectal
bleeding was selected as an end point. Interes-
tingly, the probability of not developing rectal
bleeding within 5 years after treatment was signif-
icantly lower (p = 0.013) in the "X-rays + pro-
ton" arm (66%) than in the "X-rays only" arm
(84%). The result correlated with the volume of
the anterior rectum treated at high dose : patients
who had received 75 CGE or more to at least
40 % of this structure showed a statistically signif-
icant higher risk (p = 0.003) for bleedings .
Fractionated Ion Beam Therapy
of Abdominal Malignancies
Liver
Preliminary results of the hepatic tolerance to
protons are available from T§ujii and coworkers
(25, see also Chapter 14). They evaluated a group
of 24 patients with hepatocellular carcinomas
treated with 50 to 87 Gy (mean 76.5) physical pro-
ton dose, given in 2.5 to 4Gy fractions. At the
time of treatment, all patients suffered from liver
cirrhosis of variable severity ; according to the
ChildTurcott classification, 11 had grade A, 7
grade B, and 6 gradeC. All patients were inoper-
able because of local extension or poor general
condition. Multiple field arrangements were
designed to focus the beam on the tumor volume
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and to minimize the safety margin to 5-10 mm.
Despite the poor baseline conditions of the pa-
tients, none experienced any serious side effects
which would have required discontinuation of
irradiation. No fatigue, loss of appetite, nausea,
pains, or pleural effusion were reported . Merely
7/24 (29%) patients demonstrated transcient
elevation of aspartate or alanine aminotransfer-
ase of twice or more the baseline values . It was
concluded that this was a safe procedure even for
patients with poor liver condition .
Liver tolerance to light ion therapy was also
evaluated by Austin-Seymour et al . [26] in 11 pa-
tients that hadbeen treated at Lawrence Berkeley
Laboratory (LBL) for carcinoma of the pancreas
or the biliary system . The patients received whole
liver coverage plus an additional boost with
helium or neon ions . According to an averaged
RBE of 1.3 and 2.7, respectively, the total dose
ranged from 18 to 24 CGE to the whole liver, and
53 .5 to 70 CGE to the primary tumor. 1/11 (9 %)
patients died of radiation hepatitis . ADVH inter-
comparison suggested that for 18 Gy-equivalent
administered to the whole gland at 2Gy/fraction,
an additional cone-down boost had to be
restricted to 30 % or less of the hepatic volume, if
the additional dose exceeded 30-35Gy.
Intestine
Intestinal complications have been reported spo-
radically. This is in part due to the fact that only
few intra-abdominal malignancies have been
treated by ion beam therapy. Small and large
bowel injuries have been reported following pion
therapy of pelvic tumors [27] and retroperitoneal
sarcomas . Butthese studies should be regarded as
preliminary evaluations of clinical normal tissue
tolerance to this particular type of radiation . As a
matter of fact, Greiner et al . reported no further
complications when the pion dose was reduced to
less than 36 Gy and the treated volume limited to
500 ml [28] .
Radiosurgery with Ion Beams
Radiosurgery differs in several aspects from con-
ventional external beam radiotherapy : it gener-
ally deals with small volumes (<_ 5 ml) which are
exposed to single fractions of high doses with the
aim of inducing focal tissue necrosis (cf. the previ-
ous chapter) .
Besides the knowledge of dose and volume
dependence gathered in the 60's and early 70's
from radiobiological and clinical studies on brain
tissue tolerance to single fractions, it is owing to
the stereotactic approach introduced by neurosur-
geons that the complication rate of radiosurgery
is so remarkably low.
Acute side effects are generally limited to an
increased seizure activity in patients with seizures
at presentation . Very rarely, severe headaches,
vomiting, and elevated temperature have been
reported . Delayed effects can be various forms of
vasculopathy or radionecrosis [29] .
Vasogenic edema seems related to injuries to
the endothelium of small vascular shunts that per-
mit fluid diffusion to the surrounding tissues;
white matter is commonly affected . On T2-
weighted MRI, these areas appear with enhanced
signal . These modifications are generally asymp-
tomatic . Only 10 to 15 % of the patients show
symptoms . In the LBL series with helium ions,
such complications were never observed for doses
<25Gy-equivalent.
Arterial occlusions result from injuries to the
arterial vasculature included in the treatment
field. They reveal no sign of edema on MRI .
Aneurysms were reported in the follow-up of
patients with arteriovenous malformations
(AVMs) . The suggested pathophysiology was an
increased pressure in the arterial branches as a
consequence of the AVM obliteration . Venous
thrombosis seemed extremely rare .
Radionecrosis was described in less than 5
of patients receiving 25 to 45 CGE, although
doses as low as 15 CGE have been incriminated
to cause cerebral radiation necrosis [30] .
Most complications have been reported for
lesions situated in the brain stem, thalamus, or
basal ganglia. Of 17 such patients treated at LBL
for AVMs, symptoms were minor in 7 and major
in 10 ranging from visual deficit, diplopia, hearing
impairment, to ataxia and/or paresis .
Kjellberg [31] reported his experience with
protons in 2118 patients treated over 25 years. In
pituitary adenomas, visual field disturbances,
e.g ., were observed in less than 2% of the treated
patients .
Hypopituitarism was seen in about one out of
10 patients . One patient developed brain sarcoma
several years after therapy. In arteriovenous mal-
formations the complication rate fell to 0.5
after changes of dose and field size .
These results are difficult to compare with
those of other stereotactic approaches since the
indications can differ markedly, the complications
are generally not reported with actuarial statis-
tics, and the end points - clinical, radiological or
both - can be different, too. But problems in
AVM treatment can obviously also be kept below
10 % with gamma knife [32] or linear accelerator
[33] .
Conclusion
Over 13000 patients have been treated with pro-
tons, and 3500 with pions and heavy ions world-
wide. Large patient series are becoming available
with follow-up periods exceeding 5 years. A
remarkably low rate of complications and late
sequelae has been reported given the large doses
generally administered . Major improvements
regarding treatment planning, patient set-up,
knowledge of normal tissue tolerance, and RBE
will help to reduce these risks, further.
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18 . Future Directions of Clinical Ion Beam Radiation
Background
J . M . SLATER
Loma Linda University Medical Center, Loma Linda, CA, USA
Ionizing radiation has been used for therapeutic
purposes since 1896, within months of Roentgen's
discovery of X-rays [1], and has developed into
one of the two most successful modalities for
treating localized cancer. Historically, this success
story can be divided into four eras of roughly 30
years each . These time periods might be thought
of as the discovery era (1895-1925), the kilovolt-
age era (1925-1955), the megavoltage era
(1955-1985), and a fourth, the ion beam era,
which is now in progress .
In each era, developments occurred in physics
laboratories which led to the subsequent eras .
Roentgen's discovery of X-rays was followed by
identification of subatomic particles, emission of
gamma rays, atomic structure characteristics, and
engineering advances which provided new capa-
bilities for measuring the characteristics of X-
rays, gamma rays and the other subatomic parti-
cles . Such discoveries, along with milestones such
as the development of the Coolidge X-ray tube,
made kilovoltage-era achievements possible [2] .
The concept of accelerating charged particles in
small steps and using subatomic particles as car-
riers of energy (rather than the secondary wind-
ings in the transformer) overcame the insulation
properties that severely limited the energy capa-
bilities of high-tension accelerators of the kilo-
voltage era and provided further bases for devel-
oping the megavoltage andion beam eras [3] . The
Betatron, linac and cyclotron all evolved from the
concept that a type of transformer could be
devised wherein the energized particles formed
the secondary windings . In addition, E.O.
Lawrence developed the first proton cyclotron at
the University of California, Berkeley [4] . The
device and its successors generated high-energy
neutrons and led, eventually, to the first clinical
neutron trials . By 1946, 150+ MeVprotons were
available andRobertWilson published his insight
that accelerated protons would be superior to
photons for clinical therapy [5] . Heavy particle
therapy experimentation began at Lawrence
Berkeley Laboratory in the early 1950s [6] . Dur-
ing the megavoltage era, linear electron accelera-
tors became widely available to clinics, as did the
Betatron . These technological developments
occurred in tandem with a greater understanding
of cancer biology; together, these advancements
resulted in major improvements in cancer patient
survival . This progress continued through the
megavoltage era as particle energies increased
with the development of high-megavoltage elec-
tron accelerators [7]. Another improvement in
cancer patient survival was demonstrated with
the clinical use of ion beams from heavy charged
particle accelerators [8-12] . Radiation oncolo-
gists realize that increasing the total doses of
ionizing radiation is essential for improving local
control of many tumors that presently are not
controlled .
The major improvements in tumor control
seen as these eras progressed, related to the more
favorable distribution of energy deposited in the
patient as each increase in photon energy
occurred, allowing in turn increased doses to the
target volume . It is now clear, however, that fur-
ther increases in the energy of photon or electron
beams is no longer a satisfactory approach . New
particles, with more favorable characteristics, are
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essential for optimal improvements in cancer con-
trol by radiation .
This need for further major improvements in
the therapeutic aspect of cancer patient manage-
ment, along with the major successes achieved
with ionizing radiation to date, has led to the ion
beam era. This era might be said to have begun in
January 1985, when an international group of 93
scientists responded to an invitation to meet at
Fermi National Accelerator Laboratory. The pur-
pose of the initial meeting was to develop the
design requirements for a heavy charged particle
medical facility, including the accelerator, beam
transport system, beam delivery system, the
building housing the equipment, and the nature
of the clinical studies to be conducted . The group,
known as Proton Therapy Cooperative Group
(PTCOG), included from its inception members
from North America, Asia, and Eastern and
Western Europe. Heavy ions and protons have
been under discussion ever since. PTCOG has
continued to meet on a twice yearly basis ; pro-
tons have gained the major attention partly due to
their lower linear energy transfer properties and
partly due to their significantly lower costs com-
pared to ion beams.
Current Status
Successful control of localized tumors by tradi-
tional radiation is constrained by dose limitations
imposed by the unavoidable integral dose
received in normal tissues outside the target vol-
ume. Energized subatomic particles having clini-
cally more favorable attributes for depositing
their energy within a patient are now being
investigated to overcome this limitation of photon
and electron beams . Many subatomic particles
are now available, each having its own character-
istics for depositing energy. To avoid losses of
time and resources involved in working with all of
the available particles, it is imperative that we
first define the optimum clinical requirements
needed from a new therapy beam. Next, we need
to evaluate each of the particles in terms of their
ability to satisfy the defined clinical requirements
and their potential for clinical use at this time .
Finally, we need to work on an international basis
to develop the ideal technology for accelerating
and delivering the particle(s) selected, and follow
with coordinated clinical trials and superb quality
assurance programs .
The macrodosimetric properties of the parti-
cles to be evaluated should be the primary prior-
ity in determining their therapeutic utility ; the
microdosimetric characteristics, which greatly
influence biological effects, should become the
secondary priority. The minimal macrodosimetric
attribute should be the ability to control each
beam in three dimensions. Microdosimetric char-
acteristics should include minimum ionization
density of the particle track as it traverses normal
cells; moderate increases in the ionization density
of the track should ideally begin as the particles
enter the target region . There are other macro-
and microdosimetric requirements, too numerous
to discuss here, which should be met, but the
foregoing are fundamental. Subatomic charged
particles of the hadron family, and heavier ions,
possess the greatest potential to fulfill these
requirements .
To date, more than 17600 patients have been
treated with particle beams in facilities around
the world; more than 14000 of them with protons
(cf. Chapter 1 for more details) . Patient totals
will rise in the future, not only as patients are
treated in existing facilities but also as new,
expanded or modified facilities, currently being
constructed or planned worldwide, are employed
(see Tab. 1 and Chapter 139) . The rapid increases
in facilities and patients treated indicates the
worldwide increasing recognition of the superior-
ity of these heavy charged particles for thera-
peutic purposes .
Cost is the only meaningful constraint to the
development of this form of irradiation . The
physics of heavy charged particles supports their
superiority for therapeutic use. Development of
the first hospital-based clinical proton treatment
facility at Loma Linda University Medical Center
in 1990 established that the technology is now
available to develop a highly integrated facility
with the sophistication, reliability, safety, effi-
ciency and friendly environs essential for a suc-
cessful hospital operation. The financial aspects
of this pioneering patient-dedicated facility have
been demonstrated to be acceptable ; new facil-
Table 1 . New particle therapy facilities (adapted from Par-
ticles, The Newsletter of the Proton Therapy Co-operative
Group 14, July 1994)
Place
	
Particle Opening
Date
Villigen, Switzerland (PSI)
Chiba, Japan (HIMAC)
Vancouver, Canada (TRIUMF)
Berlin, Germany (HMI)
Munich, Germany
Darmstadt, Germany (GSI)
Moscow, Russia (TTEP)
Jülich, Germany (KFA)
Groningen, Netherlands (KVI)
MGH Boston, MA, USA(NPTC)
North Carolina, USA (NC STAR)
Italy (TERA)
Novosibirsk, Russia
Chicago, Illinois, USA
Clatterbridge, UK
'Rukuba, Japan
Krakow, Poland
Basic Need for Utilization
p+
ion
p+
p+
p+
ion
p+
p+
p+
p+
p+
ion
p+
P+
p+
p+
p+
Ion Beam Therapy: The Future
1994
1994
1994
1995
1995/6
1996
1996
1997
19979
1998
1999?
2000?.o
.o
ities will experience significantly lower costs . The
LLUMC experience relieves the substantive con-
cerns regarding future development of proton
therapy.
The process of developing a clinical ion beam
facility is essentially the same as is followed to
develop any new modality for clinical use. Con-
sideration of the clinical requirements imposed
on a new modality is essential if the facility is to
be successful . Several factors must be considered :
Surgery and radiation therapy are the only two
modalities currently available for effectively
treating either local or regional gross cancer. The
basic need for improving the treatment and man-
agement of cancer is undisputed : American Can-
cer Society statistics for 1993 indicate that 1.2 mil-
lion new patients will be diagnosed with cancer in
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1994, and that there will be an expected 500000
survivors [13] . No data are reported for morbidity
because of the difficulty of adequately assessing
that outcome. It is commonly known, however,
that patients frequently delay early diagnosis
because they fear the morbidity that results from
the cancer and its treatment, further supporting
the need for improving current therapeutic cap-
abilities.
Efficacy
The effectiveness of ion beams for treating ocular
melanomas, pituitary adenomas and chordomas
and chondrosarcomas of the base of skull, has
been demonstrated [14-20] and preceding chap-
ters). Selecting the most appropriate particle for
specific therapeutic purposes, however, includes
consideration of the macrodosimetric, microdosi-
metric and financial characteristics of each parti-
cle. The vast majority of subatomic particles are
too unstable to consider for clinical use, with
present technology, leaving very few to select
from (Table 2) .
To ensure appropriate control of energy
deposition for most clinical purposes, the particle
should have a charge and amass many times that
* Clinically applicable
Table 2 . Families of particles
Familiy Particles
Photon Photon*
Lepton Electron*
Muon
Thu
Hadron
Mesons Pion*
Kaon
Eta
Baryons Proton*
Neutron*
Lambda
Sigma
Xi
Omega
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of electrons . This leaves for our consideration
charged particles of the hadron family and the
heavier ions .
Morbidity and Associated Risks
The risks associated with ion beam radiation
largely relate to the repair capabilities of normal
cells traversed by the particles and the potential
for oncogenic transformation of cells surviving
their exposure . Studies thus far have not detected
significant differences between photon and pro-
ton beam oncogenic transformation capabilities ;
oncogenic transformation in mammalian cell cul-
tures has been shown to be directly related to the
density of the ionization track of the particle
used, and appears to decrease with fractionated
dose schedules [21] .
Operational Reliability
The total system should be designed to remain
operational 100% of the time, or as close to that
as possible ; mechanical failures resulting in short
delays of patient treatments during any given day
are considered acceptable if their occurrence is
not routine. The ability to develop this level of
reliability within a hospital setting has been
demonstrated at the Loma Linda University Pro-
ton Facility (LLUPROF), where the "uptime"
has exceeded 98 % since the facility opened in
October 1990 .
Efficiency
A clinically successful hospital-based proton ther-
apy system must be efficient. The high initial
costs must be amortized by clinical funds from
relatively large numbers of patients to reduce
individual costs; inefficiencies in operations may
preclude success in an otherwise worthwhile pro-
gram .
Patient requirements should dictate the design
of the clinical support portion of the facility. The
use of gantries and/or fixed beam treatment
rooms determines the design of the treatment
portions of the facility. Efficiency refers to the
entire facility design ; every patient activity and
each support activity must be performable with
ease and should flow in a logical sequence, free of
functional obstructions . The director should be
able to unify and lead the entire operation in a
manner akin to a conductor leading an orchestra .
The conceptual design of the building, therefore,
is fundamental to success in this aspect of effi-
ciency. By outlining each activity to be performed
on a patient, in preparation for the patient's treat-
ment, the optimal room layout for convenience
and efficiency can be determined . Associated
with the facility's conceptual design is the engi-
neering design that translates the concept into a
functioning entity. Engineering designs based
upon physical, clinical and operational design
requirements should assure development of a suc-
cessful hospital-based, heavy charged particle
facility. The ultimate success of any new heavy
particle facility will depend on the facility design,
its quality of operations, and the clinical results it
produces .
Functionality, which refers to the facility's
responsiveness to clinical demands, is an integral
aspect of efficiency. All anatomic sites must be
targeted precisely in both patient set-up and
treatment. Patients' needs and feelings must be
considered . The facility should be designed with a
friendly, inviting and comforting environment .
The equipment should be sufficiently sophisti-
cated to permit each treatment room to be oper-
ated by the attending nursing and technologist
staff . Engineering and physics staff should be
available for unusual circumstances . Physician
staff should be involved with the verification of
each set-up and should aid technologists and
nurses with difficult patient positioning and med-
ical support needs.
Financial Considerations
Self-sustaining operations are essential for a suc-
cessful program at most institutions . This means
that the facility should be designed to accommo-
date a volume of patients that will make self-
sustenance possible, and that the particle selected
is cost-effective, both in its initial and operational
expenses. The stability of the particle, and its
mass, affect the initial costs and the operational
expenses .
Summary
Photon therapy has been developing for nearly
100 years . Enormous improvements in the treat-
ment of cancer and some benign diseases have
resulted . Patient morbidity from radical surgical
procedures has been greatly reduced by the pho-
tons' capability to selectively destroy undesirable
abnormal cells while sparing sufficient normal
cells to enable repair to proceed . Its success as a
modality is immense and undeniable in spite of
the controversial periods it has experienced .
Photon therapy, however, as the mainstream
modality for delivering ionizing energy for human
disease, has reached a plateau that further energy
changes and delivery techniques have not been
able to surmount . Technology has progressed and
with it has come the opportunity to use other par-
ticles for carrying ionizing energy ; particles hav-
ing increased controllability and new energy
deposition attributes . One of them likely will
emerge as the primary, mainstream particle while
others will function in secondary, support roles,
much as electrons and radioisotopes now support
photon beams. The primary particle will combine
maximal controllability with minimal ionization
density, attributes which allow it to be focused on
target volumes with minimal effect on normal tis-
sues and thus maximize its clinical applicability.
Radioresistant tumors will require more densely
ionizing characteristics, which suggests the need
for more than one type of ion beam . Based upon
the significant success of photon and electron
beams and the capability of present technology,
the proton most closely approximates the com-
bination of attributes suggested for the main-
stream particle, and therefore seems most appro-
priate to replace the photon as the primary parti-
cle in radiation oncology. Cost analyses of the
Loma Linda experience further support the pro-
ton as the primary particle for current therapeutic
purposes .
It is extremely unlikely that any single particle
will adequately satisfy the physician's demands .
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Protons, heavy ions and neutrons [22, 23] have all
demonstrated success in specific clinical applica-
tions . Modulation of the ionization density of the
target volume may be achieved by mixing ion
beams of different characteristics to optimize the
therapeutic ratio in some clinical situations . Ulti-
mately, the physician needs to have the ability to
use the particle, or combination of particles, that
will yield the highest probability of disease con-
trol and minimize the undesirable side effects .
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Introduction*
Radiation therapy with beams of protons and
heavier ions has reached the stage where inten-
sive clinical research must be performed to
develop protocols for best application of this
modality for the treatment of cancer and other
lesions . Results from many years of research,
both clinical and radiobiological, and many thou-
sands of patients treated have demonstrated the
effectiveness of the dose localization abilities of
these beams, and have hinted at benefits from
high-LET radiation . Until recently, all the pro-
gress in the field has taken place at accelerator
facilities in large laboratories or universities,
accelerators built originally for physics research
to which medical facilities have been added. The
new treatment facilities at Loma Linda, USA and
Chiba, Japan break this pattern, and are the first
accelerators designed and built primarily for ion
treatments .
To continue the rapid progress made in recent
years, more hospital-based facilities that are
optimized for patient treatments are necessary.
Ziwo primary goals should be kept in mind in plan-
ning such facilities : they should permit the treat-
ment of large numbers of patients easily and
efficiently to accrue statistics and develop the
necessary protocols ; and they should both assist
in the development of, and incorporate into clin-
* Material for this chapter is drawn largely form LBL
report 33749 "Performance Specifications for Proton
Medical Facility by W.T. Chu, J.W. Staples, B.A .
Ludewigt, T.A. Renner, R.P. Singh, M.A . Nyman, J.M.
Collier, L.K . Daftari, H. Kubo, PL . Petti, L.J . Verhey,
J.R . Castro and J.R . Alonso, March 1993 .
ical use the best possible beam delivery technol-
ogy to take maximum advantage of the properties
of ion beams.
To accomplish these goals efficiently, careful
attention must be paid to the specifications for
the performance of the technical components of
the treatment facility, including the accelerator,
beam delivery, and patient handling systems.
Very important is the order in which these speci-
fications are determined: first must be the
requirements for clinical performance, then the
beam delivery system that will meet these
requirements, and finally the accelerator that will
provide beams tailored to the specified beam
delivery system .
Clinical Specifications
As part of a joint study program sponsored by the
US National Cancer Institute [1] to evaluate spec-
ifications and designs for a dedicated proton ther-
apy facility, clinical groups from UCSF (Univer-
sity of California at San Francisco) and MGH
(Massachusetts General Hospital), with assis-
tance from staff members of the Lawrence Berke-
ley and Harvard Cyclotron laboratories
developed a set of clinical specifications that
could be used as the basis for the beginning of a
design effort . Although these specifications were
written with protons in mind, the clinical require-
ments for heavier ions, such as helium, carbon, or
neon would be essentially the same . The only
area where a real technological challenge would
exist in meeting the specifications would be in
providing isocentric delivery for ion beams. These
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beams. These specifications, reported recently by
Gall et al . [2] canbe classified into several group-
ings, and are described below.
Position and Precision of Stopping Beam
The basic aim of ion beam therapy is to be able to
place stopping particles in any point of the body,
and so to define a treatment volume that con-
forms as closely as possible to the generally irreg-
ular, three-dimensional shape of the diseased tis-
sue to be treated, while keeping the dose to adja-
cent normal tissue to its lowest possible value.
Table 1 lists the accuracy and range of parameters
desired to effect this placement . The maximum
range, roughly 32 cm in tissue, is expected to be
able to handle over 95% of the desired ports.
While shallowpenetration beams can be obtained
by simply degrading the energy of the beam, such
degrading also spoils the good properties of the
beam, losing the precision that is most likely
required for these shallow-field treatments, such
as for ocular melanomas. Achieving shallow
ranges, then, must be accomplished without
degradation of beam quality.
Table 1 . Range and precision requirements of the stopping
beam
Parameter Desired Specification
Deepest range 32 g/cm2
of penetration
Shallowest range 3.5 g/cm'
of penetration
Precision in setting 0.1 g/cm2
the deepest range
Steps of range adjustment 0.5 g/CM Z
within a given field
Maximum field size in a
fixed-beam room 40 cm x40 cm
gantry room 26 cm x20 cm
Sharpness of distal 0.1 gkm2 above limit
dose fall-off set by range straggling
Sharpness of lateral 2mm above limit set
penumbra by multiple scattering
in the patient
Effective SAD >3m
(Source-to-axis distance)
Precision in setting the distal extent of the field
(around 0.3 % of the maximum range) relates to
the accuracy of setting the beam energy ; from an
accelerator standpoint achieving this accuracy is
not a problem, typical accelerator energy resolu-
tion and energy control is of the order of 0.1 % or
better, it is more critical to know accurately the
electron density of the material to be traversed to
reach this stopping point. This accuracy must be
folded into the treatment planning process, the
translation of CTnumbers to electron density and
the careful accounting for thickness of material
traversed. The depth steps called for relate to the
natural thickness of the Bragg peak and expected
depth dimension of the voxels that would be used
in the planning and delivery of treatment . As
these range changes will occur many times during
the treatment, this requirement constrains the
time allowed to effect range changes, be they by
changing the energy of the accelerator or by
inserting energy degrading material in the beam.
Field size is related to the largest dimension
one wishes to treat at one time . For example, an
esophagus field may require a rectangular band
with 40 cm extent along one axis . It is unlikely
that whole-body irradiations will be performed
with proton beams, so the full 40 cm x 40 cm field
would not be used at one time . Nonetheless, the
call for this maximum field extent sets the size of
instrumentation, collimators, and beam spread-
ing system . Typically, such large fields will be
obtained by placing the patient further away from
the point of origin of the spreading system, allow-
ing more drift for the beam. This is easily
obtained in a fixed-beam port, but not so in a
gantry, thus the smaller field specification for the
gantry port, in an attempt to contain the size and
cost of the gantry. The 3-meter SAD also relates
to the gantry size, lower numbers can lead to
shorter beam delivery systems, or "nozzles" as
they are sometimes referred to, but will increase
the skin dose . As there is not the same skin spar-
ing with protons that one encounters with high-
energy photons, this could be a serious considera-
tion in treatment planning . The goal of minimiz-
ing gantry size and preserving large SADs can be
achieved by integrating the beam spreading into
the magnetic deflection system of the gantry, in
the manner being implemented at the PSI proton
therapy facility (cf. Chapter 23) . This integration
process, however, is extremely complex, both in
magnet systems for the gantry as well as in achiev-
ing desired control over field size, shape and dosi-
metry. One should note another aspect of the PSI
implementation : field spreading is performed in
only one transverse direction, patient translation
is used to provide the other coordinate . This "line
scanning" concept was not endorsed by the
UCSF/MGH clinicians, who felt it important that
the whole treatment field be illuminated without
moving the patient.
Sharpness of the placement of stopping beam
particles is limited by certain physical effects
associated with the interactions of particles as
they slow down in tissue, namely the small-angle
collisions between these particles and the elec-
trons and nuclei in the tissue . These effects,
multiple Coulomb scattering and range strag-
gling, are well-understood, andcan be folded into
treatment planning programs . The specifications
on sharpness relate then to additional spoiling of .
beam quality that may result from beam spread-
ing techniques upstream of the patient. Specifi-
cally, the introduction of energy spread in the
beam, due to a poorly compensated compound
scattering system, or even the presence of exces-
sive scattering material close to the patient or the
patient collimator will introduce emittance
growth in the beam that will lead to loss of sharp-
ness in the stopping region of the beam. How-
ever, as these emittance growth mechanisms add
in quadrature to the normal multiple scattering
and range straggling phenomena, some lattitude
is allowed in delivery system design ; but this will
be dependent on each particular field geometry.
Dose Deposition and Dosimetry
The desire of the clinicians is to complete a treat-
ment in the shortest possible time, commensurate
with accuracy and safety. Typical times for treat-
ment should be less than two minutes for most
fields, which will probably be treated to a dose of
around 2 Gy. The 25 cm x 25 cm field specified in
Table 2 represents a mean field size, defining a typ-
ical particle density, or dose rate . The depth in this
specification is important, as placing particles in a
19 Design Criteria for Medical Accelerators
	
173
Table 2. Dose and dose rate requirements
Paranzeter Dashed Specification
Average dose rate 1 Gy/min for a 25 cm x25 cm
field at a depth of 32 g/cm2
Time structure of the suitable for beam scanning
beam
Dose compliance ± 2.5 % for each volume ele-
ment in the entire treatment
field
Dose accuracy ± 2%
Dosimetry day-to-day : ± 1.5%
reproducibility week : ± 3.0%
shallower field leads to a higher rate of energy
deposition . These factors together translate into
the required beam current from the accelerator.
The clinicians recognized that an active scan-
ning system will ultimately provide the best con-
trol over the treatment field, shape, and quality.
The time structure requirement places great con-
straints on the accelerator parameters and
performance, as will be shown below. The basic
requirement is that the ability to scan the beam
across the treatment field is not restricted or con-
strained because of beam time structure. For
instance, if the accelerator produces very short
pulses with a very low duty factor (e.g ., a few mil-
liseconds of beam at a 10 Hz rate) one will not be
able to sweep the beam continuously across the
field unless the sweep rate is very slow, less than a
few beam widths per second . This wouldproduce
unacceptably long treatment times, and so pre-
cludes using a scanning system for this type of
accelerator. For accelerators which deliver long
duty factor beams, the critical element is the con-
trol over the intensity of the beam at all times dur-
ing the time the beam is coming to the treatment
room . If there are irregular spikes in the beam,
these can lead to field inhomogeneities and lack
of dose deposition control.
Clinical dose-response data indicate that 5%
changes in dose represent about the smallest
increment for which a clinical effect can be
detected . This was used to establish the tolerance
allowed on dose delivery and measurement in the
treatment field, or the dose compliance to that
specified in the treatment plan . For the simplest
passive beam delivery systems this specifies the
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requirement on the field uniformity, for more
advanced systems, in which one may wish to tai-
lor the actual dose delivered to each voxel of the
treatment field, it specifies the control required
over beam delivery to each coordinate, and the
ability to measure this dose accurately.
The dose accuracy specification relates to the
required precision of the calibration procedures
and measurements themselves, as well as to the
linearity and stability of the dosimetry system
employed . The dose detected by an ionization
chamber in the nozzle upstream of the patient
will be different from what actually is delivered to
the relevant voxel in the patient, owing to differ-
ent energy and particle density profiles at the two
locations . Onemust rely on calibrations, then, or
calculational models based on empirical measure-
ments of ratios ofresponse of the ion chambers or
other dosimeters in the nozzle with a standard
dosimeter placed in a phantom configured to
match the actual voxel under treatment .
Experience has shown that in a typical
charged particle treatment beam line employing
many redundant channels for dose measurement,
there will be a daily variation observed in the
ratios of all the different channels . These varia-
tions arise from many sources : slight irregularities
in beam tuning, electronic drifts, slight positional
errors in placement of instrumentation, environ-
mental variations (temperature, pressure) . The
tolerances specified have been shown to provide
an acceptable excursion in the measured ratios
that do not contribute to a measurable loss of
accuracy in clinical parameters.
Controls, Safety, Availability
The control system is a critical part of the treat-
ment facility (see Chapter 27 for details) . It must
ensure that the beam line instrumentation, beam
shaping devices and positions are all those speci-
fied in the patient prescription . It must control all
parameters of the treatment : scanning magnet
currents, collimator settings, range adjustments,
accelerator settings, beam currents, and assure
compliance of these parameters with requested
values at all times . It must collect all the data gen-
erated by the dosimeters during the treatment
and verify that ratios of all measurements are
within acceptable limits . It must control the ter-
mination of the irradiation, either normal ter-
mination when desired dose values have been
reached, or rapid termination in the event of the
detection of a parameter that is out of range. It
must also be able to resume the treatment from
the point it was prematurely terminated once the
problem has been corrected, and deliver the
remaining dose to the prescribed accuracy. It
must provide archiving services, to keep a record
of all parameters associated with each treatment.
Many man-years of effort have been required
to generate control systems for existing research
facilities, but the quality control requirements for
hospital-based clinical facilities will add signifi-
cant time and effort to new control system devel-
opment. The costs for the control system will be a
very large fraction of the total technical system
costs, much more than what onewould encounter
in a normal accelerator facility.
Added costs as well accrue from the require-
ment for 95 % overall system availability.
Although high for a research establishment, in
which flexibility of configuration and always
pushing the performance limits seems to be the
norm, this level of reliability can be, and has been
achieved where required . Both the Harvard Cy-
clotron and the LBL 184-inch synchrocyclotron,
when used as dedicated clinical accelerators, had
availability statistics at least as good as the
required 95 %.
Facility Requirements
Early work with charged particle beams has all
been done with static, mostly horizontal beam
lines. This has generally required the patient to be
treated in a seated position, or in awkward
recumbent orientations . Although the seated
position does allow for "isocentric" delivery by
rotating the patient around the beam axis, immo-
bilization and patient comfort are more difficult.
In addition, the very important requirement of
coordinating the patient orientation with the
diagnostic images on which the treatment plan-
ning is based, indicates that a supine treatment
position is highly preferred . This means that the
beam must be brought around the patient, in the
form it is done for conventional megavoltage
treatments . Much of the cost and technological
challenge in bringing ion beam treatments into
the realm of practicality have revolved around the
development of effective, inexpensive and practi-
cal gantry systems . (cf. Chapter 23). It should be
noted that the UCSF/MGH team recognized the
value of static horizontal ports for specialized
applications, namely ocular treatments, and very
large fields that could not easily be obtained with
a gantry system .
Support areas required in a facility designed to
handle many patients include systems for ensur-
ing smooth patient flow, maximizing the through-
put in the treatment rooms, ensuring positional
accuracy of the patients andproviding for storage
of patient-related hardware such as collimators,
compensators and immobilization devices. All of
these factors require careful planning and study,
and inevitably much space. Noteworthy on the
alignment accuracy issue, is the HIMAC facility
in Japan, in which a CT scanner has been
installed in each treatment room in such a way
that the patient can be scanned, then translated
accurately to the treatment position, with the
coordinates determined from the scan being
transferred to the delivery system controller.
The biggest problem in establishing shielding
requirements has turned out not to be the atten-
uation of neutrons and other radiations, but that
of compliance with moving regulations . As the
field is still very young, standards for allowed
high-energy neutron fluxes in a hospital environ-
ment are still being adjusted . This has led to
overly conservative specifications for shielding at
facilities like Loma Linda, and added signifi-
cantly to the costs in concrete and floor space.
Hopefully, this situation should become more
stable in the coming years.
Performance Specifications
Beam delivery systems are covered extensively in
a subsequent chapter, so it suffices to state here
that accelerator performance must be matched to
those delivery systems most suitable for placing
stopping particles in an arbitrarily-shaped three-
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dimensional volume . The best candidates are the
raster scanner employing a small beam spot and
tight control over the scanner sweep velocity and
beam current, and the voxel scanning system
which places aplanned dose at each coordinate in
the field. Suitable also, but not to the same
degree, although presenting significantly fewer
technical challenges, is range-stacking with a pas-
sive scattering system and a multileaf collimator.
The performance specifications discussed below
are matched to the needs of these three delivery
systems . The discussion will be kept general, to
include accelerators suitable for both protons and
heavier ions, and, although problems with partic-
ular accelerator technologies will be mentioned,
particular judgments as to the suitability of accel-
erator types will be kept to a minimum.
Beam Energy
To achieve a range of 32 g/cmZ in tissue, abeam of
approximately 225 MeVprotons, 430 MeV/u car-
bon or 610 MeV/u neon is required . The maxi-
mum energy of the beam from the accelerator
should, however, allow for energy loss in material
placed in front of the patient, to include scatter-
ing systems, dosimetry devices, range modula-
tors, and compensators . The active scanning sys-
tems are less burdensome in this regard, but the
scattering systems will introduce significant
energy loss . The amount of material required for
scattering depends on the scattering angle, which
is closely related to the maximum field size and
the SAD, and so to gantry dimensions . For most
accelerator types, the top energy is relatively soft,
the cost of adding a few more MeV is not that
great, so specifying a comfortable energy margin,
of approx . 10% over the required energy, is rec-
ommended . This translates into 250 MeVfor pro-
tons . The maximum energy for a light ion
machine is closely related to the heaviest ion that
will be used in therapy, and whether there is a
desire to push this particle to the maximum
depth . As the normal tissue damage from plateau
irradiation of heavier ions may be substantial, the
heavier ions may be preferrable for shallower
irradiations, thus requiring less energy. If neon is
the heaviest ion to be contemplated for full-range
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treatments, then a 670 MeV/u top energy would
be satisfactory.
It could be noted that 250 MeVfor protons can
be conveniently reached with linacs, cyclotrons or
synchrotrons . However, the high rigidity of ion
beams, 8.7 T-m in our 670 MeV/uexample, pretty
much rules out cyclotrons as a viable accelerator
technology for light ion therapy.
Energy changes take two forms: the establish-
ment of the highest energy for each treatment cor-
responding to the deepest portion of the treatment
port, and then the changes that are necessary to
treat the shallower portions of the target volume .
Adjustment ofthis energy can be performed in the
treatment room itself ; this has been the normal
mode of operation for many years, and allows the
transport of a fixed-energy beam to the treatment
room . However, the use of large amounts of
degrading material leads to degradation of beam
quality and to a substantial neutron background in
the treatment room . In fact, the clinical specifica-
tions quoted above are carefully given so they
could not be met with a configuration in which the
beam enters the treatment room at a significantly
higher energy than what is required to reach the
distal end of the treatment field. Either, then, the
beam must be degraded in the transport line, and
cleaned up with emittance and momentum selec-
tion systems (at a significant loss of intensity, and
activation of material in the transport gallery), or
the beam must be extracted from the accelerator at
or close to the desired maximum energy. Tuning
for the maximum energy can be done without
much demand for haste, it must be ready after the
patient has been installed and aligned in the treat-
ment position . A minute or two is satisfactory for
this set-up . However, once the treatment has
started, the energy changes to treat the shallower
voxels must be performed quickly, within a second
or two at most . With a synchrotron this requires
extracting the beam on subsequent pulses at differ-
ent field settings (so-called pulse-to-pulse energy
variation), for the cyclotron and linac, in which
energy might be variable only in fairly large dis-
crete steps, the degrading material must be
switched quickly. In all cases the beam transport
lines must track the new energy of the beam, a
non-trivial requirement considering the large num-
ber of bends and focusing elements in the trans-
port line, and the very large dynamic range
required for the overall energy changes, and the
precision required for beam stability at isocenter
(see below) . It should be noted, on this point,
however, that synchrotrons with many discrete
magnets do track very large energy gains of parti-
cles with high precision and speed; the same tech-
niques of common excitation of families of mag-
nets and very tight control will have to be applied
to these transport lines .
The energy spread of the beam affects the distal
fall-off of the treatment field, although this effect is
for most accelerators insignificant compared to the
range straggling suffered by the beam as it pene-
trates to its end-of-range point. Of greater impor-
tance is the aperture of the transport magnets: a
poorly defined beam will require very large aperture
magnets for efficient transport, adding weight and
power costs to the transport and gantry systems . A
typical accelerator will have an extracted beam of ±
0.1 % energy spread . Placing this same specification
on the momentum selection and clean-up system for
the degrader used to tailor the beam from a fixed-
energy accelerator will specify the width of the
momentum selection slits, and hence the beam loss
that will be experienced when this selection takes
place. The accelerator must be capable of delivering
the added beam current to ensure that the dose rate
of the beam surviving the clean-up process is still
within the specification for maximum treatment
time . This could be very significant, for large energy
changes as much as a factor of 100 to 1000 .
The energy precision specification relates to
the ability to matchthe required distal edge of the
field. To meet the requirement of ± 0.1 g/cm2
(Tab . 1) one should have a proton energy adjust-
able to ± 0.4 MeV, or about ± 0.2% of the maxi-
mum beam energy. With typical synchrotron sys-
tems this represents a flat-top field accuracy of
around ± 5 Gauss (out of 10 to 15 kG), well
within the state of normal practice .
Often times the absolute accuracy of the beam
energy is difficult to obtain, however, this is not rele-
vant in our case, as we only need to set the beam
range to correspond to a given desired range. This
number can be obtained by empirical measure-
ments, translating a range value into a particular
magnetic field value, so high-precision knowledge of
the absolute beam energy is not important .
Lateral Beam Quality
As was the case with the energy spread, the typ-
ical emittance of beams coming directly from the
accelerator is very small, and contributes little to
the lateral penumbra experienced in the treat-
ment field . The penumbra specification is
affected primarily by the material the beam tra-
verses in the nozzle, most particularly whatever
material is within a meter or two of the patient.
Thebeam emittance primarily affects the size and
weight of the transport magnets and gantry sys-
tems . Typical beam emittance from an accelerator
will be around 5 itmm mrad (unnormalized), pro-
ducing beams that can be transported with dipole
magnet gaps of less than 5 cm. Again, the goal of
a degrading/clean-up system from a fixed-energy
accelerator should be to produce beams pre-
sented to the gantry transport system with emit-
tances close to this value. In the absense of any
tissue that would increase the beam size, the
smallest beam spot (for protons) that can be
obtained at isocenter is around 1 cm FWHM.
Beam emittance contributes somewhat to this,
because of the large distance from the last focus-
ing magnet to isocenter, but the main contribu-
tion to beam size is the material the beam pene-
trates, even in the cleanest scanning system : vac-
uum windows, ion chambers, and air.
The accuracy of a treatment system, particu-
larly one in which a small beam spot is swept
across the treatment field, is strongly dependent
on the positional stability of the beam spot . If the
spot has motion at isocenter, because of improper
extraction tuning or system noise or ripple, the
precision required for the treatment to define the
field boundary, and more particularly, to ensure
conformity of the dose to the prescription inside
the field, will suffer. This problem can be particu-
larly difficult to control considering the very long
moment arm between the last magnetic element
and isocenter, maybe as much as 3 m or more .
Acceptable motion of the beam spot at isocenter
is ± 1 mm (about 10 % of the best beam size), and
an angular variation of ± 1 mrad. This places
great stress on the stability of the magnet ele-
ments, and on excellent control over the extrac-
tion process from the accelerator. Synchrotron
extraction, in particular, can be prone to beam
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sweeping, and pulse-to-pulse variations . Great
care must be taken in the design process to con-
trol these effects. The stability requirement at iso-
center also constrains the design of the beam
transport systems to be as insensitive as possible
to beam motion or fluctuations .
Beam Intensity and Time Structure
The beam current must be adequate to meet the
specification for maximum dose rate of 1 Gy/min
for a 25 cm x 25 cm field at a depth of 32 g/cm2.
This dose rate corresponds to approximately 10'2
protons per minute actually stopping within the
treatment field. One must fold into this the effi-
ciencies of the system, i.e ., beam lost in the trans-
port system, and more importantly beam lost in
the beam spreading system . For a well-designed
scattering system, efficiencies of approx . 20% are
encountered. These factors translate into a
requirement for a proton current of the order of
10" protons per second from the accelerator. This
number is then carried back to specify the per-
formance of the injector and ion source, folding
in repetition rate, as well as transfer and accelera-
tion efficiencies . Onewould think that a scanning
system would require less beam owing to higher
efficiencies of utilization . In practice, it is difficult
to achieve a higher overall efficiency, or stated
differently a shorter treatment time for the same
beam current. Thereason is that the scanning sys-
tems often place greater constraints on the rate of
use of the particles, by either switching the beam
on and off to move between voxels, or by adjust-
ing the rate of spill to correspond to sweep
speeds . The result is that not all the particles
available are used in the treatment . This situation
is still more desirable than the scattering system,
as in the scattering system the beam is actually
lost in material close to the patient, specifically
the scattering foils and collimators, producing
background radiation and an additional body-
burden to the patient . The specification of 10"
protons per second (-~ 15 nA) can be met by any
of the accelerator technologies : linacs typically
produce beam currents far in excess of this num-
ber, cyclotrons now produce currents in the hun-
dreds of microamperes, while synchrotrons can
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reach this intensity figure, producing beams of
the requisite characteristics provided care is taken
in the design and optimization of accelerator
parameters .
Duty factor refers to the fraction of time the
beam is on . This can be divided into two basic
regimes: macroscopic and microscopic . The divid-
ing line between "micro" and "macro" occurs
somewhere between the millisecond and micro-
second time scale, so megahertz and higher fre-
quencies are typically considered "microstruc-
ture", while lower frequencies will be "macro-
structure" . The macroscopic nature of the beam
can be either CW ("continuous wave" or 100%
duty factor), or pulsed . Cyclotron - at least iso-
chronous cyclotron - beams are typically CW
synchrotrons with slow extraction systems pro-
duce beams with typically 25% duty factor and
spills of a fewhundred milliseconds to a second or
two. Conventional (room temperature) linacs are
typically very short duty factor machines, beam
pulses last around a millisecond, with repetition
rates of a few hertz to a few tens of hertz. These
linacs are generally optimized for injection into
synchrotrons, where very short pulses at low
repetition rates are desired. High duty factor lin-
acs have been built, but are very expensive
because of the high-power RF systems needed to
produce the field gradients necessary for efficient
acceleration, this power requirement is largely
wasted for the very small beams needed for ther-
apy. Superconducting linacs would be a better
match, but this technology, particularly for pro-
tons or ions is expensive and furthermore is far
from mature at this point.
The importance of macroscopic duty factor is
in the matching of the accelerator with the beam
delivery system to be used, particularly in active
delivery systems . Passive systems do not sweep
the beam across the treatment field, so time struc-
ture in the beam is relatively unimportant, except
to assure accuracy in cut-off when the desired
dose is reached. If the sweep rate of the scanning
system is matched to the length of the beam
pulse, then a straightforward relationship will
exist allowing a painting of the field once per
beam spill. A good match exists with the syn-
chrotron spill length of a few hundred millisec-
onds and scanning rates for magnet systems of
conservative design . CW beams place no con-
straint on the delivery system ; beam is simply
switched off and on according to the needs of the
scanner. Very low duty factor machines interface
very poorly with a scanning system, sweep rates
cannot match a millisecond pulse, so a short-
pulse machine would have to work with a voxel
scanner with one or several pulses to be delivered
for each voxel. The issue will then be one of con-
trol of the number of particles in each pulse to
achieve the required level of dose accuracy per
voxel. This is not easy for this type of machine,
but a practical system could be designed if the
pulse repetition rate were at least 100 Hz to 1
kHz. Again, because of the requirement to fill
large structures with RF power, rapid repetition
rates are difficult to achieve in this type of linac.
Another concern with very short-pulse
machines is the high instantaneous dose rate
which can lead to saturation of the dose monitor-
ing ion chambers . The critical time constant for
these chambers is around a millisecond (the clear-
ing time of ions produced in the gas), if this dose
rate exceeds 20 Gy/s integrated over a millisecond
[3], ion recombination, hence chamber non-
linearity will result . Unless the beam is made very
large, as for a scattering system, beam currents
will have to be kept very low to prevent this non-
linearity, extending the treatment times well
beyond the specified requirement.
Microscopic beam structure is completely
unavoidable for any accelerator extracting beam
without turning off the RR The only machines for
which this would be possible is the synchrotron,
but often even here the RF is left on to provide
greater control over the beam during the resonant
extraction process. The RF-structure ranges from
nanoseconds for linacs to tens of nanoseconds for
cyclotrons to microseconds for synchrotrons, with
pulse trains typically filling only 10 % of the time .
The question one must ask is whether this time
structure is important for the treatment . From the
biological standpoint effects attributable to accel-
erator RF-structure have not been reported, but
it is not clear that this specific question has really
been addressed with adequate experiments. On
the physical side, the question to ask is whether
this structure will affect the uniformity of a
scanned field. One only needs to look at the time
between pulses, the distance the beam is swept by
the scanning system in this time, and the size of
the spot being swept to see that this will not be a
problem. Fastest sweep rates may approach 1000
cm/s, or 1 cm in a millisecond. If the beam struc-
ture is 1 MHz, about 1000 pulses will strike the
target while the beam moves one beam width.
Similarly, ion chamber saturation is not an issue
as long as the integrated current (in one millisec-
ond) is below the critical density.
Beam Control and Safety Aspects
Control of the beam current is critical to ensure
the specified dose compliance . In the most
straightforward case, the scattering system, the
beam is typically delivered at a high dose rate
until 90% of the desired dose is delivered, then
the beam current is reduced to allow for accurate
topping off of the dose and a clean cut-off of the
beam. Dose rate control to the 10 % level is
adequate, as long as reliable attenuation of the
beam is achievable and an absolute cut-off of the
beam can take place in a few milliseconds . The
situation is more demanding for interfacing with
scanning systems . For a raster scanner sweeping
at 1000 cm/s, accurate response is needed with a
bandwidth of at least 1 kHz to control the dose
delivered to each coordinate along the sweep
path . By sweeping over the field several times,
and again topping off at a lower dose rate, better
accuracies can also be achieved . Most important
in this process is having good, fast and accurate,
dosimetry to be able to assess the dose accumu-
lated at each coordinate, so as to calculate the
correction doses to be given in the final passes .
Within each sweep, a dynamic range of at least a
factor of 10 in instantaneous current is required,
with a tracking accuracy of at least 10 %, to assure
proper dose compliance. Voxel scanning requires
the ability to modulate the beam on and off very
rapidly, perhaps as high as at a megahertz rate, to
correspond to filling each voxel to the required
level .
Very fast on-off control is best performed with
kickers in the transport line, and does not rely on
accelerator response, although most accelerators
can easily turn beam off in a millisecond. Linear
19 Design Criteria for Medical Accelerators
	
179
control of the instantaneous beam current is quite
difficult with short-pulse linacs, but can be done
in a relatively easy fashion with feedback systems
for both cyclotrons and synchrotrons . In the cy-
clotron, beam current modulation is obtained
either by direct control of the ion source,
although this is more difficult than the other
option : optics manipulations in an axial injection
line, such as variable transmission through an iris
via a rapidly varying focusing or deflecting ele-
ment . This scheme requires an axial injection line
instead of an internal ion source, but such an
arrangement has many advantages in any case .
Linear control for the synchrotron is best
obtained by modulating the resonant extraction
system parameters, although this is a very sensi-
tive and difficult exercise to perform properly and
maintain the desired control over the beam.
To achieve the level of conformation of the
dose to the prescribed values at each coordinate
in the treatment field, we must have extremely
good control over the dose deposition rate at all
times . Particularly in a scanning system, where
the exercise of treating to a prescribed dose is
repeated for each coordinate, the presence of
uncontrolled beam spikes can be extremely
bothersome . Such spikes can come from ion
source bursts in cyclotron or linac systems, or
from any area where the beam is being throttled
back, and where a small parameter change can
cause a sudden increase in beam current. Most
difficult to control, however, is the structure that
accompanies resonant extraction in synchrotrons .
Beam being accelerated in the synchrotron is in
inherently stable orbits, but to extract the beam,
a resonance is excited to render these orbits
unstable and allow growth in oscillations that will
lead to the beam spilling out through the exit
channel. Because this process is basically intro-
ducing an instability, and attempting to control
the growth of this instability to control the rate of
particles flowing out from the synchrotron, it is
inherently difficult to control. Any small amount
of noise, for example ripple on the magnet power
supply, will cause beam to emerge in an uncon-
trolled fashion bearing the frequency of this
noise. Achieving damped feedback response is
very difficult. In spite of all this, the problem is
not insurmountable, provided proper care is
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taken in designing the synchrotron and its extrac-
tion system . Quiet and controlled spills have been
obtained from modern synchrotrons .
The level of control needed can be estimated
from the dose compliance requirement, and the
characteristics ofthe delivery system . Again, for a
scattering system, where the whole field is being
irradiated at once, beam spikes are less of a prob-
lem. A spike that has duration shorter than the
system cut-off time must have less than 2% of the
total for the whole field. For scanning systems the
constraints are much more severe . If there are 104
separate volume elements in the target volume,
and a dose compliance of 2% must be achieved
for each element, then a spike cannot contain
more than 2% of the dose for that element, or
2 x 10-6 of the total dose . If the total treatment
contains about 10'2 protons, then each spike must
contain less than 106 protons. From the stand-
point of measuring current spikes, this is a very
small amount of charge .
System safety requires the ability to rapidly cut
off the beam, either to effect normal termination
of the treatment, or to respond to an emergency
or detected system abnormality. Following the
analysis developed above, cut-off for a scattering
system that occurs in a few milliseconds will
ensure adequate patient safety, with little chance
of patient overdose . For scanning systems, the
desired cut-off time is less than 10 microseconds,
to account for a sudden spike at a rate approxi-
mately 100 times the normal rate at a voxel. This
type of cut-off can be effected with a fast kicker in
the transport line to divert the beam away from
the transport channel, to be followed by clamping
of the beam through shut-off of the extraction sys-
tem, cutting magnet power to a transport magnet,
or shutting off the ion source . All these will shut
beam off in about 1 to 10 milliseconds, thus deter-
mining the required length of the pulse to the fast
kicker. For the scattering system, the kicker would
not be required to ensure proper safety.
Summary
Design criteria for accelerators for proton or ion
therapy are driven first of all by the clinical
requirements for the treatment fields to be
employed, and then more directly by the technol-
ogy that is employed to obtain these fields namely
the beam delivery system employed . The basic
principle is to best apply the dose localization
characteristics of the charged particles, so one
would want to adopt a beam delivery system that
allows placement of stopping particles in an arbi-
trarily shaped three-dimensional volume, a vol-
umethat corresponds to the most desirable target
as defined by the clinician . This type of field pro-
file can be achieved with a properly designed pas-
sive system, or by different scanning techniques .
Scanning systems place very severe demands
on the accelerator performance. Very fast
response times for feedback systems with large
dynamic ranges are needed to control beam cur-
rent, and great care must be given to safety con-
siderations to detect and shut off beam in the
event of a system irregularity.
Developments have not progressed to the
point where clinicians or physicists can feel com-
pletely comfortable in directly applying scanning
technology in a hospital setting . In the opinion of
the author, the best approach to adopt today is to
specify an accelerator system which will begin its
career treating with a scattering system, but
which will be adaptable to a scanning system
when this technology has progressed to a suitable
level of maturity.
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Pros and Cons of Various Accelerator Types
P MANDRILLON
Introduction
Laboratoire du Cyclotron, Centre Antoine Lacassagne, Nice, France
Improving the quality of radiation therapy by
using new irradiation technologies is one of the
radiotherapist's constant concerns . The use of
accelerators for delivering protons, heavier ions
and secondary beams as neutrons brings further
improvement in dose distribution and in interest-
ing biological properties .
Accelerators have been present in this field
since the early history of radiotherapy and they
could play a major role in the future as part of
hospital-based facilities with specific beam trans-
port and beam delivery systems. Modern acceler-
ator technology exists today to meet all of the
clinical requirements within a reasonable budget .
Various types of dedicated accelerators are
planned or already under construction, but it is
worth mentioning that the physician is not only
concerned with the choice of an accelerator in the
medium energy range but wants a system which
yields the best conformation therapy and a mini-
mum of dose in non-target tissues . These aspects
are closely related when designing the "equip-
ment" for an ion beam treatment facility.
Medical Requirements
The choice of the accelerator for ion beam ther-
apy is strongly dependent on the medical require-
ments which could be summarized as follows :
1. The treatment unit should be installed in a
large hospital in order to make the benefits of
ion beam therapy available to a large number
of cancer patients and to provide the medical
and scientific staff for high level diagnosis and
treatment.
2. The accelerator has to be highly reliable, easy
to operate and eventual repair time should be
short.
3 . The beam delivery system should permit scan-
ning of the beam.
4. Irradiation should be possible from any angle,
e.g ., by a rotating isocentric gantry.
5 . Ion ranges from a minimum of 3 cm to amaxi-
mumof approx . 30 cm are required (this speci-
fication fixes the energy range) .
6. A dose rate of 5 Gray/minute in a 2 liter vol-
ume is necessary which fixes the necessary
intensity (Tab . 1) of the accelerator.
7. Irradiation of 30 x 30 cmzmaximum field size .
Themagnetic rigidity listed in Table 1 fixes the
bending radius of the particles which determines
the size of the accelerator and the beam delivery
system .
Table 1 . Energy, magnetic rigidity and required intensity for
various ions ranging 20 cm in tissue and giving a dose rate of
2.5 Gy min-'
Energy
	
Magnetic rigi- Intensity
dity required
McV/u TIM PPS
p 175 2.00 2x10"
He 175 4.00 5x10 9
C 330 5.67 109
O 400 6.34 7x10 8
Ne 470 6.98 Sx108
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From the energy required and the intensity
needed, it is quite clear that proton machines and
light ion machines will differ in size and cost .
Three kinds of accelerators - cyclotron, linac and
synchrotron - seem feasible for proton therapy,
whereas for light ion therapy the cyclotron is
close to the limit for carbon already and the syn-
chrotron is considered the better choice for
heavier particles . Each of these accelerator types
has its advantages and disadvantages for therapy,
but the beam delivery systems make the deficits
particularly obvious.
The beam delivery system warrants that the
tumor is irradiated in three dimensions . To
achieve this task it requires the following features :
lateral deflection of the beam
variable range
variable exposure time to achieve
uniform radiation doses
position-sensitive monitors
rapid switch-off in case of malfunction
A number of factors affect the choice of the
beam delivery system, including the time struc-
ture, the extracted beam emittances and energy
dispersion of the output beam .
Characteristics of the
Various Accelerator Types
Cyclotrons
Since its early history in Berkeley the cyclotron
has been used for medical purposes . For several
aspects, including simple design and operation,
compactness and high ion intensities, cyclotrons
are good candidates .
Fixed energy makes the design simple . The
magnet can be optimized and trimming coils are
not necessary. The accelerator operates at a fixed
radiofrequency and all the settings of the beam
lines are predetermined . No sophisticated con-
trols are needed . A simple programmable logic
controller (PLC) is sufficient . Operation is easy
and this, in turn, reduces the manpower costs .
The dimensions of a cyclotron can be reduced
by choosing a high magnetic field . But this has
two important consequences : negatively charged
ions cannot be accelerated due to electromagnetic
stripping but superconducting magnets which
have only about half the weight of room tempera-
ture magnets can be considered .
An isochronous cyclotron provides a continu-
ous beam (CW) with ample intensity. This is a key
factor for reliability. The beam intensity is easily
controlled and the beam can be very stable - an
important advantage for a dynamic beam spread-
ing system . To fully benefit from these advantages,
an external injection system should complement
the cyclotron for flexibility. The MEDICYC cy-
clotron [1] in Nice, e.g ., has an axial injection at 33
kV and uses a few volts on the bunching cavity as
feedback control of the extracted beam intensity.
With this approach, a beam stability better than
1% has been achieved ( Fig. 1) .
Acceleration of the particles in the cyclotron
takes only 10-20 [,s . By acting on the injection
process, the beam can rapidly be turned on and
off. It is also possible to set up a dynamic control
of the beam intensity with a fast ionization cham-
ber in the extracted beam as reference . This way,
the beam can be stabilized at any required level
W'beam
16
Fig. 1. MEDICYC intensity fine adjustment cp and control (V)
with response times of less than 100 [ts . This pro-
cess can be fully automatic. A separate safety cir-
cuit has to ensure that misoperation of this servo-
mechanism does not overdose the patient. In case
of failure, the beam of such a system can be
turned off in less than 100 As .
The lateral deflection of the beam for irradiat-
ing large fields can be obtained either by passive
scattering using contoured scatterers [2] or by
active methods using a magnetic field to deflect
the beam. Thepassive method is safe and simple,
but demands higher ion energies to compensate
for the range losses in the scatterer.
At the PSI, a discrete (spot or pixel) scanning
technique [3], has been developed (see also
Chapter 35) . It uses a pencil beam which deposits
individual dose spots and is shifted stepwise by a
kicker magnet located within the gantry.
Recently, Farley [4] has proposed a simple
method for dynamic beam spreading, which
should be easy to implement with a cyclotron (cf.
Fig. 2) . It requires
an upstream modulator for scanning in range
at 50 Hz to spread the beam to a Gaussian spot
a magnet which scans the spot linearly along a
line perpendicular to the axis at a low fre-
quency (typically 1Hz, i.e ., only low power is
needed in the magnet, which can have a small
Fig . 2. A simple dynamic beam spreading mode (according to [4])
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gap because the deflection is only in one
plane),
a motor-driven transport system which moves
the patient steadily at 5 mm/sec (patient col-
limator and bolus move with the patient, too)
This system is said to produce a continuous
scan, called a raster scan, with uniform inten-
sity.
Synchrotrons
A synchrotron produces pulsed beams and the
energy of the extracted beam can be varied from
one cycle to the next in steps of a few MeV
Hence, modulating the Bragg peak to scan a tar-
get in depth can be achieved without absorbers,
avoiding scattering and momentum spread
degradation of the beam.
The weight of the different magnets (dipoles,
quadrupoles) is low. This makes the transport and
assembly easy and reduces the statical conditions
for the building .
Therequired intensities canbe achieved, if the
synchrotron is fed by an adequate injector. Losses
might occur when using the traditional resonant
extraction system, because small perturbations
from variations in the excitation of the magnets
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can induce time-modulations of the extracted
beam intensity. An alternative is a non-resonant
extraction as in H" synchrotrons where charge-
exchange extraction processes are used .
Synchrotrons request rapid magnetic field vari-
ations and operation is more complex than oper-
ating a cyclotron. Moreover, undesired intensity
variations require careful control. Nevertheless,
many sophisticated synchrotrons are running
smoothly for high energy physics applications at a
high reliability level.
The variable energy of a synchrotron is cer-
tainly a strong argument for this kind of acceler-
ator, because it allows to irradiate tumors in dis-
crete slices of equal range (cf . preceding chapter
for more information) . A synchrotron-supported
scanning system can operate approx . twice as fast
as a similar system connected to a CW accelerator
(cyclotron) . This requires, however, more power
in the scanning magnets . The HITAG facility at
GSI, Darmstadt, plans to use such a scanning sys-
tem associated with the slowly extracted beam
from their SIS-synchrotron (cf. Chapter 36 for
more details) .
Linear Accelerators (Linacs)
For proton therapy in the 200 MeV range, linacs
are the third class of possible accelerators . Ambi-
tious extrapolations from electron linac
technology using a high frequency structure, have
been proposed to shorten the length of the accel-
erator tube, thus reducing the costs for a hospital-
based facility.
The output energy of a linac is usually fixed.
But recently an interesting variable energy con-
cept has been proposed which suggests to adjust
the energy by switching on and off the power of
short tank modules in the last section of the linac
structure [5, 6] . Attractive as it seems, this novel
design requires careful optimization of the struc-
ture and detailed calculations of transverse emit-
tances .
Linacs can provide high ion intensities deliv-
ered in shortbeam pulses . This time structure has
important consequences for the beam delivery
system, in particular, for any dynamic beam
spreading device . Discrete spot scanning, is well
suited for a linac. In combination with a system
which varies the output energy, even a three-
dimensional spot scanning with pulse-to-pulse
energy variation should be feasible .
Examples of Dedicated Designs
ACyclotron with
a Room Temperature Magnet
The Belgium industrial company Ion Beam
Applications (cf. Chapter 22 for more details) has
chosen a high field design (2.15 T on the extrac-
tion radius) produced by conventional coils (cf .
Fig. 3 and Tab. 2) . This cyclotron and the associ-
ated gantry will be installed in the coming years in
the new proton therapy facility to be built at Mas-
sachusetts General Hospital in Boston (USA).
Fig. 3. I[3A 235 MeV room temperature cyclotron
Compact Superconducting
Cyclotron Designs
Figure 4 depicts a sketch of a compact supercon-
ducting sector-focused cyclotron for a continuous
beam of 238 MeV protons . It has three spiral sec-
tors with a supplementary groove along the cen-
ter of each sector, making it more like a six-sector
Fig . 4 . The CAVSiemens-238 MeV superconducting
cyclotron
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Miscellaneous
Injection (2 options) axial or radial
(neutral beam
+ central strip
per)
machine, avoiding the well known Vr=3/2 reso-
nance (this technique has been well established
by AGOR, Groningen) . Three RF cavities,
galvanically connected in the central part, are
operating on the third harmonic of the particle
frequency. They provide a high energy gain per
turn, completing the acceleration in about 400
turns. Table 3 summarizes the main characteris-
tics of this design, jointly developed by Siemens
andthe Cyclotron Laboratory of CALin Nice [7].
Blosser and associates [8] of Michigan State
University (USA) have designed a250 MeVfour-
sector compact superconducting cyclotron for
proton therapy. Magnet hills and dees repeat with
90-degree spacing in this design and an internal
ion source produces the protons .
A new 3-sector superconducting isochronous
cyclotron is being designed by the LASA/Milan
and the Cyclotron laboratory of CAL in Nice in
the frame work of the TERA project [9].
Table 2. Basic parameters of the IBA 235 MeV cyclotron Table 3 . Basic parameters of the CAVSiemens-238 MeV
superconducting cyclotron .
Magnet
Number of sectors 4 Magnet
Yoke external diameter 4.30 m Number of sectors 3 resp . 6
Current density in the coil 155 A/cm2 ("pseudo sec-
Total weight 220 tons tors")
Power 200 kW Yoke external diameter 3.10m
Current density in 6 800 A/cm2
RF superconducting coil
Number of dees in opposite valleys 2 Total weight 80 tons
Frequency 107.17 MHz Power including refrigerator 35 kWHarmonic mode 4
Dee voltage injection 60 kV RF
Dee voltage extraction 130 kV Number of dees (galvanically 3
RF power 85 kW connected)
Frequency 110 MHz
Miscellaneous Harmonic mode 3
Injection internal source Dee voltage injection 80 kV
Dee voltage extraction 130 kV
RF power 120 kW
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Booster Cyclotron
The Loma Linda Accelerator -
An Outstanding Example
0
Several neutron therapy centers which apply their
accelerators also for low energy proton therapy
are examining the potential for boosting the pro-
ton energy to the 200 MeVrange.
With minor modifications any cyclotron can
accelerate negatively charged ions . From such a
beam, it is easy to extract neutral particles by a
thin stripper. This beam will have good optical
properties, in particular, a small divergence,
allowing transport over long distances and tra-
versing the magnetic field of a compact supercon-
ducting accelerator. At the appropriate radius,
the neutral beam penetrates a second stripping
foil yielding singly charged protons [10] . An inter-
esting feature is that all commercial cyclotrons for
radioisotope production accelerate negatively
charged ions . They could act as injector for such a
booster (Fig . 5) .
The first high energy proton accelerator built in a
hospital environment is located at Loma Linda,
California . It is a zero-gradient proton synchro-
tron yielding a variable energy beam from 70
MeVup to 250MeV It has eight 45-degree dipole
magnets arranged to four straight sections provid-
5m Fig . 5. Boosting an existing cyclotron
ing space for injection, acceleration and extrac-
tion systems . The 30 keV proton beam from the
duoplasmatron source is injected into a 2 MeV
radiofrequency quadrupole (RFQ) operating at
425 MHz. Acceleration to 250 MeV is achieved
via a simple ferrite-loaded RF cavity operating on
the first harmonic . The beam is extracted from
the synchrotron by using half-integral resonance .
The cycle time is 2, 4 or 8 seconds and the extrac-
tion time is variable between 0.4 and 10 sec. The
design intensity is 1011 protons/sec. This design is a
result of a collaboration between the Loma Linda
University Medical Center, the Fermi National
Laboratory and the Science Applications Interna-
tional Corporation (SAIC) Company.
Compact Synchrotron
Avery compact synchrotron [11] operating with
pulsed high magnetic fields has recently been pre-
sented by the Budker Institute of Nuclear Physics
in Novosibirsk (Russia) . The main parameters are
listed in Table 4. This design is one of three possi-
ble candidates for a compact accelerator studied
by theTERA collaboration in Italy [12] .
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Table 4. Main parameters of a compact synchrotron
designed by the Budker Institute of Nuclear Physics (INP),
Novosibirsk, Russia
Circumference 6.4 m
Max. field in bending magnet 4.0T
Energy range 80-200 MeV
Repetition rate at 200 MeV 1 Hz
Energy consumption 80 kW
MultiTask Synchrotron
The TERA collaboration proposes also a multi-
task synchrotron for its Hadron Therapy Center
which should be able to provide: 250 MeV pro-
tons and light ion beams up to 1608+ with energies
up to 400 MeV/u (Fig . 6) . The concept which has
been proposed by ITEP in Moscow [13] and Ron
L. Martin of ACCTEK Assoc. in the United
States (see also Chapter 22) considers the acceler-
ation of H- which simplifies the extraction, but
requires a low magnetic field and a very good
vacuum in order to avoid electromagnetic strip-
ping of the H--ions .
Ion Therapy Machines
The Heavy Ion Medical Accelerator (HIMAC) in
Chiba, Japan, is the first hospital-based facility in
the world to treat patients with heavy ions . Accel-
erator and facility are described in detail in Chap-
ter 34 . Only one remarkable feature should be
mentioned. This is the fact that it has two syn-
chrotron rings which can be used simultaneously
or alternatingly with the same or with different
ion types.
A synchrotron solution was also studied for
EULIMA, a European initative for a light ion
medical accelerator [14] . It is projected for pulsed
beams with an average intensity of 109 particles/s
and energies ranging from 100-400 MeV/nucleon.
Two possibilities were investigated : a separate
function machine (SFM) of 59 m circumference
which offers more flexibility for developments,
and a combined function machine (CFM) with a
circumference of 48 .6 m, if space is crucial. The
maximum number of injected turns is 20, with an
efficiency close to 50% . An injected intensity of
Table 5. Basic parameters of the EULIMA synchrotrons
SFM
New Linacs
Standing Wave Design
about 2x109 ions was proposed for both machines
using an electron cyclotron resonance (ECR) ion
source feeding a small RFQ linac, followed by a
conventional linac (5 MeV/u) with a repetition
rate of about 1 Hz. Table 5 displays the prelimi-
nary parameters of these designs . The layouts are
depicted in Figure 7.
The use of a conventional S-band standing wave
electron linac structure to accelerate low current
protons up to 250 MeV for proton therapy was
first suggested in 1991 by the California-based
company AccSys Technology [5]. An updated
design considering commercially available RF
power tubes has recently been presented [6] . The
low energy sections, consisting of a RFQ and a
drift tube linac (DTL) operate at 357 MHz. The
main DTL operates at 714 MHz. The 70 MeV
beam from the DTL is injected into a series of
conventional side-coupled linac (SCL) cavities
operating at 2856 MHz. These 10 short tanks can
be turned on and off to vary the proton beam
energy between 70 and 250 MeV
Crandall andWeiss [6] have recently proposed
a compact linac structure consisting of a RFQ
operated at 750 MHz, to accelerate a 80 keVpre-
accelerated beam to 5 MeV a coupled-cavity
DTL operated at 3 GHz to reach 70 MeV and a
General layout
Circumference 59.08 m 48.64m
Length of short straight 1 .50 m 1.50m
sections
Length of long straight sections 4.00 m 3.20 m
Bending radius 4.53 m 5.24m
Lattice:
Qn 1 .67 1.66
Q,,max 1 .76 1.80
pbmax 11 .41 In 7.10 m
p,max 10.97 m 9.44m
D 5 .40 m 3.16 m
A classical linac structure has recently been pro-
posed as a booster for the 62 MeV cyclotron of
the Douglas Centre for Oncology, Clatterbridge,
UK, permitting to implement a high energy pro-
ton therapy program at 200 MeV
Fig . 7 . General layout of the SFM (left) and CFM (right) EULIMA synchrotrons . From [14]
SCL operated at 3 GHz to reach the final 200
MeV
Traveling Wave Design
Based on an electron linac structure using short
wavelength (3 GHz instead of the traditional 200
MHz for a proton linac), anew geometry acceler-
ating in traveling wave mode has been proposed
byD. Tronc [15] . This mode removes the coupling
cells and permits simultaneous acceleration and
focusing . But the focusing problems need to be
further investigated andthe author suggests a test
to confirm the results of the simulations .
Booster Linac
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Conclusions
Designing a cost-effective accelerator which is
easy to install in a hospital and simple to operate
is a challenge to the accelerator community. An
important factor to reduce the total cost of such a
facility is certainly a small footprint of the acceler-
ator, its associated switchyard and gantries . Com-
pactness will, therefore, be one of the crucial
demands for anynewdesign, be it linac, cyclotron
or synchrotron.
In the coming years new medical experience
with high energy charged particles will be avail-
able, e.g ., from two dedicated, hospital-based
proton accelerators (the synchrotron in Loma
Linda and a cyclotron at MGH) and the dedi-
cated HIMAC facility in Japan. They will soon
have treated a large number of patients and will
gain experience with new technical develop-
ments. The work of these and other users will
very likely yield new insights as to the pros and
cons of synchrotrons and cyclotrons and will facil-
itate the task to tailor the next generation of med-
ical accelerators .
190
	
P. Mandrillon
References
1 Mandrillon, P, Farley, E, Brassart, N., Herault, J.,
Susini, A., and Ostojic, R. Commissioning and imple-
mentation of the MEDICYC cyclotron programme, in
Proc . 12th Int . Conf. on Cyclotrons and their Applica-
tions, Berlin, May, 1989, pp . 156-159.
2 Gottschalk, B. and Wagner, M.S . Contoured scatterer
for proton dose flattening . Harvard Cyclotron Labora-
tory, Internal Report 3/29/89, 1989 .
3 Pedroni, E., Bacher, R., Blattmann, H., Boehringer,
T, Coray, A., Egger, E., Phillips, M., and Scheib, S.
The 200 MeV proton therapy project at PSI: A status
report, in Proc . Int. Heavy Particle Therapy Workshop,
Blattmann, H. (ed.), PSI-Report 69, pp . 1-8.
4 Farley, F Supertwist gantry and dynamic beam spread-
ing. Presented at PTCOG XIX, October 31-November
2, 1993, Cambridge, USA.
5 Hamm, R.W, Crandall K.R., and Potter, J.M . Prelimi-
nary design of a dedicated proton therapy linac, in
Proc. of the IEEE Particle Accel. Conf . San Francisco,
May 6-9, 1991, pp . 2583-2585.
6 Crandall, K. and Weiss, M. Preliminary design of a
compact Linac for TERA, July 1994, TERA Internal
note .
7 Mandrillon, P, Farley, F, Fi6tier, N., Tang, J.Y,
Anton, F, and Savoy, R. A compact facility for high-
energy proton therapy based on a superconducting cy-
clotron, in Proc. of EPAC 94, June 27-July 1, 1994, Sul-
ler, V and Petit-Jean-Genaz, Ch . (eds .), London,
World Scientific, Singapore, pp . 2604-2606.
8 Blosser, H.G. Proposal for manufacturing a prototype
superconducting cyclotron for advanced cancer ther-
apy. NSCL-MSU, February 1993 .
9 Acerbi, E., Alessandria, F, Bellomo, G., Birattari, C.,
Castiglioni, M., De Martinis, C., Fidtier, N., Giove,
D., Mandrillon, P, and Sorbi, M., Preliminary results
on the superconducting cyclotron, Internal Report
TERA 94/36 ACC 21, October 1994 .
10 Mandrillon, P and Farley, R Cyclotrons as booster for
high energy proton therapy. To be published .
11 Averbukh, I., Bayanov, B., Below, V., Chernyakin, A.,
Jull, I., Karasyuk, V, Marusov, V, Palchikov, V.,
Ruvinsky, S., Silvestrov, G., Sokolova, S., Vechesla-
vova, G., Volokhov, V, Vsevolozhskaya, T., and Wille-
wald, G. Status of compact proton therapy facility pro-
ject . Presented at EPAC 94, London, June 27-July 1,
1994 .
12 Amaldi, U. and Silari, M. (eds.)TheTERAproject and
the Center for Oncological Hadrontherapy. INFN-
LNF-SIS Ufficio Pubblicazioni, Frascati, Italy,1994 .
13 Khoroshkov, VS., Onosovsky, K.K ., Breev, VM., Gol-
din, L.L ., Kleinbock, YL., Lomanov, M.F, Lyulevitch,
VI., Vorontsov, I .A ., Klenov, G.I ., Rybalko, VS., and
Ivanov Yu .S . Soviet Project of PTE Proc. of the NIRS
Int . Workshop on Heavy Charged Particle Therapy and
Related Subjects, Chiba, Japan, July 4-5, 1991, pp .
204-212.
14 Mandrillon, P, Carli, C., Farley, F , Fietier, N., Ostojic,
R., Pinardi, M., Postiau, N., Rocher, C., Ryckewaert,
G., and Tang, J.Y. Feasibilities studies of the EULIMA
light ion medical accelerator. Proc . EPAC 92, Berlin,
March 24-28, 1992, pp . 179-184.
15 Tronc, D. Compact proton therapy unit predesign .
Proc. of the IEEE Part . Accel. Conf., Washington,
D.C ., May 17-20, 1993, p.1768 .
21
	
Shielding and Radioprotection
Introduction
J . V. SIEBERS
Loma Linda University Medical Center, Loma Linda, CA, USA
The health physics concerns for ion beam therapy
include the challenges present at both conven-
tional radiation therapy facilities and nuclear
physics facilities . Like the conventional radiation
therapy facility, ion beam therapy facilities must
allow access to an uncontrolled population, thus
radiation shielding must lower dose levels suffi-
cient for general population occupancy. Similar to
the nuclear physics facilities, high energy second-
ary neutron fluences exist which have large atten-
uation lengths andmust be protected against. The
limited and expensive space available in hospital
locations make construction of adequate, yet
cost-effective shielding an important feature of
facility design .
The primary radioprotection concerns for
biomedical particle accelerators are shielding
from the high energy neutrons produced by inter-
actions of the primary protons with the acceler-
ator, beam line, and ultimately the patient. The
shielding situation is complicated by the need for
convenient, prompt patient access, requiring
effective design of mazes or labyrinths . As well as
radioprotection against the prompt radiation haz-
ard produced by the beam, particle energies are
sufficient to produce a residual radiation hazard
from radioactivation of beam line components .
This exposure also must be limited.
The methods used to determine the shielding
requirements for ion beam therapy are similar to
those used for conventional radiation therapy.
Shielding must reduce dose levels below limits set
by governing bodies, usually following the recom-
mendations of the ICRU. In determining the
shielding, use factors, transmission factors, and
other room/facility-dependent factors may be
taken into account. The difficulties for ion beam
therapy arise from the fact that the source term is
not typically limited to the treatment head and
patient as in conventional therapy, but instead
results from a largely distributed source consist-
ing of the accelerator, beam transport system, the
treatment head, and the patient.
This chapter will cover the radiation protec-
tion concerns for ion beam therapy facilities, with
principle emphasis on shielding from the second-
ary neutrons . An introduction to shielding
methodology is given, a discussion of shielding
materials, as well as a review of attenuation
parameter measurements and calculations . As
rapid entry to patients in treatment rooms is par-
ticular to therapy, design of hallways is also dis-
cussed . Performance of facility design calcula-
tions is discussed, as well as a section on radioac-
tivation of beam line components .
Shielding Basics
The neutrons produced by ion beam bombard-
ment of materials have a large angular depen-
dence and a broad energy spectrum . Calculated
energy spectra for 230MeVproton bombardment
of a Fe target are shown in Figure 1 for several
angular intervals [1] . Such spectra must be
shielded against for personnel protection .
The dose-equivalent fall-off in shielding mate-
rial from a point source of neutron production is
expressed as
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Fig . 1 . Neutron spectra produced by 230 MeV proton bom-
bardment of a stopping length iron target. Spectra were cal-
culated using the computer code LAHET by Siebers [1 ]
H(t,0) = Ho(E) eRe)
with H(t,0) being the dose-equivalent at depth t
in the shielding at angle O with respect to the
incident beam direction, H.(O) the dose-
equivalent at angle O extrapolated to zero shield
depth, r the distance from the target material to
the point of interest, and X(O) the attenuation
length . An equivalent expression exists for the
absorbed dose attenuation with H(t,0) and
HO(O) being replaced with D(t,E)) and D,)(19),
respectively. The attenuation length for absorbed
dose may differ from the dose-equivalent atten-
uation length due to the energy dependence of
the neutron radiation quality factor and the
changing neutron spectrum with shield depth .
Using Equation [1], the thickness t of shielding
required at angle O to reduce the dose rate to a
value of H (Sv/h) from a location where N (pro-
tons/h) interact with a target material, with a dis-
tance between the source and the shielding wall
entrance of 1, can be determined :
t
H = H.(O) N/(t + 1)2 eX()
The shield thickness t can then be solved for using
computer methods . Oneonly requires knowledge
of X(O) and H.(O) for the beam species, energy,
and target combination . Unfortunately, even
given the broad experience with particle accelera-
tors in the therapy energy range, the values of
X(O) and H.(O) are still highly uncertain.
A number of variables are involved in deter-
mination of shielding attenuation parameters,
X(O) and H.(O), including incident beam type,
incident beam energy, target material, target
geometry, angle of interest, and shielding com-
position . Direct measurements of the attenuation
properties of a bulk shielding material provide
the most accurate determination of attenuation
parameters for that shielding material . However,
due to the number of variables involved, one can
rarely directly apply measurement results to the
shield design . One must, therefore, rely signifi-
cantly on calculations of the shield attenuation
properties . This requires detailed knowledge of
the atomic and nuclear interactions produced by
the secondary neutrons andphotons in the shield-
ing material, and the transport of these second-
aries through the shield . This may be completed
through use of Monte Carlo techniques or
through solution of the Boltzmann transport
equation .
Shield Materials
For the neutron shielding for medical accelerator
applications, shielding material choices are typi-
cally limited to concrete, loaded or heavy con-
crete, earth, and steel. Other materials, including
polyethylene, water, and lead are occasionally
used, however, the cost of supporting these mate-
rials or the bulk material cost itself results in
minimization of their use.
Concrete is most often used as a shielding
material since it is an inexpensive, structurally
sound, easy to use material with good nuclear
properties . The silicon and calcium have suffi-
ciently large inelastic neutron cross sections
above 20 MeV to attenuate the high energy flu-
ence, while the large hydrogen content from
bound water provides an effective means for
slowing down neutrons below afew MeV Being a
mixture of a stone aggregate, sand, and acement-
ing agent, the properties of concrete can vary sig-
nificantly. Bulk densities of concrete typically fall
in the range of 2200-2300 kghn3, but selection of
special aggregates increases it from 1300-4800 kg/
m3 [2] . The variability in bulk density between
batches of concrete made from the same plant or
in the same locality is usually within acceptable
limits for shielding applications .
The use of concrete as shielding material has
been explored greatly for the use in nuclear reac-
tor shield designs where low energy neutrons
dominate the spectra [2] . In reactor applications,
the effect of water content in concrete on the
neutron spectrum below 1 MeV is dramatic, with
a decrease in the water content by 1/3 resulting in
an increase in neutron leakage by a factor of 3.
Similarly, variation in the water content of high
energy neutron shielding modifies the low energy
neutron spectrum . However, since attenuation
lengths in shields for ion beam facilities are dic-
tated by the inelastic interactions of the high
energy neutrons [3, 4], the bulk shield density is
of primary importance and the hydrogen content
only determines the shape of the lowenergy equi-
librium spectrum . Conversion between types of
concrete with different aggregates can typically
be accomplished by expressing the shield thick-
ness in terms of the mass-thickness (kg/m2) .
Radiation therapy installations are typically
based below ground level to take advantage of
the shielding provided by the surrounding earth
on at least a single wall, and typically located in a
corner to gain the shielding advantage from two
walls. On other walls, the containment required
for earth shielding usually limits the shielding
material use to concrete .
With the primary interaction mechanism for
high energy neutrons being inelastic interactions
and only the bulk density of the shielding mate-
rial being of primary importance, use of a high
density material such as steel is useful in the
design of compact radiation shields. Below the
threshold for inelastic interactions in steel (600
keV), few mechanisms exist for further neutron
energy loss, since energy degradation by elastic
interactions with iron atoms in steel is highly
inefficient. To be effective, high Z (atomic num-
ber) shielding must be followed by 0.5-1 m of
concrete to remove the low energy neutron com-
ponent .
As concrete is the most widely used shielding
material for attenuation of secondary neutrons
produced in target materials, discussion will be
limited to this material .
Attenuation Parameters
Measurements
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To measure the attenuation properties of con-
crete, absorbed dose and dose-equivalent values
are measured as a function of depth in the mate-
rial . Preferably, agood geometry situation, with a
semi-infinite planar secondary fluence incident
upon a semi-infinite planar shield, or a spherical
geometry with a point source located in the cen-
ter of a sphere of shielding material is used . Dose
and/or dose-equivalent are then measured as a
function of depth and angle in the shield. The
resultant measured dose values at a given angle in
the shield are then fit with Equation (1) to pro-
vide the effective source term and attenuation
length . These values can then be used in facility
shielding calculations .
Few measurements of attenuation properties
of concrete have been made in the therapy energy
range. Recently, attenuation parameters have
been measured for 230 MeV protons impinging
upon Fe, Al, and Pb target materials. Dose and
dose-equivalent were measured as a function of
concrete depth at angles of 0°, 22°, 45°, and 90°.
Results of these measurements are displayed in
Figure 2 for the Al and Pb target materials . The
Fe target results are similar to the Al and Pb
results. Minimal differences in the dose values
exist for different target materials at depths
greater than 1100 kg/m . This suggests that high
energy neutron production is target material
independent, as would be expected for direct
interactions between the incident protons and
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Fig. 2 . Dose-equivalent values measured for 230 MeV
bombardment of stopping length AI (open symbols) and Pb
targets (filled symbols) as a function of depth in a concrete
shield
neutrons bound in the target nuclei [1, 5, 6] . The
result of this is that for deep shielding penetra-
tions, attenuation parameters of the concrete are
target material independent . At depths less than
1100 kg/m', the dose and dose-equivalent con-
tributions from low energy neutrons vary strongly
with the target Z, due to the strong target mate-
rial dependence of low energy neutron produc-
tion . At depth in the shield, this component is
attenuated away, leaving only the equilibrium
neutron spectra produced by the high energy
neutrons .
Absorbed dose and dose-equivalent attenua-
tion parameters for concrete were determined by
fitting the Al, Fe, andPb data to Equation (1) . As
similar results were found for each target mate-
rial, results for all targets were combined and fit
to a common curve. These target-independent
results for 230 MeV proton bombardment are
listed in Table 1. The attenuation length and pro-
duction term decrease with increasing angle . For
shielding design of a 230 MeV proton facility,
these results could be used directly, for any target
material . Design at other energies requires either
additional measurements or calculations .
Table 1 . Measured and calculated absorbed dose (Da) and formed using the Monte Carlo code LCS for a fit to concrete
dose-equivalent (H o) attenuation parameters for 230 MeV depth ranging from 1000-4000 kg/m2 in each angular inter-
protons impinging upon Fe. The calculations were per- val
Angle
Experiment
(10,15 Crym2/p)
7t
(kg/m')
Angle
Calculation
Da
(10-150yma/p)
h
(kg/m2)
0 ° 1.12 ± 0.08 860 ± 21 0°-10 0 1 .36 ± 0.06 1013 ± 24
10 °-30 ° 1.05 ± 0.03 1043 ± 19
45 ° 0.27 ± 0.05 700 ± 50 30°-60° 0.506 ±0.025 867 ± 19
90 0 0.077 ± 0 .010 532 ± 20 60°-120 0 0.212 t 0.026 600 ± 21
120 °-180° 0.204 ± 0.026 436 ± 15
Angle Ha x Angle H o 1.
(10-"svm2/p) (kg/ma) (10-1sS z/P) (kg/ma)
0 0 7.8±0.5 891±18 0°-10° 13.2±0.8 991±28
22 ° 4.2 ± 0.5 860 ± 30 10°-30° 10.0 ± 0.4 1040 ± 21
45 ° 2.2 ± 0.5 730 ± 60 40 °-50 0 4.58 ± 0.24 895 ± 21
90 0 0.76 ± 0.07 519 ± 15 85 °-95 ° 2.0 ± 03 534 ± 26
Calculations
Shielding attenuation parameters are calculated
using a variety of methods . Each method starts
with an estimation or determination of the spec-
trum of secondary particles (neutrons) produced
by ion beam bombardment of the target material .
This could be through neutron spectrum measure-
ments, however, neutron spectrum calculations
are typically used . The neutron spectra are then
either convolved with monoenergetic neutron
attenuation data to determine the attenuation
parameters, or are transported into a geometry,
where the dose or dose-equivalent is determined
as a function of shield depth. Similar to the mea-
surement case, these dose values as a function of
depth and angle are then fit to determine the
attenuation parameters.
The calculation methods used to transport
incident spectra into shielding material can be
divided into two categories, discrete ordinates
and Monte Carlo techniques . In discrete ordi-
nates calculations, the neutron spectrum in a given
angular interval is broken up into several energy
groups . The transport of neutrons from one group
to another progresses as the neutrons progress
through the shield, approximating a solution to
the Boltzmann transport equation . Examples of
discrete ordinates codes are ANISN, TORT, and
TWO-DANT [7-9] .
In the Monte Carlo technique, primary and
secondary interaction products are stochastically
transported through the shielding media. The
computation of interaction probabilities is based
upon either measured or calculated cross-
sections . Resultant interaction products deter-
mined using the cross-section information are
then transported further through the specified
shielding geometry. Due to the stochastic nature
of the Monte Carlo technique, a large number of
initial particles incident upon the target material
must be used to get sufficient statistics . This typi-
cally takes considerable computing resources.
Examples of Monte Carlo codes useful for ion
beam shielding design are HETC, LCS, and
FLUKA [10-12] .
Table 2 lists attenuation parameters of con-
crete for protons at several energies and angular
regions for several recent calculations . Several
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Table 2. Attenuation parameters for concrete from cal-
culations by several authors (see ref. [5, 6, 17-191)
195
other shielding calculations have been completed
[13-15], however, the tabulated results represent
recent values . In Hagan's calculations, the High
Energy Transport Code (HETC) was used to
computethe secondary neutron source term . This
was followed by transport calculations using the
discrete ordinates code ANISN to determine the
dose-equivalent at depth in the shield . Siebers
used the LAHETCode System (LCS), a LosAla-
mos revision version of the HETC code coupled
with MCNP, alow energy neutron transport code,
to compute both the secondary neutron produc-
rergy
Wev)
Hagan et
150
Angle
al ., Fe target
0°-15°
Ho
(10-'Sve/p)
7.9
(kg/e)
910
150 5'-30° 5.3 870
150 30'-45' 2.3 810
150 45°-60° 0.87 770
150 60'--90' 0.20 720
150 90'-180' 0.0086 740
200 0'-15' 15 1020
200 15'-30' 10 980
200 30'-45' 3.9 970
200 5'-60' 1 .5 870
200 600-90' 0.49 790
200 90'-180' 0.05 710
250 0'-15' 23 1090
250 15'-30' 16 1050
250 30'-45' 7.3 990
250 45'-60' 3 .1 920
250 60'-90' 0.87 870
250 90'-180' 0.11 770
Siebers, Fe target
230 0'-10' 13.2±0.8 991±28
230 10'-30' 10 .0 ± 0.4 1040 ± 21
230 40'-50' 4.58 ± 0.24 895 ± 21
230 85'-95' 2.0±0.3 534±26
Braid/IAEA, Cu target
50 0'-30' 1 .4 470
50 90' 0.18 320
100 0'-30' 1 .8 770
100 90' 0.48 460
200 0'-30' 7.4 880
200 90° 1.3 690
230 0'-30' 8.7 925
230 90' 1.6 731
300 0'-30' 12 1010
300 90' 2.3 810
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tion and to transport the secondaries into the
shielding material. IAEA used Braid's method to
determine the secondary neutron production by
integrating thin target neutron production over
the proton slowing down spectrum. The neutron
spectra were then convolved with monoenergetic
neutron attenuation data to determine the dose-
equivalent attenuation parameters .
The similarity of the calculated attenuation
parameters in Table 2 is initially striking . How-
ever, the target secondary neutron production
used as the input for all of these calculations is
based on the Bertini intranuclear cascade model
(INC), as embodied in either the HETC or an
analytical representation based upon HETC
results [10, 16] . In the INC model, particle-
nucleus interactions are treated as a series of two-
body collisions in the nucleus . Resulting collision
products are determined based upon theoretical
and experimental particle-particle total and dif-
ferential cross-section data . The same cross-
sectional data were used for all source calcula-
tions, resulting in the same approximate source
term for each calculation . Since the source term is
similar in all of the calculations, the similarity in
the resultant attenuation results is not surprising .
The applicability of calculation models can be
determined by a direct intercomparison between
shielding measurements and the calculations per-
formed with similar source, material, and geome-
try conditions. Such a comparison has recently
been completed [1, 17] . The calculations very
nearly modelled the measurement geometry, with
a stopping-length Fe target surrounded by a 1 rn
air sphere, followed by a 5 m diameter concrete
shielding sphere . The solid spherical concrete
shield was divided into concentric spherical shells
for scoring the neutron and photon fluence as a
function of depth in the concrete shield . Dose
and dose-equivalent were computed by multiply-
ing the fluenes by fluence-to-dose conversion
factors. The values in a given angular bin as a
function of depth were then fit with Equation (1)
to determine the attenuation length and the
source term Resultant values listed in Table 1 are
for fits on the calculated and measured data over
the same shielding depth intervals . Choice of
depth interval in the fitting process is important
since the neutron spectrum hardens with increas-
ing shield penetration, resulting in larger attenua-
tion lengths . The LAHETbased Monte Carlo cal-
culation predicts the measured dose and dose-
equivalent in the shield with fair accuracy. Atten-
uation lengths are slightly overestimated in the
forward direction, but overall agreementbetween
the measured and calculated values are quite
good .
A compilation of attenuation lengths and pro-
duction terms for forward and lateral shielding as
a function of incident proton beam energy is dis-
played in Figures 3 and 4. In these figures, the
open symbols are for the forward direction while
the closed symbols are for lateral shielding. Also
plotted are the curves suggested by IAEA-report
number 283 [18] and Braid et al . [19] for forward
and lateral shielding. In these graphs, no correc-
tions for target material differences were made
since measurements indicate that these differ-
5
a
0
b
1200
N1000
800
600
400
200
0
0 50 100 150 200 250 300 350 400 450
Incident Proton Energy
Fig . 3 . Attenuation length as a function of incident proton
energy for forward (open symbols) and lateral shielding
(filled symbols) . The curves indicate the values recom-
mended in IAEA report 283 [18), with the dashed line for
forward directed neutrons and the solid line for lateral
neutron shielding
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Fig . 4. Secondary neutron dose-equivalent production
term as a function of incident proton energy for forward
(open symbols) and lateral shielding (filled symbols) . The
curves indicate the values recommended in IAEA report 283
[18] . The dashed line is for the forward directed neutrons
and the solid line for lateral directed neutrons
ences are minimal for large shielding penetra-
tions. Overall, agreement between the IAEA/
Braid-recommended curve and the measured val-
ues are substantial, with the measured values at
230 MeVonly being slightly below the curves .
Alternative Calculation Methods
All calculation methods covered to this point
have used calculations for both the source and the
transport. As measured neutron spectra are now
available for a number of proton energies inci-
dent upon a number of targets [20-27], these
spectra can be used as input to either the discrete
ordinates or the Monte Carlo calculations . The
resultant attenuation parameters calculated
would then at least have the right source term .
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Hallways, Mazes, Ducts
In addition to the shielding material required for
the walls, floors, and roofs of ion beam therapy
facilities, access to irradiation areas must be
allowed for both measurement devices and the
patient by means of hallways and ducts. Whileuse
of a thick shielding door similar to those in use at
many nuclear physics installations eliminates the
need for a special maze to reduce the neutron flu-
ence, the need for rapid patient access during
irradiation procedures necessitates their use.
Mazes in ion beam treatment facilities typically
must have a large cross-sectional area, sufficient
to allow a patient gurney or bed to enter the treat-
ment room .
Due to the high penetrability of material and
low reflectivity (albedo) of neutrons above 20
MeV, only neutrons produced below 20 MeV
need to be considered in maze transmission prob-
lems . Measurements of maze transmission are
made using activation foils, plastic scintillators,
or other neutron-sensitive instrumentation. Sev-
eral calculation codes exist for determining maze
transmission, including AMC, SAM-CE, ZEUS,
as well as the traditional Monte Carlo codes
MORSE, HETC and LCS [10, 28-31] . All of
them follow the secondaries through the various
legs of the maze . In general, the calculation
schemes do a good job in predicting the maze
transmission and estimate the dose within a factor
of two [32, 33] .
General conclusions from maze measurements
and calculations show:
1. Typical mazes will have at least two 90-degree
angles requiring at least two bounces for the
neutrons to escape the area.
2. The high energy component of the neutron
spectra falls off more quickly than the low
energy portion, with the energy spectra rap-
idly falling off with 1/E.
3. The neutron spectra intensity in the first leg of
the maze follows an inverse square fall-off,
while the dose fall-off in higher order legs
(2 and greater) follows a sum of exponentials,
with the source term requiring re-evaluation at
the end of each leg.
198
	
1.V. Siebers
Due to their small cross-sectional areas, duct
calculations are typically more straight forward
than maze calculations . Ducts are small access
locations (30 cm or less) that allow entry of wires/
cables, water, air and power into the radiation
area . Again, duct calculations are understood
from the experience in reactor design . Generally,
the flux attenuation in a circular duct can be
taken to be d2/(8L2) (d = diameter, L = Length).
For bends in the duct near 90°, an additional
attenuation proportional to csc (O) due to the
reflected neutron fluence is utilized . Rectangular
ducts are typically estimated by use of circular
ducts with the same cross-sectional area . Duct
calculations usually assume the duct is empty, yet
in reality, the duct is typically filled with some
material thereby reducing the duct transmission
through attenuation. For safety sake, mazes and
ducts should not point directly at a source of sec-
ondary neutrons, nor at areas occupied by per-
sonnel .
Actual Shielding Calculations
In determining the shielding required for a given
area of the facility, estimations of the locations of
the beam losses, the dose limits, and the esti-
mated type and duration of occupancy of each
location must be determined . Once these pa-
rameters are known, a shielding code that con-
volves the various sources with production and
attenuation terms over the desired geometry can
then be used to determine the shielding . These
calculations can be performed in a manner similar
to calculations that are performed for conven-
tional radiotherapy installations . An example of
such a code is PTF-shield developed for a shield-
ing study for the University of California-Davis
Medical Center Proton Therapy Facility [33] .
Several facility design criteria do greatly affect
the shielding design . For a given beam energy and
shielding material, the shielding attenuation
lengths and source terms per proton are inde-
pendent of the acceleration technique . The beam
losses, however, depend significantly on the beam
line design and the acceleration technique. For
example, if a 250 MeV proton cyclotron is used
for therapy with less penetrating beams obtained
by slowing the beam down in an absorber, then
shielding must exist to shield against the neutrons
produced in the energy degrader. For a synchro-
tron, however, the acceleration energy can be
changed to produce lower penetrating beams,
eliminating this source of neutron production .
Similarly, the type of beam delivery system
affects the neutron source term . For passive scat-
tering systems, proton energy lost in the scat-
terers results in neutron production, With only
30-50% of the beam in the useful patient field,
the residual 50-70% of the beam is stopped in
apertures and collimators, resulting in significant
neutron production . With active scanning tech-
niques (raster or voxel scanning), both the neu-
tron production in the scattering system is
avoided and the beam-use efficiency is greater
resulting in lower neutron production . These
examples show that the acceleration techniques
and the choice of the beam delivery system
greatly affect the production of secondaries that
must be shielded from .
Due to the uncertainty in patient loads, field
types, irradiation angles, beam energies, and
beam loss locations, estimations of the quantity
of secondary radiation that must be shielded
against may be the single most uncertain part of
facility shielding calculations . As with any shield-
ing design, adequate safety factors must be built
into the design to account for errors in values
used in the calculations and to account for possi-
ble future increased secondary production due to
use changes and equipment upgrades . Further-
more, one must forecast as to what the dose limits
will be in the future and ensure that the facility is
adequately shielded . For example, adjustments in
the radiation quality factor for the secondary
neutron radiation must be taken into account.
The neutron quality factor, as determined from
fluence to dose-equivalent conversion factors,
was recommended to be doubled by the ICRU in
1987 . This change has not promulgated through to
regulations in many countries, however, is likely
to do so in the near future . This alone causes a
factor of two uncertainty in the source term .
Shielding Verification
Shielding verification is the process, after a facil-
ity is constructed, of ensuring the dose levels out-
side the shield are within acceptable limits . Two
classes of verification measurements are custom-
arily required :
1 . Commissioning measurements : these include
measurements of the dose/dose-equivalent at
sites of interest for given test conditions which
are needed for obtaining use permits . These
measurements are often done with active do-
simeters (Bonner Spheres, Long Counters,
scintillators, or gas proportional counters) .
While these measurements do provide reassur-
ance that the shielding is adequate, they do not
reveal the dose levels for long-term exposure
for the use conditions that the area is under.
2 . Long-term verification measurements : these
measurements are typically made with inte-
grating type dosimeters (TLDs, film, track
etch dosimeters) over long periods of time .
These will give dose profiles at locations with
the dose averaged out over periods ofmonths .
Often, an energy correction must be made to
the response of both active and integrating do-
simeters to correct for the high energy compo-
nent of the neutron spectrum (>10 MeV), for
which the response of most detectors is signifi-
cantly suppressed . Unfortunately, commercial
instrumentation that responds adequately to high
energy neutron spectra is virtually non-existent.
Use of a tissue-equivalent proportional counter
(TEPC) and analyzing the event size spectra to
determine both the absorbed dose and radiation
quality is tedious, however, provides accurate
results .
Activation
Following termination of beam delivery, residual
radiation is present in beam delivery areas due to
the activation of items the beam intercepts . This
includes the beam line components such as detec-
tors and beam collimators, as well as patient aper-
tures, patient compensators, and the patient .
Fixed objects located in the beam line typically
are activated to the highest levels, however, since
these components are rarely accessed, and then
only by trained personnel, the exposure hazards
are minimal . Items between twice the back-
ground but less than 0.1 mSv/h 30 cm from the
surface must be handled as radioactive material .
Items that exceed an exposure of 0.1 mSv/h 30 cm
from the surface must be handled by qualified
personnel . Items producing excessive exposure
can usually be allowed to decay before handling,
with half-lives of components typically being less
than 3 hours .
For the most part in ion beam therapy facil-
ities, activation of removable beam line compo-
nents (patient apertures and compensators) is
minimal due to the low beam currents and short
irradiation times, however, in facilities where
high beam currents and long irradiation times are
used, activation may be a significant concern . As
usual, personnel should be trained in the impor-
tance of using time and distance as primary meth-
ods of reducing radiation exposure .
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P COHILIS
Introduction
Commercial Concepts for
Ion Beam Therapy Facilities
Ion Beam Applications (IBA) s.a ., Louvain-la-Neuve, Belgium
There are only a few centers around the world
offering a treatment of tumors based on ion beam
irradiation, and in fact most of them propose only
proton therapy. Proton therapy is, indeed, the
only ion beam therapy technique which is begin-
ning to be used on a nearly routine basis. For
therapy with heavier ions only limited clinical
experience is available and research and feasibil-
ity studies still have to be done. Therefore, this
chapter will concentrate on commercial concepts
for proton therapy facilities .
Most of the centers offering the possibility of
treating tumors with proton beams use equipment
initially designed for nuclear physics research . In
fact, the development of proton therapy as a clin-
ical tool has been hampered by the complexity,
the size and the cost of proton therapy facilities .
Indeed, to be medically effective, protons require
high energy accelerators not adapted, in the past,
to the hospital environment. Pioneering institu-
tions had to work with complex and inadequate
equipment .
Today things are changing . A number of spe-
cialists and commercial companies are proposing,
or working on, systems specially dedicated to
proton therapy. The objective is, or should be, to
meet all the clinical specifications of a state-of-
the-art proton therapy facility in the most simple,
reliable and cost-effective manner.
One of these specially dedicated facilities is
already in use, at the Radiation Oncology
Department of the Loma Linda University Med-
ical Center (LLUMC), Loma Linda, California,
USA, since the end of 1990 [1] . Another one, the
Northeast Proton Therapy Center is under con-
struction at the Massachusetts General Hospital
(MGH), in Boston, Massachusetts, USA. Opera-
tion of the NPTC is scheduled to begin in 1998
[2]. These two facilities were proposed by two dif-
ferent companies or groups of companies and are
based on different concepts, particulary, from the
point of the accelerator design . Both will be pre-
sented in the next paragraphs, together with a
description of a few conceptual systems which
have not yet been implemented commercially.
It should be noted that the various systems
may differ because of different concepts regard-
ing the gantries, the nozzles, the patient position-
ers or the safety and control systems for example.
However, the concept proposed for proton accel-
eration is probably the one which best distin-
guishes individual systems from each other. This
concept may have important consequences
regarding beam performance, cost, power con-
sumption, and complexity to name a few. There-
fore, the type of accelerator used for proton
acceleration will be a key concept for classifica-
tion .
Design Requirements
Any design of a proton therapy equipment should
take into account all ofthe following concepts [1] :
- Simplicity. In contrast to what is frequently the
case for nuclear physics research, the equipment
designed for routine in-hospital use should be
easy-to-operate and automated (as much as pos-
sible push-button operation, automatic tuning,
control systems with friendly interfaces) . The
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need of a team of several engineers and techni-
cians to start-up the machine during several
hours each morning is certainly not compatible
with the objectives of a proton therapy center!
Reliability. Excessive downtime can compro-
mise patient safety and convenience, and
affects the cost of the treatment because it
reduces patient throughput and requires main-
tenance specialists and/or a large inventory of
spare parts.
Safety. The safety of the patient and personnel
is paramount. Each component of the equip-
ment and the beam characteristics at strategic
points must be monitored and configured cor-
rectly before the safety system allows the beam
to enter the treatment zone .
Flexibility. As much as possible, the design
should be adaptable to changing concepts and
ideas, especially in the treatment zone .
Cost . This is strongly related to other concepts,
such as simplicity and reliability, for example.
The simpler and more reliable the system is,
the higher the patient throughput andthe lower
the operating and maintenance costs will be . A
judicious arrangement location of the different
rooms composing the facility can also help to
reduce the costs.
State of the art clinical specifications . Arecent
paper [2] defines what is required of a state of
the art facility. These specifications concern,
e.g ., the range in the patient, the range
modulation and adjustment, the average dose
rate, the field size, the dose uniformity, the dis-
tal dose fall-off and the lateral penumbra. The
design which meets these requirements best
will be the state of the art in proton therapy.
Description of Commercially
Available Turnkey Systems
A Synchrotron-Based Proton Therapy
System
The proton therapy system at Loma Linda is of
this type . It was jointly built by a team of the
Fermi National Accelerator Laboratory in Chi-
cago, Illinois, the Loma Linda University Med-
ical Center, the Lawrence Berkeley Laboratory
and SAIC (Science Applications International
Corporation), a private company based in San
Diego. As the Loma Linda University Medical
Center system is already described in another
chapter of this book (see Chapter 33), we will not
discuss it here . Instead, the paragraph on concep-
tual systems will present a design for a "next gen-
eration" of synchroton-based proton therapy
equipment.
A Cyclotron-Based Proton Therapy System
The Northeast Proton Therapy Center at the
Massachusetts General Hospital in Boston, USA,
will be equipped with a cyclotron-based proton
therapy system custom-designed for in-hospital
operation . The equipment is under construction
and will be ready by 1998 . It is a complete turnkey
therapy center based on a compact, automated,
high-energy cyclotron and isocentric gantries . It
is fabricated by IBA (Ion Beam Application s. a.,
Belgium) and a number of subcontractors, for
example General Atomics in the USA and Sumi-
tomo Heavy Industries in Japan.
The basic configuration of the IBA proton
therapy system comprises the following elements :
A 235-MeV isochronous cyclotron, able to
deliver beams of up to 1.5 [,A, but hardware-
limited to 300 nA, in order to limit the maxi-
mum possible dose rate to the patient.
An energy selection system transforming the
fixed energy beam extracted from the cyclotron
into a variable energy beam (235 to 70 MeV
range) provided with energy spread and emit-
tance limitations and verification .
A beam transport and switching system con-
necting the exit of the energy selection system
to the entrance points of a number of gantries
and fixed beam lines. At strategic points along
the beam transport system, the beam character-
istics are monitored with non-interceptive
multiwire ionization chambers, e .g ., for auto-
matic tuning .
Three gantries fitted with a nozzle, and a sys-
tem consisting of two horizontal beam lines, of
which one (for large fields) is equipped with a
Fig . 1 . Schematic view of the IBA 235 MeV cyclotron
(a) . This cyclotron splits at the median plane allowing
easy maintenance (b)
a
nozzle . Forbeam spreading on the gantries and
on the horizonal large field line, both beam
scattering and beam wobbling are available.
- A global control system which comprises an
"accelerator control unit" plus three indepen-
dent, but networked "irradiation control sta-
tions" . Through the network, each of the
irradiation control systems can also take con-
trol of the PLC (programmable logic control-
lers) based accelerator control unit directing
the cyclotron, the beam line and the gantry
optics .
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A global safety management system indepen-
dent of the global control system . This safety
management system uses a combination of
hardwired interlocks and independent PLCs to
achieve a safety level meeting applicable stan-
dards.
A robotic patient positioning system . Com-
bined with the gantry, the equipment provides
complete 4a coverage of the patient.
The advantages of this system, and in particu-
lar, the choice of a cyclotron for proton acceler-
ation are the following according to IBA:
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Fig . 2. Example of an IBA proton therapy center
Simplicity, reliability and operability. An iso-
chronous cyclotron is probably the simplest and
most inexpensive way to produce 235 MeVpro-
tons . This technology is well-known and wide-
spread . Thecyclotron operates in CW (continu-
ous wave) mode . The machine parameters are
constant in time and only 5-7 of them are
adjustable . None of these parameters requires
operator tuning during machine operation or
during the morning start-up : reference values
are stored by the control system and fine-tuned
using well-developed computer algorithms .
There is no need for fast computer algorithms,
as there are no time-critical tunings but only
the need to compensate for slow drifts .
Scanning ready. The high-intensity, continu-
ously extracted beam can be intensity-
controlled from the ion source within 15 I,sec
turn-on/turn-off time, and only 30 [tsec sepa-
rate the beam leaving the source and reaching
the patient. The beam is, therefore, perfectly
suited for beam scanning and wobbling . The
high intensity easily allows for respiration gat-
ing without extending treatment times, even
for very large fields .
Safety. The extracted beam is characterized by
a fixed energy, a low energy dispersion and a
fixed, low emittance. The accelerator is unable
to produce an extracted beam with incorrect
energy, energy dispersion or emittance pattern .
The safety system ensures the safety of the
patient and personnel . The choice of PLCs
offers the best choice in reliability, perfor-
mance and cost .
Maintenance. The cyclotron splits at the
median plane allowing easy maintenance . The
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More details about the equipment may be
found in [5] . According to ACCTEK the advan-
tages are the following:
Regarding the accelerator, the proposed system
has probably a lower cost than a cyclotron or
the more compact, higher field proton syn-
chrotrons . The extraction system is simple,
inexpensive and flexible, and many extraction
ports are possible . Compared to proton syn-
chrotrons and cyclotrons, the extracted beams
have a very low emittance, making small aper-
ture transport and gantry systems possible . The
proposed system offers superior control of the
extracted beam current in comparison to pro-
ton synchrotrons, and compared to cyclotrons,
it offers energy variability on a pulse-to-pulse
basis without degradation of the beam quality.
The rotating vertical beam delivery system is
an alternative to an isocentric gantry at much
lower cost . Along with horizontal beams it can
accomplish nearly everything desired for pro-
ton therapy. In addition, it will have a very sig-
nificant impact on reducing the shielding
requirements for therapy.
The raster scanning beam delivery system will
provide higher beam utilization efficiency, per-
mit 3D-dose deposition, and make the patient
alignment procedure simpler and faster by
eliminating the necessity of a bolus and by
using proton radiography for alignment. Raster
scanning is required for practical real-time ra-
diography and computed tomography.
For radiography and computed tomography a
300 MeV beam of protons is desirable . Their
use will impact therapy by providing real-time
radiography for alignment and for improved
treatment planning with proton computed
tomography.
A "Second Generation" Synchrotron-based
Proton Therapy System
A design concept for a next generation of
synchrotron-based proton therapy equipment is
proposed by SAIC (Science Applications Interna-
tional Corporation, SanDiego, California, USA)
and PAC (Particle Accelerator Corporation,
Downers Grove, Illinois, USA) . This design
builds up on the experience gained from the
Loma Linda facility. It includes the following :
An accelerator system based on a "next genera-
tion" proton synchrotron delivering a 70 to 250
MeV beam. The "next generation" label is
given by comparison to the Loma Linda syn-
chrotron . The main objective of the new gen-
eration is to achieve higher intensity perfor-
mances .
According to the proposers, it is the request for
rapid energy changes in therapy that speaks for
a synchrotron. In addition, the extracted beam
size is relatively small allowing for small bore
magnets to be used . The accelerator is coupled
with a radiofrequency quadrupole (RFQ)
accelerator which will serve as injection sys-
tem. The RFQ will be of an improved design,
as compared to the Loma Linda type, allowing
for a reduction of the momentum spread at the
injection point, and hence, a reduction of the
beam loss at injection .
A beam transport system transporting the
beam to the treatment rooms. The switchyard
is based on three y-shaped magnets that shuttle
the beam into any of four treatment lines . The
gantry lines are on the right and on the left, and
the fixed-beam room is straight ahead.
Gantry systems allowing to support and posi-
tion the bending, focusing and steering mag-
nets and the beam nozzle, in order to focus the
proton beam precisely on the patient from any
desired angle in the plane of rotation . The
gantry concept is the proven corkscrew config-
uration (cf . Chapter 23) . This configuration
incorporates achromatic beam transport and
accommodates the necessary nozzle compo-
nents.
Apatient positioner system . The gantry allows
the beam to be rotated throughout a full circle
of 360° (41t radians), enabling the tumor to be
irradiated from any therapeutically desirable
angle. Axial position of the patient is accom-
plished by the patient positioning system,
which moves the patient perpendicular to the
beam along the gantry axis .
TRUSS/GANTRY
WELDMENT BRACKET
VERTICAL SEISMIC SUPPORT
ACCELERATOR LADDER
GANTRYWELDMENT
CABLE DRUM
Fig . 4. The SAIC gantry system assembly
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1 meter
1.2 Beam accelerating line
2.1 RF sources & electronics 2 .2
According to the authors, the proposed gan-
tries are of a new generation, as compared to the
Loma Linda type . Improvements concern the
positional accuracy of the beam, an easier align-
ment of the gantry, the motion control, and a
reduction of installation and/or operating costs .
Figure 4 presents the SAIL gantry system
assembly. More details about the whole equip-
ment may be found in [6] .
A LLndc-Based Proton Therapy System
A predesign of a compact proton therapy unit
based on a H-coupled traveling wave linac has
recently been published by D. Tronc, General
Electric Medical Systems (Buc Cedex, France)
[8] . The main idea is to make use of existing RF-
linacs, e.g ., the industrial standard for accelera-
tion of electrons for radiotherapy, to accelerate
protons of low and variable velocity and high
rigidity. The conceptual guidelines for this com-
pact therapy unit which, according to the author,
delivers a high quality beam and is able to spread
the use of protons within hospitals, are presented
in detail in [7] and [8] . They are based on innova-
tions, such as simpler accelerating RF geome-
tries, improved focusing, and an original com-
bination of head optics and treatment bed access .
In particular, the treatment cell is a chamber large
enough to allow bed rotations and human assis-
Fixed therapy
A Superconducting Cyclotron
for Proton Therapy
A Proton Therapy Center Based
on an ECRIPAC
Fig . 5 . The linac-based proton therapy system proposed by D . Tronc : beam line (1 .1, 1 .2, and 1 .3), RF sources (2 .1, 2.2, 2 .3
and 2.4), therapy fixed head (3 .1, 3.2, 3 .3, and 3 .4), and therapy mobile head . See (8) for more details
tance at set-up location . The patient moves sym-
metrically to the magnet inside this treatment cell
which is part of the rotating head. This non-
isocentric choice - similar to the PSI patient posi-
tioner, (cf . Chapters 23 and 35) - allows repro-
ducible error at the level of the rollers' rotation
mechanism, the linac-head colinear adjustment
being electronically controlled .
The design of a compact facility for proton ther-
apy based on a superconducting cyclotron was
presented by the Siemens AG (Erlangen, Ger-
many) at the EPAC'94 Conference in London [9] .
The electron cyclotron resonance (ECR) plasmas
are well known, e.g ., inside ion sources . How-
ever, an ECR plasma cannot only produce highly
stripped ions but can also accelerate them in situ
up to very high energies of several hundreds of
MeV/nucleon . Such an ECR ion plasma acceler-
ator (ECRIPAC) could be extremely compact
(length approx . 1 m), remarkably economic and
technologically simple . A conceptual design of a
proton ECRIPAC is presented in detail in [10] .
The physical basis of the ECRIPAC concept
has been known for several decades [11] but
methods for putting it into practice have not been
successful up to now. If the construction and oper-
ation of a future prototype based on [10] can be
achieved, the ECRIPAC could be considered a
revolutionary competitive device for proton
acceleration in the framework of proton therapy.
Table 1 .
	
Commercial Companies Proposing Proton Therapy Equipment and/or Conceptual Designs
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Addendum
Table 1 presents the addresses and telephone
numbers of commercial companies active in the
proton therapy field .
ACCSYS Technology, Inc . 1177 Quarry Lane TEL. : 1510 462 6949
Pleasanton, CA 94566 FAX: 1510 462 6993
USA
ACCTEK Associates, Inc . 901 S . Kensington TEL. : 1708 252 6786
LaGrange, II. 60525 FAX: 1708 252 4007
USA
Electus Technology, Inc . P.O . Box 608 TEL. : 1909 799 8300
Loma Linda, CA 92354 FAX: 1909 799 8348
USA
GE Medical Systems s .a . 283 rue de la Minilire, B.P. 34 TEL. : 33 130 70 43 21
78533 Buc Cedex FAX: 33 139 56 4135
France
IBA s . a . 6 rue J.E . Lenoir TEL . : 32 10 47 58 58
B-1348 Louvain-la-Neuve FAX: 32 10 47 58 10
Belgium
Maxwell Brobeck Division 4905 Central Avenue TEL. : 1510 524 8664
Richmond, CA 94804 FAX: 1510 524 8472
USA
SAIC 4161 Campus Point Court TEL. : 1619 458 5285
San Diego, CA 92121 FAX: 1 619 546 6800
USA
Siemens AG KWU-Umwelttechnik GmbH TEL. : 49 09131 18 4683
Erlangen FAX: 49 09131 18 9166
Germany
PAC 4513 Cornell, Avenue TEL . : 1 708 969 0750
Downers Grove, IL 60515 FAX: 1708 969 0750
USA
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V. Beam Preparation and Control
Introduction
Concepts for Gantry Systems
E. PEDRONI
Paul Scherrer Institute, Division of Radiation Medicine, Villigen, Switzerland
Experience with proton therapy has been
acquired in the past in research laboratories using
protons with horizontal beam lines. It is only with
the installation of the Loma Linda proton facility
in California in 1991 that protons have been made
available on an isocentric gantry and in a hospital
environment [1] .
The success of photons in hospitals is strongly
related to the possibility of applying the beam on
the supine patient using multiple fields delivered
by an isocentric gantry. It is only through the
overlapping of multiple beams at the target vol-
ume that photons can be used at all for the treat-
ment of deep-seated tumors .
The questions whichwe want to discuss in this
chapter are :
- Why should we not use the same strategy for
proton therapy and apply protons using iso-
centric gantries?
- What are the possible draw-backs of such an
approach?
- What are the technical solutions available?
The Purpose of a
Proton Isocentric Gantry
The term "proton gantry" means a structure sup-
porting a beam line which rotates around the
patient . The purpose o£ such an instrument is to
provide the application of a proton beam on the
supine patient from many directions without the
need to change the patient's position during the
treatment .
As a first rule, for any precision radiation
treatment, the patient position during treatment
should be kept invariant with respect to gravity, in
order to avoid possible internal shifts of organs .
Uncontrolled changes of the patient anatomy
would otherwise rapidly spoil the precision of the
treatment . The obvious exception to this rule are
treatments in the rigid skull where organ shifts
are negligible .
The most preferred patient treatment position
is the supine position . It is most comfortable for
sick patients and also the usual orientation for
taking CT and MRI images used for treatment
planning .
The freedom to apply the beam on the gantry
from any direction is expected to bring some sig-
nificant advantages . The most obvious is to
reduce the dose burden to sensitive structures sur-
rounding the target volume . By choosing a differ-
ent beam direction one can often avoid sensitive
structures and by distributing the entrance dose
of the beam over a larger area of the body one
can also reduce the local dose at given points to
be below the tolerance level . Having the flexibil-
ity to choose the direction of the beam freely is,
therefore, an important tool for minimizing the
risks of treatment complications .
Optimizing the beam direction pursues an-
other goal, namely, to avoid having the beam tra-
verse complex density heterogeneities which
could produce unacceptable error in the dose
distribution . Possible examples are range uncer-
tainty errors due to the combined effect of multi-
ple Coulomb scattering and of `range modifica-
tions due to body density heterogeneities [2] .
These effects cannot completely be corrected
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with compensators outside the patient's body [3]
nor with dynamic variations of the energy of a
scanned beam. They can only be predicted by
Monte Carlo calculations but are difficult to con-
trol . The choice of the beam direction is, there-
fore, a factor which can be used to improve both
the tolerance and the precision of the treatment.
The major drawback of a proton gantry is the
size (several meters in diameter) of the rotating
structure supporting the beam . Since proton ther-
apy requires a maximum beam energy of 200-250
MeV the beam lines have to be designed for a
correspondingly large magnetic rigidity. The
bending radius of such a beam using non-
superconducting magnets operating below satura-
tion limits is of the order of 1.3 m. The magnetic
elements used for transporting the beam are cor-
respondingly bulky, making the rotating structure
large and heavy. This is probably the major
obstacle to a rapid permeation of proton therapy
into the hospital environment . Optimizing the
design of proton gantries is, therefore, a crucial
issue for the future development of this modality.
Alternatives to a Gantry Solution
For treatments in the skull it is not strictly neces-
sary to rotate the beam around the patient. Since
the skull is rather rigid, it can be scanned in a CT
in supine position and then be rotated in space
without changing the properties relevant to the
penetration of the beam and the precision of the
treatment . An elegant patient positioning unit
based on this idea is in use for stereotactic treat-
ments in a horizontal beam line at Harvard Uni-
versity. This very precise positioning system,
developed by the company Genesis Inc., is illus-
trated in Figure 1 . It permits rotation of the
patient around the body axis, in addition to rota-
tion of the patient table in the horizontal plane,
thus providing two independent rotations of the
patient skull with respect to the beam [4] .
Another alternative to the gantry solution is to
treat the patient in the upright position, or sitting
on a chair, using a horizontal beam line . The
patient support is then rotated around the vertical
axis . This way, the patient is maintained in an
invariant position with respect to gravity and the
Fig . 1 . The patient positioning system used at Harvard for
non-invasive treatment of various intracranial disorders .
Courtesy of the producer Product Genesis Inc . [5]
beam can be applied from many directions with-
out the need of a gantry. The major problems
encountered when using this solution are that CT
images of the patient must be taken in this
unusual position and that reproducible immobi-
lization of the patient during each treatment frac-
tion is difficult. The first problem may be solved
by modifying the CT-equipment to have the axis
of rotation in the vertical direction. This solution
was adopted at Harvard and Berkeley for proton
and ion therapy in the 80's . The remaining prob-
lem is precise positioning of the patient in the
modified CT. Immoblilization moulds for the
upright or seated position are more difficult to
manufacture than for the supine position and they
are less precise since, as treatment proceeds, the
patient gets more and more relaxed and tends to
sink inside the mould.
Another possible alternative to a gantry is to
use multiple fixed beam lines, each with a differ-
ent fixed beam direction . The simplest solution is
the combination of horizontal and vertical beam
lines . This arrangement was adopted for the pro-
ton therapy facility in Tsukuba. A similar solution
has been chosen for the very recent installation of
the ion therapy facility HIMAC at Chiba (see
Chapter 34) . The magnetic rigidity of a thera-
peutic light ion beam is a factor of two to three
larger than for proton therapy and a gantry for
ion therapy would, therefore, be rather gigantic .
To further enhance the flexibility in the choice
of the beam direction, one can use fixed beam
lines in combination with a small pitch rotation of
the patient table. If the pitch rotation angle is
maintained below some limit (e.g ., ±15°) the
deformation of the patient anatomy is expected
to be small enough not to affect the precision of
the treatment .
When we discuss fixed beam line arrange-
ments, we have to ask: how many beam lines,
how many angles and how many rooms are opti-
a) "usual gantry" for
	
b) "cork-screw gantry" c) "divergent scanning"
scattering for scattering
___~ 7
d) "upstream" scattering e)"upstream" scanning f) "eccentrinc" gantry
Fig . 2 . Comparison of different gantry
types (see text) g) 900 bending
mal? One also has to consider carefully, if one
wants a single fixed beam line for each treatment
room or many beam lines for the same room
(with the option to have the beam lines converg-
ing on the patient table) . The first solution clearly
reduces the costs per room, but scheduling the
treatments in different "dedicated" rooms is diffi-
cult to mangage. If the use of the rooms is not
well optimized, the saving of investment costs is
jeopardized by an under-usage of the whole facil-
ity.
The option to have more beams in the same
room offers more flexibility but is more expen-
sive . There are not only additional installation
23 Concepts for Gantry Systems 21 5
h) multi-room i) PSI gantry
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costs for the increased number of beam lines; one
also has to worry about the extra work of per-
forming all the necessary set-up and calibration
procedures repeatedly on each single beam port .
As a first approximation, it is probably reason-
able to assume that a solution with two converg-
ing beam lines has similar total costs as an iso-
centric gantry.
Gantry Designs
The choice of the beam delivery technique and
the design of the isocentric gantry are strongly
related. The different solutions can, therefore, be
classified according to the beam spreading tech-
nique used . In Figure 2, sketches of the different
concepts discussed in the following section are
given for comparison .
The 'Conventional Gantry' for the Scatter
Foil Technique
This is the most straightforward design . The basic
principle of this gantry design is depicted in Fig-
ure 2a . The beam is first bent away from the axis
and then bent back, to come in perpendicular to
the supine patient along the radial direction of the
rotating structure. The devices used for spreading
and shaping the beam in the patient are placed at
the end of the beam line following the last bend-
ing magnet . The beam is scattered at least 3 or
4m ahead of the patient in order to provide suffi-
cient uniformity of the spread beam over all pos-
sible target sizes. The radius of the rotating struc-
ture must, therefore, be of the order of 5-6 m.
This is probably the major disadvantage of this
solution .
The conventional gantry discussed here is ded-
icated to the scatter foil technique, but, in princi-
ple, this design can accommodate any other dose
application method including the most advanced
beam scanning techniques . Thepassive scattering
method represents the state of the art of proton
beam delivery [5] . It is known to work reliably
and is the most common for patient treatments .
However, many of the presently proposed
installations offer the option for an upgrade to a
dynamic beam scanning technique as part of their
design .
For the second hospital-based proton facility
in the world, which will be realized at the Massa-
chusetts General Hospital in Boston, USA, the
choice has fallen in favor of a conventional gantry
for scattering (Chapter 39) with mechanical and
ion optical design carefully optimized to provide
both scanning and scattering beam delivery tech-
niques . Figure 3 shows the cross-section of the
gantry for the Northeast Proton Therapy Center
(NPTC), designed by IBAin Belgium [6] .
The 'Cork-Screw' Gantry
The cork-screw gantry concept was invented in
Harvard by Koehler [7] . The major difference to
the previous design is given by the different beam
path within the gantry structure (Fig . 2b) . The
bending of the beam is confined to a plane per-
pendicular to the gantry axis . This requires a
larger total bending angle of the beam but allows
for a reduced gantry volume, saving space and
lowering shielding costs .
Three identical cork-screw gantries have been
built at Loma Linda, presently the only hospital-
based proton facility in the world and the only
place where proton treatment is performed using
a gantry [1] . Figure 4 shows a photograph of a
patient treatment at the Loma Linda gantry. The
cork-screw design has also been adopted for the
proposed TERA project in Italy [8] .
The 'Supertwist Gantry'
A possible disadvantage of the cork-screw gantry
is the short distance between the isocenter and
the coupling point of the beam with the gantry.
An intermediate design between cork-screw and
normal gantry which allows for a better utiliza-
tion of the space in the isocenter region has
recently been presented by Farley [9] .
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Fig . 3. View of the IBA gantry for the new proton therapy facility in Boston, USA. Courtesy of I . Jongen 171
The 'Uppsala' Gantry
The design proposed by Graffman et al . [10] is a
`conventional' gantry with a very short distance
between the last bendingmagnet andthe patient,
designed specifically for the spot scanning tech-
nique (Fig . 2c) .
The basic idea behind this concept is to apply a
focused proton pencil beam directly on the
patient and to scan the beam under computer
control using two magnets placed upstream of the
patient following the last bending magnet . For
the variation in range a range shifter system with
moving double wedges is conceived in front of the
patient. The drift space after the double magnetic
scanning system is minimal and the divergence of
the beam is correspondingly large with a source-
to-skin distance (SSD) of less than one meter. A
possible disadvantage of this approach is the
increased skin dose due to the short SSD whilst
the advantage of this solution is the reduced size
of the rotating system resulting in a radius of the
order of 3 m.
The 'Upstream Scattering' Gantry
By placing the devices for lateral broadening of
the beam ahead of the last bending magnet, one
can try to eliminate the long drift distance
between the last bending magnet and the isocen-
ter and reduce the radius of the rotating structure
(Fig . 2d).
Due to the large deterioration of the phase
space (multiple scattering and energy spread)
caused by the spreading and range modulation
devices, the beam optics in this case is rather dif-
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Fig . 4. Photograph of a patient being treated on the Loma
Linda gantry, the only gantry presently operational in the
world . Courtesy of J .M . Slater [1]
ficult to handle . The scattered beam must be
transported through the last portion of the gantry
while preserving a good homogeneity of the dose
field at the isocenter. In order to accommodate a
maximum field size capable of covering most tar-
gets, the last bending magnet has to be designed
not only with a large pole face but also with an
unusually large pole gap .
Gantry solutions which place scatterers in the
beam before bending it onto the patient were
studied and proposed independently by Enge [11]
and Jongen [6] . The gantry radius for these solu-
tions is estimated to be of the order of 3 or 4 m .
The major disadvantage of the upstream scatter-
ing design is the large size of the last bending
magnet needed to contain the broadening of the
beam in both lateral directions, which results in
an increase in weight and power consumption.
The 'Upstream Scanning' Gantry
If the beam optics is combined with dynamic
scanning of the beam and the beam is only
scanned in the dispersive direction of the last
bending magnet, the gap of the magnets can be as
small as permitted by the size of the unscanned
beam (Fig . 2e) . The other transverse direction
can then be scanned mechanically, either by mov-
ing the patient or by rotating the last bending
magnet and the nozzle . Designs based on these
ideas were proposed independently by Pedroni
[12] and Jongen [6] .
The 'Eccentric' Gantry
A possible reduction of the gantry diameter can
be achieved by mounting the patient support
eccentrically on the gantry (Fig . 2f) .
A gantry design with a cylindrical patient
chamber mounted eccentrically on the gantry was
studied by the proton therapy group of Tsukuba
[13] . It is shown in Figure 5 . The devices for the
passive scattering method, which are usually
mounted along the radius of the rotating struc-
ture, can here be distributed along its diameter,
thus reducing the radius of the gantry by about a
factor of two. The price paid for this solution is
the extra mechanics needed to keep the patient
support horizontal at all times, and an important
safety issue has to be solved, namely, quick access
to the patient chamber, in case of failure of the
motors which rotate the gantry.
Gantries with a 90° Bending Magnet
The possibility of reducing the rotating beam
transport system to a single 90° bending system,
which directs the beam onto a patient support
rotating with the magnet, was discussed in an early
phase of the Italian TERA project . The special
merits of this design (Fig . 2g) would be low weight
of the rotating structure and extreme simplicity of
the beam transport system . If used for the scatter-
ing foil technique, the diameter of the structure
would, however, be as big as for the "long throw"
solutions (Fig . 2a and b) discussed above .
Fig. 5. Sketch of the proposed gantry for Tsukuba. Courtesy of S. Fukumoto [16]
A similar idea has been proposed by Martin
[14] . His solution conceives a single rotating 90°
bending magnet and limits the use of the angle of
rotation to a few selected directions which brings
the beam directly into different treatment rooms
(Fig . 2h, see also Chapter 22) . That way, he
avoids moving the patient support in space.
Superconducting Solutions
Important developments in the future may be
based on superconducting [15] and pulsed mag-
nets [16] . These new technologies could be used
to reduce drastically the size the beam transport
system and the accelerator. Blosser proposed to
rotate the whole accelerator, a superconducting
cyclotron, around the patient. That such a solu-
tion is possible in principle has been demon-
strated by the successful operation of his gantry
for neutron therapy at the Harper Hospital in
Detroit [15] . For proton therapy, one would, how-
ever, need to rotate a cyclotron of much higher
energy.
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The Compact Gantry at PSI
Figure 6 shows the cross-section of the PSI gantry.
The beam is first bent by two 35° bending mag-
nets shifted parallel to the gantry axis at a dis-
tance of 1.27 m, and then bent towards the
patient with a 90° bending magnet . The patient
table is mounted on the front wheel of the gantry
and is off-center by 1.1 m. When the gantry ro-
tates the patient table at the nominal isocenter
(defined as the crossing point of the beams in the
reference frame of the patient table) moves on a
circle of 1.1 m. A mechanical counter-rotation
maintains the patient table horizontal at all times
during rotation of the gantry. By mounting the
table eccentrically on the gantry and by integrat-
ing the scanning of the beam into the beam optics
of the beam transport system, the diameter of the
rotating structure could be reduced to 4 m, the
smallest size proposed so far for a gantry using
non-superconducting technology.
The PSI gantry is specifically designed for the
spot scanning technique (see succeeding chap-
ter) . The scanning of the beam is performed in
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one transverse direction by the action of a
sweeper magnet placed before the last 90° bend-
ing magnet . A range shifter system moves the
Braggpeak in depth . The third scanning motion is
performed by moving the patient table itself .
The 90° bending magnet has been carefully
designed to achieve a parallel scanning of the
swept beam at the isocenter. The PSI scanning
system is in this way completely Cartesian, with
an infinite source-to-skin distance . The beam op-
tics of this gantry is described in more detail in
the literature [17] .
The PSI facility started its operation in summer
1994. It will soon be the second facility in the world
working with a proton gantry. Figure 7 shows a
photograph of the gantry during commissioning.
General Considerations
for Gantry Designs
Fig . 6. Cross-section of the PSI gantry
One of the most important issues to be consid-
ered in the design of the gantry is the beam op-
tics . At the coupling point of the beam to the
gantry the beam should be symmetric in phase
space and achromatic in order to allow the trans-
port of the beam through the gantry independent
of the gantry angle. For the spot scan technique,
one should try to focus the beam directly at the
isocenter in both transverse directions, whereas
with scatterer foils the focus should be at the
starting point of the beam spreading system . Both
solutions require a double non-dispersive focus-
ing of the beam at the end of the gantry beam
Fig . 7 . Photograph of the PSI gantry
during commissioning in summer
1994
line . If both scanning and scattering techniques
are planned for the same gantry, two different
beam optics solutions must be simultaneously
available in the same layout .
Another important issue is mechanics. This
includes precision of the mechanical design of the
gantry and the patient table. The structure should
be very rigid in order to avoid misalignment
errors of the beam line elements during rotation .
The degrees of freedom necessary to direct the
beam on the supine patient need also careful con-
siderations. For example, the PSI gantry allows
for an additional horizontal rotation of the
patient table for treatments in the head . This per-
mits to direct the beam onto the patient's head
essentially from any direction .
At least 3 meters of free space are needed to
rotate the beam line and the nozzle under the
patient table. One should, therefore, pay atten-
tion to the potential risk of patients or personnel
falling into the "pit" underneath the patient
table . A moving platform covering the gantry pit
or a protection shell mounted around the patient
table can be used to eliminate this hazard . Afalse
floor solution capable of covering the gantry pit
permanently in all treatment situations is difficult
to realize, especially if one chooses to treat the
patients with two independent beam angles and
mounts nozzle and diagnostic devices very close
to the patient. The alternative in this case is to
treat with an open pit and to provide the neces-
sary safety by not allowing the patient to leave the
couch during treatment in the highest position,
i.e ., when being treated with the beam coming
from below.
The devices to control the positioning of the
patient with respect to the beam are also impor-
tant design components . The solution adopted at
PSI is to position the patient outside the treat-
ment room using a dedicated CTunit . The
patient, already positioned in the couch, will then
be transported into the treatment room on a spe-
cial vehicle. The mechanism of the CT-table, the
proton gantry and the patient transporter have
been designed to allow an automated and repro-
ducible transfer of the coordinates between all
these devices. The positioning of the patient will
also be checked directly on the gantry using a
retractable X-ray device or by directly using the
proton beam for proton radiography images ([18],
see also Chapter 31) .
Conclusions
The design of a proton gantry is a complex task
and requires careful optimization of many differ-
ent parameters . These are not only purely techni-
cal aspects, such as the type of accelerator or the
beam quality, but also more general considera-
tions, such as the scope of the facility, whether a
major center with broad research activities or a
small facility for special indications under strong
economical constraints is to be planned . The field
has just started to unfold, so that significant pro-
gress can be expected in the future .
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Beams of heavy charged particles, protons and
heavier ions, have the potential to achieve a
higher degree of dose localization than is possible
with conventional radiation, due to the sharp
peak in the depth-dose distributions of monoen-
ergetic beams and their lower lateral scattering .
The Bragg peak must be spread out into a high
dose region which covers the entire target vol-
ume . This is achieved by modulating the range of
the beam, i .e ., generating radiation fields con-
taining a mix of particles with different residual
energies . Various methods for shaping the depth-
dose distribution are described in the following
section .
Ion beams are generally tightly focused for the
transport into the treatment room where the
beam must be spread laterally in order to gener-
ate a large radiation field . Passive beam delivery
systems, which are based on scattering foils for
spreading the beam across the entire treatment
volume were the first to be used clinically. A more
recent approach are dynamic beam spreading sys-
tems, such as raster scanning, which move a beam
spot in a predetermined way across the treatment
area . Both methods will be discussed as will
three-dimensional pencil beam scanning meth-
ods .
Tumor sites treated with ion beams include
small ocular melanomas and large sites like pros-
tate and biliary tract . The required radiation
fields vary accordingly from 1 em' to several liters
and differ in their specifications for dose unifor-
mity and lateral dose fall-off. A variety of beam
spreading methods are used to serve these diverg-
ing needs . Important considerations for the
design of beam spreading systems are the sharp-
ness of the lateral and the distal dose fall-off, the
beam utilization efficiency, neutron production,
beam fragmentation, accuracy of the delivered
dose distributions, and patient safety. Constraints
are presented by the accelerator, the beam trans-
port system, and the available space in the treat-
ment room.
Before choosing a particular beam spreading
system it is essential to ask how well the high dose
region is expected to conform to the target vol-
ume and how much flexibility is desired in shap-
ing the dose distribution . As has been shown
recently [1], the conventional goal of delivering
uniform dose distributions with the sharpest pos-
sible dose fall-off does not necessarily represent
the best treatment . In order to optimize the
biological effect, that is to maximize the tumor
control probability for an acceptable level of com-
plication probability, it may be necessary to
deliver more complex dose distributions . This can
only be achieved by three-dimensional pencil
beam scanning .
The development of beam scanning systems
has also been motivated by the desire for iso-
centric rotating gantries with a small diameter.
The large diameter of conventional isocentric
gantries, such as the ones built at Loma Linda
University Medical Center (LLUMC) [2], is
largely due to a long drift space required by the
beam spreading system to generate large. fields .
New ways are being explored to reduce the over-
all gantry diameter by incorporating the beam
spreading system into the gantry itself.
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Range Modulation
The depth-dose distribution deposited by a
monoenergetic ion beam in water or tissue and
described by the Bragg ionization curve [3] exhib-
its asharp peak at the end of the range. The width
of the unmodulated peak, which is only used for
treating very small lesions, depends on the energy
spread of the beam and the energy straggling
introduced in the tissue . For most clinical applica-
tions the Bragg peak must be spread out in depth
in order to cover the target volume . The range of
the beam particles must be modulated in such a
way that the desired depth-dose profile results.
For proton beams a uniform dose coverage of
the target volume is usually desired since it is
assumed that the biological effectiveness does not
significantly change as a function of depth. A uni-
form or "flat" distribution can be produced by
superimposing individual Bragg curves that are
spaced 1 to 5 mm apart dependingon the width of
the Bragg peak . The weights of the individual
contributions (beam weights) can be determined
by a least-squares fitting procedure which mini-
mizes the difference between the desired dose
level and the sum of the individual contributions
at all points in the spread-out Bragg peak .
For ions heavier than protons the dependency
of the biological effectiveness on the ionization
density or linear energy transfer (LET) must be
taken into account. Towards the end of the range
the cell killing probability is markedly increased.
This needs to be compensated for by reducing the
dose towards the distal end if uniform cell killing
throughout the target volume is to be achieved [4,
5] .
Bragg peaks are spread out by inserting
absorbing material of different thicknesses before
the beam enters the patient . The desired depth-
dose distribution results when the fraction of time
each section is in the beam (assuming a constant
beam current) is proportional to the beam weight
for the corresponding residual range. For treat-
ments with helium ions at LBL [5] a computer-
controlled device was used to insert absorber
plates from a binary set of thicknesses. In this
method, whenever the dose corresponding to the
beam weight has been delivered at a particular
setting, the absorber thickness is changed and the
Bragg peaks are sequentially stacked in depth.
This method makes it easy to change or adjust a
depth-dose distribution by changing the beam
weights contained in a control system data file .
Widely used is the so-called modulator wheel,
a fan-shaped stepped and rotating absorber,
which was first proposed by Wilson [6] and later
Fig .1 a) Modulator wheel with scattering compensation . The
beam passes through the stepped part off axis . Courtesy of
M . Wagner, HCL . b) Schematic cross section of a bimaterial
contoured filter. Courtesy of B . Gottschalk, HCL
implemented at the Harvard Cyclotron Labora-
tory (HCL) [7], at LBL, and more recently at
LLUMC [8] and other facilities . A new and spe-
cial version is shown in Figure 1a . The beam is
intercepted by the stepped part of the modulator
with the thickest section pulling the beam back to
the proximal end of the spread-out Bragg peak
(SOBP) . The modulator wheel is rotated at typi-
cally 100 rpm in a cyclotron beam while the pulse
structure of a synchrotron may require ten times
that frequency. It is designed such that the angular
coverage of a specific thickness is proportional to
the beam weight assigned to the corresponding
range . The simplicity of the mechanical device and
the fact that the target volume is filled simultane-
ously at all depths are the main advantages of this
method compared to sequential beam stacking .
For heavy ion beams the degradation of the
beam quality due to fragmentation in the scatter-
ing and range shifting material is an important
concern . For the same reduction in range a high-
Wobbler Magnets
Horizontally Deflecting
Vertically Deflecting
Unwobbled Beam
Wobbled Beam 1
Wobbled Beam 2
Radius
Fig . 2 . Scheme of the LBL wobbler beam delivery system
Z (atomic number) material produces less frag-
mentation than a low-Z material . On the other
hand the heavier material produces more scatter-
ing. As a result the use of high-Z materials is
often advantageous for heavy ion beams whereas
low-Z materials are preferred for proton beams.
Bar ridge filters [9], which consist of narrow
parallel ridges (Fig . 2), have been machined from
brass for the range modulation of heavy ion
beams . Particles going through different sections
of a ridge lose different amounts of energy. By
giving the ridges the correct shape the desired
depth-dose distribution is produced . Care must
be taken to avoid imaging the ridges and to
ensure complete mixing of the particles with dif-
ferent residual ranges at the patient location . A
bar ridge filter must be made from metal in order
to limit the height of the ridges . This is important
to make them sufficiently narrow and to machine
them precisely. Metal bar ridge filters have also
been used with proton beams [10-12] .
Range Degrader
Ridge Filters
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Scattering Systems
A narrow ion beam is most simply spread into a
large radiation field for patient treatments by
directing it through a scattering foil . Multiple
Coulomb scattering leads to approximately Gaus-
sian distributions for the scattering angle and sub-
sequently produces a two-dimensional, Gaussian
dose distribution at isocenter [9, 13] . For a radia-
tion treatment only the innermost part of the
Gaussian distribution can be used since the dose
distribution must be sufficiently uniform. This
results in a low beam utilization efficiency, about
equal to the uniformity in percent [9] . For exam-
ple, for a required dose uniformity of ± 2.5 %,
which corresponds to the part of the Gaussian
distribution larger than 95 % of the peak value,
the beam utilization efficiency is 5% . The single
scatterer method is often used for generating
small treatment fields where the beam utilization
efficiency is not important. Examples are eye
treatment beam lines at the Harvard cyclotron,
the Loma Linda University proton therapy facil-
ity, the Crocker cyclotron at UC Davis and
others .
For the generation of larger fields a higher
beam utilization efficiency is needed . Double
scattering methods have been employed for
spreading proton [12, 14, 15] and heavier ion
beams [16] . A first scatterer spreads the beam
such that the projected full width at half maxi-
mum at the patient location is about equal to the
desired field size . A second scatterer is needed to
transform the Gaussian distribution into a "flat"
one with steep lateral fall-offs. In the past this was
facilitated by mounting occluding rings onto the
second scatterer in order to absorb particles from
the center of the distribution . This method, which
is described in detail in references [9] and [14],
achieves a beam utilization efficiency of typically
20% .
Anew and improved method in which the sec-
ond scatterer with the occluding ring assembly is
replaced by a "contoured filter," a bimaterial
scattering foil, has successfully been developed at
the HCL [17] and adapted at LLUMC. The
design of the bimaterial filter is illustrated in Fig-
ure 1b . A foil made of a high-Z material (e .g .,
lead), which decreases in thickness from the cen-
ter towards the outside, scatters more particles
from the central ray towards the outside than in
the reverse direction, thus flattening the Gaussian
distribution produced by the first scatterer. The
different energy losses of particles traversing the
foil at different distances from the center are
compensated for by combining the high-Z and
strongly scattering foil with a foil made from a
low-Z material (e.g ., Lucite) which produces
much less scattering . By increasing the thickness
of the Lucite from the center towards the outside
one can keep the energy loss for all particles con-
stant, independent of the distance to the central
ray, while simultaneously achieving the desired
scattering properties . The bimaterial scattering
system avoids the loss of beam particles, in con-
trast to an occluding ring assembly, and achieves
beam utilization efficiencies approaching 50% .
The idea of using two materials with different
scattering and energy absorbing properties has
also been applied to the modulator wheel [18] as
shown in Figure la . Beam particles traversing a
modulator wheel made from low-Z material are
scattered to a varying degree depending on how
much material they traverse . By attaching lead
foils of appropriate thickness to each step of the
modulator wheel the scattering strengths of all
wheel segments can be equalized while still pro-
viding the needed range modulation . The com-
pensated modulator can then be used as the first
scatterer. That way, the range modulator is placed
where the beam diameter is smallest and the
angular confusion is significantly reduced [5, 9,
18] improving the lateral dose fall-off.
For the modulation of proton beams it has
been proposed [19] to use one modulator wheel
to provide a range of spread-out Bragg peak
widths . The idea is to switch the beam "on" when
the steps with the correct thickness are in the
beam and to switch the beam "off" at other times .
In general, this method does not work for beams
of ions heavier than protons which exhibit a tail
dose beyond the Bragg peak due to fragments .
A scattering system with a fixed compensated
modulator and a bimaterial contoured filter pro-
vides dose distributions with the optimal unifor-
mity, in depth and laterally, only for a specific
beam energy. The versatility of the system can be
greatly improved by installing sets of modulator
wheels and scattering foils such that they can be
remotely moved into the beam line . A complete
scattering package is under development at the
Harvard Cyclotron Laboratory [20] . One of its
innovative features is the variable positioning of
the contoured filters which are mounted on rails
for adjusting the scattering configuration for dif-
ferent beam energies .
Dynamic Beam Spreading Systems
Large treatment fields can also be formed from
narrowly focused beams by magnetic deflection .
Magnetic beam spreading methods have been
investigated and developed for mainly two
reasons . First, they offer more flexibility then the
passive scattering methods. Different field sizes
can be generated and different beam energies can
be handled by simply changing the magnet cur-
rents. Second, magnetic methods allow to mini-
mize the amount of material in the beam thus
avoiding the degradation of the beam quality
caused by energy straggling and the generation of
unwanted radiation through nuclear reactions .
For ion beams the energy straggling due to scat-
tering foils can generally be neglected. The rela-
tively modest amount of material does not signifi-
cantly change the clinical beam parameters, in
particular, the width of the distal fall-off . For pro-
ton beams nuclear reactions in the scattering foils
lead to a small loss of primary protons and the
generation of neutrons . Both effects are usually
unimportant. Although in specific situations addi-
tional shielding may be required, the neutron
contribution from the scattering foils is minor
compared with other neutron sources in the treat-
ment room.
Forbeams of heavier ions the situation is quite
different. Here the main problem associated with
the use of scattering foils is nuclear fragmentation
of the primary beam particles . Dueto their lower
charge the fragments exhibit a lower specific
energy loss than the primary particles which
results in a longer range and a dose beyond the
Bragg peak, i.e ., a degradation of the beam qual-
ity. This disadvantage is exacerbated by the fact
that beams of heavier ions require more scatter-
ing material than proton beams in order to pro-
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duce the same scattering angle distributions. Vari-
ous magnetic beam spreading methods and their
advantages and disadvantages are discussed
below.
Dynamic beam spreading systems use dipole
magnets in order to generate large fields by
deflecting a narrow pencil beam and distributing
the beam particles evenly. The first such system
was tried more than 35 years ago [21] . It utilized
a pair of dipole magnets with orthogonal mag-
netic fields . The beam was steered by currents of
sawtooth waveform causing it to describe a peri-
odical pattern in a plane orthogonal to the beam
axis . Though the principle was successfully
demonstrated the system was never used in a clin-
ical program.
Extensively used in the heavy ion clinical trial
at the Lawrence Berkeley Laboratory (LBL) was
the so-called "wobbler" system [22] . Since beam
fragmentation is of great importance for heavy
ion beams, the development of magnetic beam
spreading systems aimed at enhancing the quality
of the radiation field was a major focus of the
technical development efforts at LBL. The wob-
bler, schematically shown in Figure 2, consists of
two dipole magnets powered sinusoidally with a
90° phase difference . This results in a circular
motion of the beam around the zero-field beam
axis . By changing the magnetic field strength in
both magnets ring-shaped dose distributions with
different radii can be deposited . Their superposi-
tion results in a uniform field if the correct
amount of dose is delivered in each ring . The
wobbler system maximizes the beam utilization
efficiency for circular radiation fields for two
reasons : first, no beam particles are absorbed or
lost besides the ones scattered outside the target
area and absorbed in the patient collimator ; sec-
ond, the diameter of the field can easily be
adjusted by changing the magnet currents to fit
the size of the target volume .
A dynamic beam spreading system like the
wobbler is inherently more complex than a pas-
sive scattering system . Beam position and inten-
sity have to be carefully monitored and con-
trolled. Small deviations from the concentricity of
the rings, i.e ., differences of more than 0.5 mm
between the positions of the centers, can cause a
significant tilt in the dose distribution . For exam-
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Raster Scan Magnets
ple, a shift of 1 mm between the center of the out-
ermost ring and the inner wobbles can lead to a
dose difference between the two opposing sides
of the radiation field of about 7 %, comparable to
what is observed for a double scattering system
with occluding rings . Similarly, the ions must be
uniformly distributed around each ring and the
total number of particles in each ring must be
within typically ± 2% of the request for satisfying
the dose uniformity requirement of ± 2% for the
combined field. At the Bevalac synchrotron at
LBL this was achieved by running the wobbler at
a frequency of 60 Hz and delivering at least sev-
eral beam spills at each magnet current setting .
The beam was clamped off within less than a
wobbled beam rotation, when the desired num-
ber of ions at that wobbler setting had been deliv-
ered .
In order to monitor the actually delivered dose
distribution, real time dosimetry devices with a
sufficient spatial resolution, for example highly
segmented ionization chambers, are needed [23] .
Wobbler systems are installed at the Heavy Ion
Medical Accelerator (HIMAC) at Chiba, Japan
[241 .
Many other patterns are also well suited for
"painting" uniform dose distributions with a nar-
row beam. Raster scanning systems have been
developed at several institutions [25-27] . The
LBL system [9, 28], shown schematically in Fig-
ure 3, employed two dipole magnets for deflect-
ing the beam in two orthogonal directions . The
magnets were mounted such that they could be
rotated up to 90°. However, in the following it is
assumed that the beam was scanned horizontally
and vertically as indicated in Figure 3. Thesystem
was matched to the pulse structure of the Bevalac
Segmented
Detector
Scanned
Radiation
Field
Fig . 3 . Scheme of the LBL
raster scanning beam deliv-
ery system
accelerator, a I-second spill every 4 seconds. An
entire port was scanned in onebeam pulse sweep-
ing the field vertically in less than the accelerator
spill time . The horizontal scan was performed at a
constant scan speed of 2400 cm/s, equivalent to a
frequency of 30 Hz for a ± 20 cm field . The
resulting scanning pattern produces a uniform
dose distribution of better than ± 2.5%, within
one complete scan, provided the distance be-
tween parallel lines is smaller than the sigma of
the Gaussian beam profile. The total number of
scans necessary for a treatment depends not only
on the maximum available beam current, which
determines how much dose can be delivered per
scan, but also on how well the beam current and
the spill structure can be controlled . It may be
necessary to scan the field many times in order to
average out dose variations due to fluctuations in
the beam current and to deliver the requested
total dose within acceptable error margins. The
basic field shape of a raster scanning system is a
rectangle, the aspect ratio of which can be varied
by adjusting the maximum fields in the scanning
magnets . This leads, in general, to a better beam
utilization efficiency than circular fields . Contrary
to double scattering systems or circular wobbler
systems, the uniformity of the dose distribution is
not affected by small variations in the position of
the zero-field central beam axis from one beam
pulse to the next during the treatment, since the
field is completely painted within every beam
pulse.
Three-Dimensional
Conformal Dose Delivery
With the beam delivery techniques discussed in
the previous sections a high degree of conforma-
tion of the high dose region to the target volume
is achieved . However, normal tissues upstream of
the target volume receive an unnecessary dose
when the width of the SOBP is fixed across the
field (cf . Fig. 4a) . The fixed modulation method
causes the spread-out Bragg peak to cover, in
general, some volume upstream of the tumor.
Techniques for avoiding this are discussed in this
section. The potential clinical benefits associated
with the improvement in dose localization have
T
® Target volume
® Treatment volume
Fig . 4 . a) Fixed modulation method producing a cylindrical
treatment volume which is equal in length to the thickest
part of the target volume . b) Variable modulation method
using a multileaf collimator to trim the treatment volume
been investigated in a number of studies [29-32] .
The variable modulation method (Fig . 4b)
employs a multileaf collimator whose leaves can
be repositioned many times during a treatment.
Using a slightly spread Bragg peak the target
region is covered in layers, starting from the distal
end, by reducing the range of the beam in a step-
wise fashion. Each layer is shaped by the multi-
leaf collimator which leads to the trimming of the
unwanted radiation. The optimal value of the
width of the miniature SOBP, i.e ., the thickness
of a layer, depends on the desired treatment time,
size and shape of the target volume .
The variable Bragg peak modulation as
described above works only with proton beams .
For heavy ion beams, which suffer from frag-
mentation and exhibit a tail in the depth-dose dis-
tribution beyond the Bragg peak, the tail dose
associated with an upstream layer contributes to
the dose in the layer behind it producing a non-
uniform dose distribution there. However, in this
case the desired uniform dose throughout the tar-
get volume can be achieved as the sum of non-
uniform distributions deposited in each layer. A
beam scanning system, which allows varying the
dose as a function of position, is needed for deliv-
ering such dose distributions (Fig. 5) .
Beam scanning techniques are being
developed and implemented for treatments with
heavier ions as well as for proton therapy because
of their unique flexibility and capability in shap-
Beam
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Fig . S. Schematic view of three-dimensional conformal
therapy delivery illustrating different dose regions in a target
volume scanned in axially stacked layers
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ing three-dimensional dose distributions . The
maximum lateral dose gradient which can be
achieved depends on the diameter of the beam.
Pencil beam scanning offers full electronic control
of the dose delivery and eliminates the need for
patient collimators and compensating boli .
A beam scanning system which is used for
three-dimensional conformal dose delivery must
control the dose deposition as a function of beam
position much more tightly than a scanning sys-
tem which is used for simply spreading the beam
into a flat distribution The raster scanning system
developed at LBL for the heavy ion radiotherapy
program [9, 28, 33] achieved the necessary con-
trol of the dose deposition by modulating the
scanning speed. Thedepth scan was performed by
inserting range shifting material in the beam. The
data for controlling the scan speed, which is pro-
portional to the inverse of the dose for a constant
beam current, were downloaded for all layers into
the memory of the raster scanner interface before
the start of the treatment. Also implemented was
the capability of modulating the beam extraction
from the accelerator, i.e ., the beam current. This
provided an alternative method of controlling the
dose delivery, made it possible not to deposit
dose in a particular region, and increased the
dynamic range when used in conjunction with the
scan speed modulation . A multileaf collimator
was added to the LBL system for safety reasons
and for providing the option of treating with a rel-
atively wide beam by using the multileaf colli-
mator for defining the lateral radiation field
boundaries . Provided that the pencil beam is nar-
row enough such a device is not needed . In fact,
the narrowest lateral fall-offs can be realized with
optimized pencil beam scans without a field
defining collimator. Although the LBL scanning
system in its conformal treatment delivery config-
uration was tested and dose distributions were
measured in phantoms, it was never clinically
implemented due to the shutdown of the Bevalac
in 1992 .
A second major motivation for the develop-
ment of beam scanning systems is the possibility
of realizing a compact isocentric gantry which has
a significantly smaller diameter than conventional
ones by incorporating the beam scanning into the
last section of the gantry optic. This approach has
been taken at the PSI in Villigen where the gantry
diameter could be reduced to 4 meters compared
to the 12 meter diameter of the world's first
gantry for proton therapy in Loma Linda (cf .
Chapter 23 for details) .
PSI's scanning system is operated in the spot
scanning (also called voxel scanning) mode . Mag-
net current, patient positioner, and energy ab-
sorber are set for filling a certain voxel before the
beam is switched on. When the predetermined
number of protons has been delivered, the beam
is switched off by energizing a kicker magnet and
the beam centroid is moved to the next position
or voxel. The fastest scanning direction is the
magnetic beam scan, the second fastest the range
shifting or depth scan, and the least frequent scan
movement is the one of the patient. The voxel
scanning method differs from raster scanning in
that it is not a continuous scan but the beam is
switched off before being moved to the next
voxel. Since no radiation is being delivered dur-
ing the magnet setting time until the new position
has been established, voxel scanning may lead to
longer treatment times than raster scanning .
At GSI Darmstadt (Germany) a raster scan-
ning system has been developed for a planned
clinical program for heavy ion radiotherapy (see
also Chapter 36). The goal is to build an active
beam delivery system based on magnetic beam
scanning and on energy variation by the acceler-
ator for conformal treatments . The target volume
is scanned in layers which are stacked in depth.
When a layer has been scanned the new beam
energy for irradiating the next layer is requested .
The lateral scan is performed by two dipole mag-
nets located 12 m upstream of the patient loca-
tion . Each layer is scanned in a zig-zag fashion
(Fig . 3) but the path of the beam is optimized in
order to accommodate irregularly shaped areas.
Additional scan lines which provide a shortcut to
the next regular line along the border of the tar-
get area are introduced . The scan is digitally con-
trolled based on 4096 possible beam positions in
each dimension and the beam is moved in a series
of small discrete steps . The incoming beam is
integrated and a signal is generated when a pre-
calculated value corresponding to the desired
dose at the current position has been reached.
Then the beam is moved at maximum speed to
the next position where it stays until the desired
dose has been delivered . The dose delivered dur-
ing the sweep is counted as deposited at the fol-
lowing voxel. Since the step size is small com-
pared to the beam diameter, the error introduced
is negligible . In contrast to the spot or voxel scan-
ning method the beam is not switched off during
the move to the new position . It should also be
noted that the step size is much smaller than that
in spot scanning systems. The validity of the GSI
concept has not only been shown in theoretical
studies but also confirmed by the delivery and
measurements of a variety of test dose distribu-
tions [26, 34] .
Conclusion
Beam scanning techniques offer not only confor-
mal treatments and a way of constructing com-
pact gantries, but also a natural way of delivering
dose distributions which are shaped according to
the results of an optimization procedure. It has
been shown that the probability for local control
can be maximized while not exceeding given com-
plication rates by optimizing the dose distribution
based on biological models [1, 35]. As part of the
treatment planning process a biological objective
function is maximized (or minimized) by adjust-
ing the Bragg peak density. The optimized Bragg
peak density can directly be translated into a
scanning pattern and dose values for each voxel.
It is important to note that, in general, the opti-
mization procedures based on biological models
result in non-uniform dose distributions in the
tumor volume and variable dose fall-offs in adja-
cent healthy organs . Such dose distributions are
difficult to produce without pencil beam scan-
ning .
On the other hand, pencil beam scanning has a
number of disadvantages compared to simpler
beam spreading methods . The sequential irradi-
ation of the target volume leads to longer treat-
ment times, the irradiation process must be much
more tightly controlled, the dosimetric require-
ments are much greater since the dose deposition
must be measured with sufficient spatial and tem-
poral resolution, patient and organ immobiliza-
tion are of greater importance [36], and the treat-
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ment planning process must include sophisticated
optimization procedures if the advantages of pen-
cil beam scanning are to be exploited .
At the present time, passive beam spreading
methods still have a lot of usefulness . They pro-
vide excellent field uniformity, good beam utiliza-
tion, and the flexibility to handle different beam
energies . For proton beams variable modulation
can be achieved in combination with a multileaf
collimator. Beam delivery systems with passive
beam spreading and field shaping devices are
most easily implemented . Dosimetric require-
ments are much less stringent and treatments can,
in principle, be performed without a sophisti-
cated control system .
However, strong arguments can be made that
pencil beam scanning will be a preferred beam
delivery method in the future . This method has
the potential for administering superior treat-
ments based on optimized dose distributions and
it will allow proton therapy to stay ahead of the
advances being made in conformal photon ther-
apy. New tools needed for optimizing treatments,
dose distributions and scanning patterns [37-40]
are being developed and will be available in the
near future (cf . also Chapter 30) . Biological
models and mathematical optimization proce-
dures, mainly aimed at three-dimensional confor-
mal photon therapy but also applicable to ion
beam therapy, are being studied and fast worksta-
tions which are able to perform the extensive cal-
culations are entering the market .
Furthermore, once the technical challenges as
presented by the need for the fast and complex
control of the beam scan have been mastered, the
best treatments can be delivered with the greatest
convenience. Optimized scanning patterns, which
will automatically be translated into the control
parameters for the beam scanning system, will be
included in the output of the treatment planning
process. The treatments will be electronically
controlled freeing the therapists from the cumber-
some handling of mechanical devices such as
range compensating boli and patient collimators.
Instead, they will be able to focus on patient care .
Both, hardware and software developments
are necessary in order to realize this vision . Hard-
ware improvements are mainly needed in the
areas of fast beam monitoring and dosimetry, and
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fast beam current and beam position control . The
availability of treatment planning and optimiza-
tion software and computer codes for translating
the treatment plan into instructions for the beam
delivery control system will be crucial for making
three-dimensional pencil beam scanning a routine
method in a clinical setting.
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Introduction
Lawrence Berkeley Laboratory, University of California, CA, Berkeley, USA
Ion beam treatments of humans with radiation
require accurate, reliable, and safe methods for
controlling the ion beams. An accurate delivery
of the prescribed dose is essential for achieving
the desired cure and preventing an overdose of
radiation . In principle, if the beam is properly
tuned and the beam delivery is functioning cor-
rectly, one absolute or properly-calibrated radia-
tion detector should be sufficient for measuring
the delivered dose . In practice, however, depend-
ing on the complexity of the beam delivery sys-
tem, several detectors, with possibly many subdi-
vided detection elements, are needed for achiev-
ing the required level of accuracy and safety.
Radiation detectors that are clinically used
perform three main functions :
1. real-time measurement of the delivered dose
to the patient in order to terminate the irradi-
ation at the prescribed dose,
2. measurement of the spatial distribution of the
radiation delivered in order to ensure that the
patient prescription is satisfied,
3. measurement of radiation field parameters at
selected points along the beam line for con-
trolling the beam delivery system .
The last function is required as ion beams
from the accelerator undergo range changes, spa-
tial deflections, and nuclear interactions before
reaching the patient.
From a utilitarian point of view, the radiation
detectors may be categorized according to their
applications, such as detectors for absolute cali-
bration measurements, dose detectors whose sig-
nals are proportional to absorbed dose, radiation
detectors that can be used to measure dose after
being calibrated for a particular type of radiation,
and specialized detectors which measure proper-
ties of individual particles, e .g ., lineal energy
transfer (LET) of the projectile particle . Basic
dosimetric detectors are usually used in an inte-
grating mode, but their time response must meet
the rapidity requirements of termination of the
irradiation procedures. Fast detector response is
also called for in controlling dynamic beam deliv-
ery or measurement of the time structure of
extracted beams from an accelerator. In order to
measure the dose delivered to the patient pre-
cisely, the dose detectors must measure a quantity
proportional to the dose imparted to the patient .
They must achieve this without significantly per-
turbing the radiation field, i.e ., without degrad-
ing the radiation quality. For light ion beams,
which contain many particle species with a wide
range of LET values due to fragmentation of the
projectile particles, the dose detectors must
measure the dose independent of the LET distri-
bution in the beam. Large radiation detectors
with fine spatial resolution are important for com-
paring the prescribed and delivered radiation dis-
tributions over the entire treatment area . A
required dose accuracy for clinical purposes of
±2.5 %, measured over a large dynamic range of
approximately six orders of magnitude, adds to
the complexity of monitoring the radiation.
Many of the radiation detectors described in
this chapter have been developed for single parti-
cle detection in nuclear physics measurements .
Several have been used in the dosimetry of con-
ventional radiation (photons and electrons) . How
these detectors are used in ion beam therapy is
the subject of this chapter. The radiation detec-
tors used in ion beam therapy were described in a
recent review article [1], therefore, in this chapter
new materials are described more extensively
while others are briefly discussed for complete-
ness .
Ionization Chambers
At many ion beam therapy facilities, ionization
chambers [2] are often used as the primary dose
measuring devices because of their accuracy, reli-
ability and ease of operation . When an ion beam
traverses an ionization chamber, it produces
ionizations in the gas, which are proportional to
the energy loss by the beam, which is in turn
approximately proportional to the dose absorbed
by the detector. This dose can then be related to
the absorbed dose in another medium, such as
human tissue, by the ratio of the stopping power
of the gas to that of the medium. The ionization
charge, Q [Coulomb], produced by the beam
passing through such a chamber is proportional to
the absorbed dose, D [Gy], which is given by the
Bragg-Gray equation [3] :
Q = DpV/W
where () [kg/m3] is the mass density, V [m3] the
volume, andW [eV] the ionization energy needed
to produce an ion pair. Hence, D can be obtained
by measuring Q if the value ofWis known.
Therefore, the accuracy of the dose measured
using ionization chambers is limited by the accu-
racy of the Wvalue. The accurate knowledge of
Fig . 1 . A cross-section
of a typical transmission
ionization chamber
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Wis particularly important if intercomparisons of
clinical results from various centers are to be
made. Recently, there have been many studies for
accurate determination of the W-values [4-7] .
Based on the results of these studies, many facil-
ities have agreed to use a Wvalue of 34.5 ± 0.7
eV [8] for proton beams (cf. also Chapter 26).
The Wvalue varies for different particle types
and velocities . This becomes a critical issue when
using heavier ion beams because the beams gen-
erally contain a mixture of particles (fragments)
at various energies produced in the beam modify-
ing devices . For heavier ions the Wvalue of 33.7
eV is used [9] .
Transmission Ionization Chambers
The most common type of ionization chamber
used in ion beam therapy is the transmission type .
A typical chamber consists of two parallel planes
with an electric field applied between them for
collection of ionization charges [10] . The effective
mass of the chamber per unit area must be
reduced so that the chamber has little effect on
scattering or fragmenting the beam particles . A
typical chamber is schematically depicted in Fig-
ure 1, which is composed of the support body, gas
windows, signal and high-voltage planes, and the
electrical and gas connections. Thin, nonconduct-
ing (e.g ., Kapton) foils make up beam entrance
and exit windows enclosing a gas volume . Addi-
tional foils define a pair of parallel planes and cre-
ate a known ionization volume . One foil is con-
nected to a high voltage source and the other, a
collecting foil, is connected to appropriate elec-
BEAM
TRACE
.,eHV
SIDE
FOIL FRAME
CARD EDGE CONNECTOR
BURNDY
CONNECTOR
SIGNALS OUT
SIMULATION IN
CABLE-
UPPORT
236
	
W.T. Chu
tronics for measuring the ionization charge . The
properties of the gas used in these chambers
determine ionization yield and recombination
probability of the charge carriers before their col-
lection.
Gases such as nitrogen, air, tissue-equivalent
gas, andargon have been regularly used in ioniza-
tion chambers . Nitrogen gas or air are most com-
monly used because their ionization potential,W-
value, and stopping power ratio of gas to tissue,
(Sm), are better known and their saturation levels
are acceptable at beam intensities used for ion
beam therapy. Air is also practical because its
temperature and pressure variations can be easily
measured and corrected for and the humidity of
the air has a negligible effect on the detector
response . At high beam intensities where satura-
tion effects become important, an inert gas which
does not form negative ions, such as Ar or He,
can be used . For example, recombination effects
for Ne ions would not be expected up to -V200
Gy/s for Ar gas as compared to -20 Gy/s with air.
For higher yields Xe gas can be used with a lower
Wvalue and a higher density. For fast response
times He gas has been used because of its higher
ion drift velocity.
Thimble Ionization Chambers
As a direct measurement of dose in the patient is
not practical, the dosimeters are calibrated
against a reference ionization detector, usually a
thimble ionization chamber, placed inside a phan-
tom target volume in conditions similar to an
actual treatment.
Thimble ionization chambers are spherical or
cylindrical chambers made from conductive
plastic with a center stem for charge collection .
The plastic walls are typically afew mm thick and
the sensitive volumes are usually between 0.1 cm3
and 1.0 cm' or greater. Smaller chambers afford
better spatial resolution, but are less sensitive .
Such detectors serve as practical calibration de-
vices after they are calibrated against a national
standard, such as the one at the National Institute
of Standards and Technology in the US. These
chambers are primarily used with air or a tissue-
equivalent gas as the ionization medium .
Segmented Ionization Chambers
When radiation fields are larger than a few centi-
meters across, it is necessary to pay close attention
to the field uniformity. An ionization chamber
with segmented collection elements located as
close as possible to the patient is best suited in pro-
viding the desired on-line information. Segmenta-
tion of the collecting planes provides a means of
obtaining information on spatial dose distribution .
The number of elements can range from several to
a few thousand and their geometric arrangement
can be tailored to suit the beam spreading system .
For example, a collecting element segmented into
a set of concentric rings can measure beam profiles
with cylindrical symmetry [11] .
Other geometric arrangements can be con-
structed to measure the beam profiles that lack
cylindrical symmetries . Examples are the 19 hex-
agonal elements (5 cm across) arranged in honey-
comb fashion (Fig . 2) and the 144-element cham-
ber (a 12 x 12 array of 2.5 cm x 2.5 cm areas)
both used at LBL [10], and the 400-element
chamber (a 20 x 20 array of 1 cm x 1 cm areas) at
Loma Linda University Medical Center
(LLUMC), Loma Linda, California [12] . In these
chambers, the signals are extracted through thin
traces located on the opposite side of the foil .
Holes drilled through the foil, which are then
plated through, allow connections between the
elements and traces, as schematically shown in
Figure 2. This method avoids collection of charge
on these traces by placing them away from any
electric field .
The 3600-Element Chamber
An ionization chamber with a sensitive area of
30 cm x 30 cm with 0.5 cm spatial resolution was
built at LBL by dividing the collecting plane into
a 60 x 60 array of 5 mm x 5 mm areas [13] . The
detector was specifically designed to minimize its
impact on the beam and the space it occupies in
the beam line ; its physical thickness is 5 cm and
the water-equivalent thickness 2 mm . The main
difficulty to be overcome was the crowded condi-
tion of bringing out signal leads from the 3600
collection areas. This problem was solved by plac-
ing the signal leads in four different planes of
laminated material as in the multilayer construc-
tion technique developed for printed circuit tech-
nology. As a result, the spacings between the
leads are made as large as 0.2 mm.
Charge Integrators
Energetic ions traversing an ionization chamber
produce a charge output proportional to the
deposited dose . Because the clinical beams from
an accelerator have temporal structures, measur-
ing the dose means measuring the total charge as
an integral of a fluctuating current . The electron-
ics for these devices are generally some form of
charge integrator with a response time fast
enough for control purposes .
Aform of charge integrator that is particularly
well suited for ion beam therapy applications is
the one which issues a pulse for every fixed incre-
ment of input charge (e .g ., 10 pC) . A standard
circuit for this purpose is the charge-balancing
current integrator or recycling integrator [14] .
When used with digital electronics these circuits
measure the dose with the advantages of a large
dynamic range, exceptional linearity, and excel-
lent noise immunity.
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Typical radiation doses used for ion beam ther-
apy range from approx . 1 mGy to 10 Gy. As an
illustration, an ionization chamber using nitrogen
gas at atmospheric pressure and room tempera-
ture with a 1.0 cm3 volume exposed to such doses
produces between 35 pC to 0.35 RC. Accounting
for the variation in volumes that are used in an
ionization chamber requires the current inte-
grator to be able to measure as little as 10 pC and
as large as 3 .5 [,C. The rate at which this dose can
be delivered can vary from 10-3 to 1 Gy/s andeven
higher instantaneous dose rates . The electronics
may saturate at these high dose rates . As satura-
tion leads to an inaccurate dose measurement,
some means of detecting a saturation condition
must be provided .
Secondary Emission Monitors (SEMS)
A typical SEM consists of a set of parallel foils
(e .g ., 6 Rm thick aluminum foils separated by 3
mm) in a vacuum enclosure . The foils alternate
between collection foils and bias foils . The more
foils are used, the greater is the signal . The num-
ber of secondary electrons produced by traversing
ions depends on the energy deposited in the layer,
called the escape zone . Thework function of the
-0 TRACES
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Fig. 2. A schematic drawing of the LBL
19-element segmented ionization chamber.
The segmented collection elements are
shown in dotted lines and the signal traces
in solid lines. The collecting elements and
the signal traces are on the opposite sides
of the insulating foil . The electric connec-
tions are made via holes in the foil which
are plated through
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material and the condition of the surface deter-
mine the thickness of this escape zone . Electron
production scales linearly with foil thickness up to
the point where electrons do not escape the foil .
Good vacuum in the chamber is important for
keeping the foil surfaces free of absorbed material
which can affect the secondary electron emission .
Pressure below 1 mPa reduces the ionization of
the residual gas to an acceptable level ; however,
the better the vacuum the more consistent the per-
formance . Avacuum of 1 [,Pa is routinely used for
the purpose of beam line monitoring . A bias volt-
age of approximately -50 V is applied to the bias
foils to ensure nearly complete collection of the
electrons which have energies less than 25 eV
Dose measuring accuracy of an SEM can be
better than 1% and the long-term stability of its
output is excellent . A calibration of the SEM can
be done against a calibrated ionization chamber
or by using the foil activation technique, a calo-
rimeter, or a Faraday cup .
As mentioned above, at high dose rate satura-
tion in ionization chambers can be a major prob-
lem in their use as dose-detecting devices. SEMs
can serve as alternative detectors to ionization
chambers . Saturation in SEMs has not been seen
in electron-beam current densities of up to tens of
mA/cm', making their use ideal in situations
where there is a concern about ionization cham-
ber saturation . The SEM outputs are linear until
space charge effects become important, which
has been estimated to be above 10' Gy/s . Another
advantage of a SEM detector is its fast response
time, which is determined by the travel time of
the electrons rather than the slower migration
time of ions in an ionization chamber. Responses
in the nanosecond time scale are possible . Their
major disadvantage is the low yield of secondary
electrons per primary particle compared with ion-
ization chambers, that limits their use for low
beam particle fluxes .
Wire Chambers
In the simplest form, a wire chamber consists of
two planes of evenly spaced parallel wires sepa-
rated by a given distance, with the intervening
volume filled with gas . One wire plane is used as
the signal plane, and the other as the high-voltage
plane. The high-voltage plane can also be a solid
foil conductor instead of a plane of parallel wires.
While the common application of wire chambers
in particle physics is to detect traversing particles
on a particle-by-particle basis, in ion beam ther-
apy applications wire chambers are more often
used as integrating devices that integrate spatially
along a wire as well as temporarily during an
irradiation procedure. Typical clinical ion beam
intensities are between 0 .1 pA and 0 .1 mA.
Wire chambers are typically operated in a pro-
portional mode where a multiplication of the
initial ionization occurs, but can be operated in
an ionization mode where the gain is unity. In the
former mode, multiplication of the initial ioniza-
tion occurs when the ionized electrons, acceler-
ated by the strong potential gradient around a
wire, cause further ionization . The gain is depen-
dent on the type and pressure of the gas, the wire
spacing, and the high voltage. By decreasing the
wire spacings, increased spatial resolution can be
achieved at the price of decreased gain due to the
decrease in potential gradient around the wires.
Wire spacing as coarse as 6 mm and as fine as
0.2 mm are practical . Gold-coated beryllium/cop-
per wires of 50 [m diameter are often used
because of their longevity and mechanical stabil-
ity in the beam . Common gases used in such de-
vices are air, argon, or gas mixtures such as 10
argon and 90% CO2. Atmospheric pressure is a
convenient gas pressure ; however, lower as well
as higher pressures have been used . The princi-
ples of construction and operation of wire cham-
bers have been discussed widely [15] .
Two planes of sense wires placed orthogonally
can show the horizontal and vertical projections
of the beam profile. The centroid and the width of
the beam can be computed in each plane for
beam-tuning purposes . Monitoring beam profiles
is important for efficiently transporting the ion
beams and obtaining the correct dose distribu-
tions with the beam delivery system . Typically, a
wire chamber is positioned upstream of the beam
delivery system and a second wire chamber is lo-
cated downstream of the delivery system, near
the patient . The active area of the second cham-
ber is typically large to accommodate the large
radiation fields .
MEDUSA
Amulti wire, multiplane wire chamber, called the
Medical Dose Uniformity Sampler (MEDUSA),
was developed at LBL to reconstruct the two-
dimensional dose profile of a beam [16] . It has 16
wire planes, each of which has 64 wires separated
by 4 mm. Each plane samples the beam profile
projected into the particular wire direction, which
is offset by 11.25 degrees (180 degrees divided
into 16 equal angles) from adjacent planes . Based
on the 16 projected profile data sets, MEDUSA
reconstructs the two-dimensional dose profile
within a circular area of 256 mm diameter. The
reconstruction of the two-dimensional image
relies on the 'filtered back projection' algorithm .
Diodes and Diode Arrays
The usefulness of diodes as dose detectors derives
from their small size [17] . Measuring dose dis-
tributions with fine spatial resolution is difficult
with ionization chambers, but simple with diodes
which intrinsically have small active areas . As a
solid, they absorb a lot more dose in a small vol-
ume. Generally speaking, there are two disparate
applications of diodes in a typical ion beam ther-
apy facility : Efficient mapping of large dose
fields, where the feasibility of a diode array is par-
amount, and mapping of very small dose fields
(e.g ., for eye treatments), where ionization
chambers maybe too large to serve. A calibration
of the diode must be done before use since they
suffer radiation damage over extended exposure .
They are, however, excellent for relative mea-
surements over short time periods. Arrays of di-
odes have successfully been used for measuring
profiles of radiation fields and Bragg ionization
curves [18] .
Junction diodes, connected to an electrometer
which keeps the voltage across the diode nearly
equal to zero, exhibit a current (in the `reverse'
direction) nearly proportional to the dose rate
over a wide range [19] . There is extensive litera-
ture on this subject ; however, most of it is about
photon and electron beam applications [20] .
Nearly any diode will work ; power rectifiers,
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small-signal diodes, microwave diodes, LEDs and
photodiodes have all been used . Their advantages
are small size, low cost, ruggedness and simplicity
of use (no polarizing voltage) . Their disadvan-
tages include sensitivity to electrometer voltage
burden, decline of output with accumulated dose,
and small temperature and dose rate effects.
Commercial diodes for electronics are N-type .
P-type diodes built especially for dosimetry are
available. They exhibit less radiation damage and
smaller dose rate effect [20], but their cost almost
rules them out for large arrays .
The associated electrometer is usually an
integrator, to measure total charge produced in a
monitored exposure . Diodes place a special
demand on the electrometer, and their use may
be frustrating unless one takes into account that
the voltage burden (voltage appearing at the
integrator input during normal operation) is crit-
ically important. This is not the case with either
an ionization chamber or a Faraday cup. This
voltage, appearing across the effective resistance
of the diode, causes a drift current which will vary
with time and temperature unless the electrome-
ter amplifier is carefully chosen . Many popular
commercial electrometers are inadequate in this
regard but it is not difficult to find an inexpensive
operational amplifier (e.g ., the Texas Instruments
TLC27L2) which is suitable [21] . Unfortunately
this leaves the potential user (especially of diode
arrays) with an in-house construction project. A
64-channel integrator has been designed,
developed and tested at the Harvard Cyclotron
Laboratory (HCL), and is available on request.
Otherwise, the use of diode arrays is straight-
forward. They should feed an array of integrators
which is scanned, digitized and read out using
some standard scheme, e.g ., RS-232 or CAMAC.
Each channel should be read out before and after
the exposure so that the difference can be taken.
Also, in lengthy experiments one should calibrate
the diodes before and after the run and keep
track of the dose so that final corrections can be
made. As the degradation of sensitivity with
integrated dose is initially larger, it helps to pre-
irradiate the diodes to approx . 1000 Gy.
The sensitivity range of diodes is significant;
e.g ., roughly 140 pC/cGy for a 1N4004 (1-A recti-
fier), 100 pC/cGy for the Hamamatsu S2164 pho-
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todiode, 10 pC/cGy for a typical small-signal
diode, and 1 pC/cGy for one element of an ELB-
1001HDA 10-element LED array useful in map-
ping very small fields . These numbers will
decrease substantially over the useful life of the
diode . For comparison, a0.05 cm3 thimble ioniza-
tion chamber registers about 10 pC/cGy.
When mapping large fields of high-energy ions
the diode package makes no difference, but for
precise work (especially near end-of-range) the
photodiode, with its thin and precisely known cov-
ering layer, is an elegant package. Of course, pho-
todiodes and LEDs must be carefully light-
proofed . Exposed conductors should be covered
with coil dope or RTVsealant so that charge is not
picked up from ionized air. Depending on the
environment, electrostatic shielding (aluminum
foil crimped to the shield of the output cable) may
be needed . RG-17813/U miniature Teflon insu-
lated cable works well in this and other low signal
applications because the cable itself produces lit-
tle signal when exposed to radiation or when
flexed . Avoid connectors, except coaxial types,
wherever they might be exposed to radiation .
The use of single diodes for precise dose mea-
surements, though convenient, is somewhat prob-
lematic. Koehler [19] reported about 8% more
output from a particular diode (long since
unavailable) than from a parallel-plate ionization
chamber in the Bragg-peak region, when the two
were made to agree in the `entrance' region . If a
thimble chamber is used as the reference do-
simeter additional geometric effects come into
play, and total discrepancies of approx . 15
(diode vs . thimble chamber at the Bragg peak)
are found at HCL [22] . At present, there is a
wealth of (sometimes contradictory) observa-
tions, but very few published . One can only con-
clude that there is an energy-dependent problem
- diodes and ionization chambers, more often
than not, exhibit different Bragg curves -that dif-
ferent diodes seem to give different results, as do
different ionization chambers, and that the prob-
lem may lie with the diodes, the ionization cham-
bers, or both . Energy dependence in proton
beam dosimetry at the 5-10% level simply re-
quires further study.
At HCL a dose scanner within a water phan-
tom has been developed . A small water phantom
with approximately 15 cm x 15 cm entrance win-
dow and 18 cm depth along the proton beam is
supported on a three-axis computer-controlled
positioning system that can quickly and reprodu-
cibly place the tank anywhere in a therapy field.
Within the tank, a fourth axis controls the depth
of a detector module containing a thimble ioniza-
tion chamber, an 8 x 6 array of diodes, a 'stair-
step' array of diodes for depth detection, and 3
diodes for edge scanning . The system can be
manually controlled either locally or remotely, or
by a computer command file .
The system takes advantage of the reduced
scattering of protons vis-ä-vis photons to use a
much smaller tank . It is only necessary to ensure
that any detector within the tank is surrounded
laterally by a radius R of water (or plastic) such
that any beam conditions outside of R have an
insignificant effect on the dose at the detector.
For 160 MeV protons, R = 2 cm is sufficient for
most situations but R = 5 cm was chosen for a
wide safety margin . The weight of the resulting
tank is small enough to move the entire tank and
position the detectors laterally after moving from
a parking position out of the way of patients
undergoing therapy. Deployment of the tank
which remains filled with water, aligned with the
beam, and connected to the necessary integrators
and electrometer can be accomplished in about a
minute . Quicker and more detailed scans of
patient treatment beams are the result .
The detector module supports the various
detectors in a dry environment, surrounded by
plastic, within the water tank . An Exradin T1
tissue-equivalent ionization chamber is laterally
centered in the module, but with only a small
amount of plastic window upstream . The cham-
ber is connected to an electrometer (Keithley 617)
about 30 m away, operated in the floating mode .
An array of 48 photodiodes (Hamamatsu S2164)
in 6 columns of 8 diodes with 10 mm column spac-
ing and 8 mm row spacing are connected to a 64-
channel integrator with very low input voltage
burden using individual 3 m coaxial cables
(RG174) . The diode connections to the coaxial
cable are concealed in RTV silicon, the entire
module is electrically shielded with silver paint,
and protected from light by an additional coat of
black paint. Edge-mounted diodes are used for
lateral scans of beams with very sharp penumbra.
A stairstep of 8 diodes spanning 16 mm in depth
in 2 mm steps is used to quickly measure a depth
dose in a region of relatively uniform depth.
The Exradin ionization chamber is used for
routine beam line checks as well as individual
patient therapy beam calibrations . The diodes are
used for more detailed scans and for apertures
too small to be accurately measured by a larger
ionization chamber. The diodes can be recali-
brated automatically in 2 minutes by a sequence
that measures the dose in the central region of a
flat field using the ionization chamber and then
serially brings the diodes into the same region in
four groups to be calibrated . This procedure is
necessitated by the inevitable radiation damage
to the diodes, and must be repeated frequently
only if large volume scans at high accuracy are
required . Figure 3 shows adepth scan using a row
of 8 diodes with points taken every 1mm of depth
in the region of the Bragg peak . The alignment of
the data points from diode to diode at the distal
50% shows that the variation in depth is about
0 .1 mm of water. This regularity, together with
accurate lateral diode positioning and ease of cali-
bration, results in large data sets that display con-
tinuity over the many diodes involved in the scan .
Fig . 3. A depth scan obtained using
the HCL diode array. The Bragg
curves are taken at every 1 mm
(near the peaks) and 2 mm (on the
plateaus) interval using a row of
eight diodes . Courtesy of M. Wag-
ner, HCL
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Other Types of Radiation Detectors
Several types of devices other than ionization
chambers, SEMs, wire chambers, and diodes
have been successfully used in ion beam therapy
applications . Each, as discussed below, has its
special application.
Semiconductor Detectors
Aside from the use of diodes, semiconductor
detectors are used for many different purposes in
ion beam therapy applications .
Semiconductor detectors such as Si surface
barrier detectors or thin Ge detectors are excel-
lent for measuring the energy loss of a particle
since they have high sensitivity, and their
response is independent of the particle type and
proportional to the energy deposited. A much
smaller amount of energy is required to produce
an electron-hole pair compared to -35 eV
needed in a gas ionization chamber to produce an
ion pair. However, they do suffer from a pulse
height defect associated with large energy deposi-
tions leading to recombination of electron-hole
pairs . A Ge crystal of sufficient thickness to stop
CONSTANCY CHECK
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an incoming particle can serve as a total energy
detector. Ge detectors have excellent particle
energy resolution, typically dE/E -~~ 0.1%, but
radiation damage can lead to a degradation in
their energy resolution . These detectors are used
primarily for single particle detection and are not
suitable for measurements at normal clinical
beam intensities.
The biological damages due to high-LET radi-
ation cannot completely be described by the dose
and average LET The actual composition of the
beam in terms of the particle types and their rela-
tive contributions to the biological damages must
be determined . Aparticle detector system known
as the BERKLET, has been developed at LBL in
order to identify the particle charge, but not
mass, along with its residual energy and LET[23] .
The system consists of a 300 [,m thick Si detector
followed by a 5.5 cm thick Ge detector. The two
detectors, operated in coincidence, measure the
dE/dx and the total energy of the particle, respec-
tively. The total energy that can be measured in
the Ge detector corresponds to a particle with an
18.7 cm penetration in water. Another application
at LBL of solid-state detectors is the use of
position-sensitive Si detectors to measure multi-
ple Coulomb scattering and compare the data
against several scattering formulas [24] .
Scintillators
In high-energy and nuclear physics experiments,
scintillators have been used extensively for single
particle detection . In ion beam therapy, they have
been used primarily for beam controls because of
their fast response times and large dynamic
ranges of operation when used in conjunction
with phototubes . Large beam currents cause radi-
ation damages to the solid scintillators, which
limit their lifetime and affect their response .AXe
gas scintillator has been used to control the beam
at Loma Linda [25] . As light production in the
scintillator is not simply proportional to the
energy loss of the particle due to quenching, their
use as a dose detector requires special calibration .
Recently, they have been used in conjunction
with charge-coupled devices (CCD) to measure
the lateral uniformity of a radiation field and to
measure the scintillation light as a function of
depth for range verification [26] .
Calorimeters
The temperature rise of a material from energy
deposited in it by an ion beam may be used for
absolute dose measurement. Water temperature
increases by 2.4 x 10' per Gray of deposited
dose ; but, making an accurate measurement is
difficult . Calorimeters are no practical means of
measuring dose for on-line clinical dosimetry, but
rather serve as calibration standards (see subse-
quent chapter for details) .
Faraday Cups
Faraday cups measure the number of particles by
measuring the charges collected on an electrically
isolated and evacuated container which stops the
beam [27] . When monoenergetic ions impinge
upon the Faraday cup, the dose is calculated from
the measured number of particles per unit area
andthe mass stopping power of the particle at the
given energy in tissue .
Film
Film is the most economical method for measur-
ing spatial dose distributions with the finest spa-
tial resolution available, yet it is not a rapid
instrument . The spatial resolution achievable
with film is limited by the resolution of the digitiz-
ing procedure, the speed of which is in turn lim-
ited by the time required for digitization and data
reduction. The darkening of the film, i .e ., optical
density, after exposure to an ion beam can be
used to measure the dose . In retrospective studies
at LBL, film is shown to provide better than
±5% absolute dose accuracy if the development
conditions are closely controlled ; however, few
rely on film for clinical dosimetry. The optical
density depends more on the particle fluence than
the dose deposited . In other words, it depends on
the LET of the particles . For this reason, film is
primarily a relative dose detector and is used for
measuring lateral dose distributions rather than
depth-dose distributions which exhibit pro-
nounced LET dependence .
Thermoluminescent Dosimeters (TLDs)
TLDs are inorganic materials, such as LiF or
CaF2 , that do not scintillate promptly, but rather
trap electron-hole pairs created from the expo-
sure to ionizing radiation. Upon heating the
exposed material, the trapped electrons can
escape, leading to light emission which can be
detected, and related to the absorbed dose .
Chemical Dosimeters
In chemical dosimetry, radiation dose is deter-
mined by measuring the chemical change pro-
duced in an irradiated medium . The most well-
known chemical dosimeter is the Fricke dosime-
ter, which determines the dose by measuring the
ferric-ion yield from the oxidation of Fe 21 to Fe3l
by the interaction of the ionization and the
ferrous-ion. The measurement of optical density
of the irradiated solution at a specific wavelength
can be interpreted in terms of the ferric-ion den-
sity, which is in turn related to the dose .
One of the recent developments in ion beam
dosimetry is the application of alanine com-
pound . Radiation changes the chemical structure
of alanine crystals, and the degrees of the chemi-
cal changes can be determined by analyzing the
Zeeman hyperfine molecular levels through elec-
tron spin resonance (ESR) . Its advantages are
portability, tissue-equivalence, and minimal fad-
ing at ambient temperature which provides per-
manent irradiation record . Its LET dependence
and reproducibility are still to be investigated
[28] .
Nuclear Activation
Foil activation utilizes the ion beam undergoing a
nuclear reaction of a known cross-section in a foil
of a known thickness . The radioactive yield can
then be measured by means of its decay over
time, which determines the initial beam intensity,
and hence the imparted dose . For example, the
reaction
has been used to determine absolute fluence and
absorbed dose of protons for therapy. This
method is used more for verification than on-line
analysis .
As a variation of the above method, in vivo
dosimetry for assessing the integral dose of an ion
beam irradiation has been studied by detecting
the decay products of "C, 13N and '50 from tissue
activation [29] .
Solid-State Nuclear Track Detectors
The passage of energetic ions through most insu-
lators forms narrow regions of radiation damages,
called `latent tracks' . In crystals, such a track may
be detected by viewing with an electron micro-
scope; in polymers by means of special coloring
of the track. A more practical method is to use
plastic sheets and to etch the latent tracks selec-
tively, which can subsequently be viewed with an
optical microscope. Plastics such as CR39 have
been extensively used to measure the LETdistri-
bution of heavy ion beams [30] . Measurements of
an individual track left by traversing or stopping
heavy charged particles in plastic detectors render
information about their dE/dx, charge and mass
number and sometimes velocity. Recently, the use
of solid-state nuclear track detectors in nuclear
physics has been reviewed [31], and lists of com-
mercial sources of most commonly used material
for solid-state nuclear track detectors are found in
publications [32] .
Concluding Remarks
25 Radiation Detectors
	
243
12C+p-~ uC+p+n
Many accurate and reliable radiation detectors
have been developed and used in ion beam ther-
apy applications . However, important questions
that must still be answered remain for complete
understanding. For example, the discrepancies in
the Bragg curves obtained by different detectors,
such as diodes and ionization chambers, should
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be explained . Some areas of future developments
in radiation detectors are the development of
dose detectors which can provide a spatial resolu-
tion (- 1 mm) sufficient for reconstruction of
dose distributions deposited in a patient using
pencil-beam scanning, development of two-
dimensional amorphous silicon detector arrays,
new detectors such as the use of scintillating
material or Fricke gels for three-dimensional dose
measurements with a high spatial resolution .
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Dosimetry Techniques for Ion Beams
S. VYNCKIER
Introduction
Universite Catholique de Louvain, Cliniques Universitaires St-Luc, Brussels, Belgium
Dosimetry of a therapy beam means determina-
tion of the absorbed dose at a point of reference
and measurement of dose distributions in a tis-
sue-equivalent phantom . The first is essential in
order to verify the prescriptions of the protocol
whereas the latter is indispensable for planning
and quality assurance purposes . The choice of a
particular dosimeter will depend on several fac-
tors, such as the accuracy and sensitivity desired,
and the size of the detector with respect to beam
size and gradients involved .
Ion beam dosimetry can be performed using
different types of dosimeters including calorime-
ters, ionization chambers, or Faraday cups [1, 2],
see also preceding chapter) . National standard
dosimetry laboratories will not provide, however,
a standard for the dosimetry of ion beams . In
order to achieve uniformity on an international
level, the use of an ionization chamber, calibrated
in terms of air-kerma in a "Co beam has to be
considered .
In conventional photon dosimetry the calorim-
eter [3,4] yields the smallest uncertainty in the
determination of the absorbed dose, as the mea-
sured quantity is the heat equivalent of absorbed
energy. Although the use of calorimeters for do-
simetry is cumbersome and not suitable for daily
practice, research with calorimeters should be
encouraged and continued .
Faraday cup measurements are based on the
determination of the ion beam fluence . In prac-
tice, these Faraday cup measurements are com-
bined with an ionization chamber, exposed to air,
in order to calibrate the ionization chamber for
later dose determinations in a phantom . This
method requires a perfect monoenergetic beam .
Moreover, the efficiency of the determination of
the fluence will be susceptible to the design of the
cup, i.e ., wall thickness, quality of the vacuum,
guard ring bias voltage, etc. [1, 2,5] .
Practical dosimetry for conventional therapy
beams is based on ionization chambers used
under well defined conditions . Ionization cham-
bers provide accuracy as well as convenience in
use. They can be compared to other dosimetric
methods and, if used under these well defined
conditions, they will provide uniformity in beam
dosimetry, which is one of the main goals of the
recommendations.
For ion beam dosimetry, a "Protocol for Heavy
Charged Particle Beam Dosimetry" exists which
was developed by Task Group 20 of the American
Association of Physicists in Medicine (AAPM)
[6] . This protocol describes the methods and
recommendations for the determination of the
absorbed dose in a heavy charged particle beam.
With respect to proton beams, a "Code of Prac-
tice for Clinical Proton dosimetry" [7, 8] was writ-
ten by a working group of the European Clinical
Heavy Particle Dosimetry (ECHED) association.
The following paragraphs will surnmerize the
basic principles and recommendations for the
dose determination in a proton beam, based on
the "Code of Practice for Clinical Proton dosime-
try" [7, 8] . This code recommends the use of a
water calorimeter as reference instrument or, if
not available, an ionization chamber, calibrated
in terms of air-kerma in a "Co beam. These prin-
ciples can also be applied to other heavy charged
particle beams. However, so far there is no inter-
national consensus for adopting the values of the
basic physical parameters in a charged particle
beam. Moreover, the uncertainty on theW-value
(i.e ., the mean energy to produce an ion pair in
the cavity gas) [9] is rather large for ion beams.
Some recommendations can be found in the
AAPM Report 16 [6] . Therefore, it should be rec-
ommended that for ion beams, other than pro-
tons, the ionization chamber be calibrated
directly with respect to a calorimeter in terms of
absorbed dose .
Measurement Conditions
for Ionization Chamber Dosimetry
in a Proton Beam
At present, there are two major types of clinical
applications of proton beams [10-12] : low-energy
protons (Ep <90MeV), for the treatment of ocu-
lar melanomas [13,14] and higher energy protons
(Ep > 150 MeV) for the treatment of large and/or
deep-seated tumors . For the former kind of treat-
ment, small field sizes (field area 15 cm2) and high
dose rates (dD/dt >10 Gy/min) are applied
whereas in the latter, conventional field sizes with
conventional dose rates as utilized in photon or
electron radiotherapy are employed .
Ionization Chamber Specification
In principle, any type of reliable ionization cham-
ber, as used for photon dosimetry, can be
employed . However, most of the medical physi-
cists performing proton dosimetry are using
tissue-equivalent (TE) ionization chambers,
made of A-150 [1,7,8] . Therefore, the formalism
developed here is typically for TE ionization
chambers . For other types [15,16], the formalism
should be adapted, accordingly.
The choice of the cavity gas in the ionization
chamber is strongly dependent on the knowledge
of the (Wsa,)p value for proton beams. Due to its
simplicity, preference should be given to air.
Recently, Hiraoka et al . [17] measured the (Wgas)p
ratios in a 70 MeV proton beam for different
gases. As a result the (Wgas)p for air can be
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Table 1 . AWa  factors for tissue-equivalent ionization cham-
bers
Exradin T1 0.05 0.992
FW IC18 0.1 0.991
Exradin T2 0.5 0.985
FWTIC 17 1.0 0.983
obtained from determinations in another gas, as
for instance N2. All formalism that will follow is
only valid for air, used as cavity gas.
Proton Energy and
Absorbed Dose Specification
For ionization dosimetry in a proton beam, mass
stopping power ratios need to be known (see
below) . However, these ratios vary slowly with
energy (Table 2) . A clinical proton beam
with a spread-out Bragg peak (SOBP) will not be
Table 2 . Mass stopping powers for water and air and their
ratio. From Ref. 18
Proton energy Mass stopping powers
kMvV) (MeV cm
water
g')
air water/air
10 45.67 40.06 1.1400
20 26.07 22.94 1.1364
30 18.76 16.53 1.1349
40 14.88 13.12 1.1341
50 12.45 10.99 1.1328
60 10.78 9.517 1.1327
70 9.559 8.443 1.1322
80 8.625 7.620 1.1319
90 7.888 6.970 1.1317
100 7.289 6.443 1.1313
125 6.192 5.475 1.1310
150 5.445 4.816 1.1306
175 4.903 4.338 1.1302
200 4.492 3.976 1.1298
225 4.170 3.691 1.1298
250 3.911 3.462 1.1297
275 3.698 3.275 1.1292
300 3.520 3.118 1.1289
350 3.241 2.871 1.1289
400 3.032 2.687 1.1284
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moncenergetic and knowledge of the mean
energy or the proton energy spectrum at the cali-
bration point is requested . The energy of the pro-
ton beam can be specified with its effective
energy (Ep)ef if the energy spectrum or the resid-
ual range at the point of interest is unknown. The
effective energy can be defined as the energy of
the monoenergetic protons which have a continu-
ous slowing down approximation (CSDA) range
in water equal to the residual range behind the
middle of the SOBP CSDA energy range data for
proton beams in different materials are found in
the ICRU 49 [18] .
The effective energy is only a rough representa-
tion of the energy spectrum, but can easily be
obtained from dosimetric data . Water is used as
material for absorbed dose specification as in the
case of photon and electron beams, since the mass
stopping power ratios for different tissues relative
to water do not deviate to much from unity [19] .
Reference Phantom Material and
Reference Depth for Measurement
In clinical dosimetry, phantom materials should
be closely matched to tissue, i.e ., they should
have very similar absorption and scattering prop-
erties for the radiation beam considered . They are
used for two purposes : to simulate the presence
of tissue when determining the absorbed dose
under reference conditions (reference field size,
reference depth, etc.) and secondly, to obtain
basic dose distributions, e.g ., percent depth
doses, off-axis data and isodose contours .
Absorbed dose for proton beams is specified in
water and so, by preference, calibration measure-
ments should be performed in water. However, for
simplicity, routine output checks can always be per-
formed in an acrylic phantom (PMMA or "solid
water") as long as the depth of measurement is
scaled to the SOBP in water. This scaling can be
obtained from the CSDA ranges in the different
materials which can be found in ICRU 49 [18] .
The center of the SOBP is a region of dose uni-
formity. Therefore, calibration should be per-
formed in the middle of the SOBP or - if no
SOBP is produced (spot scanning) -in a region of
high dose uniformity.
Determination of the Absorbed
Proton Dose by a 'Co-calibrated
Ionization Chamber
Determination of the absorbed dose using ioniza-
tion chambers is based on the Bragg-Gray cavity
theory [20]
D = Q x W x SW19 (1)m e
where D is the dose to the wall surrounding the
cavity, m the mass of the gas in the cavity, W the
energy required to form an ion pair in the gas and
sWg the mass stopping power ratio of the wall
material, wto the gas, g. The assumptions for the
application of the Bragg-Gray relation are stan-
dard, i.e ., the dimensions of the cavity are small
compared to the range of the particles that ionize
the gas and the presence of the cavity does not
disturb the proton fluence .
Calibration of the Ionization Chamber
in a Photon Beam
Calibration of an ionization chamber for proton
dosimetry can be performed by exposure to a
60Co-gamma beam in free air (or to an equivalent
2MV X-ray beam) . The calibration must then be
obtained by comparison with another ionization
chamber calibrated to a reference source of a
national standard laboratory. National standard
laboratories provide either air-kerma calibration
factors, NK (Gy/reading) or exposure calibration
factors, N,, (C/(kg x reading)) . The air-kerma cal-
ibration factor andthe exposure calibration factor
are related by :
NK = N,,(Waj~e)e (2)1-g
where g is the fraction of energy of secondary
charged particles that is converted to Bremsstrah-
lung in air. The index c stands for calibration
beam.
By application of the Bragg-Gray cavity theory
for an ionization chamber filled with air, the mass
of the gas (mair) in the cavity of the chamber can
be obtained from the 60Co-calibration through:
or when using an exposure calibration factor :
In Equations (3) and (4), Awall is a factor that
corrects the chamber response for the absorption
and scattering in the chamber wall, its build-up
cap and stem during the calibration in air in the
60Co beam, (Wair/e)c is the average energy
expense per ion pair formed in dry air by the pho-
ton calibration source, [(Iren/,)Ar150]c is the mean
energy absorption coefficient ratio of wall material
(A-150) to air for "Co and [(L/Q)ä-15']c is the mean
restricted collision mass stopping power ratio of air
to wall material for the slowing down spectrum of
electrons released by the calibration radiation.
The mass of the gas (mair) can be related to the
cavity-gas calibration factor, Ngas, known from the
American protocol (AAPM, Report 21) for
absorbed dose determination from high energy
photon and electron beams [16] :
i
or :
mai - (Wair/e)c X [(L/Q)ar ls
o]c[(Fen/Q)Ar150]c
	
(3)r - Nk (1-g) X Awall
[(L'/(J)aaiir 1 50 ]c [&n/Q)A-150]cmair - N,, X Awall
Ngas = Nair = (Wair/e)cmair
Nair = Awall X (1 - g) X NK X [(L-air X
(6)[(Iten/Q)aAir 150]c
Since most national standard laboratories are
providing air-kerma calibration factors, it is rec-
ommended to use Equations (3) or (4) for the cal-
ibration expression .
Ionization Chamber Dosimetry
in Proton Beams
Substitution of these calibration factors in the
general Bragg-Gray formula, applied during the
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measurement with this ionization chamber in a
phantom, irradiated with the proton beam, will
yield (by combination of Equations (1) and (3))
the absorbed dose to the chamber wall (A-150),
DA-15o :
DA-15o = Mcorr X NK X (1-9) XAwau X [(_jXen/Q)airteIc
X Made), X _ [(S/0air
150]P (7)
(Wair/e)c [(L/Q)'150]c X [(i'en/Q)At150]c
In this equation (Wair/e)c is the average energy
expense per ion pair formed in dry air by the pro-
ton source, [(S/Q)äirlso]p is the mass stopping
power ratio of air to the wall material (A-150) at
the proton energy considered and Mc,,rr is the
chamber reading corrected for ambient condi-
tions such as temperature, pressure, ion collec-
tion etc. The absorbed dose to water is then
obtained from Equation (7) by multiplication with
the mass stopping power ratio of water to A-150 :
Dwater = Mcorr X NK X (1 - g) X Awall X
X (Wade), X _ [(S/()airater]P (8)
(WaiPe)c [(L/Q)air150]c X [(fi'en/~)A-150]c
Under these conditions the absorbed dose in a
proton beam, measured with an ionization cham-
ber can be written in the following simple formula
with :
Dwater = Mcorr X NK X Cp (9)
Cp =Awall X [(S/Q)airter]p X k .	 10
In this equation Awall is a chamber-dependent
factor, [(S/Qgater]p a proton energy-dependent fac-
tor andk a constant whose expression is
airk=(1-g)X X A1507(Wair/e)c [(L/Q)air Jc
(1- 9) X (Wair/e)p X kni(Wair/e)c
In this Equation k, is the parameter that cor-
rects for the non-air equivalence of the chamber
wall and build-up cap .
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If other ionization chambers are used, as rec-
ommended in the IAEA Report 277 or AAPM
Report 21 [15,16] with wall and build-up cap con-
structed from different materials, then the wall
correction factor, also known as the katt factor, can
be found in the paperfrom Nath and Schultz [21)
or in the existing photon dosimetry protocols .
For these ionization chambers Equations (3)
to (12) are not valid and the non-air equivalence
of the wall and build-up cap should be corrected
by the km value
airkm = { a X [(L/Q)airle X [(~en/~)wall]c + (1 - a)(12)
where a is the fraction of ionization due to
electrons set in motion in the chamber wall during
calibration. Values for these quantities for differ-
ent ionization chambers can be found in existing
photon dosimetry protocols [15,16] .
The values of all physical parameters in order
to obtain the absorbed dose and their uncertain-
ties are discussed in the following section. Utiliz-
ing the values given there, k is equal to 0.993 for
A-150 ionization chambers .
Correction Factors on the
Ionization Chamber Reading
In Equation (9) M.rr is the corrected reading and
is obtained from the true reading, M, by
Mcorr =MX IiI pi (13)
with II pi the product of factors in order to correct
the electrometer reading to the charge produced
in the cavity under standard temperature and
pressure conditions . It is defined as
II Pi = PT,P X Phum X (hpI)c X (Pion)c X pi (14 )
The indices p and c refer to the proton beam
and calibration beam, respectively. The parame-
ters are
pT, p, temperature and pressure correction fac-
tor correcting the reading with respect to the
reference temperature andpressure . Reference
temperature and pressure are generally equal
to 20 °C and 101.3 kPa.
Phum, humidity correction factor. It corrects the
chamber reading from ambient air to dry air
conditions . A value of 1.0025 [22] which corre-
sponds to 50 % humidity can be used . An
alternative way is to flush the ionization cham-
ber with dry air.
(ppol)p,c, polarity correction factor. It corrects
for the change in chamber reading as a result of
a change in polarity of the polarizing voltage.
For most of the recommended tissue-
equivalent ionization chambers this effect is
small in the calibration beam as well as in the
proton beam.
(Pion)p,c, ion recombination correction factor.
This factor corrects for any losses in charge due
to recombinations . If the calibration beam is
6°Co this effect is negligible . For the pulsed
radiations the effect can be calculated from
Boag's theory [23] . Proton beams are produced
by different types of accelerators, including
those that have a brief duty cycle. Therefore,
the recombination effect (pioa)p should be
checked by measuring the saturation curve.
p;, product of any other correction factors such
as electrometer calibration, leakage currents,
cable length etc.
Physical Parameters for Ionization
Chamber Dosimetry and Estimation
of the Uncertainties
The uncertainty in the measurement of the
absorbed dose in proton beams is mainly influ-
enced by the uncertainty on the (Wair)p value
(Tab . 3) . Up to now, some measurements are
available for this parameter [9,17, 24-26] . On the
other hand, continuing efforts are being made
[27-31] with different types of calorimeters .
Comparison of calorimeter dosimetry with ion-
ization dosimetry will yield more information
with regard to physical parameters . The parame-
ters that follow are typically for tissue-equivalent
ionization chambers made of A-150 and filled
Table 3. Comparison of absorbed dose determinations with
ion chambers and calorimeters
Physical Factors Used in Calibration
with air, as discussed above. For other ionization
chambers the values can be found in photon do-
simetry protocols [15,16].
Most of the factors to be used are, at present, rec-
ommended uniformly in the different photon
dosimetry protocols
- g: the most recent value for the fraction of
energy of secondary charged particles, con-
verted to Bremsstrahlung for the calibration
beam is 0 .003 [32] .
- (Wa;r), : the value for the average energy
expense per ion pair in dry air for the calibra-
tion beam is 33.97 ± 0 .06 J/C [33] .
the mean energy absorption
coefficients for photon energies near 1 MeVare
taken from Hubbell or the ICRU 46 [19, 34] .
The ratio of air to A-150 is 1 .101 .
_ [(L/~)arisn]~ ; the mean restricted collision mass
stopping powers are found in the ICRU 46 or
for instance the AAPM protocol . The ratio for
air to A-150 is 1 .145 .
Ionization Chamber-Dependent Factors
- A,, : values for the wall correction factor for
commercially available tissue-equivalent ion-
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ization chambers (A-150 wall + buid-up cap
with a total thickness of 0 .59 g/CMZ) are taken
from Gastorf et al . [35] and shown in Table 1.
The uncertainty was estimated by Rogers et al .
[36] .
Proton Beam-Dependent Factors
[(s/~)air ter]P : in the past, stopping powers for
protons were taken from tables of Janni [37] .
Recently, the ICRU published stopping power
values for monoenergetic proton beams for dif-
ferent materials [18] . Mass stopping power
ratios must be calculated from these tables . For
ionization chamber dosimetry only the mass
stopping power ratio air to water has to be
known . This ratio varies only slightly with
energy. The proton beam energy is specified
with its effective energy (Ep),ff . Table 2 shows
the stopping power values for water and air and
their ratio.
(Wa, ; C)p : the (Wa;r)p value yields the greatest
uncertainty and its choice is susceptible to dis-
cussion. Avalue of 34.3 J/C is recommended by
the AAPM [1, 6], whereas the ECHED proto-
col [7, 8] together with the Japanese centers
[38] recommends avalue of 35 .2 J/C, based on
ICRU data [9] . Measurements of (WN,)r were
performed recently at Boston [24] andat Lou-
vain [25, 26]. They found values of 36.3 J/C at
150 MeVand 36.84 J/C at 65 MeV, respectively,
which is close to the ICRU value for nitrogen
of 36.5 J/C. Hiraoka et al . [17] measured rela-
tive W-values for air to nitrogen at 70 MeV
Assuming a value of 36 .5 J/C for nitrogen
(taken from the ICRU) their mesurements con-
firmed the recommended value of the ICRU of
35 .2 J/C. In the absence of further experi-
ments, the value of 35.2 J/C for (Wa;r)p can be
used at all energies . At present, water calo-
rimeters results have become available [27, 28,
30, 31] . These measurements indicate (Table 3)
a difference of approximately 2% between the
ionization chambers (applying a value of35 .2 J/
C for (Wa;r)P) and the calorimeter. This would
mean that in the future a ± 2% lower value for
(Wair)p might be recommended or a supple-
mentary correction factor of -2% should be
Calorimeter
material
Proton
beam energy
Wevj
D;m/D w center
referenee
A-150 51 .9 1.015 Orsay -
LPRI [28]
A-150 32 .6 1.003 Orsay -
LPRI [28]
A-150 186 1.024 Orsay -
LPRI [28]
water 160 1.01 Boston -
MGH [27]
water 180 1.022 Loma
Linda [30]
water 47 1 .027 Louvain-
Ghent [31]
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Table 4. Estimation of the uncertainties (1 SD) in measure-
ments of absorbed dose for proton beams by an ionization
chamber calibrated in air-kerma
applied in order to obtain agreement between
calorimetry and ionization chamber dosimetry.
Final recommendations will be given in an ICRU
report on proton dosimetry, which is in prepara-
tion [39] .
Under these conditions, the overall uncer-
tainty on the absorbed dose in water, utilizing a
tissue-equivalent ionization chamber shown in
Table 4, is assessed to be equal to 4.3 %. The
uncertainties which were not discussed here, were
taken from the discusions in ICRU 45 [40] .
The overall uncertainty for dose determina-
tions in proton beams is larger than for photon or
electron beams but comparable to neutron beams
[40,41] . On the other hand, the uncertainty of
determining the absorbed dose with a calorimeter
is smaller (±2%) [4] and depends on the uncer-
tainty of the assumed heat defect of the calo-
rimeter material (water or A-150 plastic) .
For the measurement of the absorbed dose in
other heavy charged particle beams, the ioniza-
tion chamber should be calibrated directly with
reference to a calorimeter.
Relative Dosimetry
Acquisitions of absorbed dose distributions are
neccesary for two purposes :
as basic beam parameters for planning pur-
poses (supplementary corrections for the RBE
variation as a function of energy will be neces-
sary for ion beams)
for quality control procedures (beam align-
ment, symmetry, flatness and beam energy) .
The detectors used should, therefore, respond
to several criteria :
the dose distributions should be as in tissue or
the neccesary corrections to tissue should be
possible
the detectors should be small with respect to
the steep dose gradients of the heavy charged
particle beams
heavy charged particle beams will also show
large variations in LET, (even for proton
beams, large variations in LET might be
expected at the end of their range) ; therefore,
the detectors should not show any LETeffect
they need to have the appropriate dose sensitiv-
ity and a linear dose response .
It will not be easy to find a detector responding
correctly to these criteria . Several detectors are
commonly used in conventional photon or elec-
tron beams for relative dosimetry.
Small Ionization Chambers
They have the advantage that the principles
explained in the preceding chapters can be
applied. They will yield the exact dosimetry
result, if the correct factors are applied. If
thimble chambers are not small enough with
respect to the dose gradients a combination with
parallel-plate ionization chambers should be con-
sidered. These parallel-plate ionization chambers
will have a perfect definition of the measurement
point as a function of depth.
Electrometer reading M 0.1
Reading correction factor II Pi 0.2
Air-kerma calibration factor NK 1.0
A,Y .,, correlation factor A.~an 0.2
Mass stopping power ratios ~(`S~e)ai~rerl P 1.2
Average energy required to (Wair/e)p 4.0
form an ion pair for protons
Average energy required to (Wair/e)c 0.2
form an ion pair for the
calibration beam
Ratio of the photon mass I(Ten1Q)air i5'h 0.1
absorption coefficients
Ratio of the mean We)ärr 1501 c 0.1
restricted collision mass
stopping powers
Overall uncertainty on the 4.3
absorbed dose in water
for proton beams
Thermoluminescence Dosimeters (TLD)
Several types of thermoluminescence dosimeters
are used for dosimetry in conventional radiother-
apy; most commonly are LiF:Mg:Ti, CaF2:Tm
and CaS04 phosphors. All these materials have
their owndosimetry characteristics, as far as dose
response and sensitivity, tissue-equivalence, or
temperature response (glow curve) are con-
cerned . When these phosphors are treated care-
fully (i.e ., standard conditions for annealing,
reading, and calibration) a precision of ±3% can
be achieved [42] .
For ion beam therapy extra care must be taken
as to the LETdependence of these materials. The
average distance between ionizing events along
the track can become much less than the distance
between the nearest trapping centers . For LiF a
strong decrease of dose sensitivity with increasing
LEThas been observed [43-46] for ion and neu-
tron beams . These phosphors will also show a de-
creasing supralinearity with increasing LET [47]
and an LET-dependent glow curve. For LiF the
height of peak no. 6 (-285 °C ) is much more
LETdependent than the other peaks as was
observed with protons and other ion beams [48,
49] . An even more pronounced effect has found
for CaF2:Tm phosphors . For these phosphors, an
analysis of the ratio of peak 3 (-150 °C ) and 5
(-240 °C) allows an indication of the beam qual-
ity [50, 51].
Photographic Film Emulsion
Films also show a very strong LET-dependence .
It is related to the film dose sensitivity and conse-
quently to its grain size [52] . Therefore, it will not
be possible to use them for depth-dose deter-
minations . The decrease of the film sensitivity
might even be more important than the increase
of dose as a function of depth. On the other hand,
films still have their usefulness for field mapping.
When the beam composition does not change sig-
nificantly perpendicular to the beam direction,
analysis of the optical density of the film yields
acceptable results for the determination of the
beam profile. In this case, it is possible to exploit
fully the advantages of film dosimetry including
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good spatial resolution and the availability of
storable hard copies .
Silicon Diode Detectors
Silicon diode detectors are used in various dosi-
metric situations : In conventional radiotherapy
they serve as in-vivo detectors [53] or as detectors
for relative dosimetry [54] . In any case, one can
benefit from their excellent spatial resolution and
dose sensitivity (cf. preceding chapter for
details) . For ion beam dosimetry Si-diodes can
be used under the same conditions . However, it is
known that they will loose their sensitivity with
the accumulation of dose . Rikner [54] has
observed a reduction of 30 % in sensitivity after a
proton dose of 10 kGy. Care must further be
taken because of small differences which have
been observed between the Si- and ion chamber
response when measuring depth-dose data in pro-
ton beams [55, 56] . These differences cannot be
explained by variations of the stopping power
ratio with energy.
Other Detectors
Other detectors, such as activation detectors, dia-
mond detectors, alanine or radiographic films
might be useful for different clinical dosimetry
tasks (cf. preceding chapter) . Their dosimetry
characteristics are, at present, studied [57,58].
However, not even for proton beams enough data
are available at this moment to report on.
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Introduction
Control Systems for
Ion Beam Radiotherapy Facilities
T RENNER, M. NYMAN, and R. F SINGH
Lawrence Berkeley Laboratory, Berkeley, CA, USA
The advent of hospital-based ion beam radiother-
apy facilities has recently focused attention on
their requirements [1, 2] . The control system for
patient treatments in these facilities is central to
the safe and accurate realization of this type of
radiotherapy.
A control system for charged particle radio-
therapy ensures patient safety, controls the
patient treatment, measures compliance of the
actual treatment with the prescribed one, and
provides feedback to the treatment planning pro-
cess . In the future, this latter role will expand in
several ways . Data obtained through patient do-
simetry or other imaging methods will provide
information for refining treatment plans. Radio-
active beam imaging or PET scanning of isotopes
produced within the patient by the particle beam
will provide more accurate pictures of the actual
treatment volume and its changes during the
course of treatment [3, 4] . With the expanding
role of 3D-conformal radiotherapy, accurate char-
acterization of the treatment delivery system will
be required to calculate treatment plans. These
new technologies will require a treatment control
system with a solid foundation . A description of
such a foundation will be given .
This work is, in large part, an outgrowth of the
work of the heavy particle radiotherapy program
at the Lawrence Berkeley Laboratory. The his-
tory of this system began in 1979, with the devel-
opment of a system architecture that could be
used to treat patients and provide a basis for
future development and growth in the technology
of beam delivery. The system, which originally
ran on a PDP 11-45, eventually ran on five kinds
of computers over the last fourteen years, and
was robust enough to support several kinds of
beam delivery systems . A double scattering sys-
tem, the wobbler beam delivery system, the first
raster scanning beam delivery system and a three-
dimensional conformal therapy delivery system
have been controlled with it [5, 6] . In addition,
the system operated two separate treatment
rooms and one biological research facility. It has
been used with pulsed beams from a synchrotron
and continuous beams from a cyclotron . Our
experience with this control system is condensed
into a set of functional requirements . No attempt
has been made to impose a particular imple-
mentation .
Overview of Individual Functions
Thefunctions required for the control of a patient
irradiation fall into three categories : a 'set for
beam delivery, a set for beam production, and a
set of ancillary functions. They are further subdi-
vided as follows:
- Functions for beam delivery
Interlocks are conditions which are prerequi-
sites for an irradiation and are expected to be
steady state during an irradiation .
Beam modification is the process of tailoring
the radiation field for a particular irradiation .
Beam measurement dynamically determines
radiation field parameters for beam control
purposes .
Software beam delivery control comprises the
software control algorithms and procedures
that determine, set, and control the system
parameters for a particular irradiation .
Hardware beam delivery control comprises the
hardware control functions necessary for the
initiation, termination and control of an irradi-
ation. Often key control functions, such as
starting and stopping of the beam, are imple-
mented in both software and hardware for
increased safety and reliability.
Monitoring is the verification of critical condi-
tions during an irradiation .
Beam production functions
Accelerator and transport control conducts the
generation and transport of the beam to a treat-
ment room .
The accelerator interface consists of a switch
function for connecting the accelerator and a
treatment delivery system, and a communica-
tion link between accelerator and treatment
delivery systems . It also provides the capability
of independent operation of the accelerator
and the treatment control systems.
The timing subsystem creates a set of time
points which drive the sequence of events for
both accelerator control andtreatment control .
Beam abort/halt terminates the delivery of
beam into a treatment room .
Ancillary functions
The human interface provides displays of per-
tinent information for the medical and opera-
tions personnel .
Simulation mimics measurement information
and status to allow testing of the system opera-
tion without the use of beam.
Dispatching is the process of allocating the
accelerator to a particular treatment room .
The prescription server serves as the conduit
between the treatment planning system and the
treatment control system .
Archiving is the nonvolatile recording of both
raw and processed data sufficient to : recon-
struct a patient treatment, provide an accumu-
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lative history of each patient's treatments and
create a data base for accelerator andtreatment
control system operation. Aschematic overview
of the treatment control process is shown in Fig-
ure 1. The relationship of these functions with
one another is shown in Figure 2.
General Discussion
of Individual Functions
As seen in Figure 1 the line of information is from
the treatment planning system to the treatment
control system to the accelerator control system .
Rather than following this information flow, the
Planning
Prescription Server
Treatment Treatment
Control Control
Accelerator
Accelerator & Beam Transport
Archiving
Fig . 1 . Overview of the treatment control system . A pre-
scription created by the treatment planning system resides
in the prescription server until needed by the treatment con-
trol system . The prescription in this context is the informa-
tion necessary for the delivery system to deliver the dose dis-
tribution specified in the treatment plan . A method for com-
municating with the accelerator and beam transport control
system is embodied in the accelerator interface . All relevant
data, parameters, tunes, and set points are recorded in
archiving . The lighter lines indicate that several independent
treatment control systems are possible
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Fig. 2 . Relationship of control system functions . This sche-
matic diagram shows the relationship between functions
found in a treatment control system
discussion will start with the heart of any radio-
therapy system, the functions related to beam
delivery.
Interlocks
As stated before, the prerequisite, steady state
conditions of the treatment system that are not
unique to a particular treatment and must be met
before an irradiation commences, are interlocks .
These interlocks are generally independent of the
control of a device and their status is visible to
operations and medical personnel . Several exam-
ples of such conditions requiring interlocks are:
1. personnel radiation safety circuits that restrict
access to radiation areas,
2. the assignment of the accelerator to a particu-
lar treatment room,
3. the control system being in a simulation mode,
4. diagnostic X-ray equipment in the beam line,
or
5. power supplies whose malfunction can cause
harm to a patient and which must be opera-
tional before a treatment is allowed to begin.
Beam Modification
Modification of the beam by the control system
occurs for each treatment and involves devices
such as : collimators, range shifters, lateral
spreading devices, range modulators, and a
gantry/patient positioner. The fail-safe control
and status of these devices are required for
patient safety. For example patient-specific colli-
mators need to be identified and their position
monitored . For variable collimators, the size and
shape has to be controlled to the required resolu-
tion within some specified time window. The
physical position (location and rotation) of such a
collimator is monitored if it is variable .
For changing the beam range, by accelerator
energy changes and/or by mechanical degraders,
the energy range and step size must be controlled
to satisfy the treatment specifications . If compen-
sation of the range is accomplished with a
mechanical bolus a means of identifying the
patient-specific bolus is important. Large num-
bers of patients being treated in several treatment
rooms mandates a method of verification inde-
pendent of human verification .
During patient treatments the ion beam is
laterally spread out to produce the desired dose
distribution . The methods of accomplishing this
usually, involve several control parameters . For
active systems, these parameters can include: the
target shape (e.g ., a boundary/shape matrix of
the port), a matrix for controlling beam motion
and position and possibly abeam current modula-
tion matrix that can be a function of beam posi-
tion . Double, single, or bi-material scattering sys-
tems also require verification of their parameters
if they are adjustable on a patient-by-patient
basis.
Energy modulation to produce a modulated
depth dose distribution, whether achieved elec-
trically or mechanically, and whether discrete or
continuously variable, needs to be done on an
appropriate time scale by the control system .
Monitoring of all relevant parameters necessary
to insure the correct beam energy is critical for a
safe treatment. For example, accelerator energy
changes require an established set of machine and
beam transport parameters for each energy to be
used . Consequently, monitoring by the treatment
control system of critical accelerator parameters
is necessary.
The patient positioner/gantry position is oper-
ated with a particular resolution, extent of
motion and accuracy of patient positioning. The
speed and the extent of movement must be con-
trolled to prevent damage to the device or injury
to the patient and only executed with proper
human authorization . A manual override of any
computer control of such devices is essential, as is
monitoring to insure the correct position is main-
tained at all times during an irradiation .
Beam Measurement
The beam measurement function dynamically
determines the radiation field parameters for con-
trolling the treatment and insuring it is delivered
correctly. Measurements before the beam under-
goes any of the kinds of modification discussed
previously, insure the beam characteristics are
correct before entering the beam delivery system .
After the appropriate modification, an additional
measurement as close to the patient as possible,
insures the beam modification is correct and more
accurately measures what the patient is actually
receiving . Such measurements are performed on
three time scales as defined below.
Asystem unit oftime or clock cycle is the basic
unit that allows accurate control of the dose being
delivered to the patient. Typically this is in the
millisecond or faster time scale . A dosimetry
cycle, which is on the time-scale of a second, is
the set of operations, triggered cyclically by the
timing system, and which involve the collection,
display and monitoring of data . During this cycle
a snap-shot of the system performance allows
periodic assessment and archiving of the state of
the system . Quantities typically measured on this
time scale are: the beam current, the transverse
dose profile and centroid before and after beam
modification, andthe integrated delivered dose at
isocenter. The third time-scale is the entire treat-
27 Control Systems for Ion Beam Radiotherapy Facilities
	
259
ment time during which the delivered integrated
dose at isocenter is measured by at least two inde-
pendent detectors. Treatment times are on the
scale of one to three minutes . During this time a
verification of the beam range is also performed .
Software Beam Delivery Control
Software beam delivery control consists of the
software procedures and control algorithms which
determine and control the parameters for a
particular type of irradiation . Figure 3 shows
schematically the relationship of the components
of this function . Included in this function are sev-
eral kinds of irradiation procedures which, in gen-
eral, satisfy the following requirements :
Display
Subsystem
AllOtherFunctions
Fig. 3 . Software control function scheme, This shows a set
of applications which draw on a data base updated by a set
of primitive functions which collect, scale, and monitor data
in a cyclic fashion . Input from various control system func-
tions are shown, e .g . monitoring, accelerator interface, etc.
Patient Rx Calibration Physics DiagnosticsApplication &Tools
DataBase
Foundation
ReadDtaaw
Data Scaled data
operating System
Software Control
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1. critical parameters are verified before an irradi-
ation begins,
2 . the startup time for aprocedure is minimized,
3 . the time from initiating an irradiation (turning
the beam on) to the actual commencement of
the irradiation (beam on target) is minimized,
4. information determined as representative of
the state of the treatment is presented to med-
ical and operations personnel every dosimetry
cycle.
Three types of irradiation procedures are par-
ticularly useful: a treatment procedure for per-
forming a therapeutic irradiation or for exposing
diagnostic film for patient alignment purposes, a
calibration procedure for determining calibration
factors of dosimeters for an irradiation pro-
cedure, and physics application procedures for
dosimetry measurements .
The treatment procedure involves several
tasks. The first task acquires dosimetry calibra-
tion information from the calibration procedure
described below. Patient set-up parameters are
verified against the patient's prescription and
hardware parameters set to desired values, e .g .,
gantry/patient positioner parameters. The state of
the interlocks and gantry/patient positioner set-
tings are important to verify before and during
the treatment . To recover from an interruption
caused by a computer failure, the state of the sys-
tem is saved on disk every dosimetry cycle . An
abort of the irradiation is initiated upon normal
completion of an irradiation . This occurs when all
the steps of a procedure have been finished, or
upon detection of any fault condition . To guard
against a software procedure failing without ter-
minating the treatment, an acknowledgment
within an appropriate time window of a
procedure-specific watchdog occurs every dosim-
etry cycle. Failure of such acknowledgment leads
to an abort of the treatment by the hardware
beam delivery control function . Any abort of the
treatment (by human intervention, interlock
dropout, critical hardware failure, monitoring
veto, computer watchdog acknowledgment fail-
ure, or a preset scaler trigger) should preserve the
state of the system . Support of an immediate
resumption or resumption at a later time provides
the necessary clinical option of how to proceed
with a treatment after an abort. The time to re-
cover from an interruption needs to be prompt
and the maximum dose uncertainty after recovery
should not exceed the dose delivered in a dosim-
etry cycle. At the end of a patient treatment, the
treatment data is archived and a summary to the
appropriate medical personnel is provided .
The calibration procedure establishes the con-
version of the raw measured data to delivered
dose in several contexts . Two important tasks of
this function are calibrating an individual detector
against a certified dosimeter and creating a cali-
bration reference for the dosimetry system . On a
daily basis the dosimetry system response is then
compared against this calibration reference . Most
importantly the calibration procedure measures
the dosimetry system response relative to a certi-
fied dosimeter placed at isocenter within an
appropriate phantom target volume . This estab-
lishes the calibration for a patient specific radia-
tion treatment setup. Calibration of a patient
treatment can also be extrapolated from a mea-
sured database provided the dosimetry system
behavior and beam characteristics are sufficiently
reproducible or can be compensated for. Dose
measurements are required to be traceable to a
fundamental standard using well-established cali-
bration procedures [7] .
Physics application procedures are used to
characterize the beam and radiation field proper-
ties . Frequently, a measurement over an entire
treatment, a part of an entire treatment, a
sequence of individual steps of an irradiation or
even an unmodified beam irradiation is required .
Dose measurements in a water phantom in any of
three orthogonal axes is a standard technique
supported by these procedures . The ability to ter-
minate the irradiation based on time, monitor
units or dose is also advantageous . Both perma-
nent dosimetry detectors and those installed only
for a particular experiment, e .g ., a diode, calo-
rimeter or scintillator, are often used for beam
and radiation field characterizations with these
applications . Additional features that are useful
are the ability to enable or disable specific beam
monitoring, to set beam modification devices, to
interrupt a measurement and resume it without
loss of data, and to connect additional devices
through 1/O ports .
Diagnostic tools are also important for trou-
bleshooting and verifying the proper working of
the system . These aids are used continuously or
upon demand and often concurrently with other
procedures . Their access is generally restricted .
Hardware Beam Delivery Control
Hardware beam delivery control comprises the
functions necessary for starting, stopping and
controlling an irradiation as shown in Figure 4.
Since the time frame for controlling the irradi-
ation can be too short for computer control, dedi-
cated hardware is often required or at least advis-
able for redundancy and reliability. Starting an
irradiation requires all interlocks are satisfied, all
watchdogs acknowledged, and all monitoring
vetoes absent . An irradiation can then be initi-
ated after the proper authorization from a quali-
fied person is given, and the beam abort/halt sys-
tem is under the control of the treatment control
system . Computer-read scalers and preset scalers
connected to the beam measurement system track
the delivered dose . The beam enable/disable logic
based on input from numerous sources initiates
an abort of the beam as shown in Figure 4. Device
Measurements
software
Control
Pr~ "et
Sc l ers
Radiation
Enable / Disable
Logic
Hardware Control
Device
ControIIers
Devices
AcceleratorInterfte
Timing
Monitoring
Watchdog
I Interlocks
Fig. 4. Hardware control function scheme . Preset scalers,
device status, timing faults, monitored parameters, interlock
failure, watchdog acknowledgment failure, and software
flags are input to the logic which enables and triggers the
beam abort/halt system
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controllers provide computer and manual control
of the operation of a device, and status on its
operation. Full closed loop control of a device is
desirable where feasible and appropriate.
Stopping an irradiation, as discussed below,
involves a halt or an abort action initiated by the
hardware beam delivery control. Several condi-
tions can stop an irradiation : an interruption initi-
ated by a qualified person, a preset staler trigger,
a fault signal from a critical device controller, a
broken interlock, a failure of a watchdog
acknowledgment, or any hardware or software
monitoring veto . Continuation of the irradiation
after its interruption is synchronized with the
dosimetry cycle. The contribution of errors due to
the interruption process to any dose error should
be clinically acceptable .
Monitoring
Monitoring is an independent function for over-
seeing critical conditions and parameters during
an irradiation . It is not a monolithic system, but
rather a function contained within other functions
and components of the treatment control system .
The conditions and parameters monitored can
involve beam modification devices, radiation
properties, or accelerator parameters . Monitor-
ing is capable of vetoing an operation and termi-
nating an irradiation, but is not designed for
initiating an action or controlling a device . Mon-
itoring also contains the watchdog function which
is a hardware-driven periodic check of a software
operation. Watchdogs are armed by the system
timing signal . The software operation in turn
acknowledges the hardware component within a
required time or else an abort of the beam is initi-
ated . Upon acknowledgment, a handshake be-
tween the two parts is performed and the watch-
dog rearmed. The computer operation, the treat-
ment procedure, and particular displays are
examples of software operations requiring watch-
dogs .
Monitoring by the treatment control system
also involves verification of critical accelerator
parameters, separate from any verification per-
formed for accelerator control purposes . Some
parameters may require monitoring every acceler-
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ator cycle or even continuously. These can include
beam time structure, beam energy or rigidity,
beam current, beam alignment and profile at the
exit of the accelerator.
Critical beam modifying device parameters are
also monitored at least every dosimetry cycle as
are the radiation properties before and after these
devices . Thebeam range or a quantity from which
the range can be inferred, the beam current, the
beam alignment (position and angle), and the
beam profile are commonly monitored . In addi-
tion, after the beam modifying devices, the deliv-
ered dose and the radiation field compliance with
the prescribed field are monitored . The beam
transport system switchyard is also important to
monitor, e.g ., magnetic fields and magnet cur-
rents, as is the part of the beam transport system
involved in the abort/halt function .
Accelerator and Beam Transport Control
The generation and travel of the particle beam
with the desired characteristics to a treatment
room is managed by the accelerator control sys-
tem. This involves, besides an accelerator, the
control of an ion generator, an injection system
for initial acceleration and transport of particles
to the accelerator, an extraction system for
removing the beam from the accelerator, a beam
transport system for channeling the particles to
the desired treatment room, and a timing refer-
ence for process control. The performance of
each of these parts is monitored and a watchdog
function performed, where necessary, to insure a
part is operative. A monitoring system that in-
sures correct and safe operation, and a system for
saving and restoring control parameters are also
necessary parts. Measurement ofbeam properties
and critical device parameters are also critical to
this control function .
Communication links between the various
accelerator control parts and their corresponding
components employ several types of communica-
tion links including:
1. a data line for the exchange of information
between subsystems and for stamping data as a
certain type (e.g ., real beam data, simulated
data),
2. a timing line for synchronizing particular oper-
ations and procedures and time stamping data
for control and archiving purposes,
3. a fast protection line that synchronizes several
actions to halt/abort the beam.
Temporarily saving and restoring a partial or
complete set of accelerator control parameters
(e.g., machine tune) allows efficient switching
between treatment rooms. Long term archiving
of the accelerator parameters is advantageous for
reconstructing the state of the system, creating an
operational database for determining new operat-
ing conditions and for diagnosing problems .
Simulation in the accelerator system can also
be useful for hardware and software testing with-
out actual beam acceleration or magnet opera-
tion . Such a system must, of course, be inter-
locked and simulation status provided to the
accelerator control system and the dispatching
function . Ablatant visual indication of simulation
operation is also prudent .
Accelerator Interface
The accelerator interface is a software and hardware
switch for connecting the accelerator and a treat-
ment room . The software switch gives exclusive use
of the accelerator to a particular treatment room.
Similarly a hardware switch allows hardware signals
only from the chosen treatment room to go between
that treatment room and the accelerator. The
extraction status, the abort/halt status, the beam
energy, current, position, shape, and the necessary
beam transport data (e.g ., beam transmission, posi-
tion, shape) are sent to the treatment control system
while parameters, such as the desired energy and
intensity, are sent to the accelerator control system
via this accelerator interface .
Timing
The timing function drives the cycles of both the
accelerator control and treatment control, includ-
ing the dosimetry cycle, via a dedicated commu-
nication line . A loss or variation in this timing
function as detected by a watchdog warrants the
abort of the beam.
Beam Abort/Halt
The most important function is the beam abort/
halt function which stops the delivery of a beam
into a treatment room upon human command .
Starting of an irradiation is in some sense the
undoing of this function whose design must be
fail-safe and the status of its state of operation
known at all times. Any reasonable design in-
cludes redundant methods for stopping the beam
(e .g ., the beam transport system de-energized for
fail-safe reasons, the beam extraction system
turned off, a beam stop inserted at the acceler-
ator and treatment room) and a means of easily
activating this all critical function . The distinction
between an abort and a halt is important and will
now be discussed.
With aresponse time that satisfies clinical dose
compliance specifications, a halt turns the beam
off when: activated by a qualified person (e . g., by
pushing a halt button), undesirable patient
motion is detected, or a step in an irradiation pro-
cedure is completed . The end of a halt occurs at
the removal of a halt request and is synchronized
with the dosimetry cycle.
An abort first halts the beam and then inserts
a physical beam-stop . Continuing the irradiation
is not possible by simple removal of the abort
request. An abort is intentionally a more drastic
Table 1 . Human Interface Displays
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form of treatment interruption, requiring a well-
defined set of steps to start the treatment again.
An action by a qualified person, completion of an
irradiation procedure, loss of any interlock, or
the monitoring system's detection of anomalies
potentially hazardous to the patient (e .g .,
unwanted gantry rotation) are situations that
should cause an abort.
Special, dedicated hardwired links for aborting
the beam are advisable along with buttons at
appropriate locations . Reset of the beam abort
control circuits should be independently per-
formed by the accelerator and treatment control
systems to insure both are ready to proceed.
Human Interface
The human interface connects the control system
and the medical or operations personnel via the
information displays shown in Table 1. These dis-
plays provide the medical and operations person-
nel with graphics and alphanumeric displays of
data, development and diagnostic tools, visual
hardware-status displays, error notification, or
alarms . Refreshing the displays at least once per
dosimetry cycle allows human surveillance of the
progress of the treatment. Acknowledgment of a
watchdog by critical displays insures the beam
Location
Control Setup Treatment Accelerator
Console room room Control
Room
Pretreatment Prescription information
information
Irradiation information Information on a treatment in progress
Irradiation summary Results/summary of a single irradiation
Treatment summary Summary of treatments for a specified
patient
Facility Status Status of patient treatments and
and Scheduling accelerator operations
Beam Delivery Information on the beam delivery
system operation
Measurement Data Numerical/ graphical display of data v
Alarms and Error Information of error conditions and v
Notification alarms
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will be aborted if the displays are not updating .
Direct visual hardware status, visual and auditory
alarms, and a means of archiving errors are
needed for debugging and trouble shooting .
Simulation
A means of testing the treatment control system
or the accelerator control system without the
actual use of beam is an invaluable capability. The
simulation function generates measurement and
status information that mimics real beam data for
this purpose. This function clearly must be fully
interlocked at the lowest possible level of its
implementation to prevent confusion of real and
simulated beam. Before its use, a handshake with
the dispatcher verifying the treatment room is
"off-line" is prudent, as is an interlock of the
beam transport to prevent beam inadvertently
entering the room . If abeam stop is used for each
treatment room it should be inserted and deacti-
vated.
Simulation also generates beam-modification
device control and status information, accelerator
parameter values and responses, beam abort/halt
control and status information, beam-stop and
beam transport status, timing signals and neces-
sary monitoring status of the accelerator systems
and treatment control systems. Simulation of the
monitoring function may require the capability of
suppressing some monitoring function vetoes, but
those functions must be enabledwhen leaving the
simulation mode .
Dispatching
Formultiple treatment room facilities a method is
required for deciding which room will receive
beam from the accelerator. This function is called
the dispatching function . The dispatching func-
tion receives requests from treatment rooms,
assesses the availability of accelerator and beam
transport systems, and allocates the use of the
accelerator to a treatment room . The allocation is
based on an algorithm which could be as simple
as "first come first serve" or complex following a
preset queuing algorithm . After a first mutual
check ("handshaking") between the treatment
and accelerator control systems this function sets
the accelerator interface switches to allow com-
munication between the treatment and acceler-
ator systems . This gives exclusive use of the accel-
erator to a certain treatment room until released
by the treatment control . An abort or halt does
not release the use of the accelerator.
The Prescription Server
The prescription server is the link between the
treatment planning system and the treatment con-
trol system for the exchange of the necessary
information such as the beam delivery parame-
ters for a treatment . Because this information is
confidential and critical to a patient treatment, it
is necessary to prevent unauthorized or inadver-
tent alteration of treatment parameters . By hav-
ing the treatment plan reside outside the control
system, verification of patient-specific parameters
can be done before being transferred and exe-
cuted by the treatment system . Results of each
delivered treatment, which are useful feedback
for refining the treatment plan, can be stored on
this server. By having such a server the patient
prescription information can be used by any treat-
ment room. This allows greater flexibility and
improved efficiency in scheduling treatments .
Archiving
A summary of the treatment including the deliv-
ered dose and a record of all critical raw and pro-
cessed data are kept for each dosimetry and accel-
erator cycle. This process, called archiving, is a
nonvolatile method of preserving information. In
case of a system crash or treatment interruption,
a system recovery or treatment resumption can be
performed from this information . Clinical infor-
mation, such as the patient identification, tumor
dose for both an individual treatment and accu-
mulative treatments and the names of personnel
involved in the treatment, is archived . Protection
of archived information from unauthorized or
inadvertent modification is obviously important .
Archived data is also needed for the creation and
refinement of the parametrization of control sys-
tem variables, treatment planning and research
analysis .
Conclusion
The safety of a radiation therapy facility is deci-
sively determined by its control system . The gen-
eral functions are needed in a treatment control
system, but the true measure of such a system is
in its implementation . To achieve the desired
safety, reliability and flexibility, three basic design
principles are important : fail-safe design, redun-
dant design and fault-tolerant design . Fail-safe
design requires that, at each level of implementa-
tion, the most probable failures will result in a
safe state. No single hardware or software failure
leads to a system failure or a compromise of
safety. Redundant design decreases the probabil-
ity of system failure from a particular failure
mode by repeating a design implementation .
Fault-tolerant design is achieved by computing or
measuring a variable in several ways rather than
simply redundantly. This increases the safety of
the control system, adds to its monitoring capa-
bility and aids in diagnosing problems . It is from
the use of these guiding principles that this
summation is based on and the success of a con-
trol system is accredited.
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V1. Patient Positioning
and Treatment Planning
Introduction
Imaging and Tumor Localization
W. SCHLEGEL and J . PRCSS*
Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany
Computer-assisted radiation treatment planning
(RTP), and especially the newly developed three-
dimensional treatment planning techniques, provide
a tool to find the optimum configuration ofradiation
beams for the treatment of an individual patient. In
clinical practice, RTP has traditionally been based
on two-dimensional sectional representations of the
treatment of the patient. However, the shape of the
tumor and adjacent uninvolved anatomical struc-
tures may vary substantially from one section to
another. The sectional two-dimensional planning
approach may lead to uncertainties in localizing the
volume and target volume as well as internal organs,
a problem that can still be considered to be one of
the most frequent sources of error in the whole radi-
ation treatment procedure.
Today, the situation is gradually changing due to
several technical developments, among which the
advent of whole-body X-ray computed tomography
(CT) and magnetic resonance imaging (MRI) are
the most important. With the availability of CT and
MRI, the ability to visualize anatomical structures
in detail has been tremendously improved .
In order to take full advantage of these new
imaging developments within the field of radia-
tion therapy, new tools have to be developed and
evaluated that permit easy and precise extraction
of the therapy-relevant information from 3D-
images, 3D-display of anatomical structures, and
computer simulation for accurate placement of
radiation beams. This contribution focuses on the
* present address: Fa . Leibinger GmbH, Freiburg,
Germany
application of computers in the step that is cur-
rently considered the bottleneck of three-
dimensional treatment planning : segmentation of
therapy-relevant anatomical structures .
Therapy-Relevant
Anatomical Structures
Of all the therapy-relevant structures, two vol-
umes should be defined prior to treatment plan-
ning (Fig.1): the gross tumor volume (GTV) and
the clinical target volume (CTV).
Fig . 1 . Schematic illustration of the different volumes in
radiotherapy planning : gross tumor volume (GTV) denotes
the demonstrated tumor, clinical target volume (CTV) de-
notes the demonstrated tumor (when present) and also vol-
umes with suspected subdinical tumor, the planning target
volume (PTV) consists of the CTV and a margin to account
for variations in size, shape and position relative to the treat-
ment beam . The treatment volume receives the tumor dose
or the dose considered important for local cure or palliation,
and the irradiated volume is the volume which receives a
dose considered important for normal tissue tolerance
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During the treatment planning process, fur-
ther volumes can be described, including the
planning target volume (PTV) and the organs at
risk (OARs) . The final result of the treatment
planning process are the treated volume and the
irradiated volume [1].
The Gross Tumor Volume
The GTV comprises all the tissue that can be
recognized and identified as tumor tissue within
the tomographic images . The identification of
tumor tissue may be based on different criteria,
e.g ., enhanced or decreased soft tissue contrast in
the MR or CT images, with well-defined, blurred
or even invisible margins (after subtotal or total
tumor resection) . Further criteria for the defini-
tion of the tumor volume are the displacement of
neighboring anatomical structures or the appear-
ance of edematous tissue .
The Clinical Target Volume
and the Planning Target Volume
After defining the GTV, the CTV and the PTV
have to be defined. The PTV is the volume that
has to be completely covered by the therapeutic
dose during the irradiation of the patient. It in-
cludes the CTV, i.e ., the gross tumor volume,
plus possible tumor extensions, possible sites of
metastasis such as lymphatic regions in the vicin-
ity of the tumor volume, preferred paths of fur-
ther tumor growth and a so-called "safety mar-
gin" around the tumor. This safety region is essen-
tial as it takes into account the uncertainties dur-
ing the irradiation of the patient caused by patient
movement and/or inaccurate patient alignment.
Tumor and target volume definition remain crit-
ical quantities which depend on histological and
anatomical classification of tumor and safety mar-
gins .
Organs at Risk
The goal of radiotherapy is not only to apply a
high radiation dose to the tumor, but also to avoid
side effects in the surrounding healthy tissue,
especially in those anatomical structures that will
not tolerate radiation burdens above certain crit-
ical doses.
These non-target tissues or OARs are the third
important type of therapy-relevant volume that
has to be defined during the treatment planning
process. For targets in the skull brain stem, white
matter, optic nerve, eyes, or lenses are examples
of OARs. There are several good reasons for a
complete and accurate segmentation of OARs :
1. The geometrical shape and the location of the
three-dimensional surfaces of the OARS can
subsequently be used to optimize the position,
shapes, and incidence angles of the radiation
fields .
2. It is possible to precalculate the dose distribu-
tion within the target volumes, and, by adjust-
ing the irradiation technique, minimize the
physical dose in the critical areas.
3 . With the help of radiobiological models, it is
possible to estimate the risk of radiation injury
(the treatment-related morbidity probability
or TRMP) of critical organs and the probabil-
ity for tumor control (tumor control probabil-
ity or TCP) .
Optimization of radiation treatment plans on
the basis of TCPs andTRMPs seems much more
promising than just a geometrical and physical
consideration of the treatment planning problem.
To make this biological treatment planning a rou-
tine tool in the future requires procedures for
individual three-dimensional image segmentation
for the definition of critical organs or even func-
tional subunits of critical organs in addition to
more elaborate and realistic radiobiological
models .
Tumor tissue not included in the target volume
will - with high probability - be underdosed .
Unconsidered OARS, on the other hand, may
eventually be overexposed . Errors, inaccuracies,
and omissions made during the first step of image
segmentation, influence the effectiveness of the
treatment plan and the outcome of the whole
radiotherapeutic process dramatically. This shows
the importance of optimal treatment planning in
radiotherapy.
Segmentation of Target Volumes
and Organs at Risk
The method currently used in clinical practice for
extracting 3D-information from CT and MR
images is manual segmentation of the respective
data sets . A three-dimensional image may consist
of 20 to 60 slices . As many as ten or more struc-
tures may need to be outlined on each of these
images . This is a major effort, if carried out for
every patient. Until now, there have been few
automatic tools available in clinical practice to
facilitate this process and speed it up. However,
some groups are developing fast and user-friendly
three-dimensional image segmentation and
modeling tools [2-7]. One of these systems will
subsequently be described in some detail to char-
acterize the state of the art in manual segmenta-
tion .
A Manual Tool for 3D-Segmentation
An interactive workstation program called
TOMAS (=tool for manual segmentation) has
been developed at the German Cancer Research
Center (DKFZ) [4] . It is an example of an
advanced program for 3D-segmentation of tumor
volumes, target volumes, and organs at risk and is
routinely applied in radiation treatment planning.
The program considers the following issues of
tomographic image segmentation :
image presentation
efficient segmentation tools for drawing
on tomographic images
layout of the user interface
visualization of the segmentation results
Image Presentation
Figure 2 shows the different sections of tomo-
graphic images . Three small windows appear at the
top of the display screen . One presents the image
data in the original form which is transversal for
CT and transversal, sagittal, or frontal (depend-
ing on the image acquisition mode) for MRI. The
two other small windows display multiplanar
reconstructed views of the image data . One of the
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three views can be selected for presentation in the
larger working window (see Fig. 2, bottom).
The spatial position of an actual section is indi-
cated by reference lines in the two other corre-
sponding views. The reference lines can also be
used to select an interesting slice simply by mov-
ing the line with the computer mouse to the
requested position . This method allows the radio-
therapist to get an impression of the patient's
anatomy in all three dimensions.
The working window is used to outline ana-
tomical structures on the images . For the seg-
mentation of small structures, the images can be
enlarged up to a factor of eight of their original
size . The area to zoom in upon is selected inter-
actively by moving a rectangle on the image. A
presentation with a high zoom factor can be
smoothed by low-pass filtering.
The Segmentation Tools
Segmentation of three-dimensional images into
tumor volumes, target volumes, and organs at
risk is performed in the working window by
contouring "regions of interest" in successive
transversal, sagittal, or frontal sections with a
tomographic image as background . The drawing
instrument is the computer mouse. Three differ-
ent drawing functions are available : free-hand,
polygon drawing, and ellipse drawing.
When drawing free-hand, a line on the screen
follows the movements of the mouse. Unwanted
lines can be deleted at anytime . It is often neces-
sary to keep a well-defined safety margin to an
anatomical structure, e .g ., for the definition of
the target volumes. For this purpose, the cursor
can be changed into a circle with the center
being the active point andthe radius correspond-
ing to the desired boundary. Polygons can be
drawn by labelling, only the corner points . With
the help of a spline interpolation, additional
points can be regarded . This way, it is quite easy
to create naturally shaped curves that approxi-
mate anatomical structures . To segment structures
with nearly elliptical shape, e.g ., the eyes or the
lenses, it is convenient to use the circle and el-
lipse-drawing functions . This significantly reduces
the time needed for outlining these objects .
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Fig . 2 . User interface for manual segmentation of the Program TOMAS [2]
All manually drawn objects are "mouse-
sensitive" and can be selected simply by clicking
with the left mouse button on an object's outline .
Selected objects can be moved, copied, or
deleted interactively. It is also possible to scale
and edit objects by clicking the mouse button on
special control points and to move them to the
required position .
As contours of an anatomical structure are
often similar for adjacent slices (spacing between
slices is usually 2-8 mm) the copy and edit func-
tions are very convenient for three-dimensional
segmentation of medical images . After a region
has been drawn manually in the first slice to cut
the anatomical structure of interest, it is copied to
a neighboring slice . Usually, only small parts of
the contours need then to be edited or redrawn to
match the structure of the object in the new slice .
The interactive delineation of contours is a
time-consuming task . A contour interpolation fea-
ture is therefore included in the program to calcu-
late the preliminary contour in a slice, if contours
in adjacent slices have already been defined. The
interpolation algorithm is based on triangulation
of the surface defined by two contours . With this
feature, volumes of interest are defined as follows :
the region of interest in the first, central, and
last slices of the CT or MRI data set are out-
lined
the program interpolates preliminary contours
in all intermediate slices
the contour in an intermediate slice is
checked; if the interpolation is unsatisfactory,
the contour is edited with the described func-
tions
the program reinterpolates in all slices where
no user-defined contours exist.
Layout of the User Interface
All user interface objects may be manipulated by
computer mouse . Functions of the program can
be started simply by activating the mouse on
icons in a control panel or by selecting entries of
pull-down menus. Dialogs with the user are han-
dled by dialog boxes.
A dialog box consists of interactive elements
such as text entry fields, radio boxes, list and
scale boxes. All program functions are displayed
and the user can fully concentrate on working on
the screen . This user-friendly interface makes the
program easy to use even for inexperienced
users.
Visualization
During and at the end of the segmentation pro-
cedure, it is important to have the possibility of
checking the shape andthe consistency of the vol-
ume under consideration, preferably in a three-
dimensional view. Three visualization aids are
currently implemented in the program:
A contour drawn in the working window is
also shown in the corresponding small over-
view window. The other two overview win-
dows show the intersection of the previous and
current contours with the slices perpendicular
to the slice in the working window.
A fifth window may be opened that shows a
selection of up to 16 CT or MRI images with
the contours of different previously segmented
volumes.
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A perspective view of the different contour
stacks can be accessed which provides a three-
dimensional impression of the segmented vol-
umes .
The Future: Semi-Automatic and
Automatic Segmentation Tools
It is obvious that the manual contouring pro-
cedure is very time-consuming for the radio-
therapist, in particular, when 3D-pictures are to
be built-up . More sophisticated computer algo-
rithms are requested to automate this process as
far as possible . Only then can more patients ben-
efit from a fully three-dimensional treatment,
which is to improve tumor control and reduce
side effects .
The remainder of this paper reports on work
which has been carried out to achieve this goal .
Image Processing Approaches
for Segmentation of
Therapy-Relevant Volumes
Besides manual segmentation, objects with suffi-
cient grey-level contrast can be segmented auto-
matically using a threshold-based contouring
algorithm . This algorithm, which is commonly
used in image segmentation, has been very help-
ful in defining the outline contour of a patient and
in segmenting bony structures or lung tissue in CT
images . However, it fails completely for more
complex objects with only small grey-level differ-
ences to the surrounding tissue .
Image segmentation on the basis of edge
definition looks for local discontinuities in the
grey-level intensity function of the image [3) .
These local discontinuities (i .e ., sites of high
gradient) characterize abrupt intensity variations
which often indicate the presence of an object in
the image. Many techniques for edge detection
have been developed. Their purpose is to describe
an image by a set of points which constitute the
boundaries of different objects in the image.
A second type of image segmentation identi-
fies homogeneous regions in the image [7] . The
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idea behind this approach is to describe the image
by segmenting it into sets of points that possess a
certain homogeneity. Different classes of homo-
geneity have been used to characterize "stan-
dard" regions, for example, smooth regions with
uniform contrast or only slowly varying intensity
or textured regions which can be detected on the
basis of their typical structure pattern .
From a theoretical point of view, edge and
region detection are complementary, in the sense
that knowledge of the edges allows to deduce the
regions and vice versa. However, in practice the
two methods give rise to different algorithms that
produce different results, each having its own
peculiarities . The edge detector uses information
from a limited number of points with a high
image intensity gradient, whereas the region
detector exploits information from many more
points and can fill gaps left by an edge detector.
Some simple images can be satisfactorily seg-
mented using edges alone, even though gaps may
appear where imaging noise disrupts the perfor-
mance of the edge detector. The boundaries of
smooth regionsmayidentify edges untraceable by
an edge detector ; however, they maybe false, and
without physical significance .
Rather than using edge and region detectors
alone, it should, therefore, be attempted when-
ever possible, to combine their information in
order to produce a more reliable result .
In classical low-level segmentation approaches
such as automatic edge detection or region-
growing methods, problems occur when the con-
trast between a structure and its background is
low. Unfortunately, OARs and their background
yield very often in CT and occasionally in MR
images of low contrast . This is usually no problem
for the human expert who will contour in such
cases on the basis of additional anatomical knowl-
edge .
Most OARs of the head are very similar from
patient to patient as far as size and shape are con-
cerned . This well-known fact led to the idea of
using anatomical models for different medical
applications [8-12] . To support the contouring
process of the OARs of the head we have
developed methods to fit individual patient data
three-dimensionally by a standardized anatomical
model.
TheAnatomical Model-Based
Segmentation Approach
The anatomical template atlas was established
based on a high-resolution MR data set of a
healthy individual . This data set consists of 128
slices (256 x 256 pixels) with an isotropic voxel
size of approx . 1 mm and shows no significant
anatomical deviations (Fig . 3) . In this data set an
experienced therapist defined the contours of all
therapy-relevant OARs manually slice by slice .
The next step was a 3D-surface model (Fig . 3)
generated by triangulation of the contours of sub-
sequent slices according to the method of Bois-
sonnat [13] . The surface representation is a very
compact method of data handling and permits
usage of the model in real time . At present, the
anatomical template atlas includes the following
structures : outlines of the head, brain, cerebel-
lum, eyes, optic nerves, chiasm, brain stem and
pituitary gland.
Adapting the template atlas to individual
brains is carried out in two steps: the model is
first aligned globally to compensate for different
positioning of patient and model during image
acquisition . In the second step, the anatomical
variations in brain size andshape between patient
and model are taken into consideration.
A prerequisite for the global alignment of
patient and model is to define a common refer-
ence coordinate system which allows to quantify
the difference in position and orientation
between the two. The bicommissural coordinate
system according to Talairach andTournoux [8] is
an internationally accepted intracerebral coordi-
nate system (Fig . 4), which serves this purpose.
We use it in a variation of Schütz et al . [14] .
Talairach et al . came to the conclusion that the
anatomical variation between different individual
brains is smaller when scaled to their proportional
coordinate system . This system consists of 6
cuboids for each hemisphere . The cuboids are
defined on the basis of the maximum extension of
the brain and two lines (VCA and VCP) through
the commissures (CAand CP in Fig. 4) which are
perpendicular to the bicommissural plane.
To evaluate the template atlas approach, we
integrated a sample implementation of the tem-
plate atlas into theTOMASprogram [15] . The 2D-
Fig . 3. Top : Sagittal section
of the MR data set which
serves as basis for the
template atlas .
Bottom left : Triangulated
network model of the head
surface .
Bottom right : Template atlas
model shown as shaded sur-
faces
YON
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atlas contours can be interactively moved and ro-
tated in order to align the model to the patient's
position and orientation . This way, variations in
brain size and shape can be considered . A com-
plete interactive matching procedure is illustrated
in Figures 5 through 7. Figure 5 shows the starting
position with model and patient more or less ran-
domly oriented to each other. In a first step, the
model is aligned to the patient's position in the
axial section (Fig . 6, left) . Subsequently, the axial
rotation (Fig . 6, middle) can be compensated in a
sagittal section (Fig.6, right) . After this global
alignment, position and orientation of model and
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patient correspond quite well . An interactive pro-
portional scaling is carried out (Fig . 7, left) to
compensate anatomical variations . The result is
shown in the middle of Figure 7: model and
patient match fairly good . A separate translation
and rotation of the eyes and the optic nerves
improved the result even further to the level illus-
trated on the right hand side of Figure 7 .
In a first evaluation, the model-based seg-
mentation approach was tested with 17 clinical
patient data sets selected at random .
The first criterion was the time needed for the
model-based approach as compared to the con-
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Frontal plane
ventional manual segmentation . The mean seg-
mentation time with the model-based approach
ran up to 8 minutes making it 2-3 times faster
than the manual method which requires 15 to 30
minutes depending on the number of slices .
Concerning the accuracy, we found only a 10
difference between the model-based approach
and the interpersonal variability even though 5 of
the 17 test data sets had the brain stem displaced
Bicommissural plane
Fig . 5. Starting position of the anatomical model relative to the patient's image data set
Fig. 4. The bicommissural coordinate system
by a tumor. Non-linear deformations like this can-
not be modelled with the slice-by-slice linear scal-
ing approach of the proportional scaling method .
The study also showed, that in nearly all cases
the contours of the eyes could be used for therapy
planning without any modification . In case of the
brain stem and the pituitary gland nearly 70% of
the contours were suitable without modification
and 25 % after a simple translation . However,
Fig . 6 . Different intermediate matching steps for the global alignment
most contours of the optic nerves were inaccept-
able . The reason for this is the small size of the
optic nerves which are poorly visualized in CT
images with a 4 mm slice distance (e.g ., partial
volume effects) . Their classification is highly sub-
jective and, therefore, problematic .
Summary
Defining the tumor volume, target volume and
organs at risk in CT or MRI data sets is one of the
most critical steps in three-dimensional radio-
therapy treatment planning . The accuracy with
which the volumes can be detected and the
Fig . 7 . Different intermediate matching steps to compensate anatomical variations
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required time for the delineation are still far
beyond the clinical wishes .
Replacing time-consuming manual image seg-
mentation by computer-assisted interactive image
segmentation is a means to facilitate the process .
The computer relieves the user of much of the
tedious work, and enables the operator to use
clinical judgement to achieve the desired result .
The approaches described in this chapter are cur-
rently subjected to extensive clinical evaluation .
First experience shows, that the existing problems
can be solved at least for lesions in the head and
neck area .
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Treatment Planning for Proton Beams
Introduction
M. URIE*
Massachusetts General Hospital, Boston, MA, USA
The specific energy deposition characteristics of
protons offer the potential of dose distributions
which conform more closely to target volumes
than can X-rays, but also place higher require-
ments on the planning of treatments .
These requirements imply the use of reproduc-
ible immobilization techniques compatible with
the diagnostic imaging modalities and treatment
planning imaging studies of fine resolution .
The treatment planning system must be able to
handle large volumes of data, perform the neces-
sary calculations, provide the pattern for the
required field defining devices and information
for a correct positioning of the patient.
Presently, X-ray CT is the only imaging modal-
ity available which can provide the data needed to
calculate the required range of protons. No MR
echo sequence has been developed which can
reliably be translated into proton stopping
powers, nor are there other 3D-imaging tech-
niques on the horizon which will . Hence treat-
ment planning for proton therapy is based on CT.
Exceptions are "shoot-through" techniques in
which high energy protons are used and no
attempt is made to not treat distal tissues by con-
trolling their range, and secondly a few sites in
which the entire pathlength of the protons is
through homogeneous tissue of well-known com-
position and target volumes are regularly shaped .
A brief discussion of treatment planning for
eye tumors with non-CT based patient informa-
* present address: University of Massachusetts Medical
Center, Worcester, MA, USA
tion can be found in Chapter 13 . In this chapter
the discussion will concentrateon treatment plan-
ning based on CT information with the intent to
conform the range and modulation of the protons
to the target volumes.
Acquisition and Processing
of Imaging Data
To treat most target volumes, passage through
heterogeneities in the body is required . For pro-
ton therapy the position of each heterodense
structure and its density must be defined; the
range of the protons for any portal must be calcu-
lated and then compensated for in order to
achieve the desired dose distribution pattern in
the individual patient at each treatment session.
Presently CT is the only method available to
obtain these necessary data .
Converting CT Data into
Proton Stopping Powers
CT data are acquired with highly filtered 120-140
kVp X-rays (effective energy of ca . 90 kVp) . The
mathematically reconstructed Hounsfield units
represent the linear attenuation coefficients of
these X-rays . These linear attenuation coeffi-
cients need to be converted into proton stopping
powers in order to calculate the energy or range,
required . Most treatment planning systems calcu-
late the areal density by integrating the radio-
graphic pathlength from the effective proton
source to the distal target volume, and converting
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the Hounsfield unit of each encountered voxel
into a stopping power using a look-up table.
Historically, the conversion table was empiri-
cally established at the Massachusetts General
Hospital and Harvard Cyclotron Laboratory
using fresh cadaver parts; the accuracy of predict-
ing the protons' range with these data was esti-
mated to be ca . 3.5 % (unpublished data) . More
recent work using proton radiography and an ani-
mal's head [1] has examined the accuracy of dif-
ferent conversion tables . For a relatively homoge-
neous lateral brain irradiation, measurements
and calculations based on a tissue substitute con-
version table had arms deviation of 2.5 mm, with
a maximum of 11.1 mm. Correcting the table for
tissue substitute composition (oxygen/hydrogen
content) the rms deviation was reduced to 1.9 mm
(maximum 6 .0 mm) . This is still substantial and
most likely due to the effects of atomic composi-
tion of the tissues. By adjusting the Hounsfield
units for specific organ composition (brain, bone,
etc.) and using the tissue substitute corrected for
composition conversion table, the rms deviation
was reduced to 1.0 mm, with a maximum of 2.3
mm. This approach uses theoretical values of tis-
sue composition. Another suggestion [2] has been
to deduce this elemental composition by using
dual energy CT scans. This is an accepted tech-
nique but as yet not routinely incorporated into
planning treatments for proton therapy. Instead,
usually a single energy CT scan is acquired and
uncertainties in the range compensated for when
prescribing the required penetration by adding a
few millimeters or approx . 3 % of the maximum
range to assure target volume coverage .
CT data include the effects of statistical varia-
tions . They vary from time to time, with the field
of view, and sometimes within the field of view. It
is highly recommended that phantom studies be
performed regularly to characterize the particular
CT scanner being used for treatment planning
scans and to include phantom material of well
known composition in each patient scan . The
treatment planning system should have the tools
to scale the conversion table for each individual
patient study.
Spatial Resolution
The extent to which inhomogeneities can be com-
pensated for depends on a number of factors,
including the scattering characteristics of the pro-
tons, the size and density of the inhomogeneities,
the amount of physiological and anatomical
movements, the stability of the patient, and fi-
nally, the ability to reproduce the set-up from CT
scan to treatment and from treatment to treat-
ment. In general, it is very difficult to achieve a
reproducibility better than 2mm, 3-5mm is more
common. However, it is better to take into
account these variations intentionally with
mathematical techniques than to be limited by
the spatial resolution of the planning study.
The in-plane spatial resolution of present CT
scanners is typically 0.4-1 mm, depending on the
field of view. The spatial resolution along the lon-
gitudinal body axis is determined by the slice
thickness and spacing. The thinner the slices, the
greater the spatial resolution but the noisier the
data ; also there is a greater volume of data to be
handled.
Sampling theory predicts better spatial resolu-
tion by overlapping the slices, i .e ., to acquire 3
mm thick slices at 1.5 mm increments . Studies
performed at Massachusetts General Hospital
(unpublished data) concluded that the increased
resolution was not significant enough clinically
for proton therapy to justify the doubling of the
data . Hence, unless very specific anatomy or
fiducial markers are being localized, contiguous 2
or 3 mm thick slices are judged to be appropriate
for treatment planning in the head; 3 or 5 mm is
usually adequate for the body.
Treatment planning systems need to calculate
the areal density from the effective proton source
to the target volume . CT scans must therefore
include all materials in the beam path, including
any immobilization material which will be there
when the patient is treated. Scans are performed
with the patient in the immobilization device, in
the treatment position, with a large enough field
of view to encompass the entire patient circumfer-
ence and extending far enough superior and infe-
rior of the target volume to allow calculation of
range for oblique fields .
Most proton therapy centers have fixed beam
lines ; the majority are horizontal . To deliver pos-
teriorly and anteriorly oblique fields, patients are
treated in seated or standing positions . Studies
performed at MGH comparing CT scans taken
with the patient supine to the patient seated have
shown that intracranial contents shift with respect
to the bony landmarks less than 2 mm between
the two (unpublished data) . However, below the
base of skull, not only do the relative positions of
the bony structures change but also the soft tissue
thickness varies significantly between the two
positions, in spite of apparently tightly conform-
ing immobilization devices. These changes can
vary significantly and unpredictably from patient
to patient, even in the neck . In the thorax, abdo-
men, and pelvis these changes are much greater;
planning studies in these sites must, therefore, be
performed in the treatment position and in the
immobilization device .
Delineaton and Segmentation
of Volumes of Interest
After the CT data are loaded into the treatment
planning system, several steps are necessary
before designing treatment portals . First, the data
for this particular scan need to be scaled for the
conversion table to proton stopping powers . Typ-
ically the Hounsfield units of the included phan-
tom material (water, bone equivalent, etc.) are
sampled and the conversion table uniformly
adjusted by giving air, water, and bone values .
Secondly, the surface from which the proton
range will be calculated needs to be delineated .
Often this is the skin surface, but should include
the immobilization material if it will be in place
for the treatment . Automatic segmentation tech-
niques may be useful, but their results need to be
reviewed carefully and edited if necessary.
Thirdly, target volumes and normal tissues of
particular interest need to be delineated (Fig . 1) .
Computer extraction techniques may be an aid
for certain normal tissues, but their results again
need to be reviewed carefully (cf . preceding chap-
ter) .
It is essential prior to beginning portal selec-
tion and design to know the prescribed dose to
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Fig . 1 . Axial CT section in the head with the target volume
and brain stem delineated . No immobilization material is
apparent ; the skin would be defined as entrance surface. A
posterior oblique portal, shown schematically, would
maximize target volume coverage while limiting the brain
stem surface to 50% dose . The potential variation in range-
modifying bolus thickness is illustrated, as is the potential air
gap if the bolus is not contoured to the patient surface
the target volume(s), the maximum tolerable
doses to critical normal tissues, and the partial
volume dose constraints to any organ.
Portal Selection
Although much work is underway for computer-
assisted and optimized selection of portals, cur-
rently this work is done by experienced planners .
Taking into consideration the overall aim of the
therapy, i .e ., to achieve the desired dose to the
target and to limit the normal tissue doses, the
planner develops on overall strategy. Typically 3
to 4 portals per target are selected from an overall
3D-visualization of the target(s) and its relation-
ship to these normal tissues. Entrance directions
are preferentially selected such that they do not
overlap, e .g ., right lateral, left lateral, posterior,
and vertex fields .
The beam's eye view (BEV) display [3] is a
valuable tool allowing 3D-visualization of any
and all delineated volumes of interest (VOls) . In
BEV, the relative geometries of the VOIs are
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viewed and the patient's position interactively
modified to optimize treatment of the target and
sparing of normal tissues. The VOIs may be dis-
played as linear segments, wire frames, translu-
cent volumes and/or solid structures .
Target volumes often have a geometrical rela-
tionship to critical normal tissues which suggest
one, or two, optimal beam angles to minimize
normal tissue doses. It is usually not desirable to
employ only these one or two fields because tis-
sues in the path still receive more dose than is
desirable, since entrance doses are >75% in typ-
ically modulated beams.
Design of a Single Field
Having selected a portal direction in the BEV, a
field-defining aperture may be designed . The geo-
metrical projection of the aperture edge usually
corresponds to the 50 % dose decrement ; margins
need to be added around the target to account for
the penumbra width from the 50 % to the pre-
scribed dose level (typically 90-95%) and to
account for set-up uncertainties .
Penumbra width for proton beams varies with
the beam line parameters. It increases with
increasing scattering material in the beam line
and with depth within the patient. Usually, a
median depth to the target volume is estimated
11SIMPLE
COMPENSATING
BOLUS
Fig. 2. Design of a bolus for protons of range R to compen-
sate for surface and target irregularities and tissue hetero-
geneities . Left : Sample line ray along which a line integral is
performed to obtain the water-equivalent areal density
for a preliminary design of the aperture and the
set-up uncertainty for this portal is estimated
(typically 3-5 mm). Most planning systems have
the ability to outline the projection of the target
volume from the BEV and to add a margin
around this projection, which can then become
the aperture . Most programs also allow viewing
the projection of this aperture on the axial CT
slices and on sagittal, coronal and oblique planes
reconstructed from the axial slices . Viewing this
projection allows the planner to make any
modifications which were not appreciated in the
BEV
Having defined the field shape perpendicular
to the beam with the aperture, the ranges
required for the protons throughout the field
need to be calculated . Not only is the range to the
most distal target from the entrance surface
needed, but also the extent in depth of the target
in order to know how much the Braggpeak needs
to be spread out (modulated). This calculation is
performed with the correct perspective from the
effective proton source . It is usually done on a
regular grid at a spacing commensurate with the
spatial resolution of the scan and the scattering
characteristics of protons (typically 1 to 2 mm).
Since the treatment portal extends outside the
target volume - to account for penumbra and set-
up margin - an extrapolation scheme (radial is the
most common) is required in this region .
"EXPANDED"
COMPENSATING
BOLUS
between the skin (s) and the proximal (Tp) and distal (Td) tar-
get volume surfaces . Right: Expansion of the bolus to ensure
target volume treatment within positioning and motion
uncertainties of distanced
The result of this calculation is a matrix of
required ranges and modulation. In a passively
scattered beam, the maximum range throughout
the field defines the energy required of the inci-
dent beam. The difference of each matrix point
from this maximum range defines the thickness of
the range-modifying bolus throughout the field
(Fig . 2a, left) . The thickness is zero at the point of
maximum range.
In present planning systems, this calculation is
only a radiographic pathlength calculation . There
are no estimates of Coulomb scattering of the
protons nor of range straggling . It is also a point-
by-point calculation, presuming that the beam
and beam-modifying devices can be aligned per-
fectly with the patient as defined at the time of
the CT scan . However, there is always some
uncertainty in the reproducibility of the patient
positioning and in the alignment. To assure target
volume treatment or normal tissue sparing, this
misalignment needs to be addressed.
One approach has been described by Urie et
al . [4] and is illustrated in Figure 2, on the right.
Assuming an uncertainty of a given amount, e .g .,
3 mm, the range-modifying bolus can be
"expanded" to assure target volume coverage . At
each point in the raw radiographic pathlength
matrix of required range, the neighborhood
within a radius of that uncertainty is examined
and the range at that point replaced with the
greatest range found within the neighborhood .
This process is repeated at each point. The resul-
tant matrix of "expanded" range requirements
will assure adequate range as long as the patient is
aligned within the given uncertainty. Typically,
the radius for "expansion" is the same as the mar-
gin added to the aperture for set-up uncertainty.
The counterside of this approach is that if the
patient is "perfectly" aligned, the protons will
overpenetrate into normal tissues.
Having "expanded" the range-modifying
bolus, the required modulation of the beam needs
to be recalculated . In passively scattered beams,
the modulation is uniform throughout the field
and the maximum required modulation is used .
In scanned beams, the "expanded" modulation
needs to be incorporated .
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Multi-Portal Design
The protons' characteristic of a well-defined
range and steep dose fall-off not only spares distal
normal tissues but also allows the use of multiple
proton portals from different angles to treat a tar-
get volume uniformly while delivering essentially
no dose to a critical normal tissue it envelops . The
basic principle is to treat part of the target volume
with one field, using beam edge to stay off the
critical structure and another field (or fields) to
treat the remainder of the target and have the
protons range out in the penumbra of the first
field [5].
Figure 3 shows an example for discussion . The
target volume abuts and wraps around the brain
stem . The first proton portal is a lateral, which
treats the target volume anterior of the cord . The
range and the range-modifying bolus are calcu-
P+
Fig . 3 . Axial CT section with a target volume (dotted line)
which wraps around and abuts the brain stem (solid white
line) . Fields are illustrated to treat the target volume uni-
formly while sparing the brain stem . The lateral field treats
the target anterior of the brain stem, placing 50% of the
prescribed dose level on the brain stem surface . The poste-
rior field treats the target lateral to the brain stem not
included in the lateral field and stops in the penumbra of the
lateral field
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lated as if it were a standard single field. Set-up
and penumbra margin are added in all regions
except the brain stem . To treat the target on the
lateral side of the brain stem a posterior proton
field is designed . Again, the field edge is used to
limit the brain stem dose (50% to the surface in
this example) . To define the range and the range
modifying bolus, a new target volume is defined.
For this posterior portal, the distal part of the
new target volume is the field edge of the lateral
field; the proximal portion is the actual target vol-
ume lateral of the cord .
Because the distal fall-off and the lateral
penumbra are not identical in most proton beam
lines, there is no perfect match of the two at the
abutment junction . A dose non-uniformity
results . Howto match them is a clinical judgment ;
whether to accept a "hot" region of likely over-
treatment or to accept a potentially "cool" region
near the junction line needs to be decided by the
physician. A reasonable and common solution is
to match the nominal 50 % dose decrement lines,
i.e ., to prescribe the range of the posterior field
to be the raw calculated range to the new target
volume minus the 95 % to 50 % distal fall-off dis-
tance (typically 2 mm) .
In the planning algorithms which "expand" the
raw range-modifying bolus to assure target vol-
ume coverage, the effect in these situations can
be a significant region of probable overtreatment.
At the edges of the fields a significant overshoot
may occur if the entrance surface is curved, such
as in the neck . This effect can be minimized by
defining the new target volume discussed above
to extend laterally outside the field. In Figure 3,
the target volume is extended laterally to the mid
brain stem and medially approx . 1 cm into the
petrous ridge. This modified new target volume is
solely for calculational purposes to pull the range
of the protons back as desired. The "expansion"
of the range-modifying bolus may cause likely
regions of overtreatment, particularly in regions
with significant inhomogeneities . The radius of
"expansion" may therefore require reduction for
this posterior field but must be consistent with
set-up uncertainty.
The overall result of these combinations of
fields is a very low dose to the brain stem, a sharp
gradient dose to the target volume abutting the
brain stem, and a nearly uniform dose to the
remainder of the target volume except at the
abutment junction . This technique is a particu-
larly powerful tool to treat tumors to higher doses
than normal tissues in close proximity can toler-
ate. Because of inadequacies in present dose cal-
culation algorithms and because of imperfect
match of distal fall-off to lateral penumbra, it is
recommended that, if significant dose (e.g ., >10
Gy) is to be delivered with this type of multiple-
field treatment, alternative abutment junctions
be used . In Figure 3, for example, the posterior
field could treat all the target lateral to the brain
stem and the opposite lateral field could be
designed to stop in its lateral penumbra. This
spreads the regions of potential "hot" and "cold"
regions into two junction regions, reducing the
absolute dose of potential over- or under-
treatment .
Developing the "Best" Plan
Often there are several overall approaches to
deliver the dose to the target while maintaining
tolerable doses to normal tissues. Which is the
"best" remains a clinical decision, though there
are attempts to model biological responses, of
both tumors and normal tissues, and use these to
"optimize" the treatment plan .
Tools to aid in evaluation of a plan and to com-
pare plans are essential . The vast amount of data
from 3D-planning systems soon becomes over-
whelming without summary and comparison
tools. Capabilities of planning systems which
have proven particularly useful [5, 6] include
- side-by-side displays (different plans shown on
the same slice),
- dose difference displays (dose distributions of
two plans subtracted and regions and amounts
of difference displayed),
- dose statistics (average dose, maximum dose,
minimum dose, etc.),
- dose-volume histograms of volumes ofinterest,
- predictions of modeling of tumor control prob-
ability (TCP) and normal tissue complication
probability (NTCP) .
Delivering the Planned Treatment
Having developed the desired treatment, several
steps are involved in assuring it is delivered as
planned . First, the beam modifying devices, aper-
ture and range modifying bolus need to be fabri-
cated and the beam line correctly configured for
energy and modulation . Usually, the portal/
patient specific devices are milled or poured
according to computer files generated in the plan-
ning system .
To position the patient correctly for the portal
designed from the planning study with the
required degree of accuracy (2-3 mm typically) is
not a small effort . The technique most widely
used is to align the patient to bony landmarks
and/or fiducial markers using diagnostic radio-
graphs, and to compare these to radiographs cal-
culated from the CT planning scan . These digi-
tally reconstructed radiographs (DRRs) are cal-
culated with the correct magnification and per-
spective for each film, and measurements of
appropriate landmarks are used to assure the
patient is correctly aligned. Often standard ortho-
gonal projections (lateral and anterior-posterior)
are used for the initial set-up of the patient and a
portal film taken to confirm correct alignment
when all rotations have been incorporated .
Several algorithms are available to calculate
the required DRRs . Some use interpolation
(smoothing) algorithms, or separate "bony"
Hounsfield units from "soft tissue" Hounsfield
units and allow different relative contrast . Which-
ever algorithm is employed, the resultant image
must be available for high quality output . Radio-
graphic film using either an optical or laser prin-
ter output is presently the method of choice to
obtain films to compare to the set-up radio-
graphs . Techniques for computer-aided registra-
tion are being implemented in some treatment
facilities [7] . Using well-defined landmarks and/
or fiducial markers identified on orthogonal
radiographs, computer programs aid in defining
the translations and rotations needed on a day-to-
day basis for correct patient alignment . In the
near future, digital radiographs should be able to
be compared to DRRs electronically and these
assessments made without hardcopy.
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To be able to display VOIs and points of interest
on the DRRs is a useful tool . Fiducial markers and
specific bony landmarks should be delineated on the
axial slices and displayed on the DRRs . A portal
DRR, showing the correct alignment of the anat-
omy with respect to the central axis and the aper-
ture, is extremely valuable to confirm final position-
ing correctness prior to treating the patient.
Caveats and Other Considerations
Present planning systems do not have dose cal-
culation algorithms which accurately predict the
dose when protons pass through heterogeneous
tissues in the actual treatment situation . These
inadequacies must be kept in mind when planning
the treatment and reviewing the dose display.
The penumbra of a proton field is not uniform
with depth in the patient. It broadens predictably
as protons pass through homogeneous material .
This is accurately modeled by most planning sys-
tems . The effects of heterogeneities on the lateral
penumbra, however, are not taken into account
by present dose algorithms .
Penumbra characteristics are very dependent
upon beam line configurations and any material
in the beam path . In passively scattered beams
with energy variability, the 80%-20% distance
may be < 1 mm (at 5 cm depth in water) . The
energy is often degraded by placing absorbers in
the beam line . For example, a cyclotron-
generated beam with single output energy of 20 g/
cm2 may need to be degraded to a penetration of
12 g/cm 2 by placing 8 g/cm2 absorber in the beam
path . The absorber introduces angular confusion
to the protons and the penumbra is broadened ;
even when using low-Z materials such as lucite to
minimize the scattering angles, the penumbra
may be broadened to 4-5 mm (at 5 cm depth in
water) with 8-10 cm of in-line absorber [8].
In passively scattered beams, the Bragg peak is
modulated in depth to create a region of uniform
dose great enough to encompass the target . Dif-
ferent schemes are employed, including modu-
lator wheels and wobblers (cf . Chapter 24), but
all introduce additional material into the beam
line . Hence, scattering of protons occurs, ad-
versely affecting the lateral penumbra .
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To minimize the degradation of the penumbra,
energy absorbers and modulation devices are
placed as far upstream (away from the patient) as
possible . But field-defining apertures and range-
modifying boluses should be as close to the
patient as possible . An air gap introduces a region
in which the effects of angular confusion of the
protons are magnified . Ideally, the range-
modifying bolus should be shaped to conform to
the patient's surface and just touch it ; the aper-
ture should be on the surface.
In present delivery systems, the range-
modifying bolus often has one flat surface, which
is attached to the downstream side ofthe aperture
(Fig . 1) . There may be gaps between portions of
the bolus andthe patient and the aperture maybe
offset significantly from the patient's surface,
depending upon the range-modifying bolus'
thickness. The thickness of the bolus and the
width of the air gap affect the lateral penumbra
[8] . Present planning systems do not have dose
calculation algorithms which accurately reflect
these factors, though some do approximate cor-
rections to the nominal penumbra . This limitation
must be kept in mind when reviewing the dose
distributions, particularly if field edges are being
used to limit doses to certain critical structures .
DEPTH (CM)
The effects of heterogeneities on the range of
proton beams have been theoretically and empir-
ically studied but are presently not incorporated
into dose calculation algorithms in treatment
planning systems. In general, the primary effect
of protons passing through heterogeneities is to
increase the spread of their effective ranges as
they are scattered, resulting in a less steep dose
gradient distally.
The effect of a slab of heterogeneity is well
understood and modeled . It modifies the pene-
tration of the proton beam. The effect of a hete-
rogeneous edge is dependent upon its density and
thickness [9]. In principle, large dose perturba-
tions can develop behind edge discontinuities and
such discontinuities can reinforce each other; in
practice, the effects of overlying tissue and beam
divergence strongly modify the dose perturba-
tions in parallel beams. The effects of thin "sliv-
ers" of heterogeneities parallel to the beam may
be either under- or over-estimated from radio-
graphic pathlength calculations on CT [10,11] . As
the sliver becomes thinner, the dose distal to the
"expected" end of range increases until it is
ca . 70 % for a 1 mm wide sliver (Fig . 4) . Concomi-
tantly, the dose is reduced within the proximal
region of the depth dose distribution, due to
CENTRAL
AXIS
Fig . 4. The effects of a thick inho-
mogeneity on the distal range of a
proton beam . A short (2 .5 cm long)
sliver at 7.5 cm depth in water
causes perturbations in the central
axis depth dose ; the perturbations
for slivers 10, 4, 2, and 1 mm thick
are shown
preferential scattering of protons out of the
sliver.
Inadequacies of CT to define precisely the
fine-anatomical structure, e.g ., mastoid air cells,
and the limitations of dose algorithms which do
not account for Coulomb scattering of protons
result in a significant error in the end-of-range
dose prediction in some structures . Phantom
C
DETECTOR
Water Tank
37 x 37 x 35 cm
Fig . 5 . The effects of multiple fine heterogeneities on the
end of range of protons . A) Measurement technique shown
schematically in a coronal plane . B) Lateral radiograph indicat-
ing the measurement points and the RAS-1 diode in position
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studies [12] and animal studies [1] have shown
that the distance from the distal 80% to 20% may
be spread from the water measured 4-5 mm to
>20 mm in such cases (Fig . 5) . Keeping this in
mind when reviewing dose distributions is essen-
tial, and it may be advisable to select portal di-
rections which minimize passage through such
heterogeneities.
- PROTONS
(16.0 g/crr 2
Residual Range)
460 MeV PROTONS
- WITH SKULL
°° WATER ONLY
for depth-dose distribution A . C) Depth-dose distributions at
the three points in (B) compared to those measured in water
(dotted line) . The numbers are the mm distances between the
90%, 80% and 20% dose decrement in the two cases
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Besides heterogeneities, air gaps between the
range-modifying bolus and the patient will affect
the intended stopping pattern of the protons as
well . The protons are scattered as they pass
through the range-modifying bolus (usually lucite
or wax) and an air space acts as a region to
magnify the increased angular confusion of the
beams. The effect of this scattering is to smooth
the desired effects of the compensating bolus
[13] . Designing immobilization devices to allow
the range-modifying bolus to be very near to the
patient and to conform the bolus to the patient
contour are important to maximize the distal tai-
loring of the dose distribution .
No present dose algorithm used for treatment
planning adequately models the effects of hetero-
geneities on the range of protons. In general,
broad beam algorithms make only first approx-
imations for these effects on penumbra and
ignore end-of-range effects . Pencil beam algo-
rithms do better with the penumbra and make
first order approximations to the distal effects .
Monte Carlo techniques can account for all of
these effects, but presently require too much
computing time to be practical for patient plan-
ning . In general, dose gradients appear to be
sharper and better defined than they really are .
This must be kept in mind when reviewing plans
and making clinical decisions about treatments .
It is therefore extremely useful for the plan-
ning system to be able to estimate and display the
likely range of uncertainty in its calculations . The
effect of imperfect patient set-up, imperfect con-
version from CT data to range of protons, and
imperfect dose algorithms are more dramatic for
proton therapy than for X-ray therapy. The poten-
tial advantage of a well-defined range for a given
proton beam also implies a great disadvantage if
it is not accurately calculated and controlled,
either because the intended target may not be
treated at all or distal normal tissues not be
spared as intended .
An estimate of the total uncertainty in the
dose displayed by the treatment planning system
is essential in order for physicians to make clinical
judgments . One method to estimate this uncer-
tainty has been implemented at MGH [4, 14] .
This method displays the dose as calculated to be
the nominal dose ; it then estimates, incorporating
the set-up uncertainty and the CT conversion
uncertainty, the greatest and least likely dose at
each point. Although not directly estimating the
straggling of protons and the degradation of the
sharp fall-off in dose distally when passing
through heterogeneities, theoretical [14] and
experimental studies [4, 12] have shown that the
distal doses in these situations are encompassed
Fig . 6 . Contour depths of the distal 50% dose behind a
phantom with multiple heterogeneities . The range-
modifying bolus was calculated to stop the protons at a uni-
form depth (zero) and then "expanded" by 3 mm . The
ranges of depths in which the 50% contour is predicted to
be as long as the range-modifying bolus and "patient" are
aligned within 3 mm is indicated by the shaded region . The
depths of the 50% contour for the "correctly" aligned situ-
ation is shown by the solid line
between the estimated greatest and least likely
penetration (Fig . 6) .
In Figure 3, for instance, the distal dose gradi-
ent (80 %-20 %) of the lateral field is known to be
degraded to approx . 20 mm in the petrous region .
The uncertainty calculations would encompass
this . The true 80 % would be more distal than the
"minimum" 80 % displayed and the true 20
would be more proximal than the "maximum"
20 % displayed .
This method has its drawbacks and is not the
only approach. However, it is believed to be
extremely important for proton therapy to give
the clinicians an estimate of the likely ranges of
dose at a particular point.
Conclusions
Proton therapy offers the potential of better con-
formation of physical dose to target volumes,
with a higher probability of tumor control or a
decreased probability of treatment related com-
plications . This has been demonstrated for a few
sites and is being explored at many others . But to
achieve these improvements requires attention to
detail and significant efforts at patient position-
ing, treatment planning, and treatment delivery.
Each patient's treatment must be planned indi-
vidually, from CT data for nearly all disease sites.
An adequate treatment planning system must
allow definition of the target volumes and normal
tissues of particular interest . It must permit delin-
eation of the field-defining aperture, calculation
of the required range, the range-modifying bolus,
and the amount of required spread of the Bragg
peak throughout each portal, and finally, it needs
to provide information for correct patient posi-
tioning which has to be assured at each treatment
session .
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Developments in Ion Beam Therapy Planning
and Treatment Optimization
A. BRAHME, P KALLMAN, and A. TILIKIDIS
Dept. of Medical Radiation Physics, Karolinska Institute and Stockholm University, Stockholm, Sweden
Ion beams pose special problems in treatment
planning due to the significant depth variation of
the radiobiological and microdosimetric proper-
ties of these beams. It is a fairly straightforward
problem to develop fixed and standardized range
modulation protocols to deliver a uniform bio-
logical effect or absorbed dose to extended,
essentially rectangular target volumes [1] . Afixed
range modulation could be generated using ridge
filters, linear, rotary or hydraulic range shifters or
by energy modulation of the extracted beam from
the accelerator. When using a fixed range
modulation, the distal part of the dose distribu-
tion could always be conformed to the target vol-
ume by advanced bolus techniques . However, to
make full use of the radiobiological and physical
advantages of ion beams it is advantageous to
perform a careful three-dimensional scanning of
the beam and predominantly locate Bragg peaks
in the target volume as illustrated in Figure 1
[2-5] . This fact becomes increasingly important as
the ionization density is increased beyond that of
protons. Therefore, accurate radiotherapy opti-
mization is a very complex problem where the
special radiobiological and dosimetric properties
of the ion beams have to be taken into account to
maximize the probability to control the tumor
growth without inducing severe damage to
healthy normal tissues . In the present chapter the
emphasis is therefore on the use of radio-
biological optimization methods rather than on,
for example, the use of modern three-
dimensional diagnostic techniques and advanced
bolus design .
From a mathematical point of view, classical
radiation therapy planning is basically a forward
process that tries to answer the question : How
will the absorbed dose and the biological effect in
the target volume and surrounding normal tissues
be distributed for a given target volume, associ-
ated normal patient geometry and suggested con-
figuration of the incident beams? Classical radia-
tion therapy optimization is, therefore, generally
a trial and error process, where gradually
improved dose plans can be found by trying an
increasing number of incident beams in gradually
improved configurations [6, 7] .
However, in mathematical terminology, radia-
tion therapy optimization is fundamentally an
inverse problem. This is so, because what we
really want to find, is the optimum combination
of incident beams for a given target and normal
tissue geometry. More exactly, the planning pro-
cess should answer the question : which configura-
tion of energy, particle species and shape of the
incident beams is best for clinical tumor control
with minimal damage to normal tissues? At least
under the assumption that the desired dose to the
target volume or the geometrical and radiobio-
logical properties of the tumorand normal tissues
of the patient are known, it should be possible to
find the optimal irradiation technique by inverse
therapy planning methods [7-10] .
Strictly speaking, there is no such thing as a
generally acceptable and truly optimal treatment
plan, because there are so many clinical factors
that are specific for each patient and for the
responsible radiotherapeutic team and all of them
have to be taken into account in the optimization .
The principal problem is that most of these fac-
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Fig . 1 . The irradiation geometry for an optimized two-field
neon ion technique applied to an esophagus cancer is
shown in (a) . The optimum Bragg peak density for the two
beams are shown in (b) . The solid curve pertains to the ante-
rior beam and the dotted to the oblique posterior beam .
Note that the algorithm produces a high Bragg peak density
tors concern incompatible entities which cannot be
compared on a common scale. In the general case,
the number of degrees of freedom in the selection
of incident beam directions, beam profiles, parti-
cle types and energy modulations is also very
large . In clinical practice it is, therefore, difficult
to integrate all advantageous and adverse radia-
tion effects on the patient to maximize the clinical
29 1
in the target volume but also that the regions for the two
fields are different . The physical dose distribution is shown in
(c) and the resultant biologically equivalent dose distribution
in (d). The isodoses are in photon-equivalent Gray from 10
and up in steps of 10
outcome, for example, in terms of the quality of
life of the patient. In a given clinical setting, such
factors as the simplicity of the irradiation tech-
nique and the accuracy in dose delivery, often have
a strong impact andmay sometimes disqualify very
complex plans . In general, a strict mathematical
optimization is, therefore, not even practical, and
several simplifications have to be made.
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Dueto the considerable variations in radiation
quality along the range of the particles (Figs . 2
and 3) the optimal use of heavy ion beams will
almost always require complex three-dimensional
scanning patterns . The method presented here
has the potential to optimally combine a very
large number (-106) of pencil beams of ions of
varying energy, ion species and angle of incidence
on the tumor such that the probability to eradi-
cate the tumorwithout causing severe damage to
normal tissues is maximized.
Instead of prescribing a certain dose distribu-
tion in the target volume, approximately known
radiobiological dose response relations for the
tumor and the normal tissues can be used to find
the optimal dose distribution with regard to
complication-free tumor control. For this purpose
we have developed a radiobiological model that
describes the response of tumors and normal tis-
sues to non-uniform irradiation . The model is
basedon clinically established dose response data
as expressed by the dose causing 50 % probability
of response, Dso , the relative seriality of the tis-
sue, S, and the steepest value of the normalized
dose response gradient, y (cf . Tab . 1) . It is impor-
tant that the model accurately describes the vol-
ume dependence of the dose response relation .
The new algorithm is able to use known dose
response relations to minimize the irradiation of
r(y s~'
5.01
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3.0
2.0
0.0
RBE
7.0
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Table 1 . The radiobiological parameters in the Neon treat-
ment presented in Figure 1
QTgau
Tumor
Lung
Heart
Spinal cord
Surrounding normal tissue
sensitive normal tissues while simultaneously era-
dicating all tumor cells . With such an algorithm
and suitable heavy ion beams, almost any target
volume can be clinically controlled by external
beam irradiation. Several methods capable of de-
livering the three-dimensional scanning patterns
are available and have been discussed extensively
elsewhere [4, 5, 11, 12].
Theory
The RBE for Radiation Fields
with Large LET Variations
The relative biological effectiveness may quite
accurately be described by an integral over the
relative biological effectiveness for each interval
Fig . 2 . The biological response func-
tions for high (s - 0.6) and low (s
0.02) survival levels (solid and broken
curves, respectively) calculated using
microdosimetric single event distribu-
tions and experimental RBE values for
the radiation qualities taken from [14] .
In the insert, RBE values for single track
lethal damage (dash dotted curve), DNA
double strand breaks (broken curve)
and DNA single strand breaks (dotted
curve) are shown for comparison
y / ev mn1 (redrawn from [22])
55 2.8 -
24 .5 2.1 0.0061
49 .2 3.0 0.2
60 1 .8 1 .0
80 2.1 1 .0
of lineal energy dy of the microdosimetric distri-
bution of energy imparted within each individual
biological target for the particular radiation qual-
ity. The relative biological effectiveness for
energy transfers in the interval y to y+dy will not
only depend on the lineal energy y, but also on
the actual survival level of interest as illustrated in
Figure 2. It should be kept in mind here that the
survival at the lineal energy y is based on the
assumption that the survival level of interest is
reached by dose delivered solely at that lineal
energy. This means that the biological effect due
to the energy deposited in the interval y to y+dy
is independent of the dose delivered at other lin-
eal energy intervals, and that an equivalent dose
exisists at y that gives the same survival as the
entire microdosimetric spectrum . This is obvi-
ously an approximation that we have to make for
the calculations to be manageable and to avoid
having to calculate the possible complex interac-
tions of high- and low-LET damage. Based on this
simplifying assumption the RBE at survival level
s may be described by the mathematical formula-
tion :
RBE(s) = f r(y, s)d(y)dy
	
(1)
0
where r(y, s) is the relative biological effective-
ness at the survival level s at the lineal energy y
and d(y) dy is the relative dose contribution in the
lineal energy interval dy around y [13, 14]. The
relative biological effictiveness r(y, s) as a func-
tion of the lineal energy over the range 10-2-103
eV/nm have been determined by a deconvolution
technique by Tilikidis and Brahme [15] . As seen
from Figure 2 the r(y, s) distribution has its maxi-
mum in the range 100-200 eV/nm, where the dif-
ferences between different survival levels also are
the largest.
The Integral Equation
of Radiation Therapy
The total three-dimensional absorbed dose distri-
bution in the patient from the incident fluence
distribution of charged particles maybe described
by an integral over its constituent pencil beams
through the integral relationship :
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D(r) fffffJrQ,E (r,Q)('jon(p)dQdEd212 (2)
where 0;o(p) is the incident fluence distribution
of the ion beam at points Q on the patient surface
and n is the pencil beam energy deposition ker-
nels . By combining Equations (1) and (2) with
the pencil beams n differential in lineal energy y,
the low-LET equivalent dose distribution for the
entire lineal energy distribution delivered to the
patient may be written as
Deq(r) =
fffff
J aJtQ,~y,@
,y)
r(y,s)(D jon(Q)dQdEdyd2C
Equation (3) may be used to calculate the equiv-
alent dose distribution and the associated relative
biological effect .
The Dose Response Relation
for High-LET Beams
293
The variation in y along the particle tracks will
not only modify the macroscopic absorbed dose
distribution required to obtain a specific
biological effect, but also the local microscopic
variance of the spatial dose distribution . On the
organ level the dose response may be described
by Poisson statistics and quantified by the dose
causing 50% probability of a given effect, DSO,
and the normalized dose response gradient y [16] :
P(D) = 2-,
eY( 1-D1D,'
(4)
If the LET is increased beyond the low-LET
region, the DSO value will decrease due to the
increasing RBE. However, the decrease in dose
and the increased energy deposition density with
LETwill also cause an increase in the microscopic
variance for a certain radiation effect as illus-
trated in Figure 3a both for helium and neon ion
beams . An increase in the microscopic variances
of the beam will leave the D50 value largely
unchanged but the steepness of the dose response
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gradient y will decrease so that the dose response
curve becomes shallower than for example in a
low-LETbeam as shown in Figure 3b . TheY-value
will decrease with increasing macro- and micro-
dosimetric variance as described by [9, 15, 17] :
1
y
__
in(6B + aD + o)
(5)
where 6B is the intrinsic variance in biological
response, csD he variance due to the macroscopic
absorbed dose distribution and ßwthe mean mi-
crodosimetric variance determined by the proper-
ties of the particle species. The microscopic vari-
ance basically depends both on variations of the
mean absorbed dose level and radiation quality
changes according to
2 2 2
Uw - Ut,D + Gw,Q
M
Ps = 11 P (Dso .i .yi) (7)
as shown in detail for helium andneon ion beams
in Figure 3a .
If an organ or a tumor is irradiated with a het-
erogeneous LETdistribution the overall response
may be calculated based on the Dso and 1'-values
for each volume element. For a tumorwe obtain
The probability of normal tissue injury, PI, can
similarly be calculated by considering the relative
seriality of the tissue [16] . A suitable objective
function for the optimization is the probability of
achieving complication-free tumor control, P+ ,
which for high LETbeams may be approximated
by [17] :
P+ = Ps(1-PI) (8)
Normally, the tumor is given an absorbed dose
above Dso,t and the normal tissues a dose below
Dso,n. Consequently, part of the benefit obtained
with high LETradiations will be counteracted by
their shallower dose response relation and lower
y-value caused by their higher microscopic vari-
ance . This is shown in Figure 3b where the de-
creased tumor control at high doses and the
increased risk for severe complications at low
doses may reduce the therapeutic window for
high-LET beams. Equations (1) through (5) may
be used to quantify the complex response of dif-
ferent organs and tumors to the high-LET com-
ponents of the beam.
The Optimization Procedure
A general optimization procedure for inverse
radiation therapy planning has recently been
developed [9, 10] by maximization of a biological
objective function [9, 16, 18, 19]. The integral in
Equation (2) may be rewritten in matrix form so
that the three-dimensional dose distribution d is
given by :
where -cD is the fluence of the incident pencil
beams and II is the pencil beam energy deposi-
tion matrix describing the energy deposition in
the patient for each one of the incident pencil
beams . Therefore II represents a mapping from
R2 to R3 , i.e ., from the fluence incident on the
patient surface to the three-dimensional dose dis-
tribution inside the patient. The probability to
achieve complication-free tumor control may now
be maximized by an efficient steepest descent
algorithm which searches for the maximum of P+
along the direction of the gradient of P+ with
respect to the fluence 4). This gradient of P.,_ is
given by :
Results
V,DP+(d) = ä(d)VdP+(d) = IITVdP+(d) (10)
The iterative scheme for maximization of P+ now
becomes:
(Dk+i = C [(,'` + AI-ITVdp+(dk)] (11)
The detailed properties of this algorithm are
described by Gustafsson [10, 20] .
To illustrate the power of the algorithm in com-
bining high- and low-LET dose contributions in
the optimization procedure, it has for simplicity
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b)
Fig . 3. (a) Depth dependence of the relative standard devia-
tion of the microscopic energy deposition and its radiation
quality and dose-level dependent components for Ne`
(solid lines) and He" (dashed lines) beams . For He the vari-
ance is just slightly higher than for X-rays [14] whereas the
Ne-ions show considerable quality changes with depth . (b)
The influence of the microdosimetric relative standard devia-
tion on the steepness of the dose response relation is quite
high for high-LET beams
been applied to a one-dimensional case with a
tumor containing a central 10 % hypoxic cell frac-
tion . The treatment is performed with a mixed
beam schedule of neutrons and photons. The
result would also approximately pertain to acom-
bination of Ne-ions and proton beams, for exam-
ple. Radiation response data for the neutrons
have been extracted from Guichard et al . .[21] and
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the data for the neutron energy deposition kernel
were taken from Moyers [22] . In Figure 4 the
resultant dose distributions for the neutron and
photon components are shown. It is seen that for
a hypoxic tumor the algorithm prefers to use the
low OER of the neutrons to eradicate the central
hypoxic cells, whereas the photons are applied to
the well oxygenated periphery of the tumor vol-
ume. This represents an interesting application of
a biological objective function, where the radio-
sensitivity of each subpopulation of cells is con-
sidered. Also seen in the figure is that the total
absorbed dose in Gray is lower in the central
region, reflecting the higher RBE of the neu-
trons. Finally, the biologically equivalent dose is
plotted, and the resultant dose distribution when
only photons are used for treatment . With pho-
tons alone the hypoxic fraction becomes more dif-
ficult to handle . The complication-free control P+
is about 90 % with the mixed beam andonly 65
with low-LET alone, even if the photon-
equivalent dose is much higher than for the mixed
schedule .
In order to illustrate some of the problems
encountered in scanned particle beam therapy
optimization with physical objective functions [4,
7], the use ofprotons on both a simple andamore
complex target volume is shown in Figures 5 and
6, respectively. The build-up properties are illus-
trated by choosing a simple triangular prism as
the first target volume irradiated laterally by a
single proton field and trying to get a uniform
dose throughout the target . The desired dose dis-
tribution in one slice through the target volume is
shown in Figure 5b . By using the energy deposi-
tion kernel from Figure 5a and the triangular tar-
get dose distribution as input into the algorithm
(11 and d, respectively), the Bragg peak density
(see Eq. 9) in Figure 5c is obtained . Finally, the
resultant dose distribution in the target area is
illustrated in Figure 5d . An excellent anduniform
coverage of the target volume is obtained by this
treatment technique . The required range modula-
tion of the proton beam is obtained directly from
scanning density in Figure 5c which, in principle,
describes the optimal density of Bragg peaks
inside the target volume . As the range modula-
tion increases towards the broad part of the trian-
gular target as seen from the direction of the inci-
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dent beam, the surface dose in the beam increases
rapidly (Fig . 5d). It is clear that the surface
dose level is minimized, if the target volume is
irradiated from the direction where the depth
range covered by the target is minimal .
In the present case it was assumed that all pro-
ton beams are incident along the same direction,
so no explicit angular dependence is included in
Equations (9)-(11) . An angular dependence
could be introduced here at the cost of considera-
bly increased computation times. However, for
proton beam therapy the best directions of inci-
dence are generally quite obvious and an analyt-
ical angular optimization is most often not
required .
A more complex target volume consisting of
an advanced cervix cancer with involved regional
lymph nodes is illustrated in Figure 6 . The desired
absorbed dose distribution in the target volume is
shown in Figure 6a . Using a single incident beam
on this more complex target results in a rather
high entrance dose level as seen in Figures 6b
and c . In Figure 6b, an arbitrary direction has
been selected, represented here by 150° . Interes-
tingly, the required dose distribution in the target
volume is very well reproduced for arbitrary
beam entrance angles . The only way to reduce the
relative dose in the entrance region, beside
choosing the optimum direction of incidence, is
Fig . 4. The optimum dose distributions for a
mixed beam treatment technique with neutrons
and photons . In the central part of the tumor,
there is a 10% fraction of hypoxic cells . The
optimum photon dose distribution fraction is
dashed dotted and the physical neutron
absorbed dose distribution (in Gray), is dotted .
The low OER of the neutrons is obviously used
to effectively eradicate the hypoxic cells . The
total absorbed dose distribution in Gy is the
densely dotted curve and the total distribution
of the biologically equivalent dose, considering
the higher RBE of the neutrons is the solid line .
The upper dashed curve is the resultant opti-
mum dose distribution, if only photons are
used in the optimization procedure
to use two or more beam portals . This is illus-
trated in Figure 6d, where the resultant dose dis-
tribution using a three-field treatment technique
is shown. The entrance dose level is now below
25% of the target dose . This should be suffici-
ently low for most organs at risk . It can also be
seen that the dose in the bladder and rectum is
fairly low with this three-field irradiation tech-
nique .
It should be pointed out here that all results
are obtained with a simple proton beam model in
a single slice through the target volume . In princi-
ple, experimental pencil proton beam data should
be used in a clinical setting to increase the accu-
racy. Furthermore, a full three-dimensional
optimization is possible in the entire target vol-
ume as the algorithm in Equation (11) is, in prin-
ciple, n-dimensional (for this case n = 3 is suffi-
cient) .
In order to illustrate the value of biological
objective functions in the algorithm [5, 7], we
have applied it to Ne-ion beams in the esophagus
configuration of Figure 1. The calculation was
performed in a tomographic slice through the tho-
rax region, where both lobes of lung, heart and
spinal cord are the principal organs at risk . It is
almost impossible to treat the entire target with-
out having to irradiate through at least one of
these organs . In our previous study [5] we chose
the spinal cord and the heart as entrance regions,
because they have the highest DSO values . The
resultant dose distribution is shown in Figure 1.
The dose response data used in the optimization
are given in Table 1. In this case both the anterior
and oblique posterior fields were allowed to
deliver arbitrary dose distributions. It is interest-
Fig . 5 . Isometric plot of the dose distribution (vertical axis)
in one slice of a triangular target volume . In (a), the elemen-
tary proton beam is shown with its Bragg peak at the center
of the 32 x 32 pixel slice . The desired dose distribution in the
triangular target volume and the required Bragg peak irradi-
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ing that it is biologically advantageous to irradiate
different parts of the target from the two direc-
tions selected to save the cord [5] . The resultant
P+ is 94% and irradiation of the spinal cord is
almost totally avoided by the oblique posterior
field.
ation density is given in (b) and (c), respectively. The resul-
tant dose distribution in the slice is finally presented in (d)
with a very good conformation to the desired target dose
distribution in (b) . The effect of varying depth modulation on
the surface dose is particularly striking
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Conclusions
C)
Fig . 6 . (a) The desired dose distribution in one slice through
a complex cervix cancer. In this case the dose to the regional
lymph nodes is slightly lower than to the gross target vol-
ume . (b) The resultant dose distribution from a single proton
Ion beams provide unique possibilities to treat
complex heterogeneous target volumes by exter-
nal beams. To fully exploit the radiobiological
properties of these beams, optimization algo-
rithms with biological objective functions are
d)
beam incident at 150° . (c) The resultant dose distribution
from a single beam at 0° . (d) The resultant dose distribution
for a three-field technique with beams at 0°, 90°, and 180°
required . It is also recognized that uncritical use
of high-LETbeamsmay lead to increased damage
to normal tissues and a decreased therapeutic
window as compared with low-LET beams. The
optimal combination of low- and high-LET dose
delivery is essential to maximize the control prob-
ability of hypoxic tumors particularly when sur-
rounded by an infiltratively growing well oxygen-
ated subchnical disease . In general, it is then
desirable to eradicate the hypoxic tumor com-
partment by the high-LET Bragg peak part of
light ion beams whereas low-LET beams such as
electrons, photons or protons are best suited for
the often well oxygenated microscopic spread .
With 3D-scanning as beam delivery mode, low-
LET proton beams are ideally suited, as they
allow an accurate combination with light ion
beams exhibiting a high LET This might be the
ideal mixed beam treatment schedule of the
future for complex hypoxic tumors with invasive
growth .
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Introduction
Proton Radiography
U. Schneider*
Paul Scherrer Institut, Villigen, Switzerland
The use of protons for radiography was first sug-
gested by Wilson [1] in 1946, but it was not until
the 60's that charged particles, as opposed to X-
rays, were first used to produce high contrast
radiographs . Proton radiography andtomography
were virtually abandoned as diagnostic tools due
to the success of X-ray computed tomography.
Interest in proton radiography is now growing in
the light of the increasing success of radiotherapy
with protons .
More proton therapy facilities will be available
in the future and the use of proton radiography
and proton tomography for both diagnostic pur-
poses and for quality control in proton therapy
should be therefore investigated from the point of
view of the increased availability of proton
sources with adequate energy (up to 270 MeV).
Proton diagnostic images are characterized by a
high density resolution and low dose to the
patient. The main disadvantage is the poor spatial
resolution as compared to conventional X-ray
images . As opposed to photons, proton radio-
graphic images contain additional information on
the range of the protons traversing the patient
which could be important for therapy and can be
used for proton treatment verification .
There are in principle two methods of taking
proton radiographies : Nuclear scattering radiog-
raphy (NSR) and transmission radiography. NSR
makes use of the scattering of high energy
protons (500-1000 MeV) at the target nuclei .
k Present address: Ludwig-Maximilians-Universität,
Munich, Germany
Only one exposure is needed to obtain a three-
dimensional reconstruction of the object [2,3] .
However, this method can only be used for diag-
nostic purposes since the images contain no range
information . Also, as only scattered protons are
detected, unnecessary dose is delivered to the
patient . Another disadvantage of this method is
the high energy required . This will exclude typical
clinical proton accelerators, because such
machines will provide only slightly higher ener-
gies than are used for proton treatments . For
these reasons this article is restricted to proton
transmission radiography. With this method, the
integrated density along the particle path can be
measured, as can local variations of the density,
by using the same technique as for X-ray com-
puted tomography.
Basic Properties
of Proton Radiography
Multiple Coulomb Scattering
and Spatial Resolution
The limiting factor affecting position resolution is
given by the multiple Coulomb scattering of the
protons in the patient. Protons undergo numer-
ous small angle deflections caused by their inter-
action with the Coulomb fields of the atoms of
the traversed material . The cumulative effect of
these random deflections can be modelled to a
first approximation by a Gaussian angular distri-
bution . This multiple Coulomb scattering deter-
mines the spatial resolution of proton radiogra-
phy and is, therefore, the limiting factor for the
utilization of proton radiography as a diagnostic
tool . A detailed discussion of the spatial resolu-
tion of proton radiography is given by Mustafa
and Jackson [4] and Schneider and Pedroni [5] .
They concluded that a spatial resolution of 1 mm
can be achieved by measuring the coordinates of
the entrance and exit points for each proton . The
resultant resolution is poorer than that of X-ray
images, but is good enough for quality control
purposes in proton therapy. As the underlying
physics of proton therapy is essentially the same
as for radiography, no improvement in spatial
resolution is required .
Energy Loss and Density Resolution
The attenuation of a beam of monochromatic
protons passing through homogeneous matter is
small until the protons reach the end of their
range. The dotted line in Figure 1 shows the flux
curve for protons, neglecting nuclear interac-
tions, which demonstrates the steep fall-off that is
found in the last portion of the proton range.
Thus a small change in the thickness of an ab-
sorber will result in a large change in the number
of particles which pass through it . The steepness
of that slope is given by the range straggling of
protons passing through matter and is character-
ized by the sensitivity of the range measurement.
16
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Fig . 1 . Flux of 219 MeV protons (dotted line) and 50 keV
photons (solid line) passing through water. The symbols
represent measurements [18]
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The range measurement of each individual proton
can either be achieved by measuring directly the
range with, for example, a range telescope or by
measuring the energy andtransforming these into
proton ranges . Whether range detection or
energy detection is the better choice depends on
the sensitivity of the detector. For comparison,
Figure 1 shows the transmission of X-rays where
the flux is attenuated in a near-exponential fash-
ion with increasing depth in the absorber.
Measurements have been performed where
variations in integral density as small as 0.05
could be detected with low dose to the patient
[6,7] . With the same dose applied to the patient,
one can detect changes in effective absorber
thickness that are considerably smaller than those
observable with other radiographic techniques .
Such a density resolution is the result of the char-
acteristic loss of energy of protons passing
through matter. For protons with energies of the
order of 200 MeV, loss of kinetic energy results
from ionization of atoms in matter. This energy
loss per centimeter, called the stopping power,
can be calculated from the well known Bethe-
Bloch equation . For protons, it reads
_dE = Kn oi [In
2meczß2
- pZ] (1)dx ß ( (1-p )I)
where K is a constant, no the electron density of
the target material, ß the velocity of the proton in
units of the speed of light (ß=%), I the mean ion-
ization energy of the target atoms and me the
mass of the electron .
The energy loss of protons is thus mainly
dependent on the electron density of the tra-
versed matter and on the ionization potential .
The value I is approx . 16 Z°-9 [eV], Z being the
atomic number of the target material . The elec-
tron density no is a function of the physical den-
sity p, the atomic number Z and atomic mass A
(no - pz/a) . For most materials in humans, z/A is
relatively constant and the stopping power is pro-
portional to the physical density Q, in contrast to
the mass absorption coefficient for X-rays, which
varies in a complicated manner with Z andA.
It is a further characteristic of protons that
they loose kinetic energy in discrete steps by
interaction with atomic electrons. As this process
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is statistically determined, a monoenergetic beam
of protons shows an energy spread after passing
through a homogeneous medium. For 215MeV
protons passing through biological material, the
standard deviation of this statistical process,
expressed as a percentage of the mean range, is
approximately 1.1 . This factor determines the
inherent physical limit for the density resolution
of a single detected proton . The density resolu-
tion increases with the number of detected pro-
tons per pixel according to the usual statistical
laws . (Fig . 2) . The data were produced by taking
images from a homogeneous water bath with dif-
ferent proton statistics . The solid line comes from
calculation (including the detector energy resolu-
tion) ; the squares represent experimental results .
Energy Deposition and Dose to the Patient
The Bethe-Bloch formula (Eqn . 1) reveals that
the stopping power of a proton increases as it
slows down. Hence the largest amount of the pro-
ton's energy is deposited at the end of its range.
Since for proton radiography the proton is
stopped in the detection system most of the dose
is deposited there and not in the patient. The
applied dose for a proton image of 25 x 15 cm2 size
obtained with roughly one million events was cal-
culated to be 0 .01 mGy. AX-ray radiograph with
Fig . 2. Plot of the density resolution as a function of the
number of detected particles per pixel . The symbols represent
measurements in a homogeneous water phantom with differ-
ent statistics . The solid line is the calculated prediction [18]
both the same spatial and density resolution,
would result in a 10 to 20 times higher dose .
Heavy Charged Particle Radiography
Due to their physical properties, heavy charged
particles are also interesting for radiography [8, 9] .
Since resolution in depth is inversely proportional
to the particle mass, it is clear that resolution
improves with increasing projectile mass. The
same is true for the spatial resolution, which also
improves with increasing particle mass .
On the other hand, the dose deposited by
heavier ions is higher than for lighter ions, since
the energies required for heavy ion beams to
penetrate thicknesses of the order of a patient's
width are several hundred MeV per nucleon . At
these energies, heavy ions undergo nuclear colli-
sions which increase the dose to the patient. In
Table 1 the spatial and depth resolutions anddose
to the patient are listed for different particles for
energies resulting in a total range of 300 mm in
water. It can be seen that the improved spatial
and density resolution which can be obtained
with heavier particles is counteracted by an
increased dose to the patient.
Proton Radiography and Tomography
for Diagnostic Purposes
Proton radiography and tomography for diagnos-
tic purposes was investigated in the 1970's
[6, 7,10] . The motivation for these studies was to
obtain images of low contrast lesions in human
Table 1 . Calculated spatial resolution, density resolution and
dose to the patient for charged particles with a total range of
300 mm [27] . All results are normalized to unity for protons
Particle Energy per
nucleon
MeV/u
Spatial
resolution
Density
resolution
Average
dose to the
patient
?He
219 1 .0 1 .0 1 .0
219 0.50 0.50 1 .01
' Zc 427 0.28 0.26 1 .53
160 514 0.24 0.22 1.69
x°Ne 590 0.21 0.19 1.80
specimens superior to conventional X-ray tech-
niques . In addition, the dose advantage of proton
radiography over X-rays encouraged these
authors.
Much of the early work was done by Koehler
and Steward [6,7] at the Harvard Cyclotron.
They used a scattered 160MeV proton beam and
detected the images by exposing photographic
films, located in the steep slope of the proton flux
shown in Figure 1. With this apparatus they could
visualize and differentiate soft body tissues,
including pathological states significantly better
than with X-rays . As Figure 3 illustrates, they
were able to resolve, e .g ., brain tumors and deep-
seated grey matter (basal ganglia) . Blood clots
from stroke patients could also be visualized since
blood is significantly more dense than brain tis-
sue . Thus, in the case of the brain, it may be pos-
sible to obtain better information on the general
nature of a tumor or a stroke . Koehler and
Steward also obtained images from fresh human
mastectomy specimens and with low doses they
could detect changes in tissue density and small
satellite tumors . In addition, brain slices contain-
ing lesions due to multiple sclerosis were detected
as being more transparent to protons than to the
surrounding tissue .
The proton radiographic work was afterwards
extended using scanning systems and plastic scin-
tillation counters to measure the proton flux
[11, 12] . In these reports diagnostically useful pro-
Fig . 3 . (a) Front view of a coronal slice 1 cm thick of a human
brain fixed in formalin . Note the glioblastoma multiforme in
the white matter of the hemisphere on the right, with swell-
ing of the hemisphere and distortion of the ventricular sys-
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ton radiographs of mastectomy and heart speci-
mens were obtained with a low surface dose of
only 0.45 mGy. For comparison, a typical dose for
X-ray mammography is around 40 mGy.
In the late 1970's and early 1980's systems for
obtaining proton CT images were developed
[8, 13-16] . These systems have the advantage of
using the high density contrast of protons to
detect local variations in density as opposed to
projected images . Proton CT images may also be
used for proton radiotherapy treatment planning
since, in contrast to X-ray CTs, they contain
direct information on relative proton stopping
power, which is used to calculate the range of the
treatment beams . The detection equipment for
such systems consisted either of multiwire propor-
tional chambers to detect the spatial information
and range telescopes for the density information
[8,13,14] or of collimators plus a magnetic
spectrometer [15,16] . The studies showed that
proton tomography yielded results similar to the
X-ray CT reconstruction while exposing the sam-
ple to a lower radiation .
Proton Radiography for the
Verification of Proton Treatments
The more precise a radiation therapy treatment
is, the more important is the quality control of
patient treatments [17, 18] . A first important task
tem . (b) Proton radiograph taken with a Polaroid TLX film .
Note the lower density in the tumor area and the visualization
of the basal ganglia . The white spots are air bubbles . With
kind permission of Andreas M . Koehler [71 and Science
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is to check the correct positioning of the patient
with respect to the beam . Another requirement is
the verification of the range and range variations
of the protons, as the calculated proton dose dis-
tribution is based on the predicted range of pro-
tons in the patient. Proton radiography can fulfil
both requirements simultaneously. Proton images
produced by range information and range uncer-
tainty information as a function of the proton
position can be compared to the predicted results
of the treatment planning algorithm .
Sources of range errors include: uncertainties in
the computer tomographic data, which are the basis
of the treatment planning program, and errors
occurring in the treatment planning software
[18,19,20] . Range variations due to inhomogeneity
interfaces parallel to the beam are also very difficult
to predict by the treatment planning software [21] .
Such uncertainties in range can result in target mis-
ses and overdosage of critical tissue . Proton radiog-
raphy can help to solve these problems or at least
provide a better understanding .
Verification of Patient Positioning
Inaccurate positioning of the patient can result in
damage of critical structures or target misses . The
usual way of checking the patient positioning
before irradiation is to provide X-ray radiogra-
phies of the patient in the treatment position and
to compare these images with digitally recon-
structed radiographs (DRRs) from the CT data
used for treatment planning .
Another possibility is to take proton radiogra-
phies . The expected advantage is that the images can
be taken exactly under the same geometrical condi-
tions as the treatment itself. Hence, the images are
true proton-beam's-eye-view projections, as opposed
to X-ray images which are conical projections from a
given point source . Studies have been made [18] to
verify the accuracy of proton radiography in proton
therapy. It has been found that, by matching the pro-
ton radiographs with images produced from the cor-
responding CT information, a positioning precision
of the order of the voxel size of the image could be
obtained . Thus, proton radiography could be a use-
ful tool for verifying the position of the patient in
proton therapy.
Detection of Range Uncertainties
Effects due to density inhomogeneities in the tra-
versed material can influence the range of pro-
tons . Neglecting them may result in cold spots in
the target volume or an unintentional dose to crit-
ical structures distal to the target volume .
A proton which passes close to an interface
between low and high density tissues can take,
due to multiple Coulomb scattering, either the
path through the low or through the high density
material . In the absence of multiple Coulomb
scattering, the inhomogeneities would simply
shift the range of protons by a distance equal to
the integrated density along the path . However,
the effect of multiple Coulomb scattering leads
protons which enter and leave the sample through
the same entrance and exit points to follow differ-
ent trajectories and thus to cause range uncertain-
ties . Similar range uncertainties are present also
for therapy and can produce significant errors in
the dose distribution . Proton radiographs detect
the range variations for the whole body and may
be used to select the most appropriate direction
for an irradiation or to determine the size of the
safety margins around the tumor volume .
Urie et al . [21] used heavy ion radiography (car-
bon and neon) to obtain the shape of the Bragg
peak behind the head and the abdomen of a
patient . The neon Bragg peak was degraded at the
base of the skull from 3 mm to 15 mm and the car-
bon Bragg peak showed a broadening in regions of
the gastrointestinal (GI) tract from 12 mm to 32
mm. Schneider and Pedroni [18] used a 219MeV
proton beam in tissue specimens and an Alderson
phantom, respectively. Images of the standard
deviation of the proton range spectra in each pixel
were taken to study quantitatively the range varia-
tions of protons traversing inhomogeneities . Fig-
ure 4 shows, as an example for such an image, the
DRR of the Alderson phantom head . The colours,
which indicate the standard deviation of the range
spectra designate the regions with additional
straggling caused by inhomogeneities . As can be
seen, range uncertainties of over 15 mm occur in
regions where the protons passed close to tissue
characterized by a strong density gradient orthogo-
nal to the beam . Such critical situations in the
Alderson head are listed in Table 2.
Fig . 4 . Digitally reconstructed radiograph
(DRR) of the Alderson head . The colours
indicate range uncertainties of the pro-
tons measured by proton radiography
(red : >15mm, 15 mm>blue >10mm,
10 mm > yellow > 5 mm) [181
Table 2 . Range uncertainties measured with proton radiog-
raphy in the head of the Alderson phantom . Data taken
from [18]
It should be noted that the radiographics in
both reports [18,211 were obtained from charged
particles traversing the whole head whereas in a
treatment situation, one is interested in the range
variation caused by protons stopping in the head .
Hence these measurements give an upper limit for
the range error which can occur during treatment .
Range variation measurements should be
helpful in estimating the necessary safety margins
around the target volume, especially, if a tumor is
located behind structures which can cause large
range variations . Range variations can influence
Range Measurement
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the dose distribution for proton treatments and
proton radiography can be used for measurin~-
these uncertainties and may help to find optim'11
beam directions .
Computer tomographic images of a patient repre-
sent the basic information for the proton therapy
treatment planning program . CT data are used to
define the position of the target volume and of
the critical structures and to quantify the inhomo-
geneities which are in the path of the proton
beam . The CT images are taken with photon
beams and are therefore images of photon atten-
uation data . The proton therapy treatment plan-
ning software calculates the dose distribution on
the basis of a range calculation for the protons
and, therefore, needs data which can be used to
describe the interaction of the proton beam with
the patient's tissue . The photon attenuation
coefficients of the CT data have, therefore, to be
converted into a water-equivalent path length,
the so-called relative proton stopping power, in
order to provide the residual range for the proton
beam . This relation between stopping power and
Hounsfield values is not unique and it raises the
question, how well one can predict ranges using
calibrated CT data in practice .
Site of passing
proton beam
Maximum
uncertainty
(mm)
Mean
uncertainty
(mm)
Oral cavity and 25 .6 17 .4
mandible ramus
Mastoid air cells and 22.2 16 .7
sigmoid sinus
Frontal sinus 22 .0 15 .7
Tangential to skull 19 .0 12 .0
Mastoid air cells and 18 .5 15 .3
bone brain interfaces
Sphenoid sinus 18 .2 12 .5
Maxillary sinus and 16 .8 13 .3
ethmoid air cells
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Experiments concerning the influence of all
these errors have been reported . They were either
done in vitro with conventional dose measure-
ments [19,201 or in vivo with proton radiography
[18] . Chen et al . [20] measured the Bragg peak
shift in an abdomen slice of the Alderson phan-
tom and compared the result with the range cal-
culation based on their CT calibration . They
obtained differences between measurements and
calculation of about 5 % of the traversed matter.
Alpen et al . [19] also measured the Bragg peak
shift of neon and helium beams in a frozen dog
for seven selected target locations . They obtained
errors of up to 11 % between CT range and mea-
sured range . They concluded that large deviations
appeared where bone or air filled cavities were in
the beam path . Recently, the author [18] has mea-
sured range calibrated proton radiographies of a
sheep's head (Fig . 5) and compared these to the
calculated projections, computed from the cali-
brated CT data, transverse to the beam . In this
study, the proton radiographs were used to
improve the range calculation, by a variation of
the relation between CT units and relative stop-
ping power [22,231 . The colours in Figure 5 mark
regions of the sheep which correspond to differ-
ences between predicted and measured range for
a certain CT calibration . Such proton images give
both, information about the amplidute of range
errors and about its dependence on the pene-
trated tissue type . The maximum deviation
between calculated and predicted range for a typ-
ical treatment of a brain tumor could be reduced
with the help of such measurements by a factor of
4 and the mean deviation by a factor of 3, respec-
tively .
Thus, a precise check of the calculated range is
important for precise proton treatments . Proton
radiography can provide better calibrations for
CT data and can help to reduce errors in the cal-
culated dose distributions for therapy.
Conclusion
Fig . 5 . Proton range image of a sheep's
head . The colours indicate range differ-
ences between calculated DRR and
experimental proton radiography (red :
I r j > 7mm, blue : 7mm > r
> 2.5mm, yellow : 2,5mm > r
> 0.7mm) [181
Proton radiography and tomography can be car-
ried out at lower doses for a given density resolu-
tion than those occurring in routine X-ray exam-
inations or can produce images with the same
dose to the patient but with an improved density
resolution . The high density resolution of proton
images can be used to detect diagnostically
important differences in soft tissues which cannot
be seen in conventional X-ray radiographies . The
limiting spatial resolution for projected radiogra-
phies, due to multiple Coulomb scattering, can be
improved if the positional information of the pro-
tons is taken in coincidence and the additional
spatial knowledge is used to reconstruct the pro-
jected images . In addition, significant improve-
ments in the spatial resolution of proton tomogra-
phies may be expected by using special algorithms
which include such reconstruction methods,
instead of the conventional algorithms used in X-
ray tomography. For clinical use of proton radiog-
raphy, an accelerator with adequate proton ener-
gies is required. Such a diagnostic tool could be
attached to a therapy machine to prove the accu-
racy of each individual treatment.
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Compensation of Target Motion
T OKUMURA, H . Tsujl, and H . Tsujil
Introduction
Proton Medical Research Center, University of Tsukuba, Tsukuba-shi, Japan
During the last decade developments in diagnos-
tics and treatment planning have been achieved
which permit individualized three-dimensional
dose delivery. In this context, special attention
has been payed to the issue of how close treat-
ment volumes can be approximated and how
much dose can be delivered safely to target vol-
umes .
Ion beam therapy is expected to play an impor-
tant role in such 3D-approaches, since the phys-
ical characteristics of ion beams provide an excel-
lent dose distribution [1] . Much work has been
contributed to the design of optimal treatment
systems for ion beam therapy. This effort
resulted, e.g ., in a successful local control of
uveal melanoma, intracranial and skull-base
tumors [2,3] . If we expect to achieve the same
results in other tumors, e.g ., of the thoraco-
abdominal area, however, some problems have to
be solved first and compensation of target motion
is one of them.
Although CT or MRI imaging techniques
allow to optimize treatment plans for conforma-
tion therapy, such images are usually static ones .
For the treatment of thoraco-abdominal targets,
images are obtained from patients interrupting
respiration or keeping, occasionally, decubital or
prone postures . But, the organs of the thoracoab-
dominal area show various kinds of motion dur-
ing the treatment period and motion of the abdo-
minal organs may result in dose uncertainties
near the edge of the treatment field. Managing
such target fluctuation is the key to success for
3D-treatment of these tumors .
Accurate compensation of target motion will
lead to minimization of the treatment volume and
dose-limiting organs can be spared from irradi-
ation, avoiding serious treatment morbidities.
It should be emphasized, however, that com-
pensation of target motion does not compensate
for inaccurate target localization and lacking
reproducibility of daily treatment conditions . The
importance of reproducible immobilization of the
patients and reliable target localization tech-
niques will be discussed elsewhere in this book .
This chapter will concentrate on organ motions
during the treatment itself and ways to compen-
sate them .
Types of Organ Motion
Despite the fact that accurate and precise posi-
tioning can be achieved with casting and other
immobilization techniques, there are several
kinds of target motion which are a result of phys-
ical or physiological characteristics of the organ .
Some of them are static and others change con-
tinuously over the treatment time . According to
their nature they can be classified into five basic
categories :
- gravity or position-related movements
- displacement or deformation by pressure
- gut movements
- respiration-related motions
- vascular pulsation
The first two categories are relatively latent
motions whereas the others are continuous or
ongoing.
There are only a few published papers describ-
ing the issue and there is still insufficient knowl-
edge to make compensated treatment planning of
mobile targets a reality. Movement of the eye ball
or tongue is very important one to be handled as
well, but it is rather a problem of immobilization
than compensation .
Gravity or Position-Related Movements
Gravity-related movement is observed in every
organ. It is a movement or displacement as a
function of the patient position . Once it happens,
the three-dimensional relationship between the
target and the surrounding organs are maintained
until the patient changes his/her position again.
For treatment positions other than horizontally
supine this might cause problems . When a
patient's skull is rotated, e.g ., there is a possibility
of intracranial motions relative to the skull and
the beam line . Movements of intracranial struc-
tures of the order of 0 .5 to 1.5 mm were detected
by Serago and colleagues [4] . Concerning the
thoraco-abdominal organs, Tsujii et al . [5]
reported that the position of most abdominal
organs was displaced caudally in the prone vs . the
supine position . The displacement was demon-
strated even for pancreatic tumors which are
retroperitoneal and more or less adherent to the
surrounding structures . These kinds of move-
ments, do not matter too much, as long as the
treatment planning is based on CTs obtained in
the treatment position .
Displacement or Deformation by Pressure
Displacement or deformation of an organ by
pressure is usually observed in organs of the
pelvic space . The bladder can change its size and
shape considerably, depending on the volume of
urine and the pressure from the surrounding gut.
Turner and colleagues [6] investigated the
degree of bladder movement during the course of
radiotherapy by comparing initial planning CTs
with subsequent pelvic CTs performed at weekly
intervals during the treatment period . They found
that the projected size of the bladder ranged from
16.2 to 80.9 cm' and patients with large bladders
on the planning CT were more likely to have a
change in the bladder size than those with small
bladders . A wall displacement of at least 1.5 cm
was observed in 60% (18/30) of the cases. There
was no chronological pattern of displacement
through patients' treatments and all walls were
approximately at equal risk of movement . Pa-
tients who had posterior margin changes of at
least 1.5 cm were also likely to have equally large
(>2 cm) rectal diameter changes.
Arimoto and colleagues [7] reported an inter-
esting technique to assume the localization of
intrapelvic tumors . They suggested to adjust pri-
marily the daily treatment field settings according
to the daily location of the internal target recogniz-
able by metallic fiducials implanted in the tumor
site . Then they request the bladder to be emptied
and refilled with a defined amount of water to
standardize the effective internal body density.
With this approach, localized proton boost irradi-
ations could play an important part in the multidis-
ciplinary treatment of locally invasive bladder can-
cer aiming at the conservation of the bladder [8].
Gut Movement
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The alimentary tract - with the exception of the
intrathoracic esophagus and lower rectum - is
barely agood candidate for conformation therapy
by ion beams ; not only because its tolerance to
radiation is relatively low, but also because it can
change its shape and position any moment
depending on its contents and peristaltic motion .
The gut is also quite mobile, because of its loose
fixation to mesenteries. It is, therefore, quite dif-
ficult to reproduce the shape and position of the
intestinal loops at every treatment session.
These difficulties lead to chronological and
geographical inhomogeneities in the region where
the ion beams pass through. Urie and co-workers
[9] investigated the effects of highly inhomoge-
nous regions, such as the base of skull and abdo-
men, on the depth-dose characteristics of charged
particle beams. They determined the stopping
distribution of carbon ions passing through intes-
tinal loops and derived the corresponding Bragg
peak distributions. The full width at half maxi-
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mum (FWHM) of the Bragg peak (nominally 5.5
mm) was found to be greater than 25 mm at air-
soft-tissue interfaces . According to the authors a
Braggpeak may not look like aBraggpeak on the
distal side of a complex inhomogeneity. Such
effects of tissue inhomogeneity along the beam
path which may influence the dose distribution
need to be further analyzed . This issue is also of
relevance in the treatment of pancreas tumors .
Concerning the esophagus, Sugahara and co-
workers investigated the displacement of the eso-
phagus in the field-localization process [10] . It is
discussed here, even though it might be classified
as a position-related rather than an involuntary
type of movement .
Measurements of corrected distances on a
total of 177 localization attempts disclosed that a
correction by >5 mm was necessary in 30 .6 % and
by >10 mm in 10.2% of all localization attempts .
Correction of more than 5 mm was required even
in 66.7 % of 60 localizations in patients older than
80 years. They recommended the use of a real-
time verification system for precise and frequent
target localization [11], in particular, for patients
with high risk factors, i.e . high age, tumor in the
lower esophagus or primary lesion T1.
Table 1 . Amplitude of respiration-related organ motion
Respiration-Related Motions
Respiratory motion canbe considered as the most
important motion to be compensated for, because
of its repetition and its close relation to the major
thoraco-abdominal organs, such as the lung, liver,
pancreas and the kidneys.
A major benefit of ion beam therapy is the
possibility to minimize the treatment volume .
Several studies [12-16] investigating the ampli-
tude of respiration-related organ motion yielded
a value of approx. 20 mm in cranio-caudal direc-
tion (Tab . 1) . It is, therefore, much too big to be
ignored, because in ion beam therapy, the safety
margins around the tumor volume are usually set
to only 5 mm . Without a special technique, a 20
mm longer treatment field in cranio-caudal direc-
tion would be necessary in order to deliver the
prescribed dose to the target volume . Moerland
and colleagues [16] calculated the dose distribu-
tion taking the kidney motion into account and
they concluded that widening of the penumbra
can occur near the edge of the kidney in a situa-
tion like this .
Not only the position of the target, but the
electron density along the beam path can alter
due to respiration movements, although Henkel-
man and Mah reported that dose variations
around the breathing cycle are less than 5 % in
the case of lung cancer treated with photon ther-
apy [17] .
Respiratory motion is a slower phenomenon
than vascular pulsation, and more regular than
the peristaltic movements of the gut. It is, there-
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fore, best suited for technical compensation
means. Some clinical trials using a compensation
technique for respiratory motion in the treatment
of liver tumors have recently begun at the Univer-
sity of Tsukuba [18,19] .
Fig . 1 . Schematic representation of the
respiration-gated irradiation system ReGIS .
An elongated treatment field in cranio-
caudal dimension (open area with multi-
leaf collimation) covers the target volume
(shaded circle) in both, expiration (A) and
inhalation (B) phase . Respiratory motion
creates dose inhomogeneity in the treat-
ment volume as demonstrated in gray-
scale (C) . Intermittent irradiation with
ReGIS allows for minimum treatment field
(D). Normal liver tissue surrounding the tar-
get volume (shaded area) is effectively
spared by means of ReGIS (E)
\gg;
INS
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Techniques for Compensation
of Continuous Organ Motions
There are different methods of beam modulation
in ion beam therapy, e.g ., scattering and fixed
range modulation [20,21] or several kinds of vari-
able modulation using scanning techniques
[22-24] . The method of compensation of continu-
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ous target motions depends on the beam modula-
tion technique applied at a certain facility.
Apossible technique of compensation compat-
ible with fixed range modulation is intermittent
beam delivery [25], or synchronous movement of
the treatment couch with motion of the target .
For facilities applying a scanning system, target-
oriented variable scanning or some kind of
mechanical method to reduce organ motion, such
as abdominal fixation [26] would be appropriate.
A Respiration-Gated Irradiation System
Although there are other possible ways to com-
pensate respiratory motion, intermittent irradi-
ation seems to be the simplest and most reliable
technique in clinical use (Fig . 1) .
Ohara and co-workers developed a respira-
tion-gated irradiation system (ReGIS) for elec-
tron linear accelerators [25,27] . Inada and col-
leagues adapted the system for proton synchro-
tron usage [28] . So far, it has been utilized clini-
cally in the treatment of liver tumors [29] .
ReGIS is a computer controlled irradiation
system triggered by signals that coincide with res-
piratory motion . The system consists of two com-
ponents, the monitoring system of the patient's
respiration and the triggering system for the pro-
ton synchrotron.
Initially, Ohara used an airbag to measure res-
piratory motion [25], but the big device sometimes
overlapped with the treatment field of upper ab-
dominal tumors .Asmall strain gauge (4 x 2 cm) is
available now for monitoring the tension of the
abdominal wall which changes parallel with
respiration . The strain gauge converts the tension
of the abdominal surface into electric signals
which, in turn, are amplified and transferred to a
signal-control unit . Following the offset and span
control, the signals are digitized and transformed
into a respiratory curve by a central processing unit
(CPU). The operator can set a gate signal at an
arbitrary point in the respiration curve displayed
on a cathode ray tube (CRT) monitor, and checks,
in parallel, the movement of the target fluoroscop-
ically.
The gate signals -one for opening the gate the
other for closing it - are usually set to late exhale
and early inhalation phase, during which protons
are delivered . With this timing, the movement of
the diaphragm is minimal and its position is most
reproducible as compared to other phases [30] .
The signals from ReGIS are sent upstream to
the ion source and protons are delivered by a fast-
cycling synchrotron which responds to the trigger-
ing signal within milliseconds [28] . By using this
system the maximum shift of the target can be
restricted to 5 mm during the beam delivery pe-
riod .
A comparative planning was made for a patient
with a hepatocellular carcinoma in the right lobe
of the liver to estimate the benefit of ReGIS. The
maximum diameter of the tumor was 5 cm, and it
shifted approx . 2cm in cephalo-caudal direction .
One of the treatment plans was designed to cover
the target volume with minimum margins, assum-
ing that successful synchronized irradiation could
be performed . The other plan was designed with
safety margins which were 2 cm longer at both,
cephalic and caudal ends, considering the target's
respiration-related fluctuation . The dose-volume
curves resulting from the two model calculations
are shown in Figure 2. It is obvious that the normal
liver tissue surrounding the target is effectively
spared by means of ReGIS.
b
e
.5 2
d
Total dose
Fig . 2. Comparative dose-volume histograms for normal
liver tissue in the treatment of a liver tumor with (gated) and
without (non-gated) contribution of a respiration-gated
irradiation system . The diameter of the liver tumor, and
respiration-related tumor shift were assumed to be 5 cm
and 2 cm, respectively
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cannot be realized without accurate patient posi-
tioning, target localization, and compensation of
the target motion . Minimizing patient move-
ments is imperative if the prescribed dose is to be
delivered with certainty to the intended target
volume . This is why patients should be immobil-
ized with various kinds of casts or shells . The next
step is to compensate internal target motions as
described in this chapter. Finally, it has to be veri-
fied if the treatment can be performed as
planned . This target localization and field veri-
fication process must be rapid, responsive and
reliable, since the target motion does not always
keep the same pattern . In this respect, internal
fiducial and real-time fluoroscopic field verifica-
tion systems can be helpful [11] .
It can be concluded that optimum ion beam
therapy cannot go without an integrated treat-
ment system which assures proper patient immo-
bilization, compensation of target motions, and
field verification.
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VII . Individual Facilities
Introduction
Factors Considered in Developing the World's First
Hospital-Based Proton Beam Facility
J . M . SLATER, J . O . ARCHAMBEAU, D. W MILLER, and J . D . SLATER
Loma Linda University Medical Center, Loma Linda, CA, USA
Proton beams provide superb control of dose dis-
tributions and the opportunity for increasing dis-
ease control while decreasing the incidence of
normal tissue morbidity. A complete therapy
facility, including three isocentric gantries, a hori-
zontal beam line and an eye beam line, now exists
at Loma Linda University Medical Center's
(LLUMC) Proton Treatment Center. In addition,
a research room with three additional beam lines
is available, reserving the clinical facilities for
their intended purpose. The developmental his-
tory of the facility has been presented elsewhere
[1, 2] ; this chapter attempts to highlight salient
aspects of the developmental process and
emphasize the important lessons learned, both of
which may interest others contemplating develop-
ment of similar facilities .
Historical Background at LLUMC
LLUMC's interest in proton beam radiation ther-
apy began in the early 1970's with the desire to
seek therapeutic dose distributions superior to
those obtainable with photon, neutron and elec-
tron irradiation . Literature existed which sug-
gested that heavy charged particles provided this
potential [3] . In addition, clinical studies of pro-
ton and helium ion therapy had suggested the
clinical value of particle therapy [4-6] . At that
time, however, because patients' anatomy could
not be imaged adequately and isodose distribu-
tions could not be superimposed precisely on ana-
tomic images, the macrodosimetric advantages
proffered by heavy charged particles could not be
exploited comprehensively.
Improved imaging modalities began to become
available after 1970 . Ultrasound imaging
appeared first ; with its appearance, LLUMC
investigators developed a system which used the
digitized information as a basis for superimposing
anatomic and dose-distribution data . When CT
scans became available, the ultrasound-based
treatment planning system was modified to
employ CT digital information [7, 8] .
As the 1970's progressed into the 1980's,
computer-assisted therapy planning became more
precise and widely used [9, 10]. Large-field pro-
ton andhelium ion therapy developed at Harvard
Cyclotron Laboratory (HCL) and Lawrence Ber-
keley Laboratory (LBL) [11, 12] . These advances
were considered by investigators at LLUMC. By
early 1984, based on the need to improve results
obtainable with conventional radiation and the
protons' potential to improve those results, a
decision was made to develop a hospital-based,
therapy-dedicated proton beam facility. In subse-
quent months, discussions were held among
faculty, administrators and trustees of LLUMC
and Loma Linda University (LLU) concerning
the cost of constructing a facility, potential bene-
fits, and future needs. In late 1984 the decision
was made to proceed to the planning phase.
Accordingly, LLUMC approached investigators
at Argonne National Laboratory and other
institutions, with inquiries about building such a
facility ; these inquiries led to plans to convene a
meeting at Fermilab in January 1985 . At that
time, ideas were exchanged about accelerators,
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facilities and clinical trials . This meeting was the
nucleus of the Proton Therapy Co-operative
Group (PTCOG), which formed less than a year
later. PTCOG is an international, informal, unfi-
nanced consulting and user group of engineers,
physicists, biologists, and physicians, all sharing a
common interest in proton radiotherapy.
PTCOG developed the design requirements
for an accelerator, beam transport system and
treatment room delivery system suitable for a
hospital-based facility. By 1987, meeting these
requirements seemed doable . LLU and LLUMC
authorized a conceptual design study, which was
completed by Fermilab and LLU/LLUMC staff in
1987 . Subsequently LLUMC contracted with Fer-
milab for an engineering design of the accelerator
and transport system ; LLUMC, working with
other laboratories and industry, developed the
engineering design of the delivery system and
facility.
Overall Design Considerations
in Planning the Facility
From the outset, it was clear that the entire pro-
ject : building, accelerator, delivery systems and
patient care areas, needed to be designed as an
integrated whole. A structure was required which
would both house the treatment delivery systems
and efficiently manage patient flow. Close col-
laboration between the architectural and equip-
ment design teams was imperative, because the
shielding concrete and steel walls could not be
adjusted, being once in place, nor could there be
any significant changes in equipment design to
accommodate building errors . Accordingly, the
various engineering design teams accomplished
their tasks in a collegial manner; regular inter-
communication among teams and team members
was maintained . Eight teams were formed, each
having tasks relevant to the overall engineering
design; LLUMC, LLU, Fermilab and NBBJ, the
architectural firm, provided staff for each team .
Weekly meetings were supplemented by monthly
meetings with hospital and university administra-
tors, and periodic meetings were held with out-
side reviewers; these meetings helped to keep the
teams communicating and aware of progress and
problems . Timely development was emphasized ;
timing in planning, fabrication and installation
was as important to the project's success as the
successful operation of its component parts,
because of the high monthly construction costs.
Pre-building arrangements with the LLUMC pur-
chasing department, suppliers, labor unions, and
all primary and secondary contractors avoided
costly delays and disputes and resulted in the abil-
ity to take early partial occupancy for installation
of certain heavy subsystems .
The building was designed to treat patients
safely and efficiently. It was also designed to : be
erected within its budget ; provide facilities for
patient, practitioner and scientist, for education
and research ; and be modifiable, to accept new
technology. Design requirements stemmed from
clinical treatment, research and educational
needs, plus marketing and financial projections.
These resulted in a facility with five therapy beam
lines in four rooms, as well as a separate research
room containing three beam lines. Clinics, treat-
ment rooms, patient preparation areas, waiting
rooms, animal research facilities and offices were
sited to promote optimal efficiency.
Accelerator and Beam Control
Considerations
The heart of the LLUMC therapy system is the
synchrotron. Fermilab and Department of
Energy administrative and engineering staff
played essential roles in transforming the acceler-
ator from a laboratory instrument to a treatment
tool . Traditional synchrotron performance and
reliability had to be retained while reducing size .
Commercial and industrial support facilitated the
transfer and integrated the synchrotron with the
beam transport and delivery systems.
Proton accelerators suitable for physics
research usually are large and expensive to oper-
ate and maintain . A hospital-based proton ac-
celerator must be compact, reliable, require little
maintenance, and operate at low cost . The flux
intensity must be sufficient to keep each patient's
treatment time short. Beam energy must be rap-
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idly variable to permit total flexibility in beam
delivery. At LLUMC, these requirements sug-
gested a synchrotron rather than a linear acceler-
ator or cyclotron.
The LLUMC machine satisfies minimum
space requirements . Its dipole magnets bend the
protons in their correct orbit and provide hori-
zontal and vertical focusing, thus conserving
space by eliminating additional focusing quadru-
pole magnets. A compact radiofrequency quadru-
pole (RFQ) injector accelerates a lowenergy (35
keV) proton beam to 2 MeV in a 1.6 meter dis-
tance, simultaneously focusing and accelerating
the beam. The synchrotron provides a pulsed,
300-msec beam to the designated treatment room
every 2.2 sec. In the ring, the protons gain energy
with each turn until they reach a maximum
energy of 70-250 MeV; at that point, the mag-
netic dipole field and RF frequency are held con-
stant until the protons are extracted and trans-
ported to the treatment rooms. After extraction,
the magnetic dipole fields return to injection level
for the next batch of 2 MeVprotons.
The beam is under computer control from its
origin in the synchrotron until delivery to the
patient, save for independent safety interlocks .
All control processors are synchronized within
microseconds by global timing signals propagated
from one clock. The accelerator's control system
can be divided conceptually into a low-level ana-
logue RF system and a high-level digital system .
The former, a closed-loop system, keeps the
beam centered in the ring during the acceleration
cycle. The latter controls beam energy and extrac-
tion, and directs the beam to delivery systems in
the treatment and calibration rooms. The system
contains multi-segmented, retractable ion cham-
bers, placed along the beam line, to monitor
beam centering and cross-sectional shape. Beam
loss monitors within the beam transport area emit
an audible alarm and stop the beam when an
unsafe condition is detected .
Users configure the system by selecting a beam
line, beam energy, and gantry angle; in doing so,
they retrieve required magnet settings from the
system database . The control system accepts
beam parameters from several subsystems, such
as treatment rooms, and responds to commands
in real time . The lowest level of interface displays
the settings and status of every device in the beam
transport system and permits the user to reset or
switch any device on or off, enabling engineers at
remote locations to diagnose and repair prob-
lems . Every device has built-in self-test functions
for early detection of malfunctions .
Treatment Planning
and Delivery Considerations
Since a proton beam's main advantage derives
from its ability to shape the dose distribution con-
form to the target, each patient's treatment plan
must describe a set of optimum treatment portals
and beam-modifying devices. These optima are
achieved by studying three-dimensional computer
simulations of patient treatment using different
beam configurations and modifiers ; the set of
beams selected provides the best potential for
tumor control with minimal damage to surround-
ing normal tissues. Three-dimensional planning
requires a set of CTimages to define the location
and shape of target volumes and radiation-
sensitive normal tissues, as well as a three-
dimensional matrix of effective tissue densities
for proton beam absorption . Other data, particu-
larly magnetic resonance images, help determine
the condition of normal structures and the extent
of disease. Using this information, each treat-
ment beam is designed to penetrate the body to a
specified margin beyond the target volume or to
irradiate a specified portion of a target volume.A
tissue compensator and rotating range-modulator
wheel are employed to shape the range distribu-
tion within each field.
Treatment planning is performed with three-
dimensional planning software acquired from
HCL [9, 10] and modified by LLU engineers . A
dedicated CT scanner supplies the planning
images . Shapes of treatment portal apertures and
tissue compensators are generated by the plan-
ning system. Apertures are made from cerrobend
alloy in Styrofoam molds made with a computer-
controlled cutter. Tissue compensators are fabri-
cated on a numerically controlled milling machine.
The treatment planning system overlays isodose
distributions on CT images and produces dose-
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volume histograms in preparation for routine ste-
reotactic fractionated treatments .
The LLUMC facility uses rotating gantries,
which allow one to select beam entry angles with-
out changing the patient's position . A cork-screw
beam optics system, suggested by HCL investiga-
tors [13], minimizes the axial dimension of the
rotating structure. Beam range is controlled by
energy and range-shift selection. Lateral spread-
ing of the beam is accomplished by dual scatter-
ing foils . A scanned beam system, to yield large
conformal treatment fields with no scatterer
range loss, is planned.
The beam delivery system monitors the dose
delivered to the patient and terminates irradi-
ation within approximately 2% of the desired
dose . In addition to the primary dose-monitoring
function, backup systems monitor dose delivered,
the shape of the beam profile, and overall field
uniformity. If any preset tolerance is exceeded
during treatment, the control system terminates
patient exposure .
The beam delivery system also protects the
patient from human, hardware and software
errors . A database contains the identification
codes of modulator wheels, range-shifting blocks,
tissue compensators and apertures for all treat-
ment portals, for every patient. Bar codes
attached to these devices must be scanned and
must agree with the database before treatment
can begin. Similarly, other patient setup parame-
ters, including gantry angle and aperture posi-
tion, must agree with database values . Measure-
ments obtained from magnetic field probes lo-
cated in the dipole bending magnets are compared
with the database to assure that the correct beam
energy is supplied . The control system monitors
the location of all movable devices in the beam
delivery system, checks for software and elec-
tronic error conditions, and monitors total treat-
ment time . One independent dose monitor is set
by the operator prior to each treatment .
Research Considerations
Proton beam therapy follows the continuum of
improved dose delivery that has historically been
observed from lowvoltage radiation therapy
through supervoltage equipment [14] . It can be
used whenever conventional external beam radia-
tion therapy is appropriate, either alone or in
multimodality regimes. It was developed to
exploit in the clinic the advantageous proton
beam dose distribution and to improve the thera-
peutic ratio . Such exploitation requires clinical
studies to document results. To develop optimal
proton therapy techniques, multi-institutional
cooperative studies are essential . Towards this
end, the Proton Radiation Oncology Group
(PROG) was organized by LLUMC, HCL and
LBL. PROG currently conducts cooperative tri-
als in CNS and in head and neck tumors . Initial
treatment site studies, using conventional time-
dose fractionation schedules, were primarily con-
cerned with treatment of patients with chondro-
sarcomas and chordomas of the base of the skull
and the cervical spine and showed improved con-
trol rates . A PROG multi-institutional study is
thus underway, randomizing the dose for patients
having those tumors and skull base and cervical
spine meningiomas. Proton boost doses are also
being used to treat paraspinal tumors, including
chondrosarcomas and thoracic and abdomino-
pelvic soft tissue sarcomas .
Protons are being used to decrease the dose to
surrounding normal brain in children and adults .
Studies are being conducted to evaluate potential
neuroendocrine, ophthalmic and neuropsychi-
atric late effects .
Accelerated fractionation schedules are being
studied in selected head and neck tumors, using
photons and protons . Initially, a concomitant
boost technique is being used to evaluate locally
advanced tumors of the oropharynx and parana-
sal sinuses. These PROG multi-institutional
phase I/II studies use significantly higher doses,
delivered in a shorter period of time, than has
been done with photons ; proton boosts limit the
extent of normal tissue treated.
Hypofractionated treatment plans are used to
treat choroidal melanomas . Proton treatment in
this anatomic site presently delivers doses in the
range of 70 CGE (cobalt-gray equivalent) in five
fractions over 7 or 8 days . The control rate has
exceeded 95% [15] . A randomized PROG study
is in progress, comparing 70 Gy in five fractions
to 50 Gy in five fractions for selected patients to
determine whether the dose reduction reduces
visual loss .
Proton radiosurgery is being performed in con-
junction with the neurosurgery and neuroradi-
ology departments at Stanford University Medical
Center and LBL's Department of Life Sciences, to
treat patients with arteriovenous malformations
(AVMs) . Compared to radiosurgery performed
on a linear accelerator or gamma knife, charged
particles can localize the dose while treating larger
fields, without the need for overlapping isocenters
or a large dose gradient in the target volume . Pro-
tons are being evaluated for large AVMs that have
been unsuccessfully treated with other forms of
radiosurgery. Other radiosurgical approaches are
being evaluated, including proton beams for iso-
lated brain metastases and to boost the dose for
high-grade gliomas.
The potential of protons is being evaluated in
other sites, including early-stage, non-small-cell,
medically inoperable lung cancer, isolated para-
aortic lymph nodes, and other pediatric tumors
including retinoblastoma and selected rhabdo-
myosarcomas. Encouraging preliminary results
from other proton institutions, wherein patients
with isolated liver metastases and unresectable
hepatocellular carcinomas have been treated,
have led to the development of LLUMC proto-
cols for these clinical entities .
The LLUMC research program also includes
basic radiobiological and physics investigations
aimed at identifying areas for clinical study, and
exploring the micro- andmacrodosimetric charac-
teristics of proton beams for the purpose of
employing thebeam optimally. Recent studies on
the LLU beam suggest that previously unrealized
microdosimetric benefits may be possible [16] .
Conclusion
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The LLUMC experience evolved from pioneer-
ing work done at other institutions andbroke new
ground in : the development and use of a syn-
chrotron designed specifically for a hospital ; iso-
centric gantries to deliver the beam; patient
immobilization systems for routine stereotactic
therapy; and a computer-driven scheduling and
charting system . Some aspects of the experience
might be relevant to those contemplating future
patient-dedicated facilities .
The LLUMC facility was conceived as a place
where the capabilities of proton beams could be
exploited optimally for patient treatment . The
planning process was conducted with that objec-
tive in mind and conceptual designs were flexible,
to encourage ideas that would meet the facility's
fundamental goal . The three gantries reflect that
flexibility. It was recognized that a gantry would
contribute to precise delivery because multiple
portals could be more easily achieved without
moving the patient. A flexible design approach
allowed for consideration of more than one
gantry.
Along with underlying flexibility in the con-
ceptual design stage, a team approach was essen-
tial . The role of LLUMC's consultants, particu-
larly within PTCOG, was very important. They
added experience and expertise, and provided a
collegial atmosphere in which ideas could be dis-
cussed . The team concept was essential in the
active development stage, as well . Once decisions
were made concerning hardware, software and
construction, the challenge became one of realiz-
ing the conceptual designs. Several teams were
formed, each with responsibility for some aspect
of the overall project, yet each charged also with
keeping the larger goal in focus. Clear and con-
stant communication among team members and
amongteamswas maintained in order to maintain
that focus; this "task force" approach was main-
tained throughout the development of the facility,
and continues today.
Since optimal exploitation of protons for treat-
ment was the underlying goal, a prime tenet of
facility design was to optimize patient flow while
conducting the basic and clinical research
required to characterize protons' behavior in tis-
sue and identify potential applications beyond
those for which protons were already used . Asep-
arate research facility, with its own beams, grew
from this intent . Research was regarded as essen-
tial, since proton beam therapy, while no longer
in its infancy, could be said to be in its adoles-
cence. It has the potential to be used for localized
solid tumors in almost any anatomic site, but
basic and clinical research are required to deter-
mine specific applications .
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Introduction
HIMAC - A New Start for Heavy Ions
K. KAWACHI
National Institute of Radiological Sciences (NIRS), Chiba-shi, Japan
The Heavy Ion Medical Accelerator in Chiba
(HIMAC) was completed in 1993, and since June
1994 heavy ion therapy has made a new start at
this facility after the close-down of the BEVA-
LAC accelerator at the Lawrence Berkeley Labo-
ratory (LBL) in Berkeley, California in 1992 . The
HIMAC is the first heavy ion accelerator in the
world dedicated exclusively to medicine, and its
design parameters are based on the radiation
oncological requirements summarized in Table 1.
Based on results of radiological studies and
clinical trials at the LBL, the ion species for the
HIMAC were chosen in the atomic number range
of 2 (helium) to 18 (argon). From clinical experi-
ence in conventional radiation therapy at the
NIRS a maximum range of 30 cm in soft tissue
appeared sufficient for any type of deep-seated
tumor and a dose rate of 5 Gy/min should permit
completion of typical treatment fractions within
oneminute . The maximum field size of the beam
- 22 cm in diameter - was also selected based on
clinical experience at the NIRS . The usage of
both, vertical and horizontal beams is considered
as another essential aspect of the facility which
assures a highly controlled dose distribution with
heavy ions .
Table 1 . Medical requirements for HIMAC
The accelerator specifications are derived from
the above mentioned radiation oncological require-
ments (see Tab. 2) . The maximum accelerating
energy was determined from the range-energy rela-
tionship for silicon which is one of the heaviest ions
considered for treatment of deep-seated, radiore-
sistant tumors . For ions lighter than silicon the
chosen 800 MeV/u provide a considerable greater
range in tissue than the required 30 cm. To satisfy
this requirement, a synchrotron was chosen as main
accelerator. Thebeam intensities for the various ion
species to be extracted from the synchrotron ring
were estimated from the expected dose rate . But
since the pulse rate of most synchrotrons is of the
order of one pulse per couple of seconds, it was nec-
essary to design the time structure of the beam with
a long flat-top intensity during the pulses in order to
achieve precise dose control.
The most suitable accelerator complex for the
HIMAC facility was determined by taking into
account the most reliable accelerator technology
existing in those days and not the least cost per-
formance. The total layout of the HIMACfacility
(Fig . 1) consists of two types of ion sources, an
RFQ and an Alvarez linac, two synchrotron rings,
high energy beam transport lines, and irradiation
sites for treatment and experimental work.
Table 2 . Accelerator specification
Ion species He to Ar
Particle species He to Ar Maximum energy 800 MeV/u (for s = 0.5)
Penetrating range 30 cm in tissue Minimum energy 100 MeV/u (for s = 0.5)
Dose rate 5 Gy/min Beam intensity 2.0 x 109 pps/ring (for C)
Max.field size 22 cm I^ö Duty factor 20%/ring
Beam direction vertical &horizontal Repetition rate 0.5 Hz/ring
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The Injector System
The injector system comprises two types of ion
sources, an RFQ linac, and Alvarez linac and a
debuncher cavity which is installed in a medium
energy beam transport line (Fig . 2) .
The two ion sources. which are a PIG (Pen-
ning ion gauge) ion source and anECR (electron
cyclotron resonance) ion source are both avail-
able in order to keep operation for the medical
facility reliable and stable . Initially, the ECR
source which is basically maintenance-free was
proposed for heavier ions, such as neon, silicon or
argon, whereas the PIG source was proposed for
the lighter ions, including helium, carbon or
neon . However, it has been found that both ion
sources are able to produce enough intensity of
all the ions, so that each ion source can serve as
back-up for the other.
The extracted beam contains only ions
(selected by an analyzing magnet) with a charge-
to-mass ratio of 1/7 to 1/2 . These ions are further
accelerated at DC acceleration gaps and focused
by solenoid and electrostatic quadrupole lenses .
Coming from the ion source, the heavy ions are
injected with 8 keV/u into a pre-injector radio-
frequency quadrupole (RFQ) (total length : 7.3 m,
cavity diameter : 0 .6 m) . The output energy of the
RFQ linac is 800 keV/u. Other parameters are
summerized in Table 3.
The ions accelerated by the RFQ linac are fed
into an Alvarez linac which is the most suitable
injector system for the low duty-factor synchro-
tron . The Alvarez linac is separated into three
cavities with a diameter of about 2.2 m anda total
length of about 24 m. It has 106 drift tubes in the
cavities : each tube is supported by horizontal and
vertical stems, and equipped with a quadrupole
Table 3. Summary of RFQ linac parameters
Input energy
Output energy
Charge-to-mass ratio
Operating frequency
Vane length
Cavity diameter
Maximum field
Peak RF power
8 keV/u
800 keV/u
1/7-1/2
100MHz
725 cm
58 .8 cm
205 kV/cm
260kW (70% Q)
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Table 4. Summary of Alvarez linac parameters
Input energy
Output energy
Charge-to-mass ratio
Operating frequency
Structure
Focusing sequence
Cavity length
Cavity diameter
Number of drift tubes
Peak RF power
0.8 MeV/u
6.0 MeV/u
1/7-1/2
100 MHz
3 independent RF cavities
FODO
9.77/7.20/6.91 m
2.20/2.18/2.16 m
56/28/22
840/830/770 kW (75% Q)
magnet for beam focusing . Its operating fre-
quency is 100 MHz, the same as that of the RFQ
linac . Ions are accelerated to 6 MeV/u by the
Alvarez linac and passed through a carbon foil to
obtain fully-stripped ions of the accelerator. Fully
stripped ions from the Alvarez linac can also be
fed into a medium-energy beam irradiation room
for low-energy heavy ion experiments. Table 4
lists the major parameters of the Alvarez linac.
The Main Accelerator
327
The main accelerator comprises a pair of
separated-function type synchrotron rings (Fig .
3) . Thetwo stacked rings consist of identical com-
ponents and are separated by a shielding floor.
The average diameter of the rings is about 41 m,
and the circumference about 130 m. Both rings
have identical lattice structure, a multi-turn injec-
tion channel and a slow extraction channel. In
addition, the lower ring will have a second injec-
tion system for high energies and fast extracted
ions, and the upper ring a fast extraction system .
Both rings and the junction beam line have a
flexible design to accommodate possible future
extensions .
The injection energy into the synchrotron rings
is 6 MeV/u. The output energy is continuously
variable from 100 to 800 MeV/u for ions with a
charge-to-mass ratio of 1/2 (cf. Tab. 5) . The vari-
able energy is a very important feature for patient
treatment because it reduces the amount of low-
LETsecondary particles (produced by fragmenta-
tion) and will be able to provide the best dose dis-
tribution to a target using the most appropriate
heavy ions . Both synchrotron rings operate with a
328
	
K. Kawachi
Upper Ring
Fig. 3. A plan view of the synchrotron rings
repetition frequency of 0 .3 to 1.5 Hz, but with a
phase difference of one half period ; this feature
will greatly contribute to reducing the reactive
power fluctuation.
Table 5. Summary of synchrotron parameters
Number of dipole magnets 12 (3 .4 meach)
Dipole field (min/max) 0.11/1.5 T
Number of quadrupole 24 (0 .4 meach)
magnets
Quadrupole gradient 0.4/7.4 T/m
(min/max)
Repetition rate 0.3-1 .5 Hz
Revolution frequency 0.262-1 .948 MHz
Rise/flat-top time 0.7/0.4 s (at 0.5 Hz, 600
MeV/u)
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The High-Energy Beam Transport
System
The accelerator system and all irradiation ports
are connected by a high-energy beam transport
system. Layouts of the high-energy beam trans-
port lines are shown in Figure 4. Each beam
extracted from the upper or lower ring will be
dedicated to a vertical or horizontal beam line .
The horizontal lines provide beams to two treat-
ment rooms (B and C), to a physical or general
irradiation area, and a secondary beam room;
however, on special occasions, the main horizon-
tal beam line can be joined to the vertical line .
The vertical lines provide vertical beams to two
treatment rooms (A andB) and horizontal beams
to a biological irradiation area . The huge vertical
beam lines represent one of the most desired radi-
ation therapy features of the whole system .
Injection energy 6 MeV/u
Maximum energy 800 MeV/u (for q/A=1/2)
Lattice structure FODO
Maximum rigidity 9.73 Tm
Periodicity 6
Cells per period 2
Circumference 129.6 m
CD (D (D @ 10 (9 12 13 (3 15 16
Fig . 4 a. A cross sectional view of the vertical beam lines
,,v Jun,. . . .Z
Junction to The Vertical Lines
High Energy Beam Tempo!, Room
Fig . 4 b . Arrangement plan of the horizontal beam lines
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The Beam Delivery System
Several devices including a pair of scanning mag-
nets, a scatterer changer, a neutron shutter, a
range shifter, a ridge filter, a block collimator, a
multi-leaf collimator and several beam monitor-
ing devices make up the beam delivery system .
Figure 5 shows the typical beam line arrangement
of treatment room B.
The scanning magnets and thin scatterers gen-
erate large uniform irradiation fields . The scan-
ning magnets are orthogonal bending magnets
which can support wobbler as well as raster or
spot scanning, according to the use of suitable
power supplies . In the beginning, our uniform
fields will be generated by a combination of beam
wobbling and scattering which is relatively fast,
yields uniform fields and less nuclear fragments
than scattering alone.
B2 FL
Reinforced iron shield
The electrical power supplies for the scanning
magnets feed the sinusoidal current with a fre-
quency of 62.8 Hz, which is selected to avoid non-
uniformity due to pickup of noise synchronized
with the line frequency. With the 90-degree phase
difference between the two magnets, the wobbler
magnets give rise to the circular rotation of the
beam spot at the isocenter.
The ridge filter spreads out the narrow Bragg
peak up to the size of the tumor. Individual filters
can be selected from the ridge filter changer, a
large circular rotational frame for up to seven dif-
ferent aluminum or copper filters .
The range shifter uses absorbers to fine-tune
the ion range to conform with the depth of the
tumor. They are nothing but energy degraders of
different thicknesses . Nine lucite absorbers, 0.5
to 128 mm thick, are combined to the desired
thickness by computer control.
Scatterer
Fixed collimator
Beam shutter
Fig . 5 . Arrangement plan of the irradiation devices for treatment room B
The Al block collimator is composed of 4 slit-
leaves (20cm thick) which roughly cut off most of
the irrelevant portion of the spread-out beam. It
reduces the production of neutrons and induced
activities as compared to the steel leaves of the
multileaf collimator. The multileaf collimator is a
field-shaping device which tailors the beam
according to the perpendicular cross-section of
the tumor. The maximum opening between two
opposite leaves is 22 cm. Each leaf has a 16 cm
stroke . The irradiation field size is 15 x 22 cm' at
maximum. There are 23 leaves at each side of the
aperture . The height of each leaf is 6.25 mm, the
thickness along the beam direction 14 cm. The
clearance between neighboring leaves is within
0.20 mm. Each leaf has two step stairs along the
beam path to block the beam passing straight
through the gap between neighboring leaves .
In order to measure and record the irradiation
dose, the principal and substitutional ionization
chambers are placed separately as dose monitors .
The flatness monitor comprises 25 segmented sen-
sitive parts in an ionization chamber. These are
continuously monitored to keep the beam intensity
distribution uniform in the irradiated area . All
these devices are operated under computer control
and the signals are monitored and displayed on a
graphic panel on a pulse-to-pulse basis.
The Patient Positioning System
Patient positioning devices for accurate patient
set-up have been installed in each treatment
room. There are laser pointers, a light localizer,
X-ray tubes, image intensifier tubes, a treatment
couch, patient immobilization aids and an X-ray
CT. The laser pointer is an indicator of the beam
center for heavy ion treatment. The light localizer
is the projector of the parallel light and placed
into the beam line alternatively with the X-ray-
tube . It is used to check the setting of the multi-
leaf collimator by projecting the shape on the
patient. X-ray tubes and image intensifier tubes
are set perpendicularly to each other, one of them
being the beam's eye view. They are used to verify
the beam direction and the target volume posi-
tion using certain reference numbers of anatom-
ical landmarks . By comparing the positions of the
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landmarks on the X-ray image taken at the time
of patient positioning on the couch and those on
the reference image from the digitally recon-
structed radiographs whichwere generated at the
time of treatment planning the displacement of
the patient's couch can be determined . The couch
can automatically be adjusted by the patient posi-
tioning computer which is linked to the image
verification device . The X-ray CT is used for a
final verification of the density and the range of
the ions in the patient body immediately before
the treatment .
Future Developments at the HIMAC
The heavy ion research project does not only
include clinical trials of heavy ion therapy, but
focuses as well on basic research in medical phys-
ics, radiation biology, and radiation chemistry.
Therefore, it is very important that the HIMAC
facility is flexible enough to allow for different
eventualities in future extensions .
One idea is to produce radioactive beams for
treatment as well as diagnosis . They could be pro-
duced just before the junction of the horizontal
and vertical beam lines. In this case, the junction
line would be used for analyzing the section of
secondary beams, and the selected radioactive
beam could be used as vertical treatment beam.
This feature seems very important for radiation
therapy, since it permits precise verification of an
irradiated volume with the treatment beam.
An effective and sophisticated parallel use of
the two synchrotron rings requires some tech-
nological improvements which could provide the
following:
- simultaneous irradiation with a horizontal and
a vertical beam in treatment room B
- two beams used simultaneously in different
treatment rooms or experimental irradiation
areas
- joining the upper and the lower beam lines to
reduce beam failure probability to some degree .
If the junction beam line between the two rings (a
fast extracted beam from the upper ring injected
into the lower one) is completed, the following
feature could be expected :
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- two-stage cascade acceleration for ions heavier
than argon by adding a stripper foil to the
extended junction beam line .
It might also be possible to use the lower ring as a
storage ring for the upper synchrotron . This could
be interesting for the following plans:
- to accumulate radioactive beams in the lower
ring for treatment and verification with the
same beam
- to treat patients for a very short time with a
single shot of an accumulated stable heavy ion .
Sophisticated 3D-irradiation with the spot scan-
ning method will also be pursued . It requests,
however, a range shifter unit andupgraded power
supplies for the scanning magnets. The procedure
has been verified with proton beams from the
NIRS medical cyclotron. Three-dimensional
irradiation treatment does not only require a spe-
cial beam delivery system, but also a very
advanced 3D-treatment planning program which
takes physical dose distribution and biological
effects into account. Although the 3D- treatment
planning program is under development, its final
completion will take some time until the neces-
sary experimental data have been compiled at the
HIMAC.
Conclusions
The construction of the accelerator facilities and
the HIMAC building started in 1988 . The entire
facility was completed in 1993 and in June of 1994
the first patient was treated. For the time being,
HIMAC will be the only medically dedicated
heavy ion accelerator in the world. NIRS is
indebted to many colleagues from abroad who
contributed important developments to the facil-
ity. HIMACwill continue to be open for domestic
and international research collaborations, and
appreciates joined clinical trials .
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Introduction
New Developments at PSI
Paul Scherrer Institute, Division of Radiation Medicine, Villigen, Switzerland
Heavy charged particles have been recognized
several decades ago to have favorable character-
istics for radiation therapy [1, 2] and more than
15 000 patients have been treated in the meantime
at various facilities with ions and pions. When the
590 MeV proton accelerator at Villigen was
planned in the sixties, pions were regarded as
probably the most promising particles for radia-
tion therapy with a superior physical dose distri-
bution and an increased biological effectiveness.
Already the first layout of the experimental
hall of the PSI (then SIN) included a biomedical
treatment site [3] . A vertical beam line was in
operation only half a year after the first beam of
590 MeVhad been extracted from the accelerator
at the end of 1974 . After a period of physical and
biological measurements, it was realized that the
dose rate was low and that it was unlikely to
increase in a reasonable time . It was, therefore,
decided to build a dedicated beam line of higher
dose rate for medical applications . Dosimetric
measurements, including determination of
energy spectra of secondary particles, emitted
after capture of negative pions in biologically rel-
evant nuclei, and microdosimetric studies in the
beam were continued. Radiobiological experi-
ments, primarily on sensitive systems like eggs of
Drosophila, Vicia faba bean roots, and mamma-
lian cell cultures were performed .
In 1975, after a study of various options for a
new medical beam line with increased dose rate,
a solution was chosen which was based on the
Stanford Medical Pion Generator (SMPG) [4],
and was given the name Piotron [5] . The geomet-
rical properties of this device, i.e ., 60 beams in a
vertical plane focused onto the axis of the Pio-
tron, and the fact that the 60 superconducting
coils were connected in series, resulting in an
equal range for each beam, limited the choice of
treatment techniques to dynamic scanning of the
target volume by ring or spot scan .
Experience from the Pion Project
In the pion project of PSI, a spot scanning tech-
nique was developed, and the first patients were
treated in early 1981. The dose rate achievable in
the Piotron was approx . 0.2 Gy/l/min, if all 60
beams were used . With this application technique
it was not only possible to get a homogeneous
physical dose distribution throughout the target
volume, but also a fairly homogeneous biologi-
cally effective dose . RBE corrections were con-
sidered to be unnecessary for 60 beam irradi-
ations .
Treatment planning was based on CT scans
taken in steps of 5 to 10 mm accross the entire tar-
get volume [6] . To guarantee the same geometry
for treatment planning and irradiation, the
patient was scanned in the same couch as was
used for treatment . In each of the CTslices the
contour of the target volume was entered. The
desired dose distribution consisted then of a
homogeneous dose inside this target volume and
a rapid fall-off outside. The dose distribution was
optimized using a xz-algorithm . The individual
treatment plans were verified by dose measure-
ments in selected points of phantoms . In addi-
tion, whenever possible, in-vivo dosimeters were
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placed in the target volume during treatment.
Biological experiments performed in different
geometries [7], intercomparisons with other cen-
ters [8], and clinical experience were used to
decide on the treatment dose .
Pions were expected to yield substantially bet-
ter results than photons due to their radiobio-
logical advantages, especially for tumors with
fractions of anoxic cells. The fractionation
scheme selected had to be close to a known frac-
tionation scheme for conventional photon radia-
tion with a low number of fractions for logistics
reasons. 20 fractions in 5 weeks were compared
with results from the Manchester technique using
20 fractions in 4 weeks. In a dose escalation pro-
gram the optimal total dose was determined as
33 Gy, which was used for most treatments
throughout the entire program [9, 10] . As many
of the initial patients had bladder tumors, it was
possible to verify the dose in the target volume
with in vivo dosimetry, an important aspect for a
new technique with individually shaped target
volumes.
The treatment with pions was assumed to pro-
tect normal tissues adjacent to the target volume
better than conventional radiation, due to the
favorable physical dose distribution and a drop in
biological efficiency outside the high dose
volume . With increasing experience it became
obvious, that the radiation quality to the nor-
mal tissue inside and to some extent outside the
target volume wasthe same as for the tumor cells .
In contrast to TRIUMF, PSI never intended to
perform any randomized trials in the pion
project. They seemed out of scope because of the
limited number of treatments feasible at our
physics facility, not attached to a large hospital .
As treatments at a research institute are sub-
stantially more expensive than conventional
radiotherapy, it was the aim to treat primarily
indications which could not be treated satisfac-
torily with conventional means . Very encouraging
results were found especially for large, mostly
irregularly shaped tumors, which could not be
treated with curative doses of other radiations .
For specific groups, e.g ., large retroperitoneal
soft tissue and bone sarcoma, conformation
radiotherapy with pions could be regarded as the
treatment of choice [9] . Even though these rare
indications would not justify a clinical pion ther-
apy facility, the necessary effort was in good rela-
tion to the result . It is yet not possible to decide
conclusively if the results are a consequence of
the increased RBE of pions, the dose conforma-
tion treatment, or a combination of both . For soft
tissue sarcoma, a comparison with results from
the literature suggests a combined effect . While a
conversion factor of two from a 20-fraction pion
treatment to a 35-fraction photon treatment could
explain normal tissue reaction as well as tumor
reaction for many of the treated tumors, the con-
verted dose of 66 Gy for large sarcomas of two
liter volume was still far below the 80 Gy, needed
in photon therapy [11] .
An important experience gained in the pion
therapy project was to recognize the significance
of conformation treatment which permitted
higher doses in the target volume and the flexibil-
ity to distribute the dose outside the target vol-
ume according to the different sensitivities of the
adjacent normal structures . The spherical spot in
the Piotron, with its moderate fall-off, made it,
however, often impossible to yield enough spar-
ing of a specific neighbouring tissue .
Treatment of Ocular Melanoma
with 72 MeV Protons
In parallel to the pion project, a proton therapy
project for ocular melanoma was established in
1984 . It has since been running successfully [12] .
The injector cyclotron of PSI is particularly well
suited for this therapy as the range of the protons
(3 cm) is sufficient and the distal fall-off excel-
lent . Proton therapy of ocular melanoma is an
exceptionally favorable situation for proton radio-
therapy as the target volume is small and well
delineated, close to the surface and generally
inoperable . Close to the target volume, there are
critical structures which can be spared best with
protons . The small target volume can be treated
in a few fractions to a tumoricidal dose, resulting
in a local control of the order of 95 % or more
without jeopardizing normal tissue tolerance . The
short overall treatment time of only one week
makes it easy for a research facility to accomo-
date regular treatment periods into the schedule
of a multiuser accelerator, and it is also of advan-
tage for the patients, who often come from far.
With only one week beam time per month,
approximately two hundred patients per year are
treated in the OPTIS program at PSI; so far, more
than 1600 patients from many different countries
in Europe have been treated. Due to the low fre-
quency of ocular melanoma, a dedicated acceler-
ator in a hospital could economically only be
justified if other indications would be treated.
The research activities of the OPTIS group focus,
therefore, on evaluating new indications for this
irradiation technique . In addition to the treat-
ment of ocular melanoma, the beam line also
serves for detector tests for the high-energy pro-
ton therapy project, and since 1993 it has also
been used for radiotherapy of selected tumors in
a veterinary radiooncology program (cf. Chapter
10).
Past
locker
T
scan priority
Fig . 1 . Principle of the discrete voxel scanning for protons at PSI . Description in the text
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High-Energy Proton Therapy Project
As a result of the experience with pion therapy
andproton therapy of ocular melanoma, aproton
therapy delivery system was planned to provide
the same flexibility concerning dose application
as modern clinical installations .
The application technique developed at the
PSI is based on a discrete pencil beam scanning on
three orthogonal axes [13-15] . The first and fast-
est movement is performed by magnetic scanning
with a sweeper magnet, the second movement is
done by a mechanical range shifter in steps of 5
mm in tissue and the slowest movement translates
the patient in the direction perpendicular to the
protons' path . Each of the approx . 10 000 spots
per liter is deposited statically in an average time
of 12 msec to a precision of one percent (Fig . 1) .
The dose fall-off for a single port, laterally and
distally is of the order of 10 mm (90-10 %) .
closimetric~ phantom l
Y
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A customized treatment planning program has
been developed for the special characteristics of
the scanning technique . The first version of this
program is running and has been tested on geo-
metrical target volumes in the beam period 1992
[16] . The dose is optimized by computer control;
in a water phantom, a homogeneity of close to
1 % in the target volume has been achieved .
The monitoring and dosimetry system, too,
had to be adapted to the scanning application
technique with a fast response time to control
each spot to the design goal of 1% homogeneity.
For absolute dosimetry, a Faraday cup and a
water calorimeter will be used in parallel to
calibrated ionization chambers .
An Isocentric gantry with a diameter of only
4 m has been installed and has undergone testing
with beam since spring 1994 . The gantry is equally
versatile in selecting treatment ports as a modern
clinical linear accelerator.
Isocentric Beam Delivery
for Deep-Seated Tumors
The target volume conform treatment technique
tested in the horizontal beam line can now be per-
formed on an Isocentric gantry (Fig . 2) . In gen-
eral, multiport irradiations will be performed . In
the present version of the treatment planning
Fig . 2. View of the gantry (wooden
model)
software each port is optimized individually. The
treatment time per port will not be longer than
for conventional linac therapy.
The design and realization of the gantry was a
challenging project, well suited for a medical
physics group at a research institute. The prob-
lems had to be solved in close contact to medical
application not generally possible in an industrial
environment . PSI with its expertise in physics,
engineering, radiobiology and radiooncology, and
with a proton beam of the appropriate energy has
been a very valuable frame for such an endeavor.
The small size of the gantry is a result of the
limited space available for the project in the
experimental hall . But the solution found, may
be particularly well suited for hospitals, where
space is often very limited, too. Apart from the
590 MeV accelerator, the facility can be consid-
ered a prototype for a hospital-based installation .
Experience can be gained using the novel applica-
tion technique, treatment planning, but also the
patient preparation technique, which is optimized
for an efficient use of the limited beam time . We
expect to prove that voxel scanning is a very effi-
cient technique for conformation therapy in
terms of staff requirements and material costs .
Individual collimators and compensators, neces-
sary for irradiation with scattered proton beams,
are needed only in special cases. Treatment by
several ports per patient can be done without
time-consuming realignments, which would be
necessary for photon treatment or for scattered
proton beam treatment with beam modification
hardware .
Special requirements arise from the high
demands on a precision treatment with a dynamic
application technique . Patient or organ move-
ment have been identified to be of special rel-
evance in the treatment with the voxel scanning
technique [17] . Fixation techniques and position
verification systems are, therefore, evaluated and
under development especially for deep-seated
tumors in the abdomen . One of the techniques is
proton radiography. It can serve as means to
check energy loss calculations in the treatment
planning program as well as position verification
method under treatment conditions (cf . Chapter
31) . As it needs a higher proton energy than the
therapeutic beam to traverse the patient com-
pletely, it is of interest to investigate if this tool
would be worthwhile in a clinical facility and
justify higher costs for the accelerator.
Even though it is usually not the primary goal
of a medical program at a research facility to
accumulate large patient numbers, it is possible
to determine the effort per patient and extrapo-
late it to a clinical environment.
The radiotherapy project at PSI is only mar-
ginally hampered by the fact that the irradiations
are performed at a physics institute with only lim-
ited medical infrastructure . The anticipated indi-
cations can, in general, be performed on an out-
patient basis . A regional hospital is available for
those needing hospitalization.
Status of the Experimental
Radiotherapy Program
Beam optics measurements of the gantry beam
line and measurements in a water phantom have
been performed to check the beam characteristics
and provide input for the treatment planning pro-
gram. Measurements in phantoms with density
inhomogeneities will follow for single beams and
entire treatment plans.
As part of an extended experimental program
on the treatment of spontaneous tumors in dogs,
a first animal was treated in fall 1994 (Fig . 3) to
study the entire chain of individual steps from
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Fig. 3 . Treatment of the first dog patient on the gantry. The
beam is coming from above, visible is the 90° bending mag-
net and the nozzle . The anaesthetized dog is positioned in
the mould, TLDs and ionization chambers are mounted to
check the skin dose
diagnostics with individual moulage and com-
puter tomography to treatment planning, dose
verification, fractionated treatment, and follow-
up . A relatively simple geometry was selected .
In a ten-fraction treatment an infiltrative
lipoma of approx . one liter in the hind leg of a
dog of 33 kg was treated with a dose of 36 CGE
(Cobalt-Gray equivalent), assuming a RBE of 1.1
for protons . Even though the target volume was
almost the entire leg, the target dose was defined
three-dimensionally on a series of CT slices to
spare a small amount of skin cranially. One single
port with a vertical beam was used . The dose dis-
tribution calculated for this treatment was veri-
fied by measurements with ionization chambers
in a solid plexiglass block and by exposing X-ray
films at various depths in a plexiglass stack per-
pendicular to the incoming protons . For each
fraction, verification films were taken proximally
and distally to the leg.
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The main goal of this first treatment was to
verify that nothing unexpected happened - nei-
ther in terms of early reactions nor in late reac-
tions - before a larger number of animals will be
treated starting early 1995 .
Protons are considered a low-LET (linear
energy transfer) radiation with a similar RBE
(relative biological effectiveness) as photons used
in conventional radiotherapy (cf. Chapter 3) . For
the dynamic application technique developed at
PSI, some uncertainty arises from the high dose
rate (10'Gy/min) in the pencil beam. Although it
is not expected that this yields RBEvalues signifi-
cantly different from proton therapy experience
at other centers, biological experiments are
planned by the Institute for Medical Radiobiol-
ogy of the University of Zurich . Mammalian cells
will be exposed to various doses under typical
radiotherapy conditions . These experiments will
be supplemented by fractionated whole-body
irradiation of mice for the intestinal crypt cell
assay. Both types of experiments can be consid-
ered biological dosimetry.
The Clinical Program
The aim of the clinical program is to find indica-
tions for which the dose distribution of proton
conformation therapy is significantly better than
for any other treatment modality. The basis of
comparison might be elaborate photon therapy
techniques with multiport, irregularly shaped
fields with or without boost treatment, photon
conformation therapy with multileaf collimators,
or external beam therapy combined with brachy-
therapy.
Intercomparisons of treatment plans for pro-
ton and photon radiotherapy have been started
already, using the Voxel Plan treatment planning
software from the German Cancer Research Cen-
ter (DKFZ), Heidelberg [18] . Preference will be
given to cases where the difference in dose distri-
bution seems large enough to expect improved
therapy results with a moderate number of pa-
tients treated.
It is generally agreed upon that proton beams,
due to their excellent distal dose fall-off, are of
special value when a radiation-sensitive normal
structure is located directly adjacent to the target
volume . This is of special importance, if, e.g ., a
port has to be chosen, which points directly
towards the normal structure .
Another goal of the clinical program is to find
indications which are significantly better treated
with conformation proton therapy than with scat-
tered proton beam therapy using fixed range
modulation.
Large, deep-seated, irregularly shaped target
volumes have high priority for three-dimensional
scanning, as for this category the impact of dose
shaping is most pronounced with a substantially
lower integral dose than conformation photon
therapy can yield . For small volumes, even if the
shape is irregular, the advantage might be limited
as only modest amounts of normal tissues would
be included in the high-dose volume . Large num-
bers of patients wouldbe needed to document the
modest improvement expected in this case .
Special attention has also to be paid to the fre-
quency of the indications selected, as one of the
goals is to demonstrate that the small gantry and
the dynamic beam application are interesting
solutions for routine use in a hospital with a wide
spectrum of indications, and that the technique
serves a real need in radiation therapy. Finally, it
is our attempt to prove that the technique is feasi-
ble, practical and can be performed with a
modest effort in manpower per patient.
The clinical program is being designed by a
"Proton Therapy Users Group", formed several
years ago. Most of the radiooncology depart-
ments of Switzerland are collaborating in this
group [19] . They will provide the patient base for
the project and decide on the protocols for the
treatment of the various indications.
Proton Radiosurgery
PSI plans to set up a beam line for cross-fire
irradiations of small volumes for functional
surgery in a similar way as was done in Uppsala in
the late 50's .
Radiosurgery is performed in single fractions
(cf . Chapter 16). This is one reason, why the pro-
gram is ideally suited for external users, e.g .,
neurosurgical groups . It is also expected that the
program opens new areas of research to the PET
program at PSI, specializing in brain research .
The 590 MeV protons of the ring cyclotron of
PSI are perfectly appropriate for cross-firing tech-
nique [20] . In the area of the former pion therapy
project a beam of up to 20 [A is available, suit-
able for functional radiosurgery in the brain . By
degrading or scattering, the intensity would be
reduced to the desired dose rate . A horizontal,
collimated beam would be available using a ste-
reotactic frame and a precise chair with five
degrees of freedom . Beam diameters of approx. 1
to 20 mm would be feasible . The dedicated beam
line for proton radiosurgery would be an ideal
supplement for the proton gantry. The time-
consuming positioning for the radiosurgery ses-
sions would also occur in a separate area, increas-
ing the efficiency and availability of the gantry
beam line .
Conclusion
A radiotherapy project at a research accelerator
facility is strongly influenced by the operation
conditions of the accelerator, and the competition
with other user groups for beam time or specific
beam requirements . Unstable beam is frequently
the result of tuning for higher beam currents . Lim-
ited availability of the beam is often the conse-
quence of shut-down periods, scheduled to
improve the performance of the accelerator for
the basic research users . Compromises made in
the design of beam lines, may lead, for example,
to reduced flexibility in selection of treatment
angles . But only if the same flexibility as for mod-
ern hospital equipment is available, the test condi-
tions for a new radiation source are really sound .
Tighter dose distributions feasible with proton
conformation therapy will in many cases enable
higher doses per fraction reducing the overall time
of the treatment and hence the costs . The favor-
able dose distributions should yield better clinical
results and hence justify higher facility costs .
Conformation therapy by voxel scanning is
characterized by minimal individual patient hard-
ware, which saves time and costs . This is of spe-
cial relevance for future routine operation in a
hospital environment . The design of a very com-
35 New Developments at PSI
	
339
pact gantry may be particularly well suited for
hospital facilities .
A medical project at a research facility should
concentrate on developing new techniques rather
than accumulating large numbers of patients .
Randomized trials which often require hundreds
of patients for each treatment arm - especially if
only modest changes in cure rates are expected -
are, therefore, generally out of scope [21] .
Instead, the focus should be on demonstrating
the potential of proton therapy for indications
which cannot be treated satisfactorily by existing
radiation types . Treatments which promise
improvements and for which it would be uneth-
ical to perform a randomized trial would be ideal
candidates .
Establishing the proton therapy sites at PSI
has been an interdisciplinary task involving not
only many different groups inside the institute but
also many links to other University institutes as
the Institute for Biomedical Techniques at the
ETH and University of Zurich, the Institute of
Medical Radiobiology, and the Veterinary School
of the University of Zurich . Many contributions
from University groups from Switzerland and
other countries are appreciated .
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Heavy Ion Therapy at GSI
G . KRAFT
Introduction
Gesellschaft für Schwerionenforschung (GSI), Darmstadt, and University of Kassel, Kassel, Germany
Plans to include heavy ion therapy to the scien-
tific program of GSI date back to the first propo-
sal for a heavy ion synchrotron (Schwer-Ionen-
Synchrotron, SIS) submitted to the German
Ministry of Research andTechnology in July 1979
[1]. In this paper the two main advantages of
heavy charged particles were emphasized : their
superior depth-dose distribution and the high
biological efficiency at the end of the particle
range. At the second GSI Workshop on Heavy
Charged Particles in Biology and Medicine 1981,
a group formed to promote the idea of heavy ion
radiotherapy. It consisted mostly of German
physicians from Heidelberg, Hamburg, Gießen
and Frankfurt, but with connections to LBL
Berkeley, USA, the Radiotherapy Department of
the Catholic University of Louvain-la-Neuve,
Belgium and the SIN (now PSI), Villigen, Swit-
zerland . In 1981, the original SIS-proposal was
upgraded to 10 GeV/u mainly for physical
reasons. However, it failed and the medical meet-
ings were discontinued after a change in the GSI
directorship . A new SIS-proposal was submitted
in March 1984, comprising a storage ring that
allowed many novel experiments in atomic and
nuclear physics [2]. It was accepted mainly
because of the new physical concept, but the final
layout of the facility included an experimental
area for biophysical experiments, as well .
In 1989, during the constuction period of the
SIS, a proposal for the medical use of the heavy
ion beams was jointly prepared by the Heidelberg
Radiological Clinic, the German Cancer Re-
search Center (DKFZ) and GSI. But at that time
the German govern ment preferred a European
solution and did not fund the proposal . With sup-
port from the EULIMA project, preparatory
work was started. But it was not sufficient to
build a therapy unit .
The first radiobiology experiments with relativ-
istic heavy ions were performed in 1991 mostly in
time-sharing mode with other physics experiments.
The "peaceful coexistence" of physics and radiobi-
ology experiments promoted the idea - after
another change in the GSI directorship -to use the
ion beams of SIS not only for pretherapeutic work,
but to install a unit for Heavy Ion Therapy at GSI
(HITAG) for the treatment of 70 to 100 patients per
year. This new proposal, jointly prepared with the
University Clinic and the German Cancer Research
Center, both at Heidelberg, was submitted to the
German Ministry of Research and Technology in
May 1993 [3] . It stressed the new techniques for
tumor conform treatment which the GSI had
developed in the meantime, and the new insights
into radiobiology which the biophysics experiments
at SIS and other acceleratiors had prompted .
The experience of LBL with heavy ions has indi-
cated superior treatment results for certain
tumors as compared to conventional therapy, but
a comparable outcome to proton therapy as per-
formed at Harvard, for example [4]. As protons
are assumed not to have an elevated biological
effictiveness in contrast to the heavier ions, iden-
tical clinical results at Berkeley and Harvard
would suggest that the potential of heavy ions
cannot be exploited clinically in an adequate way.
One reason for this result could be that LBUs
irradiation technique permitted an essential part
of the high-LET dose to be spread outside the
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tumor volume limiting the tolerance level,
another that the high-LET component of the
heavier particles observed in vitro has been over-
estimated. Therefore, in the HITAG project most
effort has been put on developing a strictly tumor
conform dose delivery system and an advanced
understanding of the radiobiological effects that
are relevant for the increased biological efficiency
of the particles .
In the following sections the novel approach to
tumor conform treatment using intensity-
controlled raster scanning, its limitations and con-
sequences for the treatment planning and the
safety system are given. In addition, require-
ments concerning the physical and biological
characterization of the particle beams are summa-
rized. Finally, a technical description of the layout
and the future perspective of the heavy ion ther-
apy at GSI is given.
Tumor Conform Treatment and
the Problems of Beam Delivery
An extensive compilation of the various methods
of beam shaping for therapy has been published
by Blattmann [5] . They can be categorized into
the following two groups :
- beam spreading techniques which affect the
lateral and longitudinal direction simulta-
neously. This is mostly done by passive beam-
forming elements like scattering systems, range
modulators, etc.
- active beam spreading methods using fast mag-
netic scanning combined with an adequate
energy variation for atumor conform treatment .
The major advantage of a passive system is that
the beam quality delivered to the patient is largely
independent of the beam quality delivered from
the accelerator to the spreading system : intensity
and emittance fluctuations do not influence the
scattering process and the spread-out beam in the
target volume does not have inhomogeneities
caused by these fluctuations . Secondly, the radia-
tion field in the target area has a cylindrical sym-
metry which allows to measure the relative bio-
logical effectiveness (RBE) for the various pene-
tration depths and to assign RBE values depend-
ing only on the penetration depth but independent
of the lateral extension of the target volume .
A major disadvantage of the passive methods,
however, is the cylindrical shape of the radiation
field which encloses the tumor in a very crude
way, affecting a large fraction of healthy tissue by
the biologically highly efficient stopping ions
when irradiating irregularly shaped tumors, for
example. Consequently, the tolerance of this
healthy tissue determines the maximum tumor
dose and possibly the success of the treatment.
Finally, passive beam spreading is also costly
because it requires individually tailored beam
shaping moduls for every patient.
Strict tumor conform treatment is very easy to
understand in its conception (Fig . 1) : the treat-
ment volume is dissected into slices of equal
thickness and each slice is treated separately by
moving the beam over the cross sectional area .
After having treated the most distal slice, the
energy is reduced and the preceding slice is
treated in the same way. The outline of consecu-
tive slices can be different, so that tumors of
arbitrary shapes can be treated in this manner fol-
lowing exactly their outer contours .
Simple as it sounds, this method of tumor con-
form treatment raises many problems concerning
the delivery control and distribution of a pencil
beam. Applying the desired physical dose pattern
and even more difficult, assigning the proper
RBEvalue to each point of the target volume are
the critical issues .
last first
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Fig . 1 . Schematic view of the magnetic scanning system .
The tumor volume is dissected into layers of equal thickness
and each layer is treated separately by "painting" the neces-
sary dose with a pencil beam
Intensity-Controlled Raster Scanning
For target conform dose delivery, a prototype of a
magnetic scanning system for lateral beam deflec-
tion has been used in the biology cave of SIS in
combination with the active energy variation by
the accelerator for range variation .
In various experiments, it has been shown that
an energy variation from pulse to pulse (- 2 s) is
possible . This includes tuning the beamline to the
experimental cave [6] . Figure 2 shows a scanning
pattern taken with four different energies deliv-
ered within a time sequence of three seconds
between the individual steps. However, a major
problem of apure active energy variation mode is
the small width of the Bragg peak that would
require more than 200 energies to cover a range
between 2 and 30 cm. For such a close spacing
between the different layers the particle covering
of each layer is small and difficult to measure in
the position sensitive ionization chamber. There-
fore, additional systems for widening the Bragg
peak to approximately 3 mm FWHM have to be
-50 0 50 50
Fig . 2 . By combining beam scanning and energy variation,
simple figures were produced to test the performance ofthe
scanning system and the quality of the beam . The energy
was changed in the accelerator from pulse to pulse within 3
seconds and the beam line was tuned in the same rhythm
36 Heavy Ion Therapy at GSI
	
343
considered . This will reduce the number of differ-
ent energies and in consequence the machine set-
tings to a more reasonable number, and the beam
intensity produces more reasonable currents in
the transmission detectors .
The lateral beam deflection is a more difficult
issue for tumor conform treatment . As the treat-
ment of the more distal layers preirradiates the
proximal ones, at least partially, the latter have to
be treated inhomogeneously in order to achieve a
homogeneous dose or inactivation effect in the
total volume . In addition, beam fluctuations from
the accelerator have to be compensated for in
order to achieve the desired particle number in
each spot . Two different strategies, raster and
voxel (or spot) scanning, have been proposed to
cope with these problems [6] .
For voxel scanning each slice of the target vol-
ume is dissected into discrete volume elements
(voxels) for which the necessary number of par-
ticles is delivered separately by turning off the
intensity when the beam is moved from onevoxel
to another. In the raster scan mode, the beam is
movedcontinuously without turning it on and off.
The deposited dose is adjusted by changing the
"writing velocity" according to the beam intensity
and particle covering.
Extensive calculations have shown [6] that with
both approaches, raster or voxel scanning, the
same quality of particle covering of any irregular
shaped cross sectional area can be obtained . More-
over, in the practical realization both methods
become very similar. For voxel scanning an opti-
mal pathway from spot to spot has to be given.
This is obviously the connection between neigh-
boring spots, i.e ., a more or less continuous path-
way. For raster scanning the given pathway has to
be digitized into coordinate elements that can be
stored in a computer. The only difference between
the two solutions is, therefore, whether the beam
has or has not to be turned off while moving from
spot to spot .
If the distance beween consecutive voxels is
much smaller than the diameter of the beam, the
dose delivered during moving from one voxel to
the next is small and interrupting the beam is not
necessary. Slight over- or underexposures of a
voxel can be compensated when exposing the
next .
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A digitized version of an intensity-controlled
raster scan, i.e ., a hybrid system of raster and
voxel scanning has been realized at the biophysics
cave at GSI (details are given in [6]) . In this set-
up, the beam is guided by two magnets in x- and
y-direction and the beam intensity is measured by
a transmission counter.
The beam path in a single slice is dissected into
up to 16000 elements and the writing velocity
(maximum 1 cm/msec) of the beam is controlled
by an ionization chamber as transmission counter.
It has been demonstrated that the use of a trans-
mission counter to control the writing velocity is
also a very elegant and efficient method to cope
with the intensity fluctuations of the extracted
beam from the accelerator. First experiments
showed that particle coverings with a homogene-
ity of 5% or better can be produced, even if the
incoming beam has large intensity fluctuations
(Fig . 3) . But in the same way and with the same
accuracy any desired inhomogeneous distribution
can be produced as well . This is necessary, e.g .,
when a three-dimensional volume has to be
exposed to a certain isodose or biological isoef-
fect with low intensities in the midsection and
higher intensities at the borderline .
Inhomogeneous radiation exposures have
been used to produce three-dimensional, spher-
ical volumes. In a water tank (as tissue equiva-
lent) a spherical volume of 6 cm in diameter, was
exposed to an isodose of carbon ions [7] .
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CR 39 nuclear track detectors immersed in the
water were used to record the dose . 30 particle
energies were necessary to produce the variation
in depth and for each particle range up to several
hundred spots were irradiated . The particle cover-
ing in the equatorial plane and a photograph of
the total exposed volume are shown in Figures 4a
and b, respectively. The result of this experiment
fully confirms the expectation that tumor con-
form treatment can be performed by an intensity-
controlled raster scanning system . In the near
future, this technique will be refined to treat any
arbitrary shaped volume .
On-line Control of the Beam
by Positron Emission Tomography
Precise beam delivery needs precise control.
Heavy ions can be monitored using the produc-
tion of radioactive isotopes that decay by positron
emission . The (3-'"-annihilation can be localized by
measuring the two coincident 511 keV gamma-
quanta in two adjacent gamma-cameras. As the
positrons are mainly emitted isotropically with
respect to the beam direction, the center of the
observed distribution of positron emission corre-
sponds to the stopping point of the radioactive
isotope.
400 450
Fig . 3 . Time profile of the extracted
beam of SIS. The beam intensity is given
as a function of the extraction time . The
feed back system of the raster scan is
5oo able to adjust the "writing velocity" to
these functions
Originally, a beam of radioactive ß+-emitting
ions was used to verify the treatment plan prior to
therapy [8]. At Lawrence Berkeley Laboratory,
this approach was successfully applied in cases,
where the treatment volume was close to a critical
organ such as the spinal cord .
Meanwhile, is has been demonstrated in phan-
tom measurements that ß+-radioactivity pro-
duced by a stable beam is sufficient to monitor
the stopping points of the projectile ions [9] .
Beams of stable ions undergo nuclear reactions,
including projectile and target fragmentation .
Most likely are stripping reactions which lead to
lighter ions, a fraction of which are ß+-isotopes.
Fig . 4. A sphere of 6 cm in diameter
was located in a water phantom
(depth 9-15 cm) and exposed to a
carbon beam [7] . a) Particle covering
in the equatorial plane of the volume,
b) photograph of a recording of the
dose by nuclear track detectors . A
small dose is visible in the entrance
channel on the left
a
36 Heavy Ion Therapy at GSI
	
345
In the case of target fragmentation, these ß+-
emitters are smeared out over the particle path .
For the projectile fragmentation the ß+-isotopes
have nearly the same range due to their similar
mass-to-charge ratio and the strongly forward-
peaked reaction kinematics . In Figure 5 the
induced ß+-activity of a Ne-beam implanted into
a plastic block is compared with the calculated
range distribution and with the range of the pri-
mary Ne-beam. From the ß+-distribution the
range of the stable Ne-ions can be calculated with
high accuracy and compared to the treatment
plan . The PET technique to verify the treatment
plan can also be used for other light ions, includ-
-3
cm
346
	
G. Kraft
U
c0
äM
Fig . 5 . Measured and calculated profiles of 0'-emitting iso-
topes are compared with the range of the primary stable
Z°Ne beam as indicated by the short arrow [9]
ing oxygen, nitrogen or carbon ions, but not for
helium ions or protons. It should be mentioned
that measuring the ß+-activity during the beam
spill is not possible, due to a high background
activity. However, the off-spill time intervals are
sufficient for PET analysis .
Figure 5 illustrates another problem of dose
localization for the heavier ions : with increasing
atomic number more and more lighter fragments
are produced. They have a longer range than the
primary beam causing a long tail of dose behind
the Bragg maximum. Therefore, the excellent
dose distribution of the heavy charged particles
deteriorates for ions heavier than neon.
Physical and Biological
Beam Characterization
Detailed knowledge of the physical and biological
interactions of the beam with the target material
is extremely important when using beam scanning
methods to achieve a tumor conform target vol-
ume.
In an arbitrarily shaped target volume the
composition of the particle field differs from
point to point. This is due, first of all, to the fact
that beams of different energies have to be super-
imposed to achieve the desired depth distribution
.. . .__.. ..».». ... ...... . . . OV3
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Fig . 6 . Schematic representation of a homogeneous dose
distribution over an extended target volume produced by
superposition of individual Bragg peaks
(Fig . 6) . Therefore, particles of different energies
contribute to the biological effect in each point.
Secondly, the composition in atomic number of
the primary beam is changed to a large extent by
nuclear fragmentation. For a carbon beam with
penetration depth of 15 cm in tissue, e.g ., approx-
imately 50 % of the primary carbon ions undergo
nuclear reactions which yield lighter fragments
down to protons [10] . Therefore, in each target
point the particle field consists of various con-
tributions of particles having atomic numbers
from the primary ions down to protons and a
complex energy distribution .
Extended measurements of beam fragmenta-
tion in thick water targets have been performed at
the fragment separator (FRS) at GSI. Because of
the double separation mode of the FRS, it was
possible in a first target to produce all isotopes of
medical interest simultaneously and then to fol-
low their fragmentation in tissue-equivalent tar-
gets using a complex analysis system for energy
and atomic number [10] . These measurements
showed that fragmentation in the second and
third generation, i.e ., the fragmentation of reac-
tion products contributes significantly to the total
amount of reaction products (Fig . 7) .
Based on a proper parametrization of the
beam fragmentation and taking into account the
energy loss and straggling of the ions, the com-
position of the particle field can be described by a
Fig . 7 . Nuclear fragmentation of heavy
ions . Left : Decrease of the primary ions
by nuclear reactions as function of the
peneträtion depth . Right : Build-up of
the heavier reaction products with
increasing penetration depth in water
[101
distribution function f(Z, E, x, y, z) of the atomic
number Z, the energy E, andthe position coordi-
nates x, y and z. The dose D(x, y, z) deposited by
such a particle distribution in a small subvolume
centered around x, y, z is then given by
D(x, y, z) = ff f(Z, E, x, y, z) x LET(Z, E) dE dZ
This dose distribution for the individual elements
of the target volume can be measured using a
position-sensitive counter as control of the
desired particle covering in each point of the tar-
get volume and to verify the distribution function
f(Z, E, x, y, z) . But the dose distribution D(x, y, z)
cannot be used to calculate directly the biological
effect, because the relative biological effetiveness
RBE(x, y, z) is also a strong function of the
atomic number and energy of the particles . [11] .
The proper RBE in each target point requires,
therefore, knowledge of the composition of the
given dose in atomic number and energy. In real-
ity, the situation is even more complex because
the RBE further depends on biological parame-
ters like dose level and dose fractionation
scheme, and most important, on the tissue type .
A solution of this problem is only possible using
an elaborate theoretical approach [12] as de-
scribed in detail in Chapter 6 .
Technical Realization
of the HITAG Project
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The heavy ion sychrotron SIS can accelerate all
ions from helium to uranium to energies between
80 MeV/u and more than 1 GeV/u. For the med-
ically relevant lighter ions, such as carbon or oxy-
gen, intensities of some 109 particles per spill are
available . This particle flux is sufficient to pro-
duce a dose of a few Gray per liter in five to ten
spills or within 10 to 20 seconds .
In each spill only a few tenths of a second are
needed for acceleration while the beam can be
extracted by resonance extraction - stochastic
wouldbe better - over a few seconds. The energy
from SIS can be changed from pulse to pulse.
Because of the high flexibility of the synchrotron,
it is planned to treat the patients in time-sharing
with the physics experiments in four two-week
periods per year and to operate the SIS with two
different ion sources, one with carbon for patient
treatment, the other with the ions for the physical
experiments. With the raster scan method, one
fraction should be administered within less than
five minutes, whereas patient positioning might
take much longer (20-40 minutes) . Therefore,
the dead-time for the physics experiments will not
exceed 10 minutes per hour.
In order to minimize possible conflict between
the physical experiments and medical treatments,
a dedicated medical cave has been constructed
and will be connected to an annex housing a con-
trol room for the beam delivery to the medical
348
	
G . Kraft
Safety System
room and other rooms necessary for physicians
and patients including waiting rooms, examina-
tion rooms and offices (Fig 8) . However, the main
examinations and diagnosis of the patients will be
performed at the Radiological Clinic Heidelberg
which will also decide on the clinical preferences
and the patient selection.
The use of a pencil beam with high local effi-
ciency for tumor killing requires special precau-
tions to guarantee that the beam meets the
desired specifications and is always located at the
correct position in the target volume . To achieve
this, a complete set of detectors and controls will
be installed to trace the beam. In order to avoid
uncontrolled movements of the beam during the
resonant extraction, the beam line between ac-
Fig . 8 . Medical cave at the SIS with beam line to the treatment room (TPM) and an annex for the control room and medical
rooms
celerator and scanning magnets is set to non-
dispersive (achromatic) beam transport . This is
especially necessary for the last part of the trans-
port system where the beam is bent from the main
beam line into the medical cave by two symmetric
dipol magnets and pairs of quadrupols symmetric
to the dipols . However, an intermediate energy
dispersive focus is produced between the dipols
which represents an image of the final focus in the
patient. Location and diameter of the beam can
be monitored in a non-destructive way using scin-
tillator paddels as beam scratchers at the inter-
mediate focus. In addition, a set of two indepen-
dent, position-sensitive counters just in front of
the patient monitor the beam on-line during
exposure. One of these detectors, a multi-wire
chamber driven in ionization mode measures the
localization of the center of the beam and its
diameter within 100 lis . These data are compared
with the precalculated irradiation pattern within
less than half a millisecond and if differences are
observed, the beam can be stopped within
another half a millisecond . During the abortion
time less than 1 mGy is deposited assuming a
dose rate of 2 Gy per 10 seconds . This represents
an infinitesimally small dose when compared to
the total dose . A sensitive ionization chamber is
dedicated for clinical dosimetry, measuring the
absolute dose in each position of the patient
entrance . The data of these transmission detec-
tors together with the previously reported PET
system guarantee a precise control of the depo-
sited dose .
Another important safety feature is the asym-
metric layout of the raster scan system . When the
magnets of the scan system are not powered, the
beam will pass by the patient and be stopped in a
beam dump . Only if the scan magnets are
powered correctly, the beam is directed to the
patient . In case of an unexpected failure of the
scan system, the beam will automatically move
away from the patient. In addition to these spe-
cial safety elements for the scanned pencil beam,
the usual precautions for radiation safety will be
followed .
Time Frame of HITAG
According to the 1993 [3] proposal, the first
patient treatment is foreseen for 1996 . In summer
of 1994, the concrete shielding of the medical
cave was completed and the beam line compo-
nents were assembled in winter 1994/95. First
tests are scheduled for summer 1995 . The PET
system has undergone testing at the FZR Dres-
den and the components for treatment planning,
i.e ., the physical and biological beam characteri-
zation are to be put together at GSI to be
included into an existing planning program
("Voxelplan") of the German Cancer Research
Center. Experiments in which the in vitro results
are to be transferred to various tissue types are
under way. From mid 1995 the interplay of all
components and the treatment program are to be
tested in sham treatments of an anthropomorphic
phantom and in a few animal experiments. Con-
sidering the progress, it should be possible to
begin with patient treatments as scheduled in
1996 .
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Introduction
NAC - The Only Proton Therapy Facility
in the Southern Hemisphere
D. T L . JONES
National Accelerator Centre, Faure, South Africa
The only heavy particle therapy facility in the
Southern Hemisphere is at the South African
National Accelerator Centre (NAC) at Faure,
about 35 km from downtown Cape Town [1-4].
Although patients were first treated on Septem-
ber 6, 1988 on the p(66)Be neutron therapy unit
[5, 6], routine treatment only began in 1989,
while proton therapy was first undertaken in the
NAC's 200 MeV horizontal beam on September
10, 1993 [7] . It is possibly the only facility in the
world where both high-energy neutrons and high-
energy protons have been used for patient treat-
ment . The NAC facilities were planned specifi-
cally to provide research opportunities in natural
sciences for users from all over the country and
other parts of the world, to supply high-energy
nuclear particles for radiation therapy and to pro-
duce radioisotopes, primarily for medical applica-
tions .
Following a detailed study of the feasibility of
a centralized accelerator facility for South Africa,
the NAC was officially established on April 1,
1977 . It took another 10 years for the local team
to complete the design and construction of the
new accelerators and other facilities, before rou-
tine operation could commence . Approximately
18 months later, neutron therapy (which for his-
torical reasons had priority as far as radiation
therapy was concerned) commenced, following
extensive dosimetric and radiobiological mea-
surements [8-10] . Once neutron therapy was
established as a routine procedure [4, 11], atten-
tion was given to the development of the proton
therapy facilities . Today NAC's facilities are uti-
lized by more than 200 medical specialists and
scientists from many disciplines and institutes in
South Africa and abroad . Included in this number
are more than 50 post-graduate students .
The NAC is probably unique in the sense that
it was designed from the outset as a multidisci-
plinary facility to meet the often conflicting
requirements (in terms of beam quality) for
nuclear physics experiments and proton therapy
on the one hand, and isotope production and
neutron therapy on the other hand . Although
many dedicated accelerator facilities for medical
applications have been constructed, medical facil-
ities at nuclear physics installations have previ-
ously been added on as an afterthought and have
often been inadequate, inefficient or inconve-
nient as clinical centers.
Operation of the Facilities
The layout of the radiation areas is shown in Fig-
ure 1. All the major facilities, with the exception
of the neutron therapy unit (Elven Precision Ltd.,
Crawley, U.K.), were designed locally. They
include a solid-pole light-ion injector cyclotron
(SPC1) and a variable-energy separated-sector
cyclotron (SSC), capable of accelerating protons
to amaximum energy of 200 MeV, while a heavy-
and polarized-ion injector cyclotron (SPC2) is
nearing completion and should be fully opera-
tional by August 1994 .
A6MVCNVan de Graaff accelerator (located
in a separate building), which has been in use for
more than 30 years, is utilized mainly for applied
research . The medical complex includes three
.:
"NA,
W,"~, i:'V
	
-as 0
_
0 ME
MM
MINE 0
00"
-,
MMM~ MEN
" : mom
P1 P2
ECR ION SOURCE
ISOTOPE
PRODUCTION
W
E
Fig . 1 . Layout of the NAC radiation areas . The isocentric
neutron therapy unit is located in vault N, while the horizon-
tal proton therapy facility is located in vault P1 . Vault P2 is
radiotherapy treatment vaults, laboratories, offices,
patient service areas, full medical physics and radio-
biology facilities (including provision for experimen-
tal animals) as well as a 30-bed on-site hospital . One
of the treatment vaults (N) contains the p(66)Be
isocentric neutron therapy unit on which more than
600 patients have been treated, while the 200 MeV
horizontal beam proton therapy facility occupies a
second vault (Pl) . A second proton therapy beam
line (possibly isocentric) is foreseen for the third
vault (P2) . Operating theaters are located close to
this vault for use in possible future intraoperative
proton therapy procedures .
At present proton therapy takes place only on
one day of the week while research, development
and quality control procedures on the proton
therapy facility are undertaken the previous night
after the energy has been changed from 66 MeV
to 200 MeV The rest of the available beam time is
taken up by radioisotope production with 66 MeV
proton beams (two nights), neutron therapy (3
days), and physics research (weekends) .
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empty at present . SSC : separated-sector cyclotron, SPC1 :
solid-pole cyclotron #1, SPC2 : solid-pole cyclotron #2
All patients, including those from other parts of
the country and from neighboring territories, are
referred to theNAC through either Groote Schuur
Hospital (University of Cape Town) or Tygerberg
Hospital (University of Stellenbosch) . Both teach-
ing hospitals are about 25 min by road from the
NAC. They treat more than 5 000 new radiother-
apy patients annually. At present all patient assess-
ment and treatment planning is undertaken at the
hospitals . Although most patients are housed in
the on-site hospital for the duration of their treat-
ments, others attend as out-patients .
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The Proton Therapy Unit
The proton therapy facility can at present only be
used for the treatment of head and neck lesions .
It consists essentially of abeam delivery system, a
treatment chair linked to an automatic position-
ing system and various field verification devices.
A schematic layout of the existing beam deliv-
ery system, which was originally developed (in
conjunction with the NAC's Accelerator Group)
for crossfire plateau irradiations, is shown in Fig-
ure 2. The beam line is 1.25 m above floor level.
Most of the components are mounted on bearings
on a precision optical bench and their positions
can easily be changed . Furthermore, they can be
retracted from and inserted into the beam by
remotely-controlled pneumatic pistons. The total
distance between the vacuum window and the
isocenter is 7 m.
The proton beam exits the vacuum through a
0.025 mm thick Havarwindow. Adouble scatterer
plus occluding ring system [12] is used to flatten
the proton beam . The beam delivery system is
designed for a maximum field diameter of 10 cm.
The first scatterer (#1) is located immediately
downstream of the vacuum window and is a 1 mm
thick lead plate. Theoccluding rings (50 mm thick
brass) are mounted on the second scatterer (#2)
which is a 1 mm thick brass plate. This assembly is
located 2.9 m downstream of the first scatterer.
The central stopper has a radius of 1.34 cm, while
the inner and outer radii of the concentric ring are
2.42 and 3.61 cm, respectively. This beam spread-
ing system is currently used for all field sizes.
The double scattering system being used is
extremely sensitive to beam positioning and it
was found essential to install an automated con-
trol system . The beam is controlled by two com-
puterized feedback systems acting on two sets
(#1 and #2) of xy steering magnets. The first
feedback system uses a multiwire ionization
chamber (MWIC#1) with 2mm resolution which
monitors the beam position in the x and y di-
rections perpendicular to the beam axis . The
steering magnets (set #1) for this system are lo-
cated 2.8 m upstream of MWIC #1. The second
feedback system uses the signals from a quadri-
segmented transmission ionization chamber
which monitors the beam symmetry and is lo-
cated close to the patient. This second feedback
system operates on the downstream steering mag-
nets (set #2). The first feedback system uses
information from the MWIC (#1) located
between these two latter steering magnets and
ensures that the beam is aligned with the beam
axis at this point. This dual feedback system en-
sures a very stable and symmetrical beam. A sec-
ond MWIC (#2) with 3 mm resolution is installed
in front of the occluding rings and is only used to
display the beam profile at this point. The seg-
mented ionization chamber system (Lawrence
Berkeley Laboratory, California) also includes an
electrode made up of 12 concentric rings which
provides information on the beam profile assum-
ing azimuthal symmetry.
There are 3 antiscatter collimators (#1, #2,
#3) in the beam as shown in Figure 2. The front
face of the final (patient) collimator (#4) is lo-
cated 27.5 cm upstream of the isocenter. Fixed
inserts, which can either be custom-made or of a
standard shape, fit into the final collimator
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Fig . 2. Layout of the 200 MeV horizontal proton therapy
beam modification system . The drawing is not to scale, but
all the beam line components are shown in their approx-
imate positions
assembly which can rotate around the beam axis
in order to align non-circular collimators with the
planned treatment field. This assembly cannot be
moved closer to the isocenter, as it will get in the
way of the cameras of the patient positioning sys-
tem (see below) . The collimator inserts are made
of brass (5 cm thick) or low-melting-point alloy (6
cm thick) . Front- and back-pointer lasers and a
field-defining light are used to indicate the beam
axis and to project the shape of the final colli-
mator onto the patient, respectively. Lateral
lasers are also provided . There are mounting
posts at various positions along the beam axis for
locating a theodolite, which is used for precise
alignment of the beamline components and for
accurately checking the patient position if
required . A coaxial X-ray tube can be mounted
close to the patient collimator and is used for
verification of the treatment fields .
A dual transmission ionization chamber sys-
tem (#2) (5 [,m thick aluminized mylar foils, 5
mm separation) located immediately upstream of
the patient collimator is used to monitor the dose
delivered . Redundant dose information can also
be obtained from the segmented ionization cham-
bers . A single transmission ionization chamber
(#1) (5 Rm thick aluminized mylar foils, 1 mm
separation) located immediately downstream of
scätterer #1 is used for experimental purposes
and to provide the reference signal for dose distri-
bution measurements . All these monitors are
filled with ambient air.
The transmission ionization chambers used for
dose monitoring are calibrated against air-filled
A-150 tissue-equivalent ionization chambers
according to the Supplement of the "Code of
Practice for Clinical Proton Dosimetry" ([13, 14],
see also Chapter 26) . Dose rates which are used
clinically are about 3 Gy/min . To achieve this dose
rate in the plateau region of an unmodulated
beam (dose measured at a depth of 5 cm in water)
a beam current of about 15 nA is required . The
total mass in the path of the beam between the
vacuum system and the isocenter is about 2.0 g/
cm 2 corresponding to an energy loss of about 9
MeV for a beam with a nominal incident energy
of 200 MeV Since the beam energy cannot be
reproduced exactly week by week, plastic range-
trimmer plates, 0.6 mg/cmZ thick, are placed on
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collimator #1 in order to routinely produce a
residual range of 24 cm in water (distal 50
level) for patient treatment. For spread-out Bragg
peak (SOBP) therapy, additional acrylic range-
shifter plates are manually inserted just upstream
of collimator #1 to achieve the required range.
Wax compensators, to correct for oblique inci-
dence in SOBP treatments, are sometimes used .
They are mounted on the downstream face of the
patient collimator. With existing hospital planning
systems only rudimentary heterogeneity correc-
tions can be made, so distal edge compensation
has not yet been implemented . Microswitches
sense whether the movable beam line compon-
ents are in their correct positions and this infor-
mation is interlocked with the safety system . A
bar code system to identify and verify treatment
field specific components such as collimator, pro-
peller (see below), range shifters etc. is under
development.
Figure 3 shows a typical isodose curve for an
unmodulated 10 cm diameter beam with a resid-
depth [cm]
5.00[-
10.001-
15.00-
20.00-
25.O OLEL~
-8.00 -4.00 0.00 4.00 8.00
crossplane [cm]
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Fig. 3. Isodose distribution measured in water with a 0.01
cm3 tissue-equivalent ionization chamber in an unmodulated
proton beam with a 10 cm diameter collimator. The 10 % to
90 % isodoses in 10 % steps are shown
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Table 1 . Beam data for an unmodulated proton beam with a 10 cm diameter collimator
? v tt(u(yii~;
~
')Over 80 % offield size ')Between 50 % dose levels
ual range of 24.5 cm. The full width at half-
maximum (FWHM) of the Bragg peak is 2.4 cm,
while the 90-10% and 80-20% distal fall-offs are
0.60 and 0.40 cm, respectively. The entrance to
peak ratio is 0.28 . Information about the flatness,
symmetry and penumbrae for this beam is given
in Table 1.
For SOBP therapy the Bragg peak is spread
out longitudinally by using a "propeller" made up
of different thicknesses of acrylic and which is ro-
tated in the proton beam [15] . The propellers are
designed on the basis of measurements of the
attenuation of a monoenergetic beam in different
ae
Fig. 4. Proton depth-dose curves measured in water with a
0 .01 cm3 tissue-equivalent ionization chamber in range-
modulated proton beams with 10 cm diameter collimators .
The calculated contributions of the individual range-shifted
monoenergetic curves which are used to design the modu-
lator propellers are also shown . The Bragg peaks are spread
out over 4.5 cm and 11 cm (90% dose level), respectively
9.84
9.75
9.63
9.41
8.85
thicknesses of acrylic placed at the position of the
propeller. Figure 4 shows measured 4 .5 and 11 cm
SOBPs (90% dose level) together with the calcu-
lated contributions from the individual monoen-
ergetic range-shifted curves . The dose uniformity
over the flat regions is ± 1.0 % .
Several radiobiological [16,17] and microdosi-
metric [18,19] measurements have been made in
both monoenergetic and modulated 200 MeV
proton beams. Proton dosimetry intercompari-
sons have been undertaken at various overseas
centers [20, 21]. The results obtained by the dif-
ferent participants with tissue-equivalent ioniza-
tion chambers agree very well . Dosimetry and
biological intercomparisons have recently been
undertaken at NAC with groups from Louvain-la-
Neuve, Belgium and Tsukuba, Japan [22,23] .
These latter data are still being evaluated, but
early indications are that the results obtained are
excellent . For example the RBEs, based on the
mouse jejunal crypt cell assay, were found to vary
from 1.11 in the plateau region to 1.23 at the distal
edge of the SOBP [23], consistent with earlier
measurements in other proton therapy beams
[24] .
The patient support and positioning system
[25,26] used at the NAC was jointly designed by
the Departments of Mechanical Engineering and
Surveying and Geodetic Engineering of the Uni-
versity of Cape Town. A special feature of the
treatment "chair" (in which the patient can
assume any position from sitting upright to lying
down) is that it can retract completely beneath
the floor. Atrolley which runs on a set of rails can
quickly and accurately be positioned over the
0,(iü7,l1) k"'%, l
l I
(on :.
%lüi
<<3lil)j
2.2 1.0 0.6 0.36 0.22 10 .23
7.4 0.7 0.4 0.54 0.33 10 .31
12.6 0.5 0.3 0.76 0.47 10 .38
17.8 1.4 0.6 1.09 0.69 10 .43
24.2 (peak) 3.0 0.3 1.57 1 .02 10.48
chair. There is also a set of rails on the trolley
itself which enables dosimetry equipment (e.g.,
water phantom) to be accurately located on the
trolley. There are several "parking bays" in the
treatment room for storing the dosimetry equip-
ment when not in use and from which the equip-
ment can be wheeled directly onto the trolley.
The patient positioning system makes use of
real-time stereophotogrammetric (SPG) tech-
niques and is linked to the patient support system
(chair) which is a computerized adjustable system
with 5 degrees of freedom (3 translations, vertical
rotation, backrest rotation) . When a patient
undergoes a CT scan to locate the treatment vol-
ume, small radiopaque reference targets (1 mm
diameter ball bearings) are affixed to a custom-
made plastic mask which fits the patient's head
precisely. From the scan three-dimensional co-
ordinates for all the targets are determined rela-
tive to a reference point in the treatment volume .
This reference point is normally taken as the
treatment isocenter. Retroreflective markers
8 mm in diameter are then fixed accurately on the
mask exactly over the radiopaque markers . A
close-fitting back section is made for each
patient's mask and fixed to the fully adjustable
chair headrest . In order to compensate for the
chair's lack of a roll motion, the patient's head
often has to be tilted slightly from the vertical to
allow positioning to be accomplished .
During the patient positioning stage, a set of
three charge-coupled device (CCD) TV cameras
capture video images through a frame grabber of
the retroreflective markers on the patient mask.
These images are then analyzed by a personal
computer using SPG techniques . Since the posi-
tions of the video cameras andthe direction of the
proton beam are accurately known in space, it is
possible to calculate the position of the reference
point in the treatment volume, relative to the
beam axis . The effects of camera distortions,
aspect ratio and perspective are taken into
account in the calculations . The co-ordinates of
the beam entry point are also required and are
obtained from the treatment planning program.
Spatial corrections to align the vector between
the beam entry point and the reference point (iso-
center), with the beam axis are then sent from the
SPG computer to a second personal computer
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which controls the chair. Computer-controlled
stepper motors move the chair by the required
amounts (x, y and z translation accuracy is within
0.1 mm; vertical and backrest rotation accuracy is
within 0.1°) to bring the treatment vector directly
into the proton beam. Additional information
regarding the rotation angle of the final patient
collimator is also calculated by the first (SPG)
computer. The collimator angle is at present
manually set. It takes typically 2-3 iterations
from an arbitrary location to align the patient in
the required position .
Once the patient is properly positioned,
according to preset tolerances of the beam entry
point, tumor and reference targets (normally
0.5 mm) the position is checked by means of the
front- and back-pointer lasers or with theodolites .
This can be verified, and the collimator rotation
angle checked, by means of a double-exposure
coaxial portal X-radiograph ; one exposure is
taken with the collimator out of the beam to show
the anatomy while for the second exposure the
collimator is in position to show its outline and
orientation. For this second exposure the X-ray
tube is moved upstream so that, if required, the
magnification can be matched to that of the ana-
tomical exposure . A typical such radiograph is
shown in Figure 5. If everything is correct, the
system is set to monitor the positions of all the
reflective targets and hence the position of the
reference point in the treatment volume as well as
the beam entry point. The beam can then be
switched on and will be switched off automati-
cally if any of these points moves by more than a
preset amount (normally 1 mm) .
A total of eight CCD video cameras are posi-
tioned approx . 2.5 m from the isocenter at differ-
ent angles symmetrically around the beam line .
Only three cameras can be used at a time and
they must find at least three reflective targets,
common to at least two cameras. A calibration
frame with retroreflective targets of which . the
three-dimensional co-ordinates have been accu-
rately surveyed relative to the beam axis is placed
over the isocenter and is used to fix the positions
of the eight cameras in space. The calibration
frame can be placed accurately and reproducibly
in its surveyed position to facilitate the camera
calibration procedure. A second accurately

Table 2. Proton treatment details (30 June 1994)
Summary
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mising the other main NAC activities . Another
constraint is the time taken to change beam
energy (which is approx . 2.5 hours on average at
present) .
As soon as more beam time can be made avail-
able for proton irradiation, more sophisticated
fractionated treatments are foreseen . These will
include larger tumors of the brain and base of
skull, e .g ., craniopharyngiomas and chordomas,
as well as boosts to head and neck tumors like the
tonsil, antrum, orbit and thyroid. In addition,
modification of the patient support and beam
delivery systems will enable boost doses to be
given to pelvic tumors like the prostate, rectum,
cervix and anus . Furthermore, because of the
unparalled facilities available at the NAC, proton
boosts of neutron treatments are possible and
such treatments, possibly for the first time in the
world, will commence shortly. Since it is a very
rare disease in South Africa it is not a viable pro-
position to develop a dedicated beamline for the
treatment of ocular melanomas.
The neutron therapy clinical program continues
to accrue 120 -130 patients annually and provides
a significant proportion of the current world-wide
neutron therapy patient load . With its constant
patient accrual and reliable operation the NAC's
neutron therapy unit is an extremely viable facil-
ity and will doubtlessly provide significant input
into defining the role of this modality.
The unique stereophotogrammetric patient
positioning system ensures precise, reproducible
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and quick patient set-up for proton therapy of
intracranial and head and neck lesions. Further-
more, since it is a non-invasive procedure, frac-
tionated treatments can be routinely given. Prep-
arations for patient treatment are, however, time-
consuming and efforts will be made to
streamline this . Possible improvements which will
be investigated include the manufacture of a
multileaf collimator system and the use of bite-
blocks carrying a standard co-ordinated frame for
patient fixation and positioning .
Because of the small, but significant increase
in RBE with depth along the spread-out Bragg
peak, it may be necessary to optimize the thera-
peutic advantage of the beam by designing the
modulation propellers to give a uniform bio-
logical dose across the SOBP as is done with
heavier ions . The nearly DC nature of the cyclo-
tron beam makes the implementation of beam
scanning much less demanding than with slowly-
pulsed synchrotron beams and investigation of
such a beam-spreading system is warranted .
Within a few years it is hoped to install another
proton beam delivery system in the third treatment
vault. This could be isocentrically mounted and
would permit intraoperative therapy as operating
theaters have been built in close proximity. It is
interesting to note that with some very minor
alterations both the Loma Linda University Med-
ical Center's cork-screw gantry and the Paul Scher-
rer Institute's compact gantry (for details cf . previ-
ous chapters) can be accomodated in this vault.
Because of its unique position as the only par-
ticle therapy facility in Africa and in the Southern
Hemisphere, its superb facilities and on-site tech-
ll(())~1)I' (Olnr ~\ i6Unnl,nXc`ir
Braiii nietastasis 10 0.6-10.6 18 Gy/125 Gy/2 1-4
Mmingionla 4 8.0--36 .0 12 Gy/2-34 Qy/3 2-4
Arteriovenous mal- 5 3.8--43 .0 14 Gy/3-34 Gy/2 3-5
formation
Acoustic neuroma 13 .6 24 Gy/3 4
Skull base tumor 9.2-25 .0 21 Gy/3 4-5
Glioma 6.6-33.0 15 Cry/3- Gy/4 1-,5
Pituitary adenoma 1 1.1 60 Gy13 4
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nological and scientific expertise, the excellent
medical services available at the local referring
hospitals, and the wide spectrum of clinical mate-
rial available in the region, there is no doubt that
the NAC is destined to play a major role in deter-
mining the future role of both high-energy neu-
trons and protons in radiation treatment.
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Ophthalmological Proton Facilities
A. KACPEREK
Introduction
Douglas Cyclotron Unit, Clatterbridge Centre for Oncology (CCO), Wirral, United Kingdom
At the time of writing, over 5000 patients have
been treated with protons for ocular lesions . Cen-
ters which are active in this work within the
western hemisphere are shown in Table 1. Most of
these treatments have concerned uveal melanoma
which is a relatively rare condition but still repre-
sents a significant workload for the small number
of proton therapy centers. Other ocular and
extraocular conditions including choroidal haem-
angiomas or retinal blastomas are also being
treated at some of the centers.
The efficacy of proton treatment may be
gauged from the number of new centers and
those at the planning stage. Most proton therapy
facilities are located in nuclear research centers,
but Clatterbridge (CCO) and Loma Linda
(LLUMC) are hospital-based facilities .
Table 1 . Active proton eye therapy centers excluding Russia, up to September 1994
1ly.~i 006kor i~7i( <~ IOÖOI(~1Qlltü
* June 1994
	
** facility has vertical beam line
Much of the pioneering developmentwork has
been carried out in the USA [1, 2] at Harvard
(HCL) and Berkeley (LBL) and in Switzerland at
the Paul Scherrer Institute (PSI) [3]. Their
designs have influenced treatment beam line
development in most centers. Some design differ-
ences have evolved, mainly in response to local
factors, influencing beam production techniques
and resulting in variations in the physical parame-
ters . Hence, no two facilities are identical.
The following sections will illustrate the com-
mon features of treatment centers as well as the
differences in construction, beam flattening,
range modifying devices and patient position
recording . Much of the physical data, where
kindly made available, are obtained by local mea-
surement techniques . Therefore, a direct compar-
ison is not appropriate, although these data can
be considered a basis for informed discussion .
Intraocular treatments
deep-sdated tumox
neutron therapy
deepaeated tumors
deep-seated tunaors
neutron therapy
deep "seated umors
neutron therapy
deep-seated tu rnors
neutron therapy
none
HCL Cambridge USA 2061 1975
LAIRS **Chiba Japan 40 1979
PSI Villigen Switzerland 1700 1984
TSL Uppsala Sweden 20 1989
CCO Clatterbridge UK 550 1989
LLUMC Loma Linda USA 32. 1990
CAL Nice France 410 1990
CPO Orsay France 450 1990
LLN Louvain*** Belgium 8 1991
UCD Davis USA 4 1994
100
80
(b) 80
40
20
lateral penumbra In water, mm
E
4~ -4
28 29 30 31 32 33
range In water, mm
ATumour volume
B Margin for tumour spread
0 Positional uncertainty
D Physical penumbra
Edge of aperture
range margin
E Range margin
F Distal fall-off
Fig. 1. Sketches showing the components of a) lateral and
b) range margins
Proton eye therapy permits the use of a single
port treatment to irradiate a defined target vol-
ume whilst sparing sensitive eye structures and
skin surface. The precise conformation of the
high dose region to the target volume, which may
be of several cubic centimeters, necessitates accu-
rate localization of the tumor and reproducible
patient positioning for each treatment fraction .
38 Ophthalmological Proton Facilities
	
361
The target volume consists of a defined tumor
volume and a margin. The size and composition
of this margin has been discussed by Goitein and
Miller [4] and is illustrated in Figure 1. It consists
principally of:
1. lateral penumbra and distal fall-off
2. microscopic tumor spread
3. estimated positioning precision
and movement during treatment
The first factor is dependent on the beam charac-
teristics specific to each facility. Tumor spread is
thought to be about 1 mm beyond the edge of the
tumor volume, although anecdotal evidence sug-
gests that this spread may be greater for larger
tumors. The third factor depends on the patient
stillness, the stability of the chair construction
and the immobilization device.
This is a simple description and it may not
appropriate to adopt concepts and terminology
used in mainstream radiotherapy [5] . For exam-
ple, some ophthalmological centers define only
visible tumor whilst others include cellular
spread . Therefore, each treatment facility must
be aware of the biological and physical factors
affecting the volume to be treated and select
appropriate margins.
Beam Characteristics
Five centers participated in a comparison of mea-
sured beam characteristics. Measurements were
made at the therapy position of a patient eye,
using local scanners and measurement devices as
shown in Tables 2 and 3.
Table 2. Penumbra measurements using a 20 mm collimator. The modulated beam was of approx . 30 mm range and 18 mm
modulation
(	Udl ovKwc ;),r IhXaoitie}
1.40 0.80 1 .60 1.10 MC459
PSI 0.90 0.60 1 .60 1.10 1N4007
CCb 1.05 0.65 1.75 1.10 BPW34
CAL 1.60 1.00 2.40 1.50 BPW34
CPO 1.15 0.70 1 .90 1.25 1N4006
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Table 3. Distal fall-off measurements for pure Bragg peak and modulated depth-doses
IC =ionization chamber PPC = parallel plate chamber
Lateral penumbra and distal fall-off character-
istics were measured for the case of an unmodu-
lated full energy beam and a spread-out Bragg
peak (SOBP) beam which would be used for eye
therapy. The measurements were performed with
a 20 mm diameter final collimator in water or by
using plastic absorbers . In the latter case, results
were corrected to water depth using simple den-
sity correction .
Profiles
The transverse beam measurements of the full
energy and modulated proton beams were per-
formed in the horizontal direction only. For clar-
ity, the scans are shown separately for each facil-
ity in Figure 2. The lateral profiles of the SOBP
were obtained by scanning across the middle of
Table 4. Beam line characteristics of eye therapy centers
the constant dose region, which corresponds to a
range of approximately 21 mm. The air gap was
the same in both measurements .
Clearly, the penumbra estimations are influ-
enced by the choice of the normalization point.
No definition of appropriate beam flatness is pro-
posed but it is remarked that the data in Figure 2
show a deviation of better than ± 3 % over 80
of the central incident field. The slight depres-
sions in the CCO and PSI profiles may be due to
attenuation by axial cross-wires. The beam line
parameters which affect the beam penumbra are
shown in Tables 4 and5. The use of X-ray verifica-
tion film may provide a relatively simple means of
comparing profiles of full-energy, unmodulated
beams, which is of limited value. Ionization den-
sity effects would preclude the accurate use of
film for profiles in modulated beams.
üW
01W1,11
inold
* distance between the beam flattening foil(s) and the patient collimator ; for double-foil systems measurement is
from the second scatter foil
** 11 .6 cm used to reduce initial beam energy
HCL 3.40 2.45 4.40 2.90 diode RET2
PSI 1.10 0.75 1.20 0.90 diode; 1N4007
CCO 0.90 0.50 0.90 0.75 diode; BPW34
LLUMC 1.60 1 .20 1 .70 1 .66 PP (home)
CAL 0.80 0.75 1.28 0.90 diode; BPW34
CPO 2.30 1 .55 2.80 1 .80 IC, 0.14 cm3,
(Wellhofer)
2.00 1 .40 2.30 1 .50 IC, PPC (NACP)
HCL 160 69 single, Lexan* 1100 1260 1,685
PSI 72 61 single, Pb 1435 1445 1600
CCO 62.5 62 .5 double,W 1450 1250 1410
TSL 200 72 double, brass 1765 470 2350
LLUMC 250 100 single, Pb 1120 1294 1669
CAL 65 65 single, Ta 8000 1930 2040
CPO 200 76 .1 single, Pb 1480 2060 2410
Table 5. Modulator characteristics of centers
*
	
18-segment adjustable propeller; range shifter and modulator combined
** includes Cu-inserts for anterior sparing
*** range shifters < lmm are ofAl foil
**** system of sliding wedges
CCO, Clatterbridge HCL, Cambridge
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Solid curve = profile of modulated beam .
Dashed curve = full energy beam .
Air gap the same in both cases.
Scans performed at treatment position
of eye.
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Fig. 2. Lateral scans of modulated
(solid line) and unmodulated
(dashed line) therapy beams
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HCL propeller Lucite 6-9 Lucite continuous 38
PST propeller* Al** continuous Al continuous 34
CCO propeller Perspex 0.84 Perspex*** 0.20 34
TSL propeller polystyrene 1.25 polystrene continuous*** 50
LLUMC propeller polycarbonate U-2.0 Lucite continuous 30
CAL propeller Perspex 0.84 Perspex 0.20 34
CPO propeller Lucite 1 .00 Lucite 0.10 40
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Depth-Doses
Figure 3 shows the SOBPs measured from five
centers. The distal fall-off measurements and
devices used are presented in Table 3 . All mea-
surements were carried out with plastic absorbers
and corrected to water-equivalent depth. The
entrance doses varied between 62 and 75 %. The
fall-offs are greater in the case of SOBPs than for
the pure Bragg peak depth-doses since there is a
contribution to the primary, least absorbed peak,
from the second Bragg peak. For 80 % of the con-
stant dose region, the deviation is less than
+2%.
Fig . 3 . Modulated proton depth-doses
for eye therapy. Normalized to mm in
water
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It must be emphasized that these data are pre-
liminary and drawing significant conclusions is
not appropriate. Their quality depends on the
measurement devices, some of which are indi-
cated in the tables . However, the data constitute
a first step in defining beam qualities between
proton therapy centers.
The effect of the positioning of beam modifying
devices has been studied [6-8] and reviewed by
Gottschalk [9]. Various parameters affect the
final beam quality including:
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1. distance from scattering (homogenizing) foils
to exit,
2. distance from range modifying devices to exit,
3 . amount of gross energy degradation,
4. distance traveled in air of proton beam,
5 . in-beam devices (e.g ., parallel-plate cham-
bers, cross-wires, vacuum windows) .
Factors 1 and 2 affect the beam divergence . In 3,
gross range absorbers, which reduce high energy
beams to approximately 70 MeV can be shown to
affect the range straggling, hence the width of the
Bragg peak . Factor 4 causes energy loss of
approximately 1 MeV/m in air at 65 MeV which
is an important consideration for centers limited
in maximum beam energy.
Scattering Foils and Beam Flattening
The use of thin foils of high atomic number to
produce beam flattening by scattering is common
as shown in Table 4. Multiple Coulomb scattering
of protons is approximately proportional to the
square root of the atomic number, the thickness
of the material and the reciprocal of the incident
proton energy. The resultant, approximately
Gaussian, lateral proton distribution is trimmed
by the primary collimators, leaving a small central
portion sufficiently uniform for therapy use. A
longer effective source distance would improve
flattening at the expense of beam intensity. Beam
defocusing, prior to the scattering foil, has been
used additionally to improve uniformity. It is
widely recognized that the single foil technique is
relatively insensitive to beam steering drift but at
the cost of some beam range loss and intensity-to-
dose efficiency.
For centers limited in maximum energy or
beam intensity, a double scattering foil technique
was discussed [9, 10] . This technique uses two
very thin foils with an occluding stopper on the
second foil, however, the resultant beam unifor-
mity is more susceptible to beam steering drift.
The Svedberg Laboratory (TSL) at Uppsala has
adopted a non-uniform second scattering foil for
their eye therapy beam line [11, 12].
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Checking and Safety Procedures
Apart from dosimetry checks, each center has
also different checks and priorities . Thefollowing
items are common in many centers:
modulator speed detector and range shifter
check,
detection of film holder or other equipment
temporarily in beam,
collimator check,
treatment emergency stop button .
Abar code system based on checking that the
correct patient mask, collimator and modulator/
range shifter combination is used at the Loma
Linda University Medical Center (LLUMC) .
Unenclosed beam lines may require measures to
ensure no occlusion of the beam. At some cen-
ters, the accelerator is used to provide proton
beams at high beam currents for other purposes,
e.g ., neutron therapy or radioisotope production .
Different methods have been adopted to avoid
high proton dose rates, e.g ., the CCO has a
power-limited ion source supply, PSI has an addi-
tional upstream scattering foil which reduces the
beam current by 90% [3] .
Patient Positioning
and Observation During Treatment
A close-circuit television camera (CCTV) with
close-up lens is used at an angle to the beam axis
to observe the eye during treatment. To improve
image contrast and minimize patient distraction,
some centers use infrared lighting conditions (cf.
Table 6) . The most effective camera position to
detect eye movement is along the eye gaze axis at
a similar position to the LED fixation light. This
is employed at facilities having long nozzles or
extended collimator tubes, e.g ., HCL and TSL.
Alternatively, viewing via a mirror down the
beam line is used but requires the collimator to be
sufficiently large to observe the eye features [3] .
Perforated thermosetting mask material (e.g .,
Aquaplast or Orfit) is used by most centers to
immobilize the patient head . It has the advantage
of rapidity and is reusable [13] . The bite-block
366
	
A. Kacperek
Table 6. Various parameters related to patient treatment
consists of common dental compound mounted
on an aluminum plate, which is attached onto the
mask holder which in turn is attached either onto
the patient chair or the therapy beam line . The
TSL at Uppsala uses an adjustable U-shape
restraint with an adjustable forehead strap [11] .
The standard treatment chair moves in three
orthogonal directions ; some chairs have a further
independent adjustment for patient height where
the mask holder is attached to the chair. The
chairs also have rotation around the vertical axis
and an angular adjustment to the mask holder.
Several facilities have extra degrees of freedom
such as chair tilt (at CPO and TSL), which are
used for eye and other treatment modalities .
Polaroid, and in some cases image intensifiers,
provide images of the radio-opaque tumor and
beam cross-wires. The amount of position cor-
rection is decided by comparing images with an
overlay generated by the EYEPLAN program as
shown in Figure 4. If the treatment is interrupted
further position films are taken . The final hard-
copy is used for patient documentation . Non-clip
treatments use field light positioning or laser
lights with prescribed landmarks . Verltcy et al .
[13] have measured a mean eye movement during
treatment of 0.5 mm ± 0.3 mm . At the CC:O the
uncertainty of the positioning check is estimated
subjectively at 0 .25 mm, mainly due to film and
overlay resolution . Similar estimates have been
made at the CPO [14] . The degree of patient
movement encountered at each facility is a com-
bination of factors which include the immobiliza-
tion devices, the chair rigidity, patient condition
and efficacy of the eye-monitoring device .
A LED (light-emitting diode) mounted on an
azimuthal stalk provides the direction of patient
gaze which has been determined from the plan-
ning program . For patients with poor vision in
both eyes some centers use personalized contact
lenses acting as eye suction devices to control the
gaze direction . If healthy eye fixation is used,
non-parallel vision may cause an apparent shift in
gaze angle. This is usually observed at simulation
and corrected for at the therapy planning stage.
a a
Fig. 4. Axial views of patient clips, collimators, cross-wires
and tantalum clips . On the right are the EYEPLAN generated
overlays used for positional checks
Center Isocenter Height above Image recording Monitoring during Head restraint Dental bite
mm floor mm method treatment block
HCL 70 1335 Polaroid with video infrared light, CCTV mask with back yes
LAIRS 50 vertical beam X-ray film CCTV mask only no
PSI 70 1550 Polaroid infrared light, CCTV mask with back yes
TSL 70 1500 Polaroid normal light, CCTV head strap yes
CCO 70 1520 Polaroid normal light, CCTV mask with back yes
LLUMC 70 1500 Polaroid infrared light, CCTV mask with back yes
CAL 70 1455 Polaroid normal and infrared mask with back yes
light, CCTV
CPO 70 1400 X-ray film infrared light, CCTV mask yes
Planning Program
EYEPLAN is an interactive, three-dimensional
therapy planning program which was developed
at the Massachusetts General Hospital for eye
tumor therapy using either proton beams [4] or
radioactive plaques. Subsequently, improvements
were made at PSI [15] . Further development, par-
ticularly in ease of use and the modelling of eye-
lids has been made at Clatterbridge [16] .
The EYEPLAN program serves to create a
model of the patient eye and of the size and loca-
tion of the tumor. Following simulation, the pro-
gram allows the planner to determine the limits of
eye fixation angle and finally to optimize the
treatment plan for an individual patient. The
computer eye model is constructed from physical
measurements of the eye such as the eye-axis
length, limbus and lens diameter. The position of
tantalum (Ta) scleral clips geographically locates
the tumor on the choroidal surface using mea-
surements obtained at time of surgery. Their
number can vary from three to five depending on
tumor size . The clip positions on the patient
simulation photographs are entered into the
EYEPLAN program either manually or, much
more conveniently, by using a high resolution
digitizer pad (accuracy < 0.1mm).
The tumor base dimensions and shape are
deduced from clinical fundus photographs, clin-
ical drawings and ultrasonography. Whilst this
may not affect directly tumortreatment, an incor-
rect model will cause unwitting irradiation of
healthy eye tissue . Ultrasound, CTand MR imag-
ing are used to provide patient eye and tumor
information. Patient MR eye scans with Ta clips
are performed at the CCO when clinical data are
inconsistent . The program can incorporate differ-
ent densities for the components of the eye
although this option has not been implemented
by any center. At present, single whole eye den-
sities of either 1.00 or 1.05 are assumed, based on
the densities of individual eye components
including the lesion [17] .
Wedges, made of aluminum or plastic, are
used by many centers, mainly to reduce the
irradiated volume within the eye and, less fre-
quently, to minimize dose to sensitive eye struc-
tures . Up to two wedges can be incorporated into
optic n
38 Ophthalmological Proton Facilities
	
367
RANGE . 28.1 mm RANGE MODULATION , 12 .4 mm
PLANE , IN BEAM AT 90 DEG. X-O.O .Y-0 .0 .2-0 .0
lens
wedge
eye-axis
Fig. 5. EYEPLAN horizontal views of isocontours with (a)
and without (b) wedge.
a patient plan (Fig . 5) . In situations where eyelids
cannot satisfactorily be retracted, one or both
eyelids can be modelled with a variety of geo-
metrical shapes . The range and modulation is
recalculated for every adjustment of wedge and
eyelid shape. Some measurements of the effect of
wedges have been performed at PSI [3] and Clat-
terbridge [18] .
Boluses, of toughened dental wax, are some-
times used to provide a flat surface in regions of
irregular geometry, e.g ., at the inner canthus.
At present, many centers employ DigitalVAX
computers with a VMS operating system . Color
graphics terminals such as the Tektronix 4105A,
to visualize both images and text, are used or are
emulated for instance, on a M4400 (Microcolour
Graphics) terminal . At Clatterbridge, a DEC
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Alpha (Model 2000/300) workstation has been
installed for eye planning, giving a five-fold speed
increase over the previous Micro VAX II . PSI
uses a VAX 4000/60 for planning with an X-
windows environment .
Treatment of Superficial Eye Lesions
Several treatments involving superficial regions in
the eye have been performed which do not use
radio-opaque markers . Presently, they include iris
melanomas and tumors of the conjunctiva.
These treatments are given by means of field
light or laser light localization . For iris melano-
mas care is taken to minimize irradiation of the
ciliary body; this can be done by reducing the pro-
ton range to a depth of a few millimeters. Proton
treatments of the conjunctiva have been given as
a boost to electron therapy. At Centre Antoine
Lacassagne (CAL) at Nice, a novel, hemispher-
ical compensator has been proposed for the con-
junctival treatments, which permits superficial
irradiation of the uvea behind eyelids [19] . PSI
uses simple boluses to protect the lens . The very
short ranges and sharp fall-offs obtained using
deuterons (requiring little in-beam absorbers,
hence sharper fall-off) of 37 MeVhave been dis-
cussed by PSI [20] .
Radiation Doses
Fractionation regimes vary from 4 fractions (fx) in
4days to 5 fx in 7 to 8 days, and were determined
originally by beam time availability especially
Table 7. Treatment details of eye facilities
r , G7 tUtOR0'(Y%
* indicates Cobalt-Grav equivalent
if a center had other treatments or beam time
users as in nuclear research facilities . Table 7
shows the prescribed doses at each center which
vary from 70 CGE (Cobalt-Gray equivalent) to
53.8 Gy.
Proton dose calibrations are performed either
directly by a standards laboratory or with a local
secondary standard which can be traced to a
national standards laboratory. The frequency of
such calibrations varies from 6 to 12 months . Meth-
ods such as calorimetry and Faraday cup dosimetry
are the subject of a separate chapter of this book
(Chapter 26) . Intercenter dosimetry comparisons
provide a check of dosimetry techniques used at
each center. Usually, groups of ionization chambers
are irradiated in the beam of the host center under
identical conditions . In addition, 'Co irradiations
may be performed to obtain local air-kerma values
and to check for any chamber performance changes
due to transport. In the future, other ways of inter-
comparing beam dose and quality may include ala-
nine dosimetry and film exposures, although these
methods are subject to non-linearity due to ioniza-
tion density effects.
Table 8 shows the checks practised prior to
patient treatment at the various facilities . The
checks reflect the machine characteristics at each
facility, e.g ., lack of proton energy or of beam
steering stability. Table 8 shows as well the in-
beam dose monitors which are calibrated for each
patient treatment . At least two devices are used
at each center. The choice of monitor is guided by
local criteria such as thin-walled ionization cham-
bers for low proton energy loss or SEMs to
minimize problems associated with pulsed beams.
HCL 50 or 70* 5 7-8 days 3 .0 2.5-3 .0 none
NIBS 70* 5 5 weeks 3 .0 3 .0 none
PSI 54.5 4 4 days 2.0 2 .5 aluminum, no
TSL 54.6 4 4 days 3 .0 2.5-3.0 plastic, no
CCO 53.1 4 4 days 2.5 2,5 (2.0) aluminum,
LLUMC 70* 5 7 days 3.0 3 .0 none
CAL 53.1 4 4 days 2.5 0--2 .5 Lucite, wax
CPO 54.5 4 4 days 2.5 2.5 Lucite, plastic
Table 8. Treatment beam checks
(oot'~x
(nn1C9~i
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PPC = parallel plate chambers
SEM = secondary emission chamber
Most centers have used copper or brass collima-
tors for low induced radioactivity and ease of
machining considerations . Several centers use
graphite primary collimators as the carbon causes
minimal proton scattering and the induced llC activ-
ity has a short half-life . Neutron shielding consisting
of iron or paraffin wax is used particularly near
beam scattering foils and primary collimators .
Measurements of patients at the CCO have
shown no neutron doses above 0.2 mSv and no
detectable photon doses using film badge dosime-
ters placed on the abdomen of the patients during
treatment, although an earlier beam line configu-
ration showed slightly higher doses [18] . PSI has
examined stray neutron doses in the proximity of
the patient head using superheated drop detec-
tors and have indicated doses of 1 mSv behind the
head andup to 16 mSv on the temple during a full
treatment course [21] . Patients completing treat-
ment hadinduced dose rates of less than 1 [,Sv/h .
Discussion
It is clear that interest in treating eye malignan-
cies with proton beams is growing rapidly. The
pioneering centers such as Harvard and PSI have
been a source of invaluable help to newerproton
treatment facilities . However, much valuable
information and experience from all facilities
remains unpublished.
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The advantageous conformal characteristics of
proton radiation require a precise knowledge of
the localization and shape of the tumor volume
and the dimensions of the treatment eye, all of
which is incorporated into the eye treatment plan .
The irradiation of healthy eye tissue is minimized,
where possible, by optimization of the patient
gaze angle, but is also dependent on selected
treatment margins of which the lateral penumbra
and distal fall-off of the beam are important com-
ponents.
There is a variation in the prescribed dose and
fractionation regime between the various centers
which may mean that the best dose and fractiona-
tion pattern is not yet determined . Also, this
makes precise comparison of patient outcomes
between facilities difficult to interpret.
This work provides a preliminary overview of
some physical parameters in the construction of
proton eye beam lines and their effect on the
therapeutic beam. Other factors affecting the pre-
cision of the treatments may differ at each center.
Most centers are subject to different local con-
straints such as operational space, access to beam
time, beam energy and stability. Therefore, there
is a different optimum design solution as each
facility responds to these local conditions .
HCL rarely each treat- each treatment
merit
PSI daily each treat- each treatment
ment
CCO each treatment weekly each treatment
TSL each treatment each treat- each treatment
ment
LLUMC rarely weekly daily
CAL. daily weekly daily
CPO daily daily daily
20-60 10-30 2PPC, unsealed
12-35 15-40 2PPC, t eased
32-41 20-25 4 diodes
-8 120-180 SEM/PPC
approx . 40 20 2PPC, unsealed
13-42 20-64 2PPC, unsealed
370
	
A. Kacperek
Acknowledgements
I thank the following for discussions and for mea-
surement data : E. Egger, Paul Scherrer Institute,
Villigen, N. Brassart, Centre Antoine Lacas-
sagne, Nice,A. Mazal, Centre de Protonth6rapie
d'Orsay, Orsay and J . Burns, Harvard Cyclotron
Laboratory, Cambridge . I appreciated the gener-
ous assistance of J . Sisterson, A. Montelius, D.
Miller, P Chauvel, A. Wambersie, T. Nakano, M.
Sheen, and J . Shaw.
References
1 Sisterson, J.M . and Johnson, K.N . As we approach
3000 : Proton radiation therapy at the Harvard Cyclo-
tron Laboratory. Am. Assoc. Med. Dosim. XI, 21-30,
1986 .
2 Gragoudas, E.S ., Goitein, M., Koehler, A.M., Verhey,
L.J., Tepper, J., Suit, H.D., Brockhurst, R., and Con-
stable, J.J . Proton irradiation of small choroidal malig-
nant melanomas . Am. J. Ophthalmol . 83, 665-673,
1977 .
3 Egger, E., Zografos, L., Perret, C., and Gailloud, C.,
Proton beam irradiation of choroidal melanomas at the
PSI: Technique and results, in Medical Radiology :
Radiotherapy of Intraocular and Orbital Tumors .
Alberti, W E. and Sagerman, R. H . (eds .), Springer-
Verlag, Berlin, Heidelberg, 1993, pp . 57-72 .
4 Goitein, M. and Miller, T Planning proton therapy of
the eye . Med . Phys. 10, 275-283, 1983 .
5 ICRU Report 50 . Prescribing, Recording and Report-
ing Beam Therapy. International Commission on Radi-
ation Units and Measurements, Maryland, Bethesda,
USA, 1993
6 Urie, M.M., Sisterson, J.M., Koehler, A.M., Goitein,
M., and Zoeman, J . Protonbeam penumbra : Effects of
separation between patient and beam modifying de-
vices . Med . Phys . 13, 734-741, 1986 .
7 Bonnett, D .E ., Kacperek, A., and Sheen, M.A . Char-
acteristics of a 62 MeV proton therapy beam, in Proc .
2nd European Particle Accelerator Conference, Nice,
France, 1990, pp . S12-S14.
8 Nauraye, C., Mazal, A., Delacroix, S ., Bridier, A.,
Chavaudra, J., and Rosenwald, J.C . An experimental
approach to the design of a scattering system for a pro-
ton therapy beam line dedicated to ophthalmological
applications . Accept . for publ . in Int . J . Radiat. Oncol .
Biol . Phys . 1995 .
9 Gottschalk, B . Double Scattering with Optimum Dose
Uniformity in Proton Radiotherapy. Harvard Cyclotron
Technical Note PTA 8/1/86, Harvard Cyclotron Labora-
tory Cambridge, USA, 1986 . Also in Abstracts of
PTCOG XX meeting, Chester, May 16-18, 1994, Parti-
cle Newsletter 14, July 1994 .
10 Koehler, A.M., Schneider, R.J ., and Sisterson, J.M .
Flattening of proton dose distributions for large-field
radiotherapy. Med . Phys . 4, 297-301, 1977 .
11 Montelius, A., Blomqvist, E., Naeser, P, Brahme, A.,
Carlsson, J ., Carlsson, A-C ., Graffman, S ., Grusell,
E., Hallen, S ., Jakobsson, P, Jung, B ., Larsson, B.,
Nilsson, B., Rikner, G., Russell, K., and Svensson, R.
The narrow proton beam therapy unit at the Svedberg
Laboratory in Uppsala, Acta Oncol. 30, 730-745,1991 .
12 Grusell, E., Montelius, A., Brahme, A., Rikner, G.,
and Russell, K. A general solution to charged particle
beam flattening using an optimized dual-scattering-foil
technique, with application to proton therapy beams .
Phys. Med . Biol . 39, 2201-2216, 1994 .
13 Verhey, L ., Goitein, M., McNulty, P, Munzenrider,
J.E ., and Suit, H.D . Precise positioning of patients for
radiotherapy. Int . J . Radiat . Oncol . Biol . Phys . 8,
289-294,1982 .
14 Delacroix, S ., Mazal, A., Brassart, N., Ozeer, R., Nau-
raye, C., Lacroix, F, Biensan, S ., Schlienger, P, and
Chauvel, P Controle du positionnement des patients
lors du traitement du m6lanome de la chorodde par un
faisceau de protons de 73 MeV. XXXIIeme Congrcs de
la Soci6t6 Frangaise des Physiciens d'H6pital, 3-5 juin
1993 . Bull . Cancer/Radioth6rapie 80, pp . 267-282 .
15 Perret, C., Greiner, R., Zografos, L., and Gailloud, C .
Die Behandlung intraokularer Melanome mit Protonen
am Paul Scherrer Institut (PSI) . Juli 1988 . ID PSI/2000 .
16 Sheen, M.A . Review of EYEPLAN at Clatterbridge .
Abstracts of XX PTCOG meeting at Chester, UK, May
16-18, 1994 . Also earlier work presented at XVIII
PTCOG meeting at Nice, France, April 19, 1993 .
17 ICRP Report of the Task Group on Reference Man .
Publication 23, Pergamon, Oxford, UK 1975 .
18 Bonnett, D.E ., Kacperek, A., Sheen, M.A., Goodall,
R., and Saxton, T.E . The 62 MeV proton beam for the
treatment of ocular melanoma at Clatterbridge . Br. J .
Radiol . 66, 907-914, 1993 .
19 Chauvel, P, Caujolle, J.P, Sauerwein, W., Friedrichs,
W, Brassart, N., and Herault, J . Protontherapy as a
possible salvage treatment for conjunctival melanomas,
in Proc . Int . Symp . on Intraocular and Epibulbar
Tumors, Firenze, March, 3-5, 1994, Frezzotti, R.,
Balestrazzi, E., Falco, L., and Esente, S ., (eds .),
Moduzzi Editore, 1994, pp . 171-181 .
20 Egger, E . Development of a Light Ion Beam for the
Treatment of Superficial Malignant Lesions of the Eye .
Internal Report . TM-21-92-O1 . Paul Scherrer Institute,
Villigen, Switzerland, Sept.1992 .
21 d'Errico, F and Egger, E . Superheated drop (bubble)
detector tests with proton therapy beams, in Particles
Newsletter 14, Abstracts of PTCOG XX, Chester, May
16-18, 1994, pp . 12-13 .
Facilities Under Construction,
Planned and Proposed
J . M . SISTERSON
Introduction
Harvard Cyclotron Laboratory, Harvard University, Cambridge, MA, USA
World-wide, there were 15 operating proton
therapy facilities andone pion beam facility at the
end of 1993 [1] . Only one facility is located in a
hospital setting with an accelerator designed and
built for proton radiation therapy. There is great
interest world-wide in building dedicated proton
and ion beam therapy facilities in a hospital set-
ting, or in adapting accelerators at existing
research facilities to provide therapy beam lines.
Four new projects are expected to come on
line in 1994 . Two of these projects - at the Paul
Scherrer Institute in Villigen, Switzerland and the
HIMAC facility at Chiba, Japan - have been dis-
cussed in detail in preceding chapters .
Brief descriptions are given in this chapter of
eleven facilities that are
1) completed and started operation in 1994,
2) under construction and expect to treat the first
patient in 1994 or 1995,
3) fully funded, but have not yet started con-
struction,
4) proceeding with testing concepts and building
equipment while additional funding is sought,
5) at the stage of actively seeking funding as the
feasibility and design studies are complete . All
these facilities hope to begin operations by the
year 2000, if funding is obtained .
One project is already operating at the UC
Davis Eye Facility, University of California,
Davis California, USA, where the first patient
was treated in May 1994 . Projects nearing com-
pletion are at the TRIUMF Eye Facility,
TRIUMF, University of British Columbia, Van-
couver, Canada, where it is hoped to treat the
first patient by the end of 1994 and The Berlin
Eye Treatment Facility, Berlin, Germany where
the first patient treatment is expected in 1995 .
The Northeast Proton Therapy Center
(NPTC), Massachusetts General Hospital in Bos-
ton, Massachusetts, USAwill begin construction
in 1995, and the first patient treatment is
expected to be in 1998 . At the Ion Beam Therapy
Project at COSYRilich, Jülich, Germany, the
experimental program is in progress . At the Mos-
cow Proton Therapy Facility, Moscow, Russia,
components are being built and the Eye Treat-
ment Facility at Munich, Germany, has recently
installed their post-accelerator.
There are several proposed facilities that have
completed the planning and feasibility study stage
and now (August 1994) funds are being sought to
build all or part of the facilities . These include the
Centre for Oncological Hadrontherapy, Italy, the
Proton Therapy Facility in Groningen, Nether-
lands, the Regional Proton Therapy Facility for
the North Carolina State University (NCSU)
Centennial Campus, North Carolina, USA and
the proton therapy centers of Proton Develop-
ment N.A., Inc., Illinois, USA.
The UC Davis Eye Facility, USA
A proton eye treatment facility has recently been
completed at the 76-inch cyclotron at the Crocker
Nuclear Laboratory on the campus of the Univer-
sity of California, Davis. This cyclotron, origi-
nally built by E.O . Lawrence in 1937 was used by
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Dr. Stone for the early neutron radiotherapy tri-
als at Lawrence Berkeley Laboratory. It was also
used to produce some of the heavy, short lived
nuclei, like Seaborgium, which was recently
named. The cyclotron was moved to Davis in the
early 70's and converted into an isochronous cy-
clotron, with a maximum energy of 68.5 MeV
protons. It also is being used for heavy ion physics
research . The eye treatment facility at Davis was
built by personnel from the Lawrence Berkeley
Laboratory. Most of the beam line elements were
from the Helium ion beam line at the Bevalac.
The facility is being operated by the Department
of Radiation Oncology at the University of Cali-
fornia .
With the variable water absorber in place, the
maximum penetration of the proton beam is 30
mm. The field is flat to within ± 3% over 3 cm
and ± 5% over 5 cm diameter. Modulator wheels
have been constructed from plastic using diode
depth-dose scans as the source of calculation
data . Thetreatment dose rate has been set to be 6
Gy/min, using less than 1% of the maximum
beam intensity of the cyclotron .
As of June 30, 1994, 4 patients have been
treated . The treatment protocol calls for 48 Gy in
4 fractions given over 4 days . Approximately 15
treatment weeks will be used during the first year
of operation, treating a total of approximately
40-50 patients .
The TRIUMF Eye Facility, Canada
The development of the proton facility for the
treatment of ocular tumors at TRIUMF in col-
laboration with the British Columbia Cancer
Agency and the University of British Columbia
Department of Ophthalmology approaches its
final stage. Recently, the installation of beam
delivery and monitoring devices at the proton
channel (2C) was completed and the first patient
treatment is anticipated by the end of 1994 .
The layout of the beam line follows closely the
standard set-ups of existing facilities . Thebeam of
70 MeVprotons, with an extracted current of 1-5
nA in order to achieve the required dose rate of
15-30 Gy/min, is monitored by a system of stan-
dard devices, consisting of 1) a secondary emis-
sion monitor (SEM) watching for beam bursts, 2)
a profile wire chamber for first beam alignment
and 3) a multipurpose ionization chamber com-
plex with an independent transmission foil as a
backup and a quadrant foil for the detection of
lateral beam displacements . The delivery of the
clinically required dose profiles is achieved by a
conventional system of a single scattering foil
1/32 inch of Pb), various collimators and the
standard range shifter and range modulator de-
vices . The various components were successfully
tested in March 1994 . The installation of the two
crucial remaining hardware components, the con-
trol console and the treatment chair, as well as the
final testing of the control software was expected
to be completed in early July 94 .
The acquisition of dosimetry data as required
for treatment planning with the code EYEPLAN
was almost completed by mid 1994 . Relative pro-
ton dosimetry data were obtained by using diode
detectors in a water phantom. For a stable cyclo-
tron tune dose calibrations and dose profiles were
observed to be reproducible within 1 % and
2-3%, respectively. A dose uniformity of ± 2%
was achieved for spread-out Bragg peaks (SOBP)
of plateau widths ranging from 5-20 mm . Further-
more, first RBE measurements were recently
completed and analyzed, indicating an average
RBE of 1.2 ± 0.1 for a SOBP of 20 mm.
Further ongoing developments in treatment
planning and dosimetry at TRIUMF are related
to the eye facility as well as to the proposed treat-
ment site for larger fields . For the eye project,
various options to improve the standard treat-
ment planning procedure are investigated, e.g .,
computer automated search for eye fixation an-
gles or the benefits of a treatment with two differ-
ent ports. For larger fields, the feasibility of quan-
titative in vivo proton dosimetry with PET tech-
niques is under study. Furthermore, a collabora-
tion with the German Cancer Research Center
(DKFZ) in Heidelberg was started to develop a
three-dimensional dose algorithm for proton
therapy of larger fields . The long term aim of this
work is to create a unified 3D-treatment planning
system for photon and proton therapy by inte-
grating the developed proton dose algorithms
into the three-dimensional photon treatment
planning system VOXELPLAN of the DKFZ.
The Berlin Eye Treatment Facility,
Germany
A collaboration between the Eye Clinic of the
Klinikum Steglitz (Free University Berlin), the
Radiotherapy Department of the Charit6 (Hum-
boldt University) and the Hahn-Meitner-Institut
(HMI) has recently been initiated to establish a
facility for the treatment of ocular melanoma
with proton beams at the IonBeam Laboratory of
the HMI. Funding of this facility will be provided
by the Klinikum Steglitz .
The accelerator of the Ion Beam Laboratory
of the HMI consists of a 6 MV single-ended Van
de Graaff injector coupled to a four-sector iso-
chronous cyclotron. The machine has been in
operation since 1978 for nuclear and solid state
physics. Positive ions from hydrogen to xenoncan
be produced in the ECR source of the Van de
Graaff injector. Heavy ions can be accelerated to
energies of 30 x A (MeV), Abeing the ion's mass .
Due to improvements of the HF-system of the cy-
clotron in 1988-89, protons can be accelerated up
to a maximum energy of 72 MeVwhich is suitable
for the treatment of ocular melanomas. Measure-
ments using a beam of 72 MeVprotons and tests
of the beam delivery reliability have been carried
out since summer 1993 .
An existing beam line wasmodified for experi-
ments with only the 72 MeV proton beam. A
50 mm tantalum foil mounted 18 m upstream of
the planned treatment place is used for spreading
the beam laterally. Depth-dose curves of a colli-
mated beam in water show Bragg peak-to-
entrance dose ratios of 5:1 . The measured relative
dose fluctuations across the lateral beam profiles
in water are smaller than 5%. Measured energy
spectra of the proton beam show the full energy
peak at 72 MeV and a continuous background
with approx . 5% of the total intensity.
A therapy control room and a patient waiting
room with a separate entrance to the treatment
area are planned and have to be added to the cy-
clotron building . The first treatments are planned
for late 1995 . The cyclotron will then be used one
week per month for proton therapy of ocular
melanoma which should give a treatment capacity
of approximately 150 patients/year.
39 Facilities Under Construction, Planned and Proposed
	
373
The Northeast Proton Therapy Center
(N PTC), USA
The Northeast Proton Therapy Center (NPTC)
will be built on the Massachusetts General Hospi-
tal (MGH) campus . The current schedule calls for
the commissioning of the proton therapy equip-
ment to be completed on July 1, 1998, and for
patient treatments to begin immediately there-
after. Funds for the NPTC, which are being
shared between MGH and the National Cancer
Institute, have been secured and the major con-
tracts have been signed.
Bechtel Corporation will be the design/building
contractor. Bechtel, providing total project man-
agement services and construction management, is
teamed with T§oi/Kobus & Associates, Architect;
McNamara/Salvia, Inc., Structural Engineer;
McPhail Associates, Geotechnical Engineer ; and
John Moriarty & Associates, Construction Con-
tractor. Bechtel will build a two-level facility, one
underground, having three treatment rooms, at
least one and probably two with gantries and the
other(s) being equipped with fixed beams and
capable of gantry installation . The layout for the
treatment level is shown in Figure 1.
IBA, Belgium-teamed with General Atomics
and the University of Louvain - was selected as
the equipment vendor. IBA will deliver a high-
field, room temperature cyclotron which will pro-
duce 235 MeV protons with a continuous beam
intensity of up to 300 nA (see Chapter 22). The
maximum energy corresponds to adepth range of
about 34 g/cm2 in the absence of absorbing or
lateral beam spreading elements in the beam line .
If passive scattering methodology is used to
achieve a 25 cm x 25 cm field size, the depth of
penetration would be about 28 g/CMZ. In addition
to a passive beam spreading system, IBA will
build a beam wobbling system to achieve large
treatment fields . Using the wobbler, a penetra-
tion of 32 g/cmZ can be achieved for a field size of
25 cm x 25 cm. A variable energy degrader will
be integrated with the cyclotron which will allow
energy changes from 235 MeVdown to 70 MeVin
a few seconds.
General Atomics will construct the beam lines,
gantries and patient positioners . The gantries will
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1 . Layout of the treatment level of the Northeast Proton Therapy Center
be conventional in design . The patient positioners
will be designed to meet the particular needs and
precision requirements of proton therapy. The
isocentric gantries will have a 360-degree rota-
tional capability with beam delivery elements
designed to bend the proton beam achromatically
while allowing for different focusing conditions .
The flexibility in focusing conditions will accom-
modate both passive beam spreading and pencil
beam scanning. The beam lines and gantries will
accommodate rapid energy changes and switch-
ing among treatment rooms .
The beam delivery nozzles will be designed by
the Cyclotron Research Center of the University
of Louvain in collaboration with their proton
therapy group and members of the Harvard
----/----_-'4-Fig.
Cyclotron Laboratory and will be manufactured
by IBA. The design will be based on the beam
spreading technology developed by Gottschalk et
al . a t the Harvard Cyclotron Laboratory [2] . The
nozzle will contain an XY sweeping magnet,
appropriate for beam wobbling . The transition to
raster scanning will be straightforward .
The NPTC is expected to treat 400 patients
during the first year. This patient load is planned
to increase to 750 by the fifth year and 1000 by the
tenth year of operation . New clinical research
protocols for the NPTC are being written and a
transition plan for moving the clinical operations
from the Harvard Cyclotron Laboratory to the
NPTC is being formulated .
The Ion Beam Therapy Project
at COSYJülich, Germany
On April 1, 1993 the cooler synchrotron and stor-
age ring COSYRilich was officially inaugurated.
COSY has been built primarily for medium
energy physics but its characteristics are well
suited for radiation therapy.
Protons injected into COSY at an energy of 40
MeV can be accelerated up to 2.5 GeV Heavier
ions such as carbon, oxygen and neon can be
accelerated in the medically necessary intensity
and energy range (-10' particles/s and E =
400-500 MeV/u), but this option will not be used
during the first few years.
At present, COSY can store approx . 2 x 1010
protons and accelerates them up to 1.4 GeV/c or
ca . 750 MeV kinetic energy. Except for the sto-
chastic cooling expected in spring 1995, COSY
should be fully developed by summer 1994 and
can store up to 2 x 1011 protons. The expected
beam intensity is 5 x 109 protons/s at maximum
energy and 2 x 1010 at 200 MeV, respectively.
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Fig. 2. Layout of the medical area within the COSY facility
Facilities Under Construction, Planned and Proposed 375
Other features that make COSY particularly
suited for therapeutic application are an ultraslow
extraction mode (spill times up to 1000 s), a low
beam emittance (2.5 nmm mrad vert . and horiz .)
and a high momentum stability during beam
pulses and from pulse to pulse (Op/p = 10-3) .
Intensity fluctuations of less than 10% during a
pulse and a reproducibility of approx . 1% is
expected . The duty cycle should typically be 50
for a repetition rate of 0.5 Hz.
The medical program at COSY (COSYmed)
comprises four main topics :
1) the technical physics program responsible for
design and development of the beam delivery
and scanning system, the patient positioning,
control and safety systems,
2) the radiation physics program for beam char-
acterization, (in vivo) dosimetry and irradi-
ation planning,
3) the technical infrastructure program for the
integration of the therapy site into the COSY
building, the design and construction of the
necessary annex,
COSY hall
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4) the biomedical program to characterize the
COSY beam biologically, develop clinically
relevant assays and optimize tumor imaging.
The projected investment costs for the therapy
project are approximately $9 million which will
have to come mostly from additional funding on
top of the present KFAbudget .
Two areas of the COSY facility are reserved
for the medical program as shown in Figure 2.
Site I is going to be used as experimental area for
the pretherapeutic physical and biological pro-
gram . Site II will be the actual therapy area with
patient preparation and treatment room .
The test site I will be equipped with a horizon-
tal beam line providing the same beam quality as
at the therapy site . Preparations for the first
experiments for beam characterization are under
way. A water and a double wedge solid phantom
are ready for use with various detector systems . A
microstrip and a Si-ring detector, fibre hodo-
scopes and a 1/2 inch tissue-equivalent propor-
tional counter have already been tested in ion
beams. Number of particles, beam profile, energy
distribution, absolute dose, dose profile in air and
tissue-equivalent phantoms are the parameters to
be measured with proton beams between 50 and
250 MeV Good spatial resolution and detailed
information about the contributions of the indi-
vidual primary and secondary beam components
are the priority in this study. In addition, a com-
parison of cooled and uncooled beams is planned.
The wide range of energies provided by COSY
and the ability to change the energy actively from
pulse to pulse in small steps without using beam
degrading absorber materials has guided the
design of the therapy site . A rotating gantry will
allow the same flexibility in choosing the treat-
ment angle(s) as in conventional irradiation and a
3D-scanning system is foreseen for tumor con-
form treatment . Design and cost comparisons for
the beam delivery system have now started . The
projected therapy site is spacious but a compact
beam line system will be designed as model for
possible use in a hospital environment.
COSY is a research accelerator mainly used by
nuclear physicists, so only a limited number of
patients can be treated . The goal will be to treat
about 100 well selected cases per year, concentrat-
ing on a few indications and to choose tumors with
well diagnosable borders close to critical struc-
tures (e.g ., irregularly shaped head and neck
tumors, pediatric tumors). The advantageous
dose distribution and steep dose gradient of the
ion beam would be most beneficial for the treat-
ment of larger, deep-seated tumors for which
treatment modalities need to be developed. Col-
laborations to define these clinical studies are
planned with several nearby University Hospitals .
The Moscow Proton Therapy Facility,
Russia
In Russia, the Institute ofTheoretical andExperi-
mental Physics (ITEP) in collaboration with
other scientific and clinical centers, has been
designing and manufacturing equipment for the
Fig . 3 . Top view of a version of the Moscow Proton Therapy
Facility (PTF) with two gantries . The treatment rooms are as
follows : fully rotational gantries in rooms 1 and 4 ; intracra-
nial irradiation in room 2 ; eye treatments in room 5 ; gyne-
cological treatments in room 6 ; research and development
in room 3 . The beams in rooms 2, 3, 5 and 6, are fixed hori-
zontal ones . The total area for the accelerator, beam chan-
nels and treatment rooms, is 1300 m2
Moscow Proton Therapy Facility (PTF). The PTF
project has two distinctive features . A synchro-
tron accelerating H--ions as the medical acceler-
ator has been chosen [3-5], and a circular
arrangement for the treatment rooms around the
accelerator selected, as shown in Figure 3 .
These choices were made for the following
reasons: The most modern methods of conformal
dose delivery, have been based on the use of
three-dimensional scanning systems receiving a
narrow pencil beam at their entrance . The
recharge system of beam ejection from the H--
synchrotron presupposes the production of such a
narrow beam with extremely small (10' m rad)
phase volume, immediately behind the ejection
system . Thus, the H--synchrotron makes it possi-
ble to get the required beam easily, without addi-
tional collimation, particle loss, or increase of
radiation level . Moreover, the delivery of a beam
with small cross section and divergence to the
treatment rooms can be made using cheap, light
and small-aperture proton channels, lenses and
magnets. This is particularly important for the
design of the gantry. The weight ratio of the Mos-
cowproject gantry andthe gantry in Loma Linda,
is better than 1:10 (7 tons vs . 90 tons).
The circular structure of the PTF allows the
treatment rooms to be very close to the acceler-
ator which makes the proton channels very short.
Therefore, the PTF footprint and the number of
lenses andmagnets are minimized . Thus the areas
occupied by the accelerator, beam channels and
six treatment rooms in the Moscow project, have
the ratio of 1:1.5 to those occupied by the Loma
Linda facility with its five treatment rooms . In
addition, each proton channel (starting from the
beam ejection system) and each treatment room,
works independently, but they can operate in
parallel . The energy and intensity of the beam in
each pulse sent successively to the treatment
rooms, are also chosen individually. The basic
parameters are given in Table 1.
Any combination is possible for the number of
treatment rooms with horizontal fixed beams and
with gantry systems .
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Table 1. Basic Parameters of the Moscow PTE
Energy of external
	
variable, up to 250MeV
proton beams
Number of particles up to 3 x 101°
per pulse
Repetition rate 3 Hz
Ejection time 200 ms
Dose field dimensions pro- up to 30 x 30 cm2
vided by the gantry
Number of treatment rooms 6
The Centre for Oncological
Hadrontherapy, Italy
377
The Eye Treatment Facility at Munich,
Germany
The two Munich Universities, Ludwig-Maxi-
milians-Universitdt and Technische-Universitdt
Mtinchen, operate a 14 MV tandem Van de
Graaff accelerator for nuclear physics research .
Recently, a post-accelerator, TRITRON, has
been installed to extend the nuclear physics pro-
gram. TRITRON is an ambitious new accelerator
type using superconducting bending magnets and
superconducting acceleration cavities operating
at T <_ 4.5 K (liquid helium). Protons have the
longest range of particles accelerated by TRI-
TRON and the maximum energy should reach 70
MeV It is planned to install an eye-treatment
facility and to perform selected dosimetry studies
in collaboration with the radiotherapy group of
the University of Regensburg.
Afeasibility study has just been completed [6] for
a hospital-based hadrontherapy facility to be built
in Italy. A request for financing is now being sub-
mitted to the authorities . The facility hopes to
treat 1000 patients/year in 5 treatment rooms
served by a H-/light ion synchrotron. The facility
will have :
1) two rooms equipped with isocentric gantries
capable of transporting protons up to 250
MeV,
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Fig. 4. Layout of the Centre for Ontological Hadrontherapy
2) one room with two 250 MeV proton beams,
one horizontal and one vertical pointing
down,
3) one room with two horizontal beam lines, one
for irradiations of eye tumors and one mainly
devoted to head and neck treatments,
4) one room with a horizontal beam for experi-
ments using both protons and light ions (do-
simetry, radiobiology, calibrations, etc.),
5) one room devoted to future light ion treat-
ments,
6) two smaller rooms served by the 11 MeV pro-
ton beam from the injector, one for the pro-
duction of positron emitting radionuclides for
PET uses, the other for thermal neutron pro-
duction for boron neutron capture therapy
(BNCT). The layout of the facility is shown in
Figure 4.
The complex will have two buildings: one
above ground with conventional facilities and
office space, and a heavily shielded area under-
ground (the "bunker") housing the accelerator
and the treatment rooms which will have a sur-
face area of about 3500m2 and amaximum height
of about 15 m to accommodate the gantry rooms .
The rooms for BNCT and for radionuclide pro-
duction will be on the lowest floor.
The accelerator is a H--synchrotron (which will
also accelerate protons) capable of providing
60-250 MeV proton beams with an average inten-
sity of about 10 nA . Injection in the synchrotron is
at 11 MeVfrom a linac (RFQ + DTL) . The design
includes the possibility to upgrade the machine in
order to accelerate fully stripped light ions up to
160 to a final energy in the range of 120-400 MeV/u
with minor interventions on the ring and the addi-
tion of a second ion source and injector.
The main advantages of accelerating H- are:
1) the simplicity of the ejection system based on
a thin target (stripping foil),
2) the very small transverse emittances (of the
order of 0.1 n mm mrad) of the extracted
beams which can be obtained with a small
stripping target . This allows the weight of the
gantry magnets to be reduced, due to their
smaller required aperture,
3) the possibility of controlling the extracted
beam intensity by a feedback from a monitor
in the beam line to the dipoles driving the
beam to the stripping foil . The allowed time
constant for such direct feedback is funda-
mentally much shorter than for resonant
extraction .
The synchrotron is provided with multiple
extraction : two charge-exchange extraction sys-
tems for H-, one resonant extraction for protons
and one fast extraction port to be used as beam
abort. The extraction of H--ions is achieved by
smoothly driving the circulating beam against a
small beryllium or carbon foil, by a local orbit
bump . A short bending magnet placed just after
the stripping foil separates the protons from the
circulating H--ions .
Two treatment rooms will be equipped with an
isocentric gantry of the "cork-screw" type, similar
to that installed at the Loma Linda University
Medical Center in California, but of reduced
weight . The outer diameter of the proposed
gantry is about 11 m with a distance between the
exit of the last dipole and the isocenter of 3.4 m.
The gantry optics are achromatic and designed to
fully exploit the small beam size . The estimated
vertical aperture of the dipole magnets is 2 cm.
The weight of the magnets is estimated to be
about 6 t and the overall weight of the gantry is
expected not to exceed 25 t.
The Proton Therapy Facility
in the Netherlands
In 1995 the new AGOR cyclotron will be commis-
sioned at the nuclear physics laboratory "Kernfy-
sisch Versneller Instituut" (KVI) in Groningen,
the Netherlands. The cyclotron was built in
Orsay, France, jointly by the French and Dutch
science agencies (AGOR: Accelerator Groningen
Orsay) . In April 1994 the machine produced its
first beam and it has passed the acceptance tests
successfully. During 1994, the cyclotron was disas-
sembled and transported to Groningen where it is
expected to be ready for the first experiments in
the summer of 1995 .
The cyclotron is equipped with superconduct-
ing coils, which makes the machine relatively
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compact. Various heavy ions can be accelerated
to kinetic energies of 600 qz/A (MeV) with q and
A being the charge and mass of the ion. Protons
can be produced with a maximum energy of 200
MeV The availability of 200 MeV protons pro-
vides a unique opportunity to introduce proton
therapy in the Netherlands and to contribute to
the international need for proton therapy facil-
ities .
A collaboration between the Radiotherapy
Departments of the University Hospitals in Gro-
ningen andUtrecht, the Daniel den Hoed Kliniek
in Rotterdam, the Radiobiology group of the
University of Groningen and KVI has been initi-
ated to plan a research facility for radiotherapy
with proton beams at the KVI. The facility should
serve as a pilot project for a possible clinical use
of protons in radiotherapy. The planned facility
consists of a dedicated beam line and a "beam
swinger" gantry in the KVI building .
The various users of the cyclotron have agreed
upon abeam-time sharing schedule with 24 weeks
of beam time for proton therapy. The facility
should be able to treat about 250 patients per
year.
Since high quality proton therapy touches the
limits of present (medical) technology, a multi-
disciplinary research program will be initiated . A
program for the development of special instru-
mentation has been started in collaboration with
clinical physicists from the participating hospitals .
During the operational phase, medical
research, consisting of several clinical studies,
and radiobiological research will be performed in
an international collaboration. It is estimated that
in the Netherlands about 1000 patients per year
have indications for proton therapy.
Presently, a detailed inventory is being made
of the different projects, both in the medical field
(e.g ., patient selection, dose distributions) and in
(clinical) physics (e.g ., design of the gantry, do-
simetry, treatment planning) . Proposals for the
proton therapy project and the associated
research programs have been submitted to vari-
ous Dutch funding agencies . It is anticipated that,
after funding has been achieved, it will take
another three years to set up the facility.
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A Regional Proton Therapy Facility
for the North Carolina State
University Centennial Campus, USA
NC STAR is a proposed project to be built on the
new "Centennial Campus" of North Carolina
State University (NCSU) in Raleigh. The major
components are two synchrotron rings . One ring,
the booster, has a dual mission. It must boost
(accelerate) electrons to full energy (2.5 GeV) for
injection into the second (storage) ring . The elec-
tron storage ring is an intense light source which
will support various research and applied pro-
grams utilizing powerful synchrotron radiation in
the X-ray, ultraviolet and far infrared regions
involving collaboration between universities,
state and federal agencies, and advanced technol-
ogy industries . The acceleration and injection of
electrons will require only a small percentage of
the time available on the booster ring . Most of
the operating time would therefore be available
for a second purpose, such as to accelerate pro-
tons and deliver them to an on-site, dedicated
cancer treatment clinic . The clinic will be oper-
ated by the Radiation Oncology Department of
the UNC School of Medicine .
At NC STAR, protons would be produced in a
duoplasmatron ion source, preaccelerated to 15
MeVin two linac stages, injected into the booster
synchrotron, accelerated to the desired energy
(70 MeVto 250 MeV, nominally), extracted, and
transported to the patient treatment area . The
booster synchrotron can generate protons of over
1700 MeV, but shielding costs will limit the energy
to a much lower value. The present booster
design will accommodate H--ions which have cer-
tain advantages over protons with regard to the
properties of the extracted beam. However, it is
not thought that the associated cost savings would
compensate for the more stringent (i .e ., expen-
sive) vacuum requirements ofH--ion beams com-
pared to the base vacuum needed for electron
acceleration . The relatively high rigidity (8.3 Tm)
of the booster makes it suitable as a heavy ion
accelerator, e.g ., for carbon ion therapy, which
might be an option in the future .
Protons will be delivered to patients in treat-
ment rooms in a clinical setting where they will be
attended by a professional staff as in a hospital-
based oncology department . The facility will fea-
ture two beam delivery systems : 1) a fixed beam
to treat patients with tumors in the head andneck
areas; a special chair with multiple adjustments
will be used for patient positioning; and 2) a
gantry system to treat patients with deep body
tumors .
The Centennial Campus site in Raleigh is
approximately 30 minutes on interstate highway
from the UNC School of Medicine in Chapel Hill .
The remote facility will be supported by a full
staff of physicians and attendants, and it will
house essential ancillary equipment such as com-
puters for retrieving patient records and treat-
ment plans. Thus, the NC STAR-based facility
will be a well-designed remote site with a number
of highly favorable local factors that favor this
particular project, including significant cost sav-
ings .
Proton Development N.A., Inc., USA
Proton Development N.A., Inc. is in the process
of arranging financing for the purpose of estab-
lishing the first of nineteen Medical Proton Ther-
apy Facilities in the Chicago area and the remain-
ing eighteen throughout the United States . Each
facility will be on the campus of a major teaching
medical complex and will have four treatment
rooms, three gantries and onehead, neck and eye
horizontal beam room .
The facilities will be run as commercial enter-
prises . Each will have two CT units, an MRIunit,
a business office, examination rooms and offices
for medical educational centers. Each medical
school will have an office in the building so that
they can treat their own patients . At the first
facility, for example, there will be seven offices,
since there are seven medical schools in Chicago.
A business plan has been completed which
includes an economic feasibility study in real dol-
lars . Operating costs have been projected
between $4.9 million to $14 million per year
depending on the hours of operation. The pro-
jected budget for the first facility is $106 million,
significantly larger than what has been quoted by
not-for-profit/government and church supported
Acknowledgements
39
institutions . These projections include treating
over 2000 patients per year with a staff of 150
personnel to cover approximately 92 hours of
operation per week .
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